01043000000000433000450099100020000070000020000270600020000470100020000609100090
00081300026000174210018000431510019000610350010000804800070000900300019001609300
00400179117000800183085000500191935001000196031000300206131000200209036000700211
04200020021820000020022006500090022212200030023104800140023404800140024804800240
02620490024002860490024003100490022003340490021003560490021003770490022003980430
06300420043006300483043006300546#1#0#i#1#20110411#Cadernos de Saúde Pública#Cad 
Saude Publica#Cad. saúde pública#0102-311X#Escola Nacional de Saúde Pública Serg
io Arouca, Fundação Oswaldo Cruz#Cad. Saúde Pública#CSP#vancouv#decs#0102-311X#2
7#1#201113#1#1#20110000#12#^les^hSumario#^lpt^hSumário#^len^hTable of Contents#^
lpt^cCSP010^tEditorial#^len^cCSP010^tEditorial#^lpt^cCSP120^tRevisão#^len^cCSP12
0^tReview#^lpt^cCSP330^tArtigo#^len^cCSP330^tArticle#^les^tCad. Saúde Pública^vv
ol.27^wsupl.1^cRio de Janeiro^a2011#^lpt^tCad. Saúde Pública^vvol.27^wsupl.1^cRi
o de Janeiro^a2011#^len^tCad. Saúde Pública^vvol.27^wsupl.1^cRio de Janeiro^a201
1##
00258000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600910009000620920007000710020007000787030
00300085#v27s1#V:\SciELO\serial\csp\v27s1\markup\01.htm#S#o#1#1#text#1#20110411#
073647#01.htm#22##
00971000000000397000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600710003000620400003000650010006000680420
00200074120000400076038000300080121000300083049000700086158000300093030001900096
03100030011513100020011806500090012001400090012903500100013812300020014801200510
0150012005100201010003800252010003900290070014900329070008800478002000700566#v27
s1#V:\SciELO\serial\csp\v27s1\markup\01.htm#S#h#2#1#text#1#ed#en#br1.1#1#4.0#ND#
01#CSP010#nd#Cad. Saúde Pública#27#1#20110000#^fs4^ls5#0102-311X#1#The HIV/AIDS 
epidemic in Brazil: three decades^len#A epidemia de HIV/AIDS no Brasil: três déc
adas^lpt#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nEuclides Ayres de^sCas
tilho#Fundação Oswaldo Cruz^iA01^1Instituto de Comunicação e Informação Científi
ca e Tecnológica em Saúde^cRio de Janeiro^pBrasil^ecelials@cict.fiocruz.br#Unive
rsidade de São Paulo^iA02^1Faculdade de Medicina^cSão Paulo^pBrasil^ecastil@usp.
br#01.htm##
01079000000000397000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600710003000620400003000650010006000680420
00200074120000400076038000300080121000300083049000700086158000300093030001900096
03100030011513100020011806500090012001400090012903500100013812300020014801200650
0150012006500215010003800280010003900318070019400357070012300551002000700674#v27
s1#V:\SciELO\serial\csp\v27s1\markup\01.htm#S#f#3#1#text#1#ed#en#br1.1#1#4.0#ND#
01#CSP010#nd#Cad. Saúde Pública#27#1#20110000#^fs4^ls5#0102-311X#1#<b>The HIV/AI
DS epidemic in Brazil</b>: <b>three decades</b>^len#<b>A epidemia de HIV/AIDS no
 Brasil</b>: <b>três décadas</b>^lpt#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^
1A02^nEuclides Ayres de^sCastilho#Fundação Oswaldo Cruz^iA01^1Instituto de Comun
icação e Informação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil^e<
a href="mailto:celials@cict.fiocruz.br">celials@cict.fiocruz.br</a>#Universidade
 de São Paulo^iA02^1Faculdade de Medicina^cSão Paulo^pBrasil^e<a href="mailto:ca
stil@usp.br">castil@usp.br</a>#01.htm##
01080000000000409000450000400060000070200410000670500020004770600020004970000020
00517010002000537090005000557080002000600640007000620710003000690400003000720010
00600075042000200081120000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400090013303500100014212300020015201200510
01540120051002050100038002560100039002940700151003330700090004840020007005740080
08900581#v27s1#V:\SciELO\serial\csp\v27s1\markup\01.htm#S#l#4#1#text#1#^a2011#ed
#en#br1.1#1#4.0#01#CSP010#nd#Cad. saúde pública#27#1#20110000#^fs4^ls5#0102-311X
#1#The HIV/AIDS epidemic in Brazil: three decades^len#A epidemia de HIV/AIDS no 
Brasil: três décadas^lpt#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nEuclid
es Ayres de^sCastilho#^iA01^1Fundação Oswaldo Cruz^2Instituto de Comunicação e I
nformação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil^ecelials@cic
t.fiocruz.br#^iA02^1Universidade de São Paulo^2Faculdade de Medicina^cSão Paulo^
pBrasil^ecastil@usp.br#01.htm#Internet^ihttp://www.scielo.br/scielo.php?script=s
ci_arttext&pid=S0102-311X2011001300001##
00329000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704011300063002000700176#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#5#1#text#18#<p align="right"><font face="Ver
dana, Arial, Helvetica, sans-serif" size="2"><b>EDITORIAL</b></font></p>     ^cY
#01.htm##
00238000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704002200063002000700085#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#6#2#text#18#<p>&nbsp;</p>     ^cY#01.htm##
00373000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704015700063002000700220#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#7#3#text#18#<p><a name="top"></a><font face=
"Verdana, Arial, Helvetica, sans-serif" size="4"><b>The    HIV/AIDS epidemic in 
Brazil: three decades</b></font></p>     ^cY#01.htm##
00238000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704002200063002000700085#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#8#4#text#18#<p>&nbsp;</p>     ^cY#01.htm##
00238000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000500055708000300060704002200063002000700085#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#9#5#text#18#<p>&nbsp;</p>     ^cY#01.htm##
00395000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704017800064002000700242#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#10#6#text#18#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2"><b>C&eacute;lia    Landmann Szwarcwald<sup>I</su
p>; Euclides Ayres de Castilho<sup>II</sup></b></font></p>     ^cY#01.htm##
00560000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704034300064002000700407#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#11#7#text#18#<p><font face="Verdana, Arial, 
Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    de Comunica&ccedil;&ati
lde;o e Informa&ccedil;&atilde;o Cient&iacute;fica e    Tecnol&oacute;gica em Sa
&uacute;de, Funda&ccedil;&atilde;o Oswaldo Cruz, Rio    de Janeiro, Brasil. <a h
ref="mailto:celials@cict.fiocruz.br">celials@cict.fiocruz.br</a>    ^cY#01.htm##
00391000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704017400064002000700238#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#12#8#text#18#<br>   <sup>II</sup>Faculdade d
e Medicina, Universidade de S&atilde;o Paulo, S&atilde;o    Paulo, Brasil. <a hr
ef="mailto:castil@usp.br">castil@usp.br</a></font></p>     ^cY#01.htm##
00239000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000500056708000300061704002200064002000700086#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#13#9#text#18#<p>&nbsp;</p>     ^cY#01.htm##
00240000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704002200065002000700087#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#14#10#text#18#<p>&nbsp;</p>     ^cY#01.htm##
00934000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704071600065002000700781#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#15#11#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">The Brazilian government's    policy to respond
 to AIDS with the universal, free supply of antiretroviral    drugs and medicati
ons for opportunistic diseases through the public health system    was heavily q
uestioned, especially when the policy was first implemented in    the 1990s. The
 program's success is now acknowledged internationally, due not    only to this 
key component, but also to interaction with other government ministries,    in c
onstant dialogue with social movements and the scientific community. Universal  
  access to antiretroviral therapy (ART) has led to a significant reduction in  
  morbidity and mortality.</font></p>     ^cY#01.htm##
00893000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704067500065002000700740#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#16#12#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">However, the program    still faces many diffic
ulties in maintaining long-term sustainability. In addition    to budget issues,
 care for persons living with HIV/AIDS poses major challenges.    Prevention eff
orts also need to be intensified. Thirty years since the first    AIDS cases in 
Brazil, young people are now living with a disease for which there    is specifi
c treatment, without having experienced the high AIDS case fatality    at the be
ginning of the epidemic. And with the increase in survival, quality    of life f
or persons living with HIV/AIDS has become increasingly relevant.</font></p>    
 ^cY#01.htm##
00802000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704058400065002000700649#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#17#13#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">This Supplement,    sponsored by the Department
 of STD, AIDS, and Viral Hepatitis, under the Ministry    of Health, includes ar
ticles on issues related to the HIV/AIDS epidemic since    the consolidation of 
universal access to ART in Brazil. Two articles discuss    the major strides in 
increasing survival among both adults and children. Despite    undeniable succes
s, the results of a case-control study presented here show    that many of the f
actors associated with AIDS deaths could be prevented.</font></p>     ^cY#01.htm
##
00612000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704039400065002000700459#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#18#14#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">As for aspects    related to quality of life, t
he article with findings from a study on patients    undergoing ART shows that a
 major proportion of these patients enjoy good self-rated    health, although th
eir concerns about the future and symptoms of depression    are still problems t
hat need to be overcome.</font></p>     ^cY#01.htm##
00513000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704029500065002000700360#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#19#15#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">Another article    proposes three different way
s of measuring adherence to ART that are appropriate    for monitoring by health
 services and allow early identification of patients    at risk of treatment fai
lure.</font></p>     ^cY#01.htm##
00685000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704046700065002000700532#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#20#16#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">From the epidemiological    point of view, the 
two studies with results from behavioral surveillance studies    suggest problem
s in the adoption of safe sex practices. The first, featuring    information col
lected in a household survey, reveals women's increased vulnerability    in vari
ous areas. Meanwhile, the study on military conscripts shows a decrease    in re
gular condom use.</font></p>     ^cY#01.htm##
00529000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704031100065002000700376#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#21#17#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">A study whose main    objective was to evaluate
 the Ministry of Health's strategies to stimulate the    municipal response to t
he HIV/AIDS epidemic shows that these strategies have    in fact contributed to 
the strides achieved.</font></p>     ^cY#01.htm##
00936000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000500057708000300062704071800065002000700783#v27s1#V:\SciELO
\serial\csp\v27s1\markup\01.htm#S#p#22#18#text#18#<p><font face="Verdana, Arial,
 Helvetica, sans-serif" size="2">On methodological    issues, two articles prese
nt appropriate probabilistic sampling techniques for    most-at-risk populations
 and discuss their application in Brazil. Another article    provides a review o
f serological methods for estimating HIV incidence, based    on data from cross-
sectional studies. Currently, the estimation of HIV incidence    in different gr
oups in the Brazilian population is crucial for understanding    the epidemic's 
recent dynamics, contributing to the development of prevention    strategies, mo
nitoring the ongoing interventions under way, and evaluating the    impact of un
iversal access to treatment.</font></p>     ^cY#01.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#o#1#1#article#1#201104
11#073653#02.htm#306##
03454000000000601000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400100013303500100014301200930015301201190
02460100037003650100036004020700075004380700124005130830974006370850010016110850
01801621085002701639085002201666083100201688085001002690085001802700085003002718
08500230274811700080277107200030277911200090278211100120279111600090280311500120
2812114000902824113001202833002000702845#v27s1#V:\SciELO\serial\csp\v27s1\markup
\02.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#02#CSP120#nd#Cad. Saúde Pública#
27#1#20110000#^fs7^ls18#0102-311X#Estimates of HIV-1 incidence based on serologi
cal methods: a brief methodological review^len#Estimativas de incidência da infe
cção pelo HIV-1 baseadas em métodos sorológicos: uma sumária revisão metodológic
a^lpt#^rND^1A01^nMariza Gonçalves^sMorgado#^rND^1A02^nFrancisco Inácio^sBastos#F
undação Oswaldo Cruz^iA01^1Instituto Oswaldo Cruz^cRio de Janeiro^pBrasil#Fundaç
ão Oswaldo Cruz^iA02^1Instituto de Comunicação e Informação Científica e Tecnoló
gica em Saúde^cRio de Janeiro^pBrasil#^len^aThe paper reviews the serological me
thods employed in the estimation of HIV incidence based on cross-sectional studi
es, as well as the main findings from studies carried out in Brazil that have us
ed such methods. Each method is briefly described, as well as their advantages a
nd limitations. The different methods are also analyzed as a set of complementar
y but sometimes contradictory strategies under permanent criticism and review, s
till far from a gold standard. Finally, an additional question % central to the 
accurate monitoring of the AIDS epidemic using such methods % is discussed: whet
her the different methods should or should not be adjusted. The debate is open a
nd controversy should be viewed as an unavoidable consequence of a very dynamic 
research field, informed by the progress in sciences as diverse as epidemiology,
 biostatistics, mathematical modeling and different branches of basic science, s
uch as immunology, virology, and molecular biology.#^ddecs^i1#^tm^len^kHIV-1^i1#
^tm^len^kHIV Infections^i1#^tm^len^kIncidence^i1#^lpt^aO artigo revisa os método
s sorológicos utilizados na estimação da incidência da infecção pelo HIV baseada
 em estudos seccionais, assim como os principais achados de estudos conduzidos n
o Brasil que utilizaram estes métodos. Cada um dos métodos foi descrito sucintam
ente, assim como suas vantagens e limitações. Os diferentes métodos foram ainda 
analisados enquanto um conjunto de estratégias complementares, por vezes, contra
ditórias, sob permanente crítica e revisão, ainda longe de um padrão-ouro. Final
mente, uma questão adicional % essencial a um monitoramento acurado da epidemia 
por meio desses métodos % é discutida: devem tais métodos ser ajustados ou não? 
O debate segue em aberto e deve ser visto como um desdobramento inevitável de um
 campo de pesquisa particularmente dinâmico, informado pelos avanços de ciências
 as mais diversas, como a epidemiologia, a estatística e a modelagem matemática,
 além das várias áreas da ciência básica, como imunologia, virologia e biologia 
molecular.#^ddecs^i2#^tm^lpt^kHIV-1^i2#^tm^lpt^kInfecções por HIV^i2#^tm^lpt^kIn
cidência^i2#vancouv#69#20091113#13/Nov/2009#20100222#22/Feb/2010#20100312#12/Mar
/2010#02.htm##
03482000000000601000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400100013303500100014301201070015301201330
02600100037003930100036004300700075004660700124005410830974006650850010016390850
01801649085002701667085002201694083100201716085001002718085001802728085003002746
08500230277611700080279907200030280711200090281011100120281911600090283111500120
2840114000902852113001202861002000702873#v27s1#V:\SciELO\serial\csp\v27s1\markup
\02.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#02#CSP120#nd#Cad. Saúde Pública#
27#1#20110000#^fs7^ls18#0102-311X#<b>Estimates of HIV-1 incidence based on serol
ogical methods</b>: <b>a brief methodological review</b>^len#<b>Estimativas de i
ncidência da infecção pelo HIV-1 baseadas em métodos sorológicos</b>: <b>uma sum
ária revisão metodológica</b>^lpt#^rND^1A01^nMariza Gonçalves^sMorgado#^rND^1A02
^nFrancisco Inácio^sBastos#Fundação Oswaldo Cruz^iA01^1Instituto Oswaldo Cruz^cR
io de Janeiro^pBrasil#Fundação Oswaldo Cruz^iA02^1Instituto de Comunicação e Inf
ormação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#^len^aThe pape
r reviews the serological methods employed in the estimation of HIV incidence ba
sed on cross-sectional studies, as well as the main findings from studies carrie
d out in Brazil that have used such methods. Each method is briefly described, a
s well as their advantages and limitations. The different methods are also analy
zed as a set of complementary but sometimes contradictory strategies under perma
nent criticism and review, still far from a gold standard. Finally, an additiona
l question % central to the accurate monitoring of the AIDS epidemic using such 
methods % is discussed: whether the different methods should or should not be ad
justed. The debate is open and controversy should be viewed as an unavoidable co
nsequence of a very dynamic research field, informed by the progress in sciences
 as diverse as epidemiology, biostatistics, mathematical modeling and different 
branches of basic science, such as immunology, virology, and molecular biology.#
^ddecs^i1#^tm^len^kHIV-1^i1#^tm^len^kHIV Infections^i1#^tm^len^kIncidence^i1#^lp
t^aO artigo revisa os métodos sorológicos utilizados na estimação da incidência 
da infecção pelo HIV baseada em estudos seccionais, assim como os principais ach
ados de estudos conduzidos no Brasil que utilizaram estes métodos. Cada um dos m
étodos foi descrito sucintamente, assim como suas vantagens e limitações. Os dif
erentes métodos foram ainda analisados enquanto um conjunto de estratégias compl
ementares, por vezes, contraditórias, sob permanente crítica e revisão, ainda lo
nge de um padrão-ouro. Finalmente, uma questão adicional % essencial a um monito
ramento acurado da epidemia por meio desses métodos % é discutida: devem tais mé
todos ser ajustados ou não? O debate segue em aberto e deve ser visto como um de
sdobramento inevitável de um campo de pesquisa particularmente dinâmico, informa
do pelos avanços de ciências as mais diversas, como a epidemiologia, a estatísti
ca e a modelagem matemática, além das várias áreas da ciência básica, como imuno
logia, virologia e biologia molecular.#^ddecs^i2#^tm^lpt^kHIV-1^i2#^tm^lpt^kInfe
cções por HIV^i2#^tm^lpt^kIncidência^i2#vancouv#69#20091113#13/Nov/2009#20100222
#22/Feb/2010#20100312#12/Mar/2010#02.htm##
03610000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000190010703100030012613100020012906500090013101400100014003500100015001200930
01600120119002530100037003720100036004090700077004450700126005220830988006480850
01001636085001801646085002701664085002201691083102001713085001002733085001802743
08500300276108500230279111700080281407200030282211200090282511100120283411600090
2846115001202855114000902867113001202876002000702888008008902895#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#tab#0
2#CSP120#nd#Cad. saúde pública#27#1#20110000#^fs7^ls18#0102-311X#Estimates of HI
V-1 incidence based on serological methods: a brief methodological review^len#Es
timativas de incidência da infecção pelo HIV-1 baseadas em métodos sorológicos: 
uma sumária revisão metodológica^lpt#^rND^1A01^nMariza Gonçalves^sMorgado#^rND^1
A02^nFrancisco Inácio^sBastos#^iA01^1Fundação Oswaldo Cruz^2Instituto Oswaldo Cr
uz^cRio de Janeiro^pBrasil#^iA02^1Fundação Oswaldo Cruz^2Instituto de Comunicaçã
o e Informação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#^len^aT
he paper reviews the serological methods employed in the estimation of HIV incid
ence based on cross-sectional studies, as well as the main findings from studies
 carried out in Brazil that have used such methods. Each method is briefly descr
ibed, as well as their advantages and limitations. The different methods are als
o analyzed as a set of complementary but sometimes contradictory strategies unde
r permanent criticism and review, still far from a gold standard. Finally, an ad
ditional question  percent central to the accurate monitoring of the AIDS epidem
ic using such methods  percent is discussed: whether the different methods shoul
d or should not be adjusted. The debate is open and controversy should be viewed
 as an unavoidable consequence of a very dynamic research field, informed by the
 progress in sciences as diverse as epidemiology, biostatistics, mathematical mo
deling and different branches of basic science, such as immunology, virology, an
d molecular biology.#^ddecs^i1#^tm^len^kHIV-1^i1#^tm^len^kHIV Infections^i1#^tm^
len^kIncidence^i1#^lpt^aO artigo revisa os métodos sorológicos utilizados na est
imação da incidência da infecção pelo HIV baseada em estudos seccionais, assim c
omo os principais achados de estudos conduzidos no Brasil que utilizaram estes m
étodos. Cada um dos métodos foi descrito sucintamente, assim como suas vantagens
 e limitações. Os diferentes métodos foram ainda analisados enquanto um conjunto
 de estratégias complementares, por vezes, contraditórias, sob permanente crític
a e revisão, ainda longe de um padrão-ouro. Finalmente, uma questão adicional  p
or cento essencial a um monitoramento acurado da epidemia por meio desses método
s  por cento é discutida: devem tais métodos ser ajustados ou não? O debate segu
e em aberto e deve ser visto como um desdobramento inevitável de um campo de pes
quisa particularmente dinâmico, informado pelos avanços de ciências as mais dive
rsas, como a epidemiologia, a estatística e a modelagem matemática, além das vár
ias áreas da ciência básica, como imunologia, virologia e biologia molecular.#^d
decs^i2#^tm^lpt^kHIV-1^i2#^tm^lpt^kInfecções por HIV^i2#^tm^lpt^kIncidência^i2#v
ancouv#69#20091113#13/Nov/2009#20100222#22/Feb/2010#20100312#12/Mar/2010#02.htm#
Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X20110
01300002##
00349000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012900067002000700196#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#5#1#article#233#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>REVIEW    </b> REVIS&Atilde;
O</font></p>     ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#6#2#article#233#<p>&nbsp;</p>     ^cY#02.htm
##
00419000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704019900067002000700266#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#7#3#article#233#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Estimates    of HIV-1 in
cidence based on serological methods: a brief methodological review</b></font></
p>     ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#8#4#article#233#<p>&nbsp;</p>     ^cY#02.htm
##
00485000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704026500067002000700332#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#9#5#article#233#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Estimativas    de incid&ecirc;ncia da infe
c&ccedil;&atilde;o pelo HIV-1 baseadas em m&eacute;todos    sorol&oacute;gicos: 
uma sum&aacute;ria revis&atilde;o metodol&oacute;gica</b></font></p>     ^cY#02.
htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#10#6#article#233#<p>&nbsp;</p>     ^cY#02.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#11#7#article#233#<p>&nbsp;</p>     ^cY#02.ht
m##
00402000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704018100068002000700249#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#12#8#article#233#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Mariza Gon&ccedil;alves    Morgado<sup>I<
/sup>; Francisco In&aacute;cio Bastos<sup>II</sup></b></font></p>     ^cY#02.htm
##
00390000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704016900068002000700237#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#13#9#article#233#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    Oswaldo Cruz, Funda
&ccedil;&atilde;o Oswaldo Cruz, Rio de Janeiro, Brasil    ^cY#02.htm##
00449000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022700069002000700296#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#14#10#article#233#<br>   <sup>II</sup>Instit
uto de Comunica&ccedil;&atilde;o e Informa&ccedil;&atilde;o    Cient&iacute;fica
 e Tecnol&oacute;gica em Sa&uacute;de, Funda&ccedil;&atilde;o    Oswaldo Cruz, R
io de Janeiro, Brasil</font></p>     ^cY#02.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#15#11#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#16#12#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#17#13#article#233#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#02.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#18#14#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#02.htm##
01308000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704108600069002000701155#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#19#15#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The paper reviews    the serological method
s employed in the estimation of HIV incidence based on    cross-sectional studie
s, as well as the main findings from studies carried out    in Brazil that have 
used such methods. Each method is briefly described, as    well as their advanta
ges and limitations. The different methods are also analyzed    as a set of comp
lementary but sometimes contradictory strategies under permanent    criticism an
d review, still far from a gold standard. Finally, an additional    question % c
entral to the accurate monitoring of the AIDS epidemic using such    methods % i
s discussed: whether the different methods should or should not be    adjusted. 
The debate is open and controversy should be viewed as an unavoidable    consequ
ence of a very dynamic research field, informed by the progress in sciences    a
s diverse as epidemiology, biostatistics, mathematical modeling and different   
 branches of basic science, such as immunology, virology, and molecular biology.
</font></p>     ^cY#02.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014000069002000700209#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#20#16#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV-1; HIV Infections;    Incidence</font><
/p> <hr size="1" noshade>     ^cY#02.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#21#17#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#02.htm##
01572000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704135000069002000701419#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#22#18#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O artigo revisa    os m&eacute;todos sorol&
oacute;gicos utilizados na estima&ccedil;&atilde;o da    incid&ecirc;ncia da inf
ec&ccedil;&atilde;o pelo HIV baseada em estudos seccionais,    assim como os pri
ncipais achados de estudos conduzidos no Brasil que utilizaram    estes m&eacute
;todos. Cada um dos m&eacute;todos foi descrito sucintamente,    assim como suas
 vantagens e limita&ccedil;&otilde;es. Os diferentes m&eacute;todos    foram ain
da analisados enquanto um conjunto de estrat&eacute;gias complementares,    por 
vezes, contradit&oacute;rias, sob permanente cr&iacute;tica e revis&atilde;o,   
 ainda longe de um padr&atilde;o-ouro. Finalmente, uma quest&atilde;o adicional 
   % essencial a um monitoramento acurado da epidemia por meio desses m&eacute;t
odos    % &eacute; discutida: devem tais m&eacute;todos ser ajustados ou n&atild
e;o?    O debate segue em aberto e deve ser visto como um desdobramento inevit&a
acute;vel    de um campo de pesquisa particularmente din&acirc;mico, informado p
elos avan&ccedil;os    de ci&ecirc;ncias as mais diversas, como a epidemiologia,
 a estat&iacute;stica    e a modelagem matem&aacute;tica, al&eacute;m das v&aacu
te;rias &aacute;reas    da ci&ecirc;ncia b&aacute;sica, como imunologia, virolog
ia e biologia molecular.</font></p>     ^cY#02.htm##
00386000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016400069002000700233#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#23#19#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV-1; Infec&ccedil;&otilde;es    por HIV; 
Incid&ecirc;ncia</font></p> <hr size="1" noshade>     ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#24#20#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#25#21#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#26#22#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#02.h
tm##
00748000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052600069002000700595#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#27#23#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV is one of the    most important emergen
t pathogens in the last century. Around 70 years after    its introduction in th
e human population as a zoonosis from non-human primates,    it has become a maj
or public health problem throughout the world. World Health    Organization (WHO
) estimates point to 33.2 million (30.6-36.1 million) adults    and children liv
ing with HIV in 2007, roughly 70% of them in Sub-Saharan Africa    <sup>1</sup>.
</font></p>     ^cY#02.htm##
00560000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033800069002000700407#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#28#24#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Latin America accounts    for 1.7 million A
IDS cases (1.5-2.1 million; 5%) in this period. In Brazil,    630,000 individual
s are estimated to be living with HIV/AIDS. This estimate    has been quite stab
le since the beginning of this century <sup>2</sup>.</font></p>     ^cY#02.htm##
01176000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704095400069002000701023#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#29#25#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Although data on    HIV seroprevalence are 
available for all countries in the world, the systematic    assessment of incide
nt cases through dedicated reporting systems is still limited    to a few countr
ies (e.g. the USA and Germany) that use serological approaches    to estimate HI
V incidence after repeated population-based studies <sup>3,4</sup>.    The estim
ation of incidence rates at the population level is of paramount importance    t
o assess the dynamics and trends of the HIV epidemic in order to implement    ad
equate preventive measures and to monitor ongoing interventions and the putative
    impact of treatment at the population level, due to its impact on HIV infect
ivity    and transmission <sup>5</sup>. Moreover, studies aiming to evaluate the
 immune    response and virus diversity in early infection are of great relevanc
e for vaccine    strategies.</font></p>     ^cY#02.htm##
00950000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072800069002000700797#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#30#26#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The first methodological    approaches used
 to estimate HIV incidence were based on the assessment of seroconversion    in 
cohorts of HIV-seronegative individuals, with the establishment of large    coho
rts in Western countries, such as the <i>Multicenter AIDS Cohort Study</i>    (M
ACS), implemented in different research centers in the US, now celebrating    it
s 25<sup>th</sup> anniversary <sup>6</sup>, the <i>Vancouver Injection Drug    U
sers Study</i> (VIDUS) in Vancouver, Canada <sup>7</sup>, and the ALIVE study,  
  also comprising injection drug users, and carried out since the late 1980s,   
 in Baltimore, United States <sup>8</sup>.</font></p>     ^cY#02.htm##
01054000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083200069002000700901#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#31#27#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This approach is    very expensive and time
 consuming due to the necessity to follow large cohorts    over time. Moreover, 
behavioral changes can take place during participation    in this type of study,
 as an expected outcome of the adoption of standard of    care interventions aim
ing to prevent HIV acquisition as mandated by ethical    requirements of any stu
dy with human beings. Such interventions much likely    reduce risky behaviors a
nd seroconversion rates over time. Besides such limitations,    secondary to the
 very characteristics of longitudinal studies with human beings,    cohort studi
es also tend to select subgroups of individuals with particular    characteristi
cs (such as those more concerned about their health) <sup>9</sup>.</font></p>   
  ^cY#02.htm##
00791000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056900069002000700638#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#32#28#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In this sense,    cohort studies should not
 be viewed as a gold standard vis-&agrave;-vis estimates    using biomarkers, bu
t rather as studies subjected to their own specific biases    <sup>10</sup>. As 
such, there is not a gold standard for assessing the validity    of new strategi
es (either biological or epidemiological), and all strategies    should be viewe
d as different attempts (with partial success) to circumvent    the limitations 
and caveats posed by each different method.</font></p>     ^cY#02.htm##
00553000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033100069002000700400#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#33#29#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to overcome    such limitations to
 detect early and recent HIV infections, several methods    based on the assessm
ent of biological parameters have been developed over time    to detect infectio
n in both pre and post-seroconversion phases.</font></p>     ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#34#30#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#35#31#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methods</b></font></p>     ^cY#02.htm##
00655000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043300069002000700502#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#36#32#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This paper summarizes    the main methods t
hat have been used to assess HIV seroincidence in cross-sectional    studies wor
ldwide. This section aims to be a tutorial for graduate students,    clinicians,
 infectologists, and health managers, as well as researchers working    in the f
ields of epidemiology, immunology, virology, and molecular biology.</font></p>  
   ^cY#02.htm##
00650000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042800069002000700497#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#37#33#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The second part    of the paper reviews the
 available evidence from Brazilian studies using such    different methods and c
omprises a comprehensive review of all published studies    available in the mai
n bibliographic databases, such as PubMed, SciELO and Scopus,    since the very 
implementation of such methods in Brazil up to September 2009.</font></p>     ^c
Y#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#38#34#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#39#35#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#02.htm##
00402000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704018000069002000700249#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#40#36#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Major methods    used in the assessme
nt of HIV incidence in cross-sectional studies</u></b></font></p>     ^cY#02.htm
##
00758000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053600069002000700605#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#41#37#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="/img/revistas/csp/v27s1/02t01.jpg"
>Table    1</a> outlines the major serological approaches used to detect the pre
 and post    HIV seroconversion phases. These approaches, based on biological pa
rameters    assessed in the sera of patients can be used in cross-sectional surv
eys as they    are able to differentiate recent from long-term HIV-1 infections.
 In this section    we will briefly describe their major characteristics and app
lications.</font></p>     ^cY#02.htm##
00337000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011500069002000700184#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#42#38#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Pre-seroconversion</b></font></p>
     ^cY#02.htm##
00874000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065200069002000700721#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#43#39#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">During the immunological    window, i.e., b
etween infection and seroconversion, it is possible to detect    HIV RNA, DNA an
d p24 antigens in absence of HIV antibodies <sup>11</sup> as    follows: p24 ant
igen and DNA PCR, 26.4 days (95% confidence interval - 95%CI:    12.6-38.7); and
 RNA PCR, 31.0 days (95%CI: 16.7-45.3). Further analyses with    highly sensitiv
e techniques reduced the time of RNA and p24 detection after    HIV-1 infection 
(<a href="/img/revistas/csp/v27s1/02t01.jpg">Table 1</a>) to    periods as short
 as 6 and 12 days, respectively <sup>12</sup>.</font></p>     ^cY#02.htm##
00694000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047200069002000700541#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#44#40#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Early in 1995,    p24 antigenemia and HIV a
ntibodies were used as a two-step algorithm to detect    the prevalence of p24 i
n absence of anti-HIV antibodies <sup>13</sup>. The HIV    incidence rate was th
en calculated by using the classical relation between prevalence,    incidence, 
and the duration of the period between the onset of p24 antigen detection    and
 the first HIV antibodies.</font></p>     ^cY#02.htm##
00798000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057600069002000700645#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#45#41#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The short window    period for seroconversi
on is a limitation for the application of methods detecting    HIV RNA or p24 an
tigen for the estimation of HIV incidence. Indeed, a very large    number of HIV
 seronegative individuals should be tested to have the chance of    identifying 
a few cases of seroconversion in order to get an accurate estimation    of HIV i
ncidence at the population level. The application of these methods to    estimat
e HIV incidence is very limited in the literature.</font></p>     ^cY#02.htm##
01312000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704109000069002000701159#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#46#42#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Notwithstanding,    the original insight fr
om the American statistician Ron Brookmeyer to use two    biomarkers emerging in
 different moments of the HIV infection over time paved    the way for all subse
quent assessments of HIV incidence based on cross-sectional    studies, always p
rofiting from the fact that incidence can be approximately    deduced from avail
able data on prevalence and the duration of a given infection    (or non-transmi
ssible medical condition). Besides the technical difficulties    secondary to th
e short window period, one must also observe that the very nature    of the stat
istical procedure imposes limitations on the accuracy of the estimates.    As sh
own by Miettinen <sup>14</sup>, the actual relation involves the prevalence    o
dds instead of prevalence itself and the estimates have as a basic assumption   
 the stability of the population under analysis, which is far from real in most 
   cases (such issues are discussed in some detail in a former paper) <sup>15</s
up>.</font></p>     ^cY#02.htm##
00338000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011600069002000700185#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#47#43#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Post-seroconversion</b></font></p
>     ^cY#02.htm##
00674000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045200069002000700521#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#48#44#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to improve    the serological esti
mates of HIV incidence, serological methods able to discriminate    recent from 
long-term seroconversion with HIV, denominated as "serological testing    algori
thm for recent HIV seroconversion" (STARHS) have been developed over time,    as
 reviewed by Parekh &amp; McDougal <sup>16</sup> and Murphy &amp; Parry <sup>17<
/sup>.</font></p>     ^cY#02.htm##
01126000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704090400069002000700973#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#49#45#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">While in the pre-seroconversion    phase th
e methods are based on the detection of p24 antigen and/or viral RNA,    in the 
post HIV seroconversion phase the STARHS are based on differences on    anti-HIV
 antibody concentration, proportion, affinity, avidity and immunoglobulin    iso
type, which are parameters associated to the maturation of the immune response  
  to target antigens (<a href="/img/revistas/csp/v27s1/02t01.jpg">Table 1</a>). 
   Although developed for distinguishing recent from long-term HIV infection, in
    general the STARHS are not considered sensitive enough to be used at the lev
el    of individual cases. Their major applications rely on population-based stu
dies,    for estimating the rate of acquisition of new infection, or incidence r
ate based    on cross-sectional serosurveys <sup>17</sup>.</font></p>     ^cY#02
.htm##
00332000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011000069002000700179#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#50#46#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Detuned assay</u></b></font></p>     
^cY#02.htm##
02358000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704213600069002000702205#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#51#47#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The first serological    strategy used to i
dentify recent seroconversion in a cross-sectional population,    developed by J
anssen et al. <sup>18</sup>, was based on a sensitive/less sensitive    testing 
algorithm using commercial ELISA assays (S/LS EIA). This approach, also    known
 as detuned assay, was based on the differences on HIV-antibody concentrations  
  between recent and long-term HIV infection. For this purpose, the firstly deve
loped    detuned assay was a modification of the commercial HIV-1 antibody assay
 3A11    (Abbott), increasing the serum dilution (1:20.000) and shortening incub
ation    times to render it less-sensitive (3A11-LS) in detecting HIV-1 antibodi
es. HIV-positive    individuals with low titer antibodies to HIV antigens, as se
en in early infections,    gave results below a pre-determined threshold cutoff 
in the LS assay, but positive    in the S assay, and were considered as recent i
nfections. The window period    was defined based on serial samples from known s
eroconverters, and was found    to be 129 days (95%CI: 109-149 days). Due to the
 nature of this method, an internal    calibrator and additional control specime
ns, provided by the Centers for Disease    Control and Prevention (CDC), were re
quested to determine the cut-off and to    monitor the assay performance <sup>16
</sup>. Differences on the window period    between HIV-1 subtype infections wer
e however detected in two studies conducted    in Thailand, comparing Thai subty
pe B (B') and CRF01_AE infected individuals.    These differences were also dete
cted between the two commercial kits adapted    for the S/LS detuned assay. Thus
, a window period of 155 days (95%CI: 128-189    days) was found for subtype B u
sing the HIV-1 antibody assay 3A11, but it was    of 270 days (95%CI: 187-349 da
ys) for CRF01_AE specimens <sup>19</sup>. Similarly,    Vironostika-LS EIA resul
ts showed a mean window period of 239 days (95%CI: 208-287    days) for subtype 
B' and 356 days (95%CI: 318-402 days) for CRF01_AE samples    from Thailand <sup
>20</sup>.</font></p>     ^cY#02.htm##
00677000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045500069002000700524#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#52#48#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">These results demonstrate    that both meth
ods have different performances in detecting recent seroconversion    between di
fferent HIV-1 subtypes. Although this method was applied in several    contexts 
and populations <sup>16,17</sup>, limitations in terms of estimates    for diffe
rent HIV subtypes, as well as the availability of commercial kits are    limitin
g issues.</font></p>     ^cY#02.htm##
00327000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010500069002000700174#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#53#49#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; BED-CEIA</b></font></p>     ^cY#0
2.htm##
01594000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704137200069002000701441#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#54#50#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A new approach    to detect HIV-1 recent in
fection was developed by Parekh et al. <sup>21</sup>    and used a branched pept
ide containing the gp41 immunodominant sequences from    HIV-1 subtypes B, E (CR
F01_AE), and D, in a competitive capture EIA, denominated    BED-capture enzyme 
immunoassay (BED-CEIA). This assay is based on the gradual    increase on the pr
oportion of anti-HIV-1 specific IgG in the total IgG, as observed    along the m
aturation of the immune response to a given antigen. In order to    define the c
ut-off to distinguish recent from long-term infections, the BED-CEIA    normaliz
ed optical density (OD-n) was calculated (ODspecimen/ODcalibrator),    using a c
alibrator specimen, to 1.0 OD-n for a seroconversion period of 160    days. Sepa
rate analysis of B and E subtype specimens yielded the same optimal    OD-n thre
shold and similar seroconversion periods and the assay was further    validated 
in African specimens <sup>21</sup>. Variations in the window period    have been
 observed for some subtypes (mean of 153 days for subtypes A to E),    however i
f these differences are due to the assay or other confounding factors    related
 to the population structure and other characteristics of the local epidemics,  
  those remain to be determined <sup>16</sup>.</font></p>     ^cY#02.htm##
00627000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040500069002000700474#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#55#51#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This assay has    been largely used in mult
iple cross-sectional studies to identify recent infections    and to estimate HI
V incidence in different countries and epidemiological scenarios    <sup>22,23,2
4,25,26</sup>. Indeed, this method was applied in a national study    to estimat
e HIV incidence in the US <sup>3</sup>.</font></p>     ^cY#02.htm##
01662000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704144000069002000701509#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#56#52#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Taking together,    these studies provide t
rends of incidence and identify associated risk factors,    which may contribute
 to establish preventive measures to control HIV-1 infection.    The BED-CEIA is
 commercially available (Calypte Biomedical, US) and the CDC    provides periodi
c proficiency panels to assess the performance of this technique    in the US an
d international laboratories for both sera and dried blood spots    (DBS). Based
 on some evidence that the BED-CEIA approach misclassifies as recent    a substa
ntial minority of long-term infections and consequently leads to overestimation 
   of the incidence rates, the UNAIDS (The United Nations Joint Programme on HIV
/AIDS)    Reference Group <sup>27</sup> recommended that the BED-assay should no
t be used    for routine surveillance applications, nor for absolute incidence e
stimates,    nor monitoring trends. Among other studies, an unexpectedly high in
cidence of    6.1%/year 95%CI: 4.2-8.0 was observed in Masaka and 6.0%/year (95%
CI: 4.3-7.7)    in Kakira, Uganda, while prospective incidence data in Masaka fr
om the same    population were found to be 1.7%/year before and 1.4%/year after 
the study <sup>28</sup>.    In order to improve the accuracy of this method, dif
ferent types of adjustments    have been suggested and will be discussed further
 in this article <sup>29,30</sup>.</font></p>     ^cY#02.htm##
00342000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012000069002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#57#53#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Avidity    index method</b></font
></p>     ^cY#02.htm##
02851000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704262900069002000702698#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#58#54#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Increases in the    antibody avidity are ob
served along the maturation of the immune response to    a given antigen. Differ
ences in the IgG avidity to HIV-1 antigens have been    described as a useful to
ol to discriminate recent from long-term HIV-1 infections    <sup>31,32,33</sup>
. In order to measure the differences on IgG avidity, a commercial    method use
d for HIV diagnostic (AxSYM HIV1/2gO test; Abbott) was modified and    the serum
 samples were tested in parallel diluted in phosphate-buffered saline    and in 
1 M guanidine. A low avidity (less than 50%) was found in recently infected    p
atients (less than 6 months), compared to long-term infected patients (more    t
han 12 months), who had a higher avidity (80 to 100%) <sup>31</sup>. The avidity
    index &#91;AI&#93;, determined as the ratio of the sample/cut-off value for 
   the guanidine aliquot to that of the phosphate-buffered saline aliquot, was  
  calculated based on serum samples with well documented dates of HIV infection,
    showed that the mean AIs were 0.68&plusmn;0.16, within 6 months of infection
,    and 0.98&plusmn;0.10 after 6 months. An AI of &lt; 0.90 correctly identifie
d    88.2% of recent infections, but misclassified as recent infections 13.2% of
    serum samples collected afterward <sup>33</sup>. Avidity indices of <u>&lt;<
/u>    0.75 and <u>&lt;</u> 0.80 consistently identified seroconversion within 1
25    (95%CI: 85-164) and 142 (95%CI, 101-183) days, respectively <sup>34</sup>.
 AIDS-defining    conditions were also found to interfere with the accuracy of t
his method, as    previously described for the detuned and BED-CEIA assays. Howe
ver, low CD4 counts    and viral load, as well as antiretroviral treatment, had 
no effect in the AI    <sup>32</sup>. Comparative studies of the avidity assay w
ith detuned or BED-CEIA    showed similar performances for the three assays to i
dentify recent infections    in a region where subtype B predominates <sup>35</s
up>. More recently, evaluating    known seroconversion rates of HIV-seropositive
 samples from Uganda, where subtypes    D and A predominate, the mean AI found f
or patients with recent infection was    0.55&plusmn;0.21, while AI of 0.93&plus
mn;0.14 was detected for those from long-term    infections <sup>36</sup>. In th
is study, a sensitivity of 85.2% and a specificity    of 85.4% for a cut-off of 
0.80 were observed, with no association between HIV    subtypes and misclassific
ation, suggesting that this method can be used in field    studies in both B and
 non-B endemic regions.</font></p>     ^cY#02.htm##
00353000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013100069002000700200#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#59#55#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Immunoglobulin    isotype changin
g</b></font></p>     ^cY#02.htm##
01191000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704096900069002000701038#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#60#56#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Based on the analysis    of serial HIV-1 se
ropositive samples with known seroconversion dates by isotype-specific    wester
n blot it was possible to identify differences on antigen reactivity according  
  to the IgG isotype <sup>37</sup>. While IgG1 was directed toward a range of   
 viral proteins, IgG3 was basically directed to p17 and p24 antigens and, as    
measured by densitometry, the intensity of the IgG3 anti-p24 response was highes
t    early after infection (days 58 and 86 post-infection), declining thereafter
.    This observation led to the isolation of p24 protein and further standardiz
ation    of an in house IgG3-specific anti-p24 enzyme-linked immunoabsorbent ass
ay able    to discriminate recent (1-4 months) from long-term HIV-1 infection. A
s of our    knowledge, no application of this method to estimate HIV-1 incidence
 in the    field has been published so far.</font></p>     ^cY#02.htm##
00353000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013100069002000700200#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#61#57#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; gp41    IDE</b> - <b>gp120V3 assa
y</b></font></p>     ^cY#02.htm##
02171000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704194900069002000702018#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#62#58#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to overcome    issues related to t
he availability and utilization of commercial kits, an in-house    indirect enzy
me-linked immunosorbent assay was developed to quantify antibodies    toward fou
r HIV-1 antigens: consensus peptides of the immunodominant epitope    of gp41 (I
DE), consensus V3 peptides, recombinant integrase, and recombinant    p24 <sup>3
8</sup>. Among them, the IDE and V3 peptides were selected due to    their capac
ity for discriminating recent (&lt; 6 months) from long-term infections.    The 
results are expressed as a ratio of the optical density (OD) sample/OD negative 
   control sera, and the median ratios for antibodies to IDE and V3 were shown  
  to be more than 20-fold higher for sera from chronically infected patients tha
n    for sera from recently infected patients <sup>38</sup>. The IDE antigen cor
responded    to two consensus oligopeptides of 30 amino acids, one HIV-1 group M
 and one    from subtype D, while a mixture of five V3 peptides representing con
sensus sequences    of clades A, B, C, D, and CRF01-AE. Combined quantification 
of antibody binding    to these antigens led to the identification of recent inf
ection with high sensitivity    (88.3%) and specificity (97.6%), when analyzing 
971 serum samples from HIV-1    positive untreated patients in France <sup>38</s
up>. This assay was also validated    for dried blood spots, which improves its 
utility for population studies. Indeed,    it has been used to estimate the inci
dence rate of HIV-1 infection in France    <sup>39</sup>. However, in a study co
nducted in Ivory Coast <sup>40</sup>, although    the IDE-V3 technique had a spe
cificity of 96.3% for HIV recent infections, a    sensitivity of around 40% was 
observed with this method, which would suggest    that differences on HIV-1 subt
ype infections could compromise the accuracy of    this method.</font></p>     ^
cY#02.htm##
00359000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013700069002000700206#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#63#59#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; HIVI/II    confirmatory line immu
noassay</b></font></p>     ^cY#02.htm##
01517000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704129500069002000701364#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#64#60#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">More recently,    the ability of an HIV con
firmatory line immunoassay (INNO-LIA HIVI/II) was tested    to distinguish recen
t from long-term HIV infection <sup>41</sup>. The authors    evaluated the perfo
rmance of various algorithms for detecting recent infections,    based on reacti
vity, and classified them into one of six possible intensity    scores of reacti
on to five HIV antigens measured in the western blot. They analyzed    356 serum
 samples, with well documented recent and long-term infections to define    the 
sensitivity and specificity of the proposed algorithms as compared to the    HIV
-1 BED-CEIA. In general, the specificity of these INNO-LIA algorithms was    abo
ve 90%, and higher than BED-CEIA in the study (80.1%), but the sensitivity,    e
ven after several adjustments, was not satisfactory. According to the authors,  
  recency information could be extracted from INNO-LIA based confirmatory assay 
   at no extra cost. However, in general this confirmatory procedure is not avai
lable    in developing countries due to its high cost. No additional papers usin
g this    approach have been made available so far, making its application to th
e estimation    of HIV incidence still tentative.</font></p>     ^cY#02.htm##
00394000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017200069002000700241#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#65#61#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Application    of serological methods
 to estimate HIV-1 incidence in Brazil</u></b></font></p>     ^cY#02.htm##
03121000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704289900069002000702968#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#66#62#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The above discussed    serological assays d
elineated to detect recent HIV-1 infections have been implemented    in Brazil s
ince the end of the 1990s as new tools to estimate the incidence    rates of HIV
-1 in different scenarios. However, no national data about the incidence    of H
IV-1 infection have so far been made available. The studies were mainly    condu
cted in the Southeastern region of the country and employed the serologic    tes
ting algorithm for detecting recent HIV seroconversion (STARHS), previously    d
enominated sensitive/less sensitive assay. Using this approach, an estimated    
HIV seroincidence of 1.9 (95%CI: 0.9%-3.9%) and 2.8 (95%CI: 1.4%-5.3%) per 100  
  person-years among high-risk heterosexual women and men seen at an HIV testing
    site in Rio de Janeiro in 1998 <sup>42</sup>. A few years later <sup>43</sup
>,    an update of the former analysis found similar results, with an estimated 
HIV    incidence among heterosexual men (1.62%; 95%CI: 0.61-3.52) and women (1.5
%;    95%CI: 0.45-3.69), screened in 2002. However, a higher incidence rate, of 
almost    seven fold, was observed for homosexual men, with a seroincidence of 1
0.89%    (95%CI: 4.28-24.81) <sup>43</sup>. A non-significant increase of recent
 HIV-1    infections (0% <i>vs.</i> 0.8%) was observed among injection drug user
s (IDU)    and ex-IDU <sup>44,45</sup> surveyed in 1994-96 and 1999-2001, in Rio
 de Janeiro.    Similar studies were conducted in Sao Paulo, estimating the inci
dence of HIV-1    infection in inmates <sup>46</sup>, cocaine users <sup>47</sup
>, and among people    seeking HIV diagnosis in voluntary centers for counseling
 and testing from Santos    (S&atilde;o Paulo State) <sup>48</sup> and Sao Paulo
 city <sup>49,50</sup>.    In the former study, sera collected between 1996 and 
1999 in Santos yielded    an overall estimated HIV incidence of 2% (95%CI: 1.1-3
.5), with 1.2% (95%CI:    0.5-2.6) in women and 2.7% (95%CI: 1.3-5.0) in men, qu
ite similar to the results    obtained in a voluntary center for counseling and 
testing in Rio de Janeiro    for the same period <sup>42</sup>. The incidence of
 HIV-1 infection based on    the STARHS has already been assessed in pregnant wo
men from S&atilde;o Paulo    <sup>51</sup>, Rio de Janeiro and Porto Alegre (Rio
 Grande do Sul State). In    the former, a cross-sectional study including sampl
es collected from 1999 to    2002 in S&atilde;o Paulo had an incidence of HIV-1 
infection of 0.2 per 100    pregnant women per year (95%CI: 0.041-0.608). Simila
r results were obtained    by our group for pregnant women from Rio de Janeiro (
0.41%; IC95%: 0.11-0.72),    diagnosed for HIV infection at delivery in the same
 time period, whereas HIV    incidence of 1.93% (IC95%: 0.88-2.97) was observed 
in southern Brazil (Morgado    MG, unpublished data).</font></p>     ^cY#02.htm#
#
00724000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050200069002000700571#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#67#63#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Incidence of HIV-1    infection was also es
timated among blood donors from S&atilde;o Paulo <sup>52</sup>,    Brazil (2.7 p
er 10,000 person-years), in a study comparing first time community    and replac
ement blood donors from 1995 and 2001. Moreover, around 21% of potential    rece
nt infections were detected using BED-CEIA among HIV-1 seropositive discharged  
  blood units from Brazilian blood donors <sup>53</sup>.</font></p>     ^cY#02.h
tm##
01669000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704144700069002000701516#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#68#64#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">More recently,    BED-CEIA has been employe
d in Brazil for estimating HIV incidence and to assess    the molecular characte
rization of newly identified HIV-1 infections in people    seeking HIV diagnosis
 in voluntary centers for counseling and testing in Rio    de Janeiro <sup>54</s
up>, and Curitiba (Paran&aacute; State) <sup>55</sup>,    and in a Public Health
 Laboratory serving communities with high prevalence of    HIV infection in Sant
a Catarina State (Cambori&uacute; and Itaja&iacute;) <sup>56</sup>.    Indeed, a
 preponderance of subtype C was detected among males with recent infection    in
 Curitiba, and the overall incidence in this study was of 2.86 persons/years    
(95%CI: 1.04-4.68). Similar results were obtained for the two Santa Catarina    
cities, that presented an overall incidence estimate of 2.6 persons/year (95%CI:
    &plusmn;0.8) <sup>56</sup>, in a virological scenario where subtype C predom
inates.    Considering the WHO criticisms <sup>30</sup> about the sensitivity an
d specificity    of the BED-CEIA to estimate HIV incidence in epidemiological sc
enarios including    non-B HIV-1 subtypes, in a preliminary study we proposed a 
criterion based on    the matching results of two assays (BED-CEIA and Avidity i
ndex) aiming to improve    the accuracy of these serological approaches to estim
ate HIV incidence rates    <sup>57</sup>.</font></p>     ^cY#02.htm##
00742000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052000069002000700589#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#69#65#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">One major limitation    of most Brazilian s
tudies is secondary to the small sample size (and then large    confidence inter
vals and less accurate estimates), as well as some degree of    heterogeneity in
 some studies, such as the ones carried out by our research    group on both act
ive and former injection drug users (as stated in the original    protocol, from
 WHO, but not necessarily defining a homogeneous sample) <sup>44,45</sup>.</font
></p>     ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#70#66#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00325000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010300069002000700172#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#71#67#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Final remarks</b></font></p>     ^cY#02.
htm##
01185000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704096300069002000701032#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#72#68#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Incidence estimates    by serological assay
s using cross-sectional surveys are very attractive as such    studies are much 
cheaper than longitudinal studies, much simpler to be implemented    and less su
bject to some of the usual bias affecting longitudinal studies. Such    biases c
omprise the decrease of both risk behaviors and seroincidence over time    as a 
consequence of the full implementation of state-of-the-art interventions    aimi
ng to prevent new infections (as mandated by ethical requirements in any    stud
y with human beings) and the loss for follow-up (usually a differential    loss)
, affecting the most vulnerable and/or those most likely to be infected    vis-&
agrave;-vis those who tend to remain in the cohort over time, who are more    li
kely to be concerned with their health and to adopt safer behaviors, as discusse
d    by Harrison et al. <sup>9</sup>.</font></p>     ^cY#02.htm##
01724000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704150200069002000701571#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#73#69#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, several    drawbacks may compromis
e the accuracy of such biomarkers as tools for estimating    HIV incidence in cr
oss-sectional studies. In general, false positive and or    false negative resul
ts have been described for all the available methods, biasing,    in opposite di
rections, the estimates of incidence of the samples under study,    with obvious
 consequences for its extrapolation for the reference population.    Moreover, d
ifferences on HIV-1 subtype infections, low CD4 counts, long term    undetectabl
e viral loads, antiretroviral therapy, total IgG concentration, among    others,
 are also associated to the misclassification of recent infections. Due    to co
ncerns about studies based on the use of BED-CEIA, conducted in scenarios    wit
h high HIV prevalence and/or viral diversity <sup>27</sup>, different adjustment
s    have been proposed aiming to improve its accuracy for HIV estimates. One su
ch    adjustment proposes "<i>the exclusion of certain specimens on clinical gro
unds,    by relying on trend differences rather than absolute incidence estimate
s, by    secondary confirmatory testing, or by analytic adjustments for misclass
ification</i>"    <sup>29</sup> (p. 945) and a second strategy adjusts some para
meters, with "<i>further    estimates of epsilon and of the window period</i>", 
in order to avoid misclassification    of subtype C infected individuals <sup>30
</sup> (p. 511).</font></p>     ^cY#02.htm##
00977000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075500069002000700824#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#74#70#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, based    on the recent literature,
 there is no consensus of whether or not the proposed    adjustments may improve
 the accuracy of HIV incidence estimates. The pioneer    of such strategies from
 the perspective of statistical methods, Ron Brookmeyer,    has recently publish
ed a paper where he discusses at length his position against    the available ad
justments <sup>10</sup>. One must observe, however, that his    position was cri
ticized by three research groups (Hargrove <sup>58</sup>, Welte    et al. <sup>5
9</sup> and McDougal <sup>60</sup>), with a further treplica by    Brookmeyer, w
ho maintained his point of view despite the criticisms <sup>61</sup>.</font></p>
     ^cY#02.htm##
01240000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704101800069002000701087#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#75#71#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">McWalter &amp;    Welte <sup>62</sup> furth
er developed the position outlined in their letter    in response to Brookmeyer'
s paper, and took a firm position in favor of adjustment.    They compared the a
ccuracy of their adjustment strategy with the adjustment    strategies proposed 
by the authors of the other two letters in response to Brookemeyer's    paper (i
.e. Hargrove <sup>58</sup> and McDougal <sup>60</sup>, and their respective    r
esearch teams). The authors conclude that their own strategy is the one which   
 can work under the less restrictive assumptions. One must observe that in spite
    of their position, the authors admit themselves in their final remarks: "<i>
all    the methods make the assumption that survival for assay non-progressors a
nd    assay progressors is the same. As we have shown, relaxing this assumption 
means    that the long-term specificity becomes epidemic state dependent</i>" <s
up>62</sup>.</font></p>     ^cY#02.htm##
01378000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704115600069002000701225#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#76#72#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">From a complementary    perspective, a rece
nt paper by Hallet et al. <sup>63</sup>, simulating scenarios    for the AIDS ep
idemic in six different African countries, highlighted another    caveat putativ
ely associated with the dynamics of each specific epidemic. For    Hallet et al.
 <sup>63</sup> the key question to be urgently evaluated is secondary    to whet
her misclassification based on the use of BED-CEIA may or may not vary    over t
ime elapsed since primary infection. The authors conclude that in the    case of
 a non-stationary misclassification bias (i.e. a bias that may vary over    time
, in this specific case, hypothetically increasing over time), estimates    woul
d be influenced by the different trajectories of specific epidemics in each    g
iven place, as well as by the underlying demographic composition of each affecte
d    population. If such hypothesis proves to be a valid one (i.e. in the case t
hat    bias actually increases over time since primary infection), post-assay ad
justments    will not improve the accuracy of the estimates using BED.</font></p
>     ^cY#02.htm##
01497000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704127500069002000701344#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#77#73#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The association    of more than one biomark
er to improve the estimates of HIV incidence has also    been recently proposed.
 In this sense, a good agreement (90%) between BED-CEIA    and Vironostika S/LS 
methods was obtained for the classification of recent HIV-1    infection <sup>64
</sup>, when compared to repeat testing in a population of    men having sex wit
h men from San Francisco, US. Lower agreement <sup>65</sup>,    however, was obs
erved when Vironostika S/LS and Avidity assays were compared    to identify rece
nt HIV-1 infections among patients entering the Johns Hopkins    Hospital Emerge
ncy Department in 2001 and 2003. All discrepant cases had undetectable    viral 
load, that were identified as recent by the Vironostika S/LS assay but    not wi
th the Avidity assay, indicating that viral suppression affects the performance 
   of cross sectional incidence assays based on antibody titer. Similar results 
   were obtained for four long-term non-progressors/elite controllers from Brazi
l,    who gave results compatible with recent infection based on the competitive
 BED-CEIA    assay, whereas only 2 out of 4 were misclassified when using the av
idity assay    <sup>66</sup>.</font></p>     ^cY#02.htm##
00880000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065800069002000700727#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#78#74#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The application    of four available tests 
(BED-CEIA, Vironostika, Avidity index, and IDE-V3) to    estimate HIV-1 incidenc
e in West Africa, where high prevalence is observed (10%)    in a virological sc
enario of non-subtype B infections, generated very discrepant    results, varyin
g from 1.2% (IDE-V3) to 11.2% (AI) <sup>40</sup>. In this study    they tested a
 panel of samples of known seroconversion dates and assessed misclassification, 
   showing that incident cases were more likely to be observed among patients in
fected    for more than 180, but less than 360 days.</font></p>     ^cY#02.htm##
01455000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704123300069002000701302#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#79#75#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Recently (April    22-24/2009), the World H
ealth Organization convened a meeting in order to standardize    the terminology
 and statistical methods used to adjust (or not adjust) the different    HIV ass
ays. Although consensus was not reached respecting the statistical methods,    a
 brand new terminology was advanced in the sense that "<i>the meaning of 'recent
ly    infected'</i> &#91;would be&#93; <i>defined by the assay itself</i> (...).
 <i>This    removes the need to speak of sensitivity and specificity of the assa
y in the    usual diagnostic sense, as the assay is no longer a proxy for any ot
her condition</i>"    <sup>67</sup> (p. 19). The WHO Working Group suggested to 
standardize the terminology,    beginning with a new, broader definition of the 
very techniques and methods    used in the estimation of recent infection as RIT
A (Recent Infection Testing    Algorithm), defined as follows: "<i>A combination
 of specific laboratory and/or    other methods that is intended to classify ind
ividuals as positive or negative    for the state of 'recent infection', for the
 purposes of estimating HIV incidence</i>"    <sup>67</sup> (p. 7).</font></p>  
   ^cY#02.htm##
02179000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704195700069002000702026#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#80#76#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A brand new development    was recently pro
posed by Karon et al. <sup>68</sup>, in a paper coauthored by    Ron Brookmeyer,
 the leading proponent of the use of back-calculation as a key    tool for estim
ating HIV incidence from reported AIDS cases, a strategy later    compromised by
 the change in surveillance AIDS and the widespread dissemination    of anti-ret
rovirals, in both high-income countries and middle-income countries    such as B
razil and Thailand. As mentioned before, Brookmeyer was also the originator    o
f the methods using biomarkers to estimate HIV incidence in the context of    cr
oss-sectional studies (as discussed at length in a former paper <sup>15</sup>). 
   The new method advanced by Karon et al. <sup>68</sup> profit from both previo
us    insights, and propose a new surveillance strategy to be adopted at the mac
ro-level    (for regions or even countries), "<i>in order to estimate the probab
ility that    an infected person will be detected as recently infected</i>" <sup
>68</sup>    (p. 4617), accounting from the intrinsic variability in terms of hi
s/her testing    behaviors (e.g. testing frequency, the availability of previous
 tests and the    reporting of results to those people). In sum, the method esti
mates "<i>the    number of persons detected as recently infected divided by the 
estimated probability    of detection</i>" <sup>68</sup> (p. 4617). Notwithstand
ing the inventiveness    of this new strategy, old phantoms still haunt it, such
 as the accuracy of the    window periods defined by the different methods/algor
ithms, as discussed by    WHO <sup>67</sup>, and the very availability of inform
ation about biomarkers    at the population level, which could be partially addr
essed by multiple imputations.    It is still precocious to say whether such new
 strategy will be found to be    a valid method in concrete situations.</font></
p>     ^cY#02.htm##
00872000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065000069002000700719#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#81#77#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In sum, methods    aiming to estimate HIV i
ncidence have progressed a lot in recent years, but    are unfortunately still f
ar from optimal, with no consensus among the experts    in terms of a gold stand
ard either respecting the methods themselves or the    best way to adjust (or no
t adjust) them. As observed by the person responsible    for the original statis
tical reasoning informing all such methods, Ron Brookmeyer    <sup>61</sup>, the
re is also no gold standard in the context of longitudinal    studies, which are
 subjected to different but relevant biases.</font></p>     ^cY#02.htm##
00643000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042100069002000700490#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#82#78#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Paraphrasing the    philosopher of science 
Hacking <sup>69</sup> (p. 11), "<i>the taming of chance</i>"    is an essential 
feature of the contemporary world, constituting the "<i>very    stuff of the fun
damental processes of nature and of society</i>". However, the    very attempt o
f taming chance is far from straightforward and simple.</font></p>     ^cY#02.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#83#79#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#84#80#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#02.h
tm##
00600000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037800069002000700447#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#85#81#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">M. G. Morgado and    F. I. Bastos made subs
tantial contributions to the conception and design, acquisition    of data, anal
ysis and interpretation of data; drafting the article or revising    it critical
ly for important intellectual content; and final approval of the    version to b
e published.</font></p>     ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#86#82#article#233#<p>&nbsp;</p>     ^cY#02.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#87#83#article#233#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#02.htm
##
00458000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704022200071002000700293#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#88#84#article#233#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Joint United    Nations Pr
ogramme on HIV/AIDS. 2008 report on the global AIDS epidemic. Geneva:    Joint U
nited Nations Programme on HIV/AIDS; 2008.    ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#89#85#article#233#</font></p>     ^cY#02.htm
##
00605000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704036900071002000700440#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#90#86#article#233#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Bastos FI, Nunn    A, Hack
er MA, Malta M, Szwarcwald CL. AIDS in Brazil: the challenge and the    response
. In: Celentano DD, Beyrer C, editors. Public health aspects of HIV/AIDS    in d
eveloping countries: epidemiology, prevention and care. New York: Springer    In
ternational; 2008. p. 629-54.    ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#91#87#article#233#</font></p>     ^cY#02.htm
##
00446000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704021000071002000700281#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#92#88#article#233#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Hall HI, Song    R, Rhodes
 P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in    the United
 States. JAMA 2008; 300:520-9.    ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#93#89#article#233#</font></p>     ^cY#02.htm
##
00532000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704029600071002000700367#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#94#90#article#233#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. B&auml;tzing-Feigenbaum   
 J, Loschen S, Gohlke-Micknis S, Zimmermann R, Herrmann A, Kamga Wambo O, et    
al. Country-wide HIV incidence study complementing HIV surveillance in Germany. 
   Euro Surveill 2008; 13:pii:18971.    ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#95#91#article#233#</font></p>     ^cY#02.htm
##
00510000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704027400071002000700345#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#96#92#article#233#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Porco TC, Martin    JN, Pa
ge-Shafer KA, Cheng A, Charlebois E, Grant RM, et al. Decline in HIV infectivity
    following the introduction of highly active antiretroviral therapy. AIDS 200
4;    18:81-8.    ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#97#93#article#233#</font></p>     ^cY#02.htm
##
00389000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704015300071002000700224#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#98#94#article#233#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. MACS celebrates    its 25t
h anniversary. AIDS Patient Care STDS 2009; 23:486-7.    ^cY#02.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#99#95#article#233#</font></p>     ^cY#02.htm
##
00507000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704027000072002000700342#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#100#96#article#233#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Tyndall MW,    Craib KJ, 
Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection    on mo
rtality in a cohort of injection drug users. J Acquir Immune Defic Syndr    2001
; 28:351-7.    ^cY#02.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#101#97#article#233#</font></p>     ^cY#02.ht
m##
00531000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704029400072002000700366#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#102#98#article#233#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Nelson KE, Vlahov    D, S
olomon L, Cohn S, Mu&ntilde;oz A. Temporal trends of incident human immunodefici
ency    virus infection in a cohort of injecting drug users in Baltimore, Md. Ar
ch Intern    Med 1995; 155:1305-11.    ^cY#02.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#103#99#article#233#</font></p>     ^cY#02.ht
m##
00524000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704028600073002000700359#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#104#100#article#233#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Harrison L,    Dunn DT, 
Green H, Copas AJ. Modelling the association between patient characteristics    
and the change over time in a disease measure using observational cohort data.  
  Stat Med 2009; 28:3260-75.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#105#101#article#233#</font></p>     ^cY#02.h
tm##
00409000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017000074002000700244#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#106#102#article#233#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Brookmeyer    R. Shoul
d biomarker estimates of HIV incidence be adjusted? AIDS 2009; 23:485-91.    ^cY
#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#107#103#article#233#</font></p>     ^cY#02.h
tm##
00598000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035900074002000700433#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#108#104#article#233#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Busch MP, Lee    LL, S
atten GA, Henrard DR, Farzadegan H, Nelson KE, et al. Time course of detection  
  of viral and serologic markers preceding human immunodeficiency virus type 1  
  seroconversion: implications for screening of blood and tissue donors. Transfu
sion    1995; 35:91-7.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#109#105#article#233#</font></p>     ^cY#02.h
tm##
00561000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032200074002000700396#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#110#106#article#233#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Busch MP, Glynn    SA,
 Stramer SL, Strong DM, Caglioti S, Wright DJ, et al. A new strategy for    esti
mating risks of transfusion-transmitted viral infections based on rates    of de
tection of recently infected donors. Transfusion 2005; 45:254-64.    ^cY#02.htm#
#
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#111#107#article#233#</font></p>     ^cY#02.h
tm##
00506000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026700074002000700341#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#112#108#article#233#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Brookmeyer    R, Quinn
 TC. Estimation of current human immunodeficiency virus incidence rates    from 
a cross-sectional survey using early diagnostic tests. Am J Epidemiol 1995;    1
41:166-72.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#113#109#article#233#</font></p>     ^cY#02.h
tm##
00395000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015600074002000700230#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#114#110#article#233#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Miettinen OS.    Theor
etical epidemiology. New York: John Wiley &amp; Sons; 1985.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#115#111#article#233#</font></p>     ^cY#02.h
tm##
00464000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022500074002000700299#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#116#112#article#233#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Bastos FI.    "Get bac
k to where you once belonged": monitoring the AIDS pandemic in the 21st    centu
ry. Cien Sa&uacute;de Coletiva 2008; 13:1719-27.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#117#113#article#233#</font></p>     ^cY#02.h
tm##
00446000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020700074002000700281#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#118#114#article#233#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Parekh BS,    McDougal
 JS. Application of laboratory methods for estimation of HIV-1 incidence.    Ind
ian J Med Res 2005; 121:510-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#119#115#article#233#</font></p>     ^cY#02.h
tm##
00461000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022200074002000700296#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#120#116#article#233#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Murphy G, Parry    JV.
 Assays for the detection of recent infections with human immunodeficiency    vi
rus type 1. Euro Surveill 2008; 13:pii:18966.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#121#117#article#233#</font></p>     ^cY#02.h
tm##
00545000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030600074002000700380#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#122#118#article#233#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Janssen RS,    Satten 
GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing    strategy
 to detect early HIV-1 infection for use in incidence estimates and    for clini
cal and prevention purposes. JAMA 1998; 280:42-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#123#119#article#233#</font></p>     ^cY#02.h
tm##
00627000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704038800074002000700462#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#124#120#article#233#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Parekh BS,    Hu DJ, V
anichseni S, Satten GA, Candal D, Young NL, et al. Evaluation of a sensitive/les
s-sensitive    testing algorithm using the 3A11-LS assay for detecting recent HI
V seroconversion    among individuals with HIV-1 subtype B or E infection in Tha
iland. AIDS Res    Hum Retroviruses 2001; 17:453-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#125#121#article#233#</font></p>     ^cY#02.h
tm##
00608000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036900074002000700443#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#126#122#article#233#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Young CL, Hu    DJ, By
ers R, Vanichseni S, Young NL, Nelson R, et al. Evaluation of a sensitive/less  
  sensitive testing algorithm using the bioM&eacute;rieux Vironostika-LS assay  
  for detecting recent HIV-1 subtype B' or E infection in Thailand. AIDS Res Hum
    Retroviruses 2003; 19:481-6.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#127#123#article#233#</font></p>     ^cY#02.h
tm##
00591000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035200074002000700426#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#128#124#article#233#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Parekh BS,    Kennedy 
MS, Dobbs T, Pau CP, Byers R, Green T, et al. Quantitative detection    of incre
asing HIV type 1 antibodies after seroconversion: a simple assay for    detectin
g recent HIV infection and estimating incidence. AIDS Res Hum Retroviruses    20
02; 18:295-307.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#129#125#article#233#</font></p>     ^cY#02.h
tm##
00617000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037800074002000700452#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#130#126#article#233#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Hu DJ, Vanichseni    S
, Mock PA, Young NL, Dobbs T, Byers Jr. RH, et al. HIV type 1 incidence estimate
s    by detection of recent infection from a cross-sectional sampling of injecti
on    drug users in Bangkok: use of the IgG capture BED enzyme immunoassay. AIDS
 Res    Hum Retroviruses 2003; 19:727-30.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#131#127#article#233#</font></p>     ^cY#02.h
tm##
00572000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033300074002000700407#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#132#128#article#233#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Nesheim S,    Parekh B
, Sullivan K, Bulterys M, Dobbs T, Lindsay M, et al. Temporal trends    in HIV t
ype 1 incidence among inner-city childbearing women in Atlanta: use    of the Ig
G-capture BED-enzyme immunoassay. AIDS Res Hum Retroviruses 2005; 21:537-44.    
^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#133#129#article#233#</font></p>     ^cY#02.h
tm##
00537000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029800074002000700372#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#134#130#article#233#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Wolday D, Meles    H, 
Hailu E, Messele T, Mengistu Y, Fekadu M, et al. Temporal trends in the incidenc
e    of HIV infection in antenatal clinic attendees in Addis Ababa, Ethiopia, 19
95-2003.    J Intern Med 2007; 261:132-7.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#135#131#article#233#</font></p>     ^cY#02.h
tm##
00543000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030400074002000700378#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#136#132#article#233#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Priddy FH,    Pilcher 
CD, Moore RH, Tambe P, Park MN, Fiscus SA, et al. Detection of acute    HIV infe
ctions in an urban HIV counseling and testing population in the United    States
. J Acquir Immune Defic Syndr 2007; 44:196-202.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#137#133#article#233#</font></p>     ^cY#02.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#138#134#article#233#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Mermin J, Musinguzi   
 J, Opio A, Kirungi W, Ekwaru JP, Hladik W, et al. Risk factors for recent HIV  
  infection in Uganda. JAMA 2008; 300:540-9.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#139#135#article#233#</font></p>     ^cY#02.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#140#136#article#233#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. UNAIDS Reference    Gr
oup on estimates, modelling and projections - statement on the use of the    BED
 assay for the estimation of HIV-1 incidence for surveillance or epidemic    mon
itoring. Wkly Epidemiol Rec 2006; 81:40.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#141#137#article#233#</font></p>     ^cY#02.h
tm##
00551000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031200074002000700386#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#142#138#article#233#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Karita E, Price    M, 
Hunter E, Chomba E, Allen S, Fei L, et al. Investigating the utility of the    H
IV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal    se
roconverter specimens from Africa. AIDS 2007; 21:403-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#143#139#article#233#</font></p>     ^cY#02.h
tm##
00612000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037300074002000700447#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#144#140#article#233#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. McDougal JS,    Parekh
 BS, Peterson ML, Branson BM, Dobbs T, Ackers M, et al. Comparison of    HIV typ
e 1 incidence observed during longitudinal follow-up with incidence estimated   
 by cross-sectional analysis using the BED capture enzyme immunoassay. AIDS Res 
   Hum Retroviruses 2006; 22:945-52.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#145#141#article#233#</font></p>     ^cY#02.h
tm##
00495000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025600074002000700330#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#146#142#article#233#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Hargrove JW,    Humphr
ey JH, Mutasa K, Parekh BS, McDougal JS, Ntozini R, et al. Improved HIV-1    inc
idence estimates using the BED capture enzyme immunoassay. AIDS 2008; 22:511-8. 
   ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#147#143#article#233#</font></p>     ^cY#02.h
tm##
00530000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029100074002000700365#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#148#144#article#233#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Le Guillou    H, Le Me
ur A, Bourdon S, Riou M, Loison J, Fialaire P, et al. Avidit&eacute;    des anti
corps: application au diagnostic d'infection r&eacute;cente &agrave;    VIH1. An
n Biol Clin (Paris) 2001; 59:41-7.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#149#145#article#233#</font></p>     ^cY#02.h
tm##
00614000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037500074002000700449#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#150#146#article#233#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Suligoi B,    Galli C,
 Massi M, Di Sora F, Sciandra M, Pezzotti P, et al. Precision and accuracy    of
 a procedure for detecting recent human immunodeficiency virus infections    by 
calculating the antibody avidity index by an automated immunoassay-based    meth
od. J Clin Microbiol 2002; 40:4015-20.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#151#147#article#233#</font></p>     ^cY#02.h
tm##
00532000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029300074002000700367#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#152#148#article#233#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Suligoi B,    Massi M,
 Galli C, Sciandra M, Di Sora F, Pezzotti P, et al. Identifying recent    HIV in
fections using the avidity index and an automated enzyme immunoassay.    J Acqui
r Immune Defic Syndr 2003; 32:424-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#153#149#article#233#</font></p>     ^cY#02.h
tm##
00615000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037600074002000700450#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#154#150#article#233#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Chawla A, Murphy    G,
 Donnelly C, Booth CL, Johnson M, Parry JV, et al. Human immunodeficiency    vir
us (HIV) antibody avidity testing to identify recent infection in newly diagnose
d    HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtype
s.    J Clin Microbiol 2007; 45:415-20.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#155#151#article#233#</font></p>     ^cY#02.h
tm##
00601000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036200074002000700436#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#156#152#article#233#35#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Gupta SB, Murphy    G,
 Koenig E, Adon C, Beyrer C, Celentano D, et al. Comparison of methods to    det
ect recent HIV type 1 infection in cross-sectionally collected specimens    from
 a cohort of female sex workers in the Dominican Republic. AIDS Res Hum    Retro
viruses 2007; 23:1475-80.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#157#153#article#233#</font></p>     ^cY#02.h
tm##
00551000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031200074002000700386#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#158#154#article#233#36#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Suligoi B,    Butt&ogr
ave; S, Galli C, Bernasconi D, Salata RA, Tavoschi L, et al. Detection    of rec
ent HIV infections in African individuals infected by HIV-1 non-B subtypes    us
ing HIV antibody avidity. J Clin Virol 2008; 41:288-92.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#159#155#article#233#</font></p>     ^cY#02.h
tm##
00534000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029500074002000700369#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#160#156#article#233#37#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Wilson KM,    Johnson 
EI, Croom HA, Richards KM, Doughty L, Cunningham PH, et al. Incidence    immunoa
ssay for distinguishing recent from established HIV-1 infection in therapy-naive
    populations. AIDS 2004; 18:2253-9.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#161#157#article#233#</font></p>     ^cY#02.h
tm##
00577000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033800074002000700412#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#162#158#article#233#38#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Barin F, Meyer    L, L
ancar R, Deveau C, Gharib M, Laporte A, et al. Development and validation    of 
an immunoassay for identification of recent human immunodeficiency virus    type
 1 infections and its use on dried serum spots. J Clin Microbiol 2005; 43:4441-7
.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#163#159#article#233#</font></p>     ^cY#02.h
tm##
00547000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030800074002000700382#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#164#160#article#233#39#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Semaille C,    Cazein 
F, Pillonel J, Lot F, Le Vu S, Pinget R, et al. Four years of surveillance    of
 recent HIV infections at country level, France, mid 2003 - 2006: experience    
and perspectives. Euro Surveill 2008; 13:pii:18968.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#165#161#article#233#</font></p>     ^cY#02.h
tm##
00538000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029900074002000700373#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#166#162#article#233#40#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Sakarovitch    C, Roue
t F, Murphy G, Minga AK, Alioum A, Dabis F, et al. Do tests devised to    detect
 recent HIV-1 infection provide reliable estimates of incidence in Africa?    J 
Acquir Immune Defic Syndr 2007; 45:115-22.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#167#163#article#233#</font></p>     ^cY#02.h
tm##
00522000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028300074002000700357#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#168#164#article#233#41#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Sch&uuml;pbach    J, G
ebhardt MD, Tomasik Z, Niederhauser C, Yerly S, B&uuml;rgisser P, et al.    Asse
ssment of recent HIV-1 infection by a line immunoassay for HIV-1/2 confirmation.
    PLoS Med 2007; 4:e343.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#169#165#article#233#</font></p>     ^cY#02.h
tm##
00599000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036000074002000700434#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#170#166#article#233#42#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Schechter M,    Lago R
F, Melo MF, Sheppard HW, Guimar&atilde;es NC, Moreira RI, et al. Identification 
   of a high-risk heterosexual population for HIV prevention trials in Rio de Ja
neiro,    Brazil. Projeto Pra&ccedil;a Onze Study Group. J Acquir Immune Defic S
yndr 2000;    24:175-7.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#171#167#article#233#</font></p>     ^cY#02.h
tm##
00630000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704039100074002000700465#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#172#168#article#233#43#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Barroso PF,    Harriso
n LH, F&aacute;tima-Melo M, Batista SM, Silva-Bastos M, Rosa-Faulhaber    JC, et
 al. Identification of a high-risk heterosexual cohort for HIV vaccine    effica
cy trials in Rio de Janeiro, Brazil, using a sensitive/less-sensitive    assay: 
an update. J Acquir Immune Defic Syndr 2004; 36:880-1.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#173#169#article#233#</font></p>     ^cY#02.h
tm##
00603000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036400074002000700438#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#174#170#article#233#44#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Guimar&atilde;es    ML
, Bastos FI, Telles PR, Galv&atilde;o-Castro B, Diaz RS, Bongertz V, et al.    R
etrovirus infections in a sample of injecting drug users in Rio de Janeiro    Ci
ty, Brazil: prevalence of HIV-1 subtypes, and co-infection with HTLV-I/II.    J 
Clin Virol 2001; 21:143-51.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#175#171#article#233#</font></p>     ^cY#02.h
tm##
00574000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033500074002000700409#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#176#172#article#233#45#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Teixeira SL,    Bastos
 FI, Telles PR, Hacker MA, Brigido LF, Oliveira CAF, et al. HIV-1 infection    a
mong injection and ex-injection drug users from Rio de Janeiro, Brazil: prevalen
ce,    estimated incidence and genetic diversity. J Clin Virol 2004; 31:221-6.  
  ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#177#173#article#233#</font></p>     ^cY#02.h
tm##
00575000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033600074002000700410#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#178#174#article#233#46#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Diaz RS, Kallas    EG,
 Castelo A, Rawal BD, Busch MP. Use of a new 'less-sensitive enzyme immunoassay'
    testing strategy to identify recently infected persons in a Brazilian prison
:    estimation of incidence and epidemiological tracing. AIDS 1999; 13:1417-8. 
   ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#179#175#article#233#</font></p>     ^cY#02.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#180#176#article#233#47#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Turchi MD,    Diaz RS,
 Martelli CM, Sabino EC, Silva WP, Filho OF, et al. Genetic diversity    and HIV
-1 incidence estimation among cocaine users in S&atilde;o Paulo, Brazil.    J Ac
quir Immune Defic Syndr 2002; 30:527-32.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#181#177#article#233#</font></p>     ^cY#02.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#182#178#article#233#48#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Alves K, Shafer    KP,
 Caseiro M, Rutherford G, Falcao ME, Sucupira MC, et al. Risk factors for    inc
ident HIV infection among anonymous HIV testing site clients in Santos, Brazil: 
   1996-1999. J Acquir Immune Defic Syndr 2003; 32:551-9.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#183#179#article#233#</font></p>     ^cY#02.h
tm##
00614000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037500074002000700449#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#184#180#article#233#49#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Kallas EG,    Bassiche
tto KC, Oliveira SM, Goldenberg I, Bortoloto R, Moreno DM, et al. Establishment 
   of the serologic testing algorithm for recent human immunodeficiency virus (H
IV)    seroconversion (STARHS) strategy in the city of S&atilde;o Paulo, Brazil.
 Braz    J Infect Dis 2004; 8:399-406.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#185#181#article#233#</font></p>     ^cY#02.h
tm##
00605000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036600074002000700440#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#186#182#article#233#50#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Bassichetto    KC, Ber
gamaschi DP, Veras MA, Sucupira MC, Mesquita F, Diaz RS. Estimating HIV-1    inc
idence using the serologic testing algorithm for recent HIV infections at    HIV
 counseling and testing centers in the city of S&atilde;o Paulo, Brazil.    Braz
 J Infect Dis. 2009; 13:9-12.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#187#183#article#233#</font></p>     ^cY#02.h
tm##
00609000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037000074002000700444#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#188#184#article#233#51#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Freitas-Oliveira    CA
, Ueda M, Yamashiro R, Rodrigues R, Sheppard HW, Macedo-Br&iacute;gido LF.    Ra
te and incidence estimates of recent human immunodeficiency virus type 1 infecti
ons    among pregnant women in S&atilde;o Paulo, Brazil, from 1991 to 2002. J Cl
in    Microbiol 2005; 43:1439-42.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#189#185#article#233#</font></p>     ^cY#02.h
tm##
00601000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036200074002000700436#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#190#186#article#233#52#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Barreto CC,    Sabino 
EC, Gon&ccedil;alez TT, Laycock ME, Pappalardo BL, Salles NA, et al.    Prevalen
ce, incidence, and residual risk of human immunodeficiency virus among    commun
ity and replacement first-time blood donors in S&atilde;o Paulo, Brazil.    Tran
sfusion 2005; 45:1709-14.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#191#187#article#233#</font></p>     ^cY#02.h
tm##
00561000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032200074002000700396#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#192#188#article#233#53#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">53. S&aacute;-Ferreira    
JA, Brindeiro PA, Chequer-Fernandez S, Tanuri A, Morgado MG. Human immunodeficie
ncy    virus-1 subtypes and antiretroviral drug resistance profiles among drug-n
a&iuml;ve    Brazilian blood donors. Transfusion 2007; 47:97-102.    ^cY#02.htm#
#
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#193#189#article#233#</font></p>     ^cY#02.h
tm##
00573000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033400074002000700408#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#194#190#article#233#54#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">54. de Castro CA,    Grins
ztejn B, Veloso VG, Bastos FI, Pilotto JH, Morgado MG. Prevalence, estimated    
HIV-1 incidence and viral diversity among people seeking voluntary counseling   
 and testing services in Rio de Janeiro, Brasil. BMC Infect Dis 2010; 10:224.   
 ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#195#191#article#233#</font></p>     ^cY#02.h
tm##
00586000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704034700074002000700421#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#196#192#article#233#55#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">55. Ferreira JL,    Thomaz
 M, Rodrigues R, Harrad D, Oliveira CM, Oliveira CA, et al. Molecular    charact
erization of newly identified HIV-1 infections in Curitiba, Brazil: preponderanc
e    of clade C among males with recent infections. Mem Inst Oswaldo Cruz 2008; 
103:800-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#197#193#article#233#</font></p>     ^cY#02.h
tm##
00566000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032700074002000700401#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#198#194#article#233#56#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">56. Br&iacute;gido    LF, 
Nunes CC, Oliveira CM, Knoll RK, Ferreira JL, Freitas CA, et al. HIV type    1 s
ubtype C and CB Pol recombinants prevail at the cities with the highest AIDS    
prevalence rate in Brazil. AIDS Res Hum Retroviruses 2007; 23:1579-86.    ^cY#02
.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#199#195#article#233#</font></p>     ^cY#02.h
tm##
00598000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035900074002000700433#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#200#196#article#233#57#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">57. Velasco-de-Castro    C
A, Grinsztejn B, Veloso V, Bastos F, Pilotto J, Morgado M. Serological approache
s    to access recent HIV-1 seroconvertion: proposal of criterion to improve the
    predictive values in BEDCEIA and Avidity Index Assay. AIDS Res Hum Retrov 20
08;    24 Suppl 1:S36.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#201#197#article#233#</font></p>     ^cY#02.h
tm##
00400000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704016100074002000700235#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#202#198#article#233#58#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">58. Hargrove JW.    BED es
timates of HIV incidence must be adjusted. AIDS 2009; 23:2061-2.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#203#199#article#233#</font></p>     ^cY#02.h
tm##
00453000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021400074002000700288#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#204#200#article#233#59#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">59. Welte A, McWalter    T
A, B&auml;rnighausen T. Reply to 'Should biomarker estimates of HIV incidence   
 be adjusted?'. AIDS 2009; 23:2062-3.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#205#201#article#233#</font></p>     ^cY#02.h
tm##
00400000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704016100074002000700235#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#206#202#article#233#60#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">60. McDougal JS.    BED es
timates of HIV incidence must be adjusted. AIDS 2009; 23:2064-5.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#207#203#article#233#</font></p>     ^cY#02.h
tm##
00445000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020600074002000700280#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#208#204#article#233#61#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">61. Brookmeyer    R. Respo
nse to correspondence on 'Should Biomarker Estimates of HIV Incidence    be Adju
sted?'. AIDS 2009; 23:2066-8.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#209#205#article#233#</font></p>     ^cY#02.h
tm##
00419000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018000074002000700254#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#210#206#article#233#62#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">62. McWalter TA,    Welte 
A. A comparison of biomarker based incidence estimators. PLoS One 2009;    4:e73
68.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#211#207#article#233#</font></p>     ^cY#02.h
tm##
00488000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024900074002000700323#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#212#208#article#233#63#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">63. Hallett TB,    Ghys P,
 B&auml;rnighausen T, Yan P, Garnett GP. Errors in 'BED'-derived estimates    of
 HIV incidence will vary by place, time and age. PLoS One 2009; 4:e5720.    ^cY#
02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#213#209#article#233#</font></p>     ^cY#02.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#214#210#article#233#64#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">64. Truong HH,    Kellogg 
T, Louie B, Klausner J, Dilley J, McFarland W. Recent HIV-1infection    detectio
n: comparison of incidence estimates derived by laboratory assays and    repeat 
testing data. J Acquir Immune Defic Syndr 2009; 51:502-5.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#215#211#article#233#</font></p>     ^cY#02.h
tm##
00568000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032900074002000700403#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#216#212#article#233#65#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">65. Laeyendecker    O, Rot
hman RE, Henson C, Horne BJ, Ketlogetswe KS, Kraus CK, et al. The effect    of v
iral suppression on cross-sectional incidence testing in the Johns Hopkins    ho
spital emergency department. J Acquir Immune Defic Syndr 2008; 48:211-5.    ^cY#
02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#217#213#article#233#</font></p>     ^cY#02.h
tm##
00556000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031700074002000700391#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#218#214#article#233#66#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">66. Bello G, Velasco-de-Ca
stro    CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, et al. Immun
e activation    and antibody responses in non-progressing elite controller indiv
iduals infected    with HIV-1. J Med Virol 2009; 81:1681-90.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#219#215#article#233#</font></p>     ^cY#02.h
tm##
00680000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704044100074002000700515#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#220#216#article#233#67#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">67. World Health    Organi
zation. Report of the WHO working group on statistical approaches for    develop
ment, validation and use of HIV incidence assays. <a href="http://www.who.int/di
agnostics_laboratory/links/hiviwg_geneva_04_09_report.pdf" target="_blank">http:
//www.who.int/diagnostics_laboratory/links/hiviwg_geneva_04_09_report.pdf</a>   
 (accessed on Apr/2009).    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#221#217#article#233#</font></p>     ^cY#02.h
tm##
00511000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027200074002000700346#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#222#218#article#233#68#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">68. Karon JM, Song    R, B
rookmeyer R, Kaplan EH, Hall HI. Estimating HIV incidence in the United    State
s from HIV/AIDS surveillance data and biomarker HIV test results. Stat    Med 20
08; 27:4617-33.    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#223#219#article#233#</font></p>     ^cY#02.h
tm##
00416000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017700074002000700251#v27
s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#p#224#220#article#233#69#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">69. Hacking I.    The tami
ng of chance (ideas in context). Cambridge: Cambridge University Press;    1990.
    ^cY#02.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#225#221#article#233#</font></p>     ^cY#02.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#226#222#article#233#<p>&nbsp;</p>     ^cY#02
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#227#223#article#233#<p>&nbsp;</p>     ^cY#02
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#228#224#article#233#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#02.htm##
00257000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003300071002000700104#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#229#225#article#233#<br>   </b> M. G. Morgad
o    ^cY#02.htm##
00261000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003700071002000700108#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#230#226#article#233#<br>   Instituto Oswaldo
 Cruz    ^cY#02.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#231#227#article#233#<br>   Funda&ccedil;&ati
lde;o Oswaldo Cruz    ^cY#02.htm##
00254000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003000071002000700101#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#232#228#article#233#<br>   Av. Brasil 4365  
  ^cY#02.htm##
00275000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005100071002000700122#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#233#229#article#233#<br>   Rio de Janeiro, R
J 21045-900, Brasil    ^cY#02.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#234#230#article#233#<br>   <a href="mailto:m
morgado@ioc.fiocruz.br">mmorgado@ioc.fiocruz.br</a></font></p>     ^cY#02.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#235#231#article#233#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 13/Nov/2009    ^cY#02.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#236#232#article#233#<br>   Final version res
ubmitted on 22/Feb/2010    ^cY#02.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\02.htm#S#p#237#233#article#233#<br>   Approved on 12/Ma
r/2010</font></p>     ^cY#02.htm##
00467000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170043000700180044001130660
00700157062004300164065000900207064000500216865000900221002000700230#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\02.htm#S#c#238#1#article#69#1#Joint United Nations 
Programme on HIV/AIDS#2008 report on the global AIDS epidemic^len#Geneva#Joint U
nited Nations Programme on HIV/AIDS#20080000#2008#20110000#02.htm##
00733000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100014000870100
01700101010001500118010002100133012005100154016002000205016001600225018009700241
06600090033806200230034706500090037006400050037901400070038486500090039100200070
0400#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#239#2#article#69#2#^rND^
sBastos^nFI#^rND^sNunn^nA#^rND^sHacker^nMA#^rND^sMalta^nM#^rND^sSzwarcwald^nCL#A
IDS in Brazil: the challenge and the response^len#^rED^sCelentano^nDD#^rED^sBeyr
er^nC#Public health aspects of HIV/AIDS in developing countries: epidemiology, p
revention and care^len#New York#Springer International#20080000#2008#629-54#2011
0000#02.htm##
00615000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100014000850100
01600099010001700115010001200132010001400144810000600158012005300164030000500217
06500090022206400050023103100040023601400060024086500090024600200070025503500100
0262801000500272#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#240#3#articl
e#69#3#^rND^sHall^nHI#^rND^sSong^nR#^rND^sRhodes^nP#^rND^sPrejean^nJ#^rND^sAn^nQ
#^rND^sLee^nLM#et al#Estimation of HIV incidence in the United States^len#JAMA#2
0080000#2008#300#520-9#20110000#02.htm#0098-7484#JAMA##
00668000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100028000700100017000980100
02400115010002000139010001800159010002100177810000600198012007900204030001400283
71000020029706500090029906400050030803100030031301400100031686500090032600200070
0335#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#241#4#article#69#4#^rND^
sBätzing-Feigenbaum^nJ#^rND^sLoschen^nS#^rND^sGohlke-Micknis^nS#^rND^sZimmermann
^nR#^rND^sHerrmann^nA#^rND^sKamga Wambo^nO#et al#Country-wide HIV incidence stud
y complementing HIV surveillance in Germany^len#Euro Surveill#2#20080000#2008#13
#pii:18971#20110000#02.htm##
00676000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100017000860100
02200103010001500125010002000140010001600160810000600176012009800182030000500280
06500090028506400050029403100030029901400050030286500090030700200070031603500100
0323801000500333#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#242#5#articl
e#69#5#^rND^sPorco^nTC#^rND^sMartin^nJN#^rND^sPage-Shafer^nKA#^rND^sCheng^nA#^rN
D^sCharlebois^nE#^rND^sGrant^nRM#et al#Decline in HIV infectivity following the 
introduction of highly active antiretroviral therapy^len#AIDS#20040000#2004#18#8
1-8#20110000#02.htm#0269-9370#AIDS##
00460000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680120041000700300023001110650
00900134064000500143031000300148014000600151865000900157002000700166035001000173
801002300183#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#243#6#article#69
#6#MACS celebrates its 25th anniversary^len#AIDS Patient Care STDS#20090000#2009
#23#486-7#20110000#02.htm#1087-2914#Aids Patient Care STDS##
00684000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100016000880100
01600104010001200120010002400132010002000156012007700176030002800253065000900281
06400050029003100030029501400060029886500090030400200070031303500100032080100280
0330#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#244#7#article#69#7#^rND^
sTyndall^nMW#^rND^sCraib^nKJ#^rND^sCurrie^nS#^rND^sLi^nK#^rND^sO'Shaughnessy^nMV
#^rND^sSchechter^nMT#Impact of HIV infection on mortality in a cohort of injecti
on drug users^len#J Acquir Immune Defic Syndr#20010000#2001#28#351-7#20110000#02
.htm#0894-9255#J Acquir Immune Defic Syndr##
00671000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870100
01700103010001400120010001500134012012400149030001600273065000900289064000500298
031000400303014000800307865000900315002000700324035001000331801001600341#v27s1#V
:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#245#8#article#69#8#^rND^sNelson^nKE#
^rND^sVlahov^nD#^rND^sSolomon^nL#^rND^sCohn^nS#^rND^sMuñoz^nA#Temporal trends of
 incident human immunodeficiency virus infection in a cohort of injecting drug u
sers in Baltimore, Md^len#Arch Intern Med#19950000#1995#155#1305-11#20110000#02.
htm#0003-9926#Arch Intern Med##
00645000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100015000880100
01500103010001600118012014000134030000900274065000900283064000500292031000300297
014000800300865000900308002000700317035001000324801000900334#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\02.htm#S#c#246#9#article#69#9#^rND^sHarrison^nL#^rND^sDunn^
nDT#^rND^sGreen^nH#^rND^sCopas^nAJ#Modelling the association between patient cha
racteristics and the change over time in a disease measure using observational c
ohort data^len#Stat Med#20090000#2009#28#3260-75#20110000#02.htm#0277-6715#Stat 
Med##
00479000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720120061000920300
00500153065000900158064000500167031000300172014000700175865000900182002000700191
035001000198801000500208#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#247#
10#article#69#10#^rND^sBrookmeyer^nR#Should biomarker estimates of HIV incidence
 be adjusted?^len#AIDS#20090000#2009#23#485-91#20110000#02.htm#0269-9370#AIDS##
00766000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100014000880100
01700102010001800119010002000137010001700157810000600174012017600180030001200356
06500090036806400050037703100030038201400050038586500090039000200070039903500100
0406801001200416#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#248#11#artic
le#69#11#^rND^sBusch^nMP#^rND^sLee^nLL#^rND^sSatten^nGA#^rND^sHenrard^nDR#^rND^s
Farzadegan^nH#^rND^sNelson^nKE#et al#Time course of detection of viral and serol
ogic markers preceding human immunodeficiency virus type 1 seroconversion: impli
cations for screening of blood and tissue donors^len#Transfusion#19950000#1995#3
5#91-7#20110000#02.htm#0041-1132#Transfusion##
00732000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01800104010001700122010001800139010001700157810000600174012014000180030001200320
06500090033206400050034103100030034601400070034986500090035600200070036503500100
0372801001200382#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#249#12#artic
le#69#12#^rND^sBusch^nMP#^rND^sGlynn^nSA#^rND^sStramer^nSL#^rND^sStrong^nDM#^rND
^sCaglioti^nS#^rND^sWright^nDJ#et al#A new strategy for estimating risks of tran
sfusion-transmitted viral infections based on rates of detection of recently inf
ected donors^len#Transfusion#20050000#2005#45#254-64#20110000#02.htm#0041-1132#T
ransfusion##
00597000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100016000920120
13000108030001500238065000900253064000500262031000400267014000700271865000900278
002000700287035001000294801001500304#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.
htm#S#c#250#13#article#69#13#^rND^sBrookmeyer^nR#^rND^sQuinn^nTC#Estimation of c
urrent human immunodeficiency virus incidence rates from a cross-sectional surve
y using early diagnostic tests^len#Am J Epidemiol#19950000#1995#141#166-72#20110
000#02.htm#0002-9262#Am J Epidemiol##
00408000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160020000720180029000920660
00900121062001800130065000900148064000500157865000900162002000700171#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\02.htm#S#c#251#14#article#69#14#^rND^sMiettinen^nOS
#Theoretical epidemiology^len#New York#John Wiley & Sons#19850000#1985#20110000#
02.htm##
00498000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720120092000890300
02000181710000200201065000900203064000500212031000300217014000800220865000900228
002000700237#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#252#15#article#6
9#15#^rND^sBastos^nFI#"Get back to where you once belonged": monitoring the AIDS
 pandemic in the 21st century^len#Cien Saúde Coletiva#2#20080000#2008#13#1719-27
#20110000#02.htm##
00542000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100019000890120
07200108030001700180065000900197064000500206031000400211014000600215865000900221
002000700230035001000237801001700247#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.
htm#S#c#253#16#article#69#16#^rND^sParekh^nBS#^rND^sMcDougal^nJS#Application of 
laboratory methods for estimation of HIV-1 incidence^len#Indian J Med Res#200500
00#2005#121#510-8#20110000#02.htm#0971-5916#Indian J Med Res##
00520000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880120
09100104030001400195710000200209065000900211064000500220031000300225014001000228
865000900238002000700247#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#254#
17#article#69#17#^rND^sMurphy^nG#^rND^sParry^nJV#Assays for the detection of rec
ent infections with human immunodeficiency virus type 1^len#Euro Surveill#2#2008
0000#2008#13#pii:18966#20110000#02.htm##
00709000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01800107010001600125010001800141010001800159810000600177012012900183030000500312
06500090031706400050032603100040033101400050033586500090034000200070034903500100
0356801000500366#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#255#18#artic
le#69#18#^rND^sJanssen^nRS#^rND^sSatten^nGA#^rND^sStramer^nSL#^rND^sRawal^nBD#^r
ND^sO'Brien^nTR#^rND^sWeiblen^nBJ#et al#New testing strategy to detect early HIV
-1 infection for use in incidence estimates and for clinical and prevention purp
oses^len#JAMA#19980000#1998#280#42-8#20110000#02.htm#0098-7484#JAMA##
00809000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100013000890100
02000102010001700122010001600139010001600155810000600171012019300177030002600370
06500090039606400050040503100030041001400060041386500090041900200070042803500100
0435801002600445#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#256#19#artic
le#69#19#^rND^sParekh^nBS#^rND^sHu^nDJ#^rND^sVanichseni^nS#^rND^sSatten^nGA#^rND
^sCandal^nD#^rND^sYoung^nNL#et al#Evaluation of a sensitive/less-sensitive testi
ng algorithm using the 3A11-LS assay for detecting recent HIV seroconversion amo
ng individuals with HIV-1 subtype B or E infection in Thailand^len#AIDS Res Hum 
Retroviruses#20010000#2001#17#453-8#20110000#02.htm#0889-2229#AIDS Res Hum Retro
viruses##
00783000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100013000880100
01500101010002000116010001600136010001600152810000600168012017000174030002600344
06500090037006400050037903100030038401400060038786500090039300200070040203500100
0409801002600419#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#257#20#artic
le#69#20#^rND^sYoung^nCL#^rND^sHu^nDJ#^rND^sByers^nR#^rND^sVanichseni^nS#^rND^sY
oung^nNL#^rND^sNelson^nR#et al#Evaluation of a sensitive/less sensitive testing 
algorithm using the bioMérieux Vironostika-LS assay for detecting recent HIV-1 s
ubtype B' or E infection in Thailand^len#AIDS Res Hum Retroviruses#20030000#2003
#19#481-6#20110000#02.htm#0889-2229#AIDS Res Hum Retroviruses##
00773000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01500107010001400122010001500136010001500151810000600166012016000172030002600332
06500090035806400050036703100030037201400080037586500090038300200070039203500100
0399801002600409#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#258#21#artic
le#69#21#^rND^sParekh^nBS#^rND^sKennedy^nMS#^rND^sDobbs^nT#^rND^sPau^nCP#^rND^sB
yers^nR#^rND^sGreen^nT#et al#Quantitative detection of increasing HIV type 1 ant
ibodies after seroconversion: a simple assay for detecting recent HIV infection 
and estimating incidence^len#AIDS Res Hum Retroviruses#20020000#2002#18#295-307#
20110000#02.htm#0889-2229#AIDS Res Hum Retroviruses##
00799000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100020000850100
01500105010001600120010001500136010002000151810000600171012018200177030002600359
06500090038506400050039403100030039901400070040286500090040900200070041803500100
0425801002600435#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#259#22#artic
le#69#22#^rND^sHu^nDJ#^rND^sVanichseni^nS#^rND^sMock^nPA#^rND^sYoung^nNL#^rND^sD
obbs^nT#^rND^sByers Jr.^nRH#et al#HIV type 1 incidence estimates by detection of
 recent infection from a cross-sectional sampling of injection drug users in Ban
gkok: use of the IgG capture BED enzyme immunoassay^len#AIDS Res Hum Retroviruse
s#20030000#2003#19#727-30#20110000#02.htm#0889-2229#AIDS Res Hum Retroviruses##
00757000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01800105010001800123010001500141010001700156810000600173012013800179030002600317
06500090034306400050035203100030035701400070036086500090036700200070037603500100
0383801002600393#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#260#23#artic
le#69#23#^rND^sNesheim^nS#^rND^sParekh^nB#^rND^sSullivan^nK#^rND^sBulterys^nM#^r
ND^sDobbs^nT#^rND^sLindsay^nM#et al#Temporal trends in HIV type 1 incidence amon
g inner-city childbearing women in Atlanta: use of the IgG-capture BED-enzyme im
munoassay^len#AIDS Res Hum Retroviruses#20050000#2005#21#537-44#20110000#02.htm#
0889-2229#AIDS Res Hum Retroviruses##
00709000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01500103010001700118010001800135010001600153810000600169012012000175030001300295
06500090030806400050031703100040032201400060032686500090033200200070034103500100
0348801001300358#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#261#24#artic
le#69#24#^rND^sWolday^nD#^rND^sMeles^nH#^rND^sHailu^nE#^rND^sMessele^nT#^rND^sMe
ngistu^nY#^rND^sFekadu^nM#et al#Temporal trends in the incidence of HIV infectio
n in antenatal clinic attendees in Addis Ababa, Ethiopia, 1995-2003^len#J Intern
 Med#20070000#2007#261#132-7#20110000#02.htm#0954-6820#J Intern Med##
00730000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01600107010001500123010001500138010001700153810000600170012010900176030002800285
06500090031306400050032203100030032701400080033086500090033800200070034703500100
0354801002800364#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#262#25#artic
le#69#25#^rND^sPriddy^nFH#^rND^sPilcher^nCD#^rND^sMoore^nRH#^rND^sTambe^nP#^rND^
sPark^nMN#^rND^sFiscus^nSA#et al#Detection of acute HIV infections in an urban H
IV counseling and testing population in the United States^len#J Acquir Immune De
fic Syndr#20070000#2007#44#196-202#20110000#02.htm#0894-9255#J Acquir Immune Def
ic Syndr##
00627000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880100
01400107010001700121010001700138010001600155810000600171012005200177030000500229
06500090023406400050024303100040024801400060025286500090025800200070026703500100
0274801000500284#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#263#26#artic
le#69#26#^rND^sMermin^nJ#^rND^sMusinguzi^nJ#^rND^sOpio^nA#^rND^sKirungi^nW#^rND^
sEkwaru^nJP#^rND^sHladik^nW#et al#Risk factors for recent HIV infection in Ugand
a^len#JAMA#20080000#2008#300#540-9#20110000#02.htm#0098-7484#JAMA##
00594000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690120184000720300019002560650
00900275064000500284031000300289014000300292865000900295002000700304035001000311
801001900321#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#264#27#article#6
9#27#UNAIDS Reference Group on estimates, modelling and projections: statement o
n the use of the BED assay for the estimation of HIV-1 incidence for surveillanc
e or epidemic monitoring^len#Wkly Epidemiol Rec#20060000#2006#81#40#20110000#02.
htm#0049-8114#Wkly Epidemiol Rec##
00715000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01600103010001600119010001500135010001300150810000600163012014900169030000500318
06500090032306400050033203100030033701400060034086500090034600200070035503500100
0362801000500372#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#265#28#artic
le#69#28#^rND^sKarita^nE#^rND^sPrice^nM#^rND^sHunter^nE#^rND^sChomba^nE#^rND^sAl
len^nS#^rND^sFei^nL#et al#Investigating the utility of the HIV-1 BED capture enz
yme immunoassay using cross-sectional and longitudinal seroconverter specimens f
rom Africa^len#AIDS#20070000#2007#21#403-8#20110000#02.htm#0269-9370#AIDS##
00794000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01900108010001800127010001500145010001600160810000600176012017200182030002600354
06500090038006400050038903100030039401400070039786500090040400200070041303500100
0420801002600430#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#266#29#artic
le#69#29#^rND^sMcDougal^nJS#^rND^sParekh^nBS#^rND^sPeterson^nML#^rND^sBranson^nB
M#^rND^sDobbs^nT#^rND^sAckers^nM#et al#Comparison of HIV type 1 incidence observ
ed during longitudinal follow-up with incidence estimated by cross-sectional ana
lysis using the BED capture enzyme immunoassay^len#AIDS Res Hum Retroviruses#200
60000#2006#22#945-52#20110000#02.htm#0889-2229#AIDS Res Hum Retroviruses##
00662000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
01600110010001700126010001900143010001700162810000600179012008000185030000500265
06500090027006400050027903100030028401400060028786500090029300200070030203500100
0309801000500319#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#267#30#artic
le#69#30#^rND^sHargrove^nJW#^rND^sHumphrey^nJH#^rND^sMutasa^nK#^rND^sParekh^nBS#
^rND^sMcDougal^nJS#^rND^sNtozini^nR#et al#Improved HIV-1 incidence estimates usi
ng the BED capture enzyme immunoassay^len#AIDS#20080000#2008#22#511-8#20110000#0
2.htm#0269-9370#AIDS##
00690000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100017000920100
01700109010001400126010001600140010001800156810000600174012008000180030002200260
06500090028206400050029103100030029601400050029986500090030400200070031303500100
0320801002200330#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#268#31#artic
le#69#31#^rND^sLe Guillou^nH#^rND^sLe Meur^nA#^rND^sBourdon^nS#^rND^sRiou^nM#^rN
D^sLoison^nJ#^rND^sFialaire^nP#et al#Avidité des anticorps: application au diagn
ostic d'infection récente à VIH1^lfr#Ann Biol Clin (Paris)#20010000#2001#59#41-7
#20110000#02.htm#0003-3898#Ann Biol Clin (Paris)##
00787000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01500104010001700119010001800136010001800154810000600172012018600178030001700364
06500090038106400050039003100030039501400080039886500090040600200070041503500100
0422801001700432#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#269#32#artic
le#69#32#^rND^sSuligoi^nB#^rND^sGalli^nC#^rND^sMassi^nM#^rND^sDi Sora^nF#^rND^sS
ciandra^nM#^rND^sPezzotti^nP#et al#Precision and accuracy of a procedure for det
ecting recent human immunodeficiency virus infections by calculating the antibod
y avidity index by an automated immunoassay-based method^len#J Clin Microbiol#20
020000#2002#40#4015-20#20110000#02.htm#0095-1137#J Clin Microbiol##
00719000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01500104010001800119010001700137010001800154810000600172012009800178030002800276
06500090030406400050031303100030031801400060032186500090032700200070033603500100
0343801002800353#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#270#33#artic
le#69#33#^rND^sSuligoi^nB#^rND^sMassi^nM#^rND^sGalli^nC#^rND^sSciandra^nM#^rND^s
Di Sora^nF#^rND^sPezzotti^nP#et al#Identifying recent HIV infections using the a
vidity index and an automated enzyme immunoassay^len#J Acquir Immune Defic Syndr
#20030000#2003#32#424-8#20110000#02.htm#0894-9255#J Acquir Immune Defic Syndr##
00788000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01800104010001600122010001700138010001600155810000600171012018900177030001700366
06500090038306400050039203100030039701400070040086500090040700200070041603500100
0423801001700433#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#271#34#artic
le#69#34#^rND^sChawla^nA#^rND^sMurphy^nG#^rND^sDonnelly^nC#^rND^sBooth^nCL#^rND^
sJohnson^nM#^rND^sParry^nJV#et al#Human immunodeficiency virus (HIV) antibody av
idity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)
-seropositive persons infected with diverse HIV-1 subtypes^len#J Clin Microbiol#
20070000#2007#45#415-20#20110000#02.htm#0095-1137#J Clin Microbiol##
00783000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01600104010001400120010001600134010001900150810000600169012016700175030002600342
06500090036806400050037703100030038201400080038586500090039300200070040203500100
0409801002600419#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#272#35#artic
le#69#35#^rND^sGupta^nSB#^rND^sMurphy^nG#^rND^sKoenig^nE#^rND^sAdon^nC#^rND^sBey
rer^nC#^rND^sCelentano^nD#et al#Comparison of methods to detect recent HIV type 
1 infection in cross-sectionally collected specimens from a cohort of female sex
 workers in the Dominican Republic^len#AIDS Res Hum Retroviruses#20070000#2007#2
3#1475-80#20110000#02.htm#0889-2229#AIDS Res Hum Retroviruses##
00716000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01500104010002000119010001700139010001800156810000600174012012200180030001300302
06500090031506400050032403100030032901400070033286500090033900200070034803500100
0355801001300365#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#273#36#artic
le#69#36#^rND^sSuligoi^nB#^rND^sButtò^nS#^rND^sGalli^nC#^rND^sBernasconi^nD#^rND
^sSalata^nRA#^rND^sTavoschi^nL#et al#Detection of recent HIV infections in Afric
an individuals infected by HIV-1 non-B subtypes using HIV antibody avidity^len#J
 Clin Virol#20080000#2008#41#288-92#20110000#02.htm#0928-0197#J Clin Virol##
00698000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01600107010001900123010001700142010002100159810000600180012011400186030000500300
06500090030506400050031403100030031901400070032286500090032900200070033803500100
0345801000500355#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#274#37#artic
le#69#37#^rND^sWilson^nKM#^rND^sJohnson^nEI#^rND^sCroom^nHA#^rND^sRichards^nKM#^
rND^sDoughty^nL#^rND^sCunningham^nPH#et al#Incidence immunoassay for distinguish
ing recent from established HIV-1 infection in therapy-naive populations^len#AID
S#20040000#2004#18#2253-9#20110000#02.htm#0269-9370#AIDS##
00753000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100015000870100
01600102010001600118010001600134010001700150810000600167012015800173030001700331
06500090034806400050035703100030036201400070036586500090037200200070038103500100
0388801001700398#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#275#38#artic
le#69#38#^rND^sBarin^nF#^rND^sMeyer^nL#^rND^sLancar^nR#^rND^sDeveau^nC#^rND^sGha
rib^nM#^rND^sLaporte^nA#et al#Development and validation of an immunoassay for i
dentification of recent human immunodeficiency virus type 1 infections and its u
se on dried serum spots^len#J Clin Microbiol#20050000#2005#43#4441-7#20110000#02
.htm#0095-1137#J Clin Microbiol##
00686000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100016000900100
01800106010001300124010001500137010001600152810000600168012012700174030001400301
71000020031506500090031706400050032603100030033101400100033486500090034400200070
0353#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#276#39#article#69#39#^rN
D^sSemaille^nC#^rND^sCazein^nF#^rND^sPillonel^nJ#^rND^sLot^nF#^rND^sLe Vu^nS#^rN
D^sPinget^nR#et al#Four years of surveillance of recent HIV infections at countr
y level, France, mid 2003 - 2006: experience and perspectives^len#Euro Surveill#
2#20080000#2008#13#pii:18968#20110000#02.htm##
00726000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100015000930100
01600108010001600124010001600140010001500156810000600171012010500177030002800282
06500090031006400050031903100030032401400070032786500090033400200070034303500100
0350801002800360#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#277#40#artic
le#69#40#^rND^sSakarovitch^nC#^rND^sRouet^nF#^rND^sMurphy^nG#^rND^sMinga^nAK#^rN
D^sAlioum^nA#^rND^sDabis^nF#et al#Do tests devised to detect recent HIV-1 infect
ion provide reliable estimates of incidence in Africa?^len#J Acquir Immune Defic
 Syndr#20070000#2007#45#115-22#20110000#02.htm#0894-9255#J Acquir Immune Defic S
yndr##
00651000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
01700110010002200127010001500149010001900164810000600183012008800189030000900277
71000020028606500090028806400050029703100020030201400050030486500090030900200070
0318#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#278#41#article#69#41#^rN
D^sSchüpbach^nJ#^rND^sGebhardt^nMD#^rND^sTomasik^nZ#^rND^sNiederhauser^nC#^rND^s
Yerly^nS#^rND^sBürgisser^nP#et al#Assessment of recent HIV-1 infection by a line
 immunoassay for HIV-1/2 confirmation^len#PLoS Med#2#20070000#2007#4#e343#201100
00#02.htm##
00769000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100015000910100
01500106010001900121010002000140010001800160810000600178012014200184030002800326
06500090035406400050036303100030036801400060037186500090037700200070038603500100
0393801002800403#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#279#42#artic
le#69#42#^rND^sSchechter^nM#^rND^sLago^nRF#^rND^sMelo^nMF#^rND^sSheppard^nHW#^rN
D^sGuimarães^nNC#^rND^sMoreira^nRI#et al#Identification of a high-risk heterosex
ual population for HIV prevention trials in Rio de Janeiro, Brazil: Projeto Praç
a Onze Study Group^len#J Acquir Immune Defic Syndr#20000000#2000#24#175-7#201100
00#02.htm#0894-9255#J Acquir Immune Defic Syndr##
00807000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100019000900100
02100109010001800130010002200148010002500170810000600195012016300201030002800364
06500090039206400050040103100030040601400060040986500090041500200070042403500100
0431801002800441#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#280#43#artic
le#69#43#^rND^sBarroso^nPF#^rND^sHarrison^nLH#^rND^sFátima-Melo^nM#^rND^sBatista
^nSM#^rND^sSilva-Bastos^nM#^rND^sRosa-Faulhaber^nJC#et al#Identification of a hi
gh-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, B
razil, using a sensitive/less-sensitive assay: an update^len#J Acquir Immune Def
ic Syndr#20040000#2004#36#880-1#20110000#02.htm#0894-9255#J Acquir Immune Defic 
Syndr##
00758000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100017000920100
01700109010002300126010001500149010001800164810000600182012015600188030001300344
06500090035706400050036603100030037101400070037486500090038100200070039003500100
0397801001300407#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#281#44#artic
le#69#44#^rND^sGuimarães^nML#^rND^sBastos^nFI#^rND^sTelles^nPR#^rND^sGalvão-Cast
ro^nB#^rND^sDiaz^nRS#^rND^sBongertz^nV#et al#Retrovirus infections in a sample o
f injecting drug users in Rio de Janeiro City, Brazil: prevalence of HIV-1 subty
pes, and co-infection with HTLV-I/II^len#J Clin Virol#20010000#2001#21#143-51#20
110000#02.htm#0928-0197#J Clin Virol##
00746000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01700108010001700125010001800142010002000160810000600180012014700186030001300333
06500090034606400050035503100030036001400060036386500090036900200070037803500100
0385801001300395#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#282#45#artic
le#69#45#^rND^sTeixeira^nSL#^rND^sBastos^nFI#^rND^sTelles^nPR#^rND^sHacker^nMA#^
rND^sBrigido^nLF#^rND^sOliveira^nCAF#et al#HIV-1 infection among injection and e
x-injection drug users from Rio de Janeiro, Brazil: prevalence, estimated incide
nce and genetic diversity^len#J Clin Virol#20040000#2004#31#221-6#20110000#02.ht
m#0928-0197#J Clin Virol##
00710000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01700104010001600121010001600137012018300153030000500336065000900341064000500350
031000300355014000700358865000900365002000700374035001000381801000500391#v27s1#V
:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#283#46#article#69#46#^rND^sDiaz^nRS#
^rND^sKallas^nEG#^rND^sCastelo^nA#^rND^sRawal^nBD#^rND^sBusch^nMP#Use of a new '
less-sensitive enzyme immunoassay' testing strategy to identify recently infecte
d persons in a Brazilian prison: estimation of incidence and epidemiological tra
cing^len#AIDS#19990000#1999#13#1417-8#20110000#02.htm#0269-9370#AIDS##
00716000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01900104010001700123010001600140010001600156810000600172012009400178030002800272
06500090030006400050030903100030031401400070031786500090032400200070033303500100
0340801002800350#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#284#47#artic
le#69#47#^rND^sTurchi^nMD#^rND^sDiaz^nRS#^rND^sMartelli^nCM#^rND^sSabino^nEC#^rN
D^sSilva^nWP#^rND^sFilho^nOF#et al#Genetic diversity and HIV-1 incidence estimat
ion among cocaine users in São Paulo, Brazil^len#J Acquir Immune Defic Syndr#200
20000#2002#30#527-32#20110000#02.htm#0894-9255#J Acquir Immune Defic Syndr##
00740000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01700104010002000121010001700141010001900158810000600177012011400183030002800297
06500090032506400050033403100030033901400060034286500090034800200070035703500100
0364801002800374#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#285#48#artic
le#69#48#^rND^sAlves^nK#^rND^sShafer^nKP#^rND^sCaseiro^nM#^rND^sRutherford^nG#^r
ND^sFalcao^nME#^rND^sSucupira^nMC#et al#Risk factors for incident HIV infection 
among anonymous HIV testing site clients in Santos, Brazil: 1996-1999^len#J Acqu
ir Immune Defic Syndr#20030000#2003#32#551-9#20110000#02.htm#0894-9255#J Acquir 
Immune Defic Syndr##
00804000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100022000890100
01900111010002000130010001900150010001700169810000600186012016500192030001800357
06500090037506400050038403100020038901400080039186500090039900200070040803500100
0415801004100425#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#286#49#artic
le#69#49#^rND^sKallas^nEG#^rND^sBassichetto^nKC#^rND^sOliveira^nSM#^rND^sGoldenb
erg^nI#^rND^sBortoloto^nR#^rND^sMoreno^nDM#et al#Establishment of the serologic 
testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (
STARHS) strategy in the city of São Paulo, Brazil^len#Braz J Infect Dis#20040000
#2004#8#399-406#20110000#02.htm#1413-8670#Brazilian Journal of Infectious Diseas
es##
00722000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100022000940100
01600116010001900132010001800151010001500169012016600184030001800350710000200368
065000900370064000500379031000300384014000500387865000900392002000700401#v27s1#V
:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#287#50#article#69#50#^rND^sBassichet
to^nKC#^rND^sBergamaschi^nDP#^rND^sVeras^nMA#^rND^sSucupira^nMC#^rND^sMesquita^n
F#^rND^sDiaz^nRS#Estimating HIV-1 incidence using the serologic testing algorith
m for recent HIV infections at HIV counseling and testing centers in the city of
 São Paulo, Brazil^len#Braz J Infect Dis#2#20090000#2009#13#9-12#20110000#02.htm
##
00757000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100027000720100014000990100
01900113010001900132010001900151010002500170012015100195030001700346065000900363
06400050037203100030037701400080038086500090038800200070039703500100040480100170
0414#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#288#51#article#69#51#^rN
D^sFreitas-Oliveira^nCA#^rND^sUeda^nM#^rND^sYamashiro^nR#^rND^sRodrigues^nR#^rND
^sSheppard^nHW#^rND^sMacedo-Brígido^nLF#Rate and incidence estimates of recent h
uman immunodeficiency virus type 1 infections among pregnant women in São Paulo,
 Brazil, from 1991 to 2002^len#J Clin Microbiol#20050000#2005#43#1439-42#2011000
0#02.htm#0095-1137#J Clin Microbiol##
00755000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01900107010001800126010002100144010001700165810000600182012015400188030001200342
06500090035406400050036303100030036801400080037186500090037900200070038803500100
0395801001200405#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#289#52#artic
le#69#52#^rND^sBarreto^nCC#^rND^sSabino^nEC#^rND^sGonçalez^nTT#^rND^sLaycock^nME
#^rND^sPappalardo^nBL#^rND^sSalles^nNA#et al#Prevalence, incidence, and residual
 risk of human immunodeficiency virus among community and replacement first-time
 blood donors in São Paulo, Brazil^len#Transfusion#20050000#2005#45#1709-14#2011
0000#02.htm#0041-1132#Transfusion##
00691000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100020000940100
02700114010001600141010001800157012012800175030001200303065000900315064000500324
031000300329014000700332865000900339002000700348035001000355801001200365#v27s1#V
:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#290#53#article#69#53#^rND^sSá-Ferrei
ra^nJA#^rND^sBrindeiro^nPA#^rND^sChequer-Fernandez^nS#^rND^sTanuri^nA#^rND^sMorg
ado^nMG#Human immunodeficiency virus-1 subtypes and antiretroviral drug resistan
ce profiles among drug-naïve Brazilian blood donors^len#Transfusion#20070000#200
7#47#97-102#20110000#02.htm#0041-1132#Transfusion##
00701000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100020000920100
01700112010001700129010001800146010001800164012015100182030001500333710000200348
065000900350064000500359031000300364014000400367865000900371002000700380#v27s1#V
:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#291#54#article#69#54#^rND^sde Castro
^nCA#^rND^sGrinsztejn^nB#^rND^sVeloso^nVG#^rND^sBastos^nFI#^rND^sPilotto^nJH#^rN
D^sMorgado^nMG#Prevalence, estimated HIV-1 incidence and viral diversity among p
eople seeking voluntary counseling and testing services in Rio de Janeiro, Brasi
l^len#BMC Infect Dis#2#20100000#2010#10#224#20110000#02.htm##
00767000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100016000910100
01900107010001600126010001900142010001900161810000600180012014900186030002200335
06500090035706400050036603100040037101400060037586500090038100200070039003500100
0397801002200407#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#292#55#artic
le#69#55#^rND^sFerreira^nJL#^rND^sThomaz^nM#^rND^sRodrigues^nR#^rND^sHarrad^nD#^
rND^sOliveira^nCM#^rND^sOliveira^nCA#et al#Molecular characterization of newly i
dentified HIV-1 infections in Curitiba, Brazil: preponderance of clade C among m
ales with recent infections^len#Mem Inst Oswaldo Cruz#20080000#2008#103#800-8#20
110000#02.htm#0074-0276#Mem Inst Oswaldo Cruz##
00744000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100016000900100
01900106010001600125010001900141010001800160810000600178012011900184030002600303
06500090032906400050033803100030034301400080034686500090035400200070036303500100
0370801002600380#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#293#56#artic
le#69#56#^rND^sBrígido^nLF#^rND^sNunes^nCC#^rND^sOliveira^nCM#^rND^sKnoll^nRK#^r
ND^sFerreira^nJL#^rND^sFreitas^nCA#et al#HIV type 1 subtype C and CB Pol recombi
nants prevail at the cities with the highest AIDS prevalence rate in Brazil^len#
AIDS Res Hum Retroviruses#20070000#2007#23#1579-86#20110000#02.htm#0889-2229#AID
S Res Hum Retroviruses##
00731000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100028000720100020001000100
01600120010001600136010001700152010001700169012015600186030002000342710000200362
06500090036406400050037303100030037803200040038101400040038586500090038900200070
0398#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#294#57#article#69#57#^rN
D^sVelasco-de-Castro^nCA#^rND^sGrinsztejn^nB#^rND^sVeloso^nV#^rND^sBastos^nF#^rN
D^sPilotto^nJ#^rND^sMorgado^nM#Serological approaches to access recent HIV-1 ser
oconvertion: proposal of criterion to improve the predictive values in BEDCEIA a
nd Avidity Index Assay^len#AIDS Res Hum Retrov#2#20080000#2008#24#^s1#S36#201100
00#02.htm##
00469000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720120052000910300
00500143065000900148064000500157031000300162014000700165865000900172002000700181
035001000188801000500198#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#295#
58#article#69#58#^rND^sHargrove^nJW#BED estimates of HIV incidence must be adjus
ted^len#AIDS#20090000#2009#23#2061-2#20110000#02.htm#0269-9370#AIDS##
00550000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100019000870100
02200106012007200128030000500200065000900205064000500214031000300219014000700222
865000900229002000700238035001000245801000500255#v27s1#V:\SciELO\serial\csp\v27s
1\markup\02.htm#S#c#296#59#article#69#59#^rND^sWelte^nA#^rND^sMcWalter^nTA#^rND^
sBärnighausen^nT#Reply to 'Should biomarker estimates of HIV incidence be adjust
ed?'^len#AIDS#20090000#2009#23#2062-3#20110000#02.htm#0269-9370#AIDS##
00469000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720120052000910300
00500143065000900148064000500157031000300162014000700165865000900172002000700181
035001000188801000500198#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#297#
60#article#69#60#^rND^sMcDougal^nJS#BED estimates of HIV incidence must be adjus
ted^len#AIDS#20090000#2009#23#2064-5#20110000#02.htm#0269-9370#AIDS##
00511000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720120093000920300
00500185065000900190064000500199031000300204014000700207865000900214002000700223
035001000230801000500240#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#298#
61#article#69#61#^rND^sBrookmeyer^nR#Response to correspondence on 'Should Bioma
rker Estimates of HIV Incidence be Adjusted?'^len#AIDS#20090000#2009#23#2066-8#2
0110000#02.htm#0269-9370#AIDS##
00478000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100015000910120
05700106030000900163710000200172065000900174064000500183031000200188014000600190
865000900196002000700205#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#299#
62#article#69#62#^rND^sMcWalter^nTA#^rND^sWelte^nA#A comparison of biomarker bas
ed incidence estimators^len#PLoS One#2#20090000#2009#4#e7368#20110000#02.htm##
00596000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100014000900100
02200104010001300126010001800139012008800157030000900245710000200254065000900256
064000500265031000200270014000600272865000900278002000700287#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\02.htm#S#c#300#63#article#69#63#^rND^sHallett^nTB#^rND^sGhy
s^nP#^rND^sBärnighausen^nT#^rND^sYan^nP#^rND^sGarnett^nGP#Errors in 'BED'-derive
d estimates of HIV incidence will vary by place, time and age^len#PLoS One#2#200
90000#2009#4#e5720#20110000#02.htm##
00729000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01500106010001800121010001600139010001900155012012400174030002800298065000900326
06400050033503100030034001400060034386500090034900200070035803500100036580100280
0375#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#301#64#article#69#64#^rN
D^sTruong^nHH#^rND^sKellogg^nT#^rND^sLouie^nB#^rND^sKlausner^nJ#^rND^sDilley^nJ#
^rND^sMcFarland^nW#Recent HIV-1infection detection: comparison of incidence esti
mates derived by laboratory assays and repeat testing data^len#J Acquir Immune D
efic Syndr#20090000#2009#51#502-5#20110000#02.htm#0894-9255#J Acquir Immune Defi
c Syndr##
00755000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100018000940100
01600112010001600128010002200144010001600166810000600182012012400188030002800312
06500090034006400050034903100030035401400060035786500090036300200070037203500100
0379801002800389#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#302#65#artic
le#69#65#^rND^sLaeyendecker^nO#^rND^sRothman^nRE#^rND^sHenson^nC#^rND^sHorne^nBJ
#^rND^sKetlogetswe^nKS#^rND^sKraus^nCK#et al#The effect of viral suppression on 
cross-sectional incidence testing in the Johns Hopkins hospital emergency depart
ment^len#J Acquir Immune Defic Syndr#20080000#2008#48#211-5#20110000#02.htm#0894
-9255#J Acquir Immune Defic Syndr##
00727000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100028000870100
01800115010002000133010002400153010001800177810000600195012011300201030001200314
06500090032606400050033503100030034001400080034386500090035100200070036003500100
0367801001200377#v27s1#V:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#303#66#artic
le#69#66#^rND^sBello^nG#^rND^sVelasco-de-Castro^nCA#^rND^sBongertz^nV#^rND^sRodr
igues^nCA#^rND^sGiacoia-Gripp^nCB#^rND^sPilotto^nJH#et al#Immune activation and 
antibody responses in non-progressing elite controller individuals infected with
 HIV-1^len#J Med Virol#20090000#2009#81#1681-90#20110000#02.htm#0146-6615#J Med 
Virol##
00551000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170026000720180122000980370
07900220110000900299109000900308865000900317002000700326#v27s1#V:\SciELO\serial\
csp\v27s1\markup\02.htm#S#c#304#67#article#69#67#World Health Organization#Repor
t of the WHO working group on statistical approaches for development, validation
 and use of HIV incidence assays^len#http://www.who.int/diagnostics_laboratory/l
inks/hiviwg_geneva_04_09_report.pdf#20090400#Apr/2009#20110000#02.htm##
00650000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100014000880100
02000102010001700122010001500139012011300154030000900267065000900276064000500285
031000300290014000800293865000900301002000700310035001000317801000900327#v27s1#V
:\SciELO\serial\csp\v27s1\markup\02.htm#S#c#305#68#article#69#68#^rND^sKaron^nJM
#^rND^sSong^nR#^rND^sBrookmeyer^nR#^rND^sKaplan^nEH#^rND^sHall^nHI#Estimating HI
V incidence in the United States from HIV/AIDS surveillance data and biomarker H
IV test results^len#Stat Med#20080000#2008#27#4617-33#20110000#02.htm#0277-6715#
Stat Med##
00430000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160017000720180044000890660
01000133062002700143065000900170064000500179865000900184002000700193#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\02.htm#S#c#306#69#article#69#69#^rND^sHacking^nI#Th
e taming of chance (ideas in context)^len#Cambridge#Cambridge University Press#1
9900000#1990#20110000#02.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#o#1#1#article#1#201104
11#073655#03.htm#185##
03992000000000685000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400110013303500100014401200640015401201040
02180100038003220100046003600100036004060100025004420100043004670100034005100700
12300544070009900667070008900766083105100855085001001906085002801916085001601944
08500210196008500310198108311090201208500100312108500330313108500160316408500200
31800850022032001170008032220720003032301120009032331110015032421160009032571150
01203266114000903278113001203287002000703299#v27s1#V:\SciELO\serial\csp\v27s1\ma
rkup\03.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#03#CSP330#nd#Cad. Saúde Públ
ica#27#1#20110000#^fs19^ls26#0102-311X#HIV-related risky practices among Brazili
an young men, 2007^len#Práticas de risco relacionadas à infecção pelo HIV entre 
jovens brasileiros do sexo masculino, 2007^lpt#^rND^1A01^nCélia Landmann^sSzwarc
wald#^rND^1A02^nCarla Lourenço Tavares de^sAndrade#^rND^1A03^nAna Roberta Pati^s
Pascom#^rND^1A03^nErika^sFazito#^rND^1A03^nGerson Fernando Mendes^sPereira#^rND^
1A01^nIsaque Terra da^sPenha#Fundação Oswaldo Cruz^iA01^1Informação Científica e
 Tecnológica em Saúde^2Instituto de Comunicação^cRio de Janeiro^pBrasil#Fundação
 Oswaldo Cruz^iA02^1Escola Nacional de Saúde Pública Sergio Arouca^cRio de Janei
ro^pBrasil#Ministério da Saúde^iA03^1Departamento de DST, AIDS e Hepatites Virai
s^cBrasília^pBrasil#^len^aBehavioral surveillance surveys have been carried amon
g military conscripts, in Brazil, since 1996. This paper presents the results of
 the 2007 survey and compares actual findings with those obtained in previous st
udies carried out in the period 1999-2002. The conscripts were selected with a t
wo stage sampling stratified by geographical region. The study included a self-r
eported questionnaire and blood collection for HIV and syphilis testing. Data fr
om 35,432 conscripts aged 17-20 years old were analyzed. The findings show a red
uction in regular condom use, with fixed and casual partners, mainly among those
 with poor educational level. The proportion of conscripts that have sex with ot
her men was maintained (3.2%), but the index of risky sexual behavioral showed w
orsening results in this group. Also, the HIV prevalence rate increased from 9 t
o 11.3 per 10,000 in 2007, though the increase was not statistically significant
. In conclusion, the evidences found in this paper indicate the need of reformul
ate policy among young adults.#^ddecs^i1#^tm^len^kSexual Behavior^i1#^tm^len^kHI
V^i1#^tm^len^kSyphilis^i1#^tm^len^kMilitary Personnel^i1#^lpt^aPesquisas periódi
cas sobre práticas de risco relacionadas à infecção pelo HIV têm sido realizadas
 entre os conscritos das Forças Armadas do Brasil, desde 1996. Este artigo traz 
os resultados da pesquisa realizada no ano de 2007, comparando com os obtidos no
 período 1999-2002. Obedecendo a um plano de amostragem estratificada por região
 geográfica em dois estágios de seleção, 35.432 conscritos de 17 a 20 anos de id
ade preencheram um questionário sobre comportamento sexual. O estudo incluiu col
eta de sangue para detecção de HIV e sífilis. Os achados mostram diminuição do u
so regular de preservativo, com parcerias fixas e casuais, sobretudo entre os jo
vens com baixo grau de escolaridade. A proporção de conscritos que têm relações 
sexuais com homens (HSH) se manteve (3,2%), mas há uma piora no índice de compor
tamento sexual de risco entre os HSH. Há também um aumento na taxa de prevalênci
a do HIV, de 9 para 11,3 por 10 mil, embora não estatisticamente significativo. 
Em conclusão, as evidências aqui encontradas indicam a necessidade de reformulaç
ão das políticas entre os jovens brasileiros.#^ddecs^i2#^tm^lpt^kComportamento S
exual^i2#^tm^lpt^kHIV^i2#^tm^lpt^kSífilis^i2#^tm^lpt^kMilitares^i2#vancouv#23#20
091029#on 29/Oct/2009#20100128#28/Jan/2010#20100308#08/Mar/2010#03.htm##
04006000000000685000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400110013303500100014401200710015401201110
02250100038003360100046003740100036004200100025004560100043004810100034005240700
12300558070009900681070008900780083105100869085001001920085002801930085001601958
08500210197408500310199508311090202608500100313508500330314508500160317808500200
31940850022032141170008032360720003032441120009032471110015032561160009032711150
01203280114000903292113001203301002000703313#v27s1#V:\SciELO\serial\csp\v27s1\ma
rkup\03.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#03#CSP330#nd#Cad. Saúde Públ
ica#27#1#20110000#^fs19^ls26#0102-311X#<b>HIV-related risky practices among Braz
ilian young men, 2007</b>^len#<b>Práticas de risco relacionadas à infecção pelo 
HIV entre jovens brasileiros do sexo masculino, 2007</b>^lpt#^rND^1A01^nCélia La
ndmann^sSzwarcwald#^rND^1A02^nCarla Lourenço Tavares de^sAndrade#^rND^1A03^nAna 
Roberta Pati^sPascom#^rND^1A03^nErika^sFazito#^rND^1A03^nGerson Fernando Mendes^
sPereira#^rND^1A01^nIsaque Terra da^sPenha#Fundação Oswaldo Cruz^iA01^1Informaçã
o Científica e Tecnológica em Saúde^2Instituto de Comunicação^cRio de Janeiro^pB
rasil#Fundação Oswaldo Cruz^iA02^1Escola Nacional de Saúde Pública Sergio Arouca
^cRio de Janeiro^pBrasil#Ministério da Saúde^iA03^1Departamento de DST, AIDS e H
epatites Virais^cBrasília^pBrasil#^len^aBehavioral surveillance surveys have bee
n carried among military conscripts, in Brazil, since 1996. This paper presents 
the results of the 2007 survey and compares actual findings with those obtained 
in previous studies carried out in the period 1999-2002. The conscripts were sel
ected with a two stage sampling stratified by geographical region. The study inc
luded a self-reported questionnaire and blood collection for HIV and syphilis te
sting. Data from 35,432 conscripts aged 17-20 years old were analyzed. The findi
ngs show a reduction in regular condom use, with fixed and casual partners, main
ly among those with poor educational level. The proportion of conscripts that ha
ve sex with other men was maintained (3.2%), but the index of risky sexual behav
ioral showed worsening results in this group. Also, the HIV prevalence rate incr
eased from 9 to 11.3 per 10,000 in 2007, though the increase was not statistical
ly significant. In conclusion, the evidences found in this paper indicate the ne
ed of reformulate policy among young adults.#^ddecs^i1#^tm^len^kSexual Behavior^
i1#^tm^len^kHIV^i1#^tm^len^kSyphilis^i1#^tm^len^kMilitary Personnel^i1#^lpt^aPes
quisas periódicas sobre práticas de risco relacionadas à infecção pelo HIV têm s
ido realizadas entre os conscritos das Forças Armadas do Brasil, desde 1996. Est
e artigo traz os resultados da pesquisa realizada no ano de 2007, comparando com
 os obtidos no período 1999-2002. Obedecendo a um plano de amostragem estratific
ada por região geográfica em dois estágios de seleção, 35.432 conscritos de 17 a
 20 anos de idade preencheram um questionário sobre comportamento sexual. O estu
do incluiu coleta de sangue para detecção de HIV e sífilis. Os achados mostram d
iminuição do uso regular de preservativo, com parcerias fixas e casuais, sobretu
do entre os jovens com baixo grau de escolaridade. A proporção de conscritos que
 têm relações sexuais com homens (HSH) se manteve (3,2%), mas há uma piora no ín
dice de comportamento sexual de risco entre os HSH. Há também um aumento na taxa
 de prevalência do HIV, de 9 para 11,3 por 10 mil, embora não estatisticamente s
ignificativo. Em conclusão, as evidências aqui encontradas indicam a necessidade
 de reformulação das políticas entre os jovens brasileiros.#^ddecs^i2#^tm^lpt^kC
omportamento Sexual^i2#^tm^lpt^kHIV^i2#^tm^lpt^kSífilis^i2#^tm^lpt^kMilitares^i2
#vancouv#23#20091029#on 29/Oct/2009#20100128#28/Jan/2010#20100308#08/Mar/2010#03
.htm##
04134000000000709000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000190010703100030012613100020012906500090013101400110014003500100015101200640
01610120104002250100038003290100046003670100036004130100025004490100043004740100
03400517070012500551070010100676070009100777083105800868085001001926085002801936
08500160196408500210198008500310200108311180203208500100315008500330316008500160
31930850020032090850022032291170008032510720003032591120009032621110015032711160
00903286115001203295114000903307113001203316002000703328008008903335#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\03.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#t
ab#03#CSP330#nd#Cad. saúde pública#27#1#20110000#^fs19^ls26#0102-311X#HIV-relate
d risky practices among Brazilian young men, 2007^len#Práticas de risco relacion
adas à infecção pelo HIV entre jovens brasileiros do sexo masculino, 2007^lpt#^r
ND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nCarla Lourenço Tavares de^sAndrad
e#^rND^1A03^nAna Roberta Pati^sPascom#^rND^1A03^nErika^sFazito#^rND^1A03^nGerson
 Fernando Mendes^sPereira#^rND^1A01^nIsaque Terra da^sPenha#^iA01^1Fundação Oswa
ldo Cruz^2Informação Científica e Tecnológica em Saúde^3Instituto de Comunicação
^cRio de Janeiro^pBrasil#^iA02^1Fundação Oswaldo Cruz^2Escola Nacional de Saúde 
Pública Sergio Arouca^cRio de Janeiro^pBrasil#^iA03^1Ministério da Saúde^2Depart
amento de DST, AIDS e Hepatites Virais^cBrasília^pBrasil#^len^aBehavioral survei
llance surveys have been carried among military conscripts, in Brazil, since 199
6. This paper presents the results of the 2007 survey and compares actual findin
gs with those obtained in previous studies carried out in the period 1999-2002. 
The conscripts were selected with a two stage sampling stratified by geographica
l region. The study included a self-reported questionnaire and blood collection 
for HIV and syphilis testing. Data from 35,432 conscripts aged 17-20 years old w
ere analyzed. The findings show a reduction in regular condom use, with fixed an
d casual partners, mainly among those with poor educational level. The proportio
n of conscripts that have sex with other men was maintained (3.2 percent), but t
he index of risky sexual behavioral showed worsening results in this group. Also
, the HIV prevalence rate increased from 9 to 11.3 per 10,000 in 2007, though th
e increase was not statistically significant. In conclusion, the evidences found
 in this paper indicate the need of reformulate policy among young adults.#^ddec
s^i1#^tm^len^kSexual Behavior^i1#^tm^len^kHIV^i1#^tm^len^kSyphilis^i1#^tm^len^kM
ilitary Personnel^i1#^lpt^aPesquisas periódicas sobre práticas de risco relacion
adas à infecção pelo HIV têm sido realizadas entre os conscritos das Forças Arma
das do Brasil, desde 1996. Este artigo traz os resultados da pesquisa realizada 
no ano de 2007, comparando com os obtidos no período 1999-2002. Obedecendo a um 
plano de amostragem estratificada por região geográfica em dois estágios de sele
ção, 35.432 conscritos de 17 a 20 anos de idade preencheram um questionário sobr
e comportamento sexual. O estudo incluiu coleta de sangue para detecção de HIV e
 sífilis. Os achados mostram diminuição do uso regular de preservativo, com parc
erias fixas e casuais, sobretudo entre os jovens com baixo grau de escolaridade.
 A proporção de conscritos que têm relações sexuais com homens (HSH) se manteve 
(3,2 por cento), mas há uma piora no índice de comportamento sexual de risco ent
re os HSH. Há também um aumento na taxa de prevalência do HIV, de 9 para 11,3 po
r 10 mil, embora não estatisticamente significativo. Em conclusão, as evidências
 aqui encontradas indicam a necessidade de reformulação das políticas entre os j
ovens brasileiros.#^ddecs^i2#^tm^lpt^kComportamento Sexual^i2#^tm^lpt^kHIV^i2#^t
m^lpt^kSífilis^i2#^tm^lpt^kMilitares^i2#vancouv#23#20091029#on 29/Oct/2009#20100
128#28/Jan/2010#20100308#08/Mar/2010#03.htm#Internet^ihttp://www.scielo.br/sciel
o.php?script=sci_arttext&pid=S0102-311X2011001300003##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#5#1#article#158#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#03.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#6#2#article#158#<p>&nbsp;</p>     ^cY#03.htm
##
00391000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704017100067002000700238#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#7#3#article#158#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>HIV-related    risky pra
ctices among Brazilian young men, 2007</b> </font></p>     ^cY#03.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#8#4#article#158#<p>&nbsp;</p>     ^cY#03.htm
##
00443000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704022300067002000700290#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#9#5#article#158#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Pr&aacute;ticas    de risco relacionadas &
agrave; infec&ccedil;&atilde;o pelo HIV entre jovens    brasileiros do sexo masc
ulino, 2007</b></font></p>     ^cY#03.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#10#6#article#158#<p>&nbsp;</p>     ^cY#03.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#11#7#article#158#<p>&nbsp;</p>     ^cY#03.ht
m##
00568000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704034700068002000700415#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#12#8#article#158#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"> <b>C&eacute;lia    Landmann Szwarcwald<sup>
I</sup>; Carla Louren&ccedil;o Tavares de Andrade<sup>II</sup>;    Ana Roberta P
ati Pascom<sup>III</sup>; Erika Fazito<sup>III</sup>; Gerson Fernando    Mendes 
Pereira<sup>III</sup>; Isaque Terra da Penha<sup>I</sup></b></font></p>     ^cY#
03.htm##
00494000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704027300068002000700341#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#13#9#article#158#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    de Comunica&ccedil;
&atilde;o e Informa&ccedil;&atilde;o Cient&iacute;fica e    Tecnol&oacute;gica e
m Sa&uacute;de, Funda&ccedil;&atilde;o Oswaldo Cruz, Rio    de Janeiro, Brasil  
  ^cY#03.htm##
00374000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015200069002000700221#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#14#10#article#158#<br>   <sup>II</sup>Escola
 Nacional de Sa&uacute;de P&uacute;blica Sergio Arouca, Funda&ccedil;&atilde;o  
  Oswaldo Cruz, Rio de Janeiro, Brasil    ^cY#03.htm##
00370000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014800069002000700217#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#15#11#article#158#<br>   <sup>III</sup>Depar
tamento de DST, AIDS e Hepatites Virais, Minist&eacute;rio    da Sa&uacute;de, B
ras&iacute;lia, Brasil</font></p>     ^cY#03.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#16#12#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#17#13#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#18#14#article#158#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#03.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#19#15#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#03.htm##
01388000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704116600069002000701235#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#20#16#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Behavioral surveillance    surveys have bee
n carried among military conscripts, in Brazil, since 1996.    This paper presen
ts the results of the 2007 survey and compares actual findings    with those obt
ained in previous studies carried out in the period 1999-2002.    The conscripts
 were selected with a two stage sampling stratified by geographical    region. T
he study included a self-reported questionnaire and blood collection    for HIV 
and syphilis testing. Data from 35,432 conscripts aged 17-20 years old    were a
nalyzed. The findings show a reduction in regular condom use, with fixed    and 
casual partners, mainly among those with poor educational level. The proportion 
   of conscripts that have sex with other men was maintained (3.2%), but the ind
ex    of risky sexual behavioral showed worsening results in this group. Also, t
he    HIV prevalence rate increased from 9 to 11.3 per 10,000 in 2007, though th
e    increase was not statistically significant. In conclusion, the evidences fo
und    in this paper indicate the need of reformulate policy among young adults.
</font></p>     ^cY#03.htm##
00380000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015800069002000700227#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#21#17#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Sexual Behavior;    HIV; Syphilis; Military
 Personnel</font></p> <hr size="1" noshade>     ^cY#03.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#22#18#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#03.htm##
01699000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704147700069002000701546#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#23#19#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Pesquisas peri&oacute;dicas    sobre pr&aac
ute;ticas de risco relacionadas &agrave; infec&ccedil;&atilde;o    pelo HIV t&ec
irc;m sido realizadas entre os conscritos das For&ccedil;as Armadas    do Brasil
, desde 1996. Este artigo traz os resultados da pesquisa realizada    no ano de 
2007, comparando com os obtidos no per&iacute;odo 1999-2002. Obedecendo    a um 
plano de amostragem estratificada por regi&atilde;o geogr&aacute;fica em    dois
 est&aacute;gios de sele&ccedil;&atilde;o, 35.432 conscritos de 17 a 20    anos 
de idade preencheram um question&aacute;rio sobre comportamento sexual.    O est
udo incluiu coleta de sangue para detec&ccedil;&atilde;o de HIV e s&iacute;filis
.    Os achados mostram diminui&ccedil;&atilde;o do uso regular de preservativo,
    com parcerias fixas e casuais, sobretudo entre os jovens com baixo grau de e
scolaridade.    A propor&ccedil;&atilde;o de conscritos que t&ecirc;m rela&ccedi
l;&otilde;es    sexuais com homens (HSH) se manteve (3,2%), mas h&aacute; uma pi
ora no &iacute;ndice    de comportamento sexual de risco entre os HSH. H&aacute;
 tamb&eacute;m um aumento    na taxa de preval&ecirc;ncia do HIV, de 9 para 11,3
 por 10 mil, embora n&atilde;o    estatisticamente significativo. Em conclus&ati
lde;o, as evid&ecirc;ncias aqui    encontradas indicam a necessidade de reformul
a&ccedil;&atilde;o das pol&iacute;ticas    entre os jovens brasileiros.</font></
p>     ^cY#03.htm##
00382000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016000069002000700229#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#24#20#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Comportamento Sexual;    HIV; S&iacute;fili
s; Militares</font></p> <hr size="1" noshade>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#25#21#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#26#22#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#27#23#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#03.h
tm##
00902000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704068000069002000700749#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#28#24#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">National and international    surveys have 
shown greater vulnerability of adolescents and young men to sexually    transmit
ted infections (STI), in particular HIV infection <sup>1,2</sup>. In    the USA 
while HIV infection has shown a decline in recent years, the incidence    of HIV
 among young adults has not been presenting the same decreasing behavior    <sup
>3</sup>. In Brazil, a survey revealed a proportion of 32% of non-planned    pre
gnancy among adolescents. Among sexually active young women, the prevalence    r
ates of chlamydia and gonorrhea were respectively 12% and 2% <sup>4</sup>.</font
></p>     ^cY#03.htm##
00930000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070800069002000700777#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#29#25#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the stage of    adolescence the individu
al develops physically and emotionally, becomes sexually    active and adopts be
haviors that are influenced by psychological aspects related    to this age grou
p, peers and social context <sup>5</sup>. Despite younger adults    constitute a
 population group that represents the greatest rate of use of condoms,    they f
requently gauge in behaviors that expose them to situations of greater    risk. 
These behaviors include flaws or inconsistencies in the use of condoms,    sexua
l activity with different partners and the use of alcohol or drugs before    int
ercourse <sup>6</sup>.</font></p>     ^cY#03.htm##
00704000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048200069002000700551#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#30#26#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Studies performed    for the investigation 
of different factors involved in the risky sexual behavior    of adolescents, as
 well as their interrelations, has been acknowledged as a    portable instrument
s for the control of HIV dissemination since they provide    elements to subside
 preventive measures, increasing effectiveness of interventions    at the level 
of collective health <sup>7,8</sup>.</font></p>     ^cY#03.htm##
00753000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053100069002000700600#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#31#27#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the international    scene, Thailand was
 the first country to perform studies of HIV prevalence among    young conscript
s in the Army <sup>9</sup>. In Brazil, due to military services    be mandatory 
for young men at the age of 18, the opportunity for conducting    studies about 
the knowledge of sexual practices of the population of young males    at a natio
nal level stimulated the performance of periodic surveys in this population    g
roup.</font></p>     ^cY#03.htm##
00768000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054600069002000700615#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#32#28#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The project for    technical cooperation be
tween the Brazilian Ministry of Health and the former    Ministry of Army in Bra
zil started in 1996, by integrating actions in order    to know and prevent HIV 
and STI infections among military conscripts and members.    This partnership eq
ually resulted in periodical surveys of risky practices related    to infection 
by HIV among conscripts by occasion of its presentation to Military    Commissio
ns <sup>10,11</sup>.</font></p>     ^cY#03.htm##
01247000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704102500069002000701094#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#33#29#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The surveys with    conscripts have focused
 on distinct objects each year, with the purpose to enhance    the knowledge abo
ut the behavior of Brazilian young men. However, part of the    questionnaire is
 periodically repeated to defining relevant changes in risky    practices and mo
nitoring of preventive actions. In the years of 1996 and 1997,    the surveys ma
inly aimed to investigate the knowledge about the infection transmission    by H
IV and means of access to information by the Brazilian young men. The year    of
 1998 was highlighted by a more comprehensive research instrument, which involve
d    several questions about sexual practices, problems related to STI and other
    factors related to the transmission of infection by HIV such as the use of i
njectable    drugs. Also for the first time there were collected blood samples f
or HIV infection    testing whose results could be attached to the behavioral su
rvey <sup>12</sup>.</font></p>     ^cY#03.htm##
00867000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064500069002000700714#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#34#30#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The 1999 survey    focused the relations be
tween the risky sexual behavior and the use of alcoholic    beverages and illici
t drugs <sup>13</sup>, while in the year of 2000 the focus    was directed towar
ds defining associations among the social condition of the    conscript, risky s
exual behavior and problems related to STI <sup>10</sup>.    In the year of 2002
, the specific purpose of the survey was to estimate the    HIV prevalence rate 
at a national level and defined the main factors associated    to the infection 
by HIV among young males <sup>11</sup>.</font></p>     ^cY#03.htm##
00783000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056100069002000700630#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#35#31#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This article presents    the results of res
earch performed in the year of 2007 among conscripts of the    Brazilian Armed F
orces, by comparing current results with those results from    previous studies 
from 1999 to 2002. In the first part of the analysis, the focus    was given to 
the comparison of results with those obtained in previous surveys,    while in t
he second part there were estimated prevalence rates of HIV and syphilis    infe
ction in some population subgroups.</font></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#36#32#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00335000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011300069002000700182#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#37#33#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Material and    methods</b></font></p>  
   ^cY#03.htm##
00574000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035200069002000700421#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#38#34#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study was performed    in 2007 by the D
epartment of STI, AIDS and Viral Hepatitis of the Brazilian    Ministry of Healt
h in a partnership with the Brazilian Ministry of Defense,    with the approval 
of the National Committee of Ethics in Research (Number 589/2006).</font></p>   
  ^cY#03.htm##
00835000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061300069002000700682#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#39#35#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">There were selected    about 39,000 conscri
pts for the survey, obeying a sampling plan by stratifying    in two selection s
tages. In the first stage, the selection commissions were    stratified by geogr
aphical macro region and selected with probability proportional    to size, whic
h was defined by the frequency of conscripts presented in the previous    year (
2006). In the second stage, there were selected conscripts at the moment    of t
heir presentation, in a number proportional to the size of the selection    comm
ission.</font></p>     ^cY#03.htm##
00589000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036700069002000700436#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#40#36#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study included    a fill-in questionnai
re and blood sample collection for testing of HIV and syphilis    infection. The
 questionnaire included information about social-demographic characteristics,   
 sexual behavior practices, problems related to STI and the use of illicit drugs
.</font></p>     ^cY#03.htm##
00816000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059400069002000700663#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#41#37#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For all selected    conscripts there were c
ollected blood samples that were submitted to two immunoenzymatic    essays (ELI
SA), with methodological principles and different antigens to detect    HIV infe
ction. At this stage, undetermined or divergent samples were analyzed    by West
ern Blot test for confirmation. Serological tests for syphilis were also    perf
ormed by ELISA. All the essays were performed in the Laboratory of the Institute
    of Biology of the Brazilian Army, in the city of Rio de Janeiro.</font></p> 
    ^cY#03.htm##
00703000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048100069002000700550#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#42#38#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the current    analysis there were consi
dered 36,945 conscripts aged 17 to 20 years old, but    it was only possible to 
analyze the data of 35,432 young men, since 1,513 (4.1%)    of them did not have
 information about the municipality of residence or level    of education. There
 were investigated all variables related to sexual behavior    of the conscripts
 by using the following indicators:</font></p>     ^cY#03.htm##
00419000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019700069002000700266#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#43#39#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">a) rate of sexual    activity - defined as 
the proportion of conscripts that have already had sexual    relations;</font></
p>     ^cY#03.htm##
00344000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012200069002000700191#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#44#40#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">b) age at the first    sexual relation;</fo
nt></p>     ^cY#03.htm##
00366000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014400069002000700213#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#45#41#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">c) total numbers    of partners in life and
 during last year;</font></p>     ^cY#03.htm##
00634000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704041200069002000700481#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#46#42#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">d) number of partners    in the last year, 
according to the following types: steady partner (male); casual    partner - fri
end, acquaintance, flirt; paid partner (male or female), whenever    the conscri
pt paid the partner to have sexual relations; paying partner, when    the partne
r paid the conscript to have sexual relations;</font></p>     ^cY#03.htm##
00357000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013500069002000700204#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#47#43#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">e) percentage of    men who have sex with m
en (MSM);</font></p>     ^cY#03.htm##
00383000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016100069002000700230#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#48#44#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">f) percentage of    conscripts that used co
ndom in their last sexual relation;</font></p>     ^cY#03.htm##
00384000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016200069002000700231#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#49#45#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">g) percentage of    conscripts that used co
ndom in their first sexual relation;</font></p>     ^cY#03.htm##
00460000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023800069002000700307#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#50#46#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">h) percentage of    conscripts that used co
ndom in all their sexual relations during last year (regular    use of condom) a
ccording to the type of partner;</font></p>     ^cY#03.htm##
00432000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021000069002000700279#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#51#47#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Additionally, it    was used the synthesizi
ng indicator of risky sexual behavior defined by Szwarcwald    et al. <sup>10</s
up>.</font></p>     ^cY#03.htm##
00610000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704038800069002000700457#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#52#48#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">i) risky sexual    behavior index in the la
st year - defined by the weighted mean of the number    of partners in the previ
ous year, taking as weights the percentage frequencies    of no use of condoms a
ccording to the type of partner. Mathematically, we may    express the risky sex
ual behavior index by:</font></p>     ^cY#03.htm##
00297000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007500069002000700144#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#53#49#article#158#<p align="center"><img src
="/img/revistas/csp/v27s1/03s1.jpg"></p>     ^cY#03.htm##
00834000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061200069002000700681#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#54#50#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">where: <i>i</i>    indicates the type of pa
rtner; <i>w<sub>i</sub></i>= 0.00 - never used a condom    with partners in cate
gory <i>i</i>; <i>w<sub>i</sub></i>= 0.25 - used a condom    in less than half o
f times with partners in category <i>i</i>; <i>w<sub>i</sub></i>    = 0.75 - use
d a condom in more than half of times with partners in category    <i>i</i>; <i>
w<sub>i</sub></i>= 1,00 - used a condom in all the times with partners    in the
 category <i>i</i>; <i>P<sub>i</sub></i> = number of partners in category    <i>
i</i>.</font></p>     ^cY#03.htm##
00773000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055100069002000700620#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#55#51#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding problems    related to STI, the c
onscripts were questioned about the following problems:    discharge (pus) in th
e urethra; wounds in the penis; small blisters in the penis;    and warts in the
 penis. After the previous selection of conscripts who declared    having the pr
oblem after the start of sexual activity, there were calculated    the percentag
es of occurrence for each one of the problems, as well as the non-occurrence    
of any of these problems.</font></p>     ^cY#03.htm##
00492000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027000069002000700339#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#56#52#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For the analysis    of the use of injecting
 drugs, two indicators were considered: Proportion of    use at least once in li
fe and the proportion of conscripts who reported current    use.</font></p>     
^cY#03.htm##
00784000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056200069002000700631#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#57#53#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Since it is a set    of data obtained by me
ans of a complex sample that combines stratification and    conglomeration, the 
design of the survey was incorporated in the statistical    analysis of data. It
 was also necessary to use a calibration procedure of the    sample, according t
o the census distribution by population size of city of residence    (less than 
50,000 inhabitants; 50,001 to 200,000 inhabitants and greater than    200,000 in
habitants), age and education level.</font></p>     ^cY#03.htm##
00487000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026500069002000700334#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#58#54#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">There were estimated    the prevalence rate
s of HIV for the total sample and by population subgroup,    established by educ
ation level, sexual preference and problems related to STI.</font></p>     ^cY#0
3.htm##
01076000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085400069002000700923#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#59#55#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the multivariate    analysis, there were
 used procedures of logistic regression to find factors    that were mostly asso
ciated to HIV infection in 2007. Initially there were used    models of univaria
te logistic regression to calculate the crude odds ratio.    In the multivariate
 analysis, there were included all variables that are potentially    associated 
to HIV infection: Education level (incomplete fundamental school);    being MSM;
 risky index of sexual behavior; more than 5 partners in a year; more    than 10
 partners in life; at least one problem related to STI. For the selection    of 
joint variables more associated to HIV, there was used a stepwise procedure,    
with inclusion and exclusion of variables in each step based on the likelihood  
  ratio.</font></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#60#56#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#61#57#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#03.htm##
00746000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052400069002000700593#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#62#58#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">There were analyzed    35,432 conscripts ag
ed 17 to 20. <a href="#t1">Table 1</a> presents indicators    of sexual behavior
 compared with those obtained in previous surveys with conscripts    (1997-2000 
and 2002). There is a decrease in sexual activity among young people    from 82%
 in 2002 to 75% in 2007. Likewise, the proportion of young people who    start t
heir sexual activity before age 14 reduced from 25% in 1999 to 17% in    2007.</
font></p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#63#59#article#158#<p><a name="t1"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#64#60#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#65#61#article#158#<p align="center"><img src
="/img/revistas/csp/v27s1/03t01.jpg"></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#66#62#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00500000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027800069002000700347#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#67#63#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the use    of injecting drugs, th
e trend for decrease is clear: the proportion of use at    least once in life re
duced from 1.9% in 1999, to 0.5% in 2007 (<a href="#t1">Table    1</a>).</font><
/p>     ^cY#03.htm##
00824000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060200069002000700671#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#68#64#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among sexually    active young men, the pro
portion of conscripts who had sexual relations with    men (MSM) remained at 3.2
%, while the proportion with more than 10 partners    in life showed a small inc
rease (22.6%). Regarding protected sex in the analyzed    period, there was a gr
adual increase in the proportion of conscripts using a    condom in their last s
exual relation, reaching 71.5% in 2007 while the proportion    of use in the fir
st sexual relation was slightly lower at 67% (<a href="#t1">Table    1</a>).</fo
nt></p>     ^cY#03.htm##
00591000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036900069002000700438#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#69#65#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the young    me who had sexual relati
ons in the last year, the proportion of paid sex was    in the same rate as the 
year of 2002 (16%), but the proportion of conscripts    who were paid to have se
x reduced considerably in more than 5% in 1999 and 2000    to less than 3% in 20
07.</font></p>     ^cY#03.htm##
00598000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037600069002000700445#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#70#66#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the regular    use of condoms amo
ng young men who had sexual relations in the past year, there    was a decrease 
in the results: the proportion in the regular use of condoms    whether with ste
ady partners or casual ones decreased 5.4% and 3.7% respectively    in compariso
n to 2002.</font></p>     ^cY#03.htm##
00941000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071900069002000700788#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#71#67#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The percentage    of regular condom use wit
h any partner and the index of risky sexual behavior    are presented on <a href
="#t2">Table 2</a> for the years of 2002 and 2007. Regarding    the regular use 
of condoms, the percentage of conscripts declined, especially    among those wit
h less education. Among young people with incomplete fundamental    education, t
he average rate of risky sexual behavior increased from 1.0 in 2002    to 1.57 i
n 2007, while among the conscripts with complete fundamental education    the ra
te remained stable. Among MSM, the index increased 36%, while among heterosexual
    young people it increased 9%.</font></p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#72#68#article#158#<p><a name="t2"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#73#69#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#74#70#article#158#<p align="center"><img src
="/img/revistas/csp/v27s1/03t02.jpg"></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#75#71#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00787000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056500069002000700634#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#76#72#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding sexually    active conscripts who
 reported problems related to STI (<a href="/img/revistas/csp/v27s1/03t03.jpg">T
able    3</a>), the percentage of occurrence of all the problems studied here (d
ischarges,    blisters, wounds and warts on the penis) decreased from 2002 to 20
07. The prevalence    rate of syphilis declined from 0.85% to 0.53%. The HIV pre
valence rate increased,    although not statistically significant, increasing fr
om 0.090% in 2002 to 0.117%    in 2007.</font></p>     ^cY#03.htm##
00472000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025000069002000700319#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#77#73#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#t4">Table    4</a> shows the esti
mated rates of HIV prevalence in population subgroups in    2007. We highlight t
he high levels of prevalence rate among MSM.</font></p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#78#74#article#158#<p><a name="t4"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#79#75#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#80#76#article#158#<p align="center"><img src
="/img/revistas/csp/v27s1/03t04.jpg"></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#81#77#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00628000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040600069002000700475#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#82#78#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The results of    multivariate logistic reg
ression with the test result for HIV as the response    variable are presented o
n <a href="#t5">Table 5</a>. The main factors associated    with HIV infection w
ere: being MSM (OR = 14.6; p &lt; 0.0001); having at least    one problem relate
d to STI; more than 10 partners in life.</font></p>     ^cY#03.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#83#79#article#158#<p><a name="t5"></a></p>  
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#84#80#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#85#81#article#158#<p align="center"><img src
="/img/revistas/csp/v27s1/03t05.jpg"></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#86#82#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#87#83#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#03.htm
##
00922000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070000069002000700769#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#88#84#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The series of surveys    performed with Bra
zilian Army conscripts represents a unique opportunity to    analyze the behavio
r of young males. Since the presentation to military service    is a legal oblig
ation of the young men when they reach 18, the continued inclusion    of questio
ns about practices related to HIV allows the monitoring of indicators    and eva
luating actions of prevention and control. Five years after the last    survey, 
the data collected in 2007 enabled the observation of relevant changes    in the
 behavior of the Brazilian young men as well as reporting risky practices    to 
HIV infection.</font></p>     ^cY#03.htm##
00833000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061100069002000700680#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#89#85#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, it is    necessary to point out so
me limitations of surveys with conscripts. The first    one refers to the exclus
ion of illiterate ones, who are only conscripted and    then dismissed from mili
tary service. The second is related to the way the survey    was conducted, with
 self-filling of questionnaires. On one hand, the self-filling    facilitates th
e veracity in response, but on the other hand, it leads to losses    by the inad
equate filling of relevant information, which is necessary for sample    calibra
tion.</font></p>     ^cY#03.htm##
00938000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071600069002000700785#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#90#86#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the comparison    of 2007 results
 with previous results, there were observed some positive changes.    Among them
, we highlight the trend of steady decline in the proportion of use    if inject
ing drugs, the increase in the proportion of condom use during the    last sexua
l relation and the reduction in the occurrence of problems related    to STI, in
cluding the reduction in the rate of prevalence of syphilis. It is    necessary 
to mention that the positive ELISA test for syphilis does not necessarily    ind
icate active syphilis, and it may refer to prior infection (serological scar)   
 by <i>Treponema pallidum</i>.</font></p>     ^cY#03.htm##
00582000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036000069002000700429#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#91#87#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A survey performed    in the United States 
with the young American population shows similar results    to ours <sup>2</sup>
. Like in Brazil, the use of condoms by males in the first    and most recent se
xual intercourse is around 70% among male adolescents aged    15-19 years.</font
></p>     ^cY#03.htm##
00985000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076300069002000700832#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#92#88#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, the 2007    study also presented n
egative results. Among MSM there is a worsening in sexual    behavior indicators
, with a significant increase in the rate of risky sexual    behavior between 20
02 and 2007. This population subgroup presents a significantly    lower percenta
ge of regular condom use when compared to the heterosexual group    14 times mor
e likely to be infected with HIV. It is important to mention that    13 of the 3
9 young men infected by HIV were MSM. These results indicate the    need to dire
ct specific efforts to young MSM, with prevention campaigns and    strategies th
at take into consideration the increased risk of this population    subgroup.</f
ont></p>     ^cY#03.htm##
00838000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061600069002000700685#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#93#89#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As discussed by    Merson et al. <sup>14</s
up>, it is necessary to understand that the prevention    strategies may not be 
unique to the total population of Brazilian young men.    The findings here amon
g homo/bisexual young men show different risk behaviors    and reinforce strateg
ies geared towards groups presenting greater risk. Access    strategies to popul
ation subgroups under higher risk through recruitment chain    have been used in
ternationally, achieving better results than with traditional    approaches <sup
>15</sup>.</font></p>     ^cY#03.htm##
01170000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704094800069002000701017#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#94#90#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The results related    to the regular use o
f condoms, in a general way, did not show progress either    and suggest that th
e prevention strategies need to be reformulated. The regular    use of condoms a
mong young people declined for both fixed and casual partners    between 2002 an
d 2007. After more than 20 years since the first cases of AIDS    in Brazil, you
ng people who were part of the present study were born with the    epidemic alre
ady present in the country, living with a disease that has treatment,    without
 having experienced the high lethality of AIDS at the onset of AIDS epidemic    
<sup>16</sup>. Although there is no longer the death sentence perception, AIDS  
  has no cure and people under antiretroviral therapy present losses in quality 
   of life, restrictions in work activities, and loss of socioeconomic condition
s    <sup>17,18</sup>.</font></p>     ^cY#03.htm##
01035000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081300069002000700882#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#95#91#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Studies have shown    that the efforts for 
prevention related to the use of condoms are without a    doubt effective and ma
y significantly reduce the incidence of HIV infection,    but they cannot elimin
ate the disease. Through mathematical modeling, it is    shown that the transiti
on from endemic to epidemic stage would be accelerated    to an elimination stag
e, in case all HIV-infected adults who were not on antiretroviral    therapy sta
rted receiving it <sup>19</sup>. In the current literature, it is    debated the
 impact of the expansion of treatment among recent cases of HIV infection    <su
p>20</sup>. However, the stigma and fear of the result still restrict many    of
 the youth to perform periodic testing for HIV.</font></p>     ^cY#03.htm##
00991000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076900069002000700838#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#96#92#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Another aspect    presented in the survey w
as the synergy of risky sexual practices. The young    people who perform unprot
ected sex have, at the same time, multiple partners    and earlier sexual initia
tion. Considering that this is also the population    segment that generally pre
sents lower education, it is the group that should    be primarily targeted with
 preventive measures and educational campaigns <sup>21</sup>.    The analysis sh
owed that the rate of risky sexual behavior has increased over    50% in the per
iod 2002-2007 among young people with incomplete fundamental education,    while
 among the conscripts with complete fundamental education index remained    stab
le.</font></p>     ^cY#03.htm##
00725000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050300069002000700572#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#97#93#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the predictor    factors of HIV infec
tion, besides being MSM, we also highlight the multiple    partners and problems
 related to STI. The survey showed an increase in the prevalence    among conscr
ipts who presented positive results for syphilis. Preventive actions    consider
ing the free distribution of condoms, treatment and control of sexually    trans
mitted infections have been cost-effective <sup>22</sup>.</font></p>     ^cY#03.
htm##
01014000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079200069002000700861#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#98#94#article#158#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite the continued    efforts and some p
ositive results, we must admit that the response to the AIDS    epidemic among y
oung people is going through a time of vulnerability. In a period    of five yea
rs there has been an increase in the HIV prevalence rate, although    not statis
tically significant. There is a clear reduction in the regular use    of condoms
 among young people with low educational level and a worsening in    the rate of
 risky sexual behavior among MSM, a group that continues to be disproportionatel
y    affected by the epidemic of HIV/AIDS <sup>23</sup>. In conclusion, the evid
ence    found in this survey indicate the need for restructuring policies among 
Brazilian    young adults.</font></p>     ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#99#95#article#158#<p>&nbsp;</p>     ^cY#03.h
tm##
00325000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704010200070002000700172#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#100#96#article#158#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#03.
htm##
00960000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704073700070002000700807#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#101#97#article#158#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">C. L. Szwarcwald    was the head of the ar
ticle, in charge of its conception and text development.    C. L. T. Andrade par
ticipated in the text conception and was responsible for    the composition of r
esults and development of tables. A. R. P. Pascom worked    on data analysis, co
mposition of methodology and discussion. E. Fazito was the    coordinator of the
 field study and participated in the development of the methodology.    G. F. M.
 Pereira coordinated the survey and participated in the development    of the me
thodology. I. T. Penha performed the bibliographic research and participated    
in the development of the development of the tables.</font></p>     ^cY#03.htm##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#102#98#article#158#<p>&nbsp;</p>     ^cY#03.
htm##
00323000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704010000070002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#103#99#article#158#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#03.ht
m##
00486000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024800073002000700321#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#104#100#article#158#1#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">1. Warren CW, Santelli    J
S, Everett SA, Kann L, Collins JL, Cassell C, et al. Sexual behavior among    U.
S. high school students, 1990-1995. Fam Plann Perspect 1998; 30:170-2.    ^cY#03
.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#105#101#article#158#</font></p>     ^cY#03.h
tm##
00508000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027000073002000700343#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#106#102#article#158#2#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2. Gavin L, MacKay    AP, B
rown K, Harrier S, Ventura SJ, Kann L, et al. Sexual and reproductive health    
of persons aged 10-24 years - United States, 2002-2007. MMWR Surveill Summ 2009;
    58:1-58.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#107#103#article#158#</font></p>     ^cY#03.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704028000073002000700353#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#108#104#article#158#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Adefuye AS,    Abiona TC
, Balogun JA, Lukobo-Durrell M. HIV sexual risk behaviors and perception    of r
isk among college students: implications for planning interventions. BMC    Publ
ic Health 2009; 9:281.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#109#105#article#158#</font></p>     ^cY#03.h
tm##
00519000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704028100073002000700354#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#110#106#article#158#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Miranda AE,    Szwarcwal
d CL, Peres RL, Page-Shafer K. Prevalence and risk behaviors for chlamydial    i
nfection in a population-based study of female adolescents in Brazil. Sex Transm
    Dis 2004; 31:542-6.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#111#107#article#158#</font></p>     ^cY#03.h
tm##
00511000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027300073002000700346#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#112#108#article#158#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Ruzany MH, Szwarcwald   
 CL. Mortalidade de adolescentes no munic&iacute;pio do Rio de Janeiro, de 1981 
   a 1995 - quantos &oacute;bitos poderiam ser evitados? J Pediatr (Rio J.) 1999
;    75:327-33.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#113#109#article#158#</font></p>     ^cY#03.h
tm##
00479000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024100073002000700314#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#114#110#article#158#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Staton M, Leukefeld    C
, Logan TK, Zimmerman R, Lynam D, Milich R, et al. Risky sex behavior and substa
nce    use among young adults. Health Soc Work 1999; 24:147-54.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#115#111#article#158#</font></p>     ^cY#03.h
tm##
00627000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704038900073002000700462#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#116#112#article#158#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. United Nations    Joint 
Programme on HIV/AIDS/United States Agency for International Development.    MAP
: monitoring of the AIDS pandemic. The status and trends of the HIV/AIDS    epid
emics in the world. Geneva: United Nations Joint Programme on HIV/AIDS/United   
 States Agency for International Development; 2000.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#117#113#article#158#</font></p>     ^cY#03.h
tm##
00458000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704022000073002000700293#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#118#114#article#158#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Piot P, Bartos    M, Lar
son H, Zewdie D, Mane P. Coming to terms with complexity: a call to action    fo
r HIV prevention. Lancet 2008; 372:845-59.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#119#115#article#158#</font></p>     ^cY#03.h
tm##
00497000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025900073002000700332#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#120#116#article#158#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Nelson KE, Celentano    
DD, Suprasert S, Wright N, Eiumtrakul S, Tulvatana S, et al. Risk factors for   
 HIV infection among young adult men in northern Thailand. JAMA 1993; 270:955-60
.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#121#117#article#158#</font></p>     ^cY#03.h
tm##
00662000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704042300074002000700497#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#122#118#article#158#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Programa Nacional    d
e DST e AIDS, Secretaria de Vigil&acirc;ncia em Sa&uacute;de Minist&eacute;rio  
  da Sa&uacute;de. Pesquisa entre conscritos do Ex&eacute;rcito Brasileiro 1996-
2002:    retratos do comportamento de risco do jovem brasileiro &agrave; infec&c
cedil;&atilde;o    pelo HIV. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de;
 2006.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#123#119#article#158#</font></p>     ^cY#03.h
tm##
00531000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029200074002000700366#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#124#120#article#158#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Szwarcwald    CL, Carv
alho MF, Barbosa J&uacute;nior A, Barreira D, Speranza FA, Castilho    EA. Tempo
ral trends of HIV-related risk behavior among Brazilian military conscripts,    
1997-2002. Clinics 2005; 60:367-74.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#125#121#article#158#</font></p>     ^cY#03.h
tm##
00655000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704041600074002000700490#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#126#122#article#158#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Szwarcwald    CL, Cast
ilho EA, Barbosa Jr. A, Gomes MR, Costa EA, Maletta BV, et al. Comportamento    
de risco dos conscritos do Ex&eacute;rcito Brasileiro, 1998: uma aprecia&ccedil;
&atilde;o    da infec&ccedil;&atilde;o pelo HIV segundo diferenciais s&oacute;ci
o-econ&ocirc;micos.    Cad Sa&uacute;de P&uacute;blica 2000; 16 Suppl 1:113-28. 
   ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#127#123#article#158#</font></p>     ^cY#03.h
tm##
00624000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704038500074002000700459#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#128#124#article#158#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Bastos FI,    Lowndes 
CM, Castello-Branco LR, Linhares-de-Carvalho MI, Oelemann W, Bernier    F, et al
. Sexual behaviour and infection rates for HIV, blood-borne and sexually    tran
smitted infections among patients attending drug treatment centres in Rio    de 
Janeiro, Brazil. Int J STD AIDS 2000; 11:383-92.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#129#125#article#158#</font></p>     ^cY#03.h
tm##
00434000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019500074002000700269#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#130#126#article#158#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Merson MH,    O'Malley
 J, Serwadda D, Apisuk C. The history and challenge of HIV prevention.    Lancet
 2008; 372:475-88.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#131#127#article#158#</font></p>     ^cY#03.h
tm##
00606000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036700074002000700441#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#132#128#article#158#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Amirkhanian    YA, Kel
ly JA, Takacs J, Kuznetsova AV, DiFranceisco WJ, Mocsonaki L, et al.    HIV/STD 
prevalence, risk behavior, and substance use patterns and predictors    in Russi
an and Hungarian sociocentric social networks of men who have sex with    men. A
IDS Educ Prev 2009; 21:266-79.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#133#129#article#158#</font></p>     ^cY#03.h
tm##
00486000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024700074002000700321#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#134#130#article#158#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Velasco-Hernandez    J
X, Gershengorn HB, Blower SM. Could widespread use of combination antiretroviral
    therapy eradicate HIV epidemics? Lancet Infect Dis 2002; 2:487-93.    ^cY#03
.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#135#131#article#158#</font></p>     ^cY#03.h
tm##
00430000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019100074002000700265#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#136#132#article#158#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Piot P, Kazatchkine   
 M, Dybul M, Lob-Levyt J. AIDS: lessons learnt and myths dispelled. Lancet 2009;
    374:260-3.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#137#133#article#158#</font></p>     ^cY#03.h
tm##
00516000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027700074002000700351#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#138#134#article#158#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Souza Junior    PRB, S
zwarcwald CL, Castilho EA. Self-rated health by HIV-infected individuals    unde
rgoing antiretroviral therapy in Brazil. Cad Sa&uacute;de P&uacute;blica    2011
; 27 Suppl 1:S56-66.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#139#135#article#158#</font></p>     ^cY#03.h
tm##
00540000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030100074002000700375#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#140#136#article#158#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Granich RM,    Gilks C
F, Dye C, Cock KM, Williams BG. Universal voluntary HIV testing with    immediat
e antiretroviral therapy as a strategy for elimination of HIV transmission:    a
 mathematical model. Lancet 2009; 373:48-57.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#141#137#article#158#</font></p>     ^cY#03.h
tm##
00549000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031000074002000700384#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#142#138#article#158#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Lima VD, Johnston    K
, Hogg RS, Levy AR, Harrigan PR, Anema A, et al. Expanded access to highly    ac
tive antiretroviral therapy: a potentially powerful strategy to curb the growth 
   of the HIV epidemic. J Infect Dis 2008; 198:59-67.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#143#139#article#158#</font></p>     ^cY#03.h
tm##
00554000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031500074002000700389#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#144#140#article#158#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Pettifor AE,    Levand
owski BA, MacPhail C, Padian NS, Cohen MS, Rees HV. Keep them in school:    the 
importance of education as a protective factor against HIV infection among    yo
ung South African women. Int J Epidemiol 2008; 37:1266-73.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#145#141#article#158#</font></p>     ^cY#03.h
tm##
00478000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023900074002000700313#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#146#142#article#158#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Creese A, Floyd    K, 
Alban A, Guinness L. Cost-effectiveness of HIV/AIDS interventions in Africa:    
a systematic review of the evidence. Lancet 2002; 359:1635-43.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#147#143#article#158#</font></p>     ^cY#03.h
tm##
00522000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028300074002000700357#v27
s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#p#148#144#article#158#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Barbosa J&uacute;nior 
   A, Szwarcwald CL, Pascom AR, Souza J&uacute;nior PB. Trends in the AIDS epide
mic    in groups at highest risk in Brazil, 1980-2004. Cad Sa&uacute;de P&uacute
;blica    2009; 25:727-37.    ^cY#03.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#149#145#article#158#</font></p>     ^cY#03.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#150#146#article#158#<p>&nbsp;</p>     ^cY#03
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#151#147#article#158#<p>&nbsp;</p>     ^cY#03
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#152#148#article#158#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#03.htm##
00260000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003600071002000700107#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#153#149#article#158#<br>   </b> C. L. Szwarc
wald    ^cY#03.htm##
00302000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007800071002000700149#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#154#150#article#158#<br>   Laborat&oacute;ri
o de Informa&ccedil;&otilde;es em Sa&uacute;de    ^cY#03.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013800071002000700209#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#155#151#article#158#<br>   Instituto de Comu
nica&ccedil;&atilde;o e Informa&ccedil;&atilde;o Cient&iacute;fica    e Tecnol&o
acute;gica em Sa&uacute;de    ^cY#03.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#156#152#article#158#<br>   Funda&ccedil;&ati
lde;o Oswaldo Cruz    ^cY#03.htm##
00295000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007100071002000700142#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#157#153#article#158#<br>   Av. Brasil 4365, 
Pavilh&atilde;o Haity Moussatch&eacute;    ^cY#03.htm##
00275000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005100071002000700122#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#158#154#article#158#<br>   Rio de Janeiro, R
J 21040-900, Brasil    ^cY#03.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#159#155#article#158#<br>   <a href="mailto:c
elials@cict.fiocruz.br">celials@cict.fiocruz.br</a></font></p>     ^cY#03.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#160#156#article#158#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 29/Oct/2009    ^cY#03.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#161#157#article#158#<br>   Final version res
ubmitted on 28/Jan/2010    ^cY#03.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\03.htm#S#p#162#158#article#158#<br>   Approved on 08/Ma
r/2010</font></p>     ^cY#03.htm##
00668000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100019000870100
01800106010001400124010001800138010001700156810000600173012006400179030001900243
06500090026206400050027103100030027601400060027986500090028500200070029403500100
0301801001900311#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#163#1#articl
e#23#1#^rND^sWarren^nCW#^rND^sSantelli^nJS#^rND^sEverett^nSA#^rND^sKann^nL#^rND^
sCollins^nJL#^rND^sCassell^nC#et al#Sexual behavior among U: S. high school stud
ents, 1990-1995^len#Fam Plann Perspect#19980000#1998#30#170-2#20110000#03.htm#00
14-7354#Fam Plann Perspect##
00647000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100017000850100
01500102010001700117010001800134010001400152810000600166012009000172030001900262
71000020028106500090028306400050029203100030029701400050030086500090030500200070
0314#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#164#2#article#23#2#^rND^
sGavin^nL#^rND^sMacKay^nAP#^rND^sBrown^nK#^rND^sHarrier^nS#^rND^sVentura^nSJ#^rN
D^sKann^nL#et al#Sexual and reproductive health of persons aged 10-24 years - Un
ited States, 2002-2007^len#MMWR Surveill Summ#2#20090000#2009#58#1-58#20110000#0
3.htm##
00610000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01800105010002400123012011700147030001800264710000200282065000900284064000500293
031000200298014000400300865000900304002000700313#v27s1#V:\SciELO\serial\csp\v27s
1\markup\03.htm#S#c#165#3#article#23#3#^rND^sAdefuye^nAS#^rND^sAbiona^nTC#^rND^s
Balogun^nJA#^rND^sLukobo-Durrell^nM#HIV sexual risk behaviors and perception of 
risk among college students: implications for planning interventions^len#BMC Pub
lic Health#2#20090000#2009#9#281#20110000#03.htm##
00646000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100021000880100
01600109010002100125012011900146030001500265065000900280064000500289031000300294
014000600297865000900303002000700312035001000319801001500329#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\03.htm#S#c#166#4#article#23#4#^rND^sMiranda^nAE#^rND^sSzwar
cwald^nCL#^rND^sPeres^nRL#^rND^sPage-Shafer^nK#Prevalence and risk behaviors for
 chlamydial infection in a population-based study of female adolescents in Brazi
l^len#Sex Transm Dis#20040000#2004#31#542-6#20110000#03.htm#0148-5717#Sex Transm
 Dis##
00575000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100021000870120
11900108030001000227065000900237064000500246031000300251014000700254865000900261
002000700270035001000277801001000287#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.
htm#S#c#167#5#article#23#5#^rND^sRuzany^nMH#^rND^sSzwarcwald^nCL#Mortalidade de 
adolescentes no município do Rio de Janeiro, de 1981 a 1995 - quantos óbitos pod
eriam ser evitados?^lpt#J Pediatr#19990000#1999#75#327-33#20110000#03.htm#0022-3
476#J Pediatr##
00657000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100019000860100
01600105010001900121010001500140010001600155810000600171012006000177030001600237
06500090025306400050026203100030026701400070027086500090027700200070028603500100
0293801001600303#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#168#6#articl
e#23#6#^rND^sStaton^nM#^rND^sLeukefeld^nC#^rND^sLogan^nTK#^rND^sZimmerman^nR#^rN
D^sLynam^nD#^rND^sMilich^nR#et al#Risky sex behavior and substance use among you
ng adults^len#Health Soc Work#19990000#1999#24#147-54#20110000#03.htm#0360-7283#
Health Soc Work##
00628000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170094000700180103001640660
00700267062009400274065000900368064000500377865000900382002000700391#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\03.htm#S#c#169#7#article#23#7#United Nations Joint 
Programme on HIV/AIDS/United States Agency for International Development#MAP: mo
nitoring of the AIDS pandemic. The status and trends of the HIV/AIDS epidemics i
n the world^len#Geneva#United Nations Joint Programme on HIV/AIDS/United States 
Agency for International Development#20000000#2000#20110000#03.htm##
00598000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100014000700100016000840100
01600100010001600116010001400132012007300146030000700219065000900226064000500235
031000400240014000700244865000900251002000700260035001000267801000700277#v27s1#V
:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#170#8#article#23#8#^rND^sPiot^nP#^rN
D^sBartos^nM#^rND^sLarson^nH#^rND^sZewdie^nD#^rND^sMane^nP#Coming to terms with 
complexity: a call to action for HIV prevention^len#Lancet#20080000#2008#372#845
-59#20110000#03.htm#0099-5355#Lancet##
00664000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100020000870100
01900107010001600126010002000142010001900162810000600181012007800187030000500265
06500090027006400050027903100040028401400070028886500090029500200070030403500100
0311801000500321#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#171#9#articl
e#23#9#^rND^sNelson^nKE#^rND^sCelentano^nDD#^rND^sSuprasert^nS#^rND^sWright^nN#^
rND^sEiumtrakul^nS#^rND^sTulvatana^nS#et al#Risk factors for HIV infection among
 young adult men in northern Thailand^len#JAMA#19930000#1993#270#955-60#20110000
#03.htm#0098-7484#JAMA##
00594000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160039000720180194001110660
00900305062002000314065000900334064000500343865000900348002000700357#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\03.htm#S#c#172#10#article#23#10#^rND^sPrograma Naci
onal de DST e^nAIDS#Secretaria de Vigilância em Saúde Ministério da Saúde: Pesqu
isa entre conscritos do Exército Brasileiro 1996-2002: retratos do comportamento
 de risco do jovem brasileiro à infecção pelo HIV^lpt#Brasília#Ministério da Saú
de#20060000#2006#20110000#03.htm##
00680000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930100
02400112010001800136010001900154010001900173012009600192030000800288065000900296
06400050030503100030031001400070031386500090032000200070032903500100033680100080
0346#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#173#11#article#23#11#^rN
D^sSzwarcwald^nCL#^rND^sCarvalho^nMF#^rND^sBarbosa Júnior^nA#^rND^sBarreira^nD#^
rND^sSperanza^nFA#^rND^sCastilho^nEA#Temporal trends of HIV-related risk behavio
r among Brazilian military conscripts, 1997-2002^len#Clinics#20050000#2005#60#36
7-74#20110000#03.htm#1807-5932#Clinics##
00672000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930100
01800112012018800130030001800318710000200336065000900338064000500347031000300352
032000400355014000700359865000900366002000700375#v27s1#V:\SciELO\serial\csp\v27s
1\markup\03.htm#S#c#174#12#article#23#12#^rND^sSzwarcwald^nCL#^rND^sCastilho^nEA
#^rND^sBarbosa^nJr#A, Gomes MR, Costa EA, Maletta BV, et al: Comportamento de ri
sco dos conscritos do Exército Brasileiro, 1998: uma apreciação da infecção pelo
 HIV segundo diferenciais sócio-econômicos^lpt#Cad Saúde Pública#2#20000000#2000
#16#^s1#113-28#20110000#03.htm##
00795000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
02600107010003100133010001800164010001700182810000600199012017200205030001500377
06500090039206400050040103100030040601400070040986500090041600200070042503500100
0432801001500442#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#175#13#artic
le#23#13#^rND^sBastos^nFI#^rND^sLowndes^nCM#^rND^sCastello-Branco^nLR#^rND^sLinh
ares-de-Carvalho^nMI#^rND^sOelemann^nW#^rND^sBernier^nF#et al#Sexual behaviour a
nd infection rates for HIV, blood-borne and sexually transmitted infections amon
g patients attending drug treatment centres in Rio de Janeiro, Brazil^len#Int J 
STD AIDS#20000000#2000#11#383-92#20110000#03.htm#0956-4624#Int J STD AIDS##
00556000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01800107010001600125012004800141030000700189065000900196064000500205031000400210
014000700214865000900221002000700230035001000237801000700247#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\03.htm#S#c#176#14#article#23#14#^rND^sMerson^nMH#^rND^sO'Ma
lley^nJ#^rND^sSerwadda^nD#^rND^sApisuk^nC#The history and challenge of HIV preve
ntion^len#Lancet#20080000#2008#372#475-88#20110000#03.htm#0099-5355#Lancet##
00777000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100016000940100
01600110010002100126010002300147010001900170810000600189012016400195030001500359
06500090037406400050038303100030038801400070039186500090039800200070040703500100
0414801001500424#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#177#15#artic
le#23#15#^rND^sAmirkhanian^nYA#^rND^sKelly^nJA#^rND^sTakacs^nJ#^rND^sKuznetsova^
nAV#^rND^sDiFranceisco^nWJ#^rND^sMocsonaki^nL#et al#HIV/STD prevalence, risk beh
avior, and substance use patterns and predictors in Russian and Hungarian socioc
entric social networks of men who have sex with men^len#AIDS Educ Prev#20090000#
2009#21#266-79#20110000#03.htm#0899-9546#AIDS Educ Prev##
00564000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100028000720100022001000100
01700122012008800139030001800227710000200245065000900247064000500256031000200261
014000700263865000900270002000700279#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.
htm#S#c#178#16#article#23#16#^rND^sVelasco-Hernandez^nJX#^rND^sGershengorn^nHB#^
rND^sBlower^nSM#Could widespread use of combination antiretroviral therapy eradi
cate HIV epidemics?^len#Lancet Infect Dis#2#20020000#2002#2#487-93#20110000#03.h
tm##
00552000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100021000860100
01500107010001900122012004500141030000700186065000900193064000500202031000400207
014000600211865000900217002000700226035001000233801000700243#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\03.htm#S#c#179#17#article#23#17#^rND^sPiot^nP#^rND^sKazatch
kine^nM#^rND^sDybul^nM#^rND^sLob-Levyt^nJ#AIDS: lessons learnt and myths dispell
ed^len#Lancet#20090000#2009#374#260-3#20110000#03.htm#0099-5355#Lancet##
00584000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100021000960100
01900117012009400136030001800230710000200248065000900250064000500259031000300264
032000400267014000700271865000900278002000700287#v27s1#V:\SciELO\serial\csp\v27s
1\markup\03.htm#S#c#180#18#article#23#18#^rND^sSouza Junior^nPRB#^rND^sSzwarcwal
d^nCL#^rND^sCastilho^nEA#Self-rated health by HIV-infected individuals undergoin
g antiretroviral therapy in Brazil^len#Cad Saúde Pública#2#20110000#2011#27#^s1#
S56-66#20110000#03.htm##
00677000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100016000900100
01300106010001500119010001900134012014600153030000700299065000900306064000500315
031000400320014000600324865000900330002000700339035001000346801000700356#v27s1#V
:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#181#19#article#23#19#^rND^sGranich^n
RM#^rND^sGilks^nCF#^rND^sDye^nC#^rND^sCock^nKM#^rND^sWilliams^nBG#Universal volu
ntary HIV testing with immediate antiretroviral therapy as a strategy for elimin
ation of HIV transmission: a mathematical model^len#Lancet#20090000#2009#373#48-
57#20110000#03.htm#0099-5355#Lancet##
00721000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
01500105010001500120010001900135010001500154810000600169012013200175030001300307
06500090032006400050032903100040033401400060033886500090034400200070035303500100
0360801001300370#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#182#20#artic
le#23#20#^rND^sLima^nVD#^rND^sJohnston^nK#^rND^sHogg^nRS#^rND^sLevy^nAR#^rND^sHa
rrigan^nPR#^rND^sAnema^nA#et al#Expanded access to highly active antiretroviral 
therapy: a potentially powerful strategy to curb the growth of the HIV epidemic^
len#J Infect Dis#20080000#2008#198#59-67#20110000#03.htm#0022-1899#J Infect Dis#
#
00718000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100022000910100
01800113010001700131010001600148010001500164012013000179030001600309065000900325
06400050033403100030033901400080034286500090035000200070035903500100036680100160
0376#v27s1#V:\SciELO\serial\csp\v27s1\markup\03.htm#S#c#183#21#article#23#21#^rN
D^sPettifor^nAE#^rND^sLevandowski^nBA#^rND^sMacPhail^nC#^rND^sPadian^nNS#^rND^sC
ohen^nMS#^rND^sRees^nHV#Keep them in school: the importance of education as a pr
otective factor against HIV infection among young South African women^len#Int J 
Epidemiol#20080000#2008#37#1266-73#20110000#03.htm#0300-5771#Int J Epidemiol##
00600000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01500103010001800118012009600136030000700232065000900239064000500248031000400253
014000800257865000900265002000700274035001000281801000700291#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\03.htm#S#c#184#22#article#23#22#^rND^sCreese^nA#^rND^sFloyd
^nK#^rND^sAlban^nA#^rND^sGuinness^nL#Cost-effectiveness of HIV/AIDS intervention
s in Africa: a systematic review of the evidence^len#Lancet#20020000#2002#359#16
35-43#20110000#03.htm#0099-5355#Lancet##
00586000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100021000960100
01700117010002300134012007900157030001800236710000200254065000900256064000500265
031000300270014000700273865000900280002000700289#v27s1#V:\SciELO\serial\csp\v27s
1\markup\03.htm#S#c#185#23#article#23#23#^rND^sBarbosa Júnior^nA#^rND^sSzwarcwal
d^nCL#^rND^sPascom^nAR#^rND^sSouza Júnior^nPB#Trends in the AIDS epidemic in gro
ups at highest risk in Brazil, 1980-2004^len#Cad Saúde Pública#2#20090000#2009#2
5#727-37#20110000#03.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#o#1#1#article#1#201104
11#073658#04.htm#229##
03723000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400110013303500100014401201040015401201190
02580100036003770100038004130700089004510700124005400830975006640850010016390850
02801649085003101677085002701708085003201735083110401767085001002871085003302881
08500360291408500300295008500360298011700080301607200030302411200090302711100120
3036116000903048115001203057114000903069113001203078002000703090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#TAB#04#CSP33
0#nd#Cad. Saúde Pública#27#1#20110000#^fs27^ls35#0102-311X#Sex inequalities in H
IV-related practices in the Brazilian population aged 15 to 64 years old, 2008^l
en#Desigualdades por sexo nas práticas relacionadas à infecção pelo HIV na popul
ação brasileira de 15 a 64 anos, 2008^lpt#^rND^1A01^nAna Roberta Pati^sPascom#^r
ND^1A02^nCélia Landmann^sSzwarcwald#Ministério da Saúde^iA01^1Departamento de DS
T, AIDS e Hepatites Virais^cBrasília^pBrasil#Fundação Oswaldo Cruz^iA02^1Institu
to de Comunicação e Informação Científica e Tecnológica em Saúde^cRio de Janeiro
^pBrasil#^len^aThe objective of this study is to analyze gender differences in H
IV-related practices in the Brazilian population. A national survey was carried 
out in 2008 with a sample size of 8,000 individuals aged 15-64 years old. The sa
mpling was stratified by macro geographical region and urban/rural areas. Logist
ic regression models were used to investigate the main predictors of consistent 
condom use. The results showed that women have less sexy, start sexual life late
r than men, have fewer casual sexual partners, but use condom less frequently th
an men. On the other hand, the coverage of HIV testing is significantly greater 
among women. Significant differences by gender were seen in all HIV-related risk
y practices. The greater vulnerability was always associated with women, with ex
ception of HIV testing. The low proportion of condom use in infidelity situation
s was a problem for box sexes and deserves special consideration when developing
 prevention strategies.#^ddecs^i1#^tm^len^kSexual Behavior^i1#^tm^len^kAIDS Sero
diagnosis^i1#^tm^len^kHIV Infections^i1#^tm^len^kSex Characteristics^i1#^lpt^aO 
objetivo do trabalho foi analisar as diferenças por sexo nas práticas relacionad
as à infecção pelo HIV na população brasileira. Inquérito de âmbito nacional foi
 realizado em 2008, com amostra de 8 mil indivíduos de 15-64 anos. A amostragem 
foi estratificada por macrorregião geográfica e situação urbano/rural. Utilizou-
se modelo de regressão logística para investigar os principais fatores associado
s às práticas de sexo protegido. Os resultados indicaram que as mulheres têm men
or taxa de atividade sexual, iniciam a vida sexual mais tardiamente, têm menos p
arceiros casuais do que os homens, mas usam menos o preservativo. Por outro lado
, a cobertura de teste de HIV é significativamente maior entre as mulheres quand
o comparadas aos homens. Foram evidenciadas grandes diferenças por sexo nas prát
icas relacionadas à infecção pelo HIV, sempre com maior vulnerabilidade associad
a às mulheres, exceto no que diz respeito ao teste de HIV. O baixo uso de preser
vativo nas situações de infidelidade foi um problema para ambos os sexos e merec
e consideração específica nas estratégias de prevenção.#^ddecs^i2#^tm^lpt^kCompo
rtamento Sexual^i2#^tm^lpt^kSorodiagnóstico da AIDS^i2#^tm^lpt^kInfecções por HI
V^i2#^tm^lpt^kCaracterísticas Sexuais^i2#vancouv#44#20091023#23/Oct/2009#2010020
6#06/Feb/2010#20100419#19/Apr/2010#04.htm##
03737000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400110013303500100014401201110015401201260
02650100036003910100038004270700089004650700124005540830975006780850010016530850
02801663085003101691085002701722085003201749083110401781085001002885085003302895
08500360292808500300296408500360299411700080303007200030303811200090304111100120
3050116000903062115001203071114000903083113001203092002000703104#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#TAB#04#CSP33
0#nd#Cad. Saúde Pública#27#1#20110000#^fs27^ls35#0102-311X#<b>Sex inequalities i
n HIV-related practices in the Brazilian population aged 15 to 64 years old, 200
8</b>^len#<b>Desigualdades por sexo nas práticas relacionadas à infecção pelo HI
V na população brasileira de 15 a 64 anos, 2008</b>^lpt#^rND^1A01^nAna Roberta P
ati^sPascom#^rND^1A02^nCélia Landmann^sSzwarcwald#Ministério da Saúde^iA01^1Depa
rtamento de DST, AIDS e Hepatites Virais^cBrasília^pBrasil#Fundação Oswaldo Cruz
^iA02^1Instituto de Comunicação e Informação Científica e Tecnológica em Saúde^c
Rio de Janeiro^pBrasil#^len^aThe objective of this study is to analyze gender di
fferences in HIV-related practices in the Brazilian population. A national surve
y was carried out in 2008 with a sample size of 8,000 individuals aged 15-64 yea
rs old. The sampling was stratified by macro geographical region and urban/rural
 areas. Logistic regression models were used to investigate the main predictors 
of consistent condom use. The results showed that women have less sexy, start se
xual life later than men, have fewer casual sexual partners, but use condom less
 frequently than men. On the other hand, the coverage of HIV testing is signific
antly greater among women. Significant differences by gender were seen in all HI
V-related risky practices. The greater vulnerability was always associated with 
women, with exception of HIV testing. The low proportion of condom use in infide
lity situations was a problem for box sexes and deserves special consideration w
hen developing prevention strategies.#^ddecs^i1#^tm^len^kSexual Behavior^i1#^tm^
len^kAIDS Serodiagnosis^i1#^tm^len^kHIV Infections^i1#^tm^len^kSex Characteristi
cs^i1#^lpt^aO objetivo do trabalho foi analisar as diferenças por sexo nas práti
cas relacionadas à infecção pelo HIV na população brasileira. Inquérito de âmbit
o nacional foi realizado em 2008, com amostra de 8 mil indivíduos de 15-64 anos.
 A amostragem foi estratificada por macrorregião geográfica e situação urbano/ru
ral. Utilizou-se modelo de regressão logística para investigar os principais fat
ores associados às práticas de sexo protegido. Os resultados indicaram que as mu
lheres têm menor taxa de atividade sexual, iniciam a vida sexual mais tardiament
e, têm menos parceiros casuais do que os homens, mas usam menos o preservativo. 
Por outro lado, a cobertura de teste de HIV é significativamente maior entre as 
mulheres quando comparadas aos homens. Foram evidenciadas grandes diferenças por
 sexo nas práticas relacionadas à infecção pelo HIV, sempre com maior vulnerabil
idade associada às mulheres, exceto no que diz respeito ao teste de HIV. O baixo
 uso de preservativo nas situações de infidelidade foi um problema para ambos os
 sexos e merece consideração específica nas estratégias de prevenção.#^ddecs^i2#
^tm^lpt^kComportamento Sexual^i2#^tm^lpt^kSorodiagnóstico da AIDS^i2#^tm^lpt^kIn
fecções por HIV^i2#^tm^lpt^kCaracterísticas Sexuais^i2#vancouv#44#20091023#23/Oc
t/2009#20100206#06/Feb/2010#20100419#19/Apr/2010#04.htm##
03847000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000190010703100030012613100020012906500090013101400110014003500100015101201040
01610120119002650100036003840100038004200700091004580700126005490830975006750850
01001650085002801660085003101688085002701719085003201746083110401778085001002882
08500330289208500360292508500300296108500360299111700080302707200030303511200090
30381110012030471160009030591150012030681140009030801130012030890020007031010080
08903108#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#l#4#1#article#1#^a2011
#oa#en#br1.1#1#4.0#tab#04#CSP330#nd#Cad. saúde pública#27#1#20110000#^fs27^ls35#
0102-311X#Sex inequalities in HIV-related practices in the Brazilian population 
aged 15 to 64 years old, 2008^len#Desigualdades por sexo nas práticas relacionad
as à infecção pelo HIV na população brasileira de 15 a 64 anos, 2008^lpt#^rND^1A
01^nAna Roberta Pati^sPascom#^rND^1A02^nCélia Landmann^sSzwarcwald#^iA01^1Minist
ério da Saúde^2Departamento de DST, AIDS e Hepatites Virais^cBrasília^pBrasil#^i
A02^1Fundação Oswaldo Cruz^2Instituto de Comunicação e Informação Científica e T
ecnológica em Saúde^cRio de Janeiro^pBrasil#^len^aThe objective of this study is
 to analyze gender differences in HIV-related practices in the Brazilian populat
ion. A national survey was carried out in 2008 with a sample size of 8,000 indiv
iduals aged 15-64 years old. The sampling was stratified by macro geographical r
egion and urban/rural areas. Logistic regression models were used to investigate
 the main predictors of consistent condom use. The results showed that women hav
e less sexy, start sexual life later than men, have fewer casual sexual partners
, but use condom less frequently than men. On the other hand, the coverage of HI
V testing is significantly greater among women. Significant differences by gende
r were seen in all HIV-related risky practices. The greater vulnerability was al
ways associated with women, with exception of HIV testing. The low proportion of
 condom use in infidelity situations was a problem for box sexes and deserves sp
ecial consideration when developing prevention strategies.#^ddecs^i1#^tm^len^kSe
xual Behavior^i1#^tm^len^kAIDS Serodiagnosis^i1#^tm^len^kHIV Infections^i1#^tm^l
en^kSex Characteristics^i1#^lpt^aO objetivo do trabalho foi analisar as diferenç
as por sexo nas práticas relacionadas à infecção pelo HIV na população brasileir
a. Inquérito de âmbito nacional foi realizado em 2008, com amostra de 8 mil indi
víduos de 15-64 anos. A amostragem foi estratificada por macrorregião geográfica
 e situação urbano/rural. Utilizou-se modelo de regressão logística para investi
gar os principais fatores associados às práticas de sexo protegido. Os resultado
s indicaram que as mulheres têm menor taxa de atividade sexual, iniciam a vida s
exual mais tardiamente, têm menos parceiros casuais do que os homens, mas usam m
enos o preservativo. Por outro lado, a cobertura de teste de HIV é significativa
mente maior entre as mulheres quando comparadas aos homens. Foram evidenciadas g
randes diferenças por sexo nas práticas relacionadas à infecção pelo HIV, sempre
 com maior vulnerabilidade associada às mulheres, exceto no que diz respeito ao 
teste de HIV. O baixo uso de preservativo nas situações de infidelidade foi um p
roblema para ambos os sexos e merece consideração específica nas estratégias de 
prevenção.#^ddecs^i2#^tm^lpt^kComportamento Sexual^i2#^tm^lpt^kSorodiagnóstico d
a AIDS^i2#^tm^lpt^kInfecções por HIV^i2#^tm^lpt^kCaracterísticas Sexuais^i2#vanc
ouv#44#20091023#23/Oct/2009#20100206#06/Feb/2010#20100419#19/Apr/2010#04.htm#Int
ernet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X20110013
00004##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#5#1#article#181#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#6#2#article#181#<p>&nbsp;</p>     ^cY#04.htm
##
00433000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021300067002000700280#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#7#3#article#181#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Sex    inequalities in H
IV-related practices in the Brazilian population aged 15 to    64 years old, 200
8</b></font></p>     ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#8#4#article#181#<p>&nbsp;</p>     ^cY#04.htm
##
00472000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704025200067002000700319#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#9#5#article#181#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Desigualdades    por sexo nas pr&aacute;ti
cas relacionadas &agrave; infec&ccedil;&atilde;o pelo    HIV na popula&ccedil;&a
tilde;o brasileira de 15 a 64 anos, 2008</b></font></p>     ^cY#04.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#10#6#article#181#<p>&nbsp;</p>     ^cY#04.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#11#7#article#181#<p>&nbsp;</p>     ^cY#04.ht
m##
00396000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704017500068002000700243#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#12#8#article#181#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Ana Roberta    Pati Pascom<sup>I</sup>; C
&eacute;lia Landmann Szwarcwald<sup>II</sup></b></font></p>     ^cY#04.htm##
00414000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704019300068002000700261#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#13#9#article#181#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Departamento    de DST, AIDS e H
epatites Virais, Minist&eacute;rio da Sa&uacute;de, Bras&iacute;lia,    Brasil  
  ^cY#04.htm##
00449000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022700069002000700296#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#14#10#article#181#<br>   <sup>II</sup>Instit
uto de Comunica&ccedil;&atilde;o e Informa&ccedil;&atilde;o    Cient&iacute;fica
 e Tecnol&oacute;gica em Sa&uacute;de, Funda&ccedil;&atilde;o    Oswaldo Cruz, R
io de Janeiro, Brasil</font></p>     ^cY#04.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#15#11#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#16#12#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#17#13#article#181#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#04.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#18#14#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#04.htm##
01309000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704108700069002000701156#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#19#15#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The objective of    this study is to analyz
e gender differences in HIV-related practices in the    Brazilian population. A 
national survey was carried out in 2008 with a sample    size of 8,000 individua
ls aged 15-64 years old. The sampling was stratified    by macro geographical re
gion and urban/rural areas. Logistic regression models    were used to investiga
te the main predictors of consistent condom use. The results    showed that wome
n have less sexy, start sexual life later than men, have fewer    casual sexual 
partners, but use condom less frequently than men. On the other    hand, the cov
erage of HIV testing is significantly greater among women. Significant    differ
ences by gender were seen in all HIV-related risky practices. The greater    vul
nerability was always associated with women, with exception of HIV testing.    T
he low proportion of condom use in infidelity situations was a problem for    bo
x sexes and deserves special consideration when developing prevention strategies
.</font></p>     ^cY#04.htm##
00402000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704018000069002000700249#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#20#16#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Sexual Behavior;    AIDS Serodiagnosis; HIV
 Infections; Sex Characteristics</font></p> <hr size="1" noshade>     ^cY#04.htm
##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#21#17#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#04.htm##
01695000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704147300069002000701542#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#22#18#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo do trabalho    foi analisar as d
iferen&ccedil;as por sexo nas pr&aacute;ticas relacionadas    &agrave; infec&cce
dil;&atilde;o pelo HIV na popula&ccedil;&atilde;o brasileira.    Inqu&eacute;rit
o de &acirc;mbito nacional foi realizado em 2008, com amostra    de 8 mil indiv&
iacute;duos de 15-64 anos. A amostragem foi estratificada por    macrorregi&atil
de;o geogr&aacute;fica e situa&ccedil;&atilde;o urbano/rural.    Utilizou-se mod
elo de regress&atilde;o log&iacute;stica para investigar os principais    fatore
s associados &agrave;s pr&aacute;ticas de sexo protegido. Os resultados    indic
aram que as mulheres t&ecirc;m menor taxa de atividade sexual, iniciam    a vida
 sexual mais tardiamente, t&ecirc;m menos parceiros casuais do que os    homens,
 mas usam menos o preservativo. Por outro lado, a cobertura de teste    de HIV &
eacute; significativamente maior entre as mulheres quando comparadas    aos home
ns. Foram evidenciadas grandes diferen&ccedil;as por sexo nas pr&aacute;ticas   
 relacionadas &agrave; infec&ccedil;&atilde;o pelo HIV, sempre com maior vulnera
bilidade    associada &agrave;s mulheres, exceto no que diz respeito ao teste de
 HIV. O    baixo uso de preservativo nas situa&ccedil;&otilde;es de infidelidade
 foi um    problema para ambos os sexos e merece considera&ccedil;&atilde;o espe
c&iacute;fica    nas estrat&eacute;gias de preven&ccedil;&atilde;o.</font></p>  
   ^cY#04.htm##
00450000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022800069002000700297#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#23#19#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Comportamento Sexual;    Sorodiagn&oacute;s
tico da AIDS; Infec&ccedil;&otilde;es por HIV; Caracter&iacute;sticas    Sexuais
</font></p> <hr size="1" noshade>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#24#20#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#25#21#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#26#22#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#04.h
tm##
00812000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059000069002000700659#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#27#23#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">By the late 1980s    and early 1990s, the n
umber of AIDS cases among women increased in Brazil <sup>1</sup>.    During this
 period of the epidemic, there was an increased incidence among injecting    dru
g users (IDU) and a high proportion of cases attributed to heterosexual transmis
sion    among men and women <sup>2</sup>. By the mid-90s, there was a sharp incr
ease    in AIDS incidence among women <sup>3</sup>, with the gender ratio rangin
g from    6.8 men per woman in 1990 to 1.6 in 2007 <sup>4</sup>.</font></p>     
^cY#04.htm##
00610000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704038800069002000700457#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#28#24#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Due to the growing    number of female AIDS
 cases in Brazil, interventions targeting women were focused    on transmission 
and prevention of HIV infection <sup>5</sup>. Among female sex    workers, self-
empowerment and self-esteem were promoted for the adoption of    HIV-preventive 
measures <sup>6</sup>.</font></p>     ^cY#04.htm##
00597000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037500069002000700444#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#29#25#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Studies involving    the monitoring of sexu
al risk behavior in the population have been recognized    as important tools fo
r controlling the spread of HIV/AIDS. A population-based    response is essentia
l to support new preventive measures and to propose effective    strategies <sup
>7</sup>.</font></p>     ^cY#04.htm##
00724000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050200069002000700571#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#30#26#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the 1990s, few    initiatives to monitor
ing risk behaviors associated with HIV infection were    undertaken in Brazil. W
e highlight the studies that have been performed with    Brazilian Army conscrip
ts since 1996 <sup>8,9</sup>; the Demography and Health    Survey (DHS) performe
d in 1996 <sup>10</sup>; and the studies performed by the    Brazilian Center fo
r Analysis and Planning, in 1998 and 2005 <sup>11</sup>.</font></p>     ^cY#04.h
tm##
00931000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070900069002000700778#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#31#27#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Continuing the    development of research o
n population-based behavior in 2004 and 2008, the Department    of STD, AIDS and
 Viral Hepatitis of the Brazilian Ministry of Health conducted    a national sur
vey to investigate the <i>Knowledge, Attitudes, and Practices</i>    (KAP) relat
ed to HIV infection and other STI (sexually transmitted infections)    among ind
ividuals aged 15-64 in Brazil. The implementation of the survey provided    an o
pportunity to develop indicators for the monitoring of preventive measures    an
d strategies, and risk practices related to sexually transmitted infections    i
n Brazil <sup>12</sup>.</font></p>     ^cY#04.htm##
00480000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704025800069002000700327#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#32#28#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To understand gender    differences with re
spect to practices related to HIV infection among individuals    aged 15-64, we 
analyzed data from the KAP survey conducted in 2008.</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#33#29#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00323000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010100069002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#34#30#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methodology</b></font></p>     ^cY#04.ht
m##
00395000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017300069002000700242#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#35#31#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In 2008, nationwide    survey was performed
 with a sample size of 8,000 people aged 15-64.</font></p>     ^cY#04.htm##
01322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704110000069002000701169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#36#32#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The sample was    stratified by geographic 
macro-region (North, Northeast, Southeast, South and    Central) and by type of 
area (urban, rural). In each of ten strata, the sample    was conducted in three
 stages: at the census tract, household and individual    level. In the first st
age, census tracts were randomly selected with probability    proportional to si
ze. Within each census tract, eight households were systematically    chosen fro
m a randomly selected point and definition of the route. In each household,    a
 list consisting of age, gender, and cohabitation of the residents was created. 
   In each stratum consisting of cohabitation (live with or without partner), ag
e    (15-24, 25-34, 35-49, 50-64) and gender only one respondent was selected fo
r    an interview with equiprobability. The number of individuals within each st
ratum    formed by overlapping all three variables was established by allocation
 proportional    to the square root of the number of inhabitants in each stratum
<sup>13</sup>.</font></p>     ^cY#04.htm##
00401000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017900069002000700248#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#37#33#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The project was    approved by of the Ethic
s Committee, at Oswaldo Cruz Foundation (nº. 243/04).</font></p>     ^cY#04.htm#
#
00549000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032700069002000700396#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#38#34#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The 2008 KAP survey    instrument included 
the following sections: socio-demographic conditions, knowledge    on the transm
ission of HIV and other STI, STI prevention and control, HIV testing,    licit a
nd illicit drug use, and sexual practice.</font></p>     ^cY#04.htm##
00736000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051400069002000700583#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#39#35#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The interviewers    used Personal Digital A
ssistants (PDA) to complete the questionnaire. All responses    were automatical
ly converted into a database. As some questions were sensitive    in nature and 
could cause embarrassment, denial or discomfort among respondents,    sections r
elating to drug use and sexual practices were self-reported on the    PDA itself
, with optional use of headset among individuals with low education.</font></p> 
    ^cY#04.htm##
00540000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031800069002000700387#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#40#36#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In this article,    results on HIV test cov
erage and sexual practices related to the HIV infection    are presented. The fo
cus was given to the comparison of indicators for gender    and age group in yea
rs (15-24, 25-34, 35-49, 50-64).</font></p>     ^cY#04.htm##
00967000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074500069002000700814#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#41#37#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Indicators for    sexual behavior included 
percentage of sexually active individual in life and    in the past 12 months; p
ercentage of individual who had onset of sexual activity    before the age of 15
; percentage of individuals having more than five casual    partners over the la
st year; percentage of individuals having sexual intercourse    with a steady pa
rtner, with casual partner, with paid partner (paid money to    have sex), with 
paying partner (received money to have sex) and with a partner    they met via t
he internet. Extramarital sex was defined as an individual reporting    a casual
 partner in the last 12 months while living with a partner.</font></p>     ^cY#0
4.htm##
00806000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058400069002000700653#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#42#38#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for protected    sex practices the follo
wing indicators were considered: the percentage of individuals    who reported u
sing male condoms at last sexual encounter in the past 12 months,    with any ty
pe of partner and casual partner; and percentage of individuals reporting    con
sistent condom use (use of condom in all sexual relations in the past 12    mont
hs), with a steady partner, with a casual partner and with any type of partner, 
   as well as according to the extramarital sex situation.</font></p>     ^cY#04
.htm##
00507000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028500069002000700354#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#43#39#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The coverage of    HIV testing among the se
xually active population was measured by the percentage    of sexually active in
dividuals who reported having been tested for HIV at least    once in lifetime.<
/font></p>     ^cY#04.htm##
00654000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043200069002000700501#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#44#40#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For statistical    analysis, data were cali
brated according to the census distribution by region,    urban-rural status, ge
nder, age group, cohabiting status and education level.    All statistic analyse
s were conducted using SPSS, version 17 (SPSS Inc., Chicago,    USA), which take
s into consideration complex sample survey features <sup>14</sup>.</font></p>   
  ^cY#04.htm##
00525000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030300069002000700372#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#45#41#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For comparison    of indicators by sex, we 
conducted statistical tests for differences between    proportions (</font><font
 size="2">&#967;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="
2"><sup>2</sup>).</font></p>     ^cY#04.htm##
01643000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704142100069002000701490#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#46#42#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to investigate    the main factors
 associated with protected sex practices, we performed a multivariate    logisti
c regression to test predictors of, consistent condom use with any partner.    A
 <i>stepwise regression</i> was performed <sup>15</sup>, based on maximizing    
statistical likelihood at each step, and significance levels of 5 and 10%, respe
ctively,    for inclusion and exclusion of variables. The following covariates w
ere investigated:    age; gender; education (incomplete primary education; compl
ete primary education    and incomplete basic education; complete basic educatio
n and more); cohabiting    status (living with a partner vs. no); skin color or 
race (white; black; brown;    other); socio-economic status criteria defined by 
the Brazilian Association    of Survey Enterprises <sup>16</sup>; household inco
me and individual income    (no income; up to one minimum wage; 1-2 minimum wage
s; 2-5 minimum wages; 5-10    minimum wages; more than 10 minimum wages); receip
t of free condoms in the last    12 months (yes; no); more than five casual part
ners in the last 12 months (yes;    no); sexual intercourse before 15 (yes; no);
 illicit drug use (cocaine, marijuana    or crack) ever (yes; no); extramarial i
ntercourse during the last year - subset    of respondents reporting casual part
ners (yes; no).</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#47#43#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#48#44#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#04.htm##
00828000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060600069002000700675#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#49#45#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#t1">Table    1</a> shows behavior
 and sexual practices of respondents aged 15 to 64. For    all age groups, sexua
l activity in the 12 months prior to the survey is higher    among men, with the
 highest gender difference observed among older subjects,    in whom 54.2% of wo
men reported at least one sexual encounter in the last 12    months. In terms of
 first sexual intercourse before age 15, men become sexually    active earlier t
han women, with the smallest gender difference seen in the younger    age group.
</font></p>     ^cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#50#46#article#181#<p><a name="t1"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#51#47#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#52#48#article#181#<p align="center"><img src
="/img/revistas/csp/v27s1/04t01.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#53#49#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00814000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059200069002000700661#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#54#50#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the types    of partner, the prop
ortion of men with casual partners is about to times higher    than of women, re
gardless of age group. The proportion of sexually active men    who reported at 
least five casual partners in the last 12 months was three times    greater than
 the proportion observed among women (13.2% and 4.1%, respectively).    For both
 sexes, younger the age, the greater proportion of respondents with    at least 
five casual partners in the last year (<a href="#t1">Table 1</a>).</font></p>   
  ^cY#04.htm##
00929000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070700069002000700776#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#55#51#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">There are no significant    differences by 
gender in the proportion of individuals that had sexual relations    with paying
 partners for any age group. However, sexual relations with paid    partners are
 more frequent among men (p &lt; 0.001) as well as partners they    met via the 
Internet (p &lt; 0.001). The proportion of individuals reporting    having paid 
partners and partners that they met on the internet is nearly eight    times gre
ater among men than women; and, the proportion of individuals that    reported h
aving partners they met on the Internet is nearly three times greater    (<a hre
f="#t1">Table 1</a>).</font></p>     ^cY#04.htm##
00800000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057800069002000700647#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#56#52#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the practices    of protected sex
, men use condoms in a greater proportion than women, and, in    general, condom
 use decreases as age increases (<a href="#t2">Table 2</a>).    Condom use at la
st sex encounter was 65% among males aged 15 to 24, and approximately    77% at 
last sex encounter with a casual partner. Among women, in the same age    group,
 condom use at last sex was significantly lower, 44% at last sexual relation    
and 50% at last sexual relation with casual partner.</font></p>     ^cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#57#53#article#181#<p><a name="t2"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#58#54#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#59#55#article#181#<p align="center"><img src
="/img/revistas/csp/v27s1/04t02.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#60#56#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00503000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028100069002000700350#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#61#57#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">When comparing    consistent condom use by 
type of partner, the largest gender difference among    young people aged 15 to 
24 was observed with casual partners: 57.4% for men    and 33.6% for women.</fon
t></p>     ^cY#04.htm##
00635000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704041300069002000700482#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#62#58#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The HIV test coverage    for the sexually a
ctive population is greater among women than men at all age    groups, with the 
largest difference seen among 15 to 24 year olds (<a href="#t3">Table    3</a>).
 The coverage for the Brazilian population aged 15 to 64 was estimated    at 36.
5%, with 45.6% among women and 27.2% among men.</font></p>     ^cY#04.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#63#59#article#181#<p><a name="t3"></a></p>  
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#64#60#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#65#61#article#181#<p align="center"><img src
="/img/revistas/csp/v27s1/04t03.jpg"></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#66#62#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00879000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065700069002000700726#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#67#63#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The results presented    on <a href="/img/r
evistas/csp/v27s1/04t04.jpg">Table 4</a> show that approximately    21% of men a
nd 11% of women had extramarital intercourse (i.e. reported living    with a par
tner and having at least one casual sexual partner in the past 12    months). In
 relation to protected sex, the use of condom (at last sex and all    sexual enc
ounters in the past 12 months) with casual partners was significantly    greater
 among those who did not live with a partner when compared with those    who liv
ed with a partner, for both genders (p &lt; 0.001).</font></p>     ^cY#04.htm##
00791000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056900069002000700638#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#68#64#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">On <a href="/img/revistas/csp/v27s1/04t05.j
pg">Table    5</a>, we present the results of a multivariate logistic regression
 model investigating    predictors consistent condom use with any partner. These
 included the analysis    of the crude odds ratio (OR) included as predictors: b
eing male; having received    free condoms at least once in lifetime; not living
 with a partner; however having    extramarital intercourse presented a negative
 association with consistent condom    use.</font></p>     ^cY#04.htm##
00846000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062400069002000700693#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#69#65#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The analysis of    the adjusted OR estimate
d in the multivariate model also presented on <a href="/img/revistas/csp/v27s1/0
4t05.jpg">Table    5</a> shows that the associations between consistent condom u
se and being male    (OR = 1.36, p &lt; 0.001); living without a partner (OR = 2
.54, p &lt; 0.001);    having received free condoms in the past 12 months before
 the survey (OR = 1.78,    p &lt; 0.001). Conversely, having used illicit drugs 
at least once in lifetime    (OR = 0.63, p &lt; 0.001) was negatively associated
 with the outcome.</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#70#66#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#71#67#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#04.htm
##
00405000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704018300069002000700252#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#72#68#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The results presented    here show great ge
nder differences with practices related to HIV infection.</font></p>     ^cY#04.
htm##
00976000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075400069002000700823#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#73#69#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In terms of sexual    behavior, women have 
lower sexual activity, start their sex life later and have    fewer casual partn
ers and more steady partners than men, but use fewer condoms    in all situation
s. More specifically, the multivariate statistical model showed    significant d
ifferences per gender in safe sex practices. Yet, controlled by    other variabl
es such as cohabiting status, being a male was a factor positively    associated
 with consistent condom use with any type of partner. Similar gender    differen
ces were found in other surveys conducted in Brazil <sup>17,18,19</sup>,    and 
also in surveys performed in other countries <sup>20,21,22,23</sup>.</font></p> 
    ^cY#04.htm##
00978000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075600069002000700825#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#74#70#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The gender differences    described in this
 study may be partially explained by gender issues, including    the different d
emeanors and practices related to the sexuality of men and women    <sup>24,25,2
6,27</sup>. Gender differences in the power of decision-making over    preventiv
e measures reflect the social role performed by women and the imbalance    of po
wer centered in men <sup>28</sup>. Poor preventive measures reflect the    socia
l role performed by women in the imbalance of power centered in men <sup>28</sup
>.    In particular, the lack of power by women in the negotiation of condoms us
e    does not favor its use among the female population <sup>29</sup>.</font></p
>     ^cY#04.htm##
01262000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704104000069002000701109#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#75#71#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Even in situations    where theoretically t
he control for protected sex is under the power of women,    such is the case of
 female condoms, the adoption of preventive measures is still    not frequent. T
he results of the present survey showed that 84% of women are    aware of the fe
male condom, but only 8% of women reported having used it once    in their lifet
imes. These findings corroborate other surveys, showing that despite    the acce
ptability of the female condom, its use is still low <sup>30</sup>.    One of th
e factors that may be influencing the low use of the female condom    in Brazil 
is its high cost when compared to the male condom. The evaluation    of strategi
es for introducing the female condom in some countries found some    factors tha
t may increase its use, such as training women how to use it, identifying    the
 priority groups, and ensuring regular supply through distribution in public    
and private sectors <sup>31</sup>.</font></p>     ^cY#04.htm##
00643000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042100069002000700490#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#76#72#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Besides the greater    frequency of unprote
cted sex among women another relevant aspect is the biological    disadvantage o
f women regarding HIV infection. Due to the physiology of the    female sexual o
rgan, women have twice the biological risk of being infected    by HIV than men 
in unprotected heterosexual relations <sup>24,32</sup>.</font></p>     ^cY#04.ht
m##
00665000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044300069002000700512#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#77#73#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A particularly    interesting finding was t
he use of Internet to search for sex partners among    men. One in 10 young men 
aged 15 to 24 had at least one sexual partner identified    through the Internet
. This new form of social network has been the target of    international resear
ch <sup>33,34,35,36</sup>. Among women, this practice is    not frequent yet.</f
ont></p>     ^cY#04.htm##
00646000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042400069002000700493#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#78#74#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding unprotected    extramarital sex b
oth men and women presented similar behavior. In the situation    of extramarita
l sex, the use of condoms was low for both men and women. Once    consistent con
dom use with a steady partner is not frequent, unprotected sex    with casual pa
rtners increases the potential risks of STI among couples.</font></p>     ^cY#04
.htm##
01292000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704107000069002000701139#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#79#75#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding already    HIV infected individua
ls, it is important to find out their serological status    to avoid spread of t
he disease. The early detection of HIV infection not only    reduces the viral t
ransmission, but it also increases the quality of life of    the infected patien
t <sup>37</sup>. The present survey suggests that the strategies    to motivate 
HIV testing among the Brazilian population, with free tests through    the publi
c health network and the introduction of the HIV test in prenatal care    have b
oth shown positive results. The test coverage for the sexually active    populat
ion in Brazil aged 15 to 64 was nearly 37%, similar to the one observed    in th
e United States <sup>38</sup>. However, relevant differences are found    by gen
der, with the HIV test coverage among men over half of that of women.    The dif
ference is related to the HIV testing during pregnancy: about 60% of    sexually
 active women reported taking the HIV test during prenatal care.</font></p>     
^cY#04.htm##
01003000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078100069002000700850#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#80#76#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the limitations    of the survey, due
 to the sensitive issues of intimate nature, the validity    of responses is que
stioned in the literature <sup>39,40</sup>. The differences    by gender observe
d in this study regarding sexual practices may also be related    to the fact th
at women, when compared to men, tend to underestimate their sexual    risk behav
iors in surveys <sup>41</sup>. With the purpose of minimizing bias    arising fr
om this type of limitation in the 2008 KAP Study, information about    sexual pr
actices were self-resported by using a PDA. The self use of computer-assisted   
 self-interviewing methods has been proven to provide accurate information <sup>
42,43,44</sup>.</font></p>     ^cY#04.htm##
01248000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704102600069002000701095#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#81#77#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In sum, the results    presented herein sho
w greater vulnerability of the female population to unsafe    sexual practices. 
The power of decision-making on preventive methods in sexual    relationships is
 generally unfavorable for women and constitutes a major obstacle    in implemen
ting strategies for practicing protected sex for the population as    a whole. T
hese difficulties must be addressed through interventions that empower    women 
in negotiations to use condoms with their sexual partners or by developing    me
thods that allow greater self-control. Among men, it is necessary to encourage  
  HIV testing for more effective control of the dissemination of the HIV/AIDS   
 epidemic. Yet, the low use of condoms in situations of extramarital sex among  
  married individuals or those living with a partner has become a problem for   
 both genders and it deserves specific consideration in the development of preve
ntive    strategies.</font></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#82#78#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#83#79#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#04.h
tm##
00505000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028300069002000700352#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#84#80#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A. R. P. Pascom    was responsible for the 
text development, statistical analysis of data and development    of tables. C. 
L. Szwarcwald participated in the text development and article    conception.</f
ont></p>     ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#85#81#article#181#<p>&nbsp;</p>     ^cY#04.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#86#82#article#181#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#04.htm
##
00483000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704024700071002000700318#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#87#83#article#181#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Rodrigues-J&uacute;nior   
 AL, Castilho EA. A epidemia de AIDS no Brasil, 1991-2000: descri&ccedil;&atilde
;o    espa&ccedil;o-temporal. Rev Soc Bras Med Trop 2004; 37:312-7.    ^cY#04.ht
m##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#88#84#article#181#</font></p>     ^cY#04.htm
##
00423000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704018700071002000700258#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#89#85#article#181#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Barcellos C,    Bastos FI.
 Redes sociais e difusao da AIDS no Brasil. Bol Oficina Sanit Panam    1996; 121
:11-24.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#90#86#article#181#</font></p>     ^cY#04.htm
##
00546000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704031000071002000700381#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#91#87#article#181#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Szwarcwald CL,    Bastos F
I, Esteves MAP, Andrade CLT. A dissemina&ccedil;&atilde;o da epidemia    da AIDS
 no Brasil, no per&iacute;odo de 1987-1996: uma an&aacute;lise espacial.    Cad 
Sa&uacute;de P&uacute;blica 2000; 16 Suppl 1:7-19.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#92#88#article#181#</font></p>     ^cY#04.htm
##
00403000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704016700071002000700238#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#93#89#article#181#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Minist&eacute;rio    da Sa
&uacute;de. Boletim Epidemiol&oacute;gico AIDST 2008; Ano V, nº. 1.    ^cY#04.ht
m##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#94#90#article#181#</font></p>     ^cY#04.htm
##
00513000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704027700071002000700348#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#95#91#article#181#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Minist&eacute;rio    da Sa
&uacute;de. Plano integrado de enfrentamento &agrave; feminiza&ccedil;&atilde;o 
   da epidemia de AIDS e outras DST. Bras&iacute;lia: Minist&eacute;rio da Sa&ua
cute;de;    2007.    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#96#92#article#181#</font></p>     ^cY#04.htm
##
00555000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704031900071002000700390#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#97#93#article#181#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Minist&eacute;rio    da Sa
&uacute;de. Profissionais do sexo: documento referencial para a&ccedil;&otilde;e
s    de preven&ccedil;&atilde;o das DST e da AIDS. Bras&iacute;lia: Minist&eacut
e;rio    da Sa&uacute;de; 2002. (S&eacute;rie Manuais, 47).    ^cY#04.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#98#94#article#181#</font></p>     ^cY#04.htm
##
00498000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704026200071002000700333#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#99#95#article#181#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Anderson JE,    Stall R. H
ow many people are at risk for HIV in the United States? The need    for behavio
ral surveys of at-risk populations. J Acquir Immune Defic Syndr 2002;    29:104-
5.    ^cY#04.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#100#96#article#181#</font></p>     ^cY#04.ht
m##
00664000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704042700072002000700499#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#101#97#article#181#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Programa Nacional    de D
ST e AIDS, Secretaria de Vigil&acirc;ncia em Sa&uacute;de, Minist&eacute;rio    
da Sa&uacute;de. Pesquisa entre os conscritos do Ex&eacute;rcito Brasileiro,    
1996-2002: retratos do comportamento de risco do jovem brasileiro &agrave; infec
&ccedil;&atilde;o    pelo HIV. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;d
e; 2002.    ^cY#04.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#102#98#article#181#</font></p>     ^cY#04.ht
m##
00528000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704029100072002000700363#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#103#99#article#181#9#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">9. Szwarcwald CL,    Carvalh
o MF, Barbosa J&uacute;nior A, Barreira D, Speranza FA, Castilho EA.    Temporal
 trends of HIV-related risk behavior among Brazilian military conscripts,    199
7-2002. Clinics 2005; 60:367-74.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#104#100#article#181#</font></p>     ^cY#04.h
tm##
00590000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035100074002000700425#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#105#101#article#181#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Sociedade Civil    Bem
-Estar Familiar no Brasil. Pesquisa Nacional sobre Demografia e Sa&uacute;de:   
 uma an&aacute;lise do n&iacute;vel de conhecimento e comportamentos de vulnerab
iliza&ccedil;&atilde;o.    Rio de Janeiro: Sociedade Civil Bem-Estar Familiar no
 Brasil; 1997.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#106#102#article#181#</font></p>     ^cY#04.h
tm##
00575000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033600074002000700410#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#107#103#article#181#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Berqu&oacute;    E, Ba
rbosa RM, Lima LP; Grupo de Estudos em Popula&ccedil;&atilde;o, Sexualidade    e
 Aids. Uso do preservativo: tend&ecirc;ncias entre 1998 e 2005 na popula&ccedil;
&atilde;o    brasileira. Rev Sa&uacute;de P&uacute;blica 2008; 42 Suppl 1:7-11. 
   ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#108#104#article#181#</font></p>     ^cY#04.h
tm##
00534000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029500074002000700369#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#109#105#article#181#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Coordena&ccedil;&atild
e;o    Nacional de DST e AIDS. PCAP - Pesquisa de Conhecimento, Atitudes e Pr&aa
cute;ticas    na Popula&ccedil;&atilde;o Brasileira 2004. Bras&iacute;lia: Minis
t&eacute;rio    da Sa&uacute;de; 2006.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#110#106#article#181#</font></p>     ^cY#04.h
tm##
00416000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017700074002000700251#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#111#107#article#181#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Bolfarine H,    Bussab
 WO. Elementos de amostragem. S&atilde;o Paulo: Editora Edgard Blucher;    2005.
    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#112#108#article#181#</font></p>     ^cY#04.h
tm##
00538000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029900074002000700373#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#113#109#article#181#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Szwarcwald    CL, Dama
cena GN. Amostras complexas em inqu&eacute;ritos populacionais: planejamento    
e implica&ccedil;&otilde;es na an&aacute;lise estat&iacute;stica dos dados.    R
ev Bras Epidemiol 2008; 11 Suppl 1:S38-45.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#114#110#article#181#</font></p>     ^cY#04.h
tm##
00429000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019000074002000700264#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#115#111#article#181#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Hosmer DW,    Lemeshow
 S. Applied logistic regression. 2<sup>nd</sup> Ed. New York: John Wiley    &amp
; Sons; 1989.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#116#112#article#181#</font></p>     ^cY#04.h
tm##
00627000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704038800074002000700462#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#117#113#article#181#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Associa&ccedil;&atilde
;o    Brasileira de Empresas de Pesquisa. Crit&eacute;rio de Classifica&ccedil;&
atilde;o    Econ&ocirc;mica Brasil. <a href="http://www.abep.org/codigosguias/Cr
iterio_Brasil_2008.pdf" target="_blank">http://www.abep.org/codigosguias/Criteri
o_Brasil_2008.pdf</a>    (accessed on 09/Aug/2009).    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#118#114#article#181#</font></p>     ^cY#04.h
tm##
00480000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024100074002000700315#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#119#115#article#181#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Almeida MC,    Aquino 
EM, Gaffikin L, Magnani RJ. Contraceptive use among adolescents at public    sch
ools in Brazil. Rev Sa&uacute;de P&uacute;blica 2003; 37:566-75.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#120#116#article#181#</font></p>     ^cY#04.h
tm##
00539000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030000074002000700374#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#121#117#article#181#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Barbosa RM,    Koyama 
MA; Grupo de Estudos em Popula&ccedil;&atilde;o, Sexualidade e AIDS.    Sexual b
ehavior and practices among men and women, Brazil 1998 and 2005. Rev    Sa&uacut
e;de P&uacute;blica 2008; 42 Suppl 1:21-33.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#122#118#article#181#</font></p>     ^cY#04.h
tm##
00483000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024400074002000700318#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#123#119#article#181#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Calazans G,    Araujo 
TW, Venturi G, Franca Junior I. Factors associated with condom use among    yout
h aged 15-24 years in Brazil in 2003. AIDS 2005; 19 Suppl 4:S42-50.    ^cY#04.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#124#120#article#181#</font></p>     ^cY#04.h
tm##
00470000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023100074002000700305#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#125#121#article#181#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Gullette DL,    Rooker
 JL, Kennedy RL. Factors associated with sexually transmitted infections    in m
en and women. J Community Health Nurs 2009; 26:121-30.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#126#122#article#181#</font></p>     ^cY#04.h
tm##
00520000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028100074002000700355#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#127#123#article#181#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Urassa W, Moshiro    C
, Chalamilla G, Mhalu F, Sandstrom E. Risky sexual practices among youth attendi
ng    a sexually transmitted infection clinic in Dar es Salaam, Tanzania. BMC In
fect    Dis 2008; 8:159.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#128#124#article#181#</font></p>     ^cY#04.h
tm##
00480000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024100074002000700315#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#129#125#article#181#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Frank S, Esterhuizen  
  T, Jinabhai CC, Sullivan K, Taylor MS. Risky sexual behaviours of high-school 
   pupils in an era of HIV and AIDS. S Afr Med J 2008; 98:394-8.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#130#126#article#181#</font></p>     ^cY#04.h
tm##
00564000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032500074002000700399#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#131#127#article#181#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Martinez-Donate    AP,
 Hovell MF, Blumberg EJ, Zellner JA, Sipan CL, Shillington AM, et al. Gender    
differences in condom-related behaviors and attitudes among Mexican adolescents 
   living on the U.S.-Mexico border. AIDS Educ Prev 2004; 16:172-86.    ^cY#04.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#132#128#article#181#</font></p>     ^cY#04.h
tm##
00503000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026400074002000700338#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#133#129#article#181#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Ehrhardt AA,    Sawire
s S, McGovern T, Peacock D, Weston M. Gender, empowerment, and health:    what i
s it? how does it work? J Acquir Immune Defic Syndr 2009; 5 Suppl 3:S96-105</fon
t></p>     ^cY#04.htm##
00493000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025400074002000700328#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#134#130#article#181#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Shawky S, Soliman    C
, Sawires S. Gender and HIV in the Middle East and North Africa: lessons for    
low prevalence scenarios. J Acquir Immune Defic Syndr 2009; 51 Suppl 3:S73-4.   
 ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#135#131#article#181#</font></p>     ^cY#04.h
tm##
00556000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031700074002000700391#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#136#132#article#181#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Paiva V, Calazans    G
, Venturi G, Dias R; Grupo de Estudos em Popula&ccedil;&atilde;o, Sexualidade   
 e AIDS. Age and condom use at first sexual intercourse of Brazilian adolescents
.    Rev Sa&uacute;de P&uacute;blica 2008; 42 Suppl 1:45-53.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#137#133#article#181#</font></p>     ^cY#04.h
tm##
00493000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025400074002000700328#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#138#134#article#181#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Kornreich JL,    Hearn
 KD, Rodriguez G, O'Sullivan LF. Sibling influence, gender roles, and the    sex
ual socialization of urban early adolescent girls. J Sex Res 2003; 40:101-10.   
 ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#139#135#article#181#</font></p>     ^cY#04.h
tm##
00452000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021300074002000700287#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#140#136#article#181#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Roth J, Krishnan    SP
, Bunch E. Barriers to condom use: results from a study in Mumbai (Bombay),    I
ndia. AIDS Educ Prev 2001; 13:65-77.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#141#137#article#181#</font></p>     ^cY#04.h
tm##
00551000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031200074002000700386#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#142#138#article#181#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Crosby RA,    DiClemen
te RJ, Wingood GM, Salazar LF, Harrington K, Davies SL, et al. Identification   
 of strategies for promoting condom use: a prospective analysis of high-risk    
African American female teens. Prev Sci 2003; 4:263-70.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#143#139#article#181#</font></p>     ^cY#04.h
tm##
00449000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021000074002000700284#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#144#140#article#181#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Madrigal J,    Schifte
r J, Feldblum PJ. Female condom acceptability among sex workers in Costa    Rica
. AIDS Educ Prev 1998; 10:105-13.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#145#141#article#181#</font></p>     ^cY#04.h
tm##
00464000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022500074002000700299#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#146#142#article#181#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Warren M, Philpott    
A. Expanding safer sex options: introducing the female condom into national    p
rogrammes. Reprod Health Matters 2003; 11:130-9.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#147#143#article#181#</font></p>     ^cY#04.h
tm##
00468000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022900074002000700303#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#148#144#article#181#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Card JJ, Amarillas    
A, Conner A, Akers DD, Solomon J, DiClemente RJ. The complete HIV/AIDS teaching 
   kit. New York: Springer Publishing Company; 2008.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#149#145#article#181#</font></p>     ^cY#04.h
tm##
00501000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026200074002000700336#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#150#146#article#181#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Al-Tayyib AA,    McFar
lane M, Kachur R, Rietmeijer CA. Finding sex partners on the internet:    what i
s the risk for sexually transmitted infections? Sex Transm Infect 2009;    85:21
6-20.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#151#147#article#181#</font></p>     ^cY#04.h
tm##
00462000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022300074002000700297#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#152#148#article#181#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Fern&aacute;ndez-D&aac
ute;vila    P, Zaragoza Lorca K. Internet y riesgo sexual en hombres que tienen 
sexo con    hombres. Gac Sanit 2009; 23:380-7.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#153#149#article#181#</font></p>     ^cY#04.h
tm##
00487000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024800074002000700322#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#154#150#article#181#35#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Zhang D, Bi    P, Hill
er JE, Lv F. Web-based HIV/AIDS behavioral surveillance among men who    have se
x with men: potential and challenges. Int J Infect Dis 2008; 12:126-31.    ^cY#0
4.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#155#151#article#181#</font></p>     ^cY#04.h
tm##
00538000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029900074002000700373#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#156#152#article#181#36#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Elford J, Bolding    G
, Davis M, Sherr L, Hart G. Web-based behavioral surveillance among men who    h
ave sex with men: a comparison of online and offline samples in London, UK.    J
 Acquir Immune Defic Syndr 2004; 35:421-6.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#157#153#article#181#</font></p>     ^cY#04.h
tm##
00479000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024000074002000700314#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#158#154#article#181#37#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Souza-Jr PR,    Szwarc
wald CL, Castilho EA. Delay in introducing antiretroviral therapy in patients   
 infected by HIV in Brazil, 2003-2006. Clinics 2007; 62:579-84.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#159#155#article#181#</font></p>     ^cY#04.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#160#156#article#181#38#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Centers for    Disease
 Control and Prevention. Number of persons tested for HIV: United States,    200
8. MMWR Morb Mortal Wkly Rep 2008; 57:845-9.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#161#157#article#181#</font></p>     ^cY#04.h
tm##
00514000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027500074002000700349#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#162#158#article#181#39#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Curtis SL,    Sutherla
nd EG. Measuring sexual behaviour in the era of HIV/AIDS: the experience    of D
emographic and Health Surveys and similar enquiries. Sex Transm Infect 2004;    
80 Suppl 2:ii22-7.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#163#159#article#181#</font></p>     ^cY#04.h
tm##
00570000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033100074002000700405#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#164#160#article#181#40#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Hawken MP,    Melis RD
, Ngombo DT, Mandaliya KN, Ng'ang'a LW, Price J, et al. Opportunity    for preve
ntion of HIV and sexually transmitted infections in Kenyan youth: results    of 
a population-based survey. J Acquir Immune Defic Syndr 2002 15; 31:529-35.    ^c
Y#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#165#161#article#181#</font></p>     ^cY#04.h
tm##
00478000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023900074002000700313#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#166#162#article#181#41#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Schroder KE,    Carey 
MP, Vanable PA. Methodological challenges in research on sexual risk behavior:  
  II. Accuracy of self-reports. Ann Behav Med 2003; 26:104-23.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#167#163#article#181#</font></p>     ^cY#04.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#168#164#article#181#42#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Nguyen TQ,    Gwynn RC
, Kellerman SE, Begier E, Garg RK, Pfeiffer MR, et al. Population prevalence    
of reported and unreported HIV and related behaviors among the household adult  
  population in New York City, 2004. AIDS 2008; 22:281-7.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#169#165#article#181#</font></p>     ^cY#04.h
tm##
00562000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032300074002000700397#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#170#166#article#181#43#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Simoes AA,    Bastos F
I, Moreira RI, Lynch KG, Metzger DS. A randomized trial of audio computer    and
 in-person interview to assess HIV risk among drug and alcohol users in Rio    d
e Janeiro, Brazil. J Subst Abuse Treat 2006; 30:237-43</font></p>     ^cY#04.htm
##
00540000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030100074002000700375#v27
s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#p#171#167#article#181#44#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Ghanem KG,    Hutton H
E, Zenilman JM, Zimba R, Erbelding EJ. Audio computer assisted self    interview
 and face to face interview modes in assessing response bias among    STD clinic
 patients. Sex Transm Infect 2005; 81:421-5.    ^cY#04.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#172#168#article#181#</font></p>     ^cY#04.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#173#169#article#181#<p>&nbsp;</p>     ^cY#04
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#174#170#article#181#<p>&nbsp;</p>     ^cY#04
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#175#171#article#181#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#04.htm##
00259000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003500071002000700106#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#176#172#article#181#<br>   </b> A. R. P. Pas
com    ^cY#04.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#177#173#article#181#<br>   Departamento de D
ST    ^cY#04.htm##
00262000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003800071002000700109#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#178#174#article#181#<br>   AIDS e Hepatites 
Virais    ^cY#04.htm##
00272000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004800071002000700119#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#179#175#article#181#<br>   Minist&eacute;rio
 da Sa&uacute;de    ^cY#04.htm##
00266000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004200071002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#180#176#article#181#<br>   SQN 213, bloco I,
 apto. 611    ^cY#04.htm##
00276000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005200071002000700123#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#181#177#article#181#<br>   Bras&iacute;lia, 
DF 70872-090, Brasil    ^cY#04.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#182#178#article#181#<br>   <a href="mailto:a
na.roberta@aids.gov.br">ana.roberta@aids.gov.br</a></font></p>     ^cY#04.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#183#179#article#181#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 23/Oct/2009    ^cY#04.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#184#180#article#181#<br>   Final version res
ubmitted on 06/Feb/2010    ^cY#04.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\04.htm#S#p#185#181#article#181#<br>   Approved on 19/Ap
r/2010</font></p>     ^cY#04.htm##
00558000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100027000700100019000970120
07100116030002200187065000900209064000500218031000300223014000600226865000900232
002000700241035001000248801002200258#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.
htm#S#c#186#1#article#44#1#^rND^sRodrigues-Júnior^nAL#^rND^sCastilho^nEA#A epide
mia de AIDS no Brasil, 1991-2000: descrição espaço-temporal^lpt#Rev Soc Bras Med
 Trop#20040000#2004#37#312-7#20110000#04.htm#0037-8682#Rev Soc Bras Med Trop##
00528000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100017000890120
04600106030002400152065000900176064000500185031000400190014000600194865000900200
002000700209035001000216801002400226#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.
htm#S#c#187#2#article#44#2#^rND^sBarcellos^nC#^rND^sBastos^nFI#Redes sociais e d
ifusao da AIDS no Brasil^lpt#Bol Oficina Sanit Panam#19960000#1996#121#11-24#201
10000#04.htm#0030-0632#Bol Oficina Sanit Panam##
00606000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100017000910100
01900108010001900127012009600146030001800242710000200260065000900262064000500271
031000300276032000400279014000500283865000900288002000700297#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\04.htm#S#c#188#3#article#44#3#^rND^sSzwarcwald^nCL#^rND^sBa
stos^nFI#^rND^sEsteves^nMAP#^rND^sAndrade^nCLT#A disseminação da epidemia da AID
S no Brasil, no período de 1987-1996: uma análise espacial^lpt#Cad Saúde Pública
#2#20000000#2000#16#^s1#7-19#20110000#04.htm##
00383000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680110020000700300029000907100
00200119065000900121064000500130032000200135865000900137002000700146#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\04.htm#S#c#189#4#article#44#4#Ministério da Saúde#B
oletim Epidemiológico AIDST#2#20080000#2008#1#20110000#04.htm##
00463000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170020000700180084000900660
00900174062002000183065000900203064000500212865000900217002000700226#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\04.htm#S#c#190#5#article#44#5#Ministério da Saúde#P
lano integrado de enfrentamento à feminização da epidemia de AIDS e outras DST^l
pt#Brasília#Ministério da Saúde#20070000#2007#20110000#04.htm##
00470000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170020000700180091000900660
00900181062002000190065000900210064000500219865000900224002000700233#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\04.htm#S#c#191#6#article#44#6#Ministério da Saúde#P
rofissionais do sexo: documento referencial para ações de prevenção das DST e da
 AIDS^les#Brasília#Ministério da Saúde#20020000#2002#20110000#04.htm##
00605000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100015000890120
11800104030002800222065000900250064000500259031000300264014000600267865000900273
002000700282035001000289801002800299#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.
htm#S#c#192#7#article#44#7#^rND^sAnderson^nJE#^rND^sStall^nR#How many people are
 at risk for HIV in the United States?: The need for behavioral surveys of at-ri
sk populations^len#J Acquir Immune Defic Syndr#20020000#2002#29#104-5#20110000#0
4.htm#0894-9255#J Acquir Immune Defic Syndr##
00590000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170088000700180143001580660
00900301062002000310065000900330064000500339865000900344002000700353#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\04.htm#S#c#193#8#article#44#8#Ministério da Saúde^d
Programa Nacional de DST e AIDS, Secretaria de Vigilância em Saúde#Pesquisa entr
e os conscritos do Exército Brasileiro, 1996-2002: retratos do comportamento de 
risco do jovem brasileiro à infecção pelo HIV^lpt#Brasília#Ministério da Saúde#2
0020000#2002#20110000#04.htm##
00678000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100019000910100
02400110010001800134010001900152010001900171012009600190030000800286065000900294
06400050030303100030030801400070031186500090031800200070032703500100033480100080
0344#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#194#9#article#44#9#^rND^
sSzwarcwald^nCL#^rND^sCarvalho^nMF#^rND^sBarbosa Júnior^nA#^rND^sBarreira^nD#^rN
D^sSperanza^nFA#^rND^sCastilho^nEA#Temporal trends of HIV-related risk behavior 
among Brazilian military conscripts, 1997-2002^len#Clinics#20050000#2005#60#367-
74#20110000#04.htm#1807-5932#Clinics##
00559000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170045000720180122001170660
01500239062004500254065000900299064000500308865000900313002000700322#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\04.htm#S#c#195#10#article#44#10#Sociedade Civil Bem
-Estar Familiar no Brasil#Pesquisa Nacional sobre Demografia e Saúde: uma anális
e do nível de conhecimento e comportamentos de vulnerabilização^lpt#Rio de Janei
ro#Sociedade Civil Bem-Estar Familiar no Brasil#19970000#1997#20110000#04.htm##
00633000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01500106011005000121012007800171030001800249710000200267065000900269064000500278
031000300283032000800286032000400294014000500298865000900303002000700312#v27s1#V
:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#196#11#article#44#11#^rND^sBerquó^nE
#^rND^sBarbosa^nRM#^rND^sLima^nLP#Grupo de Estudos em População, Sexualidade e A
ids#Uso do preservativo: tendências entre 1998 e 2005 na população brasileira^lp
t#Rev Saúde Pública#2#20080000#2008#42#^sSuppl#^s1#7-11#20110000#04.htm##
00489000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160042000720180086001140660
00900200062002000209065000900229064000500238865000900243002000700252#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\04.htm#S#c#197#12#article#44#12#^rND^sCoordenação N
acional de DST e^nAIDS#PCAP - Pesquisa de Conhecimento, Atitudes e Práticas na P
opulação Brasileira 2004^lpt#Brasília#Ministério da Saúde#20060000#2006#20110000
#04.htm##
00441000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720160017000910180
02800108066001000136062002300146065000900169064000500178865000900183002000700192
#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#198#13#article#44#13#^rND^sB
olfarine^nH#^rND^sBussab^nWO#Elementos de amostragem^lpt#São Paulo#Editora Edgar
d Blucher#20050000#2005#20110000#04.htm##
00587000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930120
11200112030001900224710000200243065000900245064000500254031000300259032000800262
032000400270014000700274865000900281002000700290#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#199#14#article#44#14#^rND^sSzwarcwald^nCL#^rND^sDamacena^nGN
#Amostras complexas em inquéritos populacionais: planejamento e implicações na a
nálise estatística dos dados^lpt#Rev Bras Epidemiol#2#20080000#2008#11#^sSuppl#^
s1#S38-45#20110000#04.htm##
00454000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160017000720160018000890180
03200107063000400139066000900143062001800152065000900170064000500179865000900184
002000700193#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#200#15#article#4
4#15#^rND^sHosmer^nDW#^rND^sLemeshow^nS#Applied logistic regression^len#2nd#New 
York#John Wiley & Sons#19890000#1989#20110000#04.htm##
00478000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170046000720180047001180370
05800165110000900223109001200232865000900244002000700253#v27s1#V:\SciELO\serial\
csp\v27s1\markup\04.htm#S#c#201#16#article#44#16#Associação Brasileira de Empres
as de Pesquisa#Critério de Classificação Econômica Brasil^lpt#http://www.abep.or
g/codigosguias/Criterio_Brasil_2008.pdf#20090809#09/Aug/2009#20110000#04.htm##
00561000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01800107010001800125012006800143030001800211710000200229065000900231064000500240
031000300245014000700248865000900255002000700264#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#202#17#article#44#17#^rND^sAlmeida^nMC#^rND^sAquino^nEM#^rND
^sGaffikin^nL#^rND^sMagnani^nRJ#Contraceptive use among adolescents at public sc
hools in Brazil^len#Rev Saúde Pública#2#20030000#2003#37#566-75#20110000#04.htm#
#
00586000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900110
03000107012009600137030001800233710000200251065000900253064000500262031000300267
032000400270014000600274865000900280002000700289#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#203#18#article#44#18#^rND^sBarbosa^nRM#^rND^sKoyama^nMA#Grup
o de Estudos em População#Sexualidade e AIDS: Sexual behavior and practices amon
g men and women, Brazil 1998 and 2005^len#Rev Saúde Pública#2#20080000#2008#42#^
s1#21-33#20110000#04.htm##
00611000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01700107010002300124012008600147030000500233065000900238064000500247031000300252
032000400255014000700259865000900266002000700275035001000282801000500292#v27s1#V
:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#204#19#article#44#19#^rND^sCalazans^
nG#^rND^sAraujo^nTW#^rND^sVenturi^nG#^rND^sFranca Junior^nI#Factors associated w
ith condom use among youth aged 15-24 years in Brazil in 2003^len#AIDS#20050000#
2005#19#^s4#S42-50#20110000#04.htm#0269-9370#AIDS##
00591000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01800108012007700126030002400203065000900227064000500236031000300241014000700244
865000900251002000700260035001000267801002400277#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#205#20#article#44#20#^rND^sGullette^nDL#^rND^sRooker^nJL#^rN
D^sKennedy^nRL#Factors associated with sexually transmitted infections in men an
d women^len#J Community Health Nurs#20090000#2009#26#121-30#20110000#04.htm#0737
-0016#J Community Health Nurs##
00630000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100017000880100
02000105010001500125010001900140012011600159030001500275710000200290065000900292
064000500301031000200306014000400308865000900312002000700321#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\04.htm#S#c#206#21#article#44#21#^rND^sUrassa^nW#^rND^sMoshi
ro^nC#^rND^sChalamilla^nG#^rND^sMhalu^nF#^rND^sSandstrom^nE#Risky sexual practic
es among youth attending a sexually transmitted infection clinic in Dar es Salaa
m, Tanzania^len#BMC Infect Dis#2#20080000#2008#8#159#20110000#04.htm##
00625000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100021000870100
01900108010001800127010001700145012007600162030001200238065000900250064000500259
031000300264014000600267865000900273002000700282035001000289801001200299#v27s1#V
:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#207#22#article#44#22#^rND^sFrank^nS#
^rND^sEsterhuizen^nT#^rND^sJinabhai^nCC#^rND^sSullivan^nK#^rND^sTaylor^nMS#Risky
 sexual behaviours of high-school pupils in an era of HIV and AIDS^len#S Afr Med
 J#20080000#2008#98#394-8#20110000#04.htm#0038-2469#S Afr Med J##
00739000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100026000720100017000980100
01900115010001800134010001600152010002200168810000600190012012500196030001500321
06500090033606400050034503100030035001400070035386500090036000200070036903500100
0376801001500386#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#208#23#artic
le#44#23#^rND^sMartinez-Donate^nAP#^rND^sHovell^nMF#^rND^sBlumberg^nEJ#^rND^sZel
lner^nJA#^rND^sSipan^nCL#^rND^sShillington^nAM#et al#Gender differences in condo
m-related behaviors and attitudes among Mexican adolescents living on the U: S.-
Mexico border^len#AIDS Educ Prev#20040000#2004#16#172-86#20110000#04.htm#0899-95
46#AIDS Educ Prev##
00662000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01800108010001700126010001600143012006700159030002800226065000900254064000500263
03100020026803200040027001400080027486500090028200200070029103500100029880100280
0308#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#209#24#article#44#24#^rN
D^sEhrhardt^nAA#^rND^sSawires^nS#^rND^sMcGovern^nT#^rND^sPeacock^nD#^rND^sWeston
^nM#Gender, empowerment, and health: what is it? how does it work?^len#J Acquir 
Immune Defic Syndr#20090000#2009#5#^s3#S96-105#20110000#04.htm#0894-9255#J Acqui
r Immune Defic Syndr##
00626000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100017000880100
01700105012009300122030002800215065000900243064000500252031000300257032000400260
014000600264865000900270002000700279035001000286801002800296#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\04.htm#S#c#210#25#article#44#25#^rND^sShawky^nS#^rND^sSolim
an^nC#^rND^sSawires^nS#Gender and HIV in the Middle East and North Africa: lesso
ns for low prevalence scenarios^len#J Acquir Immune Defic Syndr#20090000#2009#51
#^s3#S73-4#20110000#04.htm#0894-9255#J Acquir Immune Defic Syndr##
00657000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
01700105010001400122011003000136010002600166012007600192030001800268710000200286
06500090028806400050029703100030030203200040030501400060030986500090031500200070
0324#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#211#26#article#44#26#^rN
D^sPaiva^nV#^rND^sCalazans^nG#^rND^sVenturi^nG#^rND^sDias^nR#Grupo de Estudos em
 População#^rND^sSexualidade e^nAIDS#Age and condom use at first sexual intercou
rse of Brazilian adolescents^len#Rev Saúde Pública#2#20080000#2008#42#^s1#45-53#
20110000#04.htm##
00618000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100016000920100
01900108010002100127012009800148030001000246065000900256064000500265031000300270
014000700273865000900280002000700289035001000296801001000306#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\04.htm#S#c#212#27#article#44#27#^rND^sKornreich^nJL#^rND^sH
earn^nKD#^rND^sRodriguez^nG#^rND^sO'Sullivan^nLF#Sibling influence, gender roles
, and the sexual socialization of urban early adolescent girls^len#J Sex Res#200
30000#2003#40#101-10#20110000#04.htm#0022-4499#J Sex Res##
00564000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100019000860100
01500105012007500120030001500195065000900210064000500219031000300224014000600227
865000900233002000700242035001000249801001500259#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#213#28#article#44#28#^rND^sRoth^nJ#^rND^sKrishnan^nSP#^rND^s
Bunch^nE#Barriers to condom use: results from a study in Mumbai (Bombay), India^
len#AIDS Educ Prev#20010000#2001#13#65-77#20110000#04.htm#0899-9546#AIDS Educ Pr
ev##
00690000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100021000890100
01800110010001800128010002000146010001700166810000600183012012500189030000900314
71000020032306500090032506400050033403100020033901400070034186500090034800200070
0357#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#214#29#article#44#29#^rN
D^sCrosby^nRA#^rND^sDiClemente^nRJ#^rND^sWingood^nGM#^rND^sSalazar^nLF#^rND^sHar
rington^nK#^rND^sDavies^nSL#et al#Identification of strategies for promoting con
dom use: a prospective analysis of high-risk African American female teens^len#P
rev Sci#2#20030000#2003#4#263-70#20110000#04.htm##
00561000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900100
01900108012006400127030001500191065000900206064000500215031000300220014000700223
865000900230002000700239035001000246801001500256#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#215#30#article#44#30#^rND^sMadrigal^nJ#^rND^sSchifter^nJ#^rN
D^sFeldblum^nPJ#Female condom acceptability among sex workers in Costa Rica^len#
AIDS Educ Prev#19980000#1998#10#105-13#20110000#04.htm#0899-9546#AIDS Educ Prev#
#
00523000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880120
08800106030002200194710000200216065000900218064000500227031000300232014000600235
865000900241002000700250#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#216#
31#article#44#31#^rND^sWarren^nM#^rND^sPhilpott^nA#Expanding safer sex options: 
introducing the female condom into national programmes^len#Reprod Health Matters
#2#20030000#2003#11#130-9#20110000#04.htm##
00572000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160015000720160019000870160
01600106016001600122016001700138016002100155018003900176066000900215062002800224
065000900252064000500261865000900266002000700275#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#217#32#article#44#32#^rND^sCard^nJJ#^rND^sAmarillas^nA#^rND^
sConner^nA#^rND^sAkers^nDD#^rND^sSolomon^nJ#^rND^sDiClemente^nRJ#The complete HI
V/AIDS teaching kit^len#New York#Springer Publishing Company#20080000#2008#20110
000#04.htm##
00632000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100019000920100
01600111010002100127012009600148030001800244065000900262064000500271031000300276
014000700279865000900286002000700295035001000302801001800312#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\04.htm#S#c#218#33#article#44#33#^rND^sAl-Tayyib^nAA#^rND^sM
cFarlane^nM#^rND^sKachur^nR#^rND^sRietmeijer^nCA#Finding sex partners on the int
ernet: what is the risk for sexually transmitted infections?^len#Sex Transm Infe
ct#20090000#2009#85#216-20#20110000#04.htm#1368-4973#Sex Transm Infect##
00537000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100026000720100024000980120
06800122030001000190065000900200064000500209031000300214014000600217865000900223
002000700232035001000239801001000249#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.
htm#S#c#219#34#article#44#34#^rND^sFernández-Dávila^nP#^rND^sZaragoza Lorca^nK#I
nternet y riesgo sexual en hombres que tienen sexo con hombres^les#Gac Sanit#200
90000#2009#23#380-7#20110000#04.htm#0213-9111#Gac Sanit##
00619000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100012000870100
01700099010001200116012010500128030001700233065000900250064000500259031000300264
014000700267865000900274002000700283035001000290801001700300#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\04.htm#S#c#220#35#article#44#35#^rND^sZhang^nD#^rND^sBi^nP#
^rND^sHiller^nJE#^rND^sLv^nF#Web-based HIV/AIDS behavioral surveillance among me
n who have sex with men: potential and challenges^len#Int J Infect Dis#20080000#
2008#12#126-31#20110000#04.htm#1201-9712#Int J Infect Dis##
00696000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100017000880100
01500105010001500120010001400135012012800149030002800277065000900305064000500314
031000300319014000600322865000900328002000700337035001000344801002800354#v27s1#V
:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#221#36#article#44#36#^rND^sElford^nJ
#^rND^sBolding^nG#^rND^sDavis^nM#^rND^sSherr^nL#^rND^sHart^nG#Web-based behavior
al surveillance among men who have sex with men: a comparison of online and offl
ine samples in London, UK^len#J Acquir Immune Defic Syndr#20040000#2004#35#421-6
#20110000#04.htm#0894-9255#J Acquir Immune Defic Syndr##
00584000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100021000910100
01900112012009700131030000800228065000900236064000500245031000300250014000700253
865000900260002000700269035001000276801000800286#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#222#37#article#44#37#^rND^sSouza-Jr^nPR#^rND^sSzwarcwald^nCL
#^rND^sCastilho^nEA#Delay in introducing antiretroviral therapy in patients infe
cted by HIV in Brazil, 2003-2006^len#Clinics#20070000#2007#62#579-84#20110000#04
.htm#1807-5932#Clinics##
00540000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690110043000720120058001150300
02600173065000900199064000500208031000300213014000600216865000900222002000700231
035001000238801002600248#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#223#
38#article#44#38#Centers for Disease Control and Prevention#Number of persons te
sted for HIV: United States, 2008^len#MMWR Morb Mortal Wkly Rep#20080000#2008#57
#845-9#20110000#04.htm#0149-2195#MMWR Morb Mortal Wkly Rep##
00616000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100021000890120
12600110030001800236065000900254064000500263031000300268032000400271014000700275
865000900282002000700291035001000298801001800308#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#224#39#article#44#39#^rND^sCurtis^nSL#^rND^sSutherland^nEG#M
easuring sexual behaviour in the era of HIV/AIDS: the experience of Demographic 
and Health Surveys and similar enquiries^len#Sex Transm Infect#20040000#2004#80#
^s2#ii22-7#20110000#04.htm#1368-4973#Sex Transm Infect##
00769000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01700105010002000122010001900142010001500161810000600176012012800182030002800310
06500090033806400050034703100030035203200030035501400070035886500090036500200070
0374035001000381801002800391#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#
225#40#article#44#40#^rND^sHawken^nMP#^rND^sMelis^nRD#^rND^sNgombo^nDT#^rND^sMan
daliya^nKN#^rND^sNg'ang'a^nLW#^rND^sPrice^nJ#et al#Opportunity for prevention of
 HIV and sexually transmitted infections in Kenyan youth: results of a populatio
n-based survey^len#J Acquir Immune Defic Syndr#20020000#2002#15#31#529-35#201100
00#04.htm#0894-9255#J Acquir Immune Defic Syndr##
00589000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100016000910100
01800107012009600125030001400221065000900235064000500244031000300249014000700252
865000900259002000700268035001000275801001400285#v27s1#V:\SciELO\serial\csp\v27s
1\markup\04.htm#S#c#226#41#article#44#41#^rND^sSchroder^nKE#^rND^sCarey^nMP#^rND
^sVanable^nPA#Methodological challenges in research on sexual risk behavior: II.
 Accuracy of self-reports^len#Ann Behav Med#20030000#2003#26#104-23#20110000#04.
htm#0883-6612#Ann Behav Med##
00717000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
02000105010001600125010001500141010001900156810000600175012013900181030000500320
06500090032506400050033403100030033901400060034286500090034800200070035703500100
0364801000500374#v27s1#V:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#227#42#artic
le#44#42#^rND^sNguyen^nTQ#^rND^sGwynn^nRC#^rND^sKellerman^nSE#^rND^sBegier^nE#^r
ND^sGarg^nRK#^rND^sPfeiffer^nMR#et al#Population prevalence of reported and unre
ported HIV and related behaviors among the household adult population in New Yor
k City, 2004^len#AIDS#20080000#2008#22#281-7#20110000#04.htm#0269-9370#AIDS##
00701000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01800106010001600124010001800140012013900158030002000297065000900317064000500326
031000300331014000700334865000900341002000700350035001000357801002000367#v27s1#V
:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#228#43#article#44#43#^rND^sSimoes^nA
A#^rND^sBastos^nFI#^rND^sMoreira^nRI#^rND^sLynch^nKG#^rND^sMetzger^nDS#A randomi
zed trial of audio computer and in-person interview to assess HIV risk among dru
g and alcohol users in Rio de Janeiro, Brazil^len#J Subst Abuse Treat#20060000#2
006#30#237-43#20110000#04.htm#0740-5472#J Subst Abuse Treat##
00688000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01900106010001500125010002000140012012900160030001800289065000900307064000500316
031000300321014000600324865000900330002000700339035001000346801001800356#v27s1#V
:\SciELO\serial\csp\v27s1\markup\04.htm#S#c#229#44#article#44#45#^rND^sGhanem^nK
G#^rND^sHutton^nHE#^rND^sZenilman^nJM#^rND^sZimba^nR#^rND^sErbelding^nEJ#Audio c
omputer assisted self interview and face to face interview modes in assessing re
sponse bias among STD clinic patients^len#Sex Transm Infect#20050000#2005#81#421
-5#20110000#04.htm#1368-4973#Sex Transm Infect##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#o#1#1#article#1#201104
11#073700#05.htm#192##
03926000000000673000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000190010503100030012413100020012706500090012901400110013803500100014901200910
01590120116002500100037003660100036004030100038004390100025004770100028005020700
08900530070012400619070012100743070005000864083096100914085001001875085001601885
08500350190108500290193608311220196508500100308708500160309708500350311308500230
31481170008031710720003031791120009031821110012031911160009032031150012032121140
00903224113001203233002000703245#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#
S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#05#CSP330#nd#Cad. Saúde Pública#27#
1#20110000#^fs36^ls44#0102-311X#Transfer of sampling methods for studies on most
-at-risk populations (MARPs) in Brazil^len#Transferência de métodos de amostrage
m para estudos em populações sob maior risco à infecção pelo HIV no Brasil^lpt#^
rND^1A01^nAristides^sBarbosa Júnior#^rND^1A01^nAna Roberta Pati^sPascom#^rND^1A0
2^nCélia Landmann^sSzwarcwald#^rND^1A03^nCarl^sKendall#^rND^1A04^nWilli^sMcFarla
nd#Ministério da Saúde^iA01^1Departamento de DST, AIDS e Hepatites Virais^cBrasí
lia^pBrasil#Fundação Oswaldo Cruz^iA02^1Instituto de Comunicação e Informação Ci
entífica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#Tulane University^iA03^1
School of Public Health and Tropical Medicine^2Center for Global Health Equity^c
New Orleans^pUSA#University of California^iA04^cSan Francisco^pUSA#^len^aThe obj
ective of this paper was to describe the process of transferring two methods for
 sampling most-at-risk populations: respondent-driven sampling (RDS) and time-sp
ace sampling (TSS). The article describes steps in the process, the methods used
 in the 10 pilot studies, and lessons learned. The process was conducted in six 
steps, from a state-of-the-art seminar to a workshop on writing articles with th
e results of the pilot studies. The principal investigators reported difficultie
s in the fieldwork and data analysis, independently of the pilot sampling method
. One of the most important results of the transfer process is that Brazil now h
as more than 100 researchers able to sample MARPs using RDS or TSS. The process 
also enabled the construction of baselines for MARPS, thus providing a broader u
nderstanding of the dynamics of HIV infection in the country and the use of evid
ence to plan the national response to the epidemic in these groups.#^ddecs^i1#^t
m^len^kHIV^i1#^tm^len^kVulnerable Populations^i1#^tm^len^kSampling Studies^i1#^l
pt^aO objetivo deste trabalho é descrever o processo de transferência de dois mé
todos de amostragem de populações sob maior risco ao HIV: RDS (respondent driven
 sampling) e o TSS (time space sampling). São descritas as etapas da transferênc
ia, os procedimentos metodológicos utilizados nos dez estudos-piloto conduzidos 
no Brasil e as lições aprendidas desse processo. O processo de transferência foi
 realizado em seis etapas, que envolveram desde a apresentação do estado da arte
 dos métodos de amostragem até a elaboração de artigo com os resultados dos estu
dos-piloto. Os pesquisadores apontaram dificuldades tanto na execução do campo c
omo na análise dos dados dos estudos, independentemente do método de amostragem 
utilizado. Dentre os resultados mais importantes desse processo destaca-se a cap
acitação de mais de 100 pesquisadores. O processo de transferência possibilitou 
a realização de estudos específicos para construção das linhas de base para moni
toramento da epidemia nos subgrupos sob maior risco para a infecção pelo HIV, e 
implicou o maior conhecimento da dinâmica da disseminação da infecção pelo HIV.#
^ddecs^i2#^tm^lpt^kHIV^i2#^tm^lpt^kPopulações Vulneráveis^i2#^tm^lpt^kAmostragem
^i2#vancouv#29#20091029#29/Oct/2009#20100407#07/Apr/2010#20100419#19/Apr/2010#05
.htm##
03940000000000673000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000190010503100030012413100020012706500090012901400110013803500100014901200980
01590120123002570100037003800100036004170100038004530100025004910100028005160700
08900544070012400633070012100757070005000878083096100928085001001889085001601899
08500350191508500290195008311220197908500100310108500160311108500350312708500230
31621170008031850720003031931120009031961110012032051160009032171150012032261140
00903238113001203247002000703259#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#
S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#05#CSP330#nd#Cad. Saúde Pública#27#
1#20110000#^fs36^ls44#0102-311X#<b>Transfer of sampling methods for studies on m
ost-at-risk populations (MARPs) in Brazil</b>^len#<b>Transferência de métodos de
 amostragem para estudos em populações sob maior risco à infecção pelo HIV no Br
asil</b>^lpt#^rND^1A01^nAristides^sBarbosa Júnior#^rND^1A01^nAna Roberta Pati^sP
ascom#^rND^1A02^nCélia Landmann^sSzwarcwald#^rND^1A03^nCarl^sKendall#^rND^1A04^n
Willi^sMcFarland#Ministério da Saúde^iA01^1Departamento de DST, AIDS e Hepatites
 Virais^cBrasília^pBrasil#Fundação Oswaldo Cruz^iA02^1Instituto de Comunicação e
 Informação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#Tulane Uni
versity^iA03^1School of Public Health and Tropical Medicine^2Center for Global H
ealth Equity^cNew Orleans^pUSA#University of California^iA04^cSan Francisco^pUSA
#^len^aThe objective of this paper was to describe the process of transferring t
wo methods for sampling most-at-risk populations: respondent-driven sampling (RD
S) and time-space sampling (TSS). The article describes steps in the process, th
e methods used in the 10 pilot studies, and lessons learned. The process was con
ducted in six steps, from a state-of-the-art seminar to a workshop on writing ar
ticles with the results of the pilot studies. The principal investigators report
ed difficulties in the fieldwork and data analysis, independently of the pilot s
ampling method. One of the most important results of the transfer process is tha
t Brazil now has more than 100 researchers able to sample MARPs using RDS or TSS
. The process also enabled the construction of baselines for MARPS, thus providi
ng a broader understanding of the dynamics of HIV infection in the country and t
he use of evidence to plan the national response to the epidemic in these groups
.#^ddecs^i1#^tm^len^kHIV^i1#^tm^len^kVulnerable Populations^i1#^tm^len^kSampling
 Studies^i1#^lpt^aO objetivo deste trabalho é descrever o processo de transferên
cia de dois métodos de amostragem de populações sob maior risco ao HIV: RDS (res
pondent driven sampling) e o TSS (time space sampling). São descritas as etapas 
da transferência, os procedimentos metodológicos utilizados nos dez estudos-pilo
to conduzidos no Brasil e as lições aprendidas desse processo. O processo de tra
nsferência foi realizado em seis etapas, que envolveram desde a apresentação do 
estado da arte dos métodos de amostragem até a elaboração de artigo com os resul
tados dos estudos-piloto. Os pesquisadores apontaram dificuldades tanto na execu
ção do campo como na análise dos dados dos estudos, independentemente do método 
de amostragem utilizado. Dentre os resultados mais importantes desse processo de
staca-se a capacitação de mais de 100 pesquisadores. O processo de transferência
 possibilitou a realização de estudos específicos para construção das linhas de 
base para monitoramento da epidemia nos subgrupos sob maior risco para a infecçã
o pelo HIV, e implicou o maior conhecimento da dinâmica da disseminação da infec
ção pelo HIV.#^ddecs^i2#^tm^lpt^kHIV^i2#^tm^lpt^kPopulações Vulneráveis^i2#^tm^l
pt^kAmostragem^i2#vancouv#29#20091029#29/Oct/2009#20100407#07/Apr/2010#20100419#
19/Apr/2010#05.htm##
04054000000000697000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095121000300099049000700102
15800030010903000190011203100030013113100020013406500090013601400110014503500100
01560120091001660120116002570100037003730100036004100100038004460100025004840100
02800509070009100537070012600628070012300754070005200877083096100929085001001890
08500160190008500350191608500290195108311220198008500100310208500160311208500350
31280850023031631170008031860720003031941120009031971110012032061160009032181150
01203227114000903239113001203248002000703260008008903267#v27s1#V:\SciELO\serial\
csp\v27s1\markup\05.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#ilus#tab#05#C
SP330#nd#Cad. saúde pública#27#1#20110000#^fs36^ls44#0102-311X#Transfer of sampl
ing methods for studies on most-at-risk populations (MARPs) in Brazil^len#Transf
erência de métodos de amostragem para estudos em populações sob maior risco à in
fecção pelo HIV no Brasil^lpt#^rND^1A01^nAristides^sBarbosa Júnior#^rND^1A01^nAn
a Roberta Pati^sPascom#^rND^1A02^nCélia Landmann^sSzwarcwald#^rND^1A03^nCarl^sKe
ndall#^rND^1A04^nWilli^sMcFarland#^iA01^1Ministério da Saúde^2Departamento de DS
T, AIDS e Hepatites Virais^cBrasília^pBrasil#^iA02^1Fundação Oswaldo Cruz^2Insti
tuto de Comunicação e Informação Científica e Tecnológica em Saúde^cRio de Janei
ro^pBrasil#^iA03^1Tulane University^2School of Public Health and Tropical Medici
ne^3Center for Global Health Equity^cNew Orleans^pUSA#^iA04^1University of Calif
ornia^cSan Francisco^pUSA#^len^aThe objective of this paper was to describe the 
process of transferring two methods for sampling most-at-risk populations: respo
ndent-driven sampling (RDS) and time-space sampling (TSS). The article describes
 steps in the process, the methods used in the 10 pilot studies, and lessons lea
rned. The process was conducted in six steps, from a state-of-the-art seminar to
 a workshop on writing articles with the results of the pilot studies. The princ
ipal investigators reported difficulties in the fieldwork and data analysis, ind
ependently of the pilot sampling method. One of the most important results of th
e transfer process is that Brazil now has more than 100 researchers able to samp
le MARPs using RDS or TSS. The process also enabled the construction of baseline
s for MARPS, thus providing a broader understanding of the dynamics of HIV infec
tion in the country and the use of evidence to plan the national response to the
 epidemic in these groups.#^ddecs^i1#^tm^len^kHIV^i1#^tm^len^kVulnerable Populat
ions^i1#^tm^len^kSampling Studies^i1#^lpt^aO objetivo deste trabalho é descrever
 o processo de transferência de dois métodos de amostragem de populações sob mai
or risco ao HIV: RDS (respondent driven sampling) e o TSS (time space sampling).
 São descritas as etapas da transferência, os procedimentos metodológicos utiliz
ados nos dez estudos-piloto conduzidos no Brasil e as lições aprendidas desse pr
ocesso. O processo de transferência foi realizado em seis etapas, que envolveram
 desde a apresentação do estado da arte dos métodos de amostragem até a elaboraç
ão de artigo com os resultados dos estudos-piloto. Os pesquisadores apontaram di
ficuldades tanto na execução do campo como na análise dos dados dos estudos, ind
ependentemente do método de amostragem utilizado. Dentre os resultados mais impo
rtantes desse processo destaca-se a capacitação de mais de 100 pesquisadores. O 
processo de transferência possibilitou a realização de estudos específicos para 
construção das linhas de base para monitoramento da epidemia nos subgrupos sob m
aior risco para a infecção pelo HIV, e implicou o maior conhecimento da dinâmica
 da disseminação da infecção pelo HIV.#^ddecs^i2#^tm^lpt^kHIV^i2#^tm^lpt^kPopula
ções Vulneráveis^i2#^tm^lpt^kAmostragem^i2#vancouv#29#20091029#29/Oct/2009#20100
407#07/Apr/2010#20100419#19/Apr/2010#05.htm#Internet^ihttp://www.scielo.br/sciel
o.php?script=sci_arttext&pid=S0102-311X2011001300005##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#5#1#article#159#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#6#2#article#159#<p>&nbsp;</p>     ^cY#05.htm
##
00417000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704019700067002000700264#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#7#3#article#159#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Transfer    of sampling 
methods for studies on most-at-risk populations (MARPs) in Brazil</b></font></p>
     ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#8#4#article#159#<p>&nbsp;</p>     ^cY#05.htm
##
00475000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704025500067002000700322#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#9#5#article#159#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Transfer&ecirc;ncia    de m&eacute;todos d
e amostragem para estudos em popula&ccedil;&otilde;es sob    maior risco &agrave
; infec&ccedil;&atilde;o pelo HIV no Brasil</b></font></p>     ^cY#05.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#10#6#article#159#<p>&nbsp;</p>     ^cY#05.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#11#7#article#159#<p>&nbsp;</p>     ^cY#05.ht
m##
00502000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704028100068002000700349#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#12#8#article#159#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Aristides Barbosa    J&uacute;nior<sup>I<
/sup>; Ana Roberta Pati Pascom<sup>I</sup>; C&eacute;lia    Landmann Szwarcwald<
sup>II</sup>; Carl Kendall<sup>III</sup>; Willi McFarland<sup>IV</sup></b></font
></p>     ^cY#05.htm##
00414000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704019300068002000700261#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#13#9#article#159#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Departamento    de DST, AIDS e H
epatites Virais, Minist&eacute;rio da Sa&uacute;de, Bras&iacute;lia,    Brasil  
  ^cY#05.htm##
00437000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021500069002000700284#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#14#10#article#159#<br>   <sup>II</sup>Instit
uto de Comunica&ccedil;&atilde;o e Informa&ccedil;&atilde;o    Cient&iacute;fica
 e Tecnol&oacute;gica em Sa&uacute;de, Funda&ccedil;&atilde;o    Oswaldo Cruz, R
io de Janeiro, Brasil    ^cY#05.htm##
00368000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014600069002000700215#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#15#11#article#159#<br>   <sup>III</sup>Cente
r for Global Health Equity, Tulane University School of Public    Health and Tro
pical Medicine, New Orleans, USA    ^cY#05.htm##
00306000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704008400069002000700153#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#16#12#article#159#<br>   <sup>IV</sup>Univer
sity of California, San Francisco, USA</font></p>     ^cY#05.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#17#13#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#18#14#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#19#15#article#159#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#05.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#20#16#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#05.htm##
01295000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704107300069002000701142#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#21#17#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The objective of    this paper was to descr
ibe the process of transferring two methods for sampling    most-at-risk populat
ions: respondent-driven sampling (RDS) and time-space sampling    (TSS). The art
icle describes steps in the process, the methods used in the 10    pilot studies
, and lessons learned. The process was conducted in six steps,    from a state-o
f-the-art seminar to a workshop on writing articles with the results    of the p
ilot studies. The principal investigators reported difficulties in the    fieldw
ork and data analysis, independently of the pilot sampling method. One    of the
 most important results of the transfer process is that Brazil now has    more t
han 100 researchers able to sample MARPs using RDS or TSS. The process    also e
nabled the construction of baselines for MARPS, thus providing a broader    unde
rstanding of the dynamics of HIV infection in the country and the use of    evid
ence to plan the national response to the epidemic in these groups.</font></p>  
   ^cY#05.htm##
00375000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015300069002000700222#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#22#18#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV; Vulnerable    Populations; Sampling St
udies</font></p> <hr size="1" noshade>     ^cY#05.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#23#19#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#05.htm##
01718000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704149600069002000701565#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#24#20#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo deste    trabalho &eacute; descr
ever o processo de transfer&ecirc;ncia de dois m&eacute;todos    de amostragem d
e popula&ccedil;&otilde;es sob maior risco ao HIV: RDS (respondent    driven sam
pling) e o TSS (time space sampling). S&atilde;o descritas as etapas    da trans
fer&ecirc;ncia, os procedimentos metodol&oacute;gicos utilizados nos    dez estu
dos-piloto conduzidos no Brasil e as li&ccedil;&otilde;es aprendidas    desse pr
ocesso. O processo de transfer&ecirc;ncia foi realizado em seis etapas,    que e
nvolveram desde a apresenta&ccedil;&atilde;o do estado da arte dos m&eacute;todo
s    de amostragem at&eacute; a elabora&ccedil;&atilde;o de artigo com os result
ados    dos estudos-piloto. Os pesquisadores apontaram dificuldades tanto na exe
cu&ccedil;&atilde;o    do campo como na an&aacute;lise dos dados dos estudos, in
dependentemente do    m&eacute;todo de amostragem utilizado. Dentre os resultado
s mais importantes    desse processo destaca-se a capacita&ccedil;&atilde;o de m
ais de 100 pesquisadores.    O processo de transfer&ecirc;ncia possibilitou a re
aliza&ccedil;&atilde;o de    estudos espec&iacute;ficos para constru&ccedil;&ati
lde;o das linhas de base    para monitoramento da epidemia nos subgrupos sob mai
or risco para a infec&ccedil;&atilde;o    pelo HIV, e implicou o maior conhecime
nto da din&acirc;mica da dissemina&ccedil;&atilde;o    da infec&ccedil;&atilde;o
 pelo HIV.</font></p>     ^cY#05.htm##
00390000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016800069002000700237#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#25#21#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV; Popula&ccedil;&otilde;es    Vulner&aac
ute;veis; Amostragem</font></p> <hr size="1" noshade>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#26#22#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#27#23#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00326000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010400069002000700173#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#28#24#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font>  </p>     ^cY#05
.htm##
00874000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065200069002000700721#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#29#25#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Twenty-seven years    since identification 
of the first AIDS case in Brazil, the Brazilian epidemic    is still concentrate
d, with a disproportional share among most-at-risk population    groups for HIV 
infection. According to Wilson &amp; Halperin (p. 423) <sup>1</sup>    of the Wo
rld Bank, the epidemic is considered to be concentrated "<i>if transmission    o
ccurs in defined vulnerable populations, typically sex workers, men who have    
sex with men, and injecting drug users, and their sexual partners, and if protec
ting    them would protect wider society</i>".</font></p>     ^cY#05.htm##
00852000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063000069002000700699#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#30#26#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">An analysis of    the dynamics in the AIDS 
epidemic in Brazil shows much higher rates in some    groups, thereby contradict
ing more pessimistic forecasts of a generalized HIV/AIDS    epidemic in the medi
um term <sup>2</sup>. To illustrate the epidemic's unequal    distribution in Br
azil, the AIDS incidence rate in 2004 among male injecting    drug users (IDUs) 
was approximately 15 times that of heterosexual males in general.    A similar c
ontrast is observed when comparing men who have sex with men (MSM)    and hetero
sexual men <sup>3</sup>.</font></p>     ^cY#05.htm##
00971000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074900069002000700818#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#31#27#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the early years    of the epidemic in Br
azil, the main epidemiological surveillance activity was    monitoring AIDS case
s. Later, there was an evident need to monitor the principal    risk factors rel
ated to sexually transmitted infection, including the knowledge,    practices, a
nd sexual behaviors of the Brazilian general population and among    the subgrou
ps with the most AIDS cases. Beginning in 1996, various studies were    conducte
d with this objective. These included a series of studies on Brazilian    Army c
onscripts (1997, 1998, 2000, 2002, 2007) <sup>4</sup> and studies in the    over
all population (1998, 2004, 2005, and 2008) <sup>5,6,7,8</sup>.</font></p>     ^
cY#05.htm##
01096000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704087400069002000700943#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#32#28#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for monitoring    risk practices in most
-at-risk groups for HIV infection, due to the inherent    methodological difficu
lties in sampling hard-to-reach populations, until recently    the surveys condu
cted in Brazil for these populations used convenience sampling.    In addition, 
the studies were local, without a national scope, and their usefulness    for mo
nitoring activities was thus quite limited. Examples include the public    opini
on surveys conducted by the National STD/AIDS Program in 2001 and 2002    with m
ale homosexuals over 16 years of age in gay gathering places (results    unpubli
shed). Other examples include the multicenter studies among IDUs participating  
  in harm reduction projects, conducted in some Brazilian cities - the AjUDE-Bra
zil    Project <sup>9</sup>.</font></p>     ^cY#05.htm##
00891000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066900069002000700738#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#33#29#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Currently, obtaining    representative samp
les of hard-to-reach population subgroups still poses one    of the main challen
ges for HIV surveillance <sup>10</sup>. Traditional sampling    methods are inad
equate for generating representative samples, since in order    to estimate para
meters with the necessary robustness it is necessary to select    very large sam
ples, which is hindered by operational difficulties and costs    <sup>11</sup>. 
In addition, some of the population groups at greatest risk for    HIV are invol
ved in illegal activities and often remain hidden from society.</font></p>     ^
cY#05.htm##
00787000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056500069002000700634#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#34#30#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The development    and expansion of the use
 of specific and probabilistic methods like time-space    sampling (TSS) <sup>12
</sup> and respondent driven-sampling (RDS) <sup>13</sup>    brought new possibi
lities and stimulus for researchers interested in studies    on most-at-risk gro
ups for HIV infection. In recent years, the international    scenario has witnes
sed an increase in the number of studies on hard-to-reach    groups using probab
ilistic sampling methods <sup>14</sup>.</font></p>     ^cY#05.htm##
01337000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704111500069002000701184#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#35#31#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The TSS method    combines ethnographic tec
hniques with venue sampling <sup>13</sup>, and one    of its premises is that ha
rd-to-reach populations tend to gather in specific    places, for example nightc
lubs, bars, saunas, parks, and certain stretches of    streets. In each gatherin
g place for the target population identified during    the ethnographic research
, the individuals are numbered in time periods (generally    lasting four hours)
, on varying days, to construct a combined list of potential    places, days, an
d times to be sampled. The time-space units (place, day, and    hour of the day)
 where at least eight individuals from the target population    were numbered co
nstitute a list of units in the first selection stage. In the    second selectio
n stage, the individuals that frequent the primary sampled units    and that are
 apparently eligible are numbered consecutively and approached to    verify the 
study inclusion criteria. Eligible individuals are then invited to    participat
e in the study <sup>15</sup>.</font></p>     ^cY#05.htm##
00806000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058400069002000700653#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#36#32#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The RDS sampling    procedure is similar to
 that used in the so-called snowball techniques, since    it uses referral chain
s for sampling, i.e., the recruitment process is done    by the members of the s
tudy population themselves rather than by the researchers.    The difference bet
ween the two methods is that the recruitment process in RDS    was improved to e
nable calculation of the selection probabilities, and it can    thus be classifi
ed among the probabilistic sampling methods <sup>13</sup>.</font></p>     ^cY#05
.htm##
01155000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704093300069002000701002#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#37#33#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Deployment of RDS    begins with choosing i
ndividuals from the target population, called "seeds",    to participate in the 
research. Each seed receives a set number of coupons to    give to their friends
 and acquaintances in the target population. Participants    who come to the stu
dy site with a valid coupon and who meet the other inclusion    criteria are con
sidered eligible and constitute the first "wave" in the study.    These new recr
uits then receive new coupons to invite friends and acquaintances    from the sa
me population group to participate in the study. This process is    repeated unt
il reaching the initially planned sample size <sup>13</sup>. Damacena    et al. 
<sup>16</sup> describe in detail the underlying assumptions in RDS and    the ex
perience with implementing this sampling process among female sex workers    in 
Brazil.</font></p>     ^cY#05.htm##
01092000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704087000069002000700939#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#38#34#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In addition to    the increasing use of TSS
 and RDS, other events had positive effects on the    adoption of surveillance a
ctivities by national HIV/AIDS programs in most-at-risk    populations. Such dev
elopments include the use of specific indicators for most-at-risk    populations
 for HIV in countries with a concentrated epidemic, in monitoring    HIV/AIDS co
mmitments by UNGASS (the United Nations General Assembly Special    Session) <su
p>17</sup>. This process encouraged countries to seek ways of responding    to t
his demand. Meanwhile, recognition of the difficulty in developing an effective 
   preventive vaccine against HIV, at least in the medium term, also encouraged 
   the quantitative and qualitative expansion of prevention activities targeting
    most-at-risk groups.</font></p>     ^cY#05.htm##
01160000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704093800069002000701007#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#39#35#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Recognizing the    importance of monitoring
 indicators of knowledge and behaviors related to HIV    infection, as well as f
or prevalence rates for HIV and other sexually transmitted    infections (STI) a
mong subgroups at greatest risk of HIV, Brazil's Department    of STD, AIDS, and
 Viral Hepatitis, in partnership with the Global AIDS Program-Brazil    of the C
enters for Disease Control and Prevention (CDC/GAP), the University    of Califo
rnia/San Francisco (USA), Tulane University (USA), and the Oswaldo    Cruz Found
ation (Fiocruz, Brasil), conducted the transfer of specific sampling    methods 
for hard-to-reach population subgroups. The TSS <sup>18</sup> and RDS    <sup>13
</sup> sampling techniques were selected for this transfer, having been    adopt
ed in the United States for behavioral surveillance in most-at-risk groups    <s
up>19</sup>.</font></p>     ^cY#05.htm##
00570000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034800069002000700417#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#40#36#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The aim of the    current study was to desc
ribe the process of transferring methods for sampling    populations at greatest
 risk of HIV, the methodological procedures used in the    pilot studies conduct
ed in Brazil, and the lessons learned in the transfer process.</font></p>     ^c
Y#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#41#37#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00348000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012600069002000700195#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#42#38#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methodology:    the transfer process</b>
</font></p>     ^cY#05.htm##
01037000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081500069002000700884#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#43#39#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In October 2004,    experts from the Depart
ment of STD, AIDS, and Viral Hepatitis and Fiocruz participated    in the Intern
ational Consultation on Sampling Most at Risk Populations (MARPs),    held by CD
C in Atlanta. During this meeting the most appropriate methods for    sampling m
ost-at-risk populations for HIV infection were discussed. For application    in 
Brazilian studies, a commitment was made to transfer the TSS <sup>18</sup>    an
d RDS <sup>13</sup> methods. In addition to the Department of STD, AIDS, and    
Viral Hepatitis and Fiocruz, the process also involved Tulane University and    
the University of California (San Francisco). The entire process received techni
cal    and financial support from CDC/GAP-Brazil.</font></p>     ^cY#05.htm##
00589000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036700069002000700436#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#44#40#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The objective of    this initiative was not
 to obtain results for the most-at-risk groups for HIV,    but to test the feasi
bility of applying TSS and RDS in these population subgroups    in Brazil, as we
ll as to train researchers in the HIV/AIDS field to implement    the new methods
.</font></p>     ^cY#05.htm##
00682000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046000069002000700529#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#45#41#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The team in charge    of the transfer proce
ss consisted of two experts from the AIDS Department; two    experts from CDC/GA
P-Brazil; one researcher from Fiocruz; and one professor    each from Tulane Uni
versity and the University of California (San Francisco).    The transfer proces
s took place from November 2004 to September 2006, with the    stages described 
briefly below:</font></p>     ^cY#05.htm##
00719000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049700069002000700566#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#46#42#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">a) A workshop for    presenting the state o
f the art in sampling methods for hard-to-reach populations.    American scienti
sts with expertise in RDS and TSS were invited to present and    discuss these m
ethods with Brazilian epidemiologists and statisticians and representatives    o
f social movements. Participants were offered the possibility of applying one   
 of the two methods, RDS or TSS, in pilot projects;</font></p>     ^cY#05.htm##
01081000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085900069002000700928#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#47#43#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">b) Selection of    ten pilot projects, of w
hich eight proposed to use RDS in a study on MSM (one),    drug users (three), I
DU (one), and female sex workers (three). Two projects    proposed to use TSS, i
nvolving MSM and truck drivers. These studies were entirely    financed with res
ources from the cooperative project between the Department    of STD, AIDS, and 
Viral Hepatitis and CDC/GAP-Brazil. Each project was offered    a maximum of 50 
thousand Brazilian <i>Reais</i>, the equivalent of approximately    US$23,000.00
 (twenty-three thousand US dollars) at the time. The approximate    total cost o
f the ten studies was BR$ 460,000.00 (US$ 209,000.00). Funding was    only relea
sed for each study after approval of the projects by the local research    ethic
s committees;</font></p>     ^cY#05.htm##
00625000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040300069002000700472#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#48#44#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">c) A workshop was    held with the principa
l investigators of the ten selected projects to prepare    the research protocol
s. This workshop included a detailed discussion of methodological    issues, the
 basic questionnaire to be used by all the studies, and the procedures    relate
d to implementation of the fieldwork;</font></p>     ^cY#05.htm##
00465000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024300069002000700312#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#49#45#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">d) The central    team visited all pilot st
udy sites before the fieldwork began in order to prepare    the local teams to i
mplement the chosen sampling process;</font></p>     ^cY#05.htm##
00430000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020800069002000700277#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#50#46#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">e) The central    team conducted supervisor
y visits to all the pilot study sites to check progress    with the fieldwork; a
nd</font></p>     ^cY#05.htm##
00489000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026700069002000700336#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#51#47#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">f) A workshop was    held to transfer the d
ata analysis techniques. All the principal investigators    participated in this
 workshop in order to systematize the studies' main findings.</font></p>     ^cY
#05.htm##
00583000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036100069002000700430#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#52#48#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The projects' field    activities took plac
e from September 2005 to January 2006. When the transfer    process was finalize
d in September 2006, the Department of STD, AIDS, and Viral    Hepatitis held a 
symposium, broadcast live on the Internet, to publicize the    information.</fon
t></p>     ^cY#05.htm##
00848000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062600069002000700695#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#53#49#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To evaluate the    transfer process, a ques
tionnaire was submitted to the principal investigators    of the pilot projects.
 The questionnaire contained questions on prior experience    with studies in mo
st-at-risk populations for HIV, reasons for choosing the sampling    method, eva
luation of the transfer process, and difficulties in implementing    the pilot s
tudies. Data on the type of sampling method used, target population,    sample (
planned versus reached), and costs of the pilot projects were collected    from 
the project reports.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#54#50#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00377000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015500069002000700224#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#55#51#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results: pilot    projects and evaluatio
n of the transfer process</b></font></p>     ^cY#05.htm##
00486000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704026400069002000700333#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#56#52#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The transfer of    sampling methods for mos
t-at-risk subgroups for HIV included ten different studies    and nine principal
 investigators (one investigator coordinated two studies).</font></p>     ^cY#05
.htm##
00499000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027700069002000700346#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#57#53#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For each project,    <a href="#t1">Table 1<
/a> shows: the sampling method used; target population;    municipality in which
 the research was done; sample size (planned and reached),    and cost.</font></
p>     ^cY#05.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#58#54#article#159#<p><a name="t1"></a></p>  
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#59#55#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#60#56#article#159#<p align="center"><img src
="/img/revistas/csp/v27s1/05t01.jpg"></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#61#57#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00702000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048000069002000700549#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#62#58#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Of the ten pilot    studies, only two used 
TSS as the sampling method, both of which were completed    successfully <sup>20
,21</sup>. The main fieldwork problems identified by the    researchers that use
d TSS related to difficulty in updating the target population's    gathering pla
ces. They also cited difficulty in accessing the venues frequented    by individ
uals with higher purchasing power.</font></p>     ^cY#05.htm##
00826000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060400069002000700673#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#63#59#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the eight    studies that used RDS, o
nly four succeeded in reaching the planned sample sizes.    The main reasons cit
ed were limitations in funding and available time for implementing    the projec
ts. In the case of the RDS study in Curitiba, Paran&aacute; State,    with drug 
users, the planned sample size was not reached because of saturation    in the s
tudy population, since the study was limited to only two neighborhoods,    and t
he drug-using population had been overestimated by the principal investigator.</
font></p>     ^cY#05.htm##
00830000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060800069002000700677#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#64#60#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The main difficulty    in the fieldwork ide
ntified by the researchers who used RDS was the fluctuation    in the number of 
participants at the interview site, alternating idle time with    moments of hea
vy demand. Due to the exponential recruitment process, by the    end of the stud
y there was a heavy demand at the research site, which often    meant a long wai
ting period for the participants, some of whom even gave up.    The complexity o
f the coupon control system was another problematic issue cited    by researcher
s.</font></p>     ^cY#05.htm##
00801000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057900069002000700648#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#65#61#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Particularly in    the study in Porto Alegr
e with male and female sex workers, the networks that    began with female seeds
 failed to capture a sufficient number of male sex workers    (transvestites and
 non-transvestites) to reach stochastic equilibrium. Thus,    rather than consid
ering the network as having a single component (a theoretical    assumption of R
DS <sup>22</sup>), it would have been more appropriate to treat    male and fema
le sex workers as having independent social networks.</font></p>     ^cY#05.htm#
#
00777000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055500069002000700624#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#66#62#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the pilot studies    that used RDS as th
e sampling method in IDU populations, it proved impossible    to identify seeds,
 which resulted in changes in the target population in the    two studies. The i
nitial proposal was to study IDUs, but the target population    had to be expand
ed to include drug users in general. However, the research ended    up showing t
hat the difficulty was in identifying IDU seeds, since IDUs appeared    in the i
nitial waves in both studies.</font></p>     ^cY#05.htm##
00670000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044800069002000700517#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#67#63#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="/img/revistas/csp/v27s1/05f01.jpg"
>Figure    1</a>, by way of illustration, shows the recruitment network obtained
 in the    study on drug users in Manaus, using RDS as the recruitment method. T
he first    waves not only revealed injecting cocaine users, but also captured i
njecting    heroin users, previously "hidden" within the population of drug user
s.</font></p>     ^cY#05.htm##
00756000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053400069002000700603#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#68#64#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">According to the    answers by the principa
l investigators to the evaluation questionnaire, application    of the methods g
enerally entailed a medium level of difficulty. For both sampling    methods, im
plementation of the ethnographic research was identified as an additional    dif
ficulty. This was most evident in the two groups who applied TSS, due to    the 
need to identify and update the list of time-space units using ethnographic    r
esearch.</font></p>     ^cY#05.htm##
01122000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704090000069002000700969#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#69#65#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As regards analysis    of data collected wi
th TSS, the main problem encountered by the pilot projects    was calculation of
 the expansion factors, since there are still no well-established    procedures 
for weighting the sample in the two selection stages. One of the    authors of t
he current article (C.L.S.) proposed a sample weighting procedure    for the sec
ond selection stage, based on the number of persons numbered and    interviewed.
 The expansion factors are calculated based on counting the individuals    in ea
ch of the time-space units. The proposed weighting is based on the inverse    se
lection probability for each interview site, day, and time and assigned to    ea
ch individual in the sample. This type of weighting was used in the two studies 
   that used TSS as the sampling method <sup>20</sup>.</font></p>     ^cY#05.htm
##
00932000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071000069002000700779#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#70#66#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For analysis of    data collected by RDS, t
he process proposed for calibrating the data was also    problematic. As occurre
d in international studies <sup>23</sup>, the study on    female sex workers in 
Santos showed that changes in the way questions on the    network's size are for
mulated substantially modify the mean estimates and range    of target parameter
s, thereby altering the confidence intervals and design effects.    Additional l
imitations were encountered in attempts to conduct multivariate    statistical a
nalysis, not available to date in the Respondent Driven Sampling    Analysis Too
l (RDSAT) <sup>24</sup>.</font></p>     ^cY#05.htm##
01074000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085200069002000700921#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#71#67#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In response to    the evaluation questionna
ire for the transfer process, the positive points mentioned    by the principal 
investigators were: the instructors' expertise in the methods    discussed and t
he organization and logical sequence of the themes presented    in the workshops
. Also cited were the following: the transfer had been conducted    didactically
; all the stages in the study's development had been presented step    by step; 
and all stages in the fieldwork had been accompanied by the team in    charge. S
uggestions for improving the process included increasing the time devoted    to 
the workshop on data analysis, especially in the case of application of RDS,    
which is more complex and uses a specific analytical application, RDSAT <sup>22<
/sup>.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#72#68#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00325000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010300069002000700172#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#73#69#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Final remarks</b></font></p>     ^cY#05.
htm##
00466000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024400069002000700313#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#74#70#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The transfer of    sampling methods for mos
t-at-risk subgroups for HIV infection in Brazil used    two sampling techniques,
 TSS and RDS, in ten separate studies.</font></p>     ^cY#05.htm##
00990000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076800069002000700837#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#75#71#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the difficulties    with the TSS meth
od, formative research was emphasized by the principal investigators    who used
 this methodology. In order to identify all the target population's    gathering
 places, ethnographic research is generally difficult, toilsome, and    time-con
suming. Another limitation of TSS is the incomplete coverage of the    target po
pulation, since individuals that do not frequent public venues have    zero prob
ability of being selected <sup>25</sup>. The technique may also exclude    indiv
iduals who only schedule meetings through the Internet. Recent initiatives    to
 refine TSS have included considering the virtual space of Internet <sup>26</sup
>.</font></p>     ^cY#05.htm##
00525000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030300069002000700372#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#76#72#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Limitations of    another order refer to re
searchers' safety in hazardous places and difficulties    in approaching subject
s when they are having fun, often under the influence    of alcohol or other dru
gs <sup>25</sup>.</font></p>     ^cY#05.htm##
00920000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069800069002000700767#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#77#73#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Another problem    with the implementation 
of TSS in Brazil was the impossibility of performing    serological tests at the
 time of the interview, given the specific standards    for places where rapid t
ests for HIV infection can be performed <sup>27</sup>.    Since it is necessary 
to refer the research subjects to health services, this    can cause significant
 losses, thus hindering the estimation of HIV and syphilis    prevalence rates w
ith this type of sampling. Such problems can obviously be    solved, for example
 using a mobile health unit, as according to experience in    other countries <s
up>28</sup>.</font></p>     ^cY#05.htm##
01076000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085400069002000700923#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#78#74#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Meanwhile, in studies    that used RDS as t
he sampling technique, conducting the project in health units    was identified 
as the method's greatest advantage, with the understanding that    this research
 implementation approach encourages the use of health services    and opens oppo
rtunities for intervention and performing serological tests in    the subgroups 
at greatest risk of HIV infection. Another benefit of this sampling    method is
 the possibility of finding "hidden" individuals. After capturing the    most vi
sible subjects, the extended acquaintance networks end up including hidden    in
dividuals. In fact, the study on drug users in Manaus, Amazonas State, revealed 
   participants who injected heroin, a highly uncommon practice in Brazil <sup>2
9</sup>.</font></p>     ^cY#05.htm##
00726000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050400069002000700573#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#79#75#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, even a    long network does not al
ways mean that the sample captures the diversity of    types of individuals in t
he population segment under study, which is essential    for the sample to be re
presentative of the target population. In the study on    female sex workers in 
Santos, which used the RDS method to select 173 women,    121 worked in nightclu
bs, of whom 116 (96%) were concentrated in only two clubs.</font></p>     ^cY#05
.htm##
01657000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704143500069002000701504#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#80#76#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Another point that    merits discussion is 
the issue of material incentives, provided for at two moments    in the RDS depl
oyment. Each participant receives a stipend for participating    in the study, c
alled the primary incentive, plus a bonus, called the secondary    incentive, pe
r subject recruited who participates successfully in the study    <sup>13</sup>.
 From the practical point of view, in Brazil, monetary incentives    to particip
ate are not generally allowed by institutional review boards, but    must be lim
ited to providing transportation and food to cover the individual's    expense i
n order participate in the study. Furthermore, from the theoretical    and stati
stical point of view, the secondary incentive contradicts the assumption    of r
andom choice among the recruiter's friends and acquaintances <sup>22</sup>.    I
f someone receives incentives to bring a new participant, the recruiter will    
choose the closest potential person, that is, the person who works in the same  
  place or whom he or she meets frequently. Limiting the coupons to a small numb
er    (two or three) means choosing the persons at the beginning of the proximit
y    line, as reported by Heckathorn <sup>13</sup> in his initial model, but it 
contradicts    the assumption of randomness in choosing the recruit in the subse
quent model    <sup>22</sup>.</font></p>     ^cY#05.htm##
01132000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704091000069002000700979#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#81#77#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Flaws in the principles    of randomness in
 choosing recruits and the structure of dependence among observations    created
 in the RDS recruitment process are issues that were not considered in    the me
thod's original proposal, thus limiting the application of traditional    statis
tical techniques. In fact, the greatest difficulties identified in applying    R
DS in the Brazilian studies related to data analysis, including calculating    t
he expansion factors, estimating parameters, elaborating confidence intervals,  
  calculating design effects, and applying multivariate statistical techniques. 
   Studies to improve the statistical analysis are being developed in Brazil and
    other countries, from the perspective of using estimation of parameters by m
eans    of generalized regression models with correlated errors.</font></p>     
^cY#05.htm##
01101000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704087900069002000700948#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#82#78#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite the difficulties    in analyzing da
ta collected with RDS, the pilot studies financed by the project    showed that 
it is feasible to implement these sampling methods in Brazil among    population
 subgroups most at risk for HIV. In 2007, the Department of STD, AIDS,    and Vi
ral Hepatitis launched a call for research projects adopting RDS as the    sampl
ing method for monitoring most-at-risk populations in Brazil: MSM, drug    users
, and female sex workers. The research projects are currently being carried    o
ut in 10 Brazilian cities under the coordination of Brazilian researchers,    th
us demonstrating the country's self-sufficiency in conducting studies with    pr
obabilistic sampling methods. Studies done in Brazil with convenience sampling  
  would rarely be accepted today.</font></p>     ^cY#05.htm##
00676000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045400069002000700523#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#83#79#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The most important    outputs generated by 
the transfer process include human resources training.    In less than four year
s, some 50 professionals were trained during the transfer    phase, and approxim
ately 100 researchers are participating in the teams in the    three approved pr
ojects and are ready to train new local teams and further disseminate    the use
 of RDS.</font></p>     ^cY#05.htm##
00799000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057700069002000700646#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#84#80#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Training of researchers    allowed Brazilia
n scientists to participate for the first time in international    debate forums
 on sampling methodology for populations most at risk for HIV.    Application of
 the methods allowed a critical vision of the theoretical principles,    estimat
ion processes, and interpretation of the results. Importantly, at the    interna
tional level, Brazilian researchers have coordinated studies in Portuguese-speak
ing    African countries using the RDS methodology.</font></p>     ^cY#05.htm##
00947000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072500069002000700794#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#85#81#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In short, there    is now an installed capa
city in Brazil for applying sampling methods in hard-to-reach    groups, identif
ying each method's advantages and disadvantages, and improving    the existing m
ethods according to the groups' characteristics in Brazil. Meanwhile,    the eff
orts have resulted in a new approach to groups at greatest risk of HIV    infect
ion, by the National Department of STD, AIDS, and Viral Hepatitis and    the Sta
te and Municipal programs, meaning greater knowledge of the dynamics    in the s
pread of HIV infection and allowing the development of evidence-based    public 
policies in these population subgroups.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#86#82#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#87#83#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#05.h
tm##
00754000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053200069002000700601#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#88#84#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A. Barbosa J&uacute;nior    was the article
's principal mentor and prepared the text. A. R. P. Pascom participated    in dr
afting the methodology and results. C. L. Szwarcwald participated in the    arti
cle's conceptualization and in writing the introduction and discussion.    C. Ke
ndall participated in writing the discussion and revision of the final    articl
e. W. McFarland participated in the elaboration of the introduction and    discu
ssion.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#89#85#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00327000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010500069002000700174#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#90#86#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Acknowledgments</b></font></p>     ^cY#0
5.htm##
00692000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047000069002000700539#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#91#87#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The authors wish    to acknowledge the foll
owing persons that were actively engaged in the technology    transfer process: 
Bill Brady, Suzanne Westman, Keith Sabin, Eric Voltz, Henry    Raymond, John M. 
Karon, Lisa Johnston, Sanny Chen, Cyprian Wejnert, Elizabeth    Moreira; Marcos 
dos Santos, principal investigators, and teams of the pilot    projects; and Mar
cos Cleuton de Oliveira.</font></p>     ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#92#88#article#159#<p>&nbsp;</p>     ^cY#05.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#93#89#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#05.htm
##
00443000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704020700071002000700278#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#94#90#article#159#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Wilson D, Halperin    DT. 
"Know your epidemic, know your response": a useful approach, if we get it    rig
ht. Lancet 2008; 372:423-6.    ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#95#91#article#159#</font></p>     ^cY#05.htm
##
00574000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704033800071002000700409#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#96#92#article#159#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. The World Bank.    Aids: T
he World Bank's Partnership with Brazil. <a href="http://web.worldbank.org/wbsit
e/external/countries/lacext/brazilextn" target="_blank">http://web.worldbank.org
/wbsite/external/countries/lacext/brazilextn</a>    (accessed on 13/Nov/2008).  
  ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#97#93#article#159#</font></p>     ^cY#05.htm
##
00534000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704029800071002000700369#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#98#94#article#159#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Barbosa J&uacute;nior    A
, Szwarcwald CL, Pascom ARP, Souza J&uacute;nior PB. Tend&ecirc;ncias da epidemi
a    de AIDS entre subgrupos sob maior risco no Brasil, 1980-2004. Cad Sa&uacute
;de    P&uacute;blica 2009; 25:727-37.    ^cY#05.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#99#95#article#159#</font></p>     ^cY#05.htm
##
00528000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704029100072002000700363#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#100#96#article#159#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Szwarcwald CL,    Carvalh
o MF, Barbosa J&uacute;nior A, Barreira D, Speranza FA, Castilho EA.    Temporal
 trends of HIV-related risk behavior among Brazilian military conscripts,    199
7-2002. Clinics 2005; 60:367-74.    ^cY#05.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#101#97#article#159#</font></p>     ^cY#05.ht
m##
00489000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704025200072002000700324#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#102#98#article#159#5#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">5. Bastos FI, Barata    RC, 
Aquino EL, Latorre MR. Comportamento sexual e percep&ccedil;&otilde;es sobre    
HIV/Aids no Brasil. Rev Sa&uacute;de P&uacute;blica 2008; 42 Suppl 1:1-4.    ^cY
#05.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#103#99#article#159#</font></p>     ^cY#05.ht
m##
00570000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704033200073002000700405#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#104#100#article#159#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Coordena&ccedil;&atilde;
o    Nacional de DST e AIDS. Comportamento sexual da popula&ccedil;&atilde;o bra
sileira    e percep&ccedil;&otilde;es do HIV/AIDS. Bras&iacute;lia: Minist&eacut
e;rio da    Sa&uacute;de; 2000. (S&eacute;rie Avalia&ccedil;&atilde;o, 4).    ^c
Y#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#105#101#article#159#</font></p>     ^cY#05.h
tm##
00532000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704029400073002000700367#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#106#102#article#159#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Coordena&ccedil;&atilde;
o    Nacional de DST e AIDS. PCAP - Pesquisa de Conhecimento, Atitudes e Pr&aacu
te;ticas    na Popula&ccedil;&atilde;o Brasileira 2004. Bras&iacute;lia: Minist&
eacute;rio    da Sa&uacute;de; 2006.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#107#103#article#159#</font></p>     ^cY#05.h
tm##
00556000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704031800073002000700391#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#108#104#article#159#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Szwarcwald CL,    Barbos
a J&uacute;nior A, Pascom ARP, Souza J&uacute;nior PR. Knowledge, practices    a
nd behaviours related to HIV transmission among the Brazilian population in    t
he 15-54 years age group, 2004. AIDS 2005; 19 Suppl 4:S51-8.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#109#105#article#159#</font></p>     ^cY#05.h
tm##
00708000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704047000073002000700543#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#110#106#article#159#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Caiaffa WT,    Proietti 
ABC, Proietti F, Guimar&atilde;es MD, Mingoti SA, Deslandes S, et al.    Projeto
 AjUDE-Brasil: avalia&ccedil;&atilde;o epidemiol&oacute;gica dos usu&aacute;rios
    de drogas injet&aacute;veis dos projetos de redu&ccedil;&atilde;o de danos a
poiados    pela CN-DST/AIDS. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de;
 2001.    (S&eacute;rie Avalia&ccedil;&atilde;o, 6).    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#111#107#article#159#</font></p>     ^cY#05.h
tm##
00471000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023200074002000700306#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#112#108#article#159#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Magnani R,    Sabin K,
 Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden    populati
ons for HIV surveillance. AIDS 2005; 19 Suppl 2:S67-72.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#113#109#article#159#</font></p>     ^cY#05.h
tm##
00434000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019500074002000700269#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#114#110#article#159#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Frank O, Snijders    T
. Estimating the size of hidden populations using snowball sampling. J Off    St
at 1994; 10:53-67.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#115#111#article#159#</font></p>     ^cY#05.h
tm##
00412000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017300074002000700247#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#116#112#article#159#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Kalton, G,    Anderson
 DW. Sampling rare populations. J R Stat Soc Ser A Stat Soc 1986; 149:65-82.    
^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#117#113#article#159#</font></p>     ^cY#05.h
tm##
00440000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020100074002000700275#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#118#114#article#159#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Heckathorn    DD. Resp
ondent-driven sampling: a new approach to the study of hidden populations.    So
c Probl 1997; 44:174-99.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#119#115#article#159#</font></p>     ^cY#05.h
tm##
00575000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033600074002000700410#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#120#116#article#159#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Malekinejad    M, John
ston LG, Kendall C, Kerr LR, Rifkin MR, Rutherford GW. Using respondent-driven  
  sampling methodology for HIV biological and behavioral surveillance in interna
tional    settings: a systematic review. AIDS Behav 2008; 12 (4 Suppl):S105-30. 
   ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#121#117#article#159#</font></p>     ^cY#05.h
tm##
00580000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704034100074002000700415#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#122#118#article#159#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. MacKellar D,    Gallag
her KM, Finlayson T, Sanchez T, Lansky A, Sullivan PS. Surveillance of    HIV ri
sk and prevention behaviors of men who have sex with men: a national application
    of venue-based, time-space sampling. Public Health Rep 2007; 122 Suppl 1:S39
-47.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#123#119#article#159#</font></p>     ^cY#05.h
tm##
00519000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028000074002000700354#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#124#120#article#159#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Damacena GN,    Szwarc
wald CL, Barbosa J&uacute;nior A. Implementation of respondent-driven    samplin
g among female sex workers in Brazil, 2009. Cad Sa&uacute;de P&uacute;blica    2
011; 27 Suppl 1:S45-55.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#125#121#article#159#</font></p>     ^cY#05.h
tm##
00526000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028700074002000700361#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#126#122#article#159#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. United Nations    Join
t Programme on HIV/AIDS. Monitoring the declaration of commitment on HIV/AIDS:  
  guidelines on constructions of core indicators. Geneva: United Nations Joint  
  Programme on HIV/AIDS; 2005.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#127#123#article#159#</font></p>     ^cY#05.h
tm##
00492000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025300074002000700327#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#128#124#article#159#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Muhib FB, Lin    LS, S
tueve A, Miller RL, Ford WL, Johnson WD, et al. A venue-based method for    samp
ling hard-to-reach populations. Public Health Rep 2001; 116 Suppl 1:S216-22.    
^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#129#125#article#159#</font></p>     ^cY#05.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#130#126#article#159#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Gallagher KM,    Sulli
van PS, Lansky A, Onorato IM. Behavioral surveillance among people at risk    fo
r HIV infection in the U.S.: the National Behavioral Surveillance System.    Pub
lic Health Rep 2007; 122 Suppl 1:S32-38.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#131#127#article#159#</font></p>     ^cY#05.h
tm##
00516000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027700074002000700351#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#132#128#article#159#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Ferreira LOC,    Olive
ira ES, Raymond HF, Chen SY, McFarland W. Use of time-location sampling    for s
ystematic behavioral surveillance of truck drivers in Brazil. AIDS Behav    2008
; 12(4 Suppl):S32-8.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#133#129#article#159#</font></p>     ^cY#05.h
tm##
00733000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704049400074002000700568#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#134#130#article#159#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Melo LN, Sander    MA,
 Pascom ARP, Barbosa J&uacute;nior AB, Westamn S, Szwarcwald CL, et al. Serosort
ing    among men who have sex with man, Porto Alegre, Brazil, 2005. In: XVI Inte
rnational    AIDS Conference, 2006. <a href="http://www.iasociety.org/Default.as
px?pageId=11&amp;abstractId=2191358" target="_blank">http://www.iasociety.org/De
fault.aspx?pageId=11&amp;abstractId=2191358</a>    (accessed on 12/May/2010).   
 ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#135#131#article#159#</font></p>     ^cY#05.h
tm##
00470000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023100074002000700305#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#136#132#article#159#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Salganik MJ,    Heckat
horn DD. Sampling and estimation in hidden populations using respondent-driven  
  sampling. Sociological Methodology 2004; 34:193-239.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#137#133#article#159#</font></p>     ^cY#05.h
tm##
00633000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704039400074002000700468#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#138#134#article#159#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Ma X, Zhang    Q, He X
, Sun W, Yue H, Chen S, et al. Trends in prevalence of HIV, syphilis,    hepatit
is C, hepatitis B, and sexual risk behavior among men who have sex with    men. 
Results of 3 consecutive respondent-driven sampling surveys in Beijing,    2004 
through 2006. J Acquir Immune Defic Syndr 2007; 45:581-7.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#139#135#article#159#</font></p>     ^cY#05.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#140#136#article#159#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Volz E, Wejnert    C, 
Degani I, Heckathorn DD. Respondent-driven sampling analysis tool (RDSAT).    Ve
rsion 5.6. Ithaca: Cornell University; 2007.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#141#137#article#159#</font></p>     ^cY#05.h
tm##
00535000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029600074002000700370#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#142#138#article#159#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Pollack LM,    Osmond 
DH, Paul JP, Catania JA. Evaluation of the Centers for Disease Control    and Pr
evention's HIV behavioral surveillance of men who have sex with men: sampling   
 issues. Sex Transm Dis 2005; 32:581-9.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#143#139#article#159#</font></p>     ^cY#05.h
tm##
00517000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027800074002000700352#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#144#140#article#159#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Raymond HF,    Rebchoo
k G, Curotto A, Vaudrey J, Amsden M, Levine D, et al. Comparing internet-based  
  and venue-based methods to sample MSM in the San Francisco Bay Area. AIDS Beha
v    2010; 14:218-24.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#145#141#article#159#</font></p>     ^cY#05.h
tm##
00563000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032400074002000700398#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#146#142#article#159#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Brasil. Portaria    nº
. 34, de 28 de julho de 2005. Regulamenta o uso de testes r&aacute;pidos para   
 diagn&oacute;stico da infec&ccedil;&atilde;o pelo HIV em situa&ccedil;&otilde;e
s    especiais. Di&aacute;rio Oficial da Uni&atilde;o 2005; 29 jul.    ^cY#05.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#147#143#article#159#</font></p>     ^cY#05.h
tm##
00548000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030900074002000700383#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#148#144#article#159#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Shrestha RK,    Clark 
HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness    of
 finding new HIV diagnoses using rapid HIV testing in community-based organizati
ons.    Public Health Rep 2008; 123 Suppl 3:S94-100.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#149#145#article#159#</font></p>     ^cY#05.h
tm##
00504000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026500074002000700339#v27
s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#p#150#146#article#159#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Galdur&oacute;z    JC,
 Noto AR, Nappo SA, Carlini EA. Household survey on drug abuse in Brazil:    stu
dy involving the 107 major cities of the country, 2001. Addict Behav 2005;    30
:545-56.    ^cY#05.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#151#147#article#159#</font></p>     ^cY#05.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#152#148#article#159#<p>&nbsp;</p>     ^cY#05
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#153#149#article#159#<p>&nbsp;</p>     ^cY#05
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#154#150#article#159#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#05.htm##
00268000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004400071002000700115#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#155#151#article#159#<br>   </b> A. Barbosa J
&uacute;nior    ^cY#05.htm##
00283000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005900071002000700130#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#156#152#article#159#<br>   Departamento de D
ST, AIDS e Hepatites Virais    ^cY#05.htm##
00272000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004800071002000700119#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#157#153#article#159#<br>   Minist&eacute;rio
 da Sa&uacute;de    ^cY#05.htm##
00326000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010200071002000700173#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#158#154#article#159#<br>   SAF Sul Trecho 02
, bloco F, torre 1, Edif&iacute;cio Premium, t&eacute;rreo,    sala 12    ^cY#05
.htm##
00276000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005200071002000700123#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#159#155#article#159#<br>   Bras&iacute;lia, 
DF 70070-600, Brasil    ^cY#05.htm##
00315000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009100071002000700162#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#160#156#article#159#<br>   <a href="mailto:a
ristides@aids.gov.br">aristides@aids.gov.br</a></font></p>     ^cY#05.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#161#157#article#159#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 29/Oct/2009    ^cY#05.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#162#158#article#159#<br>   Final version res
ubmitted on 07/Apr/2010    ^cY#05.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\05.htm#S#p#163#159#article#159#<br>   Approved on 19/Ap
r/2010</font></p>     ^cY#05.htm##
00531000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100019000860120
08400105030000700189065000900196064000500205031000400210014000600214865000900220
002000700229035001000236801000700246#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.
htm#S#c#164#1#article#29#1#^rND^sWilson^nD#^rND^sHalperin^nDT#"Know your epidemi
c, know your response": a useful approach, if we get it right^len#Lancet#2008000
0#2008#372#423-6#20110000#05.htm#0099-5355#Lancet##
00460000000000217000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170015000700180051000850370
06900136110000900205109001200214865000900226002000700235#v27s1#V:\SciELO\serial\
csp\v27s1\markup\05.htm#S#c#165#2#article#29#2#The World Bank#Aids: The World Ba
nk's Partnership with Brazil^len#http://web.worldbank.org/wbsite/external/countr
ies/lacext/brazilextn#20081113#13/Nov/2008#20110000#05.htm##
00594000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100024000700100021000940100
01800115010002300133012008800156030001800244710000200262065000900264064000500273
031000300278014000700281865000900288002000700297#v27s1#V:\SciELO\serial\csp\v27s
1\markup\05.htm#S#c#166#3#article#29#3#^rND^sBarbosa Júnior^nA#^rND^sSzwarcwald^
nCL#^rND^sPascom^nARP#^rND^sSouza Júnior^nPB#Tendências da epidemia de AIDS entr
e subgrupos sob maior risco no Brasil, 1980-2004^lpt#Cad Saúde Pública#2#2009000
0#2009#25#727-37#20110000#05.htm##
00678000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100019000910100
02400110010001800134010001900152010001900171012009600190030000800286065000900294
06400050030303100030030801400070031186500090031800200070032703500100033480100080
0344#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#167#4#article#29#4#^rND^
sSzwarcwald^nCL#^rND^sCarvalho^nMF#^rND^sBarbosa Júnior^nA#^rND^sBarreira^nD#^rN
D^sSperanza^nFA#^rND^sCastilho^nEA#Temporal trends of HIV-related risk behavior 
among Brazilian military conscripts, 1997-2002^len#Clinics#20050000#2005#60#367-
74#20110000#05.htm#1807-5932#Clinics##
00565000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100017000870100
01700104010001800121012006300139030001800202710000200220065000900222064000500231
031000300236032000400239014000400243865000900247002000700256#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\05.htm#S#c#168#5#article#29#5#^rND^sBastos^nFI#^rND^sBarata
^nRC#^rND^sAquino^nEL#^rND^sLatorre^nMR#Comportamento sexual e percepções sobre 
HIV/Aids no Brasil^lpt#Rev Saúde Pública#2#20080000#2008#42#^s1#1-4#20110000#05.
htm##
00475000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160042000700180074001120660
00900186062002000195065000900215064000500224865000900229002000700238#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\05.htm#S#c#169#6#article#29#6#^rND^sCoordenação Nac
ional de DST e^nAIDS#Comportamento sexual da população brasileira e percepções d
o HIV/AIDS^lpt#Brasília#Ministério da Saúde#20000000#2000#20110000#05.htm##
00487000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160042000700180086001120660
00900198062002000207065000900227064000500236865000900241002000700250#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\05.htm#S#c#170#7#article#29#7#^rND^sCoordenação Nac
ional de DST e^nAIDS#PCAP - Pesquisa de Conhecimento, Atitudes e Práticas na Pop
ulação Brasileira 2004^lpt#Brasília#Ministério da Saúde#20060000#2006#20110000#0
5.htm##
00667000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100024000910100
01800115010002300133012013400156030000500290065000900295064000500304031000300309
032000400312014000600316865000900322002000700331035001000338801000500348#v27s1#V
:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#171#8#article#29#8#^rND^sSzwarcwald^
nCL#^rND^sBarbosa Júnior^nA#^rND^sPascom^nARP#^rND^sSouza Júnior^nPR#Knowledge, 
practices and behaviours related to HIV transmission among the Brazilian populat
ion in the 15-54 years age group, 2004^len#AIDS#20050000#2005#19#^s4#S51-8#20110
000#05.htm#0269-9370#AIDS##
00694000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160018000700160020000880160
01800108016002000126016001800146016001900164810000600183018014400189066000900333
062002000342065000900362064000500371865000900376002000700385#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\05.htm#S#c#172#9#article#29#9#^rND^sCaiaffa^nWT#^rND^sProie
tti^nABC#^rND^sProietti^nF#^rND^sGuimarães^nMD#^rND^sMingoti^nSA#^rND^sDeslandes
^nS#et al#Projeto AjUDE-Brasil: avaliação epidemiológica dos usuários de drogas 
injetáveis dos projetos de redução de danos apoiados pela CN-DST/AIDS^lpt#Brasíl
ia#Ministério da Saúde#20010000#2001#20110000#05.htm##
00599000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01600104010002000120012008100140030000500221065000900226064000500235031000300240
032000400243014000700247865000900254002000700263035001000270801000500280#v27s1#V
:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#173#10#article#29#10#^rND^sMagnani^n
R#^rND^sSabin^nK#^rND^sSaidel^nT#^rND^sHeckathorn^nD#Review of sampling hard-to-
reach and hidden populations for HIV surveillance^len#AIDS#20050000#2005#19#^s2#
S67-72#20110000#05.htm#0269-9370#AIDS##
00493000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870120
07000105030001100175710000200186065000900188064000500197031000300202014000600205
865000900211002000700220#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#174#
11#article#29#11#^rND^sFrank^nO#^rND^sSnijders^nT#Estimating the size of hidden 
populations using snowball sampling^len#J Off Stat#2#19940000#1994#10#53-67#2011
0000#05.htm##
00473000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880120
03000107030002800137710000200165065000900167064000500176031000400181014000600185
865000900191002000700200#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#175#
12#article#29#12#^rND^sKalton^nG#^rND^sAnderson^nDW#Sampling rare populations^le
n#J R Stat Soc Ser A Stat Soc#2#19860000#1986#149#65-82#20110000#05.htm##
00511000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720120082000930300
01000175065000900185064000500194031000300199014000700202865000900209002000700218
035001000225801001000235#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#176#
13#article#29#13#^rND^sHeckathorn^nDD#Respondent-driven sampling: a new approach
 to the study of hidden populations^len#Soc Probl#19970000#1997#44#174-99#201100
00#05.htm#0037-7791#Soc Probl##
00745000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930100
01700112010001500129010001700144010002100161012014300182030001100325065000900336
06400050034503100030035003200090035301400080036286500090037000200070037903500100
0386801001100396#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#177#14#artic
le#29#14#^rND^sMalekinejad^nM#^rND^sJohnston^nLG#^rND^sKendall^nC#^rND^sKerr^nLR
#^rND^sRifkin^nMR#^rND^sRutherford^nGW#Using respondent-driven sampling methodol
ogy for HIV biological and behavioral surveillance in international settings: a 
systematic review^len#AIDS Behav#20080000#2008#12#4^sSuppl#S105-30#20110000#05.h
tm#1090-7165#AIDS Behav##
00754000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100020000910100
01900111010001700130010001600147010001900163012014300182030001800325065000900343
06400050035203100040035703200040036101400070036586500090037200200070038103500100
0388801001800398#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#178#15#artic
le#29#15#^rND^sMacKellar^nD#^rND^sGallagher^nKM#^rND^sFinlayson^nT#^rND^sSanchez
^nT#^rND^sLansky^nA#^rND^sSullivan^nPS#Surveillance of HIV risk and prevention b
ehaviors of men who have sex with men: a national application of venue-based, ti
me-space sampling^len#Public Health Rep#20070000#2007#122#^s1#S39-47#20110000#05
.htm#0033-3549#Public health rep##
00580000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100021000910100
02400112012009000136030001800226710000200244065000900246064000500255031000300260
032000400263014000700267865000900274002000700283#v27s1#V:\SciELO\serial\csp\v27s
1\markup\05.htm#S#c#179#16#article#29#16#^rND^sDamacena^nGN#^rND^sSzwarcwald^nCL
#^rND^sBarbosa Júnior^nA#Implementation of respondent-driven sampling among fema
le sex workers in Brazil, 2009^len#Cad Saúde Pública#2#20110000#2011#27#^s1#S45-
55#20110000#05.htm##
00537000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160050000720180105001220660
00700227062004300234065000900277064000500286865000900291002000700300#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\05.htm#S#c#180#17#article#29#17#^rND^sUnited Nation
s Joint Programme on^nHIV/AIDS#Monitoring the declaration of commitment on HIV/A
IDS: guidelines on constructions of core indicators^len#Geneva#United Nations Jo
int Programme on HIV/AIDS#20050000#2005#20110000#05.htm##
00680000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100014000880100
01600102010001700118010001500135010001800150810000600168012006400174030001800238
06500090025606400050026503100040027003200040027401400080027886500090028600200070
0295035001000302801001800312#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#
181#18#article#29#18#^rND^sMuhib^nFB#^rND^sLin^nLS#^rND^sStueve^nA#^rND^sMiller^
nRL#^rND^sFord^nWL#^rND^sJohnson^nWD#et al#A venue-based method for sampling har
d-to-reach populations^len#Public Health Rep#20010000#2001#116#^s1#S216-22#20110
000#05.htm#0033-3549#Public health rep##
00675000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100019000920100
01600111010001800127012012500145030001800270065000900288064000500297031000400302
032000400306014000700310865000900317002000700326035001000333801001800343#v27s1#V
:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#182#19#article#29#19#^rND^sGallagher
^nKM#^rND^sSullivan^nPS#^rND^sLansky^nA#^rND^sOnorato^nIM#Behavioral surveillanc
e among people at risk for HIV infection in the U: S.: the National Behavioral S
urveillance System^len#Public Health Rep#20070000#2007#122#^s1#S32-38#20110000#0
5.htm#0033-3549#Public health rep##
00669000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100019000920100
01800111010001500129010001900144012010000163030001100263065000900274064000500283
03100030028803200090029101400060030086500090030600200070031503500100032280100110
0332#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#183#20#article#29#20#^rN
D^sFerreira^nLOC#^rND^sOliveira^nES#^rND^sRaymond^nHF#^rND^sChen^nSY#^rND^sMcFar
land^nW#Use of time-location sampling for systematic behavioral surveillance of 
truck drivers in Brazil^len#AIDS Behav#20080000#2008#12#4^sSuppl#S32-8#20110000#
05.htm#1090-7165#AIDS Behav##
00758000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01800104010002500122010001700147010002100164810000600185012007600191053004100267
05500120030805400080032003700670032811000090039510900120040486500090041600200070
0425#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#184#21#article#29#21#^rN
D^sMelo^nLN#^rND^sSander^nMA#^rND^sPascom^nARP#^rND^sBarbosa Júnior^nAB#^rND^sWe
stamn^nS#^rND^sSzwarcwald^nCL#et al#Serosorting among men who have sex with man,
 Porto Alegre, Brazil, 2005^len#International AIDS Conference^nXVI^i1^i1#2006000
0^i1#2006^i1#http://www.iasociety.org/Default.aspx?pageId=11&abstractId=2191358#
20100512#12/May/2010#20110000#05.htm##
00574000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100021000910120
08300112030002500195065000900220064000500229031000300234014000800237865000900245
002000700254035001000261801002500271#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.
htm#S#c#185#22#article#29#22#^rND^sSalganik^nMJ#^rND^sHeckathorn^nDD#Sampling an
d estimation in hidden populations using respondent-driven sampling^len#Sociolog
ical Methodology#20040000#2004#34#193-239#20110000#05.htm#0081-1750#SOCIOLOGICAL
 METHODOLOGY##
00817000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100012000720100015000840100
01200099010001300111010001300124010001400137810000600151012021700157030002800374
06500090040206400050041103100030041601400060041986500090042500200070043403500100
0441801002800451#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#186#23#artic
le#29#23#^rND^sMa^nX#^rND^sZhang^nQ#^rND^sHe^nX#^rND^sSun^nW#^rND^sYue^nH#^rND^s
Chen^nS#et al#Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, a
nd sexual risk behavior among men who have sex with men: Results of 3 consecutiv
e respondent-driven sampling surveys in Beijing, 2004 through 2006^len#J Acquir 
Immune Defic Syndr#20070000#2007#45#581-7#20110000#05.htm#0894-9255#J Acquir Imm
une Defic Syndr##
00528000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160014000720160017000860160
01600103016002100119018006600140066000700206062001900213065000900232064000500241
865000900246002000700255#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#187#
24#article#29#24#^rND^sVolz^nE#^rND^sWejnert^nC#^rND^sDegani^nI#^rND^sHeckathorn
^nDD#Respondent-driven sampling analysis tool (RDSAT): Version 5.6^len#Ithaca#Co
rnell University#20070000#2007#20110000#05.htm##
00662000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01500107010001800122012014100140030001500281065000900296064000500305031000300310
014000600313865000900319002000700328035001000335801001500345#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\05.htm#S#c#188#25#article#29#25#^rND^sPollack^nLM#^rND^sOsm
ond^nDH#^rND^sPaul^nJP#^rND^sCatania^nJA#Evaluation of the Centers for Disease C
ontrol and Prevention's HIV behavioral surveillance of men who have sex with men
: sampling issues^len#Sex Transm Dis#20050000#2005#32#581-9#20110000#05.htm#0148
-5717#Sex Transm Dis##
00687000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900100
01700108010001700125010001600142010001600158810000600174012009700180030001100277
06500090028806400050029703100030030201400070030586500090031200200070032103500100
0328801001100338#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#189#26#artic
le#29#26#^rND^sRaymond^nHF#^rND^sRebchook^nG#^rND^sCurotto^nA#^rND^sVaudrey^nJ#^
rND^sAmsden^nM#^rND^sLevine^nD#et al#Comparing internet-based and venue-based me
thods to sample MSM in the San Francisco Bay Area^len#AIDS Behav#20100000#2010#1
4#218-24#20110000#05.htm#1090-7165#AIDS Behav##
00515000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690110007000720120142000790300
02400221710000200245065000900247064001300256865000900269002000700278#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\05.htm#S#c#190#27#article#29#27#Brasil#Portaria nº:
 34, de 28 de julho de 2005. Regulamenta o uso de testes rápidos para diagnóstic
o da infecção pelo HIV em situações especiais^lpt#Diário Oficial da União#2#2005
0729#2005; 29 jul#20110000#05.htm##
00733000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100016000910100
01700107010001400124010002000138010001800158810000600176012010900182030001800291
06500090030906400050031803100040032303200040032701400080033186500090033900200070
0348035001000355801001800365#v27s1#V:\SciELO\serial\csp\v27s1\markup\05.htm#S#c#
191#28#article#29#28#^rND^sShrestha^nRK#^rND^sClark^nHA#^rND^sSansom^nSL#^rND^sS
ong^nB#^rND^sBuckendahl^nH#^rND^sCalhoun^nCB#et al#Cost-effectiveness of finding
 new HIV diagnoses using rapid HIV testing in community-based organizations^len#
Public Health Rep#20080000#2008#123#^s3#S94-100#20110000#05.htm#0033-3549#Public
 health rep##
00622000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100015000910100
01600106010001800122012010400140030001300244065000900257064000500266031000300271
014000700274865000900281002000700290035001000297801001300307#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\05.htm#S#c#192#29#article#29#29#^rND^sGalduróz^nJC#^rND^sNo
to^nAR#^rND^sNappo^nSA#^rND^sCarlini^nEA#Household survey on drug abuse in Brazi
l: study involving the 107 major cities of the country, 2001^len#Addict Behav#20
050000#2005#30#545-56#20110000#05.htm#0306-4603#Addict Behav##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#o#1#1#article#1#201104
11#073705#06.htm#285##
03732000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000190010503100030012413100020012706500090012901400110013803500100014901200900
01590120122002490100037003710100038004080100037004460700136004830700089006190831
00600708085001001714085001601724085002501740085002801765083114801793085001002941
08500160295108500250296708500330299211700080302507200030303311200090303611100120
3045116000903057115001203066114000903078113001203087002000703099#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#06#
CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs45^ls55#0102-311X#Implementation o
f respondent-driven sampling among female sex workers in Brazil, 2009^len#Implem
entação do método de amostragem respondent-driven sampling entre mulheres profis
sionais do sexo no Brasil, 2009^lpt#^rND^1A01^nGiseli Nogueira^sDamacena#^rND^1A
01^nCélia Landmann^sSzwarcwald#^rND^1A02^nAristides^sBarbosa Júnior#Fundação Osw
aldo Cruz^iA01^1Informação Científica e Tecnológica em Saúde^2Instituto de Comun
icação e Informação^cRio de Janeiro^pBrasil#Ministério da Saúde^iA02^1Departamen
to de DST, AIDS e Hepatites Virais^cBrasília^pBrasil#^len^aFemale sex workers ar
e known in Brazil and elsewhere in the world as one of the most-at-risk populati
ons for risk of HIV infection, due to their social vulnerability and factors rel
ated to their work. However, the use of conventional sampling strategies in stud
ies on most-at-risk subgroups for HIV is generally problematic, since such subgr
oups are small in size and are associated with stigmatized behaviors and/or ille
gal activities. In 1997, a probabilistic sampling technique was proposed for har
d-to-reach populations, called Respondent-Driven Sampling (RDS). The method is c
onsidered a variant of chain sampling and allows the statistical estimation of t
arget variables. This article describes some assumptions of RDS and all the impl
ementation stages in a study of 2,523 female sex workers in 10 Brazilian cities.
 RDS proved appropriate for recruiting sex workers, allowing the selection of a 
probabilistic sample and the collection of previously missing information on thi
s group in Brazil.#^ddecs^i1#^tm^len^kHIV^i1#^tm^len^kProstitution^i1#^tm^len^kS
exual Behavior^i1#^lpt^aO grupo das mulheres profissionais do sexo é reconhecido
, nacional e internacionalmente, como uma população de maior risco à infecção pe
lo HIV pela sua vulnerabilidade social e por fatores relacionados à atividade pr
ofissional. Porém, a utilização de estratégias convencionais de amostragem em es
tudos nos subgrupos de maior risco de contraírem HIV é, em geral, problemática, 
já que estes têm pequena magnitude em termos populacionais e estão vinculados a 
comportamentos estigmatizados ou atividades ilegais. Em 1997, foi proposta uma t
écnica de amostragem probabilística para populações de difícil acesso, o Respond
ent-Driven Sampling (RDS). O método é considerado como uma variante da amostrage
m em cadeia e possibilita a estimação estatística dos parâmetros de interesse. E
ste artigo descreve alguns pressupostos do RDS e todas as etapas de implementaçã
o em um estudo com 2.523 profissionais do sexo em dez municípios brasileiros. A 
utilização do RDS mostrou-se apropriada para recrutamento de profissionais do se
xo, possibilitando a seleção de uma amostra probabilística e a coleta de informa
ções inexistentes sobre este grupo no Brasil.#^ddecs^i2#^tm^lpt^kHIV^i2#^tm^lpt^
kProstituição^i2#^tm^lpt^kComportamento Sexual^i2#vancouv#59#20091221#21/Dec/200
9#20100608#08/Jun/2010#20100810#10/Aug/2010#06.htm##
03753000000000625000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000500083038000400088121000300092049000700095158000300102
03000190010503100030012413100020012706500090012901400110013803500100014901200970
01590120136002560100037003920100038004290100037004670700136005040700089006400831
00600729085001001735085001601745085002501761085002801786083114801814085001002962
08500160297208500250298808500330301311700080304607200030305411200090305711100120
3066116000903078115001203087114000903099113001203108002000703120#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#ILUS#TAB#06#
CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs45^ls55#0102-311X#<b>Implementatio
n of respondent-driven sampling among female sex workers in Brazil, 2009</b>^len
#<b>Implementação do método de amostragem <i>respondent-driven sampling</i> entr
e mulheres profissionais do sexo no Brasil, 2009</b>^lpt#^rND^1A01^nGiseli Nogue
ira^sDamacena#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nAristides^sBarbos
a Júnior#Fundação Oswaldo Cruz^iA01^1Informação Científica e Tecnológica em Saúd
e^2Instituto de Comunicação e Informação^cRio de Janeiro^pBrasil#Ministério da S
aúde^iA02^1Departamento de DST, AIDS e Hepatites Virais^cBrasília^pBrasil#^len^a
Female sex workers are known in Brazil and elsewhere in the world as one of the 
most-at-risk populations for risk of HIV infection, due to their social vulnerab
ility and factors related to their work. However, the use of conventional sampli
ng strategies in studies on most-at-risk subgroups for HIV is generally problema
tic, since such subgroups are small in size and are associated with stigmatized 
behaviors and/or illegal activities. In 1997, a probabilistic sampling technique
 was proposed for hard-to-reach populations, called Respondent-Driven Sampling (
RDS). The method is considered a variant of chain sampling and allows the statis
tical estimation of target variables. This article describes some assumptions of
 RDS and all the implementation stages in a study of 2,523 female sex workers in
 10 Brazilian cities. RDS proved appropriate for recruiting sex workers, allowin
g the selection of a probabilistic sample and the collection of previously missi
ng information on this group in Brazil.#^ddecs^i1#^tm^len^kHIV^i1#^tm^len^kProst
itution^i1#^tm^len^kSexual Behavior^i1#^lpt^aO grupo das mulheres profissionais 
do sexo é reconhecido, nacional e internacionalmente, como uma população de maio
r risco à infecção pelo HIV pela sua vulnerabilidade social e por fatores relaci
onados à atividade profissional. Porém, a utilização de estratégias convencionai
s de amostragem em estudos nos subgrupos de maior risco de contraírem HIV é, em 
geral, problemática, já que estes têm pequena magnitude em termos populacionais 
e estão vinculados a comportamentos estigmatizados ou atividades ilegais. Em 199
7, foi proposta uma técnica de amostragem probabilística para populações de difí
cil acesso, o Respondent-Driven Sampling (RDS). O método é considerado como uma 
variante da amostragem em cadeia e possibilita a estimação estatística dos parâm
etros de interesse. Este artigo descreve alguns pressupostos do RDS e todas as e
tapas de implementação em um estudo com 2.523 profissionais do sexo em dez munic
ípios brasileiros. A utilização do RDS mostrou-se apropriada para recrutamento d
e profissionais do sexo, possibilitando a seleção de uma amostra probabilística 
e a coleta de informações inexistentes sobre este grupo no Brasil.#^ddecs^i2#^tm
^lpt^kHIV^i2#^tm^lpt^kProstituição^i2#^tm^lpt^kComportamento Sexual^i2#vancouv#5
9#20091221#21/Dec/2009#20100608#08/Jun/2010#20100810#10/Aug/2010#06.htm##
03856000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000500090038000400095121000300099049000700102
15800030010903000190011203100030013113100020013406500090013601400110014503500100
01560120090001660120122002560100037003780100038004150100037004530700138004900700
09100628083100600719085001001725085001601735085002501751085002801776083114801804
08500100295208500160296208500250297808500330300311700080303607200030304411200090
30471110012030561160009030681150012030771140009030891130012030980020007031100080
08903117#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#l#4#1#article#1#^a2011
#oa#en#br1.1#1#4.0#ilus#tab#06#CSP330#nd#Cad. saúde pública#27#1#20110000#^fs45^
ls55#0102-311X#Implementation of respondent-driven sampling among female sex wor
kers in Brazil, 2009^len#Implementação do método de amostragem respondent-driven
 sampling entre mulheres profissionais do sexo no Brasil, 2009^lpt#^rND^1A01^nGi
seli Nogueira^sDamacena#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nAristid
es^sBarbosa Júnior#^iA01^1Fundação Oswaldo Cruz^2Informação Científica e Tecnoló
gica em Saúde^3Instituto de Comunicação e Informação^cRio de Janeiro^pBrasil#^iA
02^1Ministério da Saúde^2Departamento de DST, AIDS e Hepatites Virais^cBrasília^
pBrasil#^len^aFemale sex workers are known in Brazil and elsewhere in the world 
as one of the most-at-risk populations for risk of HIV infection, due to their s
ocial vulnerability and factors related to their work. However, the use of conve
ntional sampling strategies in studies on most-at-risk subgroups for HIV is gene
rally problematic, since such subgroups are small in size and are associated wit
h stigmatized behaviors and/or illegal activities. In 1997, a probabilistic samp
ling technique was proposed for hard-to-reach populations, called Respondent-Dri
ven Sampling (RDS). The method is considered a variant of chain sampling and all
ows the statistical estimation of target variables. This article describes some 
assumptions of RDS and all the implementation stages in a study of 2,523 female 
sex workers in 10 Brazilian cities. RDS proved appropriate for recruiting sex wo
rkers, allowing the selection of a probabilistic sample and the collection of pr
eviously missing information on this group in Brazil.#^ddecs^i1#^tm^len^kHIV^i1#
^tm^len^kProstitution^i1#^tm^len^kSexual Behavior^i1#^lpt^aO grupo das mulheres 
profissionais do sexo é reconhecido, nacional e internacionalmente, como uma pop
ulação de maior risco à infecção pelo HIV pela sua vulnerabilidade social e por 
fatores relacionados à atividade profissional. Porém, a utilização de estratégia
s convencionais de amostragem em estudos nos subgrupos de maior risco de contraí
rem HIV é, em geral, problemática, já que estes têm pequena magnitude em termos 
populacionais e estão vinculados a comportamentos estigmatizados ou atividades i
legais. Em 1997, foi proposta uma técnica de amostragem probabilística para popu
lações de difícil acesso, o Respondent-Driven Sampling (RDS). O método é conside
rado como uma variante da amostragem em cadeia e possibilita a estimação estatís
tica dos parâmetros de interesse. Este artigo descreve alguns pressupostos do RD
S e todas as etapas de implementação em um estudo com 2.523 profissionais do sex
o em dez municípios brasileiros. A utilização do RDS mostrou-se apropriada para 
recrutamento de profissionais do sexo, possibilitando a seleção de uma amostra p
robabilística e a coleta de informações inexistentes sobre este grupo no Brasil.
#^ddecs^i2#^tm^lpt^kHIV^i2#^tm^lpt^kProstituição^i2#^tm^lpt^kComportamento Sexua
l^i2#vancouv#59#20091221#21/Dec/2009#20100608#08/Jun/2010#20100810#10/Aug/2010#0
6.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311
X2011001300006##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#5#1#article#222#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#6#2#article#222#<p>&nbsp;</p>     ^cY#06.htm
##
00417000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704019700067002000700264#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#7#3#article#222#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Implementation    of res
pondent-driven sampling among female sex workers in Brazil, 2009</b> </font></p>
     ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#8#4#article#222#<p>&nbsp;</p>     ^cY#06.htm
##
00462000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704024200067002000700309#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#9#5#article#222#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Implementa&ccedil;&atilde;o    do m&eacute
;todo de amostragem <i>respondent-driven sampling</i> entre mulheres    profissi
onais do sexo no Brasil, 2009</b> </font></p>     ^cY#06.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#10#6#article#222#<p>&nbsp;</p>     ^cY#06.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#11#7#article#222#<p>&nbsp;</p>     ^cY#06.ht
m##
00445000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704022400068002000700292#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#12#8#article#222#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Giseli Nogueira    Damacena<sup>I</sup>; 
C&eacute;lia Landmann Szwarcwald<sup>I</sup>; Aristides    Barbosa J&uacute;nior
<sup>II</sup></b></font></p>     ^cY#06.htm##
00494000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704027300068002000700341#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#13#9#article#222#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    de Comunica&ccedil;
&atilde;o e Informa&ccedil;&atilde;o Cient&iacute;fica e    Tecnol&oacute;gica e
m Sa&uacute;de, Funda&ccedil;&atilde;o Oswaldo Cruz, Rio    de Janeiro, Brasil  
  ^cY#06.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014700069002000700216#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#14#10#article#222#<br>   <sup>II</sup>Depart
amento de DST, AIDS e Hepatites Virais, Minist&eacute;rio    da Sa&uacute;de, Br
as&iacute;lia, Brasil</font></p>     ^cY#06.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#15#11#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#16#12#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#17#13#article#222#<p>&nbsp;</p> <hr noshade 
size="1">     ^cY#06.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#18#14#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#06.htm##
01343000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704112100069002000701190#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#19#15#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Female sex workers    are known in Brazil a
nd elsewhere in the world as one of the most-at-risk populations    for risk of 
HIV infection, due to their social vulnerability and factors related    to their
 work. However, the use of conventional sampling strategies in studies    on mos
t-at-risk subgroups for HIV is generally problematic, since such subgroups    ar
e small in size and are associated with stigmatized behaviors and/or illegal    
activities. In 1997, a probabilistic sampling technique was proposed for hard-to
-reach    populations, called Respondent-Driven Sampling (RDS). The method is co
nsidered    a variant of chain sampling and allows the statistical estimation of
 target    variables. This article describes some assumptions of RDS and all the
 implementation    stages in a study of 2,523 female sex workers in 10 Brazilian
 cities. RDS proved    appropriate for recruiting sex workers, allowing the sele
ction of a probabilistic    sample and the collection of previously missing info
rmation on this group in    Brazil.</font></p>     ^cY#06.htm##
00364000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014200069002000700211#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#20#16#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV; Prostitution;    Sexual Behavior</font
></p> <hr size="1" noshade>     ^cY#06.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#21#17#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#06.htm##
01761000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704153900069002000701608#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#22#18#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O grupo das mulheres    profissionais do se
xo &eacute; reconhecido, nacional e internacionalmente, como    uma popula&ccedi
l;&atilde;o de maior risco &agrave; infec&ccedil;&atilde;o pelo    HIV pela sua 
vulnerabilidade social e por fatores relacionados &agrave; atividade    profissi
onal. Por&eacute;m, a utiliza&ccedil;&atilde;o de estrat&eacute;gias    convenci
onais de amostragem em estudos nos subgrupos de maior risco de contra&iacute;rem
    HIV &eacute;, em geral, problem&aacute;tica, j&aacute; que estes t&ecirc;m p
equena    magnitude em termos populacionais e est&atilde;o vinculados a comporta
mentos    estigmatizados ou atividades ilegais. Em 1997, foi proposta uma t&eacu
te;cnica    de amostragem probabil&iacute;stica para popula&ccedil;&otilde;es de
 dif&iacute;cil    acesso, o Respondent-Driven Sampling (RDS). O m&eacute;todo &
eacute; considerado    como uma variante da amostragem em cadeia e possibilita a
 estima&ccedil;&atilde;o    estat&iacute;stica dos par&acirc;metros de interesse
. Este artigo descreve alguns    pressupostos do RDS e todas as etapas de implem
enta&ccedil;&atilde;o em um estudo    com 2.523 profissionais do sexo em dez mun
ic&iacute;pios brasileiros. A utiliza&ccedil;&atilde;o    do RDS mostrou-se apro
priada para recrutamento de profissionais do sexo, possibilitando    a sele&cced
il;&atilde;o de uma amostra probabil&iacute;stica e a coleta de informa&ccedil;&
otilde;es    inexistentes sobre este grupo no Brasil.</font></p>     ^cY#06.htm#
#
00383000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016100069002000700230#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#23#19#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV; Prostitui&ccedil;&atilde;o;    Comport
amento Sexual</font></p> <hr size="1" noshade>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#24#20#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#25#21#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#26#22#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#06.h
tm##
00766000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054400069002000700613#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#27#23#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">At the national    and international levels
, HIV prevention work has been based on the natural    history of infection, exp
eriences in specific AIDS programs, and mathematical    and simulation models <s
up>1,2</sup>. Increasing importance has been assigned    to most-at-risk populat
ion groups, who, although relatively small in size, play    a preponderant role 
in the spread of the disease, especially in countries with    concentrated epide
mics <sup>3</sup>.</font></p>     ^cY#06.htm##
00916000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069400069002000700763#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#28#24#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In relation to    sexual transmission, fema
le sex workers as a group are recognized as a most-at-risk    population for HIV
 infection, both in Brazil <sup>4,5,6</sup> and in various    other countries <s
up>7,8,9,10,11,12</sup>, due to their social vulnerability    and factors relate
d to their work, such as multiple sex partners. In addition    to sexually trans
mitted infections (STI), which act as co-factors <sup>13</sup>,    studies of se
x workers have shown that time in the profession and the consumption    of illeg
al drugs are also associated with greater risk of HIV infection <sup>4,5,14,15,1
6</sup>.</font></p>     ^cY#06.htm##
00973000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075100069002000700820#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#29#25#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In Brazil, the    size of the subgroup of f
emale sex workers has been estimated at 1% of the Brazilian    female population
 15-49 years of age <sup>17</sup>, that is, more than half    a million women. S
ince 2002, prostitution has been officially recognized as    a profession in the
 country (Ministry of Labor and Employment, Brazilian Classification    of Occup
ations. <a href="http://www.mtecbo.gov.br/cbosite/pages/home.jsf" target="_blank
">http://www.mtecbo.gov.br/cbosite/pages/home.jsf</a>,    accessed on Oct/2009),
 but is still surrounded by stigma and discrimination,    which hinders access t
o the health system and other social interventions <sup>18</sup>.</font></p>    
 ^cY#06.htm##
00676000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045400069002000700523#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#30#26#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The situation of    increased risk of HIV i
nfection, syphilis, and other STI led to several studies    on female sex worker
s in Brazil beginning in the 1990s <sup>5,19</sup>. However,    these studies ge
nerally used convenience samples, thus hindering the estimation    of variables 
for nationwide monitoring of the HIV epidemic in this population    group <sup>2
0</sup>.</font></p>     ^cY#06.htm##
00935000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071300069002000700782#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#31#27#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Studies in most-at-risk    subgroups for ST
I through conventional sampling strategies are generally problematic.    Since t
hese subgroups are numerically small and linked to stigmatized or illegal    act
ivities, they are considered hard-to-reach populations <sup>21</sup>. Since    t
he mid-1990s, the development of probabilistic sampling methods has been encoura
ged,    not only to ease the difficulties in access, but also to allow statistic
al estimation    of the target variables <sup>21,22,23</sup>. In this context, t
ime-space sampling    (TSS) <sup>24</sup> and respondent-driven sampling (RDS) w
ere proposed <sup>25</sup>.</font></p>     ^cY#06.htm##
00872000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065000069002000700719#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#32#28#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Since it was first    proposed, RDS has bee
n widely used in various countries in studies of most-at-risk    population subg
roups for HIV <sup>26,27,28,29,30,31,32,33</sup>. In a recent    review of studi
es in the literature that used RDS in hard-to-reach populations,    Johnston et 
al. <sup>34</sup> identified 128 HIV surveillance studies performed    outside t
he United States from 2003 and 2007. Likewise, Malekinejad et al. <sup>35</sup> 
   identified 123 studies, 59 of which in Europe, 40 in Asia/Pacific, 14 in Lati
n    America, 7 in Africa, and 3 in Oceania.</font></p>     ^cY#06.htm##
01102000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704088000069002000700949#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#33#29#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In Brazil, the    commitment to HIV surveil
lance in most-at-risk groups required nationally representative    studies. In 2
006, the Department of STD, AIDS, and Viral Hepatitis, under the    Ministry of 
Health, promoted the transfer of sampling methodology for hard-to-reach    popul
ations <sup>36</sup>. In the years 2008 and 2009, research projects were    cond
ucted in three population subgroups (men who have sex with men - MSM, female    
sex workers, and drug users), using RDS as the sampling method. The current    a
rticle aims to describe some assumptions of the RDS sampling method and all    t
he stages in the method's implementation in a study of female sex workers,    di
sclosure of a recently proposed sampling methodology for hard-to-reach populatio
ns    in the Brazilian literature.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#34#30#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00344000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012200069002000700191#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#35#31#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Assumptions    of the RDS method</b></fo
nt></p>     ^cY#06.htm##
00712000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704049000069002000700559#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#36#32#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The RDS method    was proposed in 1997 by H
eckathorn <sup>25</sup>. It is considered a variant    of chain sampling, since 
members of the target population group recruit their    own peers to participate
 in the study, assuming that capturing individuals in    hard-to-reach populatio
ns is facilitated when the recruitment is done by individuals    from the same p
opulation, who are part of a social network.</font></p>     ^cY#06.htm##
00584000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036200069002000700431#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#37#33#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, unlike    other, non-probabilistic
 chain sampling methods like the so-called "snowball"    technique <sup>20</sup>
, RDS is implemented under statistical assumptions that    allow calculating the
 selection probabilities, thus making it a probabilistic    sampling method.</fo
nt></p>     ^cY#06.htm##
00898000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067600069002000700745#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#38#34#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">RDS assumes that    persons with a given ch
aracteristic or activity are connected in a social network    and have links to 
other persons with similar characteristics. The data collection    is done throu
gh successive recruitment cycles called "waves". First, individuals    from the 
target population called "seeds" are selected non-randomly to participate    in 
the study <sup>25</sup>. The seeds are asked to recruit a fixed number of    pee
rs from among their friends and acquaintances in the same population subgroup.  
  The peers recruited by the seed also recruit other peers, and so on.</font></p
>     ^cY#06.htm##
00684000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046200069002000700531#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#39#35#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The participants'    tendency to recruit pe
ers with similar characteristics to their own has been    called the "homophilia
 effect" <sup>37</sup>. To account for the non-random    selection of individual
s and the possible over-representation of individuals    with given characterist
ics in the study population, the recruitment is modeled    by a Markov process <
sup>22,38</sup>.</font></p>     ^cY#06.htm##
00566000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034400069002000700413#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#40#36#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A Markov process    is a given phenomenon t
hat can be classified in finite and discrete states,    and in which the probabi
lity of transition between such states, also in a discrete    time interval, onl
y depends on the current and previous state <sup>39</sup>.</font></p>     ^cY#06
.htm##
01001000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077900069002000700848#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#41#37#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">And furthermore,    according to the "law o
f large numbers" <sup>40</sup>, the probability of the    process in any state o
ver the course of a large number of steps will be independent    of the state in
 which it began. In the case of recruitment in the RDS method,    this means tha
t memory of the recruitment occurs wave-to-wave, that is, the    characteristics
 in the recruited individual only depend on the characteristics    of his/her di
rect recruiter, and not on those of the recruiter's recruiter or    of any parti
cipant in previous waves. After a sufficient number of waves, the    characteris
tics of the individuals in the final sample are independent of the    seed's cha
racteristics.</font></p>     ^cY#06.htm##
00741000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051900069002000700588#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#42#38#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Theoretically,    the suggested number of w
aves for reaching equilibrium is six, since according    to Watts <sup>41</sup>,
 all the individuals are connected to each other through    only a half dozen li
nks. However, if the homophilia effect is large, the sampling    process needs t
o consist of a sufficiently large number of waves in order to    reach Markov eq
uilibrium (for given variables) and the minimum estimated sample    size.</font>
</p>     ^cY#06.htm##
01151000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092900069002000700998#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#43#39#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the RDS method,    recruitment is done o
n the basis of a set number of coupons (usually 2 to 4)    distributed to partic
ipants in order to invite their peers. To participate in    the study, the invit
ed individuals must present their coupons as a guarantee    of the network recru
itment. Each coupon has a serial number which is used later    for the social ne
twork design and recruitment patterns. Distribution of a set    number of coupon
s to all the participants decreases the possibility that recruiters    with larg
e social networks will be over-represented in the sample as compared    to those
 with small networks. It also reduces the initial influence of the seeds    on t
he final sample and stimulates long recruitment chains, increasing the sample's 
   power to capture ""hidden" individuals in the study population <sup>25,38</su
p>.</font></p>     ^cY#06.htm##
00930000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070800069002000700777#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#44#40#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The RDS method    also draws on the strateg
y of giving incentives to the participants. The first    or "primary" incentive 
is given to participants when they complete their participation    in the study.
 The second, called the secondary incentive, is given to participants    for eac
h peer successfully recruited into the study. Incentives have been used    to pr
omote the recruitment and thus the growth of the networks. They can be    moneta
ry or not, as for example non-perishable foods or food stamps, or tickets    to 
shows or nightclubs. Choice of the type of incentive depends on the target    gr
oup's characteristics.</font></p>     ^cY#06.htm##
00562000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034000069002000700409#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#45#41#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In relation to    the study venue, it is im
portant that the study be carried out in an easy-to-reach    place for the parti
cipants and that it is free of prejudices. Health services    are often chosen, 
in order to promote their use by the study population.</font></p>     ^cY#06.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#46#42#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00350000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012800069002000700197#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#47#43#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Analysis of    data collected with RDS</
b></font></p>     ^cY#06.htm##
00898000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067600069002000700745#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#48#44#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In 2004, Salganick    &amp; Heckathorn <sup
>22</sup> proposed that data collected with RDS be weighted    according to an e
xpansion factor based on the inverse of the selection probability.    Under the 
hypothesis that the seed is selected with probability proportional    to her/his
 network size, and that participants randomly recruit their peers    from their 
network of friends and acquaintances, the authors demonstrated that    the proba
bility of selecting each participant is also proportional to the network    size
, i.e., to the number of acquaintances known in the target population.</font></p
>     ^cY#06.htm##
00776000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055400069002000700623#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#49#45#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to measure    the effect of the sa
mpling plan on the variance of the mean estimates, one uses    the so-called "de
sign effect", which is calculated as the ratio between the    estimate of the va
riance determined by the sampling plan and the estimate of    the variance obtai
ned by a simple random sample of the same size. Design effect    is also used to
 calculate the sample size of future studies that may use the    same complex sa
mpling design <sup>42</sup>.</font></p>     ^cY#06.htm##
00999000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077700069002000700846#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#50#46#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the case of    samples collected with RD
S, Salganick <sup>43</sup> initially estimated design    effects of around 2, th
rough "bootstrap" simulation methods, whose general principle    is to use the o
bserved sample to generate a set of identical samples and produce    a set of re
plicas of the estimates, thereby allowing calculation of the variance    and con
fidence intervals. Later, simulation models that take into account the    homoph
ilia effect and dependence of observations showed much larger design effects,   
 greater than 4 <sup>44</sup>. In 2010, the same authors criticized the previous
ly    proposed estimators to calculate the variance and confidence intervals <su
p>45</sup>.</font></p>     ^cY#06.htm##
00956000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704073400069002000700803#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#51#47#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For statistical    analysis of data collect
ed with RDS, an application was developed called "Respondent-Driven    Sampling 
Analysis Tool" (RDSAT - <a href="http://www.respondentdrivensampling.org/reports
/RDSAT_56_Manual.pdf" target="_blank">http://www.respondentdrivensampling.org/re
ports/RDSAT_56_Manual.pdf</a>,    accessed on 14/Aug/2009), which weighs and adj
usts the data according to the    recruitment patterns observed during the study
, considering the homophilia effect    and the size of each individual's social 
network. However, the application presents    important limitations, like the im
possibility of performing multivariate analyses.</font></p>     ^cY#06.htm##
00776000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055400069002000700623#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#52#48#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Since RDS is a    complex and relatively ne
w sampling method, the appropriate statistical techniques    for analyzing the c
ollected data are still being developed. For example, over    time, two distinct
 estimators have been proposed for estimating prevalence rates,    which have be
en discussed in the recent literature on RDS <sup>46</sup>. While    the point e
stimators are quite similar, some questions remain about the best    way to esti
mate variance <sup>47</sup>.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#53#49#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00371000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014900069002000700218#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#54#50#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Implementation    of RDS among female se
x workers in Brazil</b></font></p>     ^cY#06.htm##
00731000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050900069002000700578#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#55#51#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study, called    the "Health Chain", wa
s carried out in Brazil from August 2008 to July 2009,    aimed at estimating th
e prevalence rates for HIV and syphilis and identify knowledge,    attitudes, an
d practices related to HIV infection and other sexually transmitted    diseases 
in female sex workers. The research project was approved by the Institutional   
 Review Board of the Oswaldo Cruz Foundation (case nº. 395/07).</font></p>     ^
cY#06.htm##
00973000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075100069002000700820#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#56#52#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To conduct the    research, the Department 
of STD, AIDS, and Viral Hepatitis chose 10 Brazilian    municipalities (counties
) based on the size and importance of the local AIDS    epidemic. The sample siz
e (2,500 women) was calculated by estimating a 6% HIV    prevalence rate, with a
 95% confidence interval, and two-tailed error of 1.5%,    considering a design 
effect of 1.5. In each of the municipalities, the attempt    was made to distrib
ute the sample proportionally to the municipality's population,    while setting
 a minimum sample of 100 women. <a href="#t1">Table 1</a> shows    the distribut
ion of the planned and collected sample in the 10 municipalities.</font></p>    
 ^cY#06.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#57#53#article#222#<p><a name="t1"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#58#54#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#59#55#article#222#<p align="center"><img src
="/img/revistas/csp/v27s1/06t01.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#60#56#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00900000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067800069002000700747#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#61#57#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The eligibility    criteria were the follow
ing: (1) age 18 years or older; (2) being a woman; (3)    working as a sex worke
r in the municipality where the study was being conducted;    (4) having had sex
 in exchange for money at least once in the previous four    months; (5) accept 
participating under the study conditions and agree to sign    the free and infor
med consent form; (6) present a valid invitation to participate    in the study;
 (7) not having participated in the study previously; and (8) not    being under
 the influence of illegal drugs or alcohol at the time of the interview.</font><
/p>     ^cY#06.htm##
01503000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704128100069002000701350#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#62#58#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study consisted    of a preliminary int
erview to verify the eligibility criteria and characterize    the network and wo
rk venue, a self-completed computer questionnaire, and rapid    tests for syphil
is and HIV. In all ten municipalities, the fieldwork was done    in health servi
ces, with the teams consisting of: a supervisor, in charge of    organizing the 
field work in the health service, administering the invitations,    and supervis
ing the teamwork in the service; an interviewer, in charge of applying    the be
havioral questionnaire; a counselor, in charge of pre- and post-test counseling;
    and the testing professional, a health worker with university training in a 
   biomedical field, responsible for applying and interpreting the HIV and syphi
lis    tests. The research teams were also responsible for monitoring the networ
ks    and encouraging participation by the sex workers. For this purpose, promot
ional    materials for the study were prepared and distributed in the main prost
itution    venues in the target cities, with the following slogan: "<i>If you re
ceive an    invitation from the</i> Health Chain, <i>be sure to participate. Hel
p form the    chain of health</i>".</font></p>     ^cY#06.htm##
00979000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075700069002000700826#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#63#59#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Before the data    collection phase, in eac
h municipality a preparatory survey was done to facilitate    the study's implem
entation at each site according to the characteristics of    prostitution in eac
h city. The following issues were addressed: identification    of the main prost
itution venues, diversity of types of female sex workers present    in the city,
 choice of the health service for conducting the study, and identification    of
 possible seeds. In the preparatory survey, focus groups and/or in-depth intervi
ews    were held with the sex workers and their local representatives, using a p
reviously    prepared script and qualitative methodology <sup>48</sup>.</font></
p>     ^cY#06.htm##
00792000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057000069002000700639#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#64#60#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In each municipality,    five to ten initia
l participants were chosen, called "seeds", selected non-randomly.    Seeds were
 chosen with differences in age group, color/race, socioeconomic class,    schoo
ling, and types of work venues, like the street, nightclubs, saunas, hotels,    
call services, and others. In addition, this initial focus was on sex workers   
 that were well-connected in the community and that had reported extensive socia
l    networks during the preparatory survey.</font></p>     ^cY#06.htm##
00804000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058200069002000700651#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#65#61#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Each seed received    three coupons to give
 to her friends or acquaintances. The women invited by    the seeds that partici
pated in the study comprised the first "wave". After participating    in the int
erview, they received three coupons themselves to invite their friends    and ac
quaintances. This process was repeated until the sample was reached in    each s
ite. <a href="#f1">Figure 1</a> shows the flow of participation by each    sex w
orker, beginning with her arrival at the health service.</font></p>     ^cY#06.h
tm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#66#62#article#222#<p><a name="f1"></a></p>  
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#67#63#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#68#64#article#222#<p align="center"><img src
="/img/revistas/csp/v27s1/06f01.jpg"></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#69#65#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00872000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065000069002000700719#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#70#66#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The coupons were    numbered in order to pr
event counterfeiting and to allow identifying the recruitment    patterns in the
 population. The participants were only identified by the identification    code
 on the coupon, consisting of two letters (the municipality's initials)    and a
 set of numbers indicating the seed and the wave. The number of coupons    hande
d out for each participant to recruit her peers was predetermined (three).    In
 order to manage the invitations, a program was generated on ACCESS (Microsoft  
  Corp., USA), called "Invitations Manager".</font></p>     ^cY#06.htm##
01145000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092300069002000700992#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#71#67#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study questionnaire    was self-complet
ed and included questions on the following themes: (1) socio-demographic    char
acteristics (age, schooling, marital status, color/race, religion, economic    c
lass, etc.); (2) knowledge, attitudes, perceptions, and risk practices for    HI
V and other STI; (3) HIV transmission routes and forms of prevention; (4)    his
tory of HIV/STI testing, knowledge of serological status; (5) history of    STI 
and presentation of symptoms; (6) sexual initiation; (7) number and types    of 
sex partners (men, women; occasional, stable, commercial); (8) condom use    (la
st sexual relations, regularity, unprotected relations with different types    o
f partners and different types of sexual practices); (9) characteristic of    se
x trade; (10) drug and alcohol use; and (11) access to preventive activities.</f
ont></p>     ^cY#06.htm##
00867000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064500069002000700714#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#72#68#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The questionnaire    was filled out directl
y by the interviewee on a computer using a program called    Audio Computer-Assi
sted Self-Interview (ACASI - Tufts University, Boston, USA.    <a href="http://w
ww.tufts.edu/med/nutrition-infection/tnc-cdaar/acasi/acasi.html" target="_blank"
>http://www.tufts.edu/med/nutrition-infection/tnc-cdaar/acasi/acasi.html</a>).  
  This program allowed the interviewee to listen to all the questions and possib
le    answers, thus facilitating understanding of the questionnaire and simultan
eously    guaranteeing confidentiality.</font></p>     ^cY#06.htm##
00851000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062900069002000700698#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#73#69#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To allow calculating    the prevalence rate
s for HIV and syphilis among female sex workers, rapid tests    were performed (
using capillary blood samples) in the participants, complying    with the guidel
ines and protocols of the Department of STD, AIDS, and Viral    Hepatitis, with 
pre- and post-test counseling by the team counselor. The health    workers that 
performed the rapid tests had university training in a health field    and had b
een specifically trained by the Department of STD, AIDS, and Viral    Hepatitis 
before the study began.</font></p>     ^cY#06.htm##
00782000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056000069002000700629#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#74#70#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The participants    that tested positive re
ceived counseling in order to minimize the psychological    risks and notify the
 steady partners, having been referred to health services    under the Unified N
ational Health System (SUS) for the appropriate follow-up    according to the gu
idelines of the Department of STD, AIDS, and Viral Hepatitis.    The services fo
r referral of positive cases in each participating municipality    were identifi
ed before launching the fieldwork.</font></p>     ^cY#06.htm##
00879000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065700069002000700726#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#75#71#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">During the research    project's implementa
tion, each participant received the primary incentive when    she completed the 
interview, plus an additional reward (secondary incentive)    in the form of cas
h (varying from BR$5.00 to BR$10.00) for recruiting each peer    that successful
ly completed the study. The primary incentive consisted of condoms,    lubricant
, educational material, food stamps, and transportation vouchers, a    snack alo
ng with the interview, and a little prize picked among a variety of    beauty pr
oducts, like a hairbrush, make-up, or manicure kit.</font></p>     ^cY#06.htm##
01352000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704113000069002000701199#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#76#72#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for the statistical    analysis, the dat
a were weighted using the following question to measure the    network size: "<i
>How many female sex workers do you know personally?".</i>    In each municipali
ty, the expansion factors were inversely proportional to the    network size. In
 addition, since the study was done in 10 municipalities, in    order to produce
 results for the entire sample, calibration was performed according    to the re
lative number of women 15-49 years of age in each municipality, assuming    a co
nstant proportion of female sex workers in all the sites studied. Interestingly,
    unlike other studies that used the RDS methodology, the statistical analysis
    was done for entire sample, with the data collected in the ten municipalitie
s.    The methods proposed for data analysis, including estimation of the varian
ce    and design effect in the prevalence rates, as well as the multivariate log
istic    regression models, are beyond the scope of the current article and will
 be presented    in subsequent publications.</font></p>     ^cY#06.htm##
00946000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072400069002000700793#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#77#73#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Concerning the    possible selection bias d
escribed by Heckathorn in 2002 <sup>38</sup>, in the    case of the Chain of Hea
lth project, the homophilia effect occurred according    to HIV serological stat
us, since participants with HIV infection tended to recruit    other HIV-positiv
e participants. These findings indicate a great dependency    in the observation
s, which needs to be considered in the data analysis. By way    of illustration,
 <a href="/img/revistas/csp/v27s1/06f02.jpg">Figure 2</a> shows    the network o
f female sex workers participating in the study in the city of    Rio de Janeiro
, where this tendency can be observed.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#78#74#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#79#75#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#06.htm
##
00647000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042500069002000700494#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#80#76#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">RDS is a method    based on various statist
ical assumptions in order to reach a representative    sample of the study popul
ation. Despite its potential to produce probabilistic    samples, since it is a 
relatively recent method, it has been analyzed and rethought    with each new ap
plication of the procedure <sup>20,21,22,25,37,43,49</sup>.</font></p>     ^cY#0
6.htm##
00580000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035800069002000700427#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#81#77#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In Brazil, besides    making it possible to
 fill in existing information gaps on the population of    female sex workers, t
he study enabled evaluating the experience in the application    of the RDS samp
ling method in this population subgroup in ten Brazilian municipalities.</font><
/p>     ^cY#06.htm##
01253000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704103100069002000701100#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#82#78#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In relation to    the incentives, the prima
ry incentive was used since the beginning of the study    in all the sites. The 
secondary incentive was not used at the beginning of the    study, on the assump
tion that there would be spontaneous interest in participating,    based on the 
concepts of solidarity and the social networks among the female    sex workers. 
However, in the majority of the participating municipalities, it    proved neces
sary to use the secondary incentive in order to bolster participation    in the 
study, since the networks were developing too slowly and there were constraints 
   on time and resources to conduct the research. According to Heckathorn <sup>2
5</sup>,    while the primary incentive motivates individual participation based
 on autonomous    decisions in the concept of cooperation, the secondary incenti
ve brings the    social influence to the surface, which is taken advantage of in
 the sampling    process.</font></p>     ^cY#06.htm##
00776000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055400069002000700623#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#83#79#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, provision    of the secondary ince
ntive has generated controversy in the international literature    <sup>50</sup>
. On the one hand, if the dual incentive stimulates both recruitment    and part
icipation in the study, on the other it becomes a kind of parallel currency    i
n groups with low socioeconomic status, generating duplicities in the sample,   
 participation of non-eligible individuals, and even clashes among individuals  
  in the population segment.</font></p>     ^cY#06.htm##
00966000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074400069002000700813#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#84#80#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the case of    the Health Chain study, t
he use of the secondary incentive functioned to stimulate    and speed up the in
clusion of participants, and had the merit of obtaining the    participation of 
"hidden", socially excluded sex workers, without the slightest    awareness of t
he importance of their participation, but only interested in the    incentives t
hey were going to receive. However, although the process fostered    the use of 
health services (even though artificially), the desire to participate    without
 meeting the eligibility criteria and the improper receipt of the incentive    l
ed to cases of physical assault against the research team.</font></p>     ^cY#06
.htm##
00834000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061200069002000700681#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#85#81#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the application    of RDS among female s
ex workers in Brazil, a link was also made with the social    movement. In each 
of the municipalities in the study, focal points were chosen,    that is, person
s with influence in the community of sex workers, who helped    to publicize the
 study and accompany the participants with invitations to the    health service.
 The use of focal points helped overcome the distrust and fear    among sex work
ers, who are routinely exposed to violence and social discrimination    <sup>51<
/sup>.</font></p>     ^cY#06.htm##
00859000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063700069002000700706#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#86#82#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for the network    size, the study showe
d that some seeds take a long time to "germinate", while    some types germinate
 faster than others, interfering in the sample's diversity.    In addition, due 
to the homophilia effect, a long network does not always guarantee    capturing 
the diversity of types of individuals in the population segment, an    essential
 characteristic for the sample to be representative of the target population.   
 In this sense, the data weighting is essential for the sample to be representat
ive    of the population group.</font></p>     ^cY#06.htm##
00674000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045200069002000700521#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#87#83#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for the data    weighting in the current
 study, the size of the network among sex workers varies    according to the wor
k venue, and is smaller among women that work the streets    as compared to othe
r places (nightclubs, saunas, hotels). Thus, the original    weighting method wi
ll have to be improved, considering the possibility of stratification    by work
 area.</font></p>     ^cY#06.htm##
01184000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704096200069002000701031#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#88#84#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In relation to    the homophilia effect, a 
tendency was observed among participants with HIV infection    to also recruit H
IV-positive peers. Considering that the great majority (75%)    of HIV-positive 
participants were unaware of their serological status, this    tendency is proba
bly explained by common characteristics in their peer network,    like age, pros
titution site, type of client, social condition, price charged    for sex, drug 
use, and other factors, and should be investigated in future studies.    From th
e epidemiological point of view, while dependence of observations is    interest
ing because it allows understanding the risk factors associated with    the soci
al networks, from the statistical point of view the structure of dependence    s
hould be considered when estimating variables and requires specific statistical 
   techniques for the data analysis.</font></p>     ^cY#06.htm##
00616000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039400069002000700463#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#89#85#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In sum, international    literature, many a
uthors have used traditional multivariate statistical techniques    considering 
independent observations <sup>52,53,54,55,56,57,58</sup>, while    few studies h
ave taken into account the structure of dependence of observations    in the dat
a analysis <sup>29,59</sup>.</font></p>     ^cY#06.htm##
00786000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056400069002000700633#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#90#86#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In short, the use    of RDS proved appropri
ate for studying female sex workers in Brazil, since it    facilitated recruitme
nt and allowed the selection of a probabilistic sample    in this population sub
group. On the other hand, the experience with the implementation    of RDS leave
s some challenges to be explored, like improvement of the methodology    for sta
tistical analysis of data collected with RDS, adequate data calibration,    and 
interpretation of the social networks.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#91#87#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#92#88#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#06.h
tm##
00595000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037300069002000700442#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#93#89#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">G. N. Damacena    conceived the article's c
ontent and was responsible for elaborating the text,    table, figures, and refe
rences. C. L. Szwarcwald conceived the article's content    and participated in 
elaborating the text. A. Barbosa J&uacute;nior participated    in elaborating th
e text.</font></p>     ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#94#90#article#222#<p>&nbsp;</p>     ^cY#06.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#95#91#article#222#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#06.htm
##
00406000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704017000071002000700241#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#96#92#article#222#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. d'Cruz-Grote    D. Prevent
ion of HIV infection in developing countries. Lancet 1996; 348:1071-4.    ^cY#06
.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#97#93#article#222#</font></p>     ^cY#06.htm
##
00554000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704031800071002000700389#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#98#94#article#222#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. van Vliet C,    Meester EI
, Korenromp EL, Singer B, Bakker R, Habbema JD. Focusing strategies    of condom
 use against HIV in different behavioural settings: an evaluation based    on a 
simulation model. Bull World Health Organ 2001; 79:442-54.    ^cY#06.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#99#95#article#222#</font></p>     ^cY#06.htm
##
00523000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704028600072002000700358#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#100#96#article#222#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Joint United    Nations P
rogramme on HIV/AIDS. Monitoring the declaration of commitment on HIV/AIDS:    g
uidelines on constructions of core indicators. Geneva: Joint United Nations    P
rogramme on HIV/AIDS; 2005.    ^cY#06.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#101#97#article#222#</font></p>     ^cY#06.ht
m##
00654000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704041700072002000700489#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#102#98#article#222#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Minist&eacute;rio    da S
a&uacute;de. Avalia&ccedil;&atilde;o da efetividade das a&ccedil;&otilde;es    d
e preven&ccedil;&atilde;o dirigidas &agrave;s profissionais do sexo, em tr&ecirc
;s    regi&otilde;es brasileiras. Bras&iacute;lia: Minist&eacute;rio da Sa&uacut
e;de;    2004. (S&eacute;rie Estudos, Pesquisas e Avalia&ccedil;&atilde;o, 7).  
  ^cY#06.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#103#99#article#222#</font></p>     ^cY#06.ht
m##
00559000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704032100073002000700394#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#104#100#article#222#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Szwarcwald CL,    Bastos
 FI, Gravato N, Lacerda R, Chequer PN, Castilho EA. The relationship of    illic
it drug use to HIV infection among commercial sex workers in the city of    Sant
os, S&atilde;o Paulo, Brazil. Int J Drug Policy 1998; 9:427-36.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#105#101#article#222#</font></p>     ^cY#06.h
tm##
00555000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704031700073002000700390#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#106#102#article#222#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Szwarcwald CL,    Barbos
a J&uacute;nior A, Souza Jr. PRB, Lemos KR, Frias PG, Luhm KR, et al.    HIV tes
ting during pregnancy: use of secondary data to estimate 2006 test coverage    a
nd prevalence in Brazil. Braz J Infect Dis 2008; 12:167-72.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#107#103#article#222#</font></p>     ^cY#06.h
tm##
00523000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704028500073002000700358#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#108#104#article#222#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Carter KH, Harry    BP, 
Jeune M, Nicholson D. HIV risk perception, risk behavior, and seroprevalence    
among female commercial sex workers in Georgetown, Guyana. Rev Panam Salud P&uac
ute;blica    1997; 1:451-9.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#109#105#article#222#</font></p>     ^cY#06.h
tm##
00492000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025400073002000700327#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#110#106#article#222#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Jamal N, Khushk    IA, N
aeem Z. Knowledge and attitudes regarding AIDS among female commercial    sex wo
rkers at Hyderabad City, Pakistan. J Coll Physicians Surg Pak 2006; 16:91-3.    
^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#111#107#article#222#</font></p>     ^cY#06.h
tm##
00526000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704028800073002000700361#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#112#108#article#222#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Wei SB, Chen    ZD, Zhou
 W, Wu FB, Li SP, Shan JG. A study of commercial sex and HIV/STI-related    risk
 factors among hospitality girls in entertainment establishments in Wuhan,    Ch
ina. Sex Health 2004; 1:141-4.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#113#109#article#222#</font></p>     ^cY#06.h
tm##
00565000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032600074002000700400#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#114#110#article#222#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Singh TN, Kananbala   
 S, Thongam W, Devi KhS, Singh NB. Increasing trend of HIV seropositivity among 
   commercial sex workers attending the Voluntary and Confidential Counseling an
d    Testing Centre in Manipur, India. Int J STD AIDS 2005; 16:166-9.    ^cY#06.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#115#111#article#222#</font></p>     ^cY#06.h
tm##
00551000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031200074002000700386#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#116#112#article#222#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Shakarishvili    A, Du
bovskaya LK, Zohrabyan LS, St. Lawrence JS, Aral SO, Dugasheva LG, et al.    Sex
 work, drug use, HIV infection, and spread of sexually transmitted infections   
 in Moscow, Russian Federation. Lancet 2005; 366:57-60.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#117#113#article#222#</font></p>     ^cY#06.h
tm##
00398000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015900074002000700233#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#118#114#article#222#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Hamers FF,    Downs AM
. HIV in Central and Eastern Europe. Lancet 2003; 361:1035-44.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#119#115#article#222#</font></p>     ^cY#06.h
tm##
00496000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025700074002000700331#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#120#116#article#222#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Wasseheit JN.    Epide
miological synergy: interrelationships between human immunodeficiency virus    i
nfection and other sexually transmitted diseases. Sex Transm Dis 1992; 19:61-77.
    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#121#117#article#222#</font></p>     ^cY#06.h
tm##
00547000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030800074002000700382#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#122#118#article#222#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Bautista CT,    Sanche
z JL, Montano SM, Laguna-Torres A, Suarez L, Sanchez J, et al. Seroprevalence   
 of and risk factors for HIV-1 infection among female commercial sex workers    
in South America. Sex Transm Infect 2006; 82:311-6.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#123#119#article#222#</font></p>     ^cY#06.h
tm##
00493000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025400074002000700328#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#124#120#article#222#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Lau JT, Tsui    HY, Si
ah PC, Zhang KL. A study on female sex workers in southern China (Shenzhen):    
HIV-related knowledge, condom use and STD history. AIDS Care 2002; 14:219-33.   
 ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#125#121#article#222#</font></p>     ^cY#06.h
tm##
00530000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029100074002000700365#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#126#122#article#222#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Miguez-Burbano    MJ, 
Angarita I, Shultz JM, Shor-Posner G, Klaskala W, Duque JL, et al. HIV-related  
  high risk sexual behaviors and practices among women in Bogota, Colombia. Wome
n    &amp; Health 2000; 30:109-19.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#127#123#article#222#</font></p>     ^cY#06.h
tm##
00612000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037300074002000700447#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#128#124#article#222#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Programa Nacional    d
e DST e AIDS, Secretaria de Vigil&acirc;ncia em Sa&uacute;de, Minist&eacute;rio 
   da Sa&uacute;de. Pesquisa de conhecimento atitudes e pr&aacute;ticas na popul
a&ccedil;&atilde;o    brasileira de 15 a 54 anos, 2004. Bras&iacute;lia: Minist&
eacute;rio da Sa&uacute;de;    2006.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#129#125#article#222#</font></p>     ^cY#06.h
tm##
00559000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032000074002000700394#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#130#126#article#222#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Minist&eacute;rio    d
a Sa&uacute;de. Profissionais do sexo: documento referencial para a&ccedil;&otil
de;es    de preven&ccedil;&atilde;o das DST e da AIDS. Bras&iacute;lia: Minist&e
acute;rio    da Sa&uacute;de; 2002. (S&eacute;rie Manuais, 47).    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#131#127#article#222#</font></p>     ^cY#06.h
tm##
00509000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027000074002000700344#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#132#128#article#222#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Silva NG, Peres    CA,
 Morell MGGP, Areco KN. Fatores associados &agrave; infec&ccedil;&atilde;o    pe
lo HIV em trabalhadoras do sexo (TS) em Santos - SP. Sa&uacute;de Coletiva    20
07; 4:168-72.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#133#129#article#222#</font></p>     ^cY#06.h
tm##
00457000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021800074002000700292#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#134#130#article#222#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Semaan S, Lauby    J, 
Liebman J. Street and network sampling in evaluation studies of HIV risk-reducti
on    interventions. AIDS 2002; 4:213-23.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#135#131#article#222#</font></p>     ^cY#06.h
tm##
00471000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023200074002000700306#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#136#132#article#222#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Magnani R,    Sabin K,
 Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden    populati
ons for HIV surveillance. AIDS 2005; 19 Suppl 2:S67-72.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#137#133#article#222#</font></p>     ^cY#06.h
tm##
00461000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022200074002000700296#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#138#134#article#222#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Salganik MJ,    Heckat
horn DD. Sampling and estimation in hidden populations using respondent-driven  
  sampling. Sociol Methodol 2004; 34:193-240.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#139#135#article#222#</font></p>     ^cY#06.h
tm##
00528000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028900074002000700363#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#140#136#article#222#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Family Health    Inter
national. Evaluating programs for HIV/AIDS prevention and care in developing    
countries: a handbook for program managers and decision makers. Arlington: Famil
y    Health International; 2001.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#141#137#article#222#</font></p>     ^cY#06.h
tm##
00507000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026800074002000700342#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#142#138#article#222#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Stueve A, O'Donnell   
 LN, Duran R, Doval AS, Blome J. Time-space sampling in minority communities:   
 results with young Latino men who have sex with men. Am J Public Health 2001;  
  91:922-6.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#143#139#article#222#</font></p>     ^cY#06.h
tm##
00440000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020100074002000700275#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#144#140#article#222#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Heckathorn    DD. Resp
ondent-driven sampling: a new approach to the study of hidden populations.    So
c Probl 1997; 44:174-99.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#145#141#article#222#</font></p>     ^cY#06.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#146#142#article#222#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Jarlais DCD,    Araste
h K, Semaan S, Wood E. HIV among injection drug users: current epidemiology,    
biologic markers, respondent-driven sampling, and supervised-injection facilitie
s.    Curr Opin HIV AIDS 2009; 4:308-13.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#147#143#article#222#</font></p>     ^cY#06.h
tm##
00526000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028700074002000700361#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#148#144#article#222#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Johnston L,    Sabin K
, Hien MT, Huong PT. Assessment of respondent-driven sampling for recruiting    
female sex workers in two Vietnamese cities: reaching the unseen sex worker.    
J Urban Health 2006; 83:16-28.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#149#145#article#222#</font></p>     ^cY#06.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#150#146#article#222#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Liu H, Liu    H, Cai Y
, Rhodes AG, Hong F. Money boys, HIV risks, and the associations between    norm
s and safer sex: a respondent-driven sampling study in Shenzhen, Shina.    AIDS 
Behav 2008; 13:652-62.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#151#147#article#222#</font></p>     ^cY#06.h
tm##
00538000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029900074002000700373#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#152#148#article#222#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Pollini RA,    Alvelai
s J, Gallardo M, Vera A, Lozada R, Magis-Rodriguez C, et al. The harm    inside:
 injection during incarceration among male injection drug users in Tijuana,    M
exico. Drug Alcohol Depend 2009; 103:52-8.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#153#149#article#222#</font></p>     ^cY#06.h
tm##
00532000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029300074002000700367#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#154#150#article#222#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Reisner S,    Mimiaga 
MJ, Case P, Johnson CV, Safren AS, Mayer KH. Predictors of identifying    as a b
arebacker among high-risk New England HIV seronegative men who have sex    with 
men. J Urban Health 2008; 86:250-62.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#155#151#article#222#</font></p>     ^cY#06.h
tm##
00585000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704034600074002000700420#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#156#152#article#222#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Wattana W,    van Grie
nsven F, Rhucharoenpornpanich O, Manopaiboon C, Thienkrua W, Bannatham    R, et 
al. Respondent-driven sampling to assess characteristics and estimate    the num
ber of injection drug users in Bangkok, Thailand. Drug Alcohol Depend    2007; 9
0:228-33.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#157#153#article#222#</font></p>     ^cY#06.h
tm##
00552000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031300074002000700387#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#158#154#article#222#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Simic M, Johnston    L
G, Platt L, Baros S, Andjelkovic V, Novotny T, et al. Exploring Barriers to    "
respondent driven sampling" in sex worker and drug-injecting sex worker populati
ons    in Eastern Europe. J Urban Health 2006; 83:i6-15.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#159#155#article#222#</font></p>     ^cY#06.h
tm##
00564000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032500074002000700399#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#160#156#article#222#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Yeka W, Maibani-Michie
    G, Prybylski D, Colby D. Application of respondent driven sampling to collec
t    baseline data on FSWs and MSM for HIV risk reduction interventions in two u
rban    centres in Papua New Guinea. J Urban Health 2006; 83:i60-72.    ^cY#06.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#161#157#article#222#</font></p>     ^cY#06.h
tm##
00594000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035500074002000700429#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#162#158#article#222#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Johnston LG,    Maleki
nejad M, Kendall C, Iuppa IM, Rutherford GW. Implementation challenges    to usi
ng respondent-driven sampling methodology for HIV biological and behavioral    s
urveillance: field experiences in international settings. AIDS Behav 2008;    12
(4 Suppl):S131-41.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#163#159#article#222#</font></p>     ^cY#06.h
tm##
00576000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033700074002000700411#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#164#160#article#222#35#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Malekinejad    M, John
ston LG, Kendall C, Kerr LRFS, Rifkin MR, Rutherford GW. Using respondent-driven
    sampling methodology for HIV biological and behavioral surveillance in inter
national    settings: a systematic review. AIDS Behav 2008; 12(4 Suppl):S105-30.
    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#165#161#article#222#</font></p>     ^cY#06.h
tm##
00543000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030400074002000700378#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#166#162#article#222#36#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Barbosa J&uacute;nior 
   A, Pascom ARP, Szwarcwald CL, Kendall C, McFarland W. Transfer of sampling me
thods    for studies on most-at-risk populations (MARPs) in Brazil. Cad Sa&uacut
e;de    P&uacute;blica 2011; 27 Suppl 1:S36-44.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#167#163#article#222#</font></p>     ^cY#06.h
tm##
00504000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026500074002000700339#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#168#164#article#222#37#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Heckathorn    DD, Sema
an S, Broadhead RS, Hughes JJ. Extensions of respondent-driven sampling:    a ne
w approach to the study of injection drug users aged 18-25. AIDS Behav 2002;    
6:55-67.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#169#165#article#222#</font></p>     ^cY#06.h
tm##
00478000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023900074002000700313#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#170#166#article#222#38#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Heckathorn    DD. Resp
ondent-driven sampling II: deriving valid population estimates from    chain-ref
erral samples of hidden populations. Soc Probl 2002; 49:11-34.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#171#167#article#222#</font></p>     ^cY#06.h
tm##
00422000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018300074002000700257#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#172#168#article#222#39#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">39. Shamblin JE.    Pesqui
sa operacional: uma abordagem b&aacute;sica. S&atilde;o Paulo: Editora    Atlas;
 1979.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#173#169#article#222#</font></p>     ^cY#06.h
tm##
00420000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018100074002000700255#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#174#170#article#222#40#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">40. Kemeny JG,    Snell JL
. Finite Markov Chains. 6<sup>th</sup> Ed. London: D. van Nostrand Company;    1
960.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#175#171#article#222#</font></p>     ^cY#06.h
tm##
00417000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017800074002000700252#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#176#172#article#222#41#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">41. Watts DJ. Six    degre
es: the science of a connected age. New York: W.W. Norton &amp; Company;    2004
.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#177#173#article#222#</font></p>     ^cY#06.h
tm##
00538000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029900074002000700373#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#178#174#article#222#42#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">42. Szwarcwald    CL, Dama
cena GN. Amostras complexas em inqu&eacute;ritos populacionais: planejamento    
e implica&ccedil;&otilde;es na an&aacute;lise estat&iacute;stica dos dados.    R
ev Bras Epidemiol 2008; 11 Suppl 1:S38-45.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#179#175#article#222#</font></p>     ^cY#06.h
tm##
00462000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022300074002000700297#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#180#176#article#222#43#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">43. Salganik M.    Varianc
e estimation, design effects, and sample size calculations for respondent-driven
    sampling. J Urban Health 2006; 83:i98-112.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#181#177#article#222#</font></p>     ^cY#06.h
tm##
00420000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018100074002000700255#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#182#178#article#222#44#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">44. Goel S, Salganik    MJ
. Respondent-driven sampling as Markov chain Monte Carlo. Stat Med 2009; 28:2202
-29.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#183#179#article#222#</font></p>     ^cY#06.h
tm##
00416000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017700074002000700251#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#184#180#article#222#45#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">45. Goel S, Salganik    MJ
. Assessing respondent-driven sampling. Proc Natl Acad Sci USA 2010; 107:6743-7.
    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#185#181#article#222#</font></p>     ^cY#06.h
tm##
00438000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019900074002000700273#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#186#182#article#222#46#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">46. Volz1 E, Heckathorn   
 DD. Probability based estimation theory for respondent driven sampling. J Off  
  Stat 2008; 24:79-97.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#187#183#article#222#</font></p>     ^cY#06.h
tm##
00485000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024600074002000700320#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#188#184#article#222#47#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">47. Wejnert C.    An empir
ical test of respondent-driven sampling: point estimates, variance,    degree me
asures, and out-of-equilibrium data. Sociol Methodol 2009; 39:73-116.    ^cY#06.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#189#185#article#222#</font></p>     ^cY#06.h
tm##
00423000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018400074002000700258#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#190#186#article#222#48#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">48. Minayo MCS.    O desaf
io do conhecimento. Rio de Janeiro: ABRASCO/S&atilde;o Paulo: Editora    Hucitec
; 1994.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#191#187#article#222#</font></p>     ^cY#06.h
tm##
00491000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025200074002000700326#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#192#188#article#222#49#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">49. Abdul-Quader    AS, He
ckathorn DD, Sabin K, Saidel T. Implementation and analysis of respondent    dri
ven sampling: lessons learned from the field. J Urban Health 2006; 83:i1-5.    ^
cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#193#189#article#222#</font></p>     ^cY#06.h
tm##
00522000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028300074002000700357#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#194#190#article#222#50#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">50. Semaan S, Santibanez  
  S, Garfein RS, Heckathorn DD, Jarlais DCD. Ethical and regulatory consideratio
ns    in HIV prevention studies employing respondent-driven sampling. Int J Drug
 Policy    2009; 20:14-27.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#195#191#article#222#</font></p>     ^cY#06.h
tm##
00483000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024400074002000700318#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#196#192#article#222#51#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">51. Mazzieiro JB.    Sexua
lidade criminalizada: prostitui&ccedil;&atilde;o, lenoc&iacute;nio e outros    d
elitos - S&atilde;o Paulo 1870/1920. Rev Bras Hist 1998; 18:247-85.    ^cY#06.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#197#193#article#222#</font></p>     ^cY#06.h
tm##
00603000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036400074002000700438#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#198#194#article#222#52#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">52. Shahmanesh    M, Wayal
 S, Copas A, Patel V, Mabey D, Cowan F. A study comparing sexually transmitted  
  infections and HIV among ex-red-light district and non-red-light district sex 
   workers after the demolition of Baina red-light district. J Acquir Immune Def
ic    Syndr 2009; 52:253-7.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#199#195#article#222#</font></p>     ^cY#06.h
tm##
00507000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026800074002000700342#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#200#196#article#222#53#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">53. Bobashev GV,    Zule W
A, Osilla KC, Kline TL, Wechsberg WM. Transactional sex among men and    women i
n the South at high risk for HIV and other STIs. J Urban Health 2009;    86 Supp
l 1:S32-47.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#201#197#article#222#</font></p>     ^cY#06.h
tm##
00563000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032400074002000700398#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#202#198#article#222#54#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">54. Clark MA, Rogers    ML
, Armstrong GF, Rakowski W, Bowen DJ, Hughes T, et al. Comprehensive cancer    s
creening among unmarried women aged 40-75 years: results from the cancer screeni
ng    project for women. J Women's Health (Larchmt) 2009; 18:451-9.    ^cY#06.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#203#199#article#222#</font></p>     ^cY#06.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#204#200#article#222#55#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">55. Lauby JL, Millett    G
A, LaPollo AB, Bond L, Murrill CS, Marks G. Sexual risk behaviors of HIV-positiv
e,    HIV-negative, and serostatus-unknown Black men who have sex with men and w
omen.    Arch Sex Behav 2008; 37:708-19.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#205#201#article#222#</font></p>     ^cY#06.h
tm##
00525000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028600074002000700360#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#206#202#article#222#56#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">56. Wheeler DP,    Lauby J
L, Liu KL, Van Sluytman LG, Murrill C. A comparative analysis of sexual    risk 
characteristics of black men who have sex with men or with men and women.    Arc
h Sex Behav 2008; 37:697-707.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#207#203#article#222#</font></p>     ^cY#06.h
tm##
00545000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030600074002000700380#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#208#204#article#222#57#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">57. Deiss RG, Brouwer    K
C, Loza O, Lozada RM, Ramos R, Cruz MA, et al. High-risk sexual and drug using  
  behaviors among male injection drug users who have sex with men in 2 Mexico-US
    border cities. Sex Transm Dis 2008; 35:243-9.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#209#205#article#222#</font></p>     ^cY#06.h
tm##
00596000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035700074002000700431#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#210#206#article#222#58#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">58. Platt L, Wall    M, Rh
odes T, Judd A, Hickman M, Johnston LG, et al. Methods to recruit hard-to-reach 
   groups: comparing two chain referral sampling methods of recruiting injecting
    drug users across nine studies in Russia and Estonia. J Urban Health 2006; 8
3    Suppl 6:S39-53.    ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#211#207#article#222#</font></p>     ^cY#06.h
tm##
00575000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033600074002000700410#v27
s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#p#212#208#article#222#59#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">59. Strathdee SA,    Lozad
a R, Pollini RA, Brouwer KC, Mantsios A, Abramovitz DA, et al. Individual,    so
cial, and environmental influences associated with HIV infection among injection
    drug users in Tijuana, Mexico. J Acquir Immune Defic Syndr 2008; 47:369-76. 
   ^cY#06.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#213#209#article#222#</font></p>     ^cY#06.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#214#210#article#222#<p>&nbsp;</p>     ^cY#06
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#215#211#article#222#<p>&nbsp;</p>     ^cY#06
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#216#212#article#222#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#06.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#217#213#article#222#<br>   </b> G. N. Damace
na    ^cY#06.htm##
00302000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007800071002000700149#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#218#214#article#222#<br>   Laborat&oacute;ri
o de Informa&ccedil;&otilde;es em Sa&uacute;de    ^cY#06.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013800071002000700209#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#219#215#article#222#<br>   Instituto de Comu
nica&ccedil;&atilde;o e Informa&ccedil;&atilde;o Cient&iacute;fica    e Tecnol&o
acute;gica em Sa&uacute;de    ^cY#06.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#220#216#article#222#<br>   Funda&ccedil;&ati
lde;o Oswaldo Cruz    ^cY#06.htm##
00295000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007100071002000700142#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#221#217#article#222#<br>   Av. Brasil 4365, 
Pavilh&atilde;o Haity Moussatch&eacute;    ^cY#06.htm##
00275000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005100071002000700122#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#222#218#article#222#<br>   Rio de Janeiro, R
J 21040-900, Brasil    ^cY#06.htm##
00311000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704008700071002000700158#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#223#219#article#222#<br>   <a href="mailto:g
iselind@fiocruz.br">giselind@fiocruz.br</a></font></p>     ^cY#06.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#224#220#article#222#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 21/Dec/2009    ^cY#06.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#225#221#article#222#<br>   Final version res
ubmitted on 08/Jun/2010    ^cY#06.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\06.htm#S#p#226#222#article#222#<br>   Approved on 10/Au
g/2010</font></p>     ^cY#06.htm##
00479000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100022000700120056000920300
00700148065000900155064000500164031000400169014000700173865000900180002000700189
035001000196801000700206#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#227#
1#article#59#1#^rND^sd'Cruz-Grote^nD#Prevention of HIV infection in developing c
ountries^len#Lancet#19960000#1996#348#1071-4#20110000#06.htm#0099-5355#Lancet##
00728000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100018000890100
02000107010001600127010001600143010001800159012012700177030002400304065000900328
06400050033703100030034201400070034586500090035200200070036103500100036880100240
0378#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#228#2#article#59#2#^rND^
svan Vliet^nC#^rND^sMeester^nEI#^rND^sKorenromp^nEL#^rND^sSinger^nB#^rND^sBakker
^nR#^rND^sHabbema^nJD#Focusing strategies of condom use against HIV in different
 behavioural settings: an evaluation based on a simulation model^len#Bull World 
Health Organ#20010000#2001#79#442-54#20110000#06.htm#0042-9686#Bull World Health
 Organ##
00535000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680160050000700180105001200660
00700225062004300232065000900275064000500284865000900289002000700298#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#229#3#article#59#3#^rND^sJoint United Na
tions Programme on^nHIV/AIDS#Monitoring the declaration of commitment on HIV/AID
S: guidelines on constructions of core indicators^len#Geneva#Joint United Nation
s Programme on HIV/AIDS#20050000#2005#20110000#06.htm##
00495000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170020000700180116000900660
00900206062002000215065000900235064000500244865000900249002000700258#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#230#4#article#59#4#Ministério da Saúde#A
valiação da efetividade das ações de prevenção dirigidas às profissionais do sex
o, em três regiões brasileiras^lpt#Brasília#Ministério da Saúde#20040000#2004#20
110000#06.htm##
00680000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100017000910100
01700108010001700125010001800142010001900160012012800179030001800307710000200325
065000900327064000500336031000200341014000700343865000900350002000700359#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#231#5#article#59#5#^rND^sSzwarcwald^
nCL#^rND^sBastos^nFI#^rND^sGravato^nN#^rND^sLacerda^nR#^rND^sChequer^nPN#^rND^sC
astilho^nEA#The relationship of illicit drug use to HIV infection among commerci
al sex workers in the city of Santos, São Paulo, Brazil^len#Int J Drug Policy#2#
19980000#1998#9#427-36#20110000#06.htm##
00622000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100024000910100
01600115012015300131030001800284710000200302065000900304064000500313031000300318
014000700321865000900328002000700337#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#232#6#article#59#6#^rND^sSzwarcwald^nCL#^rND^sBarbosa Júnior^nA#^rND^sSo
uza^nJr#PRB, Lemos KR, Frias PG, Luhm KR, et al: HIV testing during pregnancy: u
se of secondary data to estimate 2006 test coverage and prevalence in Brazil^len
#Braz J Infect Dis#2#20080000#2008#12#167-72#20110000#06.htm##
00608000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870100
01500103010001900118012011700137030002400254710000200278065000900280064000500289
031000200294014000600296865000900302002000700311#v27s1#V:\SciELO\serial\csp\v27s
1\markup\06.htm#S#c#233#7#article#59#7#^rND^sCarter^nKH#^rND^sHarry^nBP#^rND^sJe
une^nM#^rND^sNicholson^nD#HIV risk perception, risk behavior, and seroprevalence
 among female commercial sex workers in Georgetown, Guyana^len#Rev Panam Salud P
ública#2#19970000#1997#1#451-9#20110000#06.htm##
00569000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100017000850100
01500102012010700117030002700224710000200251065000900253064000500262031000300267
014000500270865000900275002000700284#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#234#8#article#59#8#^rND^sJamal^nN#^rND^sKhushk^nIA#^rND^sNaeem^nZ#Knowle
dge and attitudes regarding AIDS among female commercial sex workers at Hyderaba
d City, Pakistan^len#J Coll Physicians Surg Pak#2#20060000#2006#16#91-3#20110000
#06.htm##
00654000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100014000700100015000840100
01400099010001300113010001300126010001500139012013500154030001100289710000200300
065000900302064000500311031000200316014000600318865000900324002000700333#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#235#9#article#59#9#^rND^sWei^nSB#^rN
D^sChen^nZD#^rND^sZhou^nW#^rND^sWu^nFB#^rND^sLi^nSP#^rND^sShan^nJG#A study of co
mmercial sex and HIV/STI-related risk factors among hospitality girls in enterta
inment establishments in Wuhan, China^len#Sex Health#2#20040000#2004#1#141-4#201
10000#06.htm##
00711000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880100
01700107010001600124010001600140012016100156030001500317065000900332064000500341
031000300346014000700349865000900356002000700365035001000372801001500382#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#236#10#article#59#10#^rND^sSingh^nTN
#^rND^sKananbala^nS#^rND^sThongam^nW#^rND^sDevi^nKhS#^rND^sSingh^nNB#Increasing 
trend of HIV seropositivity among commercial sex workers attending the Voluntary
 and Confidential Counseling and Testing Centre in Manipur, India^len#Int J STD 
AIDS#20050000#2005#16#166-9.#20110000#06.htm#0956-4624#Int J STD AIDS##
00717000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100023000720100021000950100
02000116010002300136010001500159010002000174810000600194012011500200030000700315
06500090032206400050033103100040033601400060034086500090034600200070035503500100
0362801000700372#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#237#11#artic
le#59#11#^rND^sShakarishvili^nA#^rND^sDubovskaya^nLK#^rND^sZohrabyan^nLS#^rND^sS
t. Lawrence^nJS#^rND^sAral^nSO#^rND^sDugasheva^nLG#et al#Sex work, drug use, HIV
 infection, and spread of sexually transmitted infections in Moscow, Russian Fed
eration^len#Lancet#20050000#2005#366#57-60#20110000#06.htm#0099-5355#Lancet##
00487000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890120
03800105030000700143065000900150064000500159031000400164014000800168865000900176
002000700185035001000192801000700202#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#238#12#article#59#12#^rND^sHamers^nFF#^rND^sDowns^nAM#HIV in Central and
 Eastern Europe^len#Lancet#20030000#2003#361#1035-44#20110000#06.htm#0099-5355#L
ancet##
00572000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720120135000920300
01500227065000900242064000500251031000300256014000600259865000900265002000700274
035001000281801001500291#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#239#
13#article#59#13#^rND^sWasseheit^nJN#Epidemiological synergy: interrelationships
 between human immunodeficiency virus infection and other sexually transmitted d
iseases^len#Sex Transm Dis#19920000#1992#19#61-77#20110000#06.htm#0148-5717#Sex 
Transm Dis##
00724000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100018000910100
01800109010002300127010001600150010001700166810000600183012011200189030001800301
06500090031906400050032803100030033301400060033686500090034200200070035103500100
0358801001800368#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#240#14#artic
le#59#14#^rND^sBautista^nCT#^rND^sSanchez^nJL#^rND^sMontano^nSM#^rND^sLaguna-Tor
res^nA#^rND^sSuarez^nL#^rND^sSanchez^nJ#et al#Seroprevalence of and risk factors
 for HIV-1 infection among female commercial sex workers in South America^len#Se
x Transm Infect#20060000#2006#82#311-6#20110000#06.htm#1368-4973#Sex Transm Infe
ct##
00618000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100015000860100
01500101010001600116012011400132030001000246065000900256064000500265031000300270
014000700273865000900280002000700289035001000296801001000306#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#241#15#article#59#15#^rND^sLau^nJT#^rND^sTsui^nH
Y#^rND^sSiah^nPC#^rND^sZhang^nKL#A study on female sex workers in southern China
 (Shenzhen): HIV-related knowledge, condom use and STD history^len#AIDS Care#200
20000#2002#14#219-33#20110000#06.htm#0954-0121#AIDS care##
00665000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100025000720100018000970100
01700115010002100132010001800153010001600171810000600187012008900193030001500282
71000020029706500090029906400050030803100030031301400070031686500090032300200070
0332#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#242#16#article#59#16#^rN
D^sMiguez-Burbano^nMJ#^rND^sAngarita^nI#^rND^sShultz^nJM#^rND^sShor-Posner^nG#^r
ND^sKlaskala^nW#^rND^sDuque^nJL#et al#HIV-related high risk sexual behaviors and
 practices among women in Bogota, Colombia^len#Women & Health#2#20000000#2000#30
#109-19#20110000#06.htm##
00576000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170088000720180089001600650
00900249064000500258066000900263062002000272065000900292064000500301865000900306
002000700315#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#243#17#article#5
9#17#Ministério da Saúde^dPrograma Nacional de DST e AIDS, Secretaria de Vigilân
cia em Saúde#Pesquisa de conhecimento atitudes e práticas na população brasileir
a de 15 a 54 anos^lpt#20040000#2004#Brasília#Ministério da Saúde#20060000#2006#2
0110000#06.htm##
00472000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170020000720180091000920660
00900183062002000192065000900212064000500221865000900226002000700235#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#244#18#article#59#18#Ministério da Saúde
#Profissionais do sexo: documento referencial para ações de prevenção das DST e 
da AIDS^les#Brasília#Ministério da Saúde#20020000#2002#20110000#06.htm##
00573000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01900104010001600123012008800139030001500227710000200242065000900244064000500253
031000200258014000700260865000900267002000700276#v27s1#V:\SciELO\serial\csp\v27s
1\markup\06.htm#S#c#245#19#article#59#19#^rND^sSilva^nNG#^rND^sPeres^nCA#^rND^sM
orell^nMGGP#^rND^sAreco^nKN#Fatores associados à infecção pelo HIV em trabalhado
ras do sexo (TS) em Santos - SP^lpt#Saúde Coletiva#2#20070000#2007#4#168-72#2011
0000#06.htm##
00559000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
01700103012009000120030000500210065000900215064000500224031000200229014000700231
865000900238002000700247035001000254801000500264#v27s1#V:\SciELO\serial\csp\v27s
1\markup\06.htm#S#c#246#20#article#59#20#^rND^sSemaan^nS#^rND^sLauby^nJ#^rND^sLi
ebman^nJ#Street and network sampling in evaluation studies of HIV risk-reduction
 interventions^len#AIDS#20020000#2002#4#213-23#20110000#06.htm#0269-9370#AIDS##
00599000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01600104010002000120012008100140030000500221065000900226064000500235031000300240
032000400243014000700247865000900254002000700263035001000270801000500280#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#247#21#article#59#21#^rND^sMagnani^n
R#^rND^sSabin^nK#^rND^sSaidel^nT#^rND^sHeckathorn^nD#Review of sampling hard-to-
reach and hidden populations for HIV surveillance^len#AIDS#20050000#2005#19#^s2#
S67-72#20110000#06.htm#0269-9370#AIDS##
00556000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100021000910120
08300112030001600195065000900211064000500220031000300225014000800228865000900236
002000700245035001000252801001600262#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#248#22#article#59#22#^rND^sSalganik^nMJ#^rND^sHeckathorn^nDD#Sampling an
d estimation in hidden populations using respondent-driven sampling^len#Sociol M
ethodol#20040000#2004#34#193-240#20110000#06.htm#0081-1750#Sociol Methodol##
00532000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170028000720180134001000660
01000234062002800244065000900272064000500281865000900286002000700295#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#249#23#article#59#23#Family Health Inter
national#Evaluating programs for HIV/AIDS prevention and care in developing coun
tries: a handbook for program managers and decision makers^len#Arlington#Family 
Health International#20010000#2001#20110000#06.htm##
00656000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100020000880100
01500108010001600123010001500139012010100154030001900255065000900274064000500283
031000300288014000600291865000900297002000700306035001000313801001900323#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#250#24#article#59#24#^rND^sStueve^nA
#^rND^sO'Donnell^nLN#^rND^sDuran^nR#^rND^sDoval^nAS#^rND^sBlome^nJ#Time-space sa
mpling in minority communities: results with young Latino men who have sex with 
men^len#Am J Public Health#20010000#2001#91#922-6#20110000#06.htm#0090-0036#Am J
 Public Health##
00511000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720120082000930300
01000175065000900185064000500194031000300199014000700202865000900209002000700218
035001000225801001000235#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#251#
25#article#59#25#^rND^sHeckathorn^nDD#Respondent-driven sampling: a new approach
 to the study of hidden populations^len#Soc Probl#19970000#1997#44#174-99#201100
00#06.htm#0037-7791#Soc Probl##
00628000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910100
01600108010001400124012014000138030001900278710000200297065000900299064000500308
031000200313014000700315865000900322002000700331#v27s1#V:\SciELO\serial\csp\v27s
1\markup\06.htm#S#c#252#26#article#59#26#^rND^sJarlais^nDCD#^rND^sArasteh^nK#^rN
D^sSemaan^nS#^rND^sWood^nE#HIV among injection drug users: current epidemiology,
 biologic markers, respondent-driven sampling, and supervised-injection faciliti
es^len#Curr Opin HIV AIDS#2#20090000#2009#4#308-13#20110000#06.htm##
00653000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100015000900100
01500105010001600120012013600136030001500272065000900287064000500296031000300301
014000600304865000900310002000700319035001000326801001500336#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#253#27#article#59#27#^rND^sJohnston^nL#^rND^sSab
in^nK#^rND^sHien^nMT#^rND^sHuong^nPT#Assessment of respondent-driven sampling fo
r recruiting female sex workers in two Vietnamese cities: reaching the unseen se
x worker^len#J Urban Health#20060000#2006#83#16-28#20110000#06.htm#1099-3460#J U
rban Health##
00628000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100013000720100013000850100
01300098010001700111010001400128012012400142030001800266710000200284065000900286
064000500295031000300300014000700303865000900310002000700319#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#254#28#article#59#28#^rND^sLiu^nH#^rND^sLiu^nH#^
rND^sCai^nY#^rND^sRhodes^nAG#^rND^sHong^nF#Money boys, HIV risks, and the associ
ations between norms and safer sex: a respondent-driven sampling study in Shenzh
en^len#Shina. AIDS Behav#2#20080000#2008#13#652-62#20110000#06.htm##
00717000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900100
01800108010001400126010001600140010002500156810000600181012010300187030002000290
06500090031006400050031903100040032401400050032886500090033300200070034203500100
0349801002000359#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#255#29#artic
le#59#29#^rND^sPollini^nRA#^rND^sAlvelais^nJ#^rND^sGallardo^nM#^rND^sVera^nA#^rN
D^sLozada^nR#^rND^sMagis-Rodriguez^nC#et al#The harm inside: injection during in
carceration among male injection drug users in Tijuana, Mexico^len#Drug Alcohol 
Depend#20090000#2009#103#52-8#20110000#06.htm#0376-8716#Drug Alcohol Depend##
00695000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01400107010001800121010001700139010001600156012011700172030001500289065000900304
06400050031303100030031801400070032186500090032800200070033703500100034480100150
0354#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#256#30#article#59#30#^rN
D^sReisner^nS#^rND^sMimiaga^nMJ#^rND^sCase^nP#^rND^sJohnson^nCV#^rND^sSafren^nAS
#^rND^sMayer^nKH#Predictors of identifying as a barebacker among high-risk New E
ngland HIV seronegative men who have sex with men^len#J Urban Health#20080000#20
08#86#250-62#20110000#06.htm#1099-3460#J Urban Health##
00761000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100023000890100
03000112010002100142010001900163010001900182810000600201012012600207030002000333
06500090035306400050036203100030036701400070037086500090037700200070038603500100
0393801002000403#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#257#31#artic
le#59#31#^rND^sWattana^nW#^rND^svan Griensven^nF#^rND^sRhucharoenpornpanich^nO#^
rND^sManopaiboon^nC#^rND^sThienkrua^nW#^rND^sBannatham^nR#et al#Respondent-drive
n sampling to assess characteristics and estimate the number of injection drug u
sers in Bangkok, Thailand^len#Drug Alcohol Depend#20070000#2007#90#228-33#201100
00#06.htm#0376-8716#Drug Alcohol Depend##
00726000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100019000870100
01500106010001500121010002100136010001700157810000600174012012900180030001500309
06500090032406400050033303100030033801400060034186500090034700200070035603500100
0363801001500373#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#258#32#artic
le#59#32#^rND^sSimic^nM#^rND^sJohnston^nLG#^rND^sPlatt^nL#^rND^sBaros^nS#^rND^sA
ndjelkovic^nV#^rND^sNovotny^nT#et al#Exploring Barriers to "respondent driven sa
mpling" in sex worker and drug-injecting sex worker populations in Eastern Europ
e^len#J Urban Health#20060000#2006#83#i6-15#20110000#06.htm#1099-3460#J Urban He
alth##
00691000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100024000860100
01900110010001500129012016500144030001500309065000900324064000500333031000300338
014000700341865000900348002000700357035001000364801001500374#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#259#33#article#59#33#^rND^sYeka^nW#^rND^sMaibani
-Michie^nG#^rND^sPrybylski^nD#^rND^sColby^nD#Application of respondent driven sa
mpling to collect baseline data on FSWs and MSM for HIV risk reduction intervent
ions in two urban centres in Papua New Guinea^len#J Urban Health#20060000#2006#8
3#i60-72#20110000#06.htm#1099-3460#J Urban Health##
00739000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100021000910100
01700112010001600129010002100145012017000166030001100336065000900347064000500356
03100030036103200040036401400080036886500090037600200070038503500100039280100110
0402#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#260#34#article#59#34#^rN
D^sJohnston^nLG#^rND^sMalekinejad^nM#^rND^sKendall^nC#^rND^sIuppa^nIM#^rND^sRuth
erford^nGW#Implementation challenges to using respondent-driven sampling methodo
logy for HIV biological and behavioral surveillance: field experiences in intern
ational settings^len#AIDS Behav#20080000#2008#12#^s4#S131-41#20110000#06.htm#109
0-7165#AIDS Behav##
00742000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930100
01700112010001700129010001700146010002100163012014300184030001100327065000900338
06400050034703100030035203200040035501400080035986500090036700200070037603500100
0383801001100393#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#261#35#artic
le#59#35#^rND^sMalekinejad^nM#^rND^sJohnston^nLG#^rND^sKendall^nC#^rND^sKerr^nLR
FS#^rND^sRifkin^nMR#^rND^sRutherford^nGW#Using respondent-driven sampling method
ology for HIV biological and behavioral surveillance in international settings: 
a systematic review^len#AIDS Behav#20080000#2008#12#^s4#S105-30#20110000#06.htm#
1090-7165#AIDS Behav##
00640000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100018000960100
02100114010001700135010001900152012009100171030001800262710000200280065000900282
064000500291031000300296032000400299014000700303865000900310002000700319#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#262#36#article#59#36#^rND^sBarbosa J
únior^nA#^rND^sPascom^nARP#^rND^sSzwarcwald^nCL#^rND^sKendall^nC#^rND^sMcFarland
^nW#Transfer of sampling methods for studies on most-at-risk populations (MARPs)
 in Brazil^len#Cad Saúde Pública#2#20110000#2011#27#^s1#S36-44#20110000#06.htm##
00627000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100016000930100
02000109010001700129012010900146030001100255065000900266064000500275031000200280
014000600282865000900288002000700297035001000304801001100314#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#263#37#article#59#37#^rND^sHeckathorn^nDD#^rND^s
Semaan^nS#^rND^sBroadhead^nRS#^rND^sHughes^nJJ#Extensions of respondent-driven s
ampling: a new approach to the study of injection drug users aged 18-25^len#AIDS
 Behav#20020000#2002#6#55-67#20110000#06.htm#1090-7165#AIDS Behav##
00549000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720120121000930300
01000214065000900224064000500233031000300238014000600241865000900247002000700256
035001000263801001000273#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#264#
38#article#59#38#^rND^sHeckathorn^nDD#Respondent-driven sampling II: deriving va
lid population estimates from chain-referral samples of hidden populations^len#S
oc Probl#20020000#2002#49#11-34#20110000#06.htm#0037-7791#Soc Probl##
00422000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720180047000910660
01000138062001400148065000900162064000500171865000900176002000700185#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#265#39#article#59#39#^rND^sShamblin^nJE#
Pesquisa operacional: uma abordagem básica^les#São Paulo#Editora Atlas#19790000#
1979#20110000#06.htm##
00447000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160017000720160016000890180
02500105063000200130066000700132062002400139065000900163064000500172865000900177
002000700186#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#266#40#article#5
9#40#^rND^sKemeny^nJG#^rND^sSnell^nJL#Finite Markov Chains^len#6#London#D. van N
ostrand Company#19600000#1960#20110000#06.htm##
00427000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160016000720180048000880660
00900136062002200145065000900167064000500176865000900181002000700190#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#267#41#article#59#41#^rND^sWatts^nDJ#Six
 degrees: the science of a connected age^len#New York#W.W. Norton & Company#2004
0000#2004#20110000#06.htm##
00567000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100019000930120
11200112030001900224710000200243065000900245064000500254031000300259032000400262
014000700266865000900273002000700282#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#268#42#article#59#42#^rND^sSzwarcwald^nCL#^rND^sDamacena^nGN#Amostras co
mplexas em inquéritos populacionais: planejamento e implicações na análise estat
ística dos dados^lpt#Rev Bras Epidemiol#2#20080000#2008#11#^s1#S38-45#20110000#0
6.htm##
00538000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720120101000900300
01500191065000900206064000500215031000300220014000800223865000900231002000700240
035001000247801001500257#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#269#
43#article#59#43#^rND^sSalganik^nM#Variance estimation, design effects, and samp
le size calculations for respondent-driven sampling^len#J Urban Health#20060000#
2006#83#i98-112#20110000#06.htm#1099-3460#J Urban Health##
00511000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100019000860120
05900105030000900164065000900173064000500182031000300187014000800190865000900198
002000700207035001000214801000900224#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#270#44#article#59#44#^rND^sGoel^nS#^rND^sSalganik^nMJ#Respondent-driven 
sampling as Markov chain Monte Carlo^len#Stat Med#20090000#2009#28#2202-29#20110
000#06.htm#0277-6715#Stat Med##
00521000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100019000860120
04100105030002300146065000900169064000500178031000400183014000700187865000900194
002000700203035001000210801002300220#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.
htm#S#c#271#45#article#59#45#^rND^sGoel^nS#^rND^sSalganik^nMJ#Assessing responde
nt-driven sampling^len#Proc Natl Acad Sci USA#20100000#2010#107#6743-7#20110000#
06.htm#0027-8424#Proc Natl Acad Sci USA##
00497000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100021000870120
07100108030001100179710000200190065000900192064000500201031000300206014000600209
865000900215002000700224#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#272#
46#article#59#46#^rND^sVolz1^nE#^rND^sHeckathorn^nDD#Probability based estimatio
n theory for respondent driven sampling^len#J Off Stat#2#20080000#2008#24#79-97#
20110000#06.htm##
00562000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720120125000890300
01600214065000900230064000500239031000300244014000700247865000900254002000700263
035001000270801001600280#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#273#
47#article#59#47#^rND^sWejnert^nC#An empirical test of respondent-driven samplin
g: point estimates, variance, degree measures, and out-of-equilibrium data^len#S
ociol Methodol#20090000#2009#39#73-116#20110000#06.htm#0081-1750#Sociol Methodol
##
00430000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160018000720180030000900660
01500120062003500135065000900170064000500179865000900184002000700193#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\06.htm#S#c#274#48#article#59#48#^rND^sMinayo^nMCS#O
 desafio do conhecimento^lpt#Rio de Janeiro#ABRASCO/São Paulo: Editora Hucitec#1
9940000#1994#20110000#06.htm##
00621000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100023000720100021000950100
01500116010001600131012009400147030001500241065000900256064000500265031000300270
014000500273865000900278002000700287035001000294801001500304#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#275#49#article#59#49#^rND^sAbdul-Quader^nAS#^rND
^sHeckathorn^nDD#^rND^sSabin^nK#^rND^sSaidel^nT#Implementation and analysis of r
espondent driven sampling: lessons learned from the field^len#J Urban Health#200
60000#2006#83#i1-5#20110000#06.htm#1099-3460#J Urban Health##
00632000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100020000880100
01800108010002100126010001900147012010500166030001800271710000200289065000900291
064000500300031000300305014000600308865000900314002000700323#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\06.htm#S#c#276#50#article#59#50#^rND^sSemaan^nS#^rND^sSanti
banez^nS#^rND^sGarfein^nRS#^rND^sHeckathorn^nDD#^rND^sJarlais^nDCD#Ethical and r
egulatory considerations in HIV prevention studies employing respondent-driven s
ampling^len#Int J Drug Policy#2#20090000#2009#20#14-27#20110000#06.htm##
00496000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720120094000920300
01400186710000200200065000900202064000500211031000300216014000700219865000900226
002000700235#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#277#51#article#5
9#51#^rND^sMazzieiro^nJB#Sexualidade criminalizada: prostituição, lenocínio e ou
tros delitos - São Paulo 1870/1920^lpt#Rev Bras Hist#2#19980000#1998#18#247-85#2
0110000#06.htm##
00776000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100015000920100
01500107010001500122010001500137010001500152012017800167030002800345065000900373
06400050038203100030038701400060039086500090039600200070040503500100041280100280
0422#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#278#52#article#59#52#^rN
D^sShahmanesh^nM#^rND^sWayal^nS#^rND^sCopas^nA#^rND^sPatel^nV#^rND^sMabey^nD#^rN
D^sCowan^nF#A study comparing sexually transmitted infections and HIV among ex-r
ed-light district and non-red-light district sex workers after the demolition of
 Baina red-light district^len#J Acquir Immune Defic Syndr#20090000#2009#52#253-7
#20110000#06.htm#0894-9255#J Acquir Immune Defic Syndr##
00660000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100015000910100
01700106010001600123010002000139012009100159030001500250065000900265064000500274
03100030027903200040028201400070028686500090029300200070030203500100030980100150
0319#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#279#53#article#59#53#^rN
D^sBobashev^nGV#^rND^sZule^nWA#^rND^sOsilla^nKC#^rND^sKline^nTL#^rND^sWechsberg^
nWM#Transactional sex among men and women in the South at high risk for HIV and 
other STIs^len#J Urban Health#20090000#2009#86#^s1#S32-47#20110000#06.htm#1099-3
460#J Urban Health##
00692000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100017000880100
02000105010001800125010001600143010001600159810000600175012012700181030001700308
71000020032506500090032706400050033603100030034101400060034486500090035000200070
0359#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#280#54#article#59#54#^rN
D^sClark^nMA#^rND^sRogers^nML#^rND^sArmstrong^nGF#^rND^sRakowski^nW#^rND^sBowen^
nDJ#^rND^sHughes^nT#et al#Comprehensive cancer screening among unmarried women a
ged 40-75 years: results from the cancer screening project for women^len#J Women
's Health#2#20090000#2009#18#451-9#20110000#06.htm##
00699000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01800106010001400124010001800138010001500156012012200171030001500293065000900308
06400050031703100030032201400070032586500090033200200070034103500100034880100150
0358#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#281#55#article#59#55#^rN
D^sLauby^nJL#^rND^sMillett^nGA#^rND^sLaPollo^nAB#^rND^sBond^nL#^rND^sMurrill^nCS
#^rND^sMarks^nG#Sexual risk behaviors of HIV-positive, HIV-negative, and serosta
tus-unknown Black men who have sex with men and women^len#Arch Sex Behav#2008000
0#2008#37#708-19#20110000#06.htm#0004-0002#Arch Sex Behav##
00670000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100016000900100
01400106010002300120010001700143012011500160030001500275065000900290064000500299
031000300304014000800307865000900315002000700324035001000331801001500341#v27s1#V
:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#282#56#article#59#56#^rND^sWheeler^n
DP#^rND^sLauby^nJL#^rND^sLiu^nKL#^rND^sVan Sluytman^nLG#^rND^sMurrill^nC#A compa
rative analysis of sexual risk characteristics of black men who have sex with me
n or with men and women^len#Arch Sex Behav#20080000#2008#37#697-707#20110000#06.
htm#0004-0002#Arch Sex Behav##
00719000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01400106010001700120010001500137010001500152810000600167012012900173030001500302
06500090031706400050032603100030033101400060033486500090034000200070034903500100
0356801001500366#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#283#57#artic
le#59#57#^rND^sDeiss^nRG#^rND^sBrouwer^nKC#^rND^sLoza^nO#^rND^sLozada^nRM#^rND^s
Ramos^nR#^rND^sCruz^nMA#et al#High-risk sexual and drug using behaviors among ma
le injection drug users who have sex with men in 2 Mexico-US border cities^len#S
ex Transm Dis#20080000#2008#35#243-9#20110000#06.htm#0148-5717#Sex Transm Dis##
00775000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100014000870100
01600101010001400117010001700131010001900148810000600167012016800173030001500341
06500090035606400050036503100030037003200040037301400070037786500090038400200070
0393035001000400801001500410#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#
284#58#article#59#58#^rND^sPlatt^nL#^rND^sWall^nM#^rND^sRhodes^nT#^rND^sJudd^nA#
^rND^sHickman^nM#^rND^sJohnston^nLG#et al#Methods to recruit hard-to-reach group
s: comparing two chain referral sampling methods of recruiting injecting drug us
ers across nine studies in Russia and Estonia^len#J Urban Health#20060000#2006#8
3#^s6#S39-53#20110000#06.htm#1099-3460#J Urban Health##
00762000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100016000920100
01800108010001800126010001800144010002100162810000600183012012900189030002800318
06500090034606400050035503100030036001400070036386500090037000200070037903500100
0386801002800396#v27s1#V:\SciELO\serial\csp\v27s1\markup\06.htm#S#c#285#59#artic
le#59#59#^rND^sStrathdee^nSA#^rND^sLozada^nR#^rND^sPollini^nRA#^rND^sBrouwer^nKC
#^rND^sMantsios^nA#^rND^sAbramovitz^nDA#et al#Individual, social, and environmen
tal influences associated with HIV infection among injection drug users in Tijua
na, Mexico^len#J Acquir Immune Defic Syndr#20080000#2008#47#369-76#20110000#06.h
tm#0894-9255#J Acquir Immune Defic Syndr##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#o#1#1#article#1#201104
11#073707#07.htm#228##
03746000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400110013303500100014401200940015401201090
02480100049003570100038004060100039004440700124004830700073006070831006006800850
01001686085004901696085001601745085002801761085001901789083109401808085001002902
08500540291208500160296608500270298208500180300911700080302707200030303511200090
3038111001203047116000903059115001203068114000903080113001203089002000703101#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#
TAB#07#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs56^ls66#0102-311X#Self-rate
d health by HIV-infected individuals undergoing antiretroviral therapy in Brazil
^len#Autoavaliação do estado de saúde por indivíduos infectados pelo HIV em tera
pia antirretroviral no Brasil^lpt#^rND^1A01^nPaulo Roberto Borges de^sSouza Juni
or#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nEuclides Ayres de^sCastilho#
Fundação Oswaldo Cruz^iA01^1Instituto de Comunicação e Informação Científica e T
ecnológica em Saúde^cRio de Janeiro^pBrasil#Universidade de São Paulo^iA02^1Facu
ldade de Medicina^cSão Paulo^pBrasil#^len^aIn 2008, a survey was applied to a pr
obabilistically selected sample of 1,245 HIV-infected patients on antiretroviral
 therapy in Brazil. In this work, the analysis was focused on self-rated health.
 The analysis was conducted according to sex, age, socioeconomic variables, and 
clinical and treatment-related patient characteristics. Through stepwise logisti
c regression procedures, the main predictors of good perception of health status
 were established. Results showed that 65% self-rated health state as good or ex
cellent, 81% do have no or slight difficulty in following treatment, but 34% men
 and 47% women reported intense or extreme degree of anxiety/worry feelings. Edu
cational level, work situation, presence of side effects and AIDS-related sympto
ms were the main predictors of good self-perception of health. Problems related 
to animus status, involving worry and anxiety about the future are still barrier
s that must be overcome to improve quality of life of people living with HIV/AID
S.#^ddecs^i1#^tm^len^kHighly Active Antiretroviral Therapy^i1#^tm^len^kHIV^i1#^t
m^len^kSelf-Assessment^i1#^tm^len^kAffect^i1#^lpt^aEm 2008, um inquérito foi con
duzido em uma amostra selecionada probabilisticamente de 1.245 pessoas infectada
s pelo HIV em terapia antirretroviral no Brasil. No presente trabalho, foram inv
estigadas associações da autoavaliação da saúde com sexo, faixa etária, nível so
cioeconômico e características do paciente. Para as análises multivariadas foram
 utilizados modelos de regressão logística, tendo como variável resposta a autoa
valiação boa ou excelente. Os resultados mostram que 65% autoavaliaram sua saúde
 como excelente ou boa, 81% relataram nenhuma ou pouca dificuldade em seguir o t
ratamento, porém, 34% dos homens e 47% das mulheres relataram grau intenso ou mu
ito intenso de sentimento de preocupação ou ansiedade. Nível de escolaridade, si
tuação de trabalho, ausência de efeitos colaterais e ausência de sintomas foram 
os principais fatores associados à boa percepção à saúde. Problemas no estado de
 ânimo, envolvendo preocupação e ansiedade com o futuro, não foram ainda superad
os e são barreiras a serem enfrentadas para a melhoria da qualidade de vida dos 
pacientes de AIDS.#^ddecs^i2#^tm^lpt^kTerapia Anti-Retroviral de Alta Atividade^
i2#^tm^lpt^kHIV^i2#^tm^lpt^kAuto-Avaliação^i2#^tm^lpt^kAfeto^i2#vancouv#38#20091
101#01/Nov/2009#20100319#19/Mar/2010#20100405#05/Apr/2010#07.htm##
03760000000000637000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400110013303500100014401201010015401201160
02550100049003710100038004200100039004580700124004970700073006210831006006940850
01001700085004901710085001601759085002801775085001901803083109401822085001002916
08500540292608500160298008500270299608500180302311700080304107200030304911200090
3052111001203061116000903073115001203082114000903094113001203103002000703115#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#
TAB#07#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs56^ls66#0102-311X#<b>Self-r
ated health by HIV-infected individuals undergoing antiretroviral therapy in Bra
zil</b>^len#<b>Autoavaliação do estado de saúde por indivíduos infectados pelo H
IV em terapia antirretroviral no Brasil</b>^lpt#^rND^1A01^nPaulo Roberto Borges 
de^sSouza Junior#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A02^nEuclides Ayres
 de^sCastilho#Fundação Oswaldo Cruz^iA01^1Instituto de Comunicação e Informação 
Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#Universidade de São Pa
ulo^iA02^1Faculdade de Medicina^cSão Paulo^pBrasil#^len^aIn 2008, a survey was a
pplied to a probabilistically selected sample of 1,245 HIV-infected patients on 
antiretroviral therapy in Brazil. In this work, the analysis was focused on self
-rated health. The analysis was conducted according to sex, age, socioeconomic v
ariables, and clinical and treatment-related patient characteristics. Through st
epwise logistic regression procedures, the main predictors of good perception of
 health status were established. Results showed that 65% self-rated health state
 as good or excellent, 81% do have no or slight difficulty in following treatmen
t, but 34% men and 47% women reported intense or extreme degree of anxiety/worry
 feelings. Educational level, work situation, presence of side effects and AIDS-
related symptoms were the main predictors of good self-perception of health. Pro
blems related to animus status, involving worry and anxiety about the future are
 still barriers that must be overcome to improve quality of life of people livin
g with HIV/AIDS.#^ddecs^i1#^tm^len^kHighly Active Antiretroviral Therapy^i1#^tm^
len^kHIV^i1#^tm^len^kSelf-Assessment^i1#^tm^len^kAffect^i1#^lpt^aEm 2008, um inq
uérito foi conduzido em uma amostra selecionada probabilisticamente de 1.245 pes
soas infectadas pelo HIV em terapia antirretroviral no Brasil. No presente traba
lho, foram investigadas associações da autoavaliação da saúde com sexo, faixa et
ária, nível socioeconômico e características do paciente. Para as análises multi
variadas foram utilizados modelos de regressão logística, tendo como variável re
sposta a autoavaliação boa ou excelente. Os resultados mostram que 65% autoavali
aram sua saúde como excelente ou boa, 81% relataram nenhuma ou pouca dificuldade
 em seguir o tratamento, porém, 34% dos homens e 47% das mulheres relataram grau
 intenso ou muito intenso de sentimento de preocupação ou ansiedade. Nível de es
colaridade, situação de trabalho, ausência de efeitos colaterais e ausência de s
intomas foram os principais fatores associados à boa percepção à saúde. Problema
s no estado de ânimo, envolvendo preocupação e ansiedade com o futuro, não foram
 ainda superados e são barreiras a serem enfrentadas para a melhoria da qualidad
e de vida dos pacientes de AIDS.#^ddecs^i2#^tm^lpt^kTerapia Anti-Retroviral de A
lta Atividade^i2#^tm^lpt^kHIV^i2#^tm^lpt^kAuto-Avaliação^i2#^tm^lpt^kAfeto^i2#va
ncouv#38#20091101#01/Nov/2009#20100319#19/Mar/2010#20100405#05/Apr/2010#07.htm##
03934000000000661000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000190010703100030012613100020012906500090013101400110014003500100015101200940
01610120109002550100049003640100038004130100039004510700126004900700075006160831
03400691085001001725085004901735085001601784085002801800085001901828083113001847
08500100297708500540298708500160304108500270305708500180308411700080310207200030
31101120009031131110012031221160009031341150012031431140009031551130012031640020
00703176008008903183#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#l#4#1#arti
cle#1#^a2011#oa#en#br1.1#1#4.0#tab#07#CSP330#nd#Cad. saúde pública#27#1#20110000
#^fs56^ls66#0102-311X#Self-rated health by HIV-infected individuals undergoing a
ntiretroviral therapy in Brazil^len#Autoavaliação do estado de saúde por indivíd
uos infectados pelo HIV em terapia antirretroviral no Brasil^lpt#^rND^1A01^nPaul
o Roberto Borges de^sSouza Junior#^rND^1A01^nCélia Landmann^sSzwarcwald#^rND^1A0
2^nEuclides Ayres de^sCastilho#^iA01^1Fundação Oswaldo Cruz^2Instituto de Comuni
cação e Informação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#^iA
02^1Universidade de São Paulo^2Faculdade de Medicina^cSão Paulo^pBrasil#^len^aIn
 2008, a survey was applied to a probabilistically selected sample of 1,245 HIV-
infected patients on antiretroviral therapy in Brazil. In this work, the analysi
s was focused on self-rated health. The analysis was conducted according to sex,
 age, socioeconomic variables, and clinical and treatment-related patient charac
teristics. Through stepwise logistic regression procedures, the main predictors 
of good perception of health status were established. Results showed that 65 per
cent self-rated health state as good or excellent, 81 percent do have no or slig
ht difficulty in following treatment, but 34 percent men and 47 percent women re
ported intense or extreme degree of anxiety/worry feelings. Educational level, w
ork situation, presence of side effects and AIDS-related symptoms were the main 
predictors of good self-perception of health. Problems related to animus status,
 involving worry and anxiety about the future are still barriers that must be ov
ercome to improve quality of life of people living with HIV/AIDS.#^ddecs^i1#^tm^
len^kHighly Active Antiretroviral Therapy^i1#^tm^len^kHIV^i1#^tm^len^kSelf-Asses
sment^i1#^tm^len^kAffect^i1#^lpt^aEm 2008, um inquérito foi conduzido em uma amo
stra selecionada probabilisticamente de 1.245 pessoas infectadas pelo HIV em ter
apia antirretroviral no Brasil. No presente trabalho, foram investigadas associa
ções da autoavaliação da saúde com sexo, faixa etária, nível socioeconômico e ca
racterísticas do paciente. Para as análises multivariadas foram utilizados model
os de regressão logística, tendo como variável resposta a autoavaliação boa ou e
xcelente. Os resultados mostram que 65 por cento autoavaliaram sua saúde como ex
celente ou boa, 81 por cento relataram nenhuma ou pouca dificuldade em seguir o 
tratamento, porém, 34 por cento dos homens e 47 por cento das mulheres relataram
 grau intenso ou muito intenso de sentimento de preocupação ou ansiedade. Nível 
de escolaridade, situação de trabalho, ausência de efeitos colaterais e ausência
 de sintomas foram os principais fatores associados à boa percepção à saúde. Pro
blemas no estado de ânimo, envolvendo preocupação e ansiedade com o futuro, não 
foram ainda superados e são barreiras a serem enfrentadas para a melhoria da qua
lidade de vida dos pacientes de AIDS.#^ddecs^i2#^tm^lpt^kTerapia Anti-Retroviral
 de Alta Atividade^i2#^tm^lpt^kHIV^i2#^tm^lpt^kAuto-Avaliação^i2#^tm^lpt^kAfeto^
i2#vancouv#38#20091101#01/Nov/2009#20100319#19/Mar/2010#20100405#05/Apr/2010#07.
htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2
011001300007##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#5#1#article#186#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#07.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#6#2#article#186#<p>&nbsp;</p>     ^cY#07.htm
##
00420000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704020000067002000700267#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#7#3#article#186#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Self-rated    health by 
HIV-infected individuals undergoing antiretroviral therapy in Brazil</b></font><
/p>     ^cY#07.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#8#4#article#186#<p>&nbsp;</p>     ^cY#07.htm
##
00448000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704022800067002000700295#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#9#5#article#186#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Autoavalia&ccedil;&atilde;o    do estado d
e sa&uacute;de por indiv&iacute;duos infectados pelo HIV em terapia    antirretr
oviral no Brasil</b></font></p>     ^cY#07.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#10#6#article#186#<p>&nbsp;</p>     ^cY#07.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#11#7#article#186#<p>&nbsp;</p>     ^cY#07.ht
m##
00452000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704023100068002000700299#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#12#8#article#186#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Paulo Roberto    Borges de Souza Junior<s
up>I</sup>; C&eacute;lia Landmann Szwarcwald<sup>I</sup>;    Euclides Ayres de C
astilho<sup>II</sup></b></font></p>     ^cY#07.htm##
00494000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704027300068002000700341#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#13#9#article#186#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Instituto    de Comunica&ccedil;
&atilde;o e Informa&ccedil;&atilde;o Cient&iacute;fica e    Tecnol&oacute;gica e
m Sa&uacute;de, Funda&ccedil;&atilde;o Oswaldo Cruz, Rio    de Janeiro, Brasil  
  ^cY#07.htm##
00346000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012400069002000700193#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#14#10#article#186#<br>   <sup>II</sup>Faculd
ade de Medicina, Universidade de S&atilde;o Paulo, S&atilde;o    Paulo, Brasil</
font></p>     ^cY#07.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#15#11#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#16#12#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#17#13#article#186#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#07.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#18#14#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#07.htm##
01343000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704112100069002000701190#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#19#15#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In 2008, a survey    was applied to a proba
bilistically selected sample of 1,245 HIV-infected patients    on antiretroviral
 therapy in Brazil. In this work, the analysis was focused    on self-rated heal
th. The analysis was conducted according to sex, age, socioeconomic    variables
, and clinical and treatment-related patient characteristics. Through    stepwis
e logistic regression procedures, the main predictors of good perception    of h
ealth status were established. Results showed that 65% self-rated health    stat
e as good or excellent, 81% do have no or slight difficulty in following    trea
tment, but 34% men and 47% women reported intense or extreme degree of anxiety/w
orry    feelings. Educational level, work situation, presence of side effects an
d AIDS-related    symptoms were the main predictors of good self-perception of h
ealth. Problems    related to animus status, involving worry and anxiety about t
he future are still    barriers that must be overcome to improve quality of life
 of people living with    HIV/AIDS.</font></p>     ^cY#07.htm##
00396000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017400069002000700243#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#20#16#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Highly Active Antiretroviral    Therapy; HI
V; Self-Assessment; Affect</font></p> <hr size="1" noshade>     ^cY#07.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#21#17#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#07.htm##
01681000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704145900069002000701528#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#22#18#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Em 2008, um inqu&eacute;rito    foi conduzi
do em uma amostra selecionada probabilisticamente de 1.245 pessoas    infectadas
 pelo HIV em terapia antirretroviral no Brasil. No presente trabalho,    foram i
nvestigadas associa&ccedil;&otilde;es da autoavalia&ccedil;&atilde;o    da sa&ua
cute;de com sexo, faixa et&aacute;ria, n&iacute;vel socioecon&ocirc;mico    e ca
racter&iacute;sticas do paciente. Para as an&aacute;lises multivariadas    foram
 utilizados modelos de regress&atilde;o log&iacute;stica, tendo como vari&aacute
;vel    resposta a autoavalia&ccedil;&atilde;o boa ou excelente. Os resultados m
ostram    que 65% autoavaliaram sua sa&uacute;de como excelente ou boa, 81% rela
taram    nenhuma ou pouca dificuldade em seguir o tratamento, por&eacute;m, 34% 
dos homens    e 47% das mulheres relataram grau intenso ou muito intenso de sent
imento de    preocupa&ccedil;&atilde;o ou ansiedade. N&iacute;vel de escolaridad
e, situa&ccedil;&atilde;o    de trabalho, aus&ecirc;ncia de efeitos colaterais e
 aus&ecirc;ncia de sintomas    foram os principais fatores associados &agrave; b
oa percep&ccedil;&atilde;o    &agrave; sa&uacute;de. Problemas no estado de &aci
rc;nimo, envolvendo preocupa&ccedil;&atilde;o    e ansiedade com o futuro, n&ati
lde;o foram ainda superados e s&atilde;o barreiras    a serem enfrentadas para a
 melhoria da qualidade de vida dos pacientes de AIDS.</font></p>     ^cY#07.htm#
#
00413000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019100069002000700260#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#23#19#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Terapia Anti-Retroviral    de Alta Atividad
e; HIV; Auto-Avalia&ccedil;&atilde;o; Afeto</font></p> <hr size="1" noshade>    
 ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#24#20#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#25#21#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#26#22#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#07.h
tm##
00794000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057200069002000700641#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#27#23#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The self-rated    health is a measure that 
has been widely employed in epidemiological surveys    to describe the health st
atus of a population <sup>1</sup>. It is considered    a useful and easily measu
red indicator, which has been used to establish differences    in morbidity in p
opulation subgroups, compare needs for health services and    resources by geogr
aphic area and to calculate other indicators of morbidity    and mortality such 
as the healthy life expectancy <sup>2,3</sup>.</font></p>     ^cY#07.htm##
00656000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043400069002000700503#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#28#24#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Personal perception    of health status has
 been considered an important indicator by itself, since    an individual's well
-being can affect motivation and quality of life. On the    other hand, self-eva
luations are also useful due to their validity, established    in relation to cl
inical status and morbidity and mortality indicators <sup>4,5</sup>.</font></p> 
    ^cY#07.htm##
00742000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052000069002000700589#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#29#25#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Studies have shown    that the individual p
erception of health frequently agrees with medical evaluation    <sup>6</sup>. I
n terms of mortality, since 1982, when researchers first proved    the associati
on between poor self-assessment of health status and increased    risk of death 
among the elderly <sup>7</sup>, several studies have shown that    poor self-rat
ed health is an important indicator of reduced survival <sup>8,9,10</sup>.</font
></p>     ^cY#07.htm##
00775000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055300069002000700622#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#30#26#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">While an objective    health evaluation fro
m a medical point of view seeks to identify disease, as    indicated by a set of
 signs, symptoms and laboratory tests, self-evaluations    are subjective, combi
ning aspects of physical and emotional well-being and satisfaction    with life.
 Self-perception of health status refers not just to feelings of pain    and dis
comfort, but also to the psychological and social consequences of having    a he
alth problem <sup>11</sup>.</font></p>     ^cY#07.htm##
00635000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704041300069002000700482#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#31#27#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The quality of    life of people living wit
h HIV/AIDS has improved considerably with the advent    of antiretroviral therap
y (ART), especially highly active antiretroviral therapy    (HAART), a treatment
 which is expected to reduce viral load to less than 50    copies/mL of blood in
 patients virgin to treatment <sup>12,13</sup>.</font></p>     ^cY#07.htm##
01075000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085300069002000700922#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#32#28#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The universal access    to ART in Brazil si
nce 1996 has resulted in an increase of survival and a significant    reduction 
in hospitalizations <sup>14,15</sup>. Chequer et al. <sup>16</sup>    estimated 
a median survival of 5.1 months for adult patients from 1982 to 1989,    while M
arins et al. <sup>15</sup> estimated a median survival of 18 months for    adult
 patients diagnosed in 1995, and 58 months for patients diagnosed in 1996,    wi
th ART being significantly associated with the survival increase. In a study    
carried out among patients diagnosed between 1998 and 1999 in the South and    S
outheast regions in Brazil, the median survival rate could not be estimated    i
n 9 years of observation as 59% of patients have survived for 108 months <sup>17
</sup>.</font></p>     ^cY#07.htm##
00789000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056700069002000700636#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#33#29#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">According to data    provided by the Depart
ment of STD, AIDS and Viral Hepatitis Monitoring System    (<a href="http://sist
emas.aids.gov.br/monitoraids" target="_blank">http://sistemas.aids.gov.br/monito
raids</a>),    the rate of hospitalizations per AIDS patients under ART reduced 
from 0.63 in    1998 to 0.13 in 2008. However, little is known about the quality
 of life of    AIDS patients under ART, nor about changes in living and working 
conditions    resulting from the disease.</font></p>     ^cY#07.htm##
01194000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704097200069002000701041#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#34#30#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the year of    2008, the Department of S
TD, AIDS and Viral Hepatitis, with the financial support    from the United Stat
es Agency for International Development (USAID), developed    a health survey am
ong patients under ART to analyze the health system responsiveness    according 
to their needs and the quality of life of AIDS patients. In respect    to qualit
y of life, with the understanding that self-rated health is a measure    that in
cludes not just physical aspects but also well-being and life satisfaction    <s
up>11</sup>, a module designed to evaluate self-perception of health in its    v
arious dimensions was included in the survey as one of the study topics. The    
aim of this study was to analyze the self-rated health and its association with 
   sex, age, socioeconomic status and characteristics related to the treatment  
  among AIDS patients receiving ART in Brazil.</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#35#31#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00323000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010100069002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#36#32#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methodology</b></font></p>     ^cY#07.ht
m##
00703000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048100069002000700550#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#37#33#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In 2008, a survey    was performed in a pro
babilistically selected sample of people infected by HIV    under ART, with the 
purpose of evaluating the quality of life and the performance    of the health s
ystem from the user's perspective. The project was approved by    the Ethics Com
mittee of the Sergio Arouca National School of Public Health,    Oswaldo Cruz Fo
undation (CAAE: 0142.0.031.031-07).</font></p>     ^cY#07.htm##
00915000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704069300069002000700762#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#38#34#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The sample size    was calculated to estima
te the proportion of patients under ART who consider    their quality of life as
 moderate or good. In an Australian study, 35% of people    living with HIV/AIDS
 under the age of 50 reported adverse health conditions    <sup>18</sup>. Using 
this estimate as a base for calculating the sample size,    considering a 95% co
nfidence interval with a 3% bilateral margin of error, a    minimum number of 97
1 subjects was obtained. As the sample was selected in two    stages, a design e
ffect of 1.3 was considered, and a final sample size of 1,260    patients was ob
tained.</font></p>     ^cY#07.htm##
00896000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067400069002000700743#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#39#35#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The sampling was    carried out in two sele
ction stages. In the first stage, 42 antiretroviral drug    dispensing units (AD
DU) were selected, using a probability proportional to their    size, according 
to the number of registered patients on lists provided by the    Department of S
TD, AIDS and Viral Hepatitis. Given the study timeframe, only    ADDU with at le
ast 200 registered patients were considered eligible for selection.    However, 
this eligibility criterion did not affect the selection of a representative    s
ample, since eligible units comprehend 90.6% of registered patients.</font></p> 
    ^cY#07.htm##
00470000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704024800069002000700317#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#40#36#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the second stage,    30 patients were ra
ndomly selected from each of the chosen ADDU during fieldwork,    from the list 
of patients scheduled in the study period.</font></p>     ^cY#07.htm##
00530000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030800069002000700377#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#41#37#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The patients answered    a modular question
naire, which included the following modules: socio-demographic,    residence and
 patient characteristics, self-rated health status, health system    performance
, and quality of life.</font></p>     ^cY#07.htm##
01083000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704086100069002000700930#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#42#38#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The modules addressing    health system per
formance and self-rated health status were based on a World    Health Organizati
on (WHO) questionnaire used in the <i>World Health Survey</i>,    applied in Bra
zil in 2003 (<a href="http://www.who.int/healthinfo/survey/en" target="_blank">h
ttp://www.who.int/healthinfo/survey/en</a>)    <sup>19,20</sup>, and the modules
 addressing quality of life were based on the    WHO survey designed for this pu
rpose (available at <a href="http://www.who.int/mental_health/media/en/557.pdf" 
target="_blank">http://www.who.int/mental_health/media/en/557.pdf</a>    - origi
nal version - or <a href="http://www.ufrgs.br/psiq/whoqol_hiv_03.pdf" target="_b
lank">http://www.ufrgs.br/psiq/whoqol_hiv_03.pdf</a>    - Portuguese version) <s
up>21,22</sup>.</font></p>     ^cY#07.htm##
00381000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015900069002000700228#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#43#39#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The module on self-rated    health status i
s the focus of the current study.</font></p>     ^cY#07.htm##
00694000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047200069002000700541#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#44#40#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The interviews    were performed face to fa
ce, whenever possible in a private room provided by    the health unit. In the c
ase of unavailability of a private room, the interviewers    were advised to sea
rch for privacy, in a place away from the waiting room to    conduct the intervi
ew. The average interview time was 20 minutes and handheld    computers were use
d for the data collection.</font></p>     ^cY#07.htm##
00751000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052900069002000700598#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#45#41#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Analysis of self-rated    health was based 
on the following question: "<i>In general, how do you currently    rate your hea
lth?</i>". The responses were ranked on a scale from 1 to 5 (1    = excellent; 2
 = good; 3 = moderate; 4 = bad; 5 = very bad). Two additional    questions were 
included with the same ranking scale: "<i>In general, how do    you rate your ab
ility to work?" and "In general, how do you rate your physical    appearance?</i
>".</font></p>     ^cY#07.htm##
00869000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064700069002000700716#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#46#42#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the dimensions    of health statu
s, questions were included about the degree of difficulty involved    in: carryi
ng out day-to-day activities; locomotion; dressing and self-care;    personal re
lationships; concentration or memory; sleeping well and disposition.    Question
s were also asked about the degree of pain or bodily discomfort experienced,    
and about feelings of sadness or depression and anxiety or worry. All of the    
questions referred to the previous 30 days, with a ranking scale from 1 to 5,   
 from the better to the worst evaluation.</font></p>     ^cY#07.htm##
00994000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077200069002000700841#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#47#43#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Analysis was conducted    according to sex,
 age (18-49 vs. 50+ years old), socio-economic status, and    clinical and treat
ment-related characteristics of patients. To examine inequalities    by socio-ec
onomic status, three variables were considered: schooling, monthly    income, an
d economic class, as defined by the Brazilian Economic Classification    Criteri
a <sup>23</sup>, which uses information about household goods and the    head of
 household's level of schooling. Among the patient characteristics evaluated    
were: category of exposure; presence of symptoms related to AIDS; most recent   
 CD4+ count; year of beginning ART; presence of side effects, including lipodyst
rophy.</font></p>     ^cY#07.htm##
00601000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037900069002000700448#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#48#44#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For the multivariate    analyses, logistic 
regression models were used, with the self-rated health as    the response varia
ble (1 = good or excellent; 0 = moderate, bad or very bad).    Through stepwise 
procedures, the main predictors of good self-perception of    health status were
 established.</font></p>     ^cY#07.htm##
00426000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020400069002000700273#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#49#45#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">SPSS version 15    (SPSS Inc., Chicago, USA
) was used for statistical analysis, taking into account    the sample design.</
font></p>     ^cY#07.htm##
00530000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030800069002000700377#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#50#46#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">At last, the self-rated    health indicator
s of AIDS patients were compared with those obtained for the    Brazilian popula
tion by the <i>World Health Survey</i> <sup>19</sup>, considering    common ques
tions to both surveys.</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#51#47#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#52#48#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#07.htm##
00745000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052300069002000700592#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#53#49#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We analyzed 1,245    patients receiving ART
 at public health facilities throughout the country. Fifty-nine    percent were 
male and 41% were female (<a href="#t1">Table 1</a>). Age varied    from 19 to 7
2 years, with mean and median values of 41 years. Distribution by    age group w
as equal for both sexes, with 79% between 15 and 49 years and 21%    age 50 or o
ver. Among patients 50 years old or over, 68.5% started ART prior    to 2003.</f
ont></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#54#50#article#186#<p><a name="t1"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#55#51#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#56#52#article#186#<p align="center"><img src
="/img/revistas/csp/v27s1/07t01.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#57#53#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00685000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046300069002000700532#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#58#54#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The results by    educational level showed 
that: 44% did not complete fundamental school (3% are    illiterate); 20% had co
mpleted primary school; 28% had completed secondary school;    and 8% had colleg
e degree. The proportion of patients who have completed at    least primary educ
ation was 56%, with 60% among men and 50% among women, according    to <a href="
#t1">Table 1</a>.</font></p>     ^cY#07.htm##
00615000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039300069002000700462#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#59#55#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the marital    status, 44.7% of t
he male patients have never been married and 34.7% are married    or live with a
 partner. Among the women, 18.6% of them have never been married.    Regarding s
kin color, 46.2% defined themselves as white, 39% as brown and 13%    as black (
<a href="#t1">Table 1</a>).</font></p>     ^cY#07.htm##
00754000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053200069002000700601#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#60#56#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding the work    status (<a href="#t1"
>Table 1</a>), in total 58% of cases was not working at    the time of the surve
y (55% among men and 62% among women). Among men, disease    retirement (31.3%),
 disability (14.7%), and to receive disease benefits (24.6%)    were the main re
asons for not working. Among women, 28% were housewives, 15.4%    were retired, 
11% were disabled, and 15.4% received disease benefits (<a href="#t1">Table    1
</a>).</font></p>     ^cY#07.htm##
00566000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034400069002000700413#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#61#57#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The distribution    of patients by income g
roup shows that 18% have no income (13.5% of the men    and 24.1% of the women);
 almost 50% earn less than twice the minimum wage; and    only 7% have monthly i
ncome greater than R$2,000.00 (<a href="#t1">Table 1</a>).</font></p>     ^cY#07
.htm##
00456000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023400069002000700303#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#62#58#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">According to the    Brazilian Economic Clas
sification Criteria <sup>23</sup>, 53% of the patients    belong to class "C" an
d 28% to classes "D" or "E".</font></p>     ^cY#07.htm##
01424000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704120200069002000701271#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#63#59#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The characteristics    of the patients by s
ex are presented in <a href="#t2">Table 2</a>. Almost 30%    of the patients sta
rted ART between 2000 and 2003 and 19% began treatment in    the past two years 
(2007-2008). Sixty-five patients (6%) started treatment before    1996, prior to
 the onset of universal anti-retrovirus distribution. Most patients    (88%) wer
e infected through sexual contact and among men, 47% via heterosexual    contact
, and 38% via homosexual contact. About 56% present symptoms of AIDS,    with a 
slightly higher proportion amongst the men, although the difference was    not s
tatistically significant. Among patients who responded to the question    about 
most recent CD4+ counts, the proportion of women with counts of less than    200
 (12%) was significantly smaller than that of the men (21%). More than 60%    of
 the patients reported that they had some kind of side effect or adverse reactio
n    to one of their anti-retroviral medications, and 22% reported having lipody
strophy.    Among those patients with lipodystrophy, 16% had received methacryla
te implants    (data not presented).</font></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#64#60#article#186#<p><a name="t2"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#65#61#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#66#62#article#186#<p align="center"><img src
="/img/revistas/csp/v27s1/07t02.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#67#63#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00789000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056700069002000700636#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#68#64#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Data regarding    different aspects of the 
self-rated health are presented in <a href="/img/revistas/csp/v27s1/07t03.jpg">T
able    3</a>. Regarding the health status, 65% of patients evaluated their heal
th status    as excellent or good. Work capacity was better for women, although 
they felt    worse about their physical appearance. An intense or very intense d
egree of    difficulty in following treatment was reported by only 7.5% of patie
nts (9%    for females and 6% for males).</font></p>     ^cY#07.htm##
00957000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704073500069002000700804#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#69#65#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among other evaluated    health status dime
nsions, 13% reported an intense or very intense degree of    difficulty in perfo
rming routine activities. A similar situation was found regarding    the degree 
of difficulty for locomotion (12%), personal relationships (12%)    and the degr
ee of difficulty associated to concentration/memory (10%). A remarkably    high 
proportion of the women reported intense or extreme pain or discomfort    (33%),
 sadness or depression (33%), and worry or anxiety (47%). Among the men,    thes
e proportions were also quite high, 21%, 23%, and 34%, respectively (<a href="/i
mg/revistas/csp/v27s1/07t03.jpg">Table    3</a>).</font></p>     ^cY#07.htm##
00898000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067600069002000700745#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#70#66#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#t4">Table    4</a> shows the prop
ortions of patients with excellent or good self-rated health    according to the
 patients' characteristics, as well as the significance levels    for the associ
ations of these variables with self-rated health. All the analyzed    social-dem
ographic characteristics, except sex and age were individually associated    to 
the health status. The variables used to measure the socioeconomic status    (ed
ucation, income and economic class) were strongly associated with health    stat
us, as higher the SES the better the self-evaluation of health status.</font></p
>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#71#67#article#186#<p><a name="t4"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#72#68#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#73#69#article#186#<p align="center"><img src
="/img/revistas/csp/v27s1/07t04.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#74#70#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00518000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704029600069002000700365#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#75#71#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding patient    characteristics, low C
D4+ counts, the occurrence of AIDS-related symptoms, reporting    of side or adv
erse effects were associated with a poor self-rated health (<a href="#t4">Table 
   4</a>).</font></p>     ^cY#07.htm##
01157000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704093500069002000701004#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#76#72#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Results of multivariate    logistic regress
ion models to investigate which of the variables were mostly    associated to ex
cellent or good self-rated health are presented in <a href="#t5">Table    5</a>.
 Regarding the variables remaining in the stepwise model, "having completed    f
undamental school" (OR = 1.70) and "belonging to economic classes A or B" (OR   
 = 2.36) were positively associated with better evaluation of the health status.
    Moreover, "having been retired due to illness, unable to work or receiving d
isease    benefits" (OR = 0.46), as well as "having reported effect and/or adver
se effects"    (OR = 0.57 and OR = 0.32 respectively, with and without lipodystr
ophy), "occurrence    of AIDS symptoms" (OR = 0.58) and "having started treatmen
t after 2007" (OR    = 0.61) were associated with a poor evaluation of the healt
h status.</font></p>     ^cY#07.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#77#73#article#186#<p><a name="t5"></a></p>  
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#78#74#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#79#75#article#186#<p align="center"><img src
="/img/revistas/csp/v27s1/07t05.jpg"></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#80#76#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#81#77#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#07.htm
##
01068000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704084600069002000700915#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#82#78#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Results of the    <i>World Health Survey</i
>, a population-based household survey carried out    in Brazil in 2003, showed 
that 53% of the Brazilian population considered their    health as good or excel
lent, varying from 47% among women to 60% among men <sup>24</sup>.    In the cur
rent study, using the exact same question as was used in the <i>World    Health 
Survey</i> for self-rated health, this proportion was 65% (64% among    women an
d 66% among men), that is, better than the evaluation of the general    populati
on, mainly among women. This result is surprising, considering that,    accordin
g to <i>World Health Survey</i>-2003 data only 27% of persons with chronic    or
 long-standing illness consider their health as good or excellent <sup>25</sup>.
</font></p>     ^cY#07.htm##
00971000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074900069002000700818#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#83#79#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">One possible explanation    for this findin
g lies in the improved quality of life of patients with AIDS    and the expectat
ion of a long lifespan after the advent of HAART <sup>15</sup>.    This hypothes
is is corroborated by the patient characteristics examined here,    such as the 
positive association of good self-rated health with the absence    of HIV-relate
d symptoms and treatment-related side-effects. It was also seen    that the lowe
r a patient's CD4<sup>+</sup> count, the worse their perception    about their h
ealth. In addition, among patients aged 50 and over, 68.5% began    treatment be
fore 2003, showing the life-prolonging effect of the treatment.</font></p>     ^
cY#07.htm##
01304000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704108200069002000701151#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#84#80#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For people diagnosed    with HIV/AIDS, give
n the high lethality of the disease at the onset of the epidemic,    it is impor
tant to consider the great impact on life perspectives at the moment    of the d
iagnosis. After beginning treatment, however, improved immune function    and we
ll-being restore a sense of hope for the future, as well as a positive    percep
tion about their health. This can be perceived in patients' responses    such as
: "<i>Compared with what I've been through, now I'm great</i>" or, "<i>I    thou
ght I was going to die</i>"; "<i>Now I've discovered that there's nothing    wro
ng with me</i>", "<i>I just have to take my medicines</i>". Besides, the    pres
ence of the word "currently" in the general question on self-rated health    may
 have contributed to the patients' comparison with their health at the time    o
f diagnosis, and to review the various physical and psychological problems    th
ey have encountered since their diagnosis until the moment of the interview.</fo
nt></p>     ^cY#07.htm##
00812000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059000069002000700659#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#85#81#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Another important    factor to explain the 
high proportion of patients with good health self-evaluation    has to do with t
he limitations of this type of study. The questionnaire was    applied to patien
ts who show up at health services to pick up their antiviral    medications, in 
other words, "healthy" patients. Patients who were hospitalized,    bed-ridden o
r not able to pick up their medications were excluded. In addition,    deceased 
patients and those who were not under ART were equally excluded.</font></p>     
^cY#07.htm##
01021000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079900069002000700868#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#86#82#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Still, despite    the positive health self-
evaluation on the part of patients on ART, intense    feelings of sadness and de
pression or worry and anxiety were present in much    greater proportions than i
n the general population <sup>26</sup>. The proportions    of intense or extreme
 pain or discomfort, difficulty sleeping or no disposition    during the day wer
e also much higher than those in the general population <sup>27</sup>.    These 
results indicate that, despite most patients' positive health self-evaluation,  
  many of them still have not overcome the psychological traumas caused by diagn
osis    with HIV/AIDS. Among female patients, almost half claimed to feel intens
e or    extreme worry or anxiety.</font></p>     ^cY#07.htm##
00654000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043200069002000700501#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#87#83#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Inequalities in    health self-perception b
y sex have been well documented in the international    literature <sup>28</sup>
. As in the current study, women in general rank their    health more poorly tha
n do men. The main explanation for this lies in gender    roles, in which women 
express pain and discomfort more easily than men <sup>29,30</sup>.</font></p>   
  ^cY#07.htm##
00676000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045400069002000700523#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#88#84#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite having    worse health self-evaluat
ions, especially for animus status related aspects,    women had better immune f
unction, measured by CD4+ counts, than did their male    counterparts. Possibly 
due to widespread testing for HIV during prenatal care,    women are diagnosed e
arlier than men and reach health services in better condition    than men <sup>3
1</sup>.</font></p>     ^cY#07.htm##
00941000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071900069002000700788#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#89#85#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The question about    most recent CD4+ coun
ts, however, was problematic. Initially, the interview    was supposed to be per
formed after the medical appointment. However, the pilot    study showed that th
e patients preferred taking part in the study during the    waiting time for the
 medical appointment. We then decided that the interview    should be conducted 
at any moment, either before or after the appointment. This    meant that many o
f the patients did not yet have their test results, and only    49% were able to
 respond to this question. As a result, this information was    excluded from th
e multivariate logistic analysis.</font></p>     ^cY#07.htm##
00876000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065400069002000700723#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#90#86#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">No distinction    was made in this study be
tween side effects and adverse drug reactions. With    the exception of lipodyst
rophy, which was considered separately, any side effects    or adverse drug reac
tions mentioned by patients were considered. These side    effects were mentione
d by great part of the sample and showed a negative association    with good sel
f-rated health, especially among women. According to a study carried    out in B
elo Horizonte, Brazil, side effects/adverse reactions were one of the    main di
fficulties in adhere to treatment <sup>32</sup>.</font></p>     ^cY#07.htm##
01244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704102200069002000701091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#91#87#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study results    indicate a higher leve
l of education among AIDS patients when compared to the    Brazilian population 
as a whole. Nonetheless, despite better education, the    pattern of wealth dist
ribution is similar. According to the <i>National Household    Sample Survey</i>
 (PNAD-2006) <sup>34</sup>, about 67% of the Brazilian population    over 18 yea
rs old has a monthly income of less than twice the minimum wage (including    al
l income sources). Among AIDS patients, the proportion was similar, 69%. However
,    when we compare the level of schooling of those receiving less than 2 minim
um    wages, in the general population, 30% have less than 3 years of schooling,
 while    among patients in the same income group only 18% have less than 3 year
s of schooling.    Results also show that the proportion of male patients who ar
e unemployed (55%)    is much higher than among the general male population (21%
) <sup>33</sup>.</font></p>     ^cY#07.htm##
00739000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051700069002000700586#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#92#88#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">When socioeconomic    status is analyzed to
gether with self-rated health, there is a clear association    between socioecon
omic variables and health status perception. As with the Brazilian    population
 as a whole <sup>24,34,35</sup>, self-rated health among AIDS patients    is poo
rer as the worse is the socioeconomic status. These findings are also    consist
ent with studies carried out in developed countries <sup>5,36,37</sup>.</font></
p>     ^cY#07.htm##
01165000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704094300069002000701012#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#93#89#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the indicators    of socioeconomic st
atus, educational level has probably been the most utilized    one, since it is 
a stable attribute in adult life, different from the occupational    and income 
status that may vary over time <sup>36</sup>, as in the case of AIDS    patients
. In fact, schooling was an important predictor of a positive health    self-eva
luation. Economic class, measured by household goods and education level    of t
he head of household, was another major contributor to a satisfactory health    
self-perception. As discussed by Martikainen et al. <sup>38</sup>, this indicato
r    of wealthy reflects not just material needs, such as the ability to acquire
    good nutrition or housing, but is also a marker of social well-being. Being 
   currently working was another important predictor of good self-rated health  
  among patients.</font></p>     ^cY#07.htm##
01159000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704093700069002000701006#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#94#90#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In sum, a poor    perception of one's own h
ealth can be seen as the result of suffering caused    by the disease in interac
tion with social, cultural, psychological and environmental    factors that modi
fy the way in which a person is affected by the experienced    problem. In the c
ase of AIDS patients, although material well-being and educational    level are 
relevant dimensions, ART seems to have a huge influence on individuals'    self-
perceptions about health status. This indicates the need to invest even    more 
to reduce the negative effects of treatment, and to continue to improve    treat
ment adherence and quality of life of those infected with HIV. Problems    relat
ed to animus status, involving worry and anxiety about the future are still    b
arriers that must be overcome to improve quality of life of people living with  
  HIV/AIDS.</font></p>     ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#95#91#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#96#92#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#07.h
tm##
00654000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043200069002000700501#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#97#93#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">P. R. B. Souza    Junior collaborated in al
l stages of development, both the survey and the article.    C. L. Szwarcwald co
ntributed in the development of the survey, data analysis,    and discussion. E.
 A. Castilho collaborated in the contextualization, interpretation    of results
 and discussion, and in the selection of bibliographic references.</font></p>   
  ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#98#94#article#186#<p>&nbsp;</p>     ^cY#07.h
tm##
00326000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010400069002000700173#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#99#95#article#186#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Acknowledgment</b></font></p>     ^cY#07
.htm##
00510000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704028700070002000700357#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#100#96#article#186#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">This work was performed    with the suppor
t of the United States Agency for International Development (USAID)    and the D
epartment of STD, AIDS and Viral Hepatitis of the Brazilian Ministry    of Healt
h.</font></p>     ^cY#07.htm##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#101#97#article#186#<p>&nbsp;</p>     ^cY#07.
htm##
00323000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704010000070002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#102#98#article#186#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#07.ht
m##
00485000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704024800072002000700320#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#103#99#article#186#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Gold M, Franks    P, Eric
kson P. Assessing the health of the nation. The predictive validity of    a pref
erence-based measure and self-rated health. Med Care 1996; 34:163-77.    ^cY#07.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#104#100#article#186#</font></p>     ^cY#07.h
tm##
00455000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704021700073002000700290#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#105#101#article#186#2#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2. Devlin N, Hansen    P, H
erbison P. Variations in self-reported health status: results from a New    Zeal
and survey. N Z Med J 2000; 113:517-20.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#106#102#article#186#</font></p>     ^cY#07.h
tm##
00478000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024000073002000700313#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#107#103#article#186#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Kind P, Dolan    P, Gude
x C, Williams A. Variations in population health status: results from    a Unite
d Kingdom national questionnaire survey. BMJ 1998; 316:736-41.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#108#104#article#186#</font></p>     ^cY#07.h
tm##
00525000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704028700073002000700360#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#109#105#article#186#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Pikhart H, Bobak    M, S
iegrist J, Pajak A, Rywik S, Kyshegyi J, et al. Psychosocial work characteristic
s    and self rated health in four post-communist countries. J Epidemiol Communi
ty    Health 2001; 55:624-30.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#110#106#article#186#</font></p>     ^cY#07.h
tm##
00441000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704020300073002000700276#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#111#107#article#186#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Franks P, Gold    MR, Fi
scella K. Sociodemographics, self-rated health, and mortality in the US.    Soc 
Sci Med 2003; 56:2505-14.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#112#108#article#186#</font></p>     ^cY#07.h
tm##
00497000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025900073002000700332#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#113#109#article#186#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Hunt SM, McKenna    SP, 
McEwen J, Backett EM, Williams J, Papp E. A quantitative approach to perceived  
  health status: a validation study. J Epidemiol Community Health 1980; 34:281-6
.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#114#110#article#186#</font></p>     ^cY#07.h
tm##
00437000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704019900073002000700272#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#115#111#article#186#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Mossey JM, Shapiro    E.
 Self-rated health: a predictor of mortality among the elderly. Am J Public    H
ealth 1982; 72:800-8.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#116#112#article#186#</font></p>     ^cY#07.h
tm##
00452000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704021400073002000700287#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#117#113#article#186#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Idler EL, Benyamini    Y
. Self-rated health and mortality: a review of twenty-seven community studies.  
  J Health Soc Behav 1997; 38:21-37.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#118#114#article#186#</font></p>     ^cY#07.h
tm##
00470000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704023200073002000700305#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#119#115#article#186#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Kaplan GA, Camacho    T.
 Perceived health and mortality: a nine-year follow-up of the human population  
  laboratory cohort. Am J Epidemiol 1983; 117:292-304.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#120#116#article#186#</font></p>     ^cY#07.h
tm##
00520000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028100074002000700355#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#121#117#article#186#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Burstrom B,    Fredlun
d P. Self rated health: is it as good a predictor of subsequent mortality    amo
ng adults in lower as well as in higher social classes? J Epidemiol Community   
 Health 2001; 55:836-40.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#122#118#article#186#</font></p>     ^cY#07.h
tm##
00485000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024600074002000700320#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#123#119#article#186#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Blank N, Diderichsen  
  F. The prediction of different experiences of longterm illness: a longitudinal
    approach in Sweden. J Epidemiol Community Health 1996; 50:156-61.    ^cY#07.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#124#120#article#186#</font></p>     ^cY#07.h
tm##
00449000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021000074002000700284#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#125#121#article#186#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Bartlett JG,    Gallan
t JE. Tratamento cl&iacute;nico da infec&ccedil;&atilde;o pelo HIV. Baltimore:  
  Johns Hopkins University; 2002.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#126#122#article#186#</font></p>     ^cY#07.h
tm##
00480000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024100074002000700315#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#127#123#article#186#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Russell J,    Krantz S
, Neville S. The patient-provider relationship and adherence to highly    active
 antiretroviral therapy. J Assoc Nurses AIDS Care 2004; 15:40-7.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#128#124#article#186#</font></p>     ^cY#07.h
tm##
00416000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017700074002000700251#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#129#125#article#186#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Levi GC, Vit&oacute;ri
a    MA. Fighting against AIDS: the Brazilian experience. AIDS 2002; 16:2373-83.
    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#130#126#article#186#</font></p>     ^cY#07.h
tm##
00482000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024300074002000700317#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#131#127#article#186#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Marins JR,    Jamal LF
, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement    in su
rvival among adult Brazilian AIDS patients. AIDS 2003; 17:1675-82.    ^cY#07.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#132#128#article#186#</font></p>     ^cY#07.h
tm##
00534000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029500074002000700369#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#133#129#article#186#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Chequer P,    Hearst N
, Hudes ES, Castilho E, Rutherford G, Loures L, et al. Determinants    of surviv
al in adult Brazilian AIDS patients, 1982-1989. The Brazilian State    AIDS Prog
ram Co-Ordinators. AIDS 1992; 6:483-7.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#134#130#article#186#</font></p>     ^cY#07.h
tm##
00548000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030900074002000700383#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#135#131#article#186#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Guibu IA, Barros    MB
A, Cordeiro MRD, Tayra A, Alves MCGP, Pereira GFM. Estudo de sobrevida de    pac
ientes de AIDS no Brasil, 1998 a 1999" - fase I - Regi&otilde;es Sul e Sudeste. 
   Boletim Epidemiol&oacute;gico AIDST 2008; V:31-3.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#136#132#article#186#</font></p>     ^cY#07.h
tm##
00535000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029600074002000700370#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#137#133#article#186#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Pitts M, Grierson    J
, Misson S. Growing older with HIV: a study of health, social and economic    ci
rcumstances for people living with HIV in Australia over the age of 50 years.   
 AIDS Patient Care STDS 2005; 19:460-5.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#138#134#article#186#</font></p>     ^cY#07.h
tm##
00457000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021800074002000700292#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#139#135#article#186#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Szwarcwald    CL, Viac
ava F. <i>Pesquisa Mundial de Sa&uacute;de</i> no Brasil, 2003. Cad    Sa&uacute
;de P&uacute;blica 2005; 21 Suppl 1:S4-5.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#140#136#article#186#</font></p>     ^cY#07.h
tm##
00540000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030100074002000700375#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#141#137#article#186#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Szwarcwald    CL, Viac
ava F. Pesquisa Mundial de Sa&uacute;de: aspectos metodol&oacute;gicos    e arti
cula&ccedil;&atilde;o com a Organiza&ccedil;&atilde;o Mundial da Sa&uacute;de.  
  Rev Bras Epidemiol 2008; 11 Suppl 1:58-66.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#142#138#article#186#</font></p>     ^cY#07.h
tm##
00471000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023200074002000700306#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#143#139#article#186#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. WHOQOLHIVGroup.    WHO
QOL-HIV for quality of life assessment among people living with HIV and AIDS:   
 results from the field test. AIDS Care 2004; 16:882-9.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#144#140#article#186#</font></p>     ^cY#07.h
tm##
00476000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704023700074002000700311#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#145#141#article#186#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Zimpel RR,    Fleck MP
. Quality of life in HIV-positive Brazilians: application and validation    of t
he WHOQOL-HIV, Brazilian version. AIDS Care 2007; 19:923-30.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#146#142#article#186#</font></p>     ^cY#07.h
tm##
00539000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030000074002000700374#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#147#143#article#186#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Associa&ccedil;&atilde
;o    Brasileira de Empresas de Pesquisa. Crit&eacute;rio de classifica&ccedil;&
atilde;o    econ&ocirc;mica Brasil. S&atilde;o Paulo: Associa&ccedil;&atilde;o B
rasileira    de Empresas de Pesquisa; 2008.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#148#144#article#186#</font></p>     ^cY#07.h
tm##
00510000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027100074002000700345#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#149#145#article#186#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Szwarcwald    CL, Souz
a Junior PR, Esteves MA, Damacena GN, Viacava F. Socio-demographic determinants 
   of self-rated health in Brazil. Cad Sa&uacute;de P&uacute;blica 2005; 21 Supp
l    1:S54-64.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#150#146#article#186#</font></p>     ^cY#07.h
tm##
00570000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033100074002000700405#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#151#147#article#186#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Theme-Filha    MM, Szw
arcwald CL, Souza Junior PR. Socio-demographic characteristics, treatment    cov
erage, and self-rated health of individuals who reported six chronic diseases   
 in Brazil, 2003. Cad Sa&uacute;de P&uacute;blica 2005; 21 Suppl 1:S43-53.    ^c
Y#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#152#148#article#186#</font></p>     ^cY#07.h
tm##
00484000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024500074002000700319#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#153#149#article#186#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Szwarcwald    CL, Bast
os FI, Esteves MA. State of animus among Brazilians: influence of socioeconomic 
   context? Cad Sa&uacute;de P&uacute;blica 2005; 21 Suppl 1:S33-42.    ^cY#07.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#154#150#article#186#</font></p>     ^cY#07.h
tm##
00495000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025600074002000700330#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#155#151#article#186#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Szwarcwald    CL, Viac
ava F, Vasconcellos MTL, Leal MC, Azevedo LO, Queiroz RSB, et al. Pesquisa    Mu
ndial de Sa&uacute;de - 2003: o Brasil em n&uacute;meros. Radis 2004; 23:14-33. 
   ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#156#152#article#186#</font></p>     ^cY#07.h
tm##
00498000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025900074002000700333#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#157#153#article#186#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Denton M, Prus    S, W
alters V. Gender differences in health: a Canadian study of the psychological,  
  structural and behavioral determinants of health. Soc Sci Med 2004; 58:2585-60
0.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#158#154#article#186#</font></p>     ^cY#07.h
tm##
00394000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015500074002000700229#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#159#155#article#186#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Verbrugge LM.    Sex d
ifferentials in health. Public Health Rep 1982; 97:417-37.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#160#156#article#186#</font></p>     ^cY#07.h
tm##
00542000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030300074002000700377#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#161#157#article#186#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Gijsbers van    Wijk C
M, van Vliet KP, Kolk AM, Everaerd WT. Symptom sensitivity and sex differences  
  in physical morbidity: a review of health surveys in the United States and The
    Netherlands. Women Health 1991; 17:91-124.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#162#158#article#186#</font></p>     ^cY#07.h
tm##
00480000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024100074002000700315#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#163#159#article#186#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Souza Jr. PR,    Szwar
cwald CL, Castilho EA. Delay in introducing antiretroviral therapy in patients  
  infected by HIV in Brazil, 2003-2006. Clinics 2007; 62:579-84.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#164#160#article#186#</font></p>     ^cY#07.h
tm##
00522000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028300074002000700357#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#165#161#article#186#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Guimar&atilde;es    MD
, Rocha GM, Campos LN, Freitas FM, Gualberto FA, Teixeira RA, et al. Difficultie
s    reported by hiv-infected patients using antiretroviral therapy in Brazil. C
linics    2008; 63:165-72.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#166#162#article#186#</font></p>     ^cY#07.h
tm##
00515000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027600074002000700350#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#167#163#article#186#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Instituto Brasileiro  
  de Geografia e Estat&iacute;stica. Pesquisa Nacional por Amostra de Domic&iacu
te;lios    (PNAD). Rio de Janeiro: Instituto Brasileiro de Geografia e Estat&iac
ute;stica;    2006.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#168#164#article#186#</font></p>     ^cY#07.h
tm##
00557000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031800074002000700392#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#169#165#article#186#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Lima-Costa    MF, Barr
eto S, Giatti L, Uchoa E. Desigualdade social e sa&uacute;de entre idosos    bra
sileiros: um estudo baseado na <i>Pesquisa Nacional por Amostra de Domic&iacute;
lios</i>.    Cad Sa&uacute;de P&uacute;blica 2003; 19:745-57.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#170#166#article#186#</font></p>     ^cY#07.h
tm##
00523000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028400074002000700358#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#171#167#article#186#35#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Dachs JNW.    Determin
antes das desigualdades na auto-avalia&ccedil;&atilde;o do estudo de    sa&uacut
e;de no Brasil: an&aacute;lise dos dados da PNAD/1998. Ci&ecirc;nc Sa&uacute;de 
   Coletiva 2002; 7:641-57.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#172#168#article#186#</font></p>     ^cY#07.h
tm##
00430000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019100074002000700265#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#173#169#article#186#36#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Heistaro S,    Vartiai
nen E, Puska P. Trends in self-rated health in Finland 1972-1992. Prev    Med 19
96; 25:625-32.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#174#170#article#186#</font></p>     ^cY#07.h
tm##
00546000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030700074002000700381#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#175#171#article#186#37#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">37. Mackenbach    JP, Kuns
t AE, Cavelaars AEJM, Gronhof F, Geurts JJM. Socioeconomic inequalities    in mo
rbidity and mortality in Western Europe. The EU Working Group on Socioeconomic  
  Inequalities in Health. Lancet 1997; 349:1655-9.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#176#172#article#186#</font></p>     ^cY#07.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#p#177#173#article#186#38#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">38. Martikainen    P, Adda
 J, Ferrie JE, Smith GD, Marmot M. Effects of income and health on GHQ    depres
sion and poor self rated health in white collar women and men in the Whitehall  
  II study. J Epidemiol Community Health 2003; 57:718-23.    ^cY#07.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#178#174#article#186#</font></p>     ^cY#07.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#179#175#article#186#<p>&nbsp;</p>     ^cY#07
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#180#176#article#186#<p>&nbsp;</p>     ^cY#07
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#181#177#article#186#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#07.htm##
00265000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004100071002000700112#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#182#178#article#186#<br>   </b> P. R. B. Sou
za Junior    ^cY#07.htm##
00362000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704013800071002000700209#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#183#179#article#186#<br>   Instituto de Comu
nica&ccedil;&atilde;o e Informa&ccedil;&atilde;o Cient&iacute;fica    e Tecnol&o
acute;gica em Sa&uacute;de    ^cY#07.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#184#180#article#186#<br>   Funda&ccedil;&ati
lde;o Oswaldo Cruz    ^cY#07.htm##
00305000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704008100071002000700152#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#185#181#article#186#<br>   Av. Brasil 4365, 
Pavilh&atilde;o Haity Moussatch&eacute;, sala 225    ^cY#07.htm##
00275000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005100071002000700122#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#186#182#article#186#<br>   Rio de Janeiro, R
J 21040-900, Brazil    ^cY#07.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#187#183#article#186#<br>   <a href="mailto:p
borges@cict.fiocruz.br">pborges@cict.fiocruz.br</a></font></p>     ^cY#07.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#188#184#article#186#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 01/Nov/2009    ^cY#07.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#189#185#article#186#<br>   Final version res
ubmitted on 19/Mar/2010    ^cY#07.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\07.htm#S#p#190#186#article#186#<br>   Approved on 05/Ap
r/2010</font></p>     ^cY#07.htm##
00592000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100014000700100016000840100
01800100012011600118030000900234065000900243064000500252031000300257014000700260
865000900267002000700276035001000283801000900293#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#191#1#article#38#1#^rND^sGold^nM#^rND^sFranks^nP#^rND^sErick
son^nP#Assessing the health of the nation: The predictive validity of a preferen
ce-based measure and self-rated health^len#Med Care#19960000#1996#34#163-77#2011
0000#07.htm#0025-7079#Med Care##
00562000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100016000860100
01800102012008100120030001000201065000900211064000500220031000400225014000700229
865000900236002000700245035001000252801001000262#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#192#2#article#38#2#^rND^sDevlin^nN#^rND^sHansen^nP#^rND^sHer
bison^nP#Variations in self-reported health status: results from a New Zealand s
urvey^len#N Z Med J#20000000#2000#113#517-20#20110000#07.htm#0028-8446#N Z Med J
##
00597000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100014000700100015000840100
01500099010001800114012010400132030000400236065000900240064000500249031000400254
014000700258865000900265002000700274035001000281801000400291#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\07.htm#S#c#193#3#article#38#3#^rND^sKind^nP#^rND^sDolan^nP#
^rND^sGudex^nC#^rND^sWilliams^nA#Variations in population health status: results
 from a United Kingdom national questionnaire survey^len#BMJ#19980000#1998#316#7
36-41#20110000#07.htm#0959-8138#BMJ##
00713000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100015000870100
01800102010001500120010001500135010001800150810000600168012009300174030002900267
06500090029606400050030503100030031001400070031386500090032000200070032903500100
0336801002900346#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#194#4#articl
e#38#4#^rND^sPikhart^nH#^rND^sBobak^nM#^rND^sSiegrist^nJ#^rND^sPajak^nA#^rND^sRy
wik^nS#^rND^sKyshegyi^nJ#et al#Psychosocial work characteristics and self rated 
health in four post-communist countries^len#J Epidemiol Community Health#2001000
0#2001#55#624-30#20110000#07.htm#0141-7681#J Epidemiol Community Health##
00550000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100015000860100
01800101012006600119030001200185065000900197064000500206031000300211014000800214
865000900222002000700231035001000238801001200248#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#195#5#article#38#5#^rND^sFranks^nP#^rND^sGold^nMR#^rND^sFisc
ella^nK#Sociodemographics, self-rated health, and mortality in the US^len#Soc Sc
i Med#20030000#2003#56#2505-14#20110000#07.htm#0037-7856#Soc Sci Med##
00677000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100018000850100
01600103010001800119010001800137010001400155012007500169030002900244065000900273
06400050028203100030028701400060029086500090029600200070030503500100031280100290
0322#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#196#6#article#38#6#^rND^
sHunt^nSM#^rND^sMcKenna^nSP#^rND^sMcEwen^nJ#^rND^sBackett^nEM#^rND^sWilliams^nJ#
^rND^sPapp^nE#A quantitative approach to perceived health status: a validation s
tudy^len#J Epidemiol Community Health#19800000#1980#34#281-6#20110000#07.htm#014
1-7681#J Epidemiol Community Health##
00535000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100017000870120
06600104030001900170065000900189064000500198031000300203014000600206865000900212
002000700221035001000228801001900238#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#197#7#article#38#7#^rND^sMossey^nJM#^rND^sShapiro^nE#Self-rated health: 
a predictor of mortality among the elderly^len#Am J Public Health#19820000#1982#
72#800-8#20110000#07.htm#0090-0036#Am J Public Health##
00550000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100019000860120
08000105030001900185065000900204064000500213031000300218014000600221865000900227
002000700236035001000243801001900253#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#198#8#article#38#8#^rND^sIdler^nEL#^rND^sBenyamini^nY#Self-rated health 
and mortality: a review of twenty-seven community studies^len#J Health Soc Behav
#19970000#1997#38#21-37#20110000#07.htm#0022-1465#J Health Soc Behav##
00564000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100017000870120
10000104030001500204065000900219064000500228031000400233014000800237865000900245
002000700254035001000261801001500271#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#199#9#article#38#9#^rND^sKaplan^nGA#^rND^sCamacho^nT#Perceived health an
d mortality: a nine-year follow-up of the human population laboratory cohort^len
#Am J Epidemiol#19830000#1983#117#292-304#20110000#07.htm#0002-9262#Am J Epidemi
ol##
00626000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900120
13200108030002900240065000900269064000500278031000300283014000700286865000900293
002000700302035001000309801002900319#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#200#10#article#38#10#^rND^sBurstrom^nB#^rND^sFredlund^nP#Self rated heal
th: is it as good a predictor of subsequent mortality among adults in lower as w
ell as in higher social classes?^len#J Epidemiol Community Health#20010000#2001#
55#836-40#20110000#07.htm#0141-7681#J Epidemiol Community Health##
00593000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100021000870120
09900108030002900207065000900236064000500245031000300250014000700253865000900260
002000700269035001000276801002900286#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#201#11#article#38#11#^rND^sBlank^nN#^rND^sDiderichsen^nF#The prediction 
of different experiences of longterm illness: a longitudinal approach in Sweden^
len#J Epidemiol Community Health#19960000#1996#50#156-61#20110000#07.htm#0141-76
81#J Epidemiol Community Health##
00460000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720160018000910180
04400109066001000153062002500163065000900188064000500197865000900202002000700211
#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#202#12#article#38#12#^rND^sB
artlett^nJG#^rND^sGallant^nJE#Tratamento clínico da infecção pelo HIV^lpt#Baltim
ore#Johns Hopkins University#20020000#2002#20110000#07.htm##
00602000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01700105012009200122030002500214065000900239064000500248031000300253014000500256
865000900261002000700270035001000277801002500287#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#203#13#article#38#13#^rND^sRussell^nJ#^rND^sKrantz^nS#^rND^s
Neville^nS#The patient-provider relationship and adherence to highly active anti
retroviral therapy^len#J Assoc Nurses AIDS Care#20040000#2004#15#40-7#20110000#0
7.htm#1055-3290#J Assoc Nurses AIDS Care##
00496000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870120
05200105030000500157065000900162064000500171031000300176014000800179865000900187
002000700196035001000203801000500213#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#204#14#article#38#14#^rND^sLevi^nGC#^rND^sVitória^nMA#Fighting against A
IDS: the Brazilian experience^len#AIDS#20020000#2002#16#2373-83#20110000#07.htm#
0269-9370#AIDS##
00649000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01500105010001700120010001600137010001800153810000600171012007300177030000500250
06500090025506400050026403100030026901400080027286500090028000200070028903500100
0296801000500306#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#205#15#artic
le#38#15#^rND^sMarins^nJR#^rND^sJamal^nLF#^rND^sChen^nSY#^rND^sBarros^nMB#^rND^s
Hudes^nES#^rND^sBarbosa^nAA#et al#Dramatic improvement in survival among adult B
razilian AIDS patients^len#AIDS#20030000#2003#17#1675-82#20110000#07.htm#0269-93
70#AIDS##
00698000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01600105010001800121010002000139010001600159810000600175012012100181030000500302
06500090030706400050031603100020032101400060032386500090032900200070033803500100
0345801000500355#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#206#16#artic
le#38#16#^rND^sChequer^nP#^rND^sHearst^nN#^rND^sHudes^nES#^rND^sCastilho^nE#^rND
^sRutherford^nG#^rND^sLoures^nL#et al#Determinants of survival in adult Brazilia
n AIDS patients, 1982-1989: The Brazilian State AIDS Program Co-Ordinators^len#A
IDS#19920000#1992#6#483-7#20110000#07.htm#0269-9370#AIDS##
00662000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
02000106010001500126010001800141010001900159012010200178030002900280710000200309
065000900311064000500320031000200325014000500327865000900332002000700341#v27s1#V
:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#207#17#article#38#17#^rND^sGuibu^nIA
#^rND^sBarros^nMBA#^rND^sCordeiro^nMRD#^rND^sTayra^nA#^rND^sAlves^nMCGP#^rND^sPe
reira^nGFM#Estudo de sobrevida de pacientes de AIDS no Brasil, 1998 a 1999" - fa
se I - Regiões Sul e Sudeste^lpt#Boletim Epidemiológico AIDST#2#20080000#2008#V#
31-3#20110000#07.htm##
00652000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100018000870100
01600105012014600121030002300267065000900290064000500299031000300304014000600307
865000900313002000700322035001000329801002300339#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#208#18#article#38#18#^rND^sPitts^nM#^rND^sGrierson^nJ#^rND^s
Misson^nS#Growing older with HIV: a study of health, social and economic circums
tances for people living with HIV in Australia over the age of 50 years^len#AIDS
 Patient Care STDS#20050000#2005#19#460-5#20110000#07.htm#1087-2914#Aids Patient
 Care STDS##
00496000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100017000930120
04600110030001800156710000200174065000900176064000500185031000300190032000400193
014000500197865000900202002000700211#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#209#19#article#38#19#^rND^sSzwarcwald^nCL#^rND^sViacava^nF#Pesquisa Mund
ial de Saúde no Brasil, 2003^lpt#Cad Saúde Pública#2#20050000#2005#21#^s1#S4-5#2
0110000#07.htm##
00555000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100017000930120
10300110030001900213710000200232065000900234064000500243031000300248032000400251
014000600255865000900261002000700270#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#210#20#article#38#20#^rND^sSzwarcwald^nCL#^rND^sViacava^nF#Pesquisa Mund
ial de Saúde: aspectos metodológicos e articulação com a Organização Mundial da 
Saúde^lpt#Rev Bras Epidemiol#2#20080000#2008#11#^s1#58-66#20110000#07.htm##
00535000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690110015000720120113000870300
01000200065000900210064000500219031000300224014000600227865000900233002000700242
035001000249801001000259#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#211#
21#article#38#21#WHOQOLHIVGroup#WHOQOL-HIV for quality of life assessment among 
people living with HIV and AIDS: results from the field test^len#AIDS Care#20040
000#2004#16#882-9#20110000#07.htm#0954-0121#AIDS care##
00565000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890120
11200105030001000217065000900227064000500236031000300241014000700244865000900251
002000700260035001000267801001000277#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.
htm#S#c#212#22#article#38#22#^rND^sZimpel^nRR#^rND^sFleck^nMP#Quality of life in
 HIV-positive Brazilians: application and validation of the WHOQOL-HIV, Brazilia
n version^len#AIDS Care#20070000#2007#19#923-30#20110000#07.htm#0954-0121#AIDS c
are##
00481000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170046000720180047001180660
01000165062004600175065000900221064000500230865000900235002000700244#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\07.htm#S#c#213#23#article#38#23#Associação Brasilei
ra de Empresas de Pesquisa#Critério de classificação econômica Brasil^lpt#São Pa
ulo#Associação Brasileira de Empresas de Pesquisa#20080000#2008#20110000#07.htm#
#
00614000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100023000930100
01800116010001900134010001700153012006600170030001800236710000200254065000900256
064000500265031000300270032000400273014000700277865000900284002000700293#v27s1#V
:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#214#24#article#38#24#^rND^sSzwarcwal
d^nCL#^rND^sSouza Junior^nPR#^rND^sEsteves^nMA#^rND^sDamacena^nGN#^rND^sViacava^
nF#Socio-demographic determinants of self-rated health in Brazil^len#Cad Saúde P
ública#2#20050000#2005#21#^s1#S54-64#20110000#07.htm##
00638000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100021000940100
02300115012014600138030001800284710000200302065000900304064000500313031000300318
032000400321014000700325865000900332002000700341#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#215#25#article#38#25#^rND^sTheme-Filha^nMM#^rND^sSzwarcwald^
nCL#^rND^sSouza Junior^nPR#Socio-demographic characteristics, treatment coverage
, and self-rated health of individuals who reported six chronic diseases in Braz
il, 2003^len#Cad Saúde Pública#2#20050000#2005#21#^s1#S43-53#20110000#07.htm##
00556000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100017000930100
01800110012007400128030001800202710000200220065000900222064000500231031000300236
032000400239014000700243865000900250002000700259#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#216#26#article#38#26#^rND^sSzwarcwald^nCL#^rND^sBastos^nFI#^
rND^sEsteves^nMA#State of animus among Brazilians: influence of socioeconomic co
ntext?^len#Cad Saúde Pública#2#20050000#2005#21#^s1#S33-42#20110000#07.htm##
00623000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100017000930100
02400110010001500134010001800149010001900167810000600186012005800192030000600250
71000020025606500090025806400050026703100030027201400060027586500090028100200070
0290#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#217#27#article#38#27#^rN
D^sSzwarcwald^nCL#^rND^sViacava^nF#^rND^sVasconcellos^nMTL#^rND^sLeal^nMC#^rND^s
Azevedo^nLO#^rND^sQueiroz^nRSB#et al#Pesquisa Mundial de Saúde - 2003: o Brasil 
em números^lpt#Radis#2#20040000#2004#23#14-33#20110000#07.htm##
00607000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100014000880100
01700102012012200119030001200241065000900253064000500262031000300267014000900270
865000900279002000700288035001000295801001200305#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#218#28#article#38#28#^rND^sDenton^nM#^rND^sPrus^nS#^rND^sWal
ters^nV#Gender differences in health: a Canadian study of the psychological, str
uctural and behavioral determinants of health^len#Soc Sci Med#20040000#2004#58#2
585-600#20110000#07.htm#0037-7856#Soc Sci Med##
00476000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720120032000920300
01800124065000900142064000500151031000300156014000700159865000900166002000700175
035001000182801001800192#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#219#
29#article#38#29#^rND^sVerbrugge^nLM#Sex differentials in health^len#Public Heal
th Rep#19820000#1982#97#417-37#20110000#07.htm#0033-3549#Public health rep##
00667000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100028000720100020001000100
01500120010001900135012013500154030001300289065000900302064000500311031000300316
014000700319865000900326002000700335035001000342801001300352#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\07.htm#S#c#220#30#article#38#30#^rND^sGijsbers van Wijk^nCM
#^rND^svan Vliet^nKP#^rND^sKolk^nAM#^rND^sEveraerd^nWT#Symptom sensitivity and s
ex differences in physical morbidity: a review of health surveys in the United S
tates and The Netherlands^len#Women Health#19910000#1991#17#91-124#20110000#07.h
tm#0363-0242#Women Health##
00585000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100021000920100
01900113012009700132030000800229065000900237064000500246031000300251014000700254
865000900261002000700270035001000277801000800287#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#221#31#article#38#31#^rND^sSouza Jr.^nPR#^rND^sSzwarcwald^nC
L#^rND^sCastilho^nEA#Delay in introducing antiretroviral therapy in patients inf
ected by HIV in Brazil, 2003-2006^len#Clinics#20070000#2007#62#579-84#20110000#0
7.htm#1807-5932#Clinics##
00682000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100016000920100
01700108010001800125010002000143010001900163810000600182012009000188030000800278
06500090028606400050029503100030030001400070030386500090031000200070031903500100
0326801000800336#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#222#32#artic
le#38#32#^rND^sGuimarães^nMD#^rND^sRocha^nGM#^rND^sCampos^nLN#^rND^sFreitas^nFM#
^rND^sGualberto^nFA#^rND^sTeixeira^nRA#et al#Difficulties reported by hiv-infect
ed patients using antiretroviral therapy in Brazil^len#Clinics#20080000#2008#63#
165-72#20110000#07.htm#1807-5932#Clinics##
00498000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170048000720180055001200660
01500175062004800190065000900238064000500247865000900252002000700261#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\07.htm#S#c#223#33#article#38#33#Instituto Brasileir
o de Geografia e Estatística#Pesquisa Nacional por Amostra de Domicílios (PNAD)^
lpt#Rio de Janeiro#Instituto Brasileiro de Geografia e Estatística#20060000#2006
#20110000#07.htm##
00614000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100017000930100
01600110010001500126012012300141030001800264710000200282065000900284064000500293
031000300298014000700301865000900308002000700317#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#224#34#article#38#34#^rND^sLima-Costa^nMF#^rND^sBarreto^nS#^
rND^sGiatti^nL#^rND^sUchoa^nE#Desigualdade social e saúde entre idosos brasileir
os: um estudo baseado na Pesquisa Nacional por Amostra de Domicílios^lpt#Cad Saú
de Pública#2#20030000#2003#19#745-57#20110000#07.htm##
00520000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720120115000890300
02100204710000200225065000900227064000500236031000200241014000700243865000900250
002000700259#v27s1#V:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#225#35#article#3
8#35#^rND^sDachs^nJNW#Determinantes das desigualdades na auto-avaliação do estud
o de saúde no Brasil: análise dos dados da PNAD/1998^lpt#Ciênc Saúde Coletiva#2#
20020000#2002#7#641-57#20110000#07.htm##
00536000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100020000900100
01500110012005300125030000900178065000900187064000500196031000300201014000700204
865000900211002000700220035001000227801000900237#v27s1#V:\SciELO\serial\csp\v27s
1\markup\07.htm#S#c#226#36#article#38#36#^rND^sHeistaro^nS#^rND^sVartiainen^nE#^
rND^sPuska^nP#Trends in self-rated health in Finland 1972-1992^len#Prev Med#1996
0000#1996#25#625-32#20110000#07.htm#0091-7435#Prev Med##
00683000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100016000930100
02200109010001700131010001800148012013800166030000700304065000900311064000500320
031000400325014000700329865000900336002000700345035001000352801000700362#v27s1#V
:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#227#37#article#38#37#^rND^sMackenbac
h^nJP#^rND^sKunst^nAE#^rND^sCavelaars^nAEJM#^rND^sGronhof^nF#^rND^sGeurts^nJJM#S
ocioeconomic inequalities in morbidity and mortality in Western Europe: The EU W
orking Group on Socioeconomic Inequalities in Health^len#Lancet#19970000#1997#34
9#1655-9#20110000#07.htm#0099-5355#Lancet##
00712000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100014000930100
01700107010001600124010001600140012013400156030002900290065000900319064000500328
031000300333014000700336865000900343002000700352035001000359801002900369#v27s1#V
:\SciELO\serial\csp\v27s1\markup\07.htm#S#c#228#38#article#38#38#^rND^sMartikain
en^nP#^rND^sAdda^nJ#^rND^sFerrie^nJE#^rND^sSmith^nGD#^rND^sMarmot^nM#Effects of 
income and health on GHQ depression and poor self rated health in white collar w
omen and men in the Whitehall II study^len#J Epidemiol Community Health#20030000
#2003#57#718-23#20110000#07.htm#0141-7681#J Epidemiol Community Health##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#o#1#1#article#1#201104
11#073710#08.htm#212##
04325000000000757000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400110013703500100014801200840
01580120088002420100034003300100032003640100039003960100041004350700067004760700
10000543070008900643070008900732083110500821085001001926085003501936085004701971
08500230201808500330204108500330207408311170210708500100322408500290323408500510
32630850024033140850038033380850031033760590024034070580035034310580007034660600
01303473117000803486072000303494112000903497111001203506116000903518115001203527
114000903539113001203548002000703560#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.
htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#08#CSP330#nd#Cad. Saúde Pública#
27#1#20110000#^fs67^ls78#0102-311X#Monitoring adherence to antiretroviral treatm
ent in Brazil: an urgent challenge^len#Monitoramento da adesão ao tratamento ant
irretroviral no Brasil: um urgente desafio^lpt#^rND^1A01^nGustavo Machado^sRocha
#^rND^1A02^nCarla Jorge^sMachado#^rND^1A03^nFrancisco de Assis^sAcurcio#^rND^1A0
4^nMark Drew Crosland^sGuimarães#Universidade Federal de São João Del-Rei^iA01^c
Divinópolis^pBrasil#Universidade Federal de Minas Gerais^iA02^1Faculdade de Ciên
cias Econômicas^cBelo Horizonte^pBrasil#Universidade Federal de Minas Gerais^iA0
3^1Faculdade de Farmácia^cBelo Horizonte^pBrasil#Universidade Federal de Minas G
erais^iA04^1Faculdade de Medicina^cBelo Horizonte^pBrasil#^len^aThe aim of this 
study was to describe the effect of non-adherence on the main laboratory outcome
s, TCD4+ lymphocyte count and viral load, routinely used to monitor patients ini
tiating treatment according to three different approaches to measure adherence t
o antiretroviral therapy. Among 288 participants, 22.9%, 31.9% and 74.3% were co
nsidered non-adherent, according to medical charts, self-report and pharmacy rec
ords, respectively. Depending on the adherence measures used, the average gain i
n TCD4+ lymphocyte count ranged from 142.4 to 195.4 cells/mm3 among adherent pat
ients, and from 58.5 to 99.8 lymphocytes TCD4+/mm3 among those non-adherent. The
 average reduction on viral load ranged from 4.25 to 4.62 log copies/mL among th
e adherent patients, and from 1.99 to 4.07 log among those non-adherent. Monitor
ing antiretroviral adherence should be considered a priority in these public AID
S referral centers in order to identify patients at high risk of developing viro
logic failure. Early interventions are necessary in order to maintain the initia
l therapeutic regimens for longer periods.#^ddecs^i1#^tm^len^kAnti-Retroviral Ag
ents^i1#^tm^len^kAcquired Immunodeficiency Syndrome^i1#^tm^len^kViral Load^i1#^t
m^len^kCD4 Lymphocyte Count^i1#^tm^len^kMedication Adherence^i1#^lpt^aO objetivo
 deste estudo foi descrever o efeito da não-adesão nos principais desfechos labo
ratoriais, contagem de linfócitos TCD4+ e carga viral, rotineiramente utilizados
 para monitoramento de pacientes iniciando tratamento segundo três diferentes fo
rmas de medir adesão à terapia antirretroviral. Entre 288 participantes, 22,9%, 
31,9% e 74,3% foram considerados não-aderentes, respectivamente, pelos registros
 em prontuários médicos, autorrelato e registros de dispensação nas farmácias. D
ependendo da medida de adesão utilizada, o ganho médio de linfócitos TCD4+ vario
u de 142,4 a 195,4 células/mm³ para participantes aderentes, comparados com 58,5
 a 99,8 para não-aderentes. A redução média na carga viral variou de 4,25 a 4,62
 log cópias/mL entre aderentes, comparados com 1,99 a 4,07 para não-aderentes. O
 monitoramento da adesão à terapia antirretroviral deve ser uma prioridade nos s
erviços de referência de AIDS, sendo capaz de identificar pacientes com alto ris
co de desenvolver falência virológica e permitindo intervenções precoces com pos
sibilidade de preservação de esquemas terapêuticos iniciais.#^ddecs^i2#^tm^lpt^k
Anti-Retrovirais^i2#^tm^lpt^kSíndrome de Imunodeficiência Adquirida^i2#^tm^lpt^k
Carga Viral^i2#^tm^lpt^kContagem de Linfócito CD4^i2#^tm^lpt^kAdesão à Medicação
^i2#National Program of STD#AIDS, Brazilian Ministry of Health#UNESCO#914 BRA 30
14#vancouv#35#20091105#05/Nov/2009#20100218#18/Feb/2010#20100405#05/Apr/2010#08.
htm##
04482000000000757000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400110013703500100014801200980
01580120102002560100034003580100032003920100039004240100041004630700067005040700
10000571070008900671070008900760083110500849085001001954085003501964085004701999
08500230204608500330206908500330210208311280213508500100326308500290327308500510
33020850024033530850038033770850031034150590083034460580035035290580007035640600
07203571117000803643072000303651112000903654111001203663116000903675115001203684
114000903696113001203705002000703717#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.
htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#08#CSP330#nd#Cad. Saúde Pública#
27#1#20110000#^fs67^ls78#0102-311X#<b>Monitoring adherence to antiretroviral tre
atment in Brazil</b>: <b>an urgent challenge</b>^len#<b>Monitoramento da adesão 
ao tratamento antirretroviral no Brasil</b>: <b>um urgente desafio</b>^lpt#^rND^
1A01^nGustavo Machado^sRocha#^rND^1A02^nCarla Jorge^sMachado#^rND^1A03^nFrancisc
o de Assis^sAcurcio#^rND^1A04^nMark Drew Crosland^sGuimarães#Universidade Federa
l de São João Del-Rei^iA01^cDivinópolis^pBrasil#Universidade Federal de Minas Ge
rais^iA02^1Faculdade de Ciências Econômicas^cBelo Horizonte^pBrasil#Universidade
 Federal de Minas Gerais^iA03^1Faculdade de Farmácia^cBelo Horizonte^pBrasil#Uni
versidade Federal de Minas Gerais^iA04^1Faculdade de Medicina^cBelo Horizonte^pB
rasil#^len^aThe aim of this study was to describe the effect of non-adherence on
 the main laboratory outcomes, TCD4+ lymphocyte count and viral load, routinely 
used to monitor patients initiating treatment according to three different appro
aches to measure adherence to antiretroviral therapy. Among 288 participants, 22
.9%, 31.9% and 74.3% were considered non-adherent, according to medical charts, 
self-report and pharmacy records, respectively. Depending on the adherence measu
res used, the average gain in TCD4+ lymphocyte count ranged from 142.4 to 195.4 
cells/mm3 among adherent patients, and from 58.5 to 99.8 lymphocytes TCD4+/mm3 a
mong those non-adherent. The average reduction on viral load ranged from 4.25 to
 4.62 log copies/mL among the adherent patients, and from 1.99 to 4.07 log among
 those non-adherent. Monitoring antiretroviral adherence should be considered a 
priority in these public AIDS referral centers in order to identify patients at 
high risk of developing virologic failure. Early interventions are necessary in 
order to maintain the initial therapeutic regimens for longer periods.#^ddecs^i1
#^tm^len^kAnti-Retroviral Agents^i1#^tm^len^kAcquired Immunodeficiency Syndrome^
i1#^tm^len^kViral Load^i1#^tm^len^kCD4 Lymphocyte Count^i1#^tm^len^kMedication A
dherence^i1#^lpt^aO objetivo deste estudo foi descrever o efeito da não-adesão n
os principais desfechos laboratoriais, contagem de linfócitos TCD4+ e carga vira
l, rotineiramente utilizados para monitoramento de pacientes iniciando tratament
o segundo três diferentes formas de medir adesão à terapia antirretroviral. Entr
e 288 participantes, 22,9%, 31,9% e 74,3% foram considerados não-aderentes, resp
ectivamente, pelos registros em prontuários médicos, autorrelato e registros de 
dispensação nas farmácias. Dependendo da medida de adesão utilizada, o ganho méd
io de linfócitos TCD4+ variou de 142,4 a 195,4 células/mm<sup>3</sup> para parti
cipantes aderentes, comparados com 58,5 a 99,8 para não-aderentes. A redução méd
ia na carga viral variou de 4,25 a 4,62 log cópias/mL entre aderentes, comparado
s com 1,99 a 4,07 para não-aderentes. O monitoramento da adesão à terapia antirr
etroviral deve ser uma prioridade nos serviços de referência de AIDS, sendo capa
z de identificar pacientes com alto risco de desenvolver falência virológica e p
ermitindo intervenções precoces com possibilidade de preservação de esquemas ter
apêuticos iniciais.#^ddecs^i2#^tm^lpt^kAnti-Retrovirais^i2#^tm^lpt^kSíndrome de 
Imunodeficiência Adquirida^i2#^tm^lpt^kCarga Viral^i2#^tm^lpt^kContagem de Linfó
cito CD4^i2#^tm^lpt^kAdesão à Medicação^i2#<span style='font-size: 10.0pt;font-f
amily:Verdana'>National Program of STD</span>#AIDS, Brazilian Ministry of Health
#UNESCO#<span style='font-size:10.0pt;font-family: Verdana'>914 BRA 3014</span>#
vancouv#35#20091105#05/Nov/2009#20100218#18/Feb/2010#20100405#05/Apr/2010#08.htm
##
04501000000000781000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090038000400094121000300098049000700101
15800030010803000190011103100030013013100020013306500090013501400110014403500100
01550120084001650120088002490100034003370100032003710100039004030100041004420700
06900483070010200552070009100654070009100745083112600836085001001962085003501972
08500470200708500230205408500330207708500330211008311440214308500100328708500290
32970850051033260850024033770850038034010850031034390590024034700580035034940580
00703529060001303536117000803549072000303557112000903560111001203569116000903581
115001203590114000903602113001203611002000703623008008903630#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\08.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#gra#tab#0
8#CSP330#nd#Cad. saúde pública#27#1#20110000#^fs67^ls78#0102-311X#Monitoring adh
erence to antiretroviral treatment in Brazil: an urgent challenge^len#Monitorame
nto da adesão ao tratamento antirretroviral no Brasil: um urgente desafio^lpt#^r
ND^1A01^nGustavo Machado^sRocha#^rND^1A02^nCarla Jorge^sMachado#^rND^1A03^nFranc
isco de Assis^sAcurcio#^rND^1A04^nMark Drew Crosland^sGuimarães#^iA01^1Universid
ade Federal de São João Del-Rei^cDivinópolis^pBrasil#^iA02^1Universidade Federal
 de Minas Gerais^2Faculdade de Ciências Econômicas^cBelo Horizonte^pBrasil#^iA03
^1Universidade Federal de Minas Gerais^2Faculdade de Farmácia^cBelo Horizonte^pB
rasil#^iA04^1Universidade Federal de Minas Gerais^2Faculdade de Medicina^cBelo H
orizonte^pBrasil#^len^aThe aim of this study was to describe the effect of non-a
dherence on the main laboratory outcomes, TCD4+ lymphocyte count and viral load,
 routinely used to monitor patients initiating treatment according to three diff
erent approaches to measure adherence to antiretroviral therapy. Among 288 parti
cipants, 22.9 percent, 31.9 percent and 74.3 percent were considered non-adheren
t, according to medical charts, self-report and pharmacy records, respectively. 
Depending on the adherence measures used, the average gain in TCD4+ lymphocyte c
ount ranged from 142.4 to 195.4 cells/mm3 among adherent patients, and from 58.5
 to 99.8 lymphocytes TCD4+/mm3 among those non-adherent. The average reduction o
n viral load ranged from 4.25 to 4.62 log copies/mL among the adherent patients,
 and from 1.99 to 4.07 log among those non-adherent. Monitoring antiretroviral a
dherence should be considered a priority in these public AIDS referral centers i
n order to identify patients at high risk of developing virologic failure. Early
 interventions are necessary in order to maintain the initial therapeutic regime
ns for longer periods.#^ddecs^i1#^tm^len^kAnti-Retroviral Agents^i1#^tm^len^kAcq
uired Immunodeficiency Syndrome^i1#^tm^len^kViral Load^i1#^tm^len^kCD4 Lymphocyt
e Count^i1#^tm^len^kMedication Adherence^i1#^lpt^aO objetivo deste estudo foi de
screver o efeito da não-adesão nos principais desfechos laboratoriais, contagem 
de linfócitos TCD4+ e carga viral, rotineiramente utilizados para monitoramento 
de pacientes iniciando tratamento segundo três diferentes formas de medir adesão
 à terapia antirretroviral. Entre 288 participantes, 22,9 por cento, 31,9 por ce
nto e 74,3 por cento foram considerados não-aderentes, respectivamente, pelos re
gistros em prontuários médicos, autorrelato e registros de dispensação nas farmá
cias. Dependendo da medida de adesão utilizada, o ganho médio de linfócitos TCD4
+ variou de 142,4 a 195,4 células/mm³ para participantes aderentes, comparados c
om 58,5 a 99,8 para não-aderentes. A redução média na carga viral variou de 4,25
 a 4,62 log cópias/mL entre aderentes, comparados com 1,99 a 4,07 para não-adere
ntes. O monitoramento da adesão à terapia antirretroviral deve ser uma prioridad
e nos serviços de referência de AIDS, sendo capaz de identificar pacientes com a
lto risco de desenvolver falência virológica e permitindo intervenções precoces 
com possibilidade de preservação de esquemas terapêuticos iniciais.#^ddecs^i2#^t
m^lpt^kAnti-Retrovirais^i2#^tm^lpt^kSíndrome de Imunodeficiência Adquirida^i2#^t
m^lpt^kCarga Viral^i2#^tm^lpt^kContagem de Linfócito CD4^i2#^tm^lpt^kAdesão à Me
dicação^i2#National Program of STD#AIDS, Brazilian Ministry of Health#UNESCO#914
 BRA 3014#vancouv#35#20091105#05/Nov/2009#20100218#18/Feb/2010#20100405#05/Apr/2
010#08.htm#Internet^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S010
2-311X2011001300008##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#5#1#article#173#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#08.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#6#2#article#173#<p>&nbsp;</p>     ^cY#08.htm
##
00411000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704019100067002000700258#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#7#3#article#173#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Monitoring    adherence 
to antiretroviral treatment in Brazil: an urgent challenge</b> </font></p>     ^
cY#08.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#8#4#article#173#<p>&nbsp;</p>     ^cY#08.htm
##
00403000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704018300067002000700250#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#9#5#article#173#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Monitoramento    da ades&atilde;o ao trata
mento antirretroviral no Brasil: um urgente desafio</b></font></p>     ^cY#08.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#10#6#article#173#<p>&nbsp;</p>     ^cY#08.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#11#7#article#173#<p>&nbsp;</p>     ^cY#08.ht
m##
00476000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704025500068002000700323#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#12#8#article#173#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Gustavo Machado    Rocha<sup>I</sup>; Car
la Jorge Machado<sup>II</sup>; Francisco de Assis Acurcio<sup>III</sup>;    Mark
 Drew Crosland Guimar&atilde;es<sup>IV</sup></b></font></p>     ^cY#08.htm##
00389000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704016800068002000700236#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#13#9#article#173#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Universidade    Federal de S&ati
lde;o Jo&atilde;o Del-Rei, Divin&oacute;polis, Brasil    ^cY#08.htm##
00359000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013700069002000700206#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#14#10#article#173#<br>   <sup>II</sup>Faculd
ade de Ci&ecirc;ncias Econ&ocirc;micas, Universidade Federal    de Minas Gerais,
 Belo Horizonte, Brasil    ^cY#08.htm##
00344000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012200069002000700191#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#15#11#article#173#<br>   <sup>III</sup>Facul
dade de Farm&aacute;cia, Universidade Federal de Minas Gerais,    Belo Horizonte
, Brasil    ^cY#08.htm##
00348000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012600069002000700195#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#16#12#article#173#<br>   <sup>IV</sup>Faculd
ade de Medicina, Universidade Federal de Minas Gerais, Belo    Horizonte, Brasil
</font></p>     ^cY#08.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#17#13#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#18#14#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#19#15#article#173#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#08.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#20#16#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#08.htm##
01445000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704122300069002000701292#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#21#17#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The aim of this    study was to describe th
e effect of non-adherence on the main laboratory outcomes,    TCD4+ lymphocyte c
ount and viral load, routinely used to monitor patients initiating    treatment 
according to three different approaches to measure adherence to antiretroviral  
  therapy. Among 288 participants, 22.9%, 31.9% and 74.3% were considered non-ad
herent,    according to medical charts, self-report and pharmacy records, respec
tively.    Depending on the adherence measures used, the average gain in TCD4+ l
ymphocyte    count ranged from 142.4 to 195.4 cells/mm3 among adherent patients,
 and from    58.5 to 99.8 lymphocytes TCD4+/mm3 among those non-adherent. The av
erage reduction    on viral load ranged from 4.25 to 4.62 log copies/mL among th
e adherent patients,    and from 1.99 to 4.07 log among those non-adherent. Moni
toring antiretroviral    adherence should be considered a priority in these publ
ic AIDS referral centers    in order to identify patients at high risk of develo
ping virologic failure.    Early interventions are necessary in order to maintai
n the initial therapeutic    regimens for longer periods.</font></p>     ^cY#08.
htm##
00447000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022500069002000700294#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#22#18#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Anti-Retroviral    Agents; Acquired Immunod
eficiency Syndrome; Viral Load; CD4 Lymphocyte Count;    Medication Adherence</f
ont></p> <hr size="1" noshade>     ^cY#08.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#23#19#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#08.htm##
01704000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704148200069002000701551#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#24#20#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O objetivo deste    estudo foi descrever o 
efeito da n&atilde;o-ades&atilde;o nos principais desfechos    laboratoriais, co
ntagem de linf&oacute;citos TCD4+ e carga viral, rotineiramente    utilizados pa
ra monitoramento de pacientes iniciando tratamento segundo tr&ecirc;s    diferen
tes formas de medir ades&atilde;o &agrave; terapia antirretroviral. Entre    288
 participantes, 22,9%, 31,9% e 74,3% foram considerados n&atilde;o-aderentes,   
 respectivamente, pelos registros em prontu&aacute;rios m&eacute;dicos, autorrel
ato    e registros de dispensa&ccedil;&atilde;o nas farm&aacute;cias. Dependendo
 da    medida de ades&atilde;o utilizada, o ganho m&eacute;dio de linf&oacute;ci
tos    TCD4+ variou de 142,4 a 195,4 c&eacute;lulas/mm<sup>3</sup> para particip
antes    aderentes, comparados com 58,5 a 99,8 para n&atilde;o-aderentes. A redu
&ccedil;&atilde;o    m&eacute;dia na carga viral variou de 4,25 a 4,62 log c&oac
ute;pias/mL entre    aderentes, comparados com 1,99 a 4,07 para n&atilde;o-adere
ntes. O monitoramento    da ades&atilde;o &agrave; terapia antirretroviral deve 
ser uma prioridade nos    servi&ccedil;os de refer&ecirc;ncia de AIDS, sendo cap
az de identificar pacientes    com alto risco de desenvolver fal&ecirc;ncia viro
l&oacute;gica e permitindo    interven&ccedil;&otilde;es precoces com possibilid
ade de preserva&ccedil;&atilde;o    de esquemas terap&ecirc;uticos iniciais.</fo
nt></p>     ^cY#08.htm##
00497000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027500069002000700344#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#25#21#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Anti-Retrovirais;    S&iacute;ndrome de Imu
nodefici&ecirc;ncia Adquirida; Carga Viral; Contagem de    Linf&oacute;cito CD4;
 Ades&atilde;o &agrave; Medica&ccedil;&atilde;o</font></p> <hr size="1" noshade>
     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#26#22#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#27#23#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#28#24#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#08.h
tm##
01019000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079700069002000700866#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#29#25#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The highly active    antiretroviral therapy
 (HAART), introduced in 1996, had a great impact in the    reduction of morbidit
y and mortality of individuals living with HIV/AIDS. In    Brazil, the universal
 distribution of antiretroviral (ARV) medication by the    Unified National Heal
th System (SUS) was guaranteed by law sanctioned in the    same year <sup>1</sup
>. In this scenario, AIDS was no longer a disease with    high letality rate, an
d it started being considered a potentially controllable    chronic disease. Ini
tial studies that evaluated the effect of antiretroviral    therapy (ART) showed
 a reduction of about 70% in mortality and of 80% in the    incidence of opportu
nistic infections <sup>2</sup>.</font></p>     ^cY#08.htm##
00838000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061600069002000700685#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#30#26#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">According to data    provided by the Minist
ry of Health <sup>3</sup>, there were 15,156 AIDS-related    deaths in Brazil in
 1995 and 11,060 in 2007, which represents a reduction of    about 27% in the to
tal number of deaths in the country. In recent years, with    the great availabi
lity of therapeutic choice, including drugs that are newer,    more powerful, sa
fer and present more convenient dosage <sup>4</sup>, the possibility    of reach
ing these benefits and improving the quality of life of these patients    is eve
n greater.</font></p>     ^cY#08.htm##
00836000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061400069002000700683#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#31#27#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, the success    of ART depends on m
any factors such as issues related to the access to treatment    and health serv
ices, viral characteristics and immunity response, besides behavioral    factors
 related to an individual, especially adherence to the treatment. According    t
o guidelines of the Ministry of Health <sup>5</sup>, adherence must be understoo
d    as a complex, wide, comprehensive, dynamic, and multifactorial process, det
ermined    by factors related to the individual, the health team and the social 
network.</font></p>     ^cY#08.htm##
01647000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704142500069002000701494#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#32#28#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Based on this complexity,    measuring adhe
rence to antiretroviral medication is difficult to be precisely    performed, wi
th no gold standard defined for its ascertainment. There is great    variability
 in the available adherence measurement with different implications    for clini
cal and research practices. Among them we mention the self-report verified    by
 structured interviews, pills count, medical and pharmacy records, electronic   
 devices, monitoring of therapeutic serum level, pictorial methods (e.g. daily  
  registries of medications, self-applicable interview <sup>6,7</sup>) and, fina
lly,    combined methods are examples of adherence measurements used in several 
studies    <sup>8,9</sup>. All of these measurements present limitations and pro
blems,    either practical or methodological, which may overestimate or underest
imate    the adherence. This wide variability complicates the interpretation of 
results    and their comparison. The measurement of adherence by self-report use
 is the    most frequently used and it has the advantages of a more accessible c
osts, practicality    and convenience of application, besides reasonable correla
tion with virologic    outcomes. Conversely, there are disadvantages such as lac
k of standard questions,    low sensitivity and a tendency to overestimate adher
ence <sup>10</sup>.</font></p>     ^cY#08.htm##
01239000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704101700069002000701086#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#33#29#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In order to obtain    therapeutic success a
nd reach undetectable plasma levels of HIV viral load,    high levels of adheren
ce, usually 95% or more, are necessary, as shown by several    studies <sup>11</
sup>. In addition to providing lower viral replication, high    adherence, also 
provides longer survival, lower incidence AIDS related diseases,    fewer hospit
alizations <sup>12</sup>, better quality of life <sup>13</sup>,    reduction of 
HIV transmission, and reduced emergence of virus strains resistant    to ARV <su
p>14</sup>. However, the great variability in the definition of non-adherence   
 used in the studies, both in the cutoff points (ranging from 80 to 100% of pres
cribed    doses), as well as in the evaluated treatment period (from one day up 
to 12    months) complicates national or international comparisons. More recent 
studies    tend to be more conservative with higher cutoff points and wider reca
ll periods.</font></p>     ^cY#08.htm##
01378000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704115600069002000701225#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#34#30#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A complete adherence    ART must be underst
ood as the primary objective of health services caring for    people living with
 HIV/AIDS. Despite this, Brazilian studies indicate average    rates of non-adhe
rence ranging between 5.7% and 67%, with 43.2% of studies reporting    values be
tween 17.5% and 30% <sup>8</sup>, showing a critical situation for    clinical m
onitoring of patients. In a more recent study, Wachholz &amp; Ferreira    <sup>1
5</sup> evaluated children up to 12 years living in the city of Porto    Alegre,
 Rio Grande do Sul State, and found a high rate of non-adherence (about    50% o
f the participants). Another study <sup>16</sup>, performed in the city    of Tu
bar&atilde;o, Santa Catarina State, found a non-adherence rate ranging    from 1
9.5% to 52.5%, depending on the definition of adherence and the analyzed    peri
od. However, in other multicenter studies recently performed in the Federal    D
istrict <sup>17 </sup>and in the state of Pernambuco <sup>18</sup>, 23.3% and   
 25.7% of the participants were, respectively considered non-adherent.</font></p
>     ^cY#08.htm##
00822000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060000069002000700669#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#35#31#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Thus, it is necessary    to implement stand
ardized procedures to monitor the adherence among service    users in order to e
nable early detection of non-adherence and the implementation    of appropriate 
intervention strategies, ideally before the emergence of viral    resistance and
 the occurrence of complications related to AIDS. In addition    to the individu
al benefits, these actions have the potential to reduce the costs    with medica
tions as simpler treatment regimens remain effective for extended    time.</font
></p>     ^cY#08.htm##
00782000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056000069002000700629#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#36#32#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The main purpose    of this study was to de
scribe the effect of non-adherence on the main laboratory    outcomes, i.e., inc
rease in TCD4+ lymphocytes counts and reduction in the HIV    viral load, accord
ing to three different methods of measuring adherence (self-report,    registry 
of pharmacy dispensation and medical records) among patients starting    antiret
roviral treatment in two reference public health services in the city    of Belo
 Horizonte, state of Minas Gerais.</font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#37#33#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00323000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010100069002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#38#34#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methodology</b></font></p>     ^cY#08.ht
m##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#39#35#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Subjects    and design</u></b></font>
</p>     ^cY#08.htm##
01130000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704090800069002000700977#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#40#36#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This study is part    of ATAR project <sup>
19</sup>, a prospective concurrent study whose main purpose    was to evaluate a
dherence to antiretroviral treatment among individuals starting    therapy. Meth
odological details have been previously publish-ed <sup>20</sup>.    The project
 was carried out in two HIV/AIDS public referral services in the    city of Belo
 Horizonte, Orestes Diniz Center for Training and Reference of Infectious    and
 Parasite Diseases (CTR-DIP - Municipality of Belo Horizonte and Federal    Univ
ersity of Minas Gerais - UFMG), and Eduardo de Menezes Hospital outpatient    ce
nter (HEM - Hospital Foundation of Minas Gerais). After the first ARV prescripti
on,    na&iuml;ve treated patients were monitored for a period of up to 12 month
s to    evaluate the occurrence of non-adherence to treatment.</font></p>     ^c
Y#08.htm##
01052000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083000069002000700899#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#41#37#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The patients were    recruited between May 
2001 and May 2002 and monitored until May 2003. Inclusion    criteria were patie
nts confirmed with HIV infection and indication for antiretroviral    therapy ac
cording to the Brazilian recommendations in the period <sup>21</sup>,    without
 history of previous ARV use, age 18 years old or over, and who agreed    to par
ticipate and had their medication provided by one of the participant centers.   
 For this analysis, pregnant women were excluded due to the specificity of their
    antiretroviral treatment whose early interruption may occur due to medical i
ndication.    The ATAR Project was approved by the Ethical Research Committee of
 both participant    services and the UFMG - COEP (ETIC 106/99).</font></p>     
^cY#08.htm##
01613000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704139100069002000701460#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#42#38#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Semi-structured    interviews were applied 
at the moment of the ARV dispensation (baseline interview),    when social econo
mic and demographic data were collected (e.g. age, skin color,    marital status
, education level), vulnerability characteristics to HIV/AIDS    (e.g. use of dr
ugs, sexual behavior), and variables indicator of health services    utilization
 (e.g. date of anti-HIV test, duration of medical follow-up, knowledge    about 
HIV/AIDS). Subsequent interviews were performed in the first, fourth and    seve
nth month after the beginning of treatment (follow-up interviews), with    the c
ollection of behavioral characteristics and information related to ART    (e.g. 
occurrence of side effects and change of medication, difficulties and    easines
s related to treatment, adherence to the ARV regimens). The maximum period    of
 follow-up was 12 months. Monthly ARV dispensations records were collected    in
 the pharmacies of the participating centers after the follow-up period. Clinica
l    and laboratory data were obtained from medical records (e.g. transmission c
ategory,    duration of follow-up, hospitalizations and AIDS related conditions,
 results    of TCD4 + lymphocytes counts and HIV viral load). All instruments us
ed in data    collection were previously tested in a pilot study.</font></p>    
 ^cY#08.htm##
00604000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704038200069002000700451#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#43#39#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Continuous variables    obtained during the
 baseline interview, i.e. age, education level, income, time    between HIV+ dia
gnosis and the first prescription of ARV, and time between the    first medical 
visit and first prescription of ARV were categorized using the    median value a
s cut-off point.</font></p>     ^cY#08.htm##
00344000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012200069002000700191#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#44#40#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Adherence    measurements</u></b></fo
nt></p>     ^cY#08.htm##
00621000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039900069002000700468#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#45#41#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For this analysis    we used three measurem
ents of adherence to antiretroviral treatment according    to ATAR project proto
col: self-report <sup>20</sup>, ARV pharmacy dispensation    records <sup>22</su
p>, and medical records <sup>19</sup>. Only the first episode    of non-adherenc
e was considered for all of them.</font></p>     ^cY#08.htm##
00330000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010800069002000700177#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#46#42#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Self-report</b></font></p>     ^c
Y#08.htm##
00951000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072900069002000700798#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#47#43#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The adherence measured    by the self-repor
t was obtained during the follow-up interviews and defined    as taking at least
 95% of the prescribed dosages in the three days prior to    the interviews. For
 patients whose treatment was altered, we considered the    current regimen at t
he time of the interview. For this analysis, all individuals    who had at least
 one follow-up interview were included, while the assessment    of non-adherence
 was performed in all available visits for each participant.    The outcome of i
nterest was considered as the first episode of non-adherence    reported in the 
first, second or third follow-up interview.</font></p>     ^cY#08.htm##
00351000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012900069002000700198#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#48#44#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Pharmacy    dispensation records<
/b></font></p>     ^cY#08.htm##
01679000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704145700069002000701526#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#49#45#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The adherence measured    by the pharmacy r
ecords was obtained by means of transcription of all ARV monthly    dispensation
s at the participant services up to the 12th month of follow-up,    including pr
escribed and dispensed regimens, dosages and posology. For this    analysis, the
 interval between ARV withdrawals was calculated in days. Differences    superio
r to 34 days were considered irregular dispensation <sup>22</sup>. In    additio
n to this interval, the number of dispensed pills was evaluated taking    into a
ccount the prescribed dosage and regimen. In exceptional cases - when    the ser
vice authorized anticipated withdrawals of larger quantities of ARV -    both th
e time and the pill count were adjusted for the monthly period. This    way, the
 ARV withdrawals for this analysis were characterized in three groups:    (1) re
gular (when there was no irregularity, neither in the interval nor in    the dis
pensed amount); (2) irregular (whenever the time between the dispensations    wa
s superior to 34 days or whenever the number of dispensed pills was inferior    
to 95% of the total pills expected for each prescribed ARV regimen); and, (3)   
 abandonment (whenever the patient remained more than 60 days without withdrawin
g    the ARV and did not return until the 12<sup>th</sup> month of follow-up), e
xcluding    deaths and transfers to other services.</font></p>     ^cY#08.htm##
00337000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011500069002000700184#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#50#46#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>&#149; Medical    records</b></font></p>
     ^cY#08.htm##
00838000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061600069002000700685#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#51#47#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The adherence measured    using medical rec
ords was performed by means of standardized transcription,    after closing of t
he monitoring period. All medical appointments were checked,    from the first p
rescription up to the 12<sup>th</sup> month of follow-up. Any    annotation indi
cating non-adherence to the antiretroviral regimen were recorded    (e.g. missin
g one dosage, skipping one day). Individuals whose medical records    did not co
ntain any annotation of non-adherence during the study period were    considered
 adherent.</font></p>     ^cY#08.htm##
00334000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011200069002000700181#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#52#48#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Outcome markers</u></b></font></p>   
  ^cY#08.htm##
00568000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034600069002000700415#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#53#49#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">TCD4+ lymphocyte    count and HIV viral loa
d were used as outcome markers to compare adherent and    non-adherent patients.
 All medical visits between the first prescription and    the 12<sup>th</sup> mo
nth of follow-up were assessed for these laboratory results.</font></p>     ^cY#
08.htm##
01292000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704107000069002000701139#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#54#50#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For comparisons,    we used the first TCD4+
 lymphocyte count and viral load performed immediately    before the start of AR
T or up to one month after the first dispensation (initial    TCD4+ lymphocyte c
ount and viral load) and the last exams registered in the    medical record duri
ng the period of study (final TCD4+ lymphocyte count and    viral load). In orde
r to allow proper assessment of the treatment response,    only those exams perf
ormed at least three months after the first prescription    of the ARV were cons
idered as the last registered exams <sup>4</sup>. For patients    with both meas
urements available (initial and final), the immunological response    to treatme
nt was verified by the average gain of TCD4+ lymphocyte, and the virological    
response by the average reduction in HIV viral load. TCD4+ lymphocytes count    
was expressed in cells per cubic millimeter while the viral load was expressed  
  as the logarithm of viral RNA copies per milliliter of plasma.</font></p>     
^cY#08.htm##
00342000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012000069002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#55#51#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Statistical    analysis</u></b></font
></p>     ^cY#08.htm##
02418000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704219600069002000702265#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#56#52#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A descriptive analysis    of each adherence
 measurement, baseline characteristics and the outcome variables    was performe
d, with frequency distribution of categorical variables and central    tendency 
measurements of continuous variables (mean and median) of exam results    (TCD4+
 lymphocyte and viral load). For each adopted measurement of adherence,    the p
roportion of patients who fulfilled the respective criteria of non-adherence    
was estimated. The average gain of TCD4+ lymphocytes and the average reduction  
  in the logarithm of viral load were estimated by comparing the final and initi
al    exams for patients who had both measurements. Student's t test for indepen
dent    samples was used for comparison of these averages between the adherent a
nd non-adherent    groups, for each adherence measurement adopted. ANOVA was use
d for comparison    of averages of values abtained from pharmacy records. In sit
uations where the    assumption of homoscedasticity was not observed, the t test
 with approximation    of Satterthwaiste or the Welch test <sup>23</sup> were us
ed. According to the    parameters adopted by the Brazilian <sup>4</sup> and the
 American <sup>24</sup>    therapeutic guidelines, it is expected an average inc
rease in the TCD4+ lymphocyte    counts of 100-150 cells/mm<sup>3</sup>/year and
 an undetectable viral loads    after 6 to 12 months of treatment. This way, for
 each adherence method adopted,    the proportion of patients who obtained an av
erage gain of TCD4+ lymphocytes    higher than 100 cells/mm<sup>3</sup> or who r
eached a viral load lower than    400 copies/mL during the study period was also
 compared between the adherent    and non-adherent groups. Chi-square test was u
sed to assess the statistical    differences between proportions and the relativ
e risk with 95% confidence interval    (95%CI) was used to estimate the magnitud
e of the associations. For all analysis,    the significance level considered wa
s 0.05. The data were stored in Paradox    (version 11.0 - Borland International
, Scotts Valley, USA) and analyzed with    SAS (SAS Inst., Cary, USA).</font></p
>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#57#53#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#58#54#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#08.htm##
01080000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085800069002000700927#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#59#55#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Among the 407 recruited    patients that fu
lfilled the criteria for this analysis, 347 agreed to participate    in the stud
y (85.3%), and among these 307 (88.5%) had at least one follow-up    visit, 280 
(80.7%) had at least two follow-up visits, and 201 (57.9%) had all    three foll
ow-up visits. The overall mean time of follow-up was 176 days, while    the mean
 times between the baseline interview and the first, second and third    follow-
up visits were 40, 142 and 248 days, respectively. There were no statistically  
  significant differences between participants and nonparticipants regarding age
,    gender and participating centers <sup>19</sup>. The recruited patients repr
esented    more than 90% of AIDS cases reported in the municipality during the s
tudy period.</font></p>     ^cY#08.htm##
00651000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042900069002000700498#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#60#56#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We were able to    obtain adherence measure
ments according to self-report, pharmacy records or    medical records for 307 (
88.5%), 323 (93.1%), and 340 (98%) of the patients,    respectively. The combina
tion of participants who had the three adherence measurements    resulted in a f
inal sample of 288 participants (83%) for the present analysis.</font></p>     ^
cY#08.htm##
00926000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704070400069002000700773#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#61#57#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The baseline characteristics    of the stud
y population are presented in <a href="#t1">Table 1</a>. Of 288 participants,   
 66% were males, 53.1% were below age 35, most were non white (73.3%), with low 
   education level (63.4%) and with monthly individual income lower than the min
imum    wage (55.3%). The behavioral characteristic indicate a low proportion of
 lifetime    condom use (66.1% of patients reported never using or using less th
an half of    the times). About one third of the participants reported to smoke 
and 37.2%    reported having drunk alcoholic beverages in the month before the b
aseline interview.</font></p>     ^cY#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#62#58#article#173#<p><a name="t1"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#63#59#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#64#60#article#173#<p align="center"><img src
="/img/revistas/csp/v27s1/08t01.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#65#61#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
01337000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704111500069002000701184#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#66#62#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Most of the participants    were recruited 
from the CTR/DIP (80.2%). Of the total, 9.1% reported difficulties    in access 
to the center, and only 5.8% were receiving psychological support.    However, m
ost individuals (75.1%) satisfactorily understood the information    provided on
 antiretroviral treatment (drug name, dosage and frequency of use,    adverse re
actions, indication and duration of treatment, precautions, and timing    of foo
d intake). The baseline clinical characteristics indicate that a large    propor
tion of patients started their ART late (67.7%), i.e., with TCD+4 lymphocyte    
count lower than 200 cells/mm3 or with CDC "C" clinical classification (AIDS    
diagnosis). Among the prescribed regimens, 52.4% were composed of analog or    n
on-analog nucleoside reverse transcriptase inhibitors, and 47.2% contained    pr
otease inhibitors. The most prescribed regimens (data not shown) were the    com
binations of Zidovudine + Lamivudine + Efavirenz (29.9%) and Zidovudine +    Lam
ivudine + Nelfinavir (22.6%).</font></p>     ^cY#08.htm##
01250000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704102800069002000701097#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#67#63#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A quarter of the    patients started ART wi
thout initial TCD4+ lymphocytes count and 56.6% without    baseline viral load (
VL). Among the available exams (<a href="/img/revistas/csp/v27s1/08t02.jpg">Tabl
e    2</a>), initial and final mean TCD4+ lymphocyte counts were 202 and 311 cel
ls/mm<sup>3</sup>,    respectively, while the initial and final mean viral load 
were 4.92 log (about    83,000 copies of viral/mL RNA of plasma) and 1.03 log, r
espectively. The average    time between the initial exams and the first prescri
ption of ARV was about two    months for TCD4+ lymphocytes and three months for 
the viral load. The average    interval between the first prescription and the f
inal TCD4+ lymphocytes and    viral load exams were nine and eight months, respe
ctively. At the end of the    study, most patients had reached TCD4+ lymphocyte 
count higher than 200 cells/mm<sup>3</sup>    (66.9%) and viral load lower than 
400 copies/mL (78.9%).</font></p>     ^cY#08.htm##
00991000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076900069002000700838#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#68#64#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Separate analysis    of each adherence meas
urement indicated a proportion of non-adherence ranging    from 23.7% (medical r
ecords) to 74.3% (pharmacy records) (<a href="#t3">Table    3</a>). Among patien
ts with the three adherence measurements of interest (n    = 288) these proporti
ons were considered statistically similar (p &gt; 0.05)    (22.9% for the medica
l records, 31.9% for self-report and 74.3% for pharmacy    records - irregular w
ithdrawal and abandonment of treatment). Among these 288    patients, 31 (10.9%)
 were classified as non-adherent by the three measurements    simultaneously, wh
ile 58 (20.4%) were considered adherent by the combination    of the three metho
ds.</font></p>     ^cY#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#69#65#article#173#<p><a name="t3"></a></p>  
   ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#70#66#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#71#67#article#173#<p align="center"><img src
="/img/revistas/csp/v27s1/08t03.jpg"></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#72#68#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
01845000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704162300069002000701692#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#73#69#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In a clear way,    individuals considered a
dherent had greater average gain of TCD4+ lymphocyte    and greater average redu
ction of HIV viral load when compared to non-adherent    ones (<a href="/img/rev
istas/csp/v27s1/08t04.jpg">Table 4</a> and <a href="/img/revistas/csp/v27s1/08f0
1.jpg">Figure    1</a>). According to the adherence measurement by self-report, 
the average gain    of TCD4+ lymphocyte was 144.6 cells/mm<sup>3</sup> and the a
verage reduction    of viral load was 4.52 log for those considered adherent, co
mpared to an average    gain of 86.3 TCD4+ lymphocyte/mm<sup>3</sup> (p = 0.023)
, and an average reduction    of 2.73 log in the viral load for those considered
 non-adherent (p &lt; 0.001).    For pharmacy records, individuals with irregula
r withdrawal of medication obtained    an average gain of 195.4 TCD4+ lymphocyte
/mm3 and an average reduction of 4.62    log in the viral load. Conversely, amon
g those with irregular withdrawal and    abandonment of therapy, the average gai
n was respectively 99.8 and 19.3 TCD4+    lymphocyte/mm<sup>3</sup> (p &lt; 0.00
1), with an average reduction of 4.07    and 2.41 log in the viral load (p &lt; 
0.001) in each group respectively. Similar    results were obtained for medical 
records. There was an average increase of    142.4 for adherent patients and 58.
5 TCD4+ lymphocyte/mm<sup>3</sup> for those    non-adherent (p &lt; 0.001), with
 an average reduction of 4.25 and 1.99 log    in the viral load among adherent a
nd non-adherent patients, respectively (p    &lt; 0.001).</font></p>     ^cY#08.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#74#70#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00972000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075000069002000700819#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#75#71#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The proportion    of individuals with final
 viral load lower than 400 copies/mL was also significantly    greater among adh
erent individuals as compared to those non-adherent, regardless    of the adopte
d adherence measurement (<a href="/img/revistas/csp/v27s1/08t04.jpg">Table    4<
/a>), 83.3% and 66% (p = 0.010), and 86.6% and 46% for respectively self-report 
   and medical records (p &gt; 0.001). Finally pharmacy records indicated that  
  the proportional of individuals with final viral load lower than 400 copies/mL
,    was 89.8%, 84.5% and 47.4% for patients with regular and irregular withdraw
al    or abandonment of treatment , respectively (p &lt; 0.001).</font></p>     
^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#76#72#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#77#73#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#08.htm
##
01315000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704109300069002000701162#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#78#74#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">ATAR project was    the first prospective s
tudy to evaluate adherence among people living with HIV/AIDS    starting antiret
roviral therapy in Brazil. In the present analysis, the effect    of non- adhere
nce on two markers used for monitoring ARV of treatment was compared    accordin
g to three different ways to verify adherence. We initially highlight    a high 
and concerning rate of non-adherence already in the first year of treatment,    
ranging from 22.9% to 74.3% according to the measure and definition of adherence
    used. Other Brazilian studies show compatible rates <sup>25 </sup>within thi
s    range. Brito et al. <sup>26</sup>, by analyzing records of pharmacy dispens
ation    during 6 months, found a percentage of treatment interruption of 35.9%.
 Blatt    et al. <sup>16</sup> assessed adherence using different measurements a
nd obtained    rates of non-dherence ranging from 20 to 50%, with lower values f
or self-reporting    and higher values when records of pharmacy dispensation wer
e used.</font></p>     ^cY#08.htm##
00942000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072000069002000700789#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#79#75#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">It is equally concerning    the fact that a
bout two thirds of the sample started ART late <sup>27</sup>,    a percentage co
nsidered high for a country where the policy for universal access    to treatmen
t is well consolidated. Moreover, baseline characteristics of the    sample, com
posed of patients with follow-up in public referral services, presented    a hig
h proportion of individuals with low income and education level. This could    c
ontribute with a greater occurrence of non-adherence episodes as these individua
ls    may potentially present increased vulnerability <sup>28</sup> and difficul
ties    in accessing the services.</font></p>     ^cY#08.htm##
00856000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063400069002000700703#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#80#76#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Although the theoretical    concept of non-
adherence is the same for all adopted measurements, these methods    (self-repor
t, records of pharmacy dispensation and medical records) may actually    reflect
 different contextual factors in different times, thus producing estimates    wi
th varying magnitudes. These are methodologies which present relatively low    c
ost <sup>9</sup> and are feasible to be applied in the reality of the Brazilian 
   services. However, the interpretation and comparison of the obtained results 
   should be carefully made.</font></p>     ^cY#08.htm##
01704000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704148200069002000701551#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#81#77#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Although self-report    may be more specifi
c, it loses in sensitivity as it reflects the patient's memory    and his/her wi
sh to inform correctly about the use of medication in specific    periods and in
tervals. Moreover, self-report is usually a point in time based    on a short pe
riod. This way, this method for measuring adherence is subjected    to memory an
d information bias, with a tendency to produce higher adherence    estimates tha
n direct methods <sup>29</sup>. Self-applicable pictorial methods    <sup>6,7,9<
/sup> and self-reported clinical outcomes <sup>29</sup> could theoretically    i
mprove the precision of the measurement. Despite its low cost, it requires    sp
ecific training in the application of the instruments and even if they are    si
mplified, the application may not be compatible with the reality of the routine 
   of most referral services in Brazil. In addition, patients who interrupted tr
eatment    may have also abandoned their medical follow-up and, therefore, were 
not available    for interview. In this analysis, 19.4% of patients who were con
sidered adherent    by self-report had abandoned the treatment according to the 
pharmacy records.    This fact may have occurred because these measurements were
 verified in different    times, i.e., a participant considered adherence by the
 self-report at an initial    moment may have later abandoned the treatment.</fo
nt></p>     ^cY#08.htm##
01811000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704158900069002000701658#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#82#78#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Non-adherence measured    by pharmacy dispe
nsation is more comprehensive and it covers longer periods,    and it was the on
ly measurement that was capable of identifying patients who    abandoned their m
edical follow-up at the services. It is possible that this    fact may have caus
ed an overestimate of non-adherence rate, considering both,    irregular withdra
wals and abandonment, as actual non-adherence. Taking into    account guidelines
 during the evaluated period, patients with short delays in    the withdrawal of
 their medication could actually be adherent to the therapy.    On the other han
d, regular withdrawal of the medication in the pharmacy does    not guarantee it
s correct use <sup>9</sup>. The strict definition herein adopted    for this mea
surement concept, i.e. not having had the medication dispensed up    to four day
s beyond the expected date may potentially overestimate non-adherence.    Howeve
r, we should note that we assessed all dispensations taking into account    the 
prescribed dosages and regimens, as well as transfers, unusual authorizations,  
  and deaths. Despite these observations, an irregular withdrawal of the medicat
ion    is an important marker of utilization of the services, since the Brazilia
n system    only allows ARV dispensation at public AIDS referral centers, and on
 a monthly    basis. Although pharmacy records primarily assess adherence to ser
vice, rather    than the treatment itself, this monitoring mechanism must be enh
anced and standardized.</font></p>     ^cY#08.htm##
01897000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704167500069002000701744#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#83#79#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Assessing adherence    by the medical recor
ds is not very sensitive either, as medical professionals    tend to register ne
gative episodes indicators of non-adherenece, especially    when immno-virologic
al failure indicates the need switch the ARV regimen <sup>29</sup>.    Actual re
gistration of non-adherence during the medical appointments, as recommended    b
y the Ministry of Health <sup>5</sup>, is not fully implemented in the routine  
  care of assistance to patients under ART. Many non-adherent patients end up   
 being identified only after the detection of treatment failure. Medical records
    can only detect non-adherence if patients attend to their regular follow-up 
   appointment, and it is naturally affected by long periods of absence or inter
ruption    of care. Unless there is a system for active search of absentees, pat
ients who    interrupt their medical follow-up may be considered adherence simpl
y due to    the lack of information. In this study, 56.3% of patients who stoppe
d withdrawing    medications at the pharmacies did not have any annotation of no
n-adherence in    their medical records. Therefore, they may have been erroneous
ly classified    as adherent by this source of information. A previous study car
ried out at the    same services showed a rate of interruption of medical follow
-up for more than    seven months of 54.3% <sup>30</sup>. In addition, analyses 
that are primarily    based on medical records are subject to methodological lim
itations such as under-reporting    and low reliability, which may potentially i
mpair proper interpretations.</font></p>     ^cY#08.htm##
02144000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704192200069002000701991#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#84#80#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We should emphasize    that the outcomes of
 interest assessed in this analysis, i.e., gain in TCD4+    lymphocyte count and
 reduction of HIV viral load, were better among adherent    patients as compared
 to those non-adherent, regardless of the method used to    measure adherence. T
his indicates the strength of the markers used to assess    the effect of non-ad
herence in this population. Although this effect varied    according to the adhe
rence measurement, it is evident the potential impact that    non-adherence to A
RV in these AIDS referral public centers has both, on the    immunological recov
ery and on virus control. These findings are consistent with    other previously
 published studies <sup>31,32</sup>. Tisson et al. <sup>33</sup>,    measuring a
dherence by pharmacy dispensation records, showed that the non-adherence    in t
he initial months of treatment may result in virus failure at six and 12    mont
hs after treatment began. According to these authors, the interval between    ex
ams could be adjusted according to the levels of adherence to medication,    esp
ecially in places with little availability of financial resources. Adherent    i
ndividuals, considered at a lower risk for the development of virus failure,    
could have viral load exams performed in longer intervals. Non-adherence increas
es    the chance for early switch of medication demanding the use of more powerf
ul    and more costly regimens, which may also result in a negative impact on co
st-effectiveness.    We should also note the high proportion of patients who sta
rted ARV treatment    without baseline TCD4+ lymphocyte count (25%) or HIV viral
 load (56.6%). Most    of these patients initiated treatment because of AIDS sym
ptoms, which resulted    in a high proportion of late access to treatment, as pr
eviously described <sup>27,34</sup>.</font></p>     ^cY#08.htm##
00440000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021800069002000700287#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#85#81#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite the possibility    of starting trea
tment without these exams, monitoring of the treatment effectiveness    is great
ly impaired.</font></p>     ^cY#08.htm##
01104000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704088200069002000700951#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#86#82#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In addition to    the limitations pertained
 to each one of the measurements used, the results    herein presented may not b
e representative or generalizable to other population    groups, and interpretat
ion should be taken carefully. It is a selected sample    of two large reference
 centers located in a large urban center. We limited our    analysis to those wi
th available information on immunological and virologic    markers before and af
ter the start of the treatment, which potentially reduces    the statistic power
 of the sampling. It is necessary that studies with national    coverage and rep
resentativeness be developed to evaluate the adherence to ARV    therapy, most l
ikely using a combination of methods and including less complex    services and 
with less availability of resources.</font></p>     ^cY#08.htm##
01065000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704084300069002000700912#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#87#83#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite these limitations,    there is clea
r evidence of the need for HIV/AIDS public referral services to    define mechan
isms to monitor adherence to antiretroviral treatment on a continuous    and eff
icient basis, especially at the beginning of therapy, a period in which    diffi
culties related to treatment are more frequent <sup>35</sup>. The early    ident
ification of patients with high risk of developing virus failure may allow    ef
fective interventions that increase the possibility of preservation of the    in
itial therapeutic regimens. It is also necessary that outcomes, markers of    tr
eatment effectiveness, i.e., TCD4+ lymphocyte count and viral load, be warranted
    to all patients and standardized in their periodicity from the beginning.</f
ont></p>     ^cY#08.htm##
01130000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704090800069002000700977#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#88#84#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">It is possible    that a single way of meas
uring adherence may be not adequate for all the realities.    With greater avail
ability of technological resources, a more complex approach    to adherence in t
he Brazilian health services is possible. A more precise and    of low cost meas
urement of adherence could be based on a combination of methods,    including st
andard information from the Logistic Control of Medications System    (SICLOM), 
physical and electronic medical records self-assessment mechanisms    assisted b
y computer, among others <sup>6</sup>. Moreover, higher level of investment    i
n human resources with continuing training, availability of specific professiona
ls    and reorganization of the medical assistance is needed for an adequate mon
itoring    of adherence to antiretroviral treatment in Brazil.</font></p>     ^c
Y#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#89#85#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#90#86#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#08.h
tm##
00746000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052400069002000700593#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#91#87#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">G. M. Rocha participated    in the developm
ent of all article sections, performing the revision of literature,    data anal
ysis, interpretation, discussion and composition. M. D. C. Guimar&atilde;es    p
articipated in the analysis, interpretation, orientation and revision of the    
article. C. J. Machado participated in the statistical analysis and the revision
    of the article. F. A. Acurcio participated in the revision of the article.</
font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#92#88#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00326000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010400069002000700173#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#93#89#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Acknowledgment</b></font></p>     ^cY#08
.htm##
00706000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048400069002000700553#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#94#90#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This study was    performed by the Group of
 Research in Epidemiology and Health Evaluation at    the Department of Social a
nd Preventive Medicine, Faculty of Medicine, Federal    University of Minas Gera
is, in collaboration with the Faculty of Pharmacy and    School of Nursing and t
he financial support from the National Program of STD    and AIDS, Brazilian Min
istry of Health (UNESCO 914 BRA 3014).</font></p>     ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#95#91#article#173#<p>&nbsp;</p>     ^cY#08.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#96#92#article#173#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#08.htm
##
00634000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704039800071002000700469#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#97#93#article#173#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Brasil. Lei    nº. 9.313, 
de 13 de novembro de 1996. Disp&otilde;e sobre a distribui&ccedil;&atilde;o    g
ratuita de medicamentos aos portadores de HIV e doentes de AIDS. <a href="http:/
/www.aids.gov.br/assistencia/lei9313.htm" target="_blank">http://www.aids.gov.br
/assistencia/lei9313.htm</a>    (accessed on 06/Aug/2009).    ^cY#08.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#98#94#article#173#</font></p>     ^cY#08.htm
##
00559000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704032300071002000700394#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#99#95#article#173#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Palella FJ,    Delaney MS,
 Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity    and
 mortality among patients with advanced immunodeficiency virus infection.    HIV
 Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.    ^cY#08.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#100#96#article#173#</font></p>     ^cY#08.ht
m##
00404000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704016700072002000700239#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#101#97#article#173#3#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">3. Minist&eacute;rio    da S
a&uacute;de. Boletim Epidemiol&oacute;gico AIDST 2008; Ano V, nº. 1.    ^cY#08.h
tm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#102#98#article#173#</font></p>     ^cY#08.ht
m##
00574000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704033700072002000700409#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#103#99#article#173#4#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">4. Secretaria de    Vigil&ac
irc;ncia em Sa&uacute;de, Minist&eacute;rio da Sa&uacute;de. Recomenda&ccedil;&o
tilde;es    para terapia anti-retroviral em adultos e adolescentes infectados pe
lo HIV 2007/2008.    Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de; 2007.  
  ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#104#100#article#173#</font></p>     ^cY#08.h
tm##
00624000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704038600073002000700459#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#105#101#article#173#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Programa Nacional    de 
DST e AIDS, Secretaria de Vigil&acirc;ncia em Sa&uacute;de, Minist&eacute;rio   
 da Sa&uacute;de. Diretrizes para o fortalecimento das a&ccedil;&otilde;es de   
 ades&atilde;o ao tratamento para pessoas que vivem com HIV e AIDS. Bras&iacute;
lia:    Minist&eacute;rio da Sa&uacute;de; 2007.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#106#102#article#173#</font></p>     ^cY#08.h
tm##
00559000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704032100073002000700394#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#107#103#article#173#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Santa-Helena    ET, Neme
s MIB, Eluf-Neto J. Desenvolvimento e valida&ccedil;&atilde;o de question&aacute
;rio    multidimensional para medir n&atilde;o-ades&atilde;o ao tratamento com m
edicamentos.    Rev Sa&uacute;de P&uacute;blica 2008; 42:764-7.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#108#104#article#173#</font></p>     ^cY#08.h
tm##
00506000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704026800073002000700341#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#109#105#article#173#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Bangsberg DR,    Bronsto
ne A, Hofmann R. A computer-based assessment detects regimen misunderstandings  
  and no adherence for patients on HIV antiretroviral therapy. AIDS Care 2002;  
  14:3-15.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#110#106#article#173#</font></p>     ^cY#08.h
tm##
00516000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027800073002000700351#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#111#107#article#173#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Bonolo PF, Gomes    RRFM
, Guimar&atilde;es MDC. Ades&atilde;o &agrave; terapia anti-retroviral (HIV/aids
):    fatores associados e medidas de ades&atilde;o. Epidemiol Serv Sa&uacute;de
 2007;    16:261-78.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#112#108#article#173#</font></p>     ^cY#08.h
tm##
00466000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704022800073002000700301#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#113#109#article#173#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Berg KM, Arnsten    JH. 
Practical and conceptual challenges in measuring antiretroviral adherence.    J 
Acquir Immune Defic Syndr 2006; 43 Suppl 1:S79-87.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#114#110#article#173#</font></p>     ^cY#08.h
tm##
00549000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031000074002000700384#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#115#111#article#173#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Simoni JM,    Kurth AE
, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures    of ant
iretroviral therapy adherence: a review with recommendations for hiv research   
 and clinical management. AIDS Behav 2006; 10:227-45.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#116#112#article#173#</font></p>     ^cY#08.h
tm##
00512000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027300074002000700347#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#117#113#article#173#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Paterson DL,    Swinde
lls S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease    i
nhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med    
2000; 133:21-30.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#118#114#article#173#</font></p>     ^cY#08.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#119#115#article#173#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Fielden SJ,    Rusch M
L, Yip B, Wood E, Shannon K, Levy AR, et al. Nonadherence increases the    risk 
of hospitalization among HIV-infected antiretroviral naive patients started    o
n HAART. J Int Assoc Physicians AIDS Care 2008; 7:238-44.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#120#116#article#173#</font></p>     ^cY#08.h
tm##
00482000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024300074002000700317#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#121#117#article#173#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Karon JM, Fleming    P
L, Steketee RW, De Cock KM. HIV in the United States at the turn of the century:
    an epidemic in transition. Am J Public Health 2001; 91:1060-8.    ^cY#08.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#122#118#article#173#</font></p>     ^cY#08.h
tm##
00555000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031600074002000700390#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#123#119#article#173#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Perno CF, Ceccherini-S
ilberstein    F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, et al. Virologic
 correlates    of adherence to antiretroviral medications and therapeutic failur
e. J Acquir    Immune Defic Syndr 2002; 31 Suppl 3:S118-22.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#124#120#article#173#</font></p>     ^cY#08.h
tm##
00498000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025900074002000700333#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#125#121#article#173#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Wachholz NIR,    Ferre
ira J. Adherence to antiretroviral therapy in children: a study of prevalence   
 and associated factors. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S424-3
4.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#126#122#article#173#</font></p>     ^cY#08.h
tm##
00515000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027600074002000700350#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#127#123#article#173#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Blatt CR, Citadin    C
B, Souza FG, Mello RS, Galato D. Avalia&ccedil;&atilde;o da ades&atilde;o aos   
 anti-retrovirais em um munic&iacute;pio no Sul do Brasil. Rev Soc Bras Med Trop
    2009; 42:131-6.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#128#124#article#173#</font></p>     ^cY#08.h
tm##
00519000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028000074002000700354#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#129#125#article#173#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Carvalho CV,    Mercha
n-Hamann E, Matsushita R. Determinantes da ades&atilde;o ao tratamento    anti-r
etroviral em Bras&iacute;lia, DF: um estudo de caso-controle. Rev Soc    Bras Me
d Trop 2007; 40:555-65.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#130#126#article#173#</font></p>     ^cY#08.h
tm##
00513000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027400074002000700348#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#131#127#article#173#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Silva MCF,    Ximenes 
RAA, Miranda Filho DB, Arraes LWMS, Mendes M, Melo ACS, et al. Risk-factors    f
or non-adherence to antiretroviral therapy. Rev Inst Med Trop S&atilde;o Paulo  
  2009; 51:135-9.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#132#128#article#173#</font></p>     ^cY#08.h
tm##
00751000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704051200074002000700586#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#133#129#article#173#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Guimar&atilde;es    MD
C, Acurcio FA, Freitas MIF, Bonolo PF, Ceccato MGB, Campos LN, et al. Fatores   
 associados &agrave; ades&atilde;o ao tratamento anti-retroviral (ARV) em indiv&
iacute;duos    infectados pelo HIV/AIDS: uma abordagem quantitativa e qualitativ
a, Belo Horizonte    (MG), 2001-2003 (Projeto ATAR). Relat&oacute;rio t&eacute;c
nico final (PN DST/Aids    914/BRA/3014). Bras&iacute;lia: Programa Nacional de 
DST/AIDS; 2003.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#134#130#article#173#</font></p>     ^cY#08.h
tm##
00562000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032300074002000700397#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#135#131#article#173#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Bonolo PF,    C&eacute
;sar CC, Acurcio FA, Ceccato MGB, Menezes-de-P&aacute;dua CA, Alvares    J, et a
l. Non-adherence among patients iniciating antiretroviral therapy: a    challeng
e for health professionals in Brazil. AIDS 2005; 19 Suppl 4:S5-13.    ^cY#08.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#136#132#article#173#</font></p>     ^cY#08.h
tm##
00641000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704040200074002000700476#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#137#133#article#173#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Coordena&ccedil;&atild
e;o    Nacional de DST e AIDS, Secretaria Executiva. Guia de tratamento: recomen
da&ccedil;&otilde;es    para terapia anti-retroviral em adultos e adolescentes i
nfectados pelo HIV 2002-2003.    Bras&iacute;lia: Minist&eacute;rio da Sa&uacute
;de; 2003. (S&eacute;rie A. Normas    e Manuais T&eacute;cnicos).    ^cY#08.htm#
#
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#138#134#article#173#</font></p>     ^cY#08.h
tm##
00638000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704039900074002000700473#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#139#135#article#173#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Gomes RRFM,    Machado
 CJ, Acurcio FA, Guimar&atilde;es MDC. Utiliza&ccedil;&atilde;o dos registros   
 de dispensa&ccedil;&atilde;o da farm&aacute;cia como indicador da n&atilde;o-ad
es&atilde;o    &agrave; terapia anti-retroviral em indiv&iacute;duos infectados 
pelo HIV. Cad    Sa&uacute;de P&uacute;blica 2009; 25:495-506.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#140#136#article#173#</font></p>     ^cY#08.h
tm##
00463000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022400074002000700298#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#141#137#article#173#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Ruxton GD.    The uneq
ual variance t-test is an underused alternative to Student's t-test    and the M
ann-Whitney U test. Behav Ecol 2006; 17:687-90.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#142#138#article#173#</font></p>     ^cY#08.h
tm##
00581000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704034200074002000700416#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#143#139#article#173#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Department    of Healt
h and Human Services. Panel on Antiretroviral Guidelines for Adults    and Adole
scents. Guidelines for the use of antiretroviral agents in HIV-1-infected    adu
lts and adolescents. Washington DC: Department of Health and Human Services;    
2008.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#144#140#article#173#</font></p>     ^cY#08.h
tm##
00572000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033300074002000700407#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#145#141#article#173#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Hacker MA,    Kaida A,
 Hogg RS, Bastos FI. The first ten years: achievements and challenges    of the 
Brazilian program of universal access to HIV/AIDS comprehensive management    an
d care, 1996-2006. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S345-59.    
^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#146#142#article#173#</font></p>     ^cY#08.h
tm##
00542000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030300074002000700377#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#147#143#article#173#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Brito AM, Szwarcwald  
  CL, Castilho EA. Fatores associados com interrup&ccedil;&atilde;o de tratament
o    anti-retroviral em adultos com Aids. Rio Grande do Norte, Brasil, 1999-2002
.    Rev Assoc Med Bras (1992) 2006; 52:86-92.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#148#144#article#173#</font></p>     ^cY#08.h
tm##
00624000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704038500074002000700459#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#149#145#article#173#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Fernandes JRM,    Acur
cio FA, Campos LN, Guimar&atilde;es MDC. In&iacute;cio da terapia anti-retrovira
l    em est&aacute;gio avan&ccedil;ado de imunodefici&ecirc;ncia entre indiv&iac
ute;duos    portadores de HIV/AIDS em Belo Horizonte, Minas Gerais, Brasil. Cad 
Sa&uacute;de    P&uacute;blica 2009; 25:1369-80.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#150#146#article#173#</font></p>     ^cY#08.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#151#147#article#173#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Bonolo PF,    Machado 
CJ, C&eacute;sar CC, Ceccato MGB, Guimar&atilde;es MDC. Vulnerability    and non
-adherence to antiretroviral therapy among HIV patients, Minas Gerais    State, 
Brazil. Cad Sa&uacute;de P&uacute;blica 2008; 24:2603-13.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#152#148#article#173#</font></p>     ^cY#08.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#153#149#article#173#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Nemes MIB,    Helena E
TS, Caraciolo JNM, Basso CR. Assessing patient adherence to chronic    diseases 
treatment: differentiating between epidemiological and clinical approaches.    C
ad Sa&uacute;de P&uacute;blica 2009; 25 Suppl 3:S392-400.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#154#150#article#173#</font></p>     ^cY#08.h
tm##
00536000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029700074002000700371#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#155#151#article#173#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Rodrigues CS,    Guima
r&atilde;es MDC, Acurcio FA, Comini CC. Interrup&ccedil;&atilde;o do acompanhame
nto    cl&iacute;nico ambulatorial de pacientes infectados pelo HIV. Rev Sa&uacu
te;de    P&uacute;blica 2003; 37:183-90.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#156#152#article#173#</font></p>     ^cY#08.h
tm##
00510000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027100074002000700345#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#157#153#article#173#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Nieuwkerk PT,    Oort 
FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection    and
 virologic treatment response: a meta-analysis. J Acquir Immune Defic Syndr    2
005; 38:445-8.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#158#154#article#173#</font></p>     ^cY#08.h
tm##
00576000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033700074002000700411#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#159#155#article#173#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Chi BH, Cantrell    RA
, Zulu I, Mulenga LB, Levy JW, Tambatamba BC, et al. Adherence to first-line    
antiretroviral therapy affects non-virologic outcomes among patients on treatmen
t    for more than 12 months in Lusaka, Zambia. Int J Epidemiol 2009; 38:746-56.
    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#160#156#article#173#</font></p>     ^cY#08.h
tm##
00539000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030000074002000700374#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#161#157#article#173#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Bisson GP,    Gross R,
 Bellamy S, Chittams J, Hislop M, Regensberg L, et al. Pharmacy refill    adhere
nce compared with cd4 count changes for monitoring HIV-infected adults    on ant
iretroviral therapy. PLoS Med 2008; 5:e109.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#162#158#article#173#</font></p>     ^cY#08.h
tm##
00479000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024000074002000700314#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#163#159#article#173#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Souza Jr. PRB,    Szwa
rcwald CL, Castilho EA. Delay in introducing antiretroviral therapy in patients 
   infected by HIV. Brazil, 2003-2006. Clinics 2007; 62:579-84.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#164#160#article#173#</font></p>     ^cY#08.h
tm##
00527000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028800074002000700362#v27
s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#p#165#161#article#173#35#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Guimar&atilde;es    MD
C, Rocha GM, Campos LN, Freitas FMT, Gualberto FAZ, Teixeira RAR, et al. Difficu
lties    reported by HIV-infected patients using antiretroviral therapy in Brazi
l. Clinics    2008; 63: 165-72.    ^cY#08.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#166#162#article#173#</font></p>     ^cY#08.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#167#163#article#173#<p>&nbsp;</p>     ^cY#08
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#168#164#article#173#<p>&nbsp;</p>     ^cY#08
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#169#165#article#173#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#08.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003100071002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#170#166#article#173#<br>   </b> G. M. Rocha 
   ^cY#08.htm##
00293000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704006900071002000700140#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#171#167#article#173#<br>   Universidade Fede
ral de S&atilde;o Jo&atilde;o Del-Rei    ^cY#08.htm##
00287000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704006300071002000700134#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#172#168#article#173#<br>   Av. Sebasti&atild
e;o Gon&ccedil;alves Coelho 400    ^cY#08.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#173#169#article#173#<br>   Divin&oacute;poli
s, MG 35501-296, Brasil    ^cY#08.htm##
00315000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009100071002000700162#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#174#170#article#173#<br>   <a href="mailto:g
usrocha.mg@gmail.com">gusrocha.mg@gmail.com</a></font></p>     ^cY#08.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#175#171#article#173#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 05/Nov/2009    ^cY#08.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#176#172#article#173#<br>   Final version res
ubmitted on 18/Feb/2010    ^cY#08.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\08.htm#S#p#177#173#article#173#<br>   Approved on 05/Ap
r/2010</font></p>     ^cY#08.htm##
00518000000000217000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170007000700180139000770370
04700216110000900263109001200272865000900284002000700293#v27s1#V:\SciELO\serial\
csp\v27s1\markup\08.htm#S#c#178#1#article#35#1#Brasil#Lei nº: 9.313, de 13 de no
vembro de 1996. Dispõe sobre a distribuição gratuita de medicamentos aos portado
res de HIV e doentes de AIDS^lpt#http://www.aids.gov.br/assistencia/lei9313.htm#
20090806#06/Aug/2009#20110000#08.htm##
00733000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100018000880100
01800106010001900124010001600143010001700159810000600176012013600182030001300318
06500090033106400050034003100040034501400070034986500090035600200070036503500100
0372801001300382#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#179#2#articl
e#35#2#^rND^sPalella^nFJ#^rND^sDelaney^nMS#^rND^sMoorman^nAC#^rND^sLoveless^nMO#
^rND^sFuhrer^nJ#^rND^sSatten^nGA#et al#Declining morbidity and mortality among p
atients with advanced immunodeficiency virus infection: HIV Outpatient Study Inv
estigators^len#N Engl J Med#19980000#1998#338#853-60#20110000#08.htm#0028-4793#N
 Engl J Med##
00383000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680110020000700300029000907100
00200119065000900121064000500130032000200135865000900137002000700146#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\08.htm#S#c#180#3#article#35#3#Ministério da Saúde#B
oletim Epidemiológico AIDST#2#20080000#2008#1#20110000#08.htm##
00517000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170055000700180103001250660
00900228062002000237065000900257064000500266865000900271002000700280#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\08.htm#S#c#181#4#article#35#4#Ministério da Saúde^d
Secretaria de Vigilância em Saúde#Recomendações para terapia anti-retroviral em 
adultos e adolescentes infectados pelo HIV 2007/2008^lpt#Brasília#Ministério da 
Saúde#20070000#2007#20110000#08.htm##
00556000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170088000700180109001580660
00900267062002000276065000900296064000500305865000900310002000700319#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\08.htm#S#c#182#5#article#35#5#Ministério da Saúde^d
Programa Nacional de DST e AIDS, Secretaria de Vigilância em Saúde#Diretrizes pa
ra o fortalecimento das ações de adesão ao tratamento para pessoas que vivem com
 HIV e AIDS^lpt#Brasília#Ministério da Saúde#20070000#2007#20110000#08.htm##
00584000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100023000700100017000930100
01900110012011800129030001800247710000200265065000900267064000500276031000300281
014000600284865000900290002000700299#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.
htm#S#c#183#6#article#35#6#^rND^sSanta-Helena^nET#^rND^sNemes^nMIB#^rND^sEluf-Ne
to^nJ#Desenvolvimento e validação de questionário multidimensional para medir nã
o-adesão ao tratamento com medicamentos^lpt#Rev Saúde Pública#2#20080000#2008#42
#764-7#20110000#08.htm##
00610000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700100019000900100
01700109012012600126030001000252065000900262064000500271031000300276014000500279
865000900284002000700293035001000300801001000310#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#184#7#article#35#7#^rND^sBangsberg^nDR#^rND^sBronstone^nA#^r
ND^sHofmann^nR#A computer-based assessment detects regimen misunderstandings and
 no adherence for patients on HIV antiretroviral therapy^len#AIDS Care#20020000#
2002#14#3-15#20110000#08.htm#0954-0121#AIDS care##
00555000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100018000870100
02100105012008800126030002100214710000200235065000900237064000500246031000300251
014000700254865000900261002000700270#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.
htm#S#c#185#8#article#35#8#^rND^sBonolo^nPF#^rND^sGomes^nRRFM#^rND^sGuimarães^nM
DC#Adesão à terapia anti-retroviral (HIV/aids): fatores associados e medidas de 
adesão^lpt#Epidemiol Serv Saúde#2#20070000#2007#16#261-78#20110000#08.htm##
00581000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100018000850120
07800103030002800181065000900209064000500218031000300223032000400226014000700230
865000900237002000700246035001000253801002800263#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#186#9#article#35#9#^rND^sBerg^nKM#^rND^sArnsten^nJH#Practica
l and conceptual challenges in measuring antiretroviral adherence^len#J Acquir I
mmune Defic Syndr#20060000#2006#43#^s1#S79-87#20110000#08.htm#0894-9255#J Acquir
 Immune Defic Syndr##
00708000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01800105010002000123010001800143010001600161012013300177030001100310065000900321
06400050033003100030033501400070033886500090034500200070035403500100036180100110
0371#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#187#10#article#35#10#^rN
D^sSimoni^nJM#^rND^sKurth^nAE#^rND^sPearson^nCR#^rND^sPantalone^nDW#^rND^sMerril
l^nJO#^rND^sFrick^nPA#Self-report measures of antiretroviral therapy adherence: 
a review with recommendations for hiv research and clinical management^len#AIDS 
Behav#20060000#2006#10#227-45#20110000#08.htm#1090-7165#AIDS Behav##
00686000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100019000910100
01400110010001700124010001700141010001600158810000600174012008800180030001500268
06500090028306400050029203100040029701400060030186500090030700200070031603500100
0323801001500333#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#188#11#artic
le#35#11#^rND^sPaterson^nDL#^rND^sSwindells^nS#^rND^sMohr^nJ#^rND^sBrester^nM#^r
ND^sVergis^nEN#^rND^sSquier^nC#et al#Adherence to protease inhibitor therapy and
 outcomes in patients with HIV infection^len#Ann Intern Med#20000000#2000#133#21
-30#20110000#08.htm#0003-4819#Ann Intern Med##
00745000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100016000900100
01300106010001400119010001700133010001500150810000600165012012100171030003300292
06500090032506400050033403100020033901400070034186500090034800200070035703500100
0364801003300374#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#189#12#artic
le#35#12#^rND^sFielden^nSJ#^rND^sRusch^nML#^rND^sYip^nB#^rND^sWood^nE#^rND^sShan
non^nK#^rND^sLevy^nAR#et al#Nonadherence increases the risk of hospitalization a
mong HIV-infected antiretroviral naive patients started on HAART^len#J Int Assoc
 Physicians AIDS Care#20080000#2008#7#238-44#20110000#08.htm#1081-454X#J Int Ass
oc Physicians AIDS Care##
00616000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01900106010001800125012008300143030001900226065000900245064000500254031000300259
014000700262865000900269002000700278035001000285801001900295#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\08.htm#S#c#190#13#article#35#13#^rND^sKaron^nJM#^rND^sFlemi
ng^nPL#^rND^sSteketee^nRW#^rND^sDe Cock^nKM#HIV in the United States at the turn
 of the century: an epidemic in transition^len#Am J Public Health#20010000#2001#
91#1060-8#20110000#08.htm#0090-0036#Am J Public Health##
00750000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100032000880100
01700120010002100137010001400158010001900172810000600191012009200197030002800289
06500090031706400050032603100030033103200040033401400080033886500090034600200070
0355035001000362801002800372#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#
191#14#article#35#14#^rND^sPerno^nCF#^rND^sCeccherini-Silberstein^nF#^rND^sDe Lu
ca^nA#^rND^sCozzi-Lepri^nA#^rND^sGori^nC#^rND^sCingolani^nA#et al#Virologic corr
elates of adherence to antiretroviral medications and therapeutic failure^len#J 
Acquir Immune Defic Syndr#20020000#2002#31#^s3#S118-22#20110000#08.htm#0894-9255
#J Acquir Immune Defic Syndr##
00551000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100018000920120
09800110030001800208710000200226065000900228064000500237031000300242032000400245
014000800249865000900257002000700266#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.
htm#S#c#192#15#article#35#15#^rND^sWachholz^nNIR#^rND^sFerreira^nJ#Adherence to 
antiretroviral therapy in children: a study of prevalence and associated factors
^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S424-34#20110000#08.htm##
00639000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01600106010001600122010001600138012007800154030002200232065000900254064000500263
031000300268014000600271865000900277002000700286035001000293801002200303#v27s1#V
:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#193#16#article#35#16#^rND^sBlatt^nCR
#^rND^sCitadin^nCB#^rND^sSouza^nFG#^rND^sMello^nRS#^rND^sGalato^nD#Avaliação da 
adesão aos anti-retrovirais em um município no Sul do Brasil^lpt#Rev Soc Bras Me
d Trop#20090000#2009#42#131-6#20110000#08.htm#0037-8682#Rev Soc Bras Med Trop##
00621000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100024000910100
02000115012010200135030002200237065000900259064000500268031000300273014000700276
865000900283002000700292035001000299801002200309#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#194#17#article#35#17#^rND^sCarvalho^nCV#^rND^sMerchan-Hamann
^nE#^rND^sMatsushita^nR#Determinantes da adesão ao tratamento anti-retroviral em
 Brasília, DF: um estudo de caso-controle^lpt#Rev Soc Bras Med Trop#20070000#200
7#40#555-65#20110000#08.htm#0037-8682#Rev Soc Bras Med Trop##
00693000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100019000890100
02400108010001900132010001600151010001600167810000600183012006100189030002800250
06500090027806400050028703100030029201400060029586500090030100200070031003500100
0317801002800327#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#195#18#artic
le#35#18#^rND^sSilva^nMCF#^rND^sXimenes^nRAA#^rND^sMiranda Filho^nDB#^rND^sArrae
s^nLWMS#^rND^sMendes^nM#^rND^sMelo^nACS#et al#Risk-factors for non-adherence to 
antiretroviral therapy^len#Rev Inst Med Trop São Paulo#20090000#2009#51#135-9#20
110000#08.htm#0036-4665#Rev Inst Med Trop São Paulo##
00808000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160021000720160018000930160
01900111016001700130016001900147016001700166810000600183018024800189066000900437
062003000446065000900476064000500485865000900490002000700499#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\08.htm#S#c#196#19#article#35#19#^rND^sGuimarães^nMDC#^rND^s
Acurcio^nFA#^rND^sFreitas^nMIF#^rND^sBonolo^nPF#^rND^sCeccato^nMGB#^rND^sCampos^
nLN#et al#Fatores associados à adesão ao tratamento anti-retroviral (ARV) em ind
ivíduos infectados pelo HIV/AIDS: uma abordagem quantitativa e qualitativa, Belo
 Horizonte (MG), 2001-2003 (Projeto ATAR). Relatório técnico final (PN DST/Aids 
914/BRA/3014)^lpt#Brasília#Programa Nacional de DST/AIDS#20030000#2003#20110000#
08.htm##
00720000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01800105010001900123010002700142010001700169810000600186012011500192030000500307
06500090031206400050032103100030032603200040032901400060033386500090033900200070
0348035001000355801000500365#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#
197#20#article#35#20#^rND^sBonolo^nPF#^rND^sCésar^nCC#^rND^sAcurcio^nFA#^rND^sCe
ccato^nMGB#^rND^sMenezes-de-Pádua^nCA#^rND^sAlvares^nJ#et al#Non-adherence among
 patients iniciating antiretroviral therapy: a challenge for health professional
s in Brazil^len#AIDS#20050000#2005#19#^s4#S5-13#20110000#08.htm#0269-9370#AIDS##
00541000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170057000720180123001290660
00900252062002000261065000900281064000500290865000900295002000700304#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\08.htm#S#c#198#21#article#35#21#Secretaria Executiv
a^dCoordenação Nacional de DST e AIDS#Guia de tratamento: recomendações para ter
apia anti-retroviral em adultos e adolescentes infectados pelo HIV 2002-2003^les
#Brasília#Ministério da Saúde#20030000#2003#20110000#08.htm##
00643000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900100
01800108010002100126012014500147030001800292710000200310065000900312064000500321
031000300326014000800329865000900337002000700346#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#199#22#article#35#22#^rND^sGomes^nRRFM#^rND^sMachado^nCJ#^rN
D^sAcurcio^nFA#^rND^sGuimarães^nMDC#Utilização dos registros de dispensação da f
armácia como indicador da não-adesão à terapia anti-retroviral em indivíduos inf
ectados pelo HIV^lpt#Cad Saúde Pública#2#20090000#2009#25#495-506#20110000#08.ht
m##
00504000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720120108000890300
01100197710000200208065000900210064000500219031000300224014000700227865000900234
002000700243#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#200#23#article#3
5#23#^rND^sRuxton^nGD#The unequal variance t-test is an underused alternative to
 Student's t-test and the Mann-Whitney U test^len#Behav Ecol#2#20060000#2006#17#
687-90#20110000#08.htm##
00583000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170040000720180156001120660
01500268062004000283065000900323064000500332865000900337002000700346#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\08.htm#S#c#201#24#article#35#24#Department of Healt
h and Human Services#Panel on Antiretroviral Guidelines for Adults and Adolescen
ts: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and
 adolescents^len#Washington^eDC#Department of Health and Human Services#20080000
#2008#20110000#08.htm##
00658000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01500104010001700119012015500136030001800291710000200309065000900311064000500320
031000300325032000400328014000800332865000900340002000700349#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\08.htm#S#c#202#25#article#35#25#^rND^sHacker^nMA#^rND^sKaid
a^nA#^rND^sHogg^nRS#^rND^sBastos^nFI#The first ten years: achievements and chall
enges of the Brazilian program of universal access to HIV/AIDS comprehensive man
agement and care, 1996-2006^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S345-59
#20110000#08.htm##
00634000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100021000880100
01900109012012900128030001900257065000900276064000500285031000300290014000600293
865000900299002000700308035001000315801001900325#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#203#26#article#35#26#^rND^sBrito^nAM#^rND^sSzwarcwald^nCL#^r
ND^sCastilho^nEA#Fatores associados com interrupção de tratamento anti-retrovira
l em adultos com Aids: Rio Grande do Norte, Brasil, 1999-2002^lpt#Rev Assoc Med 
Bras#20060000#2006#52#86-92#20110000#08.htm#0004-5241#Rev Assoc Med Bras##
00658000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100018000930100
01700111010002100128012015800149030001800307710000200325065000900327064000500336
031000300341014000800344865000900352002000700361#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#204#27#article#35#27#^rND^sFernandes^nJRM#^rND^sAcurcio^nFA#
^rND^sCampos^nLN#^rND^sGuimarães^nMDC#Início da terapia anti-retroviral em estág
io avançado de imunodeficiência entre indivíduos portadores de HIV/AIDS em Belo 
Horizonte, Minas Gerais, Brasil^lpt#Cad Saúde Pública#2#20090000#2009#25#1369-80
#20110000#08.htm##
00635000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01600107010001900123010002100142012010900163030001800272710000200290065000900292
064000500301031000300306014000800309865000900317002000700326#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\08.htm#S#c#205#28#article#35#28#^rND^sBonolo^nPF#^rND^sMach
ado^nCJ#^rND^sCésar^nCC#^rND^sCeccato^nMGB#^rND^sGuimarães^nMDC#Vulnerability an
d non-adherence to antiretroviral therapy among HIV patients, Minas Gerais State
, Brazil^len#Cad Saúde Pública#2#20080000#2008#24#2603-13#20110000#08.htm##
00639000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
02100107010001600128012012700144030001800271710000200289065000900291064000500300
031000300305032000400308014000900312865000900321002000700330#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\08.htm#S#c#206#29#article#35#29#^rND^sNemes^nMIB#^rND^sHele
na^nETS#^rND^sCaraciolo^nJNM#^rND^sBasso^nCR#Assessing patient adherence to chro
nic diseases treatment: differentiating between epidemiological and clinical app
roaches^len#Cad Saúde Pública#2#20090000#2009#25#^s3#S392-400#20110000#08.htm##
00586000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100021000920100
01800113010001700131012008800148030001800236710000200254065000900256064000500265
031000300270014000700273865000900280002000700289#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#207#30#article#35#30#^rND^sRodrigues^nCS#^rND^sGuimarães^nMD
C#^rND^sAcurcio^nFA#^rND^sComini^nCC#Interrupção do acompanhamento clínico ambul
atorial de pacientes infectados pelo HIV^lpt#Rev Saúde Pública#2#20030000#2003#3
7#183-90#20110000#08.htm##
00614000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100015000920120
12400107030002800231065000900259064000500268031000300273014000600276865000900282
002000700291035001000298801002800308#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.
htm#S#c#208#31#article#35#31#^rND^sNieuwkerk^nPT#^rND^sOort^nFJ#Self-reported ad
herence to antiretroviral therapy for HIV-1 infection and virologic treatment re
sponse: a meta-analysis^len#J Acquir Immune Defic Syndr#20050000#2005#38#445-8#2
0110000#08.htm#0894-9255#J Acquir Immune Defic Syndr##
00751000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100019000860100
01400105010001800119010001500137010002100152810000600173012015200179030001600331
06500090034706400050035603100030036101400070036486500090037100200070038003500100
0387801001600397#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#209#32#artic
le#35#32#^rND^sChi^nBH#^rND^sCantrell^nRA#^rND^sZulu^nI#^rND^sMulenga^nLB#^rND^s
Levy^nJW#^rND^sTambatamba^nBC#et al#Adherence to first-line antiretroviral thera
py affects non-virologic outcomes among patients on treatment for more than 12 m
onths in Lusaka, Zambia^len#Int J Epidemiol#20090000#2009#38#746-56#20110000#08.
htm#0300-5771#Int J Epidemiol##
00678000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01700104010001800121010001600139010002000155810000600175012012300181030000900304
71000020031306500090031506400050032403100020032901400050033186500090033600200070
0345#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#210#33#article#35#33#^rN
D^sBisson^nGP#^rND^sGross^nR#^rND^sBellamy^nS#^rND^sChittams^nJ#^rND^sHislop^nM#
^rND^sRegensberg^nL#et al#Pharmacy refill adherence compared with cd4 count chan
ges for monitoring HIV-infected adults on antiretroviral therapy^len#PLoS Med#2#
20080000#2008#5#e109#20110000#08.htm##
00584000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100021000930100
01900114012009500133030000800228065000900236064000500245031000300250014000700253
865000900260002000700269035001000276801000800286#v27s1#V:\SciELO\serial\csp\v27s
1\markup\08.htm#S#c#211#34#article#35#34#^rND^sSouza Jr.^nPRB#^rND^sSzwarcwald^n
CL#^rND^sCastilho^nEA#Delay in introducing antiretroviral therapy in patients in
fected by HIV: Brazil, 2003-2006^len#Clinics#20070000#2007#62#579-84#20110000#08
.htm#1807-5932#Clinics##
00686000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100016000930100
01700109010001900126010002100145010002000166810000600186012009000192030000800282
06500090029006400050029903100030030401400070030786500090031400200070032303500100
0330801000800340#v27s1#V:\SciELO\serial\csp\v27s1\markup\08.htm#S#c#212#35#artic
le#35#35#^rND^sGuimarães^nMDC#^rND^sRocha^nGM#^rND^sCampos^nLN#^rND^sFreitas^nFM
T#^rND^sGualberto^nFAZ#^rND^sTeixeira^nRAR#et al#Difficulties reported by HIV-in
fected patients using antiretroviral therapy in Brazil^len#Clinics#20080000#2008
#63#165-72#20110000#08.htm#1807-5932#Clinics##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#o#1#1#article#1#201104
11#073714#09.htm#220##
04283000000000709000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400110013703500100014801201010
01580120106002590100034003650100045003990100033004440100025004770100042005020700
07900544070011400623070008800737070008700825083110200912085001002014085004702024
08500410207108500350211208500220214708311610216908500100333008500510334008500220
33910850029034130850024034420580026034661170008034920720003035001120009035031110
01203512116000903524115001203533114000903545113001203554002000703566#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\09.htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#
09#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs79^ls92#0102-311X#Survival of A
IDS patients in the Southeast and South of Brazil: analysis of the 1998-1999 coh
ort^len#Sobrevida de pacientes com AIDS das regiões Sudeste e Sul do Brasil: aná
lise da coorte de 1998 a 1999^lpt#^rND^1A01 A02^nIone Aquemi^sGuibu#^rND^1A03^nM
arilisa Berti de Azevedo^sBarros#^rND^1A03^nMaria Rita^sDonalísio#^rND^1A02^nÂng
ela^sTayra#^rND^1A04^nMaria Cecília Goi Porto^sAlves#Santa Casa de São Paulo^iA0
1^1Faculdade de Ciências Médicas^cSão Paulo^pBrasil#Secretaria de Estado da Saúd
e de São Paulo^iA02^1entro de Referência e Treinamento em DST/AIDS^cSão Paulo^pB
rasil#Universidade Estadual de Campinas^iA03^1Faculdade de Ciências Médicas^cCam
pinas^pBrasil#Secretaria de Saúde do Estado de São Paulo^iA04^1Instituto de Saúd
e^cSão Paulo^pBrasil#^len^aThe aim of this study was to evaluate survival time f
or AIDS patients 13 years and older in the South and Southeast regions of Brazil
, according to socio-demographic, clinical, and epidemiological characteristics.
 The sample was selected from all cases diagnosed in 1998 and 1999 and notified 
to the Epidemiological Surveillance System of the National STD/AIDS Program. Use
 of a questionnaire allowed analyzing 2,091 patient charts. Based on the Kaplan-
Meier method, estimated survival was at least 108 months after diagnosis in 59.5
% of patients in the Southeast and 59.3% in the South. Cox regression models sho
wed, in both regions, an increase in survival in patients on antiretroviral ther
apy, those classified as AIDS cases according to the CD4 T-cell criterion, femal
es, and those with more schooling. Other factors associated with longer survival
 in the Southeast were: white skin color, no history of tuberculosis since the A
IDS diagnosis, negative hepatitis B serology, and access to a multidisciplinary 
health team. In the South, age below 40 years was associated with longer surviva
l.#^ddecs^i1#^tm^len^kAcquired Immunodeficiency Syndrome^i1#^tm^len^kSurvivorshi
p (Public Health)^i1#^tm^len^kAnti-Retroviral Agents^i1#^tm^len^kMortality^i1#^l
pt^aO estudo objetivou avaliar o tempo de sobrevida de pacientes de AIDS, com 13
 anos ou mais de idade, das regiões Sul e Sudeste do país, segundo característic
as sóciodemográficas e clínico-epidemiológicas. A amostra foi sorteada a partir 
da totalidade dos casos notificados no Sistema de Vigilância Epidemiológica do P
rograma Nacional de DST/AIDS, diagnosticados em 1998 e 1999. Utilizando-se quest
ionário foi possível analisar 2.091 prontuários médicos. Pelo método Kaplan-Meie
r, foi estimada sobrevivência de pelo menos 108 meses após o diagnóstico em 59,5
% dos pacientes no Sudeste e 59,3% no Sul. Por meio de modelos de regressão de C
ox, foi verificado, nas duas regiões, aumento da sobrevivência nos pacientes que
 usaram antirretrovirais, que foram classificados como caso de AIDS pelo critéri
o CD4, que eram do sexo feminino e com maior escolaridade. Os fatores associados
 a tempos maiores de sobrevida no Sudeste foram ainda: possuir cor da pele branc
a, não ter tido tuberculose após seu diagnóstico de AIDS, não ser reagente à hep
atite B e ter tido acesso à equipe multidisciplinar. No Sul, ter idade abaixo de
 40 anos possibilitou maior sobrevida.#^ddecs^i2#^tm^lpt^kSíndrome de Imunodefic
iência Adquirida^i2#^tm^lpt^kSobrevida^i2#^tm^lpt^kAnti-Retrovirais^i2#^tm^lpt^k
Mortalidade^i2#National Research Council#vancouv#34#20100121#21/Jan/2010#2010051
7#17/May/2010#20100706#06/Jul/2010#09.htm##
04311000000000709000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400110013703500100014801201150
01580120120002730100034003930100045004270100033004720100025005050100042005300700
07900572070011400651070008800765070008700853083110200940085001002042085004702052
08500410209908500350214008500220217508311610219708500100335808500510336808500220
34190850029034410850024034700580026034941170008035200720003035281120009035311110
01203540116000903552115001203561114000903573113001203582002000703594#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\09.htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#
09#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs79^ls92#0102-311X#<b>Survival o
f AIDS patients in the Southeast and South of Brazil</b>: <b>analysis of the 199
8-1999 cohort</b>^len#<b>Sobrevida de pacientes com AIDS das regiões Sudeste e S
ul do Brasil</b>: <b>análise da coorte de 1998 a 1999</b>^lpt#^rND^1A01 A02^nIon
e Aquemi^sGuibu#^rND^1A03^nMarilisa Berti de Azevedo^sBarros#^rND^1A03^nMaria Ri
ta^sDonalísio#^rND^1A02^nÂngela^sTayra#^rND^1A04^nMaria Cecília Goi Porto^sAlves
#Santa Casa de São Paulo^iA01^1Faculdade de Ciências Médicas^cSão Paulo^pBrasil#
Secretaria de Estado da Saúde de São Paulo^iA02^1entro de Referência e Treinamen
to em DST/AIDS^cSão Paulo^pBrasil#Universidade Estadual de Campinas^iA03^1Faculd
ade de Ciências Médicas^cCampinas^pBrasil#Secretaria de Saúde do Estado de São P
aulo^iA04^1Instituto de Saúde^cSão Paulo^pBrasil#^len^aThe aim of this study was
 to evaluate survival time for AIDS patients 13 years and older in the South and
 Southeast regions of Brazil, according to socio-demographic, clinical, and epid
emiological characteristics. The sample was selected from all cases diagnosed in
 1998 and 1999 and notified to the Epidemiological Surveillance System of the Na
tional STD/AIDS Program. Use of a questionnaire allowed analyzing 2,091 patient 
charts. Based on the Kaplan-Meier method, estimated survival was at least 108 mo
nths after diagnosis in 59.5% of patients in the Southeast and 59.3% in the Sout
h. Cox regression models showed, in both regions, an increase in survival in pat
ients on antiretroviral therapy, those classified as AIDS cases according to the
 CD4 T-cell criterion, females, and those with more schooling. Other factors ass
ociated with longer survival in the Southeast were: white skin color, no history
 of tuberculosis since the AIDS diagnosis, negative hepatitis B serology, and ac
cess to a multidisciplinary health team. In the South, age below 40 years was as
sociated with longer survival.#^ddecs^i1#^tm^len^kAcquired Immunodeficiency Synd
rome^i1#^tm^len^kSurvivorship (Public Health)^i1#^tm^len^kAnti-Retroviral Agents
^i1#^tm^len^kMortality^i1#^lpt^aO estudo objetivou avaliar o tempo de sobrevida 
de pacientes de AIDS, com 13 anos ou mais de idade, das regiões Sul e Sudeste do
 país, segundo características sóciodemográficas e clínico-epidemiológicas. A am
ostra foi sorteada a partir da totalidade dos casos notificados no Sistema de Vi
gilância Epidemiológica do Programa Nacional de DST/AIDS, diagnosticados em 1998
 e 1999. Utilizando-se questionário foi possível analisar 2.091 prontuários médi
cos. Pelo método Kaplan-Meier, foi estimada sobrevivência de pelo menos 108 mese
s após o diagnóstico em 59,5% dos pacientes no Sudeste e 59,3% no Sul. Por meio 
de modelos de regressão de Cox, foi verificado, nas duas regiões, aumento da sob
revivência nos pacientes que usaram antirretrovirais, que foram classificados co
mo caso de AIDS pelo critério CD4, que eram do sexo feminino e com maior escolar
idade. Os fatores associados a tempos maiores de sobrevida no Sudeste foram aind
a: possuir cor da pele branca, não ter tido tuberculose após seu diagnóstico de 
AIDS, não ser reagente à hepatite B e ter tido acesso à equipe multidisciplinar.
 No Sul, ter idade abaixo de 40 anos possibilitou maior sobrevida.#^ddecs^i2#^tm
^lpt^kSíndrome de Imunodeficiência Adquirida^i2#^tm^lpt^kSobrevida^i2#^tm^lpt^kA
nti-Retrovirais^i2#^tm^lpt^kMortalidade^i2#National Research Council#vancouv#34#
20100121#21/Jan/2010#20100517#17/May/2010#20100706#06/Jul/2010#09.htm##
04443000000000733000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090038000400094121000300098049000700101
15800030010803000190011103100030013013100020013306500090013501400110014403500100
01550120101001650120106002660100034003720100045004060100033004510100025004840100
04200509070008100551070011600632070009000748070008900838083111600927085001002043
08500470205308500410210008500350214108500220217608311790219808500100337708500510
33870850022034380850029034600850024034890580026035131170008035390720003035471120
00903550111001203559116000903571115001203580114000903592113001203601002000703613
008008903620#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#l#4#1#article#1#^a
2011#oa#en#br1.1#1#4.0#gra#tab#09#CSP330#nd#Cad. saúde pública#27#1#20110000#^fs
79^ls92#0102-311X#Survival of AIDS patients in the Southeast and South of Brazil
: analysis of the 1998-1999 cohort^len#Sobrevida de pacientes com AIDS das regiõ
es Sudeste e Sul do Brasil: análise da coorte de 1998 a 1999^lpt#^rND^1A01 A02^n
Ione Aquemi^sGuibu#^rND^1A03^nMarilisa Berti de Azevedo^sBarros#^rND^1A03^nMaria
 Rita^sDonalísio#^rND^1A02^nÂngela^sTayra#^rND^1A04^nMaria Cecília Goi Porto^sAl
ves#^iA01^1Santa Casa de São Paulo^2Faculdade de Ciências Médicas^cSão Paulo^pBr
asil#^iA02^1Secretaria de Estado da Saúde de São Paulo^2entro de Referência e Tr
einamento em DST/AIDS^cSão Paulo^pBrasil#^iA03^1Universidade Estadual de Campina
s^2Faculdade de Ciências Médicas^cCampinas^pBrasil#^iA04^1Secretaria de Saúde do
 Estado de São Paulo^2Instituto de Saúde^cSão Paulo^pBrasil#^len^aThe aim of thi
s study was to evaluate survival time for AIDS patients 13 years and older in th
e South and Southeast regions of Brazil, according to socio-demographic, clinica
l, and epidemiological characteristics. The sample was selected from all cases d
iagnosed in 1998 and 1999 and notified to the Epidemiological Surveillance Syste
m of the National STD/AIDS Program. Use of a questionnaire allowed analyzing 2,0
91 patient charts. Based on the Kaplan-Meier method, estimated survival was at l
east 108 months after diagnosis in 59.5 percent of patients in the Southeast and
 59.3 percent in the South. Cox regression models showed, in both regions, an in
crease in survival in patients on antiretroviral therapy, those classified as AI
DS cases according to the CD4 T-cell criterion, females, and those with more sch
ooling. Other factors associated with longer survival in the Southeast were: whi
te skin color, no history of tuberculosis since the AIDS diagnosis, negative hep
atitis B serology, and access to a multidisciplinary health team. In the South, 
age below 40 years was associated with longer survival.#^ddecs^i1#^tm^len^kAcqui
red Immunodeficiency Syndrome^i1#^tm^len^kSurvivorship (Public Health)^i1#^tm^le
n^kAnti-Retroviral Agents^i1#^tm^len^kMortality^i1#^lpt^aO estudo objetivou aval
iar o tempo de sobrevida de pacientes de AIDS, com 13 anos ou mais de idade, das
 regiões Sul e Sudeste do país, segundo características sóciodemográficas e clín
ico-epidemiológicas. A amostra foi sorteada a partir da totalidade dos casos not
ificados no Sistema de Vigilância Epidemiológica do Programa Nacional de DST/AID
S, diagnosticados em 1998 e 1999. Utilizando-se questionário foi possível analis
ar 2.091 prontuários médicos. Pelo método Kaplan-Meier, foi estimada sobrevivênc
ia de pelo menos 108 meses após o diagnóstico em 59,5 por cento dos pacientes no
 Sudeste e 59,3 por cento no Sul. Por meio de modelos de regressão de Cox, foi v
erificado, nas duas regiões, aumento da sobrevivência nos pacientes que usaram a
ntirretrovirais, que foram classificados como caso de AIDS pelo critério CD4, qu
e eram do sexo feminino e com maior escolaridade. Os fatores associados a tempos
 maiores de sobrevida no Sudeste foram ainda: possuir cor da pele branca, não te
r tido tuberculose após seu diagnóstico de AIDS, não ser reagente à hepatite B e
 ter tido acesso à equipe multidisciplinar. No Sul, ter idade abaixo de 40 anos 
possibilitou maior sobrevida.#^ddecs^i2#^tm^lpt^kSíndrome de Imunodeficiência Ad
quirida^i2#^tm^lpt^kSobrevida^i2#^tm^lpt^kAnti-Retrovirais^i2#^tm^lpt^kMortalida
de^i2#National Research Council#vancouv#34#20100121#21/Jan/2010#20100517#17/May/
2010#20100706#06/Jul/2010#09.htm#Internet^ihttp://www.scielo.br/scielo.php?scrip
t=sci_arttext&pid=S0102-311X2011001300009##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#5#1#article#182#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#6#2#article#182#<p>&nbsp;</p>     ^cY#09.htm
##
00431000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021100067002000700278#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#7#3#article#182#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Survival    of AIDS pati
ents in the Southeast and South of Brazil: analysis of the 1998-1999    cohort</
b> </font></p>     ^cY#09.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#8#4#article#182#<p>&nbsp;</p>     ^cY#09.htm
##
00431000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021100067002000700278#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#9#5#article#182#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Sobrevida de    pacientes com AIDS das reg
i&otilde;es Sudeste e Sul do Brasil: an&aacute;lise    da coorte de 1998 a 1999<
/b></font></p>     ^cY#09.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#10#6#article#182#<p>&nbsp;</p>     ^cY#09.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#11#7#article#182#<p>&nbsp;</p>     ^cY#09.ht
m##
00529000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704030800068002000700376#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#12#8#article#182#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"> <b>Ione Aquemi    Guibu<sup>I, II</sup>; Ma
rilisa Berti de Azevedo Barros<sup>III</sup>; Maria    Rita Donal&iacute;sio<sup
>III</sup>; &Acirc;ngela Tayra<sup>II</sup>; Maria    Cec&iacute;lia Goi Porto A
lves<sup>IV</sup></b></font></p>     ^cY#09.htm##
00412000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704019100068002000700259#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#13#9#article#182#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Faculdade    de Ci&ecirc;ncias M
&eacute;dicas da Santa Casa de S&atilde;o Paulo, S&atilde;o    Paulo, Brasil    
^cY#09.htm##
00389000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016700069002000700236#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#14#10#article#182#<br>   <sup>II</sup>Centro
 de Refer&ecirc;ncia e Treinamento em DST/AIDS, Secretaria    de Estado da Sa&ua
cute;de de S&atilde;o Paulo, S&atilde;o Paulo, Brasil    ^cY#09.htm##
00349000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012700069002000700196#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#15#11#article#182#<br>   <sup>III</sup>Facul
dade de Ci&ecirc;ncias M&eacute;dicas, Universidade Estadual    de Campinas, Cam
pinas, Brasil    ^cY#09.htm##
00374000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015200069002000700221#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#16#12#article#182#<br>   <sup>IV</sup>Instit
uto de Sa&uacute;de, Secretaria de Sa&uacute;de do Estado    de S&atilde;o Paulo
, S&atilde;o Paulo, Brasil</font></p>     ^cY#09.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#17#13#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#18#14#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#19#15#article#182#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#09.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#20#16#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#09.htm##
01442000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704122000069002000701289#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#21#17#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The aim of this    study was to evaluate su
rvival time for AIDS patients 13 years and older in    the South and Southeast r
egions of Brazil, according to socio-demographic, clinical,    and epidemiologic
al characteristics. The sample was selected from all cases    diagnosed in 1998 
and 1999 and notified to the Epidemiological Surveillance    System of the Natio
nal STD/AIDS Program. Use of a questionnaire allowed analyzing    2,091 patient 
charts. Based on the Kaplan-Meier method, estimated survival was    at least 108
 months after diagnosis in 59.5% of patients in the Southeast and    59.3% in th
e South. Cox regression models showed, in both regions, an increase    in surviv
al in patients on antiretroviral therapy, those classified as AIDS    cases acco
rding to the CD4 T-cell criterion, females, and those with more schooling.    Ot
her factors associated with longer survival in the Southeast were: white skin   
 color, no history of tuberculosis since the AIDS diagnosis, negative hepatitis 
   B serology, and access to a multidisciplinary health team. In the South, age 
   below 40 years was associated with longer survival.</font></p>     ^cY#09.htm
##
00429000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020700069002000700276#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#22#18#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Acquired Immunodeficiency    Syndrome; Surv
ivorship (Public Health); Anti-Retroviral Agents; Mortality</font></p> <hr size=
"1" noshade>     ^cY#09.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#23#19#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#09.htm##
01696000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704147400069002000701543#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#24#20#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">O estudo objetivou    avaliar o tempo de so
brevida de pacientes de AIDS, com 13 anos ou mais de idade,    das regi&otilde;e
s Sul e Sudeste do pa&iacute;s, segundo caracter&iacute;sticas    s&oacute;ciode
mogr&aacute;ficas e cl&iacute;nico-epidemiol&oacute;gicas. A amostra    foi sort
eada a partir da totalidade dos casos notificados no Sistema de Vigil&acirc;ncia
    Epidemiol&oacute;gica do Programa Nacional de DST/AIDS, diagnosticados em 19
98    e 1999. Utilizando-se question&aacute;rio foi poss&iacute;vel analisar 2.0
91    prontu&aacute;rios m&eacute;dicos. Pelo m&eacute;todo Kaplan-Meier, foi es
timada    sobreviv&ecirc;ncia de pelo menos 108 meses ap&oacute;s o diagn&oacute
;stico    em 59,5% dos pacientes no Sudeste e 59,3% no Sul. Por meio de modelos 
de regress&atilde;o    de Cox, foi verificado, nas duas regi&otilde;es, aumento 
da sobreviv&ecirc;ncia    nos pacientes que usaram antirretrovirais, que foram c
lassificados como caso    de AIDS pelo crit&eacute;rio CD4, que eram do sexo fem
inino e com maior escolaridade.    Os fatores associados a tempos maiores de sob
revida no Sudeste foram ainda:    possuir cor da pele branca, n&atilde;o ter tid
o tuberculose ap&oacute;s seu    diagn&oacute;stico de AIDS, n&atilde;o ser reag
ente &agrave; hepatite B e ter    tido acesso &agrave; equipe multidisciplinar. 
No Sul, ter idade abaixo de 40    anos possibilitou maior sobrevida.</font></p> 
    ^cY#09.htm##
00423000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020100069002000700270#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#25#21#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">S&iacute;ndrome    de Imunodefici&ecirc;nci
a Adquirida; Sobrevida; Anti-Retrovirais; Mortalidade</font></p> <hr size="1" no
shade>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#26#22#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#27#23#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#28#24#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#09.h
tm##
00853000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063100069002000700700#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#29#25#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Since identification    of the first AIDS c
ases in Brazil in the early 1980s, the disease has spread    slowly and steadily
 throughout the country, becoming a veritable mosaic of epidemics.    In the las
t two decades, HIV transmission has reached marginalized and vulnerable    popul
ations, with an increase in the occurrence of AIDS cases in municipalities    (c
ounties) outside the large metropolitan areas, among heterosexuals, especially  
  women, a reduction in injecting drug users (IDU), and stabilization among youn
g    people <sup>1</sup>.</font></p>     ^cY#09.htm##
00901000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067900069002000700748#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#30#26#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">There has been    a trend towards stabiliza
tion of AIDS incidence in Brazil, especially since    1997, but with significant
 regional differences. The last decade has witnessed    a decrease in incidence 
rates in the South and Southeast regions of the country    and an increase in th
e North, Northeast, and Central. In the Southeast, the    incidence rate of 24.4
 per 100 thousand in 1999 decreased to 16.8 per 100 thousand    in 2005. There w
as also a reduction in the South, although not as sharp, from    22.2 per 100 th
ousand inhabitants in 1999 to 20.0 per 100 thousand in 2005 <sup>2</sup>.</font>
</p>     ^cY#09.htm##
00557000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033500069002000700404#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#31#27#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">From 1980 to 2008,    a total of 432,890 AI
DS cases were reported in the entire country, of which    80,929 resided in the 
South and 268,398 in the Southeast. These two geographic    regions accounted fo
r 80.7% of all AIDS cases in Brazil <sup>2</sup>.</font></p>     ^cY#09.htm##
00461000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023900069002000700308#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#32#28#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Of all the cases,    96.8% were 13 years or
 older at time of AIDS diagnosis, thus defined as adult    cases under the Brazi
lian classification <sup>3</sup>.</font></p>     ^cY#09.htm##
00495000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027300069002000700342#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#33#29#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Substantial changes    in the morbidity and
 mortality caused by HIV infection were widely documented    after introduction 
of highly active antiretroviral therapy (HAART) <sup>4,5,6,7</sup>.</font></p>  
   ^cY#09.htm##
00792000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057000069002000700639#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#34#30#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The AIDS mortality    rate in Brazil droppe
d from 9.6 deaths per 100 thousand inhabitants in 1996    to 6 per 100 thousand 
in 2006. However, during this same period the rates in    the North and Northeas
t showed an important increase, along with a slight rise    in the South. The de
cline in Brazilian mortality rates resulted from a sharp    drop in the rate in 
the Southeast (from 16.3 in 1996 to 7.4 per 100 thousand    in 2006) and in part
 to a reduction in the Central <sup>2</sup>.</font></p>     ^cY#09.htm##
01025000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704080300069002000700872#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#35#31#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">With the use of    the new therapy, the cli
nical spectrum of patients with HIV infection was expanded    to include not onl
y opportunistic diseases, but also clinical conditions associated    with advers
e effects of therapy, as well as chronic diseases with progressively    increasi
ng incidence during aging <sup>8,9</sup>. The longer survival of individuals    
with HIV infection/AIDS has been observed not only in developed countries, but  
  also in poor regions of the world where access to HAART has been expanded, as 
   in some countries of Sub-Saharan Africa <sup>10</sup>. A 50% reduction in mor
tality    was observed in a cohort study in New York, in patients undergoing HAA
RT from    1995 to 2000 <sup>8</sup>.</font></p>     ^cY#09.htm##
01129000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704090700069002000700976#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#36#32#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Brazil experienced    a reduction of approx
imately 50% in deaths and 80% in hospitalizations due to    AIDS, from 1995 to 2
001 <sup>1,4,11</sup>. Median survival of AIDS patients    over 12 years of age 
was 5.1 months from 1982 to 1989 <sup>12</sup>. According    to Marins et al. <s
up>13</sup>, individuals diagnosed in 1995 has a median survival    of 16 months
, and those diagnosed in 1996 had a median survival of 58 months.    This notewo
rthy increase in survival has been attributed to the Ministry of    Health's pol
icy for care and prevention since the 1990s, investing in universal,    free acc
ess to antiretroviral drugs, widespread availability of diagnostic tests    and 
case follow-up, training of health professionals, and the creation of a    labor
atory network for monitoring drug resistance <sup>1,13</sup>.</font></p>     ^cY
#09.htm##
00622000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040000069002000700469#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#37#33#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Investments in    prevention and care for A
IDS patients in Brazil require evaluations of their    real impact. Updating the
 patient survival analyses can contribute to monitoring    the epidemic's dynami
cs and measuring the needs for care, as well as assessing    strategies for cont
rol of the disease in the country.</font></p>     ^cY#09.htm##
00533000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704031100069002000700380#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#38#34#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The aim of this    study was to evaluate su
rvival time according to socio-demographic, clinical,    and epidemiological cha
racteristics of AIDS patients diagnosed in 1998 and 1999    in the South and Sou
theast regions of Brazil.</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#39#35#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#40#36#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Method</b></font></p>     ^cY#09.htm##
00637000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704041500069002000700484#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#41#37#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A non-concurrent    cohort study was perfor
med in a sample of AIDS patients 13 years and older,    residing in the South an
d Southeast regions of Brazil, diagnosed in 1998 and    1999 and recorded in the
 Information System on Diseases of Notification (SINAN).    The database was pro
vided by the Brazilian National STD/AIDS Program.</font></p>     ^cY#09.htm##
00844000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062200069002000700691#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#42#38#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Starting with all    cases reported in the 
two regions in 1998 and 1999, the sample selection initially    excluded cases: 
from municipalities (counties) with fewer than 40 notifications    during the pe
riod, representing 18% of the total; with AIDS first diagnosed    at death; from
 an unknown notification unit; or with date of diagnosis later    than death or 
notification. After these exclusions, the remaining cases totaled    29,600 and 
8,797, distributed across 90 and 33 municipalities, respectively,    in the Sout
heast and South.</font></p>     ^cY#09.htm##
00624000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040200069002000700471#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#43#39#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Sample sizes were    determined to allow ve
rification of statistical significance between different    median survival time
s in population subgroups: from 58 to 70 months in the Southeast    and 58 to 74
 months in the South, whereas 58 months was the estimated median    survival tim
e in a previous study <sup>13</sup>.</font></p>     ^cY#09.htm##
00685000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046300069002000700532#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#44#40#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To test the hypothesis    that the risk of 
dying within a given time span was the same in two population    subgroups (I an
d II), the number de cases to be included in the study was calculated    as the 
ratio between the number of deaths needed to test the hypothesis and    the prob
ability of dying during the study period <sup>14</sup>. The number of    deaths 
was expressed as:</font></p>     ^cY#09.htm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#45#41#article#182#<p align="center"><img src
="/img/revistas/csp/v27s1/09s01.jpg"></p>     ^cY#09.htm##
01106000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704088400069002000700953#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#46#42#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">where </font><font size="2">&#945;</font><f
ont face="Verdana, Arial, Helvetica, sans-serif" size="2">    = 0.05; </font><fo
nt size="2">&#946;</font><font face="Verdana, Arial, Helvetica, sans-serif" size
="2">    = 0.20; <img src="/img/revistas/csp/v27s1/09s02.jpg" align="absmiddle">
 and    <i>z</i><sub></sub></font><sub><font size="2">&#946;</font></sub><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">    the points on the stand
ardized normal curve and </font><font size="2">&#960;</font><font face="Verdana,
 Arial, Helvetica, sans-serif" size="2"><i><sub>l</sub></i>    = </font><font si
ze="2">&#960;</font><font face="Verdana, Arial, Helvetica, sans-serif" size="2">
<i><sub>ll</sub></i>    0.5 the proportions of cases in groups I and II. The pro
bability of dying was    expressed as:</font></p>     ^cY#09.htm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#47#43#article#182#<p align="center"><img src
="/img/revistas/csp/v27s1/09s03.jpg"></p>     ^cY#09.htm##
00583000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036100069002000700430#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#48#44#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">where a = 24 months    is the study's case 
inclusion period; f = 72 months is the follow-up period;    and the term followi
ng a and (<img src="/img/revistas/csp/v27s1/09s1.jpg" align="absmiddle">)    exp
resses the estimated mean values for survival functions in groups I and II.</fon
t></p>     ^cY#09.htm##
00630000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040800069002000700477#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#49#45#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The calculations    were performed with the
 Power and Precision software (Biostat Inc., Englewwod,    USA) and indicated th
e need for a sample of 1,484 patients in the Southeast    region and 898 in the 
South. Since the study predicted losses on the order of    30%, larger numbers o
f patients were selected: 2,214 and 1,280.</font></p>     ^cY#09.htm##
01053000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083100069002000700900#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#50#46#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Composition of    the sample for each strat
um (region) used two-stage cluster sampling: municipalities    and patients. Mun
icipalities were selected with probability proportional to    size, defined as t
he number of notifications to SINAN by health units. Before    beginning the sel
ection, the municipalities that lacked the minimum number of    notifications to
 be picked in the second stage were grouped with other, larger    municipalities
. Thus, the primary sampling units became the municipalities or    sets of munic
ipalities. Eighteen were selected in the Southeast and 10 in the    South. In th
e second stage, 123 and 128 patients were selected in each primary    unit in th
e Southeast and South, respectively. The sampling fractions were:</font></p>    
 ^cY#09.htm##
00369000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704014700069002000700216#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#51#47#article#182#<p align="center"><img src
="/img/revistas/csp/v27s1/09s04.jpg"><font face="Verdana, Arial, Helvetica, sans
-serif" size="2">    </font></p>     ^cY#09.htm##
00399000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017700069002000700246#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#52#48#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">N<sub>i</sub> is    the number of AIDS case
s in the municipality (or set of municipalities) i.</font></p>     ^cY#09.htm##
00756000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053400069002000700603#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#53#49#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A pre-coded and    previously tested questi
onnaire was prepared to collect data from the clinical    charts of selected pat
ients. A manual was prepared for completing the questionnaires,    and training 
was provided for the field researchers and supervisors, who consisted    mainly 
of health professionals working in the STD/AIDS Program. After completion,    th
e questionnaires were submitted to two supervisions, one local and the other    
central.</font></p>     ^cY#09.htm##
00608000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704038600069002000700455#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#54#50#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Data were collected    from November 2006 t
o December 2007. For purposes of comparison with previous    studies <sup>12,13<
/sup>, the decision was made not to consider the estimated    survival for patie
nts that died within 7 days after diagnosis, so no data were    collected from t
hese patient charts.</font></p>     ^cY#09.htm##
00950000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072800069002000700797#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#55#51#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For this study,    the independent variable
s were: gender, age, race/color, marital status, year    of diagnosis, schooling
, HIV exposure category (all of which reported at the    time of AIDS diagnosis)
, AIDS-defining diagnostic criterion, presence of tuberculosis    at diagnosis o
r during the case evolution, <i>Pneumocystis</i> pneumonia (PCP)    prophylaxis,
 hepatitis B and C serology, the results of these tests (positive    versus nega
tive), use of ART (antiretroviral therapy), and care by a multidisciplinary    t
eam (annotation on the patient chart of having been seen by a professional    ot
her than physicians or the nursing staff).</font></p>     ^cY#09.htm##
00672000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045000069002000700519#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#56#52#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the years 1998    and 1999, the criteria
 for classifying AIDS cases were: CD4 T-cell count (less    than 350/mm<sup>3</s
up> independently of symptoms); Rio de Janeiro/Caracas criterion,    modified CD
C criterion (Centers for Disease Control and Prevention), and death    <sup>3</s
up>. The latter was not considered in the current study, as mentioned    previou
sly.</font></p>     ^cY#09.htm##
00522000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030000069002000700369#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#57#53#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Positive hepatitis    B serology was define
d as positive for least one of the two serological markers    for this infection
, except when only anti-Hbs was reactive, which was interpreted    as a marker o
f vaccination.</font></p>     ^cY#09.htm##
01266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704104400069002000701113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#58#54#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The dependent variable,    survival time, w
as calculated as date of diagnosis to date of death for patients    that died, a
nd date of diagnosis to date of the last visit to the health service    for any 
reason for patients that survived, i.e., for those in whom there was    no recor
d of death. To update the information on patient follow-up or death,    the data
base for this study was linked to the following national databanks:    Mortality
 Information System (SIM), Information System on Laboratory Exams (SISCEL),    a
nd Logistics Control System for Medicines (SICLOM). The databank linkage used   
 reclink, and the parameters for comparison were: patient's full name, date of  
  birth, and patient's mother's full name, and the State of residence was not   
 used in the blocking key. The study excluded patients for whom there was no    
record of having visited the service after diagnosis in either the patient chart
s    or the above-mentioned databanks.</font></p>     ^cY#09.htm##
00392000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704017000069002000700239#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#59#55#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study data    were keyed into the datab
ase using Epi Info 6.04 (CDC, Atlanta, USA).</font></p>     ^cY#09.htm##
00802000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058000069002000700649#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#60#56#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Patient proportions    were estimated accor
ding to categories of the independent variables, and the    differences between 
the two regions were evaluated with the chi-square test.    Survival analysis us
ed the Kaplan-Meier method, also used to calculate the percentages    of survivo
rs for different times since diagnosis. Comparison between the categories    of 
study variables in relation to patient survival used Cox regression models.    S
ignificance for the statistical tests was set at 0.05.</font></p>     ^cY#09.htm
##
00820000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059800069002000700667#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#61#57#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Weights were introduced    into the data an
alysis in order to compensate for different patient selection    probabilities. 
The analyses used the Stata 10 statistical package (Stata Corp.,    College Stat
ion, USA) by means of the <i>svy</i> module, which allows incorporating    aspec
ts referring to the sample design (weighting, stratification, and cluster    sel
ection) in the estimates, except those referring to percentages of survivors    
for given times since diagnosis, estimated with the Kaplan-Meier method.</font><
/p>     ^cY#09.htm##
00633000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704041100069002000700480#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#62#58#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study was approved    by the Institutio
nal Review Board of the Center for Referral and Training in    STD/AIDS under th
e S&atilde;o Paulo State Health Department (Case nº. 15/05    of June 20, 2005).
 It was also approved by research ethics committees at various    university hos
pitals and some municipal health departments.</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#63#59#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#64#60#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Findings</b></font></p>     ^cY#09.htm##
01058000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083600069002000700905#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#65#61#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This study considered    3,130 cases of AID
S patients, of which 1,150 from the South and 1,980 from the    Southeast of Bra
zil. It was possible to find patient charts and obtain the essential    data for
 completing the forms for 2,692 patients (996 from the South and 1,696    from t
he Southeast), corresponding respectively to 86.6% and 85.7% of the cases.    An
alysis of the data's consistency led to the exclusion of 601 questionnaires    d
ue to diagnostic dates other than 1998 or 1999; deaths less than 7 days after   
 diagnosis; and cases that failed to meet any of the AIDS criteria. The final   
 sample consisted of 2,091 cases, 782 from the South and 1,309 from the Southeas
t,    representing, respectively, 68% and 66.1% of the initial sample.</font></p
>     ^cY#09.htm##
01209000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704098700069002000701056#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#66#62#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study population    had the following c
haracteristics: most were male (male-to-female ratio 1.85);    52.7% were diagno
sed in 1998; and 54.4% had a maximum of complete primary schooling    (<a href="
/img/revistas/csp/v27s1/09t01.jpg">Table 1</a>). The socio-demographic    profil
e differed in some aspects between the two regions. In the South, the    patient
s were younger (34.1% were under 30 years of age), showed higher proportions    
of white race/skin color, were married or in common-law marriages, and showed   
 more exposure from injecting drug use, 29.4% compared to 14.9% in the Southeast
,    although the latter showed a higher proportion of missing information for e
xposure    category. Importantly, the sample did not include any AIDS cases due 
to vertical    transmission. The amount of missing information was also high for
 some variables    and was generally higher in the Southeast.</font></p>     ^cY
#09.htm##
01237000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704101500069002000701084#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#67#63#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for the diagnostic    criterion, co-morb
idities, and treatment: 50.9% were diagnosed based on CD4    T-cell count; 25.3%
 presented tuberculosis at the time of AIDS diagnosis or    during evolution of 
the disease; 86% used ART; 54.2% were tested for hepatitis    B, of which 31.7% 
tested positive, and 51.9% were tested for hepatitis C, of    which 26.7% were p
ositive. In the set of patients, 16.4% had a diagnosis of    hepatitis B (19.3% 
in the Southeast and 11.4% in the South) and 14.1% had hepatitis    C (12.8% in 
the Southeast and 18.4% in the South); 42.6% had prophylaxis for    <i>Pneumocys
tis jirovecii</i> pneumonia, and 41.4% were treated at a service    with a multi
disciplinary health team (<a href="/img/revistas/csp/v27s1/09t02.jpg">Table    2
</a>). The only significant differences between the regions were: a higher    ra
te of positive serology for hepatitis B in the Southeast and hepatitis C in    t
he South.</font></p>     ^cY#09.htm##
01016000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079400069002000700863#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#68#64#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Patients in the    IDU exposure category sh
owed the lowest survival probabilities in the two regions    (<a href="/img/revi
stas/csp/v27s1/09f01.jpg">Figure 1</a>). The lowest percentages    (below 50%) o
f survivors 108 months after diagnosis were observed in the IDU    exposure cate
gory in both regions and among black/brown patients in the Southeast    and wido
wed individuals in the South. The greatest survival rates (proportions    of sur
vivors greater than 70%) in both regions were in patients with more than    prim
ary schooling, and in the Southeast only, among individuals in the MSM (men    w
ho have sex with men) sexual exposure category (<a href="/img/revistas/csp/v27s1
/09t03.jpg">Table    3</a>).</font></p>     ^cY#09.htm##
00871000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064900069002000700718#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#69#65#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">When observing    the categories for the va
riables related to diagnosis, co-morbidities, and treatment,    extremely low pr
oportions of survivors (less than 15%) were seen among patients    not on ART (<
a href="#t4">Table 4</a>). At the other extreme, both regions showed    survivor
 rates greater than 70% in patients with CD4 T-cell count as the diagnostic    c
riterion and those not infected with hepatitis C virus. In the Southeast, higher
    survivor rates were also seen in patients tested for hepatitis B and C and t
hose    with negative hepatitis B serology.</font></p>     ^cY#09.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#70#66#article#182#<p><a name="t4"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#71#67#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#72#68#article#182#<p align="center"><img src
="/img/revistas/csp/v27s1/09t04.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#73#69#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
01276000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704105400069002000701123#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#74#70#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="/img/revistas/csp/v27s1/09t05.jpg"
>Table    5</a> shows the univariate analysis, revealing the mortality risk in b
oth regions    was significantly higher in males, patients with less schooling, 
in the IDU    or missing exposure categories, in patients diagnosed according to
 a criterion    other than CD4 T-cell count, those not on ART, those not tested 
for hepatitis    B or C, and those with positive hepatitis C serology. In the So
uth only, the    risk of dying was also greater in patients 40 years or older an
d in single,    separated, or widowed patients. In the Southeast only, risk of d
ying was greater    in black or brown patients (hazard ratio - HR = 1.42), those
 treated in health    services without other professionals besides physicians an
d nurses, those with    a diagnosis of tuberculosis (HR = 1.75) sometime during 
their follow-up, those    who did not receive <i>Pneumocystis</i> prophylaxis, a
nd those who tested positive    for hepatitis B.</font></p>     ^cY#09.htm##
00779000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704055700069002000700626#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#75#71#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#t6">Table    6</a> shows the vari
ables that were maintained in the multiple regression model,    as associated wi
th mortality risk. The models for both regions maintained the    following: gend
er, schooling, ART, and diagnostic criterion. The following were    also kept in
 the model in the Southeast only: race/color, hepatitis B serology,    tuberculo
sis, and having been seen by a multidisciplinary team. In the South,    the age 
variable remained in the model.</font></p>     ^cY#09.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#76#72#article#182#<p><a name="t6"></a></p>  
   ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#77#73#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#78#74#article#182#<p align="center"><img src
="/img/revistas/csp/v27s1/09t06.jpg"></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#79#75#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#80#76#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#09.htm
##
01093000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704087100069002000700940#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#81#77#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This study's main    findings were the surv
ival estimates and their determinants in the cohort of    AIDS patients diagnose
d in 1998-1999 in the South and Southeast regions of Brazil,    after 8-10 years
 of follow-up. The study also showed an evident increase in    the survival of t
hese patients when compared to previous studies performed with    a similar desi
gn <sup>12,13</sup>. Marins et al. <sup>13</sup> found a median    survival of 5
8 months when analyzing a nationwide patient cohort, diagnosed    in 1996, while
 in the current cohort it was not possible to calculate the median,    since app
roximately 60% of the patients were alive at 108 months after diagnosis    of th
e disease. Thus, survival had more than doubled in the two years separating    o
ne cohort from the other.</font></p>     ^cY#09.htm##
00625000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040300069002000700472#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#82#78#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the United States,    according to a sur
vival study on adults with AIDS diagnosed from 1996 to 2003,    more than 75% of
 the patients survived for at least 108 months <sup>15</sup>,    although the st
udy identified significant variations in the percentages of survivors    accordi
ng to race/ethnicity and age bracket.</font></p>     ^cY#09.htm##
00893000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067100069002000700740#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#83#79#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Cox multiple regression    analysis pointed
 to different models for the Southeast and South regions of    Brazil, but some 
variables proved to be strong and consistent predictors in    both regions: ART,
 diagnostic criterion, gender, and schooling. In the Southeast    only, predicto
rs of shorter survival included black/brown skin color as an indicator    of low
er socioeconomic status; co-morbidities like hepatitis B and history of    tuber
culosis; and a services organization variable, namely the presence of a    multi
disciplinary team. In the South, age remained in the final model.</font></p>    
 ^cY#09.htm##
00445000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704022300069002000700292#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#84#80#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Several of these    predictors have also be
en identified by other authors in Brazil and elsewhere    in the world <sup>16,1
7,18,19,20</sup>.</font></p>     ^cY#09.htm##
00940000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071800069002000700787#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#85#81#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The categories    "use of ART" and "CD4 cou
nt as the diagnostic criterion" were consistently associated    with longer surv
ival in the South and Southeast, independently of gender and    schooling. This 
indicates access to health services and antiretroviral therapy    and early diag
nosis. AIDS diagnosis according to CD4 T-cell count is more sensitive,    captur
es patients earlier, and allows access to early preventive and therapeutic    in
terventions. Late diagnosis of the disease has been identified as a predictor   
 of mortality, even before the incorporation of the CD4 criterion by health serv
ices    in Brazil <sup>12</sup>.</font></p>     ^cY#09.htm##
00815000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059300069002000700662#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#86#82#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The availability    of highly active antire
troviral therapy and adherence to the treatment regimen    have been highlighted
 by various authors as essential for the effectiveness    of individual treatmen
t, besides decreasing the spread of viral resistance at    the collective level.
 Meanwhile, the organization of health services and the    comprehensive approac
h to patients can be decisive in improving clinical follow-up    and improved tr
eatment adherence, resulting longer survival <sup>7,18,21,22</sup>.</font></p>  
   ^cY#09.htm##
00899000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704067700069002000700746#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#87#83#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">As for exposure    category, survival was s
horter among IDUs in both regions. Various authors have    identified late diagn
osis of the disease, difficulties in clinical follow-up,    and lower treatment 
adherence as determinants of shorter survival in these patients    <sup>23,24</s
up>. There was a higher proportion of "missing" information on    this variable 
in the Southeast when compared to the South, as observed in the    National STD/
AIDS Program <sup>25</sup>, where the category "missing" accounts    for 12% of 
the total for the country (13.1% in the Southeast and 9% in the South).</font></
p>     ^cY#09.htm##
01010000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078800069002000700857#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#88#84#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">According to the    bivariate analysis, the
 findings in this 1998-1999 cohort point to higher mortality    in males in both
 regions. Importantly, there was a major spread of the disease    among IDU in t
he South, a group consisting mostly of young men. Longer survival    in women co
uld result from greater enrollment in (and use of) health services    and prenat
al care and childbirth (which increase the probability of performing    diagnost
ic tests), and thus earlier diagnosis of HIV infection or AIDS. According    to 
some studies, the association between gender and risk of dying is not maintained
    after controlling for socioeconomic variables and access to health services 
   <sup>1,13,17</sup>.</font></p>     ^cY#09.htm##
01180000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704095800069002000701027#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#89#85#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Schooling was analyzed    as a marker of th
e population's socioeconomic conditions, and was the only such    information av
ailable on the patient chart disease notification forms. Individuals    with com
plete secondary or university education showed lower risk of dying,    compared 
to those with less schooling or with this information missing (the    statistica
l significance remained in the final model in both regions). Higher    AIDS mort
ality has been recorded in poor populations and countries, even with    access t
o HAART. Factors possibly related to this excess risk include later    diagnosis
, higher prevalence of co-morbidities due to chronic invasive infections    like
 tuberculosis, mycoses, and others, and more limited understanding and condition
s    to adhere to prolonged treatment, compared to population segments with high
er    schooling <sup>7,19</sup>.</font></p>     ^cY#09.htm##
00563000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704034100069002000700410#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#90#86#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the Southeast,    even after adjusting f
or schooling, longer survival was shown in white individuals    as compared to b
lack or brown. The race/color variable (self-reported) was only    incorporated 
into the AIDS investigation form in 2001 <sup>26</sup>.</font></p>     ^cY#09.ht
m##
00710000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048800069002000700557#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#91#87#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">It is thus difficult    to analyze trends, 
although recent years have seen a clear improvement in completion    of the data
: in 2000, 96% of reported AIDS cases lacked this information, whereas    this p
roportion of missing information on race/color dropped to only 15% by    2005 <s
up>26,27</sup>. In the South, even in the bivariate analysis, the race/color    
variable was not associated with survival.</font></p>     ^cY#09.htm##
00704000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048200069002000700551#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#92#88#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Various authors    have called attention to
 the difference in the risk of dying from AIDS according    to race/skin color a
nd ethnicity, attributing these differences to inequalities    in access to heal
th services and antiretroviral therapy, exposure to other diseases,    and diffe
rences in living conditions. In Brazil, few studies have investigated    this is
sue in depth <sup>16,27,28,29</sup>.</font></p>     ^cY#09.htm##
00981000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075900069002000700828#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#93#89#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Fifty-two percent    of patients in the sam
ple had tested for hepatitis C, among whom 14% were seropositive,    with no dif
ferences between the regions. This proportion of individuals tested    for HCV w
as higher than observed in the study by Marins <sup>30</sup> (29,5%),    a diffe
rence that may result from the increase in survival, allowing more opportunities
    for performing HCV serology, besides indicating improved care. Prevalence of
    co-infection in that cohort (1995-1996) was 33.4%, while in the current stud
y    (1998-1999 cohort) it was 26.7%. The decrease in the proportion of AIDS cas
es    among drug users in the last decade may have influenced this trend.</font>
</p>     ^cY#09.htm##
01169000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704094700069002000701016#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#94#90#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In relation to    hepatitis B, 54% of the p
atients had done serological tests, of which 31.7%    tested positive. In both r
egions, increased survival was related to fact that    patients had been tested 
for hepatitis B and C. Early serological testing may    be associated with incre
ased survival, and recording serological results on    the patient chart may ref
lect better quality of care. Importantly, there was    an increased risk of mort
ality in patients co-infected with hepatitis B as compared    to HBV-negative pa
tients, even after adjusting for all the other variables included    in the fina
l model in the Southeast region. Various studies cited by Ferreira    &amp; Borg
es <sup>31</sup> demonstrated greater risk of dying in patients with    HIV/HBV 
co-infection, especially in those with low CD4 T-lymphocyte counts,    as well a
s chronic alcoholics.</font></p>     ^cY#09.htm##
00492000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704027000069002000700339#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#95#91#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV/TB co-infection    only contributed to 
reduction in survival in the Southeast. Other studies have    reported worse AID
S prognosis in the presence of tuberculosis <sup>11,30,32</sup>.</font></p>     
^cY#09.htm##
01196000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704097400069002000701043#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#96#92#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the Southeast,    AIDS mortality was low
er in patients attending health services with a multidisciplinary    team, i.e.,
 with nutritionists, physical therapists, psychologists, and other    profession
als. The healthcare system in this region has a better infrastructure,    with a
 consolidated system for distribution of medicines, as compared to other    regi
ons of Brazil. According to data from QUALIAIDS, in the South, 22.1% of    servi
ces are classified as having better quality, while in the Southeast the    propo
rtion is 32/.2% <sup>33</sup>. In an evaluation on quality of care for    patien
ts with HIV/AIDS in seven Brazilian States, Melchior et al. <sup>34</sup>    hig
hlight the importance of having such professionals (in addition to physicians   
 and nurses) in the health teams, even though these services are accessed mainly
    through referral by the attending physician.</font></p>     ^cY#09.htm##
00766000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054400069002000700613#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#97#93#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">One of the current    study's limitations i
s that it analyzed secondary data, obtained from patient    charts, implying a v
ariation in quality, loss of data, and lack of data completeness.    However, th
e calculated sample considered the possibility of losses, and the    number of c
ompleted questionnaires allowed estimates with an adequate degree    of precisio
n that can be compared to previous studies, and to evaluate the increase    in s
urvival over time.</font></p>     ^cY#09.htm##
00792000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057000069002000700639#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#98#94#article#182#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite major social    disparities between
 Brazil's geographic regions and different AIDS transmission    dynamics, this s
tudy points to an important gain in survival in patients with    AIDS diagnosis 
in the two regions studied here: approximately 60% of the AIDS    patients survi
ved for at least 108 months. The findings also show persistent    major challeng
es common to both the South and Southeast, including expansion    of access to t
herapy and upgrading of healthcare services.</font></p>     ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#99#95#article#182#<p>&nbsp;</p>     ^cY#09.h
tm##
00325000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704010200070002000700172#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#100#96#article#182#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#09.
htm##
00478000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704025500070002000700325#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#101#97#article#182#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">I. A. Guibu contributed    to the study co
nception and design, data analysis and interpretation, drafting    of the articl
e, and revision and approval of the final version.</font></p>     ^cY#09.htm##
00662000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704043900070002000700509#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#102#98#article#182#<p><font face="Verdana, A
rial, Helvetica, sans-serif" size="2">M. B. A. Barros,    M. C. G. P. Alves, and
 A. Tayra collaborated in the study conception and design,    data analysis and 
interpretation, drafting of the article, and revision and    approval of the fin
al version. M. R. Donal&iacute;sio collaborated in the data    analysis and inte
rpretation, drafting of the article, and approval of the final    version.</font
></p>     ^cY#09.htm##
00245000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002200070002000700092#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#103#99#article#182#<p>&nbsp;</p>     ^cY#09.
htm##
00330000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010600071002000700177#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#104#100#article#182#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></font></p>     ^c
Y#09.htm##
00896000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704067200071002000700743#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#105#101#article#182#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">The research was    funded by the Brazili
an National STD/AIDS Program of the Ministry of Health,    through an agreement 
with the Augusto Leopoldo Ayrosa Galv&atilde;o Research    Center, affiliated wi
th the Faculdade de Ci&ecirc;ncias M&eacute;dicas da Santa    Casa de S&atilde;o
 Paulo. M. B. A. Barros received a productivity scholarship    from the National
 Research Council (CNPq). Special acknowledgments to Gerson    Fernando Pereira,
 Jos&eacute; Ricardo Pio Marins, Artur Sousa, Magda Queiroz,    M&aacute;rcia Po
lon, Rejane Freissat, Lia Zangirolani, and Maria Aparecida Vedovato.</font></p> 
    ^cY#09.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#106#102#article#182#<p>&nbsp;</p>     ^cY#09
.htm##
00324000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704010000071002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#107#103#article#182#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#09.h
tm##
00496000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704025800073002000700331#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#108#104#article#182#1#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">1. Fonseca MGP,    Bastos F
I. Twenty-five years of the AIDS epidemic in Brazil: principal epidemiological  
  findings, 1980-2005. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S333-44.
    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#109#105#article#182#</font></p>     ^cY#09.h
tm##
00405000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704016700073002000700240#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#110#106#article#182#2#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">2. Minist&eacute;rio    da 
Sa&uacute;de. Boletim Epidemiol&oacute;gico AIDST 2008; Ano V, nº. 1.    ^cY#09.
htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#111#107#article#182#</font></p>     ^cY#09.h
tm##
00504000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704026600073002000700339#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#112#108#article#182#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Minist&eacute;rio    da 
Sa&uacute;de. Crit&eacute;rios de defini&ccedil;&atilde;o de casos de AIDS    em
 adultos e crian&ccedil;as. Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de; 
   2004.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#113#109#article#182#</font></p>     ^cY#09.h
tm##
00501000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704026300073002000700336#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#114#110#article#182#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Dourado I, Veras    MASM
, Barreira D, Brito AM. Tend&ecirc;ncias da epidemia de AIDS no Brasil ap&oacute
;s    a terapia antirretroviral. Rev Sa&uacute;de P&uacute;blica 2006; 40 Suppl:
9-17.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#115#111#article#182#</font></p>     ^cY#09.h
tm##
00595000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704035700073002000700430#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#116#112#article#182#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Casseb J, Fonseca    LA,
 Veiga AP, Almeida A, Bueno A, Ferez AC, et al. AIDS incidence and mortality    
in a hospital based cohort of HIV-1 seropositive patients receiving highly activ
e    antiretroviral therapy in S&atilde;o Paulo, Brazil. AIDS Patient Care STDS 
2003;    17:447-52.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#117#113#article#182#</font></p>     ^cY#09.h
tm##
00608000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704037000073002000700443#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#118#114#article#182#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Crum NF, Riffemburg    R
H, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparison of causes of    d
eath and mortality rates among HIV infected persons: analysis of the pre, early,
    and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune 
   Defic Syndr 2006; 41:194-200.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#119#115#article#182#</font></p>     ^cY#09.h
tm##
00548000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704031000073002000700383#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#120#116#article#182#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Santos NJS,    Tayra A, 
Silva SR, Buchala CM, Laurenti R. A AIDS no estado de S&atilde;o Paulo:    as mu
dan&ccedil;as no perfil da epidemia e perspectivas da vigil&acirc;ncia    epidem
iol&oacute;gica. Rev Bras Epidemiol 2002; 5:286-310.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#121#117#article#182#</font></p>     ^cY#09.h
tm##
00478000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704024000073002000700313#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#122#118#article#182#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Messeri P, Lee    G, Abr
amson DM, Aidala A, Chiasson MA, Jessop DJ. Antiretroviral therapy and    declin
ing AIDS mortality in New York City. Med Care 2003; 41:512-21.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#123#119#article#182#</font></p>     ^cY#09.h
tm##
00531000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704029300073002000700366#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#124#120#article#182#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Vellozi C, Brooks    JT,
 Bush TJ, Conley LJ, Henry K, Carperter CCJ, et al. The study to understand    t
he natural history of HIV and AIDS in the era of effective therapy (SUN Study). 
   Am J Epidemiol 2009; 169:642-52.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#125#121#article#182#</font></p>     ^cY#09.h
tm##
00440000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020100074002000700275#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#126#122#article#182#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Quinn TC. HIV    epide
miology and the effects of antiviral therapy on long term consequences.    AIDS 
2008; 22 Suppl 3:S7-S12.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#127#123#article#182#</font></p>     ^cY#09.h
tm##
00820000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704058100074002000700655#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#128#124#article#182#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Brazilian Ministry    
of Health. Targets and commitments made by the Member-States at the United Natio
n    General Assembly Special Session on HIV/AIDS. <a href="http://www.unaids.or
g/en/dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountr
ies/brazil_2010_country_progress_report_en.pdf" target="_blank">http//www.unaids
.org/en/dataanalysis/monitoringcountryprogress/    2010progressreportssubmittedb
ycountries/brazil_2010_country_progress_report_en.pdf</a>    (accessed on Jul/20
10).    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#129#125#article#182#</font></p>     ^cY#09.h
tm##
00533000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029400074002000700368#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#130#126#article#182#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Chequer P,    Hearst N
, Hudes ES, Castilho E, Rutherford G, Loures L, et al. Determinants    of surviv
al in adult Brazilian AIDS patients, 1982-1989.The Brazilian State    AIDS Progr
am Co-ordinators. AIDS 1992; 6:483-7.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#131#127#article#182#</font></p>     ^cY#09.h
tm##
00482000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024300074002000700317#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#132#128#article#182#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Marins JR,    Jamal LE
, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement    in su
rvival among adult Brazilian AIDS patients. AIDS 2003; 17:1675-82.    ^cY#09.htm
##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#133#129#article#182#</font></p>     ^cY#09.h
tm##
00430000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019100074002000700265#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#134#130#article#182#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Collet D. Modeling    
survival data in medical research. 2<sup>nd</sup> Ed. Boca Raton: Chapman &amp; 
   Hall; 2003.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#135#131#article#182#</font></p>     ^cY#09.h
tm##
00458000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704021900074002000700293#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#136#132#article#182#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Centers for    Disease
 Control and Prevention. Epidemiology of HIV/AIDS, United States, 1981-2005.    
MMWR Morb Mortal Wkly Rep 2006; 55:589-92.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#137#133#article#182#</font></p>     ^cY#09.h
tm##
00545000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030600074002000700380#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#138#134#article#182#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Wong KH, Chan    KC, L
ee SS. Delayed progression to death and to AIDS in a Hong Kong cohort of    pati
ents with advanced HIV type 1 disease during the era of highly active antiretrov
iral    therapy. Clin Infect Dis 2004; 39:853-60.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#139#135#article#182#</font></p>     ^cY#09.h
tm##
00516000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027700074002000700351#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#140#136#article#182#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Gadelha AJ,    Accacio
 N, Costa RLB, Galhardo MC, Cotrim MR, Souza RV, et al. Morbidity and    surviva
l in advanced AIDS in Rio de Janeiro, Brazil. Rev Inst Med Trop S&atilde;o    Pa
ulo 2002; 44:179-86.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#141#137#article#182#</font></p>     ^cY#09.h
tm##
00533000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029400074002000700368#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#142#138#article#182#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Hacker MA,    Petersen
 ML, Enriquez M, Bastos FI. Highly active antiretroviral therapy in    Brazil: t
he challenge of universal access in a context of social inequality.    Rev Panam
 Salud P&uacute;blica 2004; 16:78-83.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#143#139#article#182#</font></p>     ^cY#09.h
tm##
00509000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027000074002000700344#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#144#140#article#182#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Krishnan S,    Dunbar 
MS, Minnis AM, Medlin CA, Gerdts CE, Padian NS. Poverty, gender inequalities    
and women's risk of Human Immunodeficiency Virus/AIDS. Ann N Y Acad Sci 2008;   
 1136:101-10.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#145#141#article#182#</font></p>     ^cY#09.h
tm##
00481000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704024200074002000700316#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#146#142#article#182#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Antunes JLF,    Waldma
n EA, Borrel C. Is it possible to reduce AIDS death without reinforcing    socio
economic inequalities in health? Int J Epidemiol 2005; 34:586-92.    ^cY#09.htm#
#
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#147#143#article#182#</font></p>     ^cY#09.h
tm##
00547000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030800074002000700382#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#148#144#article#182#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Castilho EA,    Szwarc
wald CL, Brito AM. Fatores associados &agrave; interrup&ccedil;&atilde;o    de t
ratamento anti-retroviral em adultos com AIDS, Rio Grande do Norte, Brasil,    1
999-2002. Rev Assoc Med Bras (1992) 2006; 52:86-92.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#149#145#article#182#</font></p>     ^cY#09.h
tm##
00413000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017400074002000700248#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#150#146#article#182#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Neme MIB, Carvalho    
HB, Souza MFM. ARV therapy adherence in Brazil. AIDS 2004; 18 Suppl 3:515-20.   
 ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#151#147#article#182#</font></p>     ^cY#09.h
tm##
00554000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031500074002000700389#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#152#148#article#182#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. P&eacute;rez-Hoyos    
S, Amo J, Muga R, Romero J, Olalla PG, Guerrero R, et al. Effectiveness of highl
y    active antiretroviral therapy in Spanish cohorts of HIV seroconverters: dif
ferences    by transmission category. AIDS 2003; 17:353-9.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#153#149#article#182#</font></p>     ^cY#09.h
tm##
00578000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033900074002000700413#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#154#150#article#182#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Rapiti E, Porta    D, 
Forastiere F, Fusco D, Perucci CA; Lazio AIDS Surveillance Collaborative    Grou
p. Socioeconomic status and survival of persons with AIDS before and after    in
troduction of Highly Active Antiretroviral Therapy. Epidemiology 2000; 11:496-50
1.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#155#151#article#182#</font></p>     ^cY#09.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#156#152#article#182#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Minist&eacute;rio    d
a Sa&uacute;de. Programa Nacional DST e AIDS. <a href="http://www.aids.gov.br/cg
i/deftohtm.exe?tabnet/aids.def" target="_blank">http://www.aids.gov.br/cgi/defto
htm.exe?tabnet/aids.def</a>    (accessed on 26/Aug/2009).    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#157#153#article#182#</font></p>     ^cY#09.h
tm##
00539000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030000074002000700374#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#158#154#article#182#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Giovanetti    MC, Sant
os NJS, Westin CP, Darr&eacute; D, Gianna MC. A implanta&ccedil;&atilde;o    do 
quesito cor/ra&ccedil;a nos servi&ccedil;os de DST/AIDS no Estado de S&atilde;o 
   Paulo. Sa&uacute;de Soc 2007; 16:163-70.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#159#155#article#182#</font></p>     ^cY#09.h
tm##
00563000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032400074002000700398#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#160#156#article#182#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Fry PH, Monteiro    S,
 Maio MC, Bastos FI, Santos RV. AIDS tem cor ou ra&ccedil;a? Interpreta&ccedil;&
atilde;o    de dados e formula&ccedil;&atilde;o de pol&iacute;ticas de sa&uacute
;de no Brasil.    Cad Sa&uacute;de P&uacute;blica 2007; 23:497-523.    ^cY#09.ht
m##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#161#157#article#182#</font></p>     ^cY#09.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#162#158#article#182#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Batista LE.    Mulhere
s e homens negros: sa&uacute;de, doen&ccedil;a e morte &#91;Doctoral    Disserta
tion&#93;. Araraquara: Fa-culdade de Ci&ecirc;ncias e Letras, Universidade    Es
tadual Paulista; 2002.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#163#159#article#182#</font></p>     ^cY#09.h
tm##
00586000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704034700074002000700421#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#164#160#article#182#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Fonseca MGP,    Lucena
 FFA, Souza A, Bastos FI. AIDS mortality, "race or color", and social    inequal
ity in a context of universal access to highly active antiretroviral    therapy 
(HAART) in Brazil, 1999-2004. Cad Sa&uacute;de P&uacute;blica 2007;    23 Suppl 
3:S445-55.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#165#161#article#182#</font></p>     ^cY#09.h
tm##
00609000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037000074002000700444#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#166#162#article#182#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Marins JRP.    Estudo 
de sobrevida dos pacientes de AIDS segundo escolaridade, co-infec&ccedil;&atilde
;o    hepatite C e tuberculose. Coorte brasileira 1995-1996 &#91;Doctoral Disser
tation&#93;.    Campinas: Faculdade de Ci&ecirc;ncias M&eacute;dicas, Universida
de Estadual    de Campinas; 2004.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#167#163#article#182#</font></p>     ^cY#09.h
tm##
00444000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020500074002000700279#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#168#164#article#182#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Ferreira MS,    Borges
 AS. Avan&ccedil;os no tratamento da hepatite pelo v&iacute;rus B. Rev    Soc Br
as Med Trop 2007; 40:451-62.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#169#165#article#182#</font></p>     ^cY#09.h
tm##
00506000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026700074002000700341#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#170#166#article#182#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Mussini C,    Manzardo
 C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, et al. Patients    presen
ting with AIDS in the HAART era: a collaborative cohort analysis. AIDS    2008; 
22:2461-9.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#171#167#article#182#</font></p>     ^cY#09.h
tm##
00553000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031400074002000700388#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#172#168#article#182#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. Nemes MIB,    Alencar 
TMD; Equipe Qualiaids. Avalia&ccedil;&atilde;o da assist&ecirc;ncia    ambulator
ial aos adultos vivendo com HIV/AIDS. Qualiaids. Relat&oacute;rio 2007/2008.    
Bras&iacute;lia: Minist&eacute;rio da Sa&uacute;de; 2008.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#173#169#article#182#</font></p>     ^cY#09.h
tm##
00560000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032100074002000700395#v27
s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#p#174#170#article#182#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Melchior R,    Nemes M
IB, Basso CRB, Castanheira ERL, Alves MTSB, Buchalla CM, et al. Avalia&ccedil;&a
tilde;o    da estrutura organizacional assist&ecirc;ncia ambulatorial em HIV/AID
S no Brasil.    Rev Sa&uacute;de P&uacute;blica 2006; 40:143-51.    ^cY#09.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#175#171#article#182#</font></p>     ^cY#09.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#176#172#article#182#<p>&nbsp;</p>     ^cY#09
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#177#173#article#182#<p>&nbsp;</p>     ^cY#09
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#178#174#article#182#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#09.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003100071002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#179#175#article#182#<br>   </b> I. A. Guibu 
   ^cY#09.htm##
00315000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009100071002000700162#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#180#176#article#182#<br>   Faculdade de Ci&e
circ;ncias M&eacute;dicas da Santa Casa de S&atilde;o Paulo    ^cY#09.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#181#177#article#182#<br>   Rua Joaquim Antun
es 852, apto. 83-A    ^cY#09.htm##
00277000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005300071002000700124#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#182#178#article#182#<br>   S&atilde;o Paulo,
 SP 05415-001, Brasil    ^cY#09.htm##
00309000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704008500071002000700156#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#183#179#article#182#<br>   <a href="mailto:i
one@cealag.com.br">ione@cealag.com.br</a></font></p>     ^cY#09.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#184#180#article#182#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 21/Jan/2010    ^cY#09.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#185#181#article#182#<br>   Final version res
ubmitted on 17/May/2010    ^cY#09.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\09.htm#S#p#186#182#article#182#<br>   Approved on 06/Ju
l/2010</font></p>     ^cY#09.htm##
00549000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100017000890120
10000106030001800206710000200224065000900226064000500235031000300240032000400243
014000800247865000900255002000700264#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.
htm#S#c#187#1#article#34#1#^rND^sFonseca^nMGP#^rND^sBastos^nFI#Twenty-five years
 of the AIDS epidemic in Brazil: principal epidemiological findings, 1980-2005^l
en#Cad Saúde Pública#2#20070000#2007#23#^s3#S333-44#20110000#09.htm##
00340000000000181000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170020000700180052000908650
00900142002000700151#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#188#2#ar
ticle#34#2#Ministério da Saúde#Boletim Epidemiológico AIDST 2008; Ano V, nº: 1^l
es#20110000#09.htm##
00445000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680170020000700180066000900660
00900156062002000165065000900185064000500194865000900199002000700208#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\09.htm#S#c#189#3#article#34#3#Ministério da Saúde#C
ritérios de definição de casos de AIDS em adultos e crianças^lpt#Brasília#Minist
ério da Saúde#20040000#2004#20110000#09.htm##
00569000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100018000870100
01800105010001600123012007600139030001800215710000200233065000900235064000500244
031000900249014000500258865000900263002000700272#v27s1#V:\SciELO\serial\csp\v27s
1\markup\09.htm#S#c#190#4#article#34#4#^rND^sDourado^nI#^rND^sVeras^nMASM#^rND^s
Barreira^nD#^rND^sBrito^nAM#Tendências da epidemia de AIDS no Brasil após a tera
pia antirretroviral^lpt#Rev Saúde Pública#2#20060000#2006#40 Suppl#9-17#20110000
#09.htm##
00767000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100018000860100
01600104010001700120010001500137010001600152810000600168012015900174030002300333
06500090035606400050036503100030037001400070037386500090038000200070038903500100
0396801002300406#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#191#5#articl
e#34#5#^rND^sCasseb^nJ#^rND^sFonseca^nLA#^rND^sVeiga^nAP#^rND^sAlmeida^nA#^rND^s
Bueno^nA#^rND^sFerez^nAC#et al#AIDS incidence and mortality in a hospital based 
cohort of HIV-1 seropositive patients receiving highly active antiretroviral the
rapy in São Paulo, Brazil^len#AIDS Patient Care STDS#20030000#2003#17#447-52#201
10000#09.htm#1087-2914#Aids Patient Care STDS##
00792000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100021000850100
01600106010001500122010001700137010001800154810000600172012016900178030002800347
06500090037506400050038403100030038901400080039286500090040000200070040903500100
0416801002800426#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#192#6#articl
e#34#6#^rND^sCrum^nNF#^rND^sRiffemburg^nRH#^rND^sWegner^nS#^rND^sAgan^nBK#^rND^s
Tasker^nSA#^rND^sSpooner^nKM#et al#Comparison of causes of death and mortality r
ates among HIV infected persons: analysis of the pre, early, and late HAART (hig
hly active antiretroviral therapy) eras^len#J Acquir Immune Defic Syndr#20060000
#2006#41#194-200#20110000#09.htm#0894-9255#J Acquir Immune Defic Syndr##
00631000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100015000880100
01600103010001800119010001800137012011300155030001900268710000200287065000900289
064000500298031000200303014000800305865000900313002000700322#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\09.htm#S#c#193#7#article#34#7#^rND^sSantos^nNJS#^rND^sTayra
^nA#^rND^sSilva^nSR#^rND^sBuchala^nCM#^rND^sLaurenti^nR#A AIDS no estado de São 
Paulo: as mudanças no perfil da epidemia e perspectivas da vigilância epidemioló
gica^lpt#Rev Bras Epidemiol#2#20020000#2002#5#286-310#20110000#09.htm##
00638000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100013000870100
01900100010001600119010001900135010001700154012007300171030000900244065000900253
06400050026203100030026701400070027086500090027700200070028603500100029380100090
0303#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#194#8#article#34#8#^rND^
sMesseri^nP#^rND^sLee^nG#^rND^sAbramson^nDM#^rND^sAidala^nA#^rND^sChiasson^nMA#^
rND^sJessop^nDJ#Antiretroviral therapy and declining AIDS mortality in New York 
City^len#Med Care#20030000#2003#41#512-21#20110000#09.htm#0025-7079#Med Care##
00705000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100017000870100
01500104010001700119010001500136010002100151810000600172012010800178030001500286
06500090030106400050031003100040031501400070031986500090032600200070033503500100
0342801001500352#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#195#9#articl
e#34#9#^rND^sVellozi^nC#^rND^sBrooks^nJT#^rND^sBush^nTJ#^rND^sConley^nLJ#^rND^sH
enry^nK#^rND^sCarperter^nCCJ#et al#The study to understand the natural history o
f HIV and AIDS in the era of effective therapy (SUN Study)^len#Am J Epidemiol#20
090000#2009#169#642-52#20110000#09.htm#0002-9262#Am J Epidemiol##
00514000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720120084000880300
00500172065000900177064000500186031000300191032000400194014000700198865000900205
002000700214035001000221801000500231#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.
htm#S#c#196#10#article#34#10#^rND^sQuinn^nTC#HIV epidemiology and the effects of
 antiviral therapy on long term consequences^len#AIDS#20080000#2008#22#^s3#S7-S1
2#20110000#09.htm#0269-9370#AIDS##
00609000000000205000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690180150000720370147002221100
00900369109000900378865000900387002000700396#v27s1#V:\SciELO\serial\csp\v27s1\ma
rkup\09.htm#S#c#197#11#article#34#11#Brazilian Ministry of Health: Targets and c
ommitments made by the Member-States at the United Nation General Assembly Speci
al Session on HIV/AIDS^len#http//www.unaids.org/en/dataanalysis/monitoringcountr
yprogress/ 2010progressreportssubmittedbycountries/brazil_2010_country_progress_
report_en.pdf#20100700#Jul/2010#20110000#09.htm##
00698000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01600105010001800121010002000139010001600159810000600175012012100181030000500302
06500090030706400050031603100020032101400060032386500090032900200070033803500100
0345801000500355#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#198#12#artic
le#34#12#^rND^sChequer^nP#^rND^sHearst^nN#^rND^sHudes^nES#^rND^sCastilho^nE#^rND
^sRutherford^nG#^rND^sLoures^nL#et al#Determinants of survival in adult Brazilia
n AIDS patients, 1982-1989: The Brazilian State AIDS Program Co-ordinators^len#A
IDS#19920000#1992#6#483-7#20110000#09.htm#0269-9370#AIDS##
00649000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01500105010001700120010001600137010001800153810000600171012007300177030000500250
06500090025506400050026403100030026901400080027286500090028000200070028903500100
0296801000500306#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#199#13#artic
le#34#13#^rND^sMarins^nJR#^rND^sJamal^nLE#^rND^sChen^nSY#^rND^sBarros^nMB#^rND^s
Hudes^nES#^rND^sBarbosa^nAA#et al#Dramatic improvement in survival among adult B
razilian AIDS patients^len#AIDS#20030000#2003#17#1675-82#20110000#09.htm#0269-93
70#AIDS##
00435000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160016000720180047000880630
00200135066001100137062001500148065000900163064000500172865000900177002000700186
#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#200#14#article#34#14#^rND^sC
ollet^nD#Modeling survival data in medical research^len#2#Boca Raton#Chapman & H
all#20030000#2003#20110000#09.htm##
00538000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690110043000720120055001150300
02600170065000900196064000500205031000300210014000700213865000900220002000700229
035001000236801002600246#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#201#
15#article#34#15#Centers for Disease Control and Prevention#Epidemiology of HIV/
AIDS, United States, 1981-2005^len#MMWR Morb Mortal Wkly Rep#20060000#2006#55#58
9-92#20110000#09.htm#0149-2195#MMWR Morb Mortal Wkly Rep##
00655000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100015000870100
01400102012016700116030001600283065000900299064000500308031000300313014000700316
865000900323002000700332035001000339801001600349#v27s1#V:\SciELO\serial\csp\v27s
1\markup\09.htm#S#c#202#16#article#34#16#^rND^sWong^nKH#^rND^sChan^nKC#^rND^sLee
^nSS#Delayed progression to death and to AIDS in a Hong Kong cohort of patients 
with advanced HIV type 1 disease during the era of highly active antiretroviral 
therapy^len#Clin Infect Dis#20040000#2004#39#853-60#20110000#09.htm#1058-4838#Cl
in Infect Dis##
00696000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01700107010001900124010001700143010001600160810000600176012007000182030002800252
06500090028006400050028903100030029401400070029786500090030400200070031303500100
0320801002800330#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#203#17#artic
le#34#17#^rND^sGadelha^nAJ#^rND^sAccacio^nN#^rND^sCosta^nRLB#^rND^sGalhardo^nMC#
^rND^sCotrim^nMR#^rND^sSouza^nRV#et al#Morbidity and survival in advanced AIDS i
n Rio de Janeiro, Brazil^len#Rev Inst Med Trop São Paulo#20020000#2002#44#179-86
#20110000#09.htm#0036-4665#Rev Inst Med Trop São Paulo##
00618000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100019000890100
01800108010001700126012012000143030002400263710000200287065000900289064000500298
031000300303014000600306865000900312002000700321#v27s1#V:\SciELO\serial\csp\v27s
1\markup\09.htm#S#c#204#18#article#34#18#^rND^sHacker^nMA#^rND^sPetersen^nML#^rN
D^sEnriquez^nM#^rND^sBastos^nFI#Highly active antiretroviral therapy in Brazil: 
the challenge of universal access in a context of social inequality^len#Rev Pana
m Salud Pública#2#20040000#2004#16#78-83#20110000#09.htm##
00674000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01700107010001700124010001700141010001700158012008700175030001700262065000900279
06400050028803100050029301400070029886500090030500200070031403500100032180100170
0331#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#205#19#article#34#19#^rN
D^sKrishnan^nS#^rND^sDunbar^nMS#^rND^sMinnis^nAM#^rND^sMedlin^nCA#^rND^sGerdts^n
CE#^rND^sPadian^nNS#Poverty, gender inequalities and women's risk of Human Immun
odeficiency Virus/AIDS^len#Ann N Y Acad Sci#20080000#2008#1136#101-10#20110000#0
9.htm#0077-8923#Ann N Y Acad Sci##
00595000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100018000910100
01600109012009800125030001600223065000900239064000500248031000300253014000700256
865000900263002000700272035001000279801001600289#v27s1#V:\SciELO\serial\csp\v27s
1\markup\09.htm#S#c#206#20#article#34#20#^rND^sAntunes^nJLF#^rND^sWaldman^nEA#^r
ND^sBorrel^nC#Is it possible to reduce AIDS death without reinforcing socioecono
mic inequalities in health?^len#Int J Epidemiol#20050000#2005#34#586-92#20110000
#09.htm#0300-5771#Int J Epidemiol##
00632000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100021000910100
01600112012012700128030001900255065000900274064000500283031000300288014000600291
865000900297002000700306035001000313801001900323#v27s1#V:\SciELO\serial\csp\v27s
1\markup\09.htm#S#c#207#21#article#34#21#^rND^sCastilho^nEA#^rND^sSzwarcwald^nCL
#^rND^sBrito^nAM#Fatores associados à interrupção de tratamento anti-retroviral 
em adultos com AIDS, Rio Grande do Norte, Brasil, 1999-2002^lpt#Rev Assoc Med Br
as#20060000#2006#52#86-92#20110000#09.htm#0004-5241#Rev Assoc Med Bras##
00526000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100019000880100
01700107012003600124030000500160065000900165064000500174031000300179032000400182
014000700186865000900193002000700202035001000209801000500219#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\09.htm#S#c#208#22#article#34#22#^rND^sNeme^nMIB#^rND^sCarva
lho^nHB#^rND^sSouza^nMFM#ARV therapy adherence in Brazil^len#AIDS#20040000#2004#
18#^s3#515-20#20110000#09.htm#0269-9370#AIDS##
00711000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100013000930100
01400106010001600120010001700136010001800153810000600171012013700177030000500314
06500090031906400050032803100030033301400060033686500090034200200070035103500100
0358801000500368#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#209#23#artic
le#34#23#^rND^sPérez-Hoyos^nS#^rND^sAmo^nJ#^rND^sMuga^nR#^rND^sRomero^nJ#^rND^sO
lalla^nPG#^rND^sGuerrero^nR#et al#Effectiveness of highly active antiretroviral 
therapy in Spanish cohorts of HIV seroconverters: differences by transmission ca
tegory^len#AIDS#20030000#2003#17#353-9#20110000#09.htm#0269-9370#AIDS##
00732000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100015000880100
02000103010001500123010001800138011004400156012012900200030001300329065000900342
06400050035103100030035601400080035986500090036700200070037603500100038380100130
0393#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#210#24#article#34#24#^rN
D^sRapiti^nE#^rND^sPorta^nD#^rND^sForastiere^nF#^rND^sFusco^nD#^rND^sPerucci^nCA
#Lazio AIDS Surveillance Collaborative Group#Socioeconomic status and survival o
f persons with AIDS before and after introduction of Highly Active Antiretrovira
l Therapy^len#Epidemiology#20000000#2000#11#496-501#20110000#09.htm#1044-3983#EP
IDEMIOLOGY##
00436000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170020000720180033000920370
05600125110000900181109001200190865000900202002000700211#v27s1#V:\SciELO\serial\
csp\v27s1\markup\09.htm#S#c#211#25#article#34#25#Ministério da Saúde#Programa Na
cional DST e AIDS^lpt#http://www.aids.gov.br/cgi/deftohtm.exe?tabnet/aids.def#20
090826#26/Aug/2009#20110000#09.htm##
00630000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100018000930100
01700111010001500128010001700143012008600160030001000246065000900256064000500265
031000300270014000700273865000900280002000700289035001000296801001000306#v27s1#V
:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#212#26#article#34#26#^rND^sGiovanett
i^nMC#^rND^sSantos^nNJS#^rND^sWestin^nCP#^rND^sDarré^nD#^rND^sGianna^nMC#A impla
ntação do quesito cor/raça nos serviços de DST/AIDS no Estado de São Paulo^lpt#S
aúde Soc#20070000#2007#16#163-70#20110000#09.htm#0104-1290#Saúde Soc##
00611000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100018000860100
01500104010001700119010001700136012009500153030001800248710000200266065000900268
064000500277031000300282014000800285865000900293002000700302#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\09.htm#S#c#213#27#article#34#27#^rND^sFry^nPH#^rND^sMonteir
o^nS#^rND^sMaio^nMC#^rND^sBastos^nFI#^rND^sSantos^nRV#AIDS tem cor ou raça?: Int
erpretação de dados e formulação de políticas de saúde no Brasil^lpt#Cad Saúde P
ública#2#20070000#2007#23#497-523#20110000#09.htm##
00501000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160018000720180076000900660
01100166062006400177065000900241064000500250865000900255002000700264#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\09.htm#S#c#214#28#article#34#28#^rND^sBatista^nLE#M
ulheres e homens negros: saúde, doença e morte [Doctoral Dissertation]^len#Arara
quara#Fa-culdade de Ciências e Letras, Universidade Estadual Paulista#20020000#2
002#20110000#09.htm##
00669000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100018000910100
01500109010001700124012016100141030001800302710000200320065000900322064000500331
031000300336032000400339014000800343865000900351002000700360#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\09.htm#S#c#215#29#article#34#29#^rND^sFonseca^nMGP#^rND^sLu
cena^nFFA#^rND^sSouza^nA#^rND^sBastos^nFI#AIDS mortality, "race or color", and s
ocial inequality in a context of universal access to highly active antiretrovira
l therapy (HAART) in Brazil, 1999-2004^len#Cad Saúde Pública#2#20070000#2007#23#
^s3#S445-55#20110000#09.htm##
00558000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160018000720180134000900460
00900224050006500233045000900298044000500307865000900312002000700321#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\09.htm#S#c#216#30#article#34#30#^rND^sMarins^nJRP#E
studo de sobrevida dos pacientes de AIDS segundo escolaridade, co-infecção hepat
ite C e tuberculose: Coorte brasileira 1995-1996^lpt#Campinas#Universidade Estad
ual de Campinas^dFaculdade de Ciências Médicas#20040000#2004#20110000#09.htm##
00531000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720100017000910120
05100108030002200159065000900181064000500190031000300195014000700198865000900205
002000700214035001000221801002200231#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.
htm#S#c#217#31#article#34#31#^rND^sFerreira^nMS#^rND^sBorges^nAS#Avanços no trat
amento da hepatite pelo vírus B^lpt#Rev Soc Bras Med Trop#20070000#2007#40#451-6
2#20110000#09.htm#0037-8682#Rev Soc Bras Med Trop##
00670000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
01700107010001800124010002200142010001800164810000600182012008400188030000500272
06500090027706400050028603100030029101400070029486500090030100200070031003500100
0317801000500327#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#218#32#artic
le#34#32#^rND^sMussini^nC#^rND^sManzardo^nC#^rND^sJohnson^nM#^rND^sMonforte^nA#^
rND^sUberti-Foppa^nC#^rND^sAntinori^nA#et al#Patients presenting with AIDS in th
e HAART era: a collaborative cohort analysis^len#AIDS#20080000#2008#22#2461-9#20
110000#09.htm#0269-9370#AIDS##
00545000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160017000720160019000890170
01700108018010700125066000900232062002000241065000900261064000500270865000900275
002000700284#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#219#33#article#3
4#33#^rND^sNemes^nMIB#^rND^sAlencar^nTMD#Equipe Qualiaids#Avaliação da assistênc
ia ambulatorial aos adultos vivendo com HIV/AIDS: Qualiaids. Relatório 2007/2008
^lpt#Brasília#Ministério da Saúde#20080000#2008#20110000#09.htm##
00665000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100017000900100
01700107010002300124010001800147010001900165810000600184012008900190030001800279
71000020029706500090029906400050030803100030031301400070031686500090032300200070
0332#v27s1#V:\SciELO\serial\csp\v27s1\markup\09.htm#S#c#220#34#article#34#34#^rN
D^sMelchior^nR#^rND^sNemes^nMIB#^rND^sBasso^nCRB#^rND^sCastanheira^nERL#^rND^sAl
ves^nMTSB#^rND^sBuchalla^nCM#et al#Avaliação da estrutura organizacional assistê
ncia ambulatorial em HIV/AIDS no Brasil^lpt#Rev Saúde Pública#2#20060000#2006#40
#143-51#20110000#09.htm##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#o#1#1#article#1#201104
11#073716#10.htm#219##
04557000000000757000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400120013703500100014901201040
01590120112002630100034003750100037004090100028004460100027004740100042005010100
04400543010003400587010002100621070009800642070007700740070007300817070008500890
07000810097507000500105608311290110608500100223508500470224508500440229208500300
23360850049023660831101024150850010035160850051035260850054035770850033036310850
05403664117000803718072000303726112000903729111001203738116000903750115001203759
114000903771113001203780002000703792#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.
htm#S#h#2#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#10#CSP330#nd#Cad. Saúde Pública#
27#1#20110000#^fs93^ls103#0102-311X#Improving survival in children with AIDS in 
Brazil: results of the second national study, 1999-2002^len#Ampliação da sobrevi
da em crianças com AIDS no Brasil: resultados do segundo estudo nacional de 1999
 a 2002^lpt#^rND^1A01^nLuiza Harunari^sMatida#^rND^1A02^nAlberto Novaes^sRamos J
r.#^rND^1A02^nJorg^sHeukelbach#^rND^1A03^nAdriana^sSañudo#^rND^1A04^nRegina Céli
a de Menezes^sSucci#^rND^1A03^nHeloisa Helena de Sousa^sMarques#^rND^1A06^nMarin
ella Della^sNegra#^rND^nNorman^sHearst#Secretaria de Estado da Saúde de São Paul
o^iA01^1Programa Estadual de DST/AIDS^cSão Paulo^pBrasil#Universidade Federal do
 Ceará^iA02^1Faculdade de Medicina^cFortaleza^pBrasil#Universidade de São Paulo^
iA03^1Faculdade de Medicina^cSão Paulo^pBrasil#Universidade Federal de São Paulo
^iA04^1Departamento de Pediatria^cSão Paulo^pBrasil#Faculdade de Ciências Médica
s da Santa Casa de São Paulo^iA05^cSão Paulo^pBrasil#University of California^iA
06^cSan Francisco^pUSA#^len^aThe objective of this study is to characterize surv
ival in children with AIDS diagnosed in Brazil between 1999-2002, compared with 
the first national study (1983-1998). This national retrospective cohort study e
xamined a representative sample of Brazilian children exposed to HIV from mother
-to-child transmission and followed through 2007. The survival probability after
 60 months was analyzed by sex, year of birth and death, clinical classification
, use of antiretroviral therapy (ART) and prophylaxis for opportunistic diseases
. 920 children were included. The survival probability increased: comparing case
s diagnosed before 1988 with those diagnosed from 2001-2002 it increased by 3.5-
fold (from 25% to 86.3%). Use of ART, initial clinical classification, and final
 classification were significant (p < 0.001) predictors of survival. Issues rega
rding quality of records and care were identified. The results point to the succ
ess of the Brazilian policy of providing ART. The improvement of clinical status
 contributes to quality of life, while indicating challenges, particularly pract
ices to improve long-term care.#^ddecs^i1#^tm^len^kAcquired Immunodeficiency Syn
drome^i1#^tm^len^kInfections Disease Transmission^i1#^tm^len^kSurvival Analysis^
i1#^tm^len^kHighly Active Antiretroviral Therapy^i1#^lpt^aEste estudo caracteriz
a a sobrevida em crianças com AIDS no Brasil entre 1999-2002, contextualizando c
om o primeiro estudo nacional (1983-1998). Trata-se de coorte histórica, com cri
anças expostas ao HIV por transmissão vertical e acompanhadas até 2007. A probab
ilidade de sobrevivência em 60 meses foi analisada segundo sexo, ano de nascimen
to e de óbito, classificação clínica, uso de terapia antirretroviral (TARV) e de
 profilaxia para doenças oportunistas. No total, 920 crianças foram incluídas. A
 probabilidade de sobrevivência foi ampliada 3,5 vezes nos dois períodos avaliad
os, passando de 25% antes de 1988 para 86,3% no período de 2001-2002. Uso de TAR
V, classificação clínica inicial e atual/final foram preditores que influíram si
gnificativamente (p < 0,001) para a ampliação da sobrevida. Os resultados deste 
estudo indicam o sucesso da política brasileira para a abordagem das crianças in
fectadas com HIV. A melhora do estado clínico contribuiu para melhora da qualida
de de vida, mas sinaliza-se para a necessidade de incorporação de práticas pauta
das na integralidade do cuidado.#^ddecs^i2#^tm^lpt^kSíndrome de Imunodeficiência
 Adquirida^i2#^tm^lpt^kTransmissão Vertical de Doença Infecciosa^i2#^tm^lpt^kAná
lise de Sobrevida^i2#^tm^lpt^kTerapia Anti-Retroviral de Alta Atividade^i2#vanco
uv#36#20091201#01/Dec/2009#20100420#20/Apr/2010#20100705#05/Jul/2010#10.htm##
04591000000000757000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400120013703500100014901201180
01590120126002770100034004030100037004370100028004740100027005020100042005290100
04400571010003400615010002100649070009800670070007700768070007300845070008500918
07000810100307000500108408311320113408500100226608500470227608500440232308500300
23670850049023970831104024460850010035500850051035600850054036110850033036650850
05403698117000803752072000303760112000903763111001203772116000903784115001203793
114000903805113001203814002000703826#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.
htm#S#f#3#1#article#1#oa#en#br1.1#1#4.0#GRA#TAB#10#CSP330#nd#Cad. Saúde Pública#
27#1#20110000#^fs93^ls103#0102-311X#<b>Improving survival in children with AIDS 
in Brazil</b>: <b>results of the second national study, 1999-2002</b>^len#<b>Amp
liação da sobrevida em crianças com AIDS no Brasil</b>: <b>resultados do segundo
 estudo nacional de 1999 a 2002</b>^lpt#^rND^1A01^nLuiza Harunari^sMatida#^rND^1
A02^nAlberto Novaes^sRamos Jr.#^rND^1A02^nJorg^sHeukelbach#^rND^1A03^nAdriana^sS
añudo#^rND^1A04^nRegina Célia de Menezes^sSucci#^rND^1A03^nHeloisa Helena de Sou
sa^sMarques#^rND^1A06^nMarinella Della^sNegra#^rND^nNorman^sHearst#Secretaria de
 Estado da Saúde de São Paulo^iA01^1Programa Estadual de DST/AIDS^cSão Paulo^pBr
asil#Universidade Federal do Ceará^iA02^1Faculdade de Medicina^cFortaleza^pBrasi
l#Universidade de São Paulo^iA03^1Faculdade de Medicina^cSão Paulo^pBrasil#Unive
rsidade Federal de São Paulo^iA04^1Departamento de Pediatria^cSão Paulo^pBrasil#
Faculdade de Ciências Médicas da Santa Casa de São Paulo^iA05^cSão Paulo^pBrasil
#University of California^iA06^cSan Francisco^pUSA#^len^aThe objective of this s
tudy is to characterize survival in children with AIDS diagnosed in Brazil betwe
en 1999-2002, compared with the first national study (1983-1998). This national 
retrospective cohort study examined a representative sample of Brazilian childre
n exposed to HIV from mother-to-child transmission and followed through 2007. Th
e survival probability after 60 months was analyzed by sex, year of birth and de
ath, clinical classification, use of antiretroviral therapy (ART) and prophylaxi
s for opportunistic diseases. 920 children were included. The survival probabili
ty increased: comparing cases diagnosed before 1988 with those diagnosed from 20
01-2002 it increased by 3.5-fold (from 25% to 86.3%). Use of ART, initial clinic
al classification, and final classification were significant (p &lt; 0.001) pred
ictors of survival. Issues regarding quality of records and care were identified
. The results point to the success of the Brazilian policy of providing ART. The
 improvement of clinical status contributes to quality of life, while indicating
 challenges, particularly practices to improve long-term care.#^ddecs^i1#^tm^len
^kAcquired Immunodeficiency Syndrome^i1#^tm^len^kInfections Disease Transmission
^i1#^tm^len^kSurvival Analysis^i1#^tm^len^kHighly Active Antiretroviral Therapy^
i1#^lpt^aEste estudo caracteriza a sobrevida em crianças com AIDS no Brasil entr
e 1999-2002, contextualizando com o primeiro estudo nacional (1983-1998). Trata-
se de coorte histórica, com crianças expostas ao HIV por transmissão vertical e 
acompanhadas até 2007. A probabilidade de sobrevivência em 60 meses foi analisad
a segundo sexo, ano de nascimento e de óbito, classificação clínica, uso de tera
pia antirretroviral (TARV) e de profilaxia para doenças oportunistas. No total, 
920 crianças foram incluídas. A probabilidade de sobrevivência foi ampliada 3,5 
vezes nos dois períodos avaliados, passando de 25% antes de 1988 para 86,3% no p
eríodo de 2001-2002. Uso de TARV, classificação clínica inicial e atual/final fo
ram preditores que influíram significativamente (p &lt; 0,001) para a ampliação 
da sobrevida. Os resultados deste estudo indicam o sucesso da política brasileir
a para a abordagem das crianças infectadas com HIV. A melhora do estado clínico 
contribuiu para melhora da qualidade de vida, mas sinaliza-se para a necessidade
 de incorporação de práticas pautadas na integralidade do cuidado.#^ddecs^i2#^tm
^lpt^kSíndrome de Imunodeficiência Adquirida^i2#^tm^lpt^kTransmissão Vertical de
 Doença Infecciosa^i2#^tm^lpt^kAnálise de Sobrevida^i2#^tm^lpt^kTerapia Anti-Ret
roviral de Alta Atividade^i2#vancouv#36#20091201#01/Dec/2009#20100420#20/Apr/201
0#20100705#05/Jul/2010#10.htm##
04724000000000781000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090038000400094121000300098049000700101
15800030010803000190011103100030013013100020013306500090013501400120014403500100
01560120104001660120112002700100034003820100040004160100028004560100027004840100
04200511010004400553010003400597010002100631070010000652070007900752070007500831
07000870090607000830099307000520107608311430112808500100227108500470228108500440
23280850030023720850049024020831119024510850010035700850051035800850054036310850
03303685085005403718117000803772072000303780112000903783111001203792116000903804
115001203813114000903825113001203834002000703846008008903853#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\10.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#gra#tab#1
0#CSP330#nd#Cad. saúde pública#27#1#20110000#^fs93^ls103#0102-311X#Improving sur
vival in children with AIDS in Brazil: results of the second national study, 199
9-2002^len#Ampliação da sobrevida em crianças com AIDS no Brasil: resultados do 
segundo estudo nacional de 1999 a 2002^lpt#^rND^1A01^nLuiza Harunari^sMatida#^rN
D^1A02^nAlberto Novaes^sRamos Júnior#^rND^1A02^nJorg^sHeukelbach#^rND^1A03^nAdri
ana^sSañudo#^rND^1A04^nRegina Célia de Menezes^sSucci#^rND^1A03^nHeloisa Helena 
de Sousa^sMarques#^rND^1A06^nMarinella Della^sNegra#^rND^nNorman^sHearst#^iA01^1
Secretaria de Estado da Saúde de São Paulo^2Programa Estadual de DST/AIDS^cSão P
aulo^pBrasil#^iA02^1Universidade Federal do Ceará^2Faculdade de Medicina^cFortal
eza^pBrasil#^iA03^1Universidade de São Paulo^2Faculdade de Medicina^cSão Paulo^p
Brasil#^iA04^1Universidade Federal de São Paulo^2Departamento de Pediatria^cSão 
Paulo^pBrasil#^iA05^1Faculdade de Ciências Médicas da Santa Casa de São Paulo^cS
ão Paulo^pBrasil#^iA06^1University of California^cSan Francisco^pUSA#^len^aThe o
bjective of this study is to characterize survival in children with AIDS diagnos
ed in Brazil between 1999-2002, compared with the first national study (1983-199
8). This national retrospective cohort study examined a representative sample of
 Brazilian children exposed to HIV from mother-to-child transmission and followe
d through 2007. The survival probability after 60 months was analyzed by sex, ye
ar of birth and death, clinical classification, use of antiretroviral therapy (A
RT) and prophylaxis for opportunistic diseases. 920 children were included. The 
survival probability increased: comparing cases diagnosed before 1988 with those
 diagnosed from 2001-2002 it increased by 3.5-fold (from 25 percent to 86.3 perc
ent). Use of ART, initial clinical classification, and final classification were
 significant (p < 0.001) predictors of survival. Issues regarding quality of rec
ords and care were identified. The results point to the success of the Brazilian
 policy of providing ART. The improvement of clinical status contributes to qual
ity of life, while indicating challenges, particularly practices to improve long
-term care.#^ddecs^i1#^tm^len^kAcquired Immunodeficiency Syndrome^i1#^tm^len^kIn
fections Disease Transmission^i1#^tm^len^kSurvival Analysis^i1#^tm^len^kHighly A
ctive Antiretroviral Therapy^i1#^lpt^aEste estudo caracteriza a sobrevida em cri
anças com AIDS no Brasil entre 1999-2002, contextualizando com o primeiro estudo
 nacional (1983-1998). Trata-se de coorte histórica, com crianças expostas ao HI
V por transmissão vertical e acompanhadas até 2007. A probabilidade de sobrevivê
ncia em 60 meses foi analisada segundo sexo, ano de nascimento e de óbito, class
ificação clínica, uso de terapia antirretroviral (TARV) e de profilaxia para doe
nças oportunistas. No total, 920 crianças foram incluídas. A probabilidade de so
brevivência foi ampliada 3,5 vezes nos dois períodos avaliados, passando de 25 p
or cento antes de 1988 para 86,3 por cento no período de 2001-2002. Uso de TARV,
 classificação clínica inicial e atual/final foram preditores que influíram sign
ificativamente (p < 0,001) para a ampliação da sobrevida. Os resultados deste es
tudo indicam o sucesso da política brasileira para a abordagem das crianças infe
ctadas com HIV. A melhora do estado clínico contribuiu para melhora da qualidade
 de vida, mas sinaliza-se para a necessidade de incorporação de práticas pautada
s na integralidade do cuidado.#^ddecs^i2#^tm^lpt^kSíndrome de Imunodeficiência A
dquirida^i2#^tm^lpt^kTransmissão Vertical de Doença Infecciosa^i2#^tm^lpt^kAnáli
se de Sobrevida^i2#^tm^lpt^kTerapia Anti-Retroviral de Alta Atividade^i2#vancouv
#36#20091201#01/Dec/2009#20100420#20/Apr/2010#20100705#05/Jul/2010#10.htm#Intern
et^ihttp://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X20110013000
10##
00343000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012300067002000700190#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#5#1#article#179#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2">    <b> ARTICLE</b> ARTIGO</fon
t></p>     ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#6#2#article#179#<p>&nbsp;</p>     ^cY#10.htm
##
00434000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021400067002000700281#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#7#3#article#179#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Improving    survival in
 children with AIDS in Brazil: results of the second national study,    1999-200
2</b> </font></p>     ^cY#10.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#8#4#article#179#<p>&nbsp;</p>     ^cY#10.htm
##
00444000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704022400067002000700291#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#9#5#article#179#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Amplia&ccedil;&atilde;o    da sobrevida em
 crian&ccedil;as com AIDS no Brasil: resultados do segundo estudo    nacional de
 1999 a 2002</b></font></p>     ^cY#10.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#10#6#article#179#<p>&nbsp;</p>     ^cY#10.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#11#7#article#179#<p>&nbsp;</p>     ^cY#10.ht
m##
00624000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704040300068002000700471#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#12#8#article#179#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"> <b>Luiza Harunari    Matida<sup>I</sup>; Al
berto Novaes Ramos Jr.<sup>II</sup>; Jorg Heukelbach<sup>II</sup>;    Adriana Sa
&ntilde;udo<sup>III</sup>; Regina C&eacute;lia de Menezes Succi<sup>IV</sup>;   
 Heloisa Helena de Sousa Marques<sup>III</sup>; Marinella Della Negra<sup>V</sup
>;    Norman Hearst<sup>VI</sup></b></font></p>     ^cY#10.htm##
00423000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704020200068002000700270#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#13#9#article#179#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Programa    Estadual de DST/AIDS
, Secretaria de Estado da Sa&uacute;de de S&atilde;o Paulo,    S&atilde;o Paulo,
 Brasil    ^cY#10.htm##
00331000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010900069002000700178#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#14#10#article#179#<br>   <sup>II</sup>Faculd
ade de Medicina, Universidade Federal do Cear&aacute;, Fortaleza,    Brasil    ^
cY#10.htm##
00335000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011300069002000700182#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#15#11#article#179#<br>   <sup>III</sup>Facul
dade de Medicina, Universidade de S&atilde;o Paulo, S&atilde;o    Paulo, Brasil 
   ^cY#10.htm##
00346000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012400069002000700193#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#16#12#article#179#<br>   <sup>IV</sup>Depart
amento de Pediatria, Universidade Federal de S&atilde;o Paulo,    S&atilde;o Pau
lo, Brasil    ^cY#10.htm##
00354000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704013200069002000700201#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#17#13#article#179#<br>   <sup>V</sup>Faculda
de de Ci&ecirc;ncias M&eacute;dicas da Santa Casa de S&atilde;o    Paulo, S&atil
de;o Paulo, Brasil    ^cY#10.htm##
00306000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704008400069002000700153#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#18#14#article#179#<br>   <sup>VI</sup>Univer
sity of California, San Francisco, USA</font></p>     ^cY#10.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#19#15#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#20#16#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#21#17#article#179#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#10.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#22#18#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#10.htm##
01475000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704125300069002000701322#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#23#19#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The objective of    this study is to charac
terize survival in children with AIDS diagnosed in Brazil    between 1999-2002, 
compared with the first national study (1983-1998). This    national retrospecti
ve cohort study examined a representative sample of Brazilian    children expose
d to HIV from mother-to-child transmission and followed through    2007. The sur
vival probability after 60 months was analyzed by sex, year of    birth and deat
h, clinical classification, use of antiretroviral therapy (ART)    and prophylax
is for opportunistic diseases. 920 children were included. The    survival proba
bility increased: comparing cases diagnosed before 1988 with those    diagnosed 
from 2001-2002 it increased by 3.5-fold (from 25% to 86.3%). Use of    ART, init
ial clinical classification, and final classification were significant    (p &lt
; 0.001) predictors of survival. Issues regarding quality of records and    care
 were identified. The results point to the success of the Brazilian policy    of
 providing ART. The improvement of clinical status contributes to quality    of 
life, while indicating challenges, particularly practices to improve long-term  
  care.</font></p>     ^cY#10.htm##
00457000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704023500069002000700304#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#24#20#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Acquired Immunodeficiency    Syndrome; Infe
ctions Disease Transmission; Survival Analysis; Highly Active    Antiretroviral 
Therapy</font></p> <hr size="1" noshade>     ^cY#10.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#25#21#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#10.htm##
01644000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704142200069002000701491#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#26#22#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Este estudo caracteriza    a sobrevida em c
rian&ccedil;as com AIDS no Brasil entre 1999-2002, contextualizando    com o pri
meiro estudo nacional (1983-1998). Trata-se de coorte hist&oacute;rica,    com c
rian&ccedil;as expostas ao HIV por transmiss&atilde;o vertical e acompanhadas   
 at&eacute; 2007. A probabilidade de sobreviv&ecirc;ncia em 60 meses foi analisa
da    segundo sexo, ano de nascimento e de &oacute;bito, classifica&ccedil;&atil
de;o    cl&iacute;nica, uso de terapia antirretroviral (TARV) e de profilaxia pa
ra doen&ccedil;as    oportunistas. No total, 920 crian&ccedil;as foram inclu&iac
ute;das. A probabilidade    de sobreviv&ecirc;ncia foi ampliada 3,5 vezes nos do
is per&iacute;odos avaliados,    passando de 25% antes de 1988 para 86,3% no per
&iacute;odo de 2001-2002. Uso    de TARV, classifica&ccedil;&atilde;o cl&iacute;
nica inicial e atual/final foram    preditores que influ&iacute;ram significativ
amente (p &lt; 0,001) para a amplia&ccedil;&atilde;o    da sobrevida. Os resulta
dos deste estudo indicam o sucesso da pol&iacute;tica    brasileira para a abord
agem das crian&ccedil;as infectadas com HIV. A melhora    do estado cl&iacute;ni
co contribuiu para melhora da qualidade de vida, mas sinaliza-se    para a neces
sidade de incorpora&ccedil;&atilde;o de pr&aacute;ticas pautadas    na integrali
dade do cuidado.</font></p>     ^cY#10.htm##
00513000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704029100069002000700360#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#27#23#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">S&iacute;ndrome    de Imunodefici&ecirc;nci
a Adquirida; Transmiss&atilde;o Vertical de Doen&ccedil;a    Infecciosa; An&aacu
te;lise de Sobrevida; Terapia Anti-Retroviral de Alta Atividade</font></p> <hr s
ize="1" noshade>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#28#24#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#29#25#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#30#26#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#10.h
tm##
00788000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056600069002000700635#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#31#27#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the past 10    years especially, evidenc
e has been accumulated regarding reduction of morbidity    and mortality from HI
V infection in both adults and children <sup>1,2,3,4,5,6,7</sup>.    Even with t
he emergence of chronic diseases associated with HIV and its treatment    <sup>8
</sup>, overall improvements have been clearly documented in both developing    
and developed countries. Brazil stands out for its sustained policies to combat 
   the epidemic <sup>8,9,10,11,12</sup>.</font></p>     ^cY#10.htm##
00693000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047100069002000700540#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#32#28#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To assess the impact    of these actions, t
he analysis of survival times in children with AIDS is crucial,    with various 
implications for both individuals and public health <sup>13</sup>.    In additio
n to assessing needs relating to patient care and the establishment    of public
 policies, it represents a key outcome to assess interventions aimed    at prolo
nging life <sup>14</sup>.</font></p>     ^cY#10.htm##
01033000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081100069002000700880#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#33#29#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In Brazil, few    studies have evaluated su
rvival in children with AIDS <sup>10</sup>. The first    national study obtained
 some of the first evidence regarding the impact of drug    access on survival i
n children infected by vertical transmission in developing    countries <sup>14,
15</sup>. Overall survival to 60 months was 52.8% (95% confidence    interval - 
95%CI: 41.9-60.8) in 914 AIDS cases reported from 1983 to 1998 and    followed t
o the end of June 2002. In this study, over time there was a significant    impr
ovement in survival among Brazilian children with AIDS infected through    verti
cal transmission, with over 75% of cases diagnosed in 1997 and 1998 still    liv
ing five years after diagnosis <sup>15</sup>.</font></p>     ^cY#10.htm##
00703000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048100069002000700550#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#34#30#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The lack of survival    studies in the coun
try, especially in the pediatric population, and changes    in medical services 
and treatments since 1998 justified a new expanded national    study of survival
 in pediatric AIDS patients. These changes require ongoing    monitoring of surv
ival time, as does the need to evaluate the impact of inequality    in access to
 preventive and treatment measures.</font></p>     ^cY#10.htm##
00995000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077300069002000700842#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#35#31#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Preliminary results    of the second nation
al study, which included children diagnosed with AIDS from    1999 to 2002, show
ed a continuation of the improving trend found in the first    study, with a sur
vival probability at 60 months of 86.3% (95%CI: 84.1-88.5)    <sup>16</sup>. It 
also drew attention to issues like quality of health care,    types of antiretro
viral therapy and prophylaxis for opportunistic infections.    This article aims
 to present a deeper analysis of survival in children with    AIDS diagnosed bet
ween 1999 and 2002, exposed to HIV through vertical transmission    and followed
 until 2007. We also place these results in the context of the first    national
 study.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#36#32#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00323000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010100069002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#37#33#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methodology</b></font></p>     ^cY#10.ht
m##
00331000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010900069002000700178#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#38#34#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Study design</u></b></font></p>     ^
cY#10.htm##
00696000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047400069002000700543#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#39#35#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This is the second    multicenter retrospec
tive cohort survival study of Brazilian children (0 to    12 years of age) with 
AIDS <sup>16</sup>. It is characterized by being a historical    cohort, followi
ng a similar methodology to the first national study (between    1983 and 1998).
 This earlier study has been described in detail previously <sup>15</sup>;    we
 note some highlights below.</font></p>     ^cY#10.htm##
00335000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011300069002000700182#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#40#36#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Study population</u></b></font></p>  
   ^cY#10.htm##
00758000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053600069002000700605#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#41#37#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A population-based    study was composed of
 AIDS cases in children living in 26 states and the Federal    District of Brazi
l. The Notifiable Diseases Information System (SINAN) specific    for AIDS in ch
ildren was taken as a reference database. This database of the    Brazilian Nati
onal STD/AIDS Program was accessed from the Brazilian Ministry    of Health in F
ebruary 2006 and included 3,826 AIDS cases in children diagnosed    between 1999
 and 2002.</font></p>     ^cY#10.htm##
00826000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060400069002000700673#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#42#38#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The sample size    was determined to allow 
significant comparisons between proportions of survivors    at particular times.
 The study sample was probabilistic, stratified, and selected    cases in two st
ages: municipalities and individual cases. It was divided into    four regional 
strata: the Northeast, Southeast, South, and a combination of    the North and M
idwest. Considering the low number of cases in this latter stratum    there was 
no sampling, and all cases diagnosed during the study period were    included.</
font></p>     ^cY#10.htm##
00858000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063600069002000700705#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#43#39#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Only municipalities    with more than two c
ases reported were included; 38.9% of municipalities had    only one reported ca
se, while 52.6% had two reported cases. Excluding these,    145 remaining munici
palities were responsible for the reporting of 3,629 cases,    94.7% of all case
s in Brazil. The Northern Region had 120 cases in 7 counties;    the Northeast R
egion, 363 cases in 16 counties; the Midwest Region, 190 cases    in 6 counties;
 the Southeast region, 1,964 cases in 73 counties; and the Southern    Region, 9
92 cases in 43 municipalities.</font></p>     ^cY#10.htm##
00728000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050600069002000700575#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#44#40#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Parameters for    the sample size calculati
on were based on the results of the first national    survival study. We assumed
 median survival of approximately 8.5 years and a    mortality coefficient of 0.
0815. Based on these criteria, we selected 1,444    children (under 13) with AID
S registered in SINAN during the period from 01    January 1999 to December 31, 
2002. Follow up continued until death or the end    of 2007.</font></p>     ^cY#
10.htm##
00334000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011200069002000700181#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#45#41#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Data collection</u></b></font></p>   
  ^cY#10.htm##
00970000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074800069002000700817#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#46#42#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The process of    data collection was conti
nued until December 2007. It consisted of initial contact    with health service
s where the case had been treated, records location and transcription    of avai
lable information for an abstraction form, based on one used in the first    nat
ional study. The local staff of the State Program for the Control of STD/AIDS   
 and of care facilities was contacted to explain the study and to confirm the   
 accuracy of data regarding medical history and current status. This included   
 health care professionals directly or indirectly involved with patient care,   
 surveillance and/or research related to HIV/AIDS in children.</font></p>     ^c
Y#10.htm##
00729000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050700069002000700576#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#47#43#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Additional sources    of information were t
he databases of the Mortality Information System (SIM-DATASUS),    the Drugs Log
istics Management System (SICLOM-MS) and the Laboratory Tests Control    System 
(SISCEL-MS). To this end, we used the software Rec Link 2.0 <sup>17</sup>,    fo
llowing the methodology adopted by the Ministry of Health and matching on    the
 child's name, mother's name and date of birth <sup>18</sup>.</font></p>     ^cY
#10.htm##
00332000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011000069002000700179#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#48#44#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Data analysis</u></b></font></p>     
^cY#10.htm##
00681000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704045900069002000700528#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#49#45#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study database    was analyzed using th
e Statistical Package for Social Sciences (SPSS Inc., Chicago,    USA) version 1
5.0. Besides descriptive analysis, the survival probability at    60 months was 
calculated, with the binomial 95%CI. We then proceeded to the    construction of
 survival curves using the Kaplan-Meier estimate of survival    probability <sup
>19,20</sup>.</font></p>     ^cY#10.htm##
00643000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042100069002000700490#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#50#46#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Survival analysis    aimed at assessing the
 occurrence of AIDS-related death as an outcome within    a period of time that 
had the date of the case definition of AIDS in children    as the starting date.
 The date of AIDS diagnosis was reassessed during the search    using the AIDS c
ase definition used in Brazil since 2004 <sup>21</sup>.</font></p>     ^cY#10.ht
m##
00584000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036200069002000700431#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#51#47#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Date of death was    established through th
e evaluation of medical records and/or mortality system    data, when available.
 For children whose information about death was not known,    the date of censur
e was set as the date of the last recorded visit to health    care services.</fo
nt></p>     ^cY#10.htm##
00525000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030300069002000700372#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#52#48#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A sensitivity analysis    showed that a wei
ghted analysis adjusting for different sampling probability    by location would
 change survival estimates by less than 1%. We present the    unweighted analysi
s for simplicity.</font></p>     ^cY#10.htm##
00654000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043200069002000700501#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#53#49#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Comparisons of    survival curves by sex, y
ear of birth, year of diagnosis, classification (stage)    of HIV infection (ini
tial and current - for the sole purpose of comparison),    use of prophylaxis fo
r opportunistic diseases and antiretroviral therapy (used    at any time) were p
erformed using the log-rank test or Breslow test <sup>20,22</sup>.</font></p>   
  ^cY#10.htm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#54#50#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Ethical considerations</u></b></font>
</p>     ^cY#10.htm##
00587000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036500069002000700434#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#55#51#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The project was    approved by the Research
 Ethics Committee at the Center for Reference and Training    in STD/AIDS of S&a
tilde;o Paulo State, under protocol nº. 090/2006, following    the guidelines of
 the National Health Council expressed in <i>Resolution nº.    196</i> of 1996.<
/font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#56#52#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#57#53#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#10.htm##
00614000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039200069002000700461#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#58#54#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In a first step,    462 (32%) of the 1.444 
cases identified were excluded for incorrect records    in SINAN: duplication (4
6 = 3.2%), AIDS diagnosis outside the study period (66    = 4.3%), cases of HIV 
infection but not AIDS (4 = 0.3%) and cases of children    exposed perinatally t
o HIV and uninfected (32 =</font></p>     ^cY#10.htm##
01010000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078800069002000700857#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#59#55#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">2.2%). We excluded    another 291 (20.1%) c
ases for which records could not be located during field    work and 23 (1.6%) w
ith loss of follow-up and no significant information available.    Of the remain
ing total of 982 children, 945 (97.5%) were exposed to HIV through    vertical t
ransmission. The 37 remaining cases had the following forms of exposure    to HI
V: unknown/no information, 20 (2%), transfusion of blood/components, 8    (0.9%)
 indeterminate, 6 (0.6%) and sexual, 3 (0.3%). We eliminated an additional    25
 cases for whom the date of death was the same as the date of diagnosis and    w
ho thus had zero follow-up time for analysis. Thus, a total of 920 cases were   
 included in analysis.</font></p>     ^cY#10.htm##
00592000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037000069002000700439#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#60#56#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The overall probability    of survival for 
60 months among these children diagnosed with AIDS in 1999 to    2002 was 0.883 
(95%CI: 0.860-0.902). There were 109 deaths observed (11.9%)    and followed unt
il the end of 2007; 78% of these deaths took place in the period    of 1999 to 2
002.</font></p>     ^cY#10.htm##
00545000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032300069002000700392#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#61#57#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="/img/revistas/csp/v27s1/10f01.jpg"
>Figure    1</a> presents an integrated survival curve of the two national studi
es, according    to different periods of AIDS diagnosis, showing the sustained g
ain in survival    of these children.</font></p>     ^cY#10.htm##
00891000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066900069002000700738#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#62#58#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the first national    study, considering
 the whole period from 1983 to 1998, the overall survival    probability at 60 m
onths was 0.528 (95%CI: 0.419-0.608): before 1988, 0.197    (95%CI: 0.112-0.300)
; from 1988 to 1992, 0.273 (95%CI: 0.229-0.319); from 1993    to 1994, 0.397 (95
%CI: 0.334-0.459); from 1995 to 1996, 0.595 (95%CI: 0.528-0.656);    and from 19
97 to 1998, 0,682 (95%CI: 0.616-0.739). In this present study, the    survival p
robability was 0.865 (95%CI: 0.830-0.893) from 1999 to 2000 (470 children),    a
nd 0.902 (95%CI: 0.870-0.927) from 2001 to 2002 (450 children).</font></p>     ^
cY#10.htm##
00854000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063200069002000700701#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#63#59#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Demographic, epidemiological    and clinica
l characteristics of the 920 studied cases are presented in <a href="#t1">Table 
   1</a>. There is a slight predominance of girls (51.7%) as well as children bo
rn    in the 1995-1998 cohort (47.3%). In terms of year of AIDS diagnosis, there
 is    a homogeneous distribution in the four years of study. Regarding initial 
clinical    classification of HIV infection, 65.4% were classified as B (B1, B2 
and B3)    or C (C1, C2 or C3). In the final clinical classification, these two 
categories    made up 40%.</font></p>     ^cY#10.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#64#60#article#179#<p><a name="t1"></a></p>  
   ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#65#61#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#66#62#article#179#<p align="center"><img src
="/img/revistas/csp/v27s1/10t01.jpg"></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#67#63#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00553000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033100069002000700400#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#68#64#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Of note is the    frequency of missing data
 for some of these variables investigated in health    services, such as: prophy
laxis administration (23.1%), current or final clinical    classification (3.7%)
, and initial clinical classification (1.9%).</font></p>     ^cY#10.htm##
00625000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040300069002000700472#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#69#65#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="/img/revistas/csp/v27s1/10f02.jpg"
>Figures    2</a> and <a href="/img/revistas/csp/v27s1/10f03.jpg">3</a> show the
 survival    curves by initial and current/final clinical classification and sur
vival curves    by use of antiretroviral therapy (ART) and prophylaxis for oppor
tunistic infections,    respectively.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#70#66#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#71#67#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#10.htm
##
00744000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052200069002000700591#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#72#68#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This second national    study of AIDS survi
val in children confirms the strengthening of positive trends    observed in the
 first study <sup>14</sup> and shows the continuing increase    in survival prob
ability. The survival rate over the period improved significantly    and consist
ently in Brazilian children with AIDS <sup>16</sup>, a fact mirrored    by other
 studies in different settings around the world <sup>7,10,14,23,24,25</sup>.</fo
nt></p>     ^cY#10.htm##
00548000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032600069002000700395#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#73#69#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The probability    of survival at 60 months
 rose from 25% before 1988 to 88% in 2001-2002, representing    a 3.5-fold incre
ase. Compared to the first national study, this study showed    an overall impro
vement of about 36% in this probability.</font></p>     ^cY#10.htm##
00740000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051800069002000700587#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#74#70#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">These improved    results were largely made
 possible by the development of a program of universal    access to ART. In this
 study, 94.8% of children had received this treatment,    with records of inform
ation of use or nonuse in 100% of cases. The survival    probability at 60 month
s in children with recorded use of HAART (highly active    antiretroviral therap
y) was significantly (p &lt; 0.001) higher compared to    those without.</font><
/p>     ^cY#10.htm##
01065000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704084300069002000700912#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#75#71#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In fact, the period    from 1999 to 2002 re
presents a period of greater consistency in the use of HAART    in the country, 
initially adopted in 1996. This is the result of the actions    and health polic
ies aimed at improving access and quality of HIV care <sup>14</sup>,    a cost-e
ffective initiative with significant impact on public health <sup>26</sup>.    I
n this study, the vast majority of children (85.1%) were born in a period of    
expanded ART availability. The higher survival rate observed in the cohort of   
 children born in the period 1995-1998 (0.909; 95%CI: 0.878-0.933) compared to  
  1999-2002 (0.855; 95%CI: 0.813-0.889), was not statistically significant and  
  may be associated with different ages of children at the time of diagnosis.</f
ont></p>     ^cY#10.htm##
01053000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083100069002000700900#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#76#72#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Moreover, greater    access to early diagno
sis and management of HIV infection and opportunistic    diseases <sup>10,11</su
p> might have contributed to the continuing increase    in survival, similar to 
that observed in developed market economies <sup>3,8</sup>.    In this study, no
 significant difference was found between having or not having    used prophylax
is in the analysis of survival at 60 months. Only 76.9% of children    had docum
entation about prophylaxis use for infections/opportunistic infections,    point
ing to the need for discussion about the importance of both the accuracy    and 
the completeness of medical records. Given the high survival rate of children   
 in this group, there was likely underreporting of this variable.</font></p>    
 ^cY#10.htm##
00546000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032400069002000700393#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#77#73#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The implementation    of the prevention of 
HIV transmission from mother to infant and early use of    HAART are factors tha
t delay the progression of the disease, demonstrated in    the increase in avera
ge age of AIDS diagnosis <sup>8</sup>.</font></p>     ^cY#10.htm##
00819000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704059700069002000700666#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#78#74#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite the steadily    increasing proporti
on of women with AIDS over the past ten years <sup>27</sup>    and the likelihoo
d of pregnancy in this population, the number of exposed children    infected ha
s been systematically reduced in Brazil <sup>17,18,28,29</sup>. This    reductio
n reflects the implementation of actions to reduce vertical transmission    of H
IV throughout the country, despite different patterns of performance across    r
egions due to operational, social and economic issues <sup>10,30</sup>.</font></
p>     ^cY#10.htm##
00971000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074900069002000700818#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#79#75#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The measures adopted    by various health s
ervices generated a pattern of improvement in clinical status    of children. Th
e results reinforce the relationship between clinical classification    and prob
ability of survival at 60 months, considering the initial classification    and 
the current/final classification, used here only for comparison. At first,    32
.7% of children were classified as N or A; by the current/final evaluation,    5
6.3% were documented to have this classification (<a href="#t1">Table 1</a>),   
 despite some missing information. In this study, we chose to consider the evolv
ing    pattern of classification only for comparative purposes.</font></p>     ^
cY#10.htm##
00741000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704051900069002000700588#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#80#76#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Other variables    were not identified as b
eing significant in the survival probability at 60 months,    such as sex, year 
of birth and year of AIDS diagnosis. Regarding gender, different    studies rein
force these results. Regarding year of birth or AIDS diagnosis,    the relativel
y short period studied and the lack of significant changes in management    prob
ably account for the lack of difference in terms of survival probability.</font>
</p>     ^cY#10.htm##
00745000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704052300069002000700592#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#81#77#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The results presented    in this analysis (
920 cases) are slightly different from those (86.3%, 95%CI:    84.1-88.5) in a p
reviously published preliminary analysis in which all cases    (945 cases) had b
een included <sup>16</sup>. In the present analysis, the elimination    of cases
 for whom the date of death was the same as the date of diagnosis and    who thu
s had zero follow-up time for analysis improved the accuracy of the analysis.</f
ont></p>     ^cY#10.htm##
01142000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704092000069002000700989#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#82#78#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Regarding limitations,    one third of pote
ntial cases had to be excluded because of poor quality in the    original databa
se (SINAN) and in records in treatment services. These difficulties    reinforce
 the need to document the care process and improve epidemiological    surveillan
ce. While these factors may have affected the estimate of survival,    they woul
d not explain the observed increase in survival, unless the magnitude    of any 
bias had increased substantially over time. The finding of duplication    and in
consistencies (children exposed to HIV but listed as uninfected, and those    in
fected but listed as being without AIDS, for example) in the SINAN database    r
einforce this need. Despite these areas of improvement, the use of this database
    has the advantage of being representative of the Brazilian population.</font
></p>     ^cY#10.htm##
01099000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704087700069002000700946#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#83#79#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Because cases are    not officially reporte
d until the criteria for AIDS are defined, it is only    possible to construct s
urvival estimates from this point, which is a limitation    in the interpretatio
n of data. Children diagnosed with HIV infection but without    AIDS diagnosis w
ere not included in the study. Thus, the degree of improvement    and current le
vels of survival achieved are difficult to compare with international    data fr
om elsewhere. Most publications that examine the survival time of AIDS    cases 
infected through vertical transmission are based on cohorts of HIV-infected    c
hildren identified at birth or soon after. The survival time is usually calculat
ed    from birth or date of HIV infection rather than the date of AIDS diagnosis
 as    evaluated in this study.</font></p>     ^cY#10.htm##
00763000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054100069002000700610#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#84#80#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Differences in    survival by region should
 also be taken into account when comparing survival    results by regions of the
 country. Compared to the first national study, any    such difference probably 
was less important considering that since 1999 various    initiatives were under
taken nationally in Brazil including HIV testing for the    general population, 
improvement of prenatal screening, and follow-up of pregnant    women and HIV ex
posed children.</font></p>     ^cY#10.htm##
00786000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704056400069002000700633#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#85#81#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Problems with the    quality and access to 
medical records of cases in terms of file organization    were observed in some 
services. This includes limitations of available data    for epidemiological fac
tors (issues relating to mother and family in general,    diagnosis knowledge by
 the child, caregiver, and others) and clinical factors    (record of important 
dates related to clinical events or the therapies adopted,    transfers, current
 situation of children, among others).</font></p>     ^cY#10.htm##
00628000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704040600069002000700475#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#86#82#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Another factor    apparent in a nationwide 
study of this magnitude is the difficulty in following    the evolution of indiv
idual cases. This is due to changes in the site of medical    care of children a
fter reporting (different from the listed site in the SINAN    data base), and p
oorly or undocumented clinic attendance.</font></p>     ^cY#10.htm##
00888000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704066600069002000700735#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#87#83#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The scenario for    the future efforts to a
ddress AIDS in children presents a number of challenges    related not only to t
he pathogenesis of HIV infection in this population <sup>31</sup>,    but also i
n relation to the management of children exposed to HIV over these    years <sup
>32,33,34</sup>. Analysis of the Brazilian experience shows that in    a country
 with limited resources, and large geographical and social inequalities,    it i
s possible to establish a system capable of providing free and universal    acce
ss to HAART and diagnosis of HIV infection <sup>17,35</sup>.</font></p>     ^cY#
10.htm##
00581000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704035900069002000700428#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#88#84#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Many low and middle    income countries sti
ll have similar survival results to Brazil in the pre-HAART    era, despite the 
advances achieved <sup>24,36</sup>. The Brazilian findings    demonstrate the pr
actical possibilities of dealing with this problem in these    countries.</font>
</p>     ^cY#10.htm##
01014000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704079200069002000700861#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#89#85#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite clear advances,    as the results s
how, there is a need to enhance the implementation of technical    and organizat
ional recommendations for the Brazilian National STD/AIDS Program.    The challe
nge is to extend improvements not only in the quantity but also the    quality o
f health care <sup>14</sup>. This reinforces the need for future population-base
d    and in-depth studies incorporating data that reflect the performance of dif
ferent    areas of the country. Survival studies are essential for the evaluatio
n of intervention    strategies aimed at prolonging the life of these patients, 
and can help inform    the needs for clinical care and the establishment of publ
ic policies <sup>15</sup>.</font></p>     ^cY#10.htm##
00593000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704037100069002000700440#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#90#86#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The Unified National    Health System faces
 new challenges. One is the presence of adolescents and adults    infected throu
gh their mothers, which increases the need for a longitudinal    and a holistic 
approach involving not only biological, but also psychological    and social asp
ects.</font></p>     ^cY#10.htm##
00873000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704065100069002000700720#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#91#87#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In conclusion,    the results of the second
 national study point to the successes of Brazilian    policies in addressing AI
DS among children, with a significant and sustained    increase in the survival 
probability over several years, due in large part to    the use of HAART. The im
provement in clinical status is a reflection of these    results and is probably
 accompanied by a similar improvement in quality of life    of these children. T
hese data demonstrate the feasibility of incorporating these    strategies, even
 in a country with great social inequalities.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#92#88#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#93#89#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#10.h
tm##
01252000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704103000069002000701099#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#94#90#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">L. H. Matida was    the coordinator, respon
sible for: design of the study, collection, consolidation    and analysis of dat
a and for writing the article in its final version. A. N.    Ramos Jr. was the a
ssistant coordinator, participating in designing the project,    the collection,
 consolidation, analysis and interpretation of data, as well    as for writing t
he article in its final version. J. Heukelbach participated    in the analysis a
nd interpretation of data and writing the article in its final    version. A. Sa
&ntilde;udo participated in the analysis and interpretation of    data and writi
ng the article in its final version. R. C. M. Succi, H. H. S.    Marques and M. 
D. Negra participated in the discussion of the design of the    study, collectio
n and writing the paper in its final version. N. Hearst participated    in the d
esign of the study, analysis and interpretation of data and writing    the artic
le in its final version.</font></p>     ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#95#91#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#96#92#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></font></p>     ^cY#
10.htm##
02091000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704186900069002000701938#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#97#93#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The authors wish    to thank the health ser
vices who participated in and the people who contributed    to this study. Mari&
acirc;ngela Sim&atilde;o, Pedro Chequer, Maria Clara Gianna,    Maria Goretti Me
deiros, Gerson Pereira, Francisca Lucena and Artur Sousa supported    and facili
tated the overall process. Adriana Sa&ntilde;udo and Maria Cec&iacute;lia    Goi
 Porto Alves provided statistical support. The Brazilian Study Group on Survival
    of Children with AIDS - Second Study - data collection team included: Adelia
    A. Bispo, Adriana V. A. Ramos, Alberto E. O. M. Silva, Alexandre Gon&ccedil;
alves,    Ana S. P. Gibbons, Aparecida H. U. Facuri, Arlete C. M. Dias, Aroldo P
. Carvalho,    Bianca R. Lucarevschi, Carlos A. Correa, Carmem L. O. Silva, Dale
l Haddad, Denise    A. Rocha, Eduardo Caminada Jr., Elizabete P. Yamaguti, Fatim
a Sumaya, Jorge    Pinto, Joria V. Guerreiro, Katharine S. Freitas, Leidiane V. 
Silva, Lilian M.    Lauria, Maly Albuquerque, Maria C. Cervi, Marcia M. F. J. D.
 Fabbro, Maria I.    S. Heyr, Maria C. S. Barbosa, Maria de Jesus F. Alencar, Ma
ria do Carmo Ferreira,    Maria Helena S. Teixeira, Marion Burger, Mylva Fonsi, 
Neuza Uchiyama, Olinda    K. Mizuta, Rosangela M. Coelho, Roseane E. Martello, S
andra F. M. Silva, Simone    G. Bernardes, Sirlene Caminada, Sueny S. Martins, T
eresa M. I. Nishimoto and    Wedja Sparinger. This work was carried out by the F
unda&ccedil;&atilde;o S&atilde;o    Vicente (Fundasv) with technical and financi
al support of the Department of    STD, AIDS and Viral Hepatitis, Secretariat of
 Health Surveillance, Brazilian    Ministry of Health through the Project of Int
ernational Technical Cooperation    AD/BRA/03/H34 between the Brazilian Governme
nt and the United Nations Office    on Drugs and Crime (UNODC).</font></p>     ^
cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#98#94#article#179#<p>&nbsp;</p>     ^cY#10.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#99#95#article#179#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#10.htm
##
00542000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704030500072002000700377#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#100#96#article#179#1#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">1. Gibb DM, Duong    T, Took
ey PA, Sharland M, Tudor-Williams G, Novelli V, et al. Decline in mortality,    
AIDS, and hospital admissions in perinatally HIV-1 infected children in the    U
nited Kingdom and Ireland. BMJ 2003; 327:1019.    ^cY#10.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#101#97#article#179#</font></p>     ^cY#10.ht
m##
00614000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704037700072002000700449#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#102#98#article#179#2#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">2. de Martino M,    Tovo PA,
 Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality    with 
availability of antiretroviral therapy for children with perinatal HIV-1    infe
ction. Italian Register for HIV Infection in Children and the Italian National  
  AIDS Registry. JAMA 2000; 284:190-7.    ^cY#10.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#103#99#article#179#</font></p>     ^cY#10.ht
m##
00584000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704034600073002000700419#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#104#100#article#179#3#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">3. Patel K, Hernan    MA, W
illiams PL, Seeger JD, McIntosh K, Van Dyke RB, et al. Long-term effectiveness  
  of highly active antiretroviral therapy on the survival of children and adoles
cents    with HIV infection: a 10-year follow-up study. Clin Infect Dis 2008; 46
:507-15.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#105#101#article#179#</font></p>     ^cY#10.h
tm##
00552000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704031400073002000700387#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#106#102#article#179#4#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">4. Gortmaker SL,    Hughes 
M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, et al. Effect of combination    
therapy including protease inhibitors on mortality among children and adolescent
s    infected with HIV-1. N Engl J Med 2001; 345:1522-8.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#107#103#article#179#</font></p>     ^cY#10.h
tm##
00552000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704031400073002000700387#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#108#104#article#179#5#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">5. Janssens B,    Raleigh B
, Soeung S, Akao K, Te V, Gupta J, et al. Effectiveness of highly active    anti
retroviral therapy in HIV-positive children: evaluation at 12 months in    a rou
tine program in Cambodia. Pediatrics 2007; 120:e1134-40.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#109#105#article#179#</font></p>     ^cY#10.h
tm##
00557000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704031900073002000700392#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#110#106#article#179#6#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">6. Viani RM, Araneta    MR,
 Deville JG, Spector SA. Decrease in hospitalization and mortality rates    amon
g children with perinatally acquired HIV type 1 infection receiving highly    ac
tive antiretroviral therapy. Clin Infect Dis 2004; 39:725-31.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#111#107#article#179#</font></p>     ^cY#10.h
tm##
00511000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027300073002000700346#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#112#108#article#179#7#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">7. Goetghebuer    T, Haelte
rman E, Le Chenadec J, Dollfus C, Gibb D, Judd A, et al. Effect of    early anti
retroviral therapy on the risk of AIDS/death in HIV-infected infants.    AIDS 20
09; 23:597-604.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#113#109#article#179#</font></p>     ^cY#10.h
tm##
00515000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704027700073002000700350#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#114#110#article#179#8#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">8. Chiappini E,    Galli L,
 Tovo PA, Gabiano C, Lisi C, Gattinara GC, et al. Changing patterns    of clinic
al events in perinatally HIV-1-infected children during the era of    HAART. AID
S 2007; 21:1607-15.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#115#111#article#179#</font></p>     ^cY#10.h
tm##
00437000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704019900073002000700272#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#116#112#article#179#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Gavin PJ, Yogev,    R. T
he role of protease inhibitor therapy in children with HIV infection. Paediatr  
  Drugs 2002:581-607.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#117#113#article#179#</font></p>     ^cY#10.h
tm##
00572000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033300074002000700407#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#118#114#article#179#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Hacker MA,    Kaida A,
 Hogg RS, Bastos FI. The first ten years: achievements and challenges    of the 
Brazilian program of universal access to HIV/AIDS comprehensive management    an
d care, 1996-2006. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S345-59.    
^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#119#115#article#179#</font></p>     ^cY#10.h
tm##
00390000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015100074002000700225#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#120#116#article#179#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. Okie S. Fighting    HI
V-lessons from Brazil. N Engl J Med 2006; 354:1977-81.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#121#117#article#179#</font></p>     ^cY#10.h
tm##
00504000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026500074002000700339#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#122#118#article#179#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Bastos FI,    Caceres 
C, Galvao J, Veras MA, Castilho EA. AIDS in Latin America: assessing    the curr
ent status of the epidemic and the ongoing response. Int J Epidemiol    2008; 37
:729-37.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#123#119#article#179#</font></p>     ^cY#10.h
tm##
00545000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030600074002000700380#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#124#120#article#179#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Jeena PM, McNally    L
M, Stobie M, Coovadia HM, Adhikari MA, Petros AJ. Challenges in the provision   
 of ICU services to HIV infected children in resource poor settings: a South    
African case study. J Med Ethics 2005; 31:226-30.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#125#121#article#179#</font></p>     ^cY#10.h
tm##
00592000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704035300074002000700427#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#126#122#article#179#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Matida LH,    Ramos Jr
. AN, Moncau JE, Marcopito LF, Sousa-Marques HH, Succi RC, et al. AIDS    by mot
her-to-child transmission: survival analysis of cases followed from 1983    to 2
002 in different regions of Brazil. Cad Sa&uacute;de P&uacute;blica 2007;    23 
Suppl 3:S435-44.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#127#123#article#179#</font></p>     ^cY#10.h
tm##
00514000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027500074002000700349#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#128#124#article#179#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Matida LH,    Marcopit
o LF, Succi RC, Marques HH, Della-Negra M, Grangeiro A, et al. Improving    surv
ival among Brazilian children with perinatally-acquired AIDS. Braz J Infect    D
is 2004; 8:419-23.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#129#125#article#179#</font></p>     ^cY#10.h
tm##
00507000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026800074002000700342#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#130#126#article#179#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Matida LH,    Ramos Jr
. AN, Heukelbach J, Hearst N. Continuing improvement in survival for    children
 with Acquired Immunodeficiency Syndrome in Brazil. Pediatr Infect Dis    J 2009
; 28:920-2.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#131#127#article#179#</font></p>     ^cY#10.h
tm##
00525000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028600074002000700360#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#132#128#article#179#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Camargo Jr.    KR, Coe
li CM. Reclink: aplicativo para o relacionamento de bases de dados, implementand
o    o m&eacute;todo <i>probabilistic record linkage</i>. Cad Sa&uacute;de P&uac
ute;blica    2000; 16:439-47.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#133#129#article#179#</font></p>     ^cY#10.h
tm##
00407000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704016800074002000700242#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#134#130#article#179#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Minist&eacute;rio    d
a Sa&uacute;de. Boletim Epidemiol&oacute;gico AIDST 2008; Ano V, nº. 1.    ^cY#1
0.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#135#131#article#179#</font></p>     ^cY#10.h
tm##
00427000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704018800074002000700262#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#136#132#article#179#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Kaplan EL,    Meier P.
 Non parametric estimation from incomplete observation. J Am Stat Assoc    1958;
 53:457-81.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#137#133#article#179#</font></p>     ^cY#10.h
tm##
00429000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019000074002000700264#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#138#134#article#179#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Kleinbaum DG,    Klein
 M. Survival analysis - a self-learning text. 2<sup>nd</sup> Ed. New York:    Sp
ringer; 2005.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#139#135#article#179#</font></p>     ^cY#10.h
tm##
00813000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704057400074002000700648#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#140#136#article#179#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Minist&eacute;rio    d
a Sa&uacute;de. Crit&eacute;rios de defini&ccedil;&atilde;o de casos de AIDS    
em adultos e crian&ccedil;as. <a href="http://www.aids.gov.br/data/documents/sto
redDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B2A9F7D1C-093E-4A04-83
80-84ED432964A5%7D/criterios.pdf" target="_blank">http://www.aids.gov.br/data/do
cuments/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B2A9F7D1C-0
93E-4A04-8380-84ED432964A5%7D/criterios.pdf</a>    (accessed on 13/Nov/2009).   
 ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#141#137#article#179#</font></p>     ^cY#10.h
tm##
00394000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704015500074002000700229#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#142#138#article#179#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Cox DR, Oakes    D. An
alysis of survival data. London: Chapman &amp; Hall; 1984.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#143#139#article#179#</font></p>     ^cY#10.h
tm##
00635000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704039600074002000700470#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#144#140#article#179#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Marazzi MC,    Nielsen
-Saines K, Buonomo E, Scarcella P, Germano P, Majid NA, et al. Increased    infa
nt human immunodeficiency virus-type one free survival at one year of age    in 
sub-Saharan Africa with maternal use of highly active antiretroviral therapy    
during breast-feeding. Pediatr Infect Dis J 2009; 28:483-7.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#145#141#article#179#</font></p>     ^cY#10.h
tm##
00559000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032000074002000700394#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#146#142#article#179#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Sutcliffe CG,    Scott
 S, Mugala N, Ndhlovu Z, Monze M, Quinn TC, et al. Survival from 9 months    of 
age among HIV-infected and uninfected Zambian children prior to the availability
    of antiretroviral therapy. Clin Infect Dis 2008; 47:837-44.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#147#143#article#179#</font></p>     ^cY#10.h
tm##
00551000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031200074002000700386#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#148#144#article#179#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Little K, Thorne    C,
 Luo C, Bunders M, Ngongo N, McDermott P, et al. Disease progression in children
    with vertically-acquired HIV infection in sub-Saharan Africa: reviewing the 
   need for HIV treatment. Curr HIV Res 2007; 5:139-53.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#149#145#article#179#</font></p>     ^cY#10.h
tm##
00569000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033000074002000700404#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#150#146#article#179#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. Sousa-Marques    HH, C
outtolenc BF, Latorre MRDO, Aquino MZG, Aveiro MI, Pluciennik AMA. Costs    of c
are provided in a university hospital for children exposed to or infected    wit
h the HIV/AIDS. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S402-13.    ^cY
#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#151#147#article#179#</font></p>     ^cY#10.h
tm##
00524000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028500074002000700359#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#152#148#article#179#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Barbosa Junior    A, S
zwarcwald CL, Pascom ARP, Souza Junior PB. Tend&ecirc;ncias da epidemia    de AI
DS entre subgrupos sob maior risco no Brasil, 1980-2004. Cad Sa&uacute;de    P&u
acute;blica 2009; 25:727-37.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#153#149#article#179#</font></p>     ^cY#10.h
tm##
00568000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032900074002000700403#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#154#150#article#179#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Ramos Jr. AN,    Matid
a LH, Saraceni V, Veras MA, Pontes RJ. Control of mother-to-child transmission  
  of infectious diseases in Brazil: progress in HIV/AIDS and failure in congenit
al    syphilis. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S370-8.    ^cY#
10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#155#151#article#179#</font></p>     ^cY#10.h
tm##
00552000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031300074002000700387#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#156#152#article#179#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Szwarcwald    CL, Barb
osa Junior A, Souza Junior PR, Lemos KR, Frias PG, Luhm KR, et al. HIV    testin
g during pregnancy: use of secondary data to estimate 2006 test coverage    and 
prevalence in Brazil. Braz J Infect Dis 2008; 12;167-72.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#157#153#article#179#</font></p>     ^cY#10.h
tm##
00618000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037900074002000700453#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#158#154#article#179#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Succi RCM;    Grupo de
 Estudo da Sociedade Brasileira de Pediatria para Avaliar a Transmiss&atilde;o  
  Materno-Infantil do HIV. Mother-to-child transmission of HIV in Brazil during 
   the years 2000 and 2001: results of a multi-centric study. Cad Sa&uacute;de  
  P&uacute;blica 2007; 23 Suppl 3:S379-89.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#159#155#article#179#</font></p>     ^cY#10.h
tm##
00413000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704017400074002000700248#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#160#156#article#179#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Levy JA. HIV    pathog
enesis: 25 years of progress and persistent challenges. AIDS 2009; 23:147-60.   
 ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#161#157#article#179#</font></p>     ^cY#10.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#162#158#article#179#32#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">32. Paintsil E,    Andiman
 WA. Update on successes and challenges regarding mother-to-child transmission  
  of HIV. Curr Opin Pediatr 2009; 21:94-101.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#163#159#article#179#</font></p>     ^cY#10.h
tm##
00498000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025900074002000700333#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#164#160#article#179#33#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">33. King E, De    Silva M,
 Stein A, Patel V. Interventions for improving the psychosocial well-being    of
 children affected by HIV and AIDS. Cochrane Database Syst Rev 2009; (2):CD00673
3.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#165#161#article#179#</font></p>     ^cY#10.h
tm##
00528000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028900074002000700363#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#166#162#article#179#34#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">34. Little KE,    Bland RM
, Newell ML. Vertically acquired paediatric HIV infection: the challenges    of 
providing comprehensive packages of care in resource-limited settings. Trop    M
ed Int Health 2008; 13:1098-110.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#167#163#article#179#</font></p>     ^cY#10.h
tm##
00448000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020900074002000700283#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#168#164#article#179#35#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">35. Galvao J. Brazil    an
d access to HIV/AIDS drugs: a question of human rights and public health.    Am 
J Public Health 2005; 95:1110-6.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#169#165#article#179#</font></p>     ^cY#10.h
tm##
00510000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027100074002000700345#v27
s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#p#170#166#article#179#36#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">36. Masanja H,    Savigny 
D, Smithson P, Schellenberg J, John T, Mbuya C, et al. Child survival    gains i
n Tanzania: analysis of data from demographic and health surveys. Lancet    2008
; 371:1276-83.    ^cY#10.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#171#167#article#179#</font></p>     ^cY#10.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#172#168#article#179#<p>&nbsp;</p>     ^cY#10
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#173#169#article#179#<p>&nbsp;</p>     ^cY#10
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#174#170#article#179#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#10.htm##
00256000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003200071002000700103#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#175#171#article#179#<br>   </b> L. H. Matida
    ^cY#10.htm##
00268000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004400071002000700115#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#176#172#article#179#<br>   Programa Estadual
 de DST/AIDS    ^cY#10.htm##
00295000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704007100071002000700142#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#177#173#article#179#<br>   Secretaria de Est
ado da Sa&uacute;de de S&atilde;o Paulo    ^cY#10.htm##
00256000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003200071002000700103#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#178#174#article#179#<br>   Rua Santa Cruz 81
    ^cY#10.htm##
00277000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005300071002000700124#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#179#175#article#179#<br>   S&atilde;o Paulo,
 SP 04221-000, Brasil    ^cY#10.htm##
00307000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704008300071002000700154#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#180#176#article#179#<br>   <a href="mailto:l
matida@gmail.com">lmatida@gmail.com</a></font></p>     ^cY#10.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#181#177#article#179#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 01/Dec/2009    ^cY#10.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#182#178#article#179#<br>   Final version res
ubmitted on 20/Apr/2010    ^cY#10.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\10.htm#S#p#183#179#article#179#<br>   Approved on 05/Ju
l/2010</font></p>     ^cY#10.htm##
00706000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100015000850100
01700100010001800117010002400135010001700159810000600176012012900182030000400311
06500090031506400050032403100040032901400050033386500090033800200070034703500100
0354801000400364#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#184#1#articl
e#36#1#^rND^sGibb^nDM#^rND^sDuong^nT#^rND^sTookey^nPA#^rND^sSharland^nM#^rND^sTu
dor-Williams^nG#^rND^sNovelli^nV#et al#Decline in mortality, AIDS, and hospital 
admissions in perinatally HIV-1 infected children in the United Kingdom and Irel
and^len#BMJ#20030000#2003#327#1019#20110000#10.htm#0959-8138#BMJ##
00776000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700100015000900100
01800105010001500123010001700138010001500155810000600170012020200176030000500378
06500090038306400050039203100040039701400060040186500090040700200070041603500100
0423801000500433#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#185#2#articl
e#36#2#^rND^sde Martino^nM#^rND^sTovo^nPA#^rND^sBalducci^nM#^rND^sGalli^nL#^rND^
sGabiano^nC#^rND^sRezza^nG#et al#Reduction in mortality with availability of ant
iretroviral therapy for children with perinatal HIV-1 infection: Italian Registe
r for HIV Infection in Children and the Italian National AIDS Registry^len#JAMA#
20000000#2000#284#190-7#20110000#10.htm#0098-7484#JAMA##
00759000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700100017000850100
01900102010001700121010001800138010001900156810000600175012015800181030001600339
06500090035506400050036403100030036901400070037286500090037900200070038803500100
0395801001600405#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#186#3#articl
e#36#3#^rND^sPatel^nK#^rND^sHernan^nMA#^rND^sWilliams^nPL#^rND^sSeeger^nJD#^rND^
sMcIntosh^nK#^rND^sVan Dyke^nRB#et al#Long-term effectiveness of highly active a
ntiretroviral therapy on the survival of children and adolescents with HIV infec
tion: a 10-year follow-up study^len#Clin Infect Dis#20080000#2008#46#507-15#2011
0000#10.htm#1058-4838#Clin Infect Dis##
00724000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100020000700100016000900100
01600106010001500122010001800137010002000155810000600175012012800181030001300309
06500090032206400050033103100040033601400070034086500090034700200070035603500100
0363801001300373#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#187#4#articl
e#36#4#^rND^sGortmaker^nSL#^rND^sHughes^nM#^rND^sCervia^nJ#^rND^sBrady^nM#^rND^s
Johnson^nGM#^rND^sSeage^nGR 3rd#et al#Effect of combination therapy including pr
otease inhibitors on mortality among children and adolescents infected with HIV-
1^len#N Engl J Med#20010000#2001#345#1522-8#20110000#10.htm#0028-4793#N Engl J M
ed##
00722000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01600105010001400121010001200135010001500147810000600162012014100168030001100309
06500090032006400050032903100040033401400090033886500090034700200070035603500100
0363801001100373#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#188#5#articl
e#36#5#^rND^sJanssens^nB#^rND^sRaleigh^nB#^rND^sSoeung^nS#^rND^sAkao^nK#^rND^sTe
^nV#^rND^sGupta^nJ#et al#Effectiveness of highly active antiretroviral therapy i
n HIV-positive children: evaluation at 12 months in a routine program in Cambodi
a^len#Pediatrics#20070000#2007#120#e1134-40#20110000#10.htm#0031-4005#Pediatrics
##
00685000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100018000860100
01800104010001800122012016100140030001600301065000900317064000500326031000300331
014000700334865000900341002000700350035001000357801001600367#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\10.htm#S#c#189#6#article#36#6#^rND^sViani^nRM#^rND^sAraneta
^nMR#^rND^sDeville^nJG#^rND^sSpector^nSA#Decrease in hospitalization and mortali
ty rates among children with perinatally acquired HIV type 1 infection receiving
 highly active antiretroviral therapy^len#Clin Infect Dis#20040000#2004#39#725-3
1#20110000#10.htm#1058-4838#Clin Infect Dis##
00675000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100021000700100020000910100
02100111010001700132010001400149010001400163810000600177012009300183030000500276
06500090028106400050029003100030029501400080029886500090030600200070031503500100
0322801000500332#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#190#7#articl
e#36#7#^rND^sGoetghebuer^nT#^rND^sHaelterman^nE#^rND^sLe Chenadec^nJ#^rND^sDollf
us^nC#^rND^sGibb^nD#^rND^sJudd^nA#et al#Effect of early antiretroviral therapy o
n the risk of AIDS/death in HIV-infected infants^len#AIDS#20090000#2009#23#597-6
04#20110000#10.htm#0269-9370#AIDS##
00679000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100015000890100
01500104010001700119010001400136010002000150810000600170012010400176030000500280
06500090028506400050029403100030029901400080030286500090031000200070031903500100
0326801000500336#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#191#8#articl
e#36#8#^rND^sChiappini^nE#^rND^sGalli^nL#^rND^sTovo^nPA#^rND^sGabiano^nC#^rND^sL
isi^nC#^rND^sGattinara^nGC#et al#Changing patterns of clinical events in perinat
ally HIV-1-infected children during the era of HAART^len#AIDS#20070000#2007#21#1
607-15#20110000#10.htm#0269-9370#AIDS##
00485000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100016000860120
07400102030001500176710000200191065000900193064000500202014000800207865000900215
002000700224#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#192#9#article#36
#9#^rND^sGavin^nPJ#^rND^sYogev^nR.#The role of protease inhibitor therapy in chi
ldren with HIV infection^len#Paediatr Drugs#2#20020000#2002#581-607#20110000#10.
htm##
00658000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890100
01500104010001700119012015500136030001800291710000200309065000900311064000500320
031000300325032000400328014000800332865000900340002000700349#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\10.htm#S#c#193#10#article#36#10#^rND^sHacker^nMA#^rND^sKaid
a^nA#^rND^sHogg^nRS#^rND^sBastos^nFI#The first ten years: achievements and chall
enges of the Brazilian program of universal access to HIV/AIDS comprehensive man
agement and care, 1996-2006^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S345-59
#20110000#10.htm##
00467000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720120037000860300
01300123065000900136064000500145031000400150014000800154865000900162002000700171
035001000178801001300188#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#194#
11#article#36#11#^rND^sOkie^nS#Fighting HIV-lessons from Brazil^len#N Engl J Med
#20060000#2006#354#1977-81#20110000#10.htm#0028-4793#N Engl J Med##
00650000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01600106010001600122010001900138012009700157030001600254065000900270064000500279
031000300284014000700287865000900294002000700303035001000310801001600320#v27s1#V
:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#195#12#article#36#12#^rND^sBastos^nF
I#^rND^sCaceres^nC#^rND^sGalvao^nJ#^rND^sVeras^nMA#^rND^sCastilho^nEA#AIDS in La
tin America: assessing the current status of the epidemic and the ongoing respon
se^len#Int J Epidemiol#20080000#2008#37#729-37#20110000#10.htm#0300-5771#Int J E
pidemiol##
00706000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01600106010001900122010001900141010001700160012012700177030001300304065000900317
06400050032603100030033101400070033486500090034100200070035003500100035780100130
0367#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#196#13#article#36#13#^rN
D^sJeena^nPM#^rND^sMcNally^nLM#^rND^sStobie^nM#^rND^sCoovadia^nHM#^rND^sAdhikari
^nMA#^rND^sPetros^nAJ#Challenges in the provision of ICU services to HIV infecte
d children in resource poor settings: a South African case study^len#J Med Ethic
s#20050000#2005#31#226-30#20110000#10.htm#0306-6800#J Med Ethics##
00723000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100020000890100
01700109010002000126010002400146010001600170810000700186012012700193030001800320
71000020033806500090034006400050034903100030035403200040035701400080036186500090
0369002000700378#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#197#14#artic
le#36#14#^rND^sMatida^nLH#^rND^sRamos Jr.^nAN#^rND^sMoncau^nJE#^rND^sMarcopito^n
LF#^rND^sSousa-Marques^nHH#^rND^sSucci^nRC#et al.#AIDS by mother-to-child transm
ission: survival analysis of cases followed from 1983 to 2002 in different regio
ns of Brazil^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S435-44#20110000#10.ht
m##
00653000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100020000890100
01600109010001800125010002100143010001900164810000600183012007900189030001800268
71000020028606500090028806400050029703100020030201400070030486500090031100200070
0320#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#198#15#article#36#15#^rN
D^sMatida^nLH#^rND^sMarcopito^nLF#^rND^sSucci^nRC#^rND^sMarques^nHH#^rND^sDella-
Negra^nM#^rND^sGrangeiro^nA#et al#Improving survival among Brazilian children wi
th perinatally-acquired AIDS^len#Braz J Infect Dis#2#20040000#2004#8#419-23#2011
0000#10.htm##
00641000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100020000890100
02000109010001700129012010200146030002100248065000900269064000500278031000300283
014000600286865000900292002000700301035001000308801002100318#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\10.htm#S#c#199#16#article#36#16#^rND^sMatida^nLH#^rND^sRamo
s Jr.^nAN#^rND^sHeukelbach^nJ#^rND^sHearst^nN.#Continuing improvement in surviva
l for children with Acquired Immunodeficiency Syndrome in Brazil^len#Pediatr Inf
ect Dis J#20090000#2009#28#920-2#20110000#10.htm#0891-3668#Pediatr Infect Dis J#
#
00554000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100022000720100017000940120
11700111030001800228710000200246065000900248064000500257031000300262014000700265
865000900272002000700281#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#200#
17#article#36#17#^rND^sCamargo Jr.^nKR#^rND^sCoeli^nCM.#Reclink: aplicativo para
 o relacionamento de bases de dados, implementando o método probabilistic record
 linkage^len#Cad Saúde Pública#2#20000000#2000#16#439-47#20110000#10.htm##
00328000000000181000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170020000720180038000928650
00900130002000700139#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#201#18#a
rticle#36#18#Ministério da Saúde#Boletim Epidemiológico AIDST 2008^lpt#20110000#
10.htm##
00522000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100015000890120
05800104030001600162065000900178064000500187031000300192014000700195865000900202
002000700211035001000218801001600228#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.
htm#S#c#202#19#article#36#19#^rND^sKaplan^nEL#^rND^sMeier^nP#Non parametric esti
mation from incomplete observation^len#J Am Stat Assoc#19580000#1958#53#457-81#2
0110000#10.htm#0162-1459#J Am Stat Assoc##
00458000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160020000720160015000920180
04500107063000400152066000900156062000900165065000900174064000500183865000900188
002000700197#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#203#20#article#3
6#20#^rND^sKleinbaum^nDG#^rND^sKlein^nM#Survival analysis - a self-learning text
^len#2nd#New York#Springer#20050000#2005#20110000#10.htm##
00567000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170020000720180066000920370
15400158110000900312109001200321865000900333002000700342#v27s1#V:\SciELO\serial\
csp\v27s1\markup\10.htm#S#c#204#21#article#36#21#Ministério da Saúde#Critérios d
e definição de casos de AIDS em adultos e crianças^lpt#http://www.aids.gov.br/da
ta/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B2A9F7
D1C-093E-4A04-8380-84ED432964A5%7D/criterios.pdf#20091113#13/Nov/2009#20110000#1
0.htm##
00425000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160014000720160015000860180
03000101066000700131062001500138065000900153064000500162865000900167002000700176
#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#205#22#article#36#22#^rND^sC
ox^nDR#^rND^sOakes^nD#Analysis of survival data^len#London#Chapman & Hall#198400
00#1984#20110000#10.htm##
00812000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100024000900100
01700114010001900131010001700150010001600167810000600183012019400189030002100383
06500090040406400050041303100030041801400060042186500090042700200070043603500100
0443801002100453#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#206#23#artic
le#36#23#^rND^sMarazzi^nMC#^rND^sNielsen-Saines^nK#^rND^sBuonomo^nE#^rND^sScarce
lla^nP#^rND^sGermano^nP#^rND^sMajid^nNA#et al#Increased infant human immunodefic
iency virus-type one free survival at one year of age in sub-Saharan Africa with
 maternal use of highly active antiretroviral therapy during breast-feeding^len#
Pediatr Infect Dis J#20090000#2009#28#483-7#20110000#10.htm#0891-3668#Pediatr In
fect Dis J##
00734000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100015000920100
01600107010001700123010001500140010001600155810000600171012013700177030001600314
06500090033006400050033903100030034401400070034786500090035400200070036303500100
0370801001600380#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#207#24#artic
le#36#24#^rND^sSutcliffe^nCG#^rND^sScott^nS#^rND^sMugala^nN#^rND^sNdhlovu^nZ#^rN
D^sMonze^nM#^rND^sQuinn^nTC#et al#Survival from 9 months of age among HIV-infect
ed and uninfected Zambian children prior to the availability of antiretroviral t
herapy^len#Clin Infect Dis#20080000#2008#47#837-44#20110000#10.htm#1058-4838#Cli
n Infect Dis##
00690000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100016000880100
01300104010001700117010001600134010001900150810000600169012013500175030001300310
71000020032306500090032506400050033403100020033901400070034186500090034800200070
0357#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#208#25#article#36#25#^rN
D^sLittle^nK#^rND^sThorne^nC#^rND^sLuo^nC#^rND^sBunders^nM#^rND^sNgongo^nN#^rND^
sMcDermott^nP#et al#Disease progression in children with vertically-acquired HIV
 infection in sub-Saharan Africa: reviewing the need for HIV treatment^len#Curr 
HIV Res#2#20070000#2007#5#139-53#20110000#10.htm##
00691000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100021000960100
02000117010001800137010001700155010002200172012010600194030001800300710000200318
06500090032006400050032903100030033403200040033701400080034186500090034900200070
0358#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#209#26#article#36#26#^rN
D^sSousa-Marques^nHH#^rND^sCouttolenc^nBF#^rND^sLatorre^nMRDO#^rND^sAquino^nMZG#
^rND^sAveiro^nMI#^rND^sPluciennik^nAMA#Costs of care provided in a university ho
spital for children exposed to or infected with the HIV/AIDS^len#Cad Saúde Públi
ca#2#20070000#2007#23#^s3#S402-13#20110000#10.htm##
00596000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100021000960100
01800117010002300135012008800158030001800246710000200264065000900266064000500275
031000300280014000700283865000900290002000700299#v27s1#V:\SciELO\serial\csp\v27s
1\markup\10.htm#S#c#210#27#article#36#27#^rND^sBarbosa Junior^nA#^rND^sSzwarcwal
d^nCL#^rND^sPascom^nARP#^rND^sSouza Junior^nPB#Tendências da epidemia de AIDS en
tre subgrupos sob maior risco no Brasil, 1980-2004^lpt#Cad Saúde Pública#2#20090
000#2009#25#727-37#20110000#10.htm##
00672000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100017000920100
01800109010001600127010001700143012013400160030001800294710000200312065000900314
064000500323031000300328032000400331014000700335865000900342002000700351#v27s1#V
:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#211#28#article#36#28#^rND^sRamos Jr.
^nAN#^rND^sMatida^nLH#^rND^sSaraceni^nV#^rND^sVeras^nMA#^rND^sPontes^nRJ#Control
 of mother-to-child transmission of infectious diseases in Brazil: progress in H
IV/AIDS and failure in congenital syphilis^len#Cad Saúde Pública#2#20070000#2007
#23#^s3#S370-8#20110000#10.htm##
00691000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100024000930100
02300117010001600140010001600156010001500172810000600187012011200193030001800305
71000020032306500090032506400050033403100030033901400070034286500090034900200070
0358#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#212#29#article#36#29#^rN
D^sSzwarcwald^nCL#^rND^sBarbosa Junior^nA#^rND^sSouza Junior^nPR#^rND^sLemos^nKR
#^rND^sFrias^nPG#^rND^sLuhm^nKR#et al#HIV testing during pregnancy: use of secon
dary data to estimate 2006 test coverage and prevalence in Brazil^len#Braz J Inf
ect Dis#2#20080000#2008#12#167-72#20110000#10.htm##
00651000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720110104000890120
11500193030001800308710000200326065000900328064000500337031000300342032000400345
014000800349865000900357002000700366#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.
htm#S#c#213#30#article#36#30#^rND^sSucci^nRCM#Grupo de Estudo da Sociedade Brasi
leira de Pediatria para Avaliar a Transmissão Materno-Infantil do HIV#Mother-to-
child transmission of HIV in Brazil during the years 2000 and 2001: results of a
 multi-centric study^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S379-89#201100
00#10.htm##
00482000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720120069000870300
00500156065000900161064000500170031000300175014000700178865000900185002000700194
035001000201801000500211#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#214#
31#article#36#31#^rND^sLevy^nJA#HIV pathogenesis: 25 years of progress and persi
stent challenges^len#AIDS#20090000#2009#23#147-60#20110000#10.htm#0269-9370#AIDS
##
00557000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900120
08500108030001800193065000900211064000500220031000300225014000700228865000900235
002000700244035001000251801001800261#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.
htm#S#c#215#32#article#36#32#^rND^sPaintsil^nE#^rND^sAndiman^nWA#Update on succe
sses and challenges regarding mother-to-child transmission of HIV^len#Curr Opin 
Pediatr#20090000#2009#21#94-101#20110000#10.htm#1040-8703#Curr Opin Pediatr##
00591000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100018000860100
01500104010001500119012009700134030002700231710000200258065000900260064000500269
032000200274014000900276865000900285002000700294#v27s1#V:\SciELO\serial\csp\v27s
1\markup\10.htm#S#c#216#33#article#36#33#^rND^sKing^nE#^rND^sDe Silva^nM#^rND^sS
tein^nA#^rND^sPatel^nV#Interventions for improving the psychosocial well-being o
f children affected by HIV and AIDS^len#Cochrane Database Syst Rev#2#20090000#20
09#2#CD006733#20110000#10.htm##
00642000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100016000890100
01700105012013800122030002000260065000900280064000500289031000300294014000900297
865000900306002000700315035001000322801002000332#v27s1#V:\SciELO\serial\csp\v27s
1\markup\10.htm#S#c#217#34#article#36#34#^rND^sLittle^nKE#^rND^sBland^nRM#^rND^s
Newell^nML#Vertically acquired paediatric HIV infection: the challenges of provi
ding comprehensive packages of care in resource-limited settings^len#Trop Med In
t Health#20080000#2008#13#1098-110#20110000#10.htm#1360-2276#Trop Med Int Health
##
00528000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720120086000880300
01900174065000900193064000500202031000300207014000700210865000900217002000700226
035001000233801001900243#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#218#
35#article#36#35#^rND^sGalvao^nJ#Brazil and access to HIV/AIDS drugs: a question
 of human rights and public health^len#Am J Public Health#20050000#2005#95#1110-
6#20110000#10.htm#0090-0036#Am J Public Health##
00676000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100017000890100
01800106010002200124010001400146010001500160810000600175012009100181030000700272
06500090027906400050028803100040029301400080029786500090030500200070031403500100
0321801000700331#v27s1#V:\SciELO\serial\csp\v27s1\markup\10.htm#S#c#219#36#artic
le#36#36#^rND^sMasanja^nH#^rND^sSavigny^nD#^rND^sSmithson^nP#^rND^sSchellenberg^
nJ#^rND^sJohn^nT#^rND^sMbuya^nC#et al#Child survival gains in Tanzania: analysis
 of data from demographic and health surveys^len#Lancet#20080000#2008#371#1276-8
3#20110000#10.htm#0099-5355#Lancet##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#o#1#1#article#1#201104
11#073718#11.htm#143##
04685000000000745000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400130013303500100014601201800015601201550
03360100048004910100033005390100030005720100028006020100036006300100033006660100
03300699010003400732010003100766070007900797070011200876070005000988070012401038
07000700116208312030123208500100243508500270244508500350247208500220250708500420
25290831153025710850010037240850030037340850029037640850024037930850041038171170
00803858072000303866112000903869111001203878116000903890115001203899114000903911
113001203920002000703932#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#h#2#1#
article#1#oa#en#br1.1#1#4.0#TAB#11#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^f
s104^ls113#0102-311X#The "AMA-Brazil" cooperative project: a nation-wide assessm
ent of the clinical and epidemiological profile of AIDS-related deaths in Brazil
 in the antiretroviral treatment era^len#Projeto cooperativo AMA-Brasil: um estu
do nacional do perfil clinico e epidemiológico dos óbitos relacionados à AIDS na
 era da terapia antirretroviral^lpt#^rND^1A01^nMaria Amelia de Sousa Mascena^sVe
ras#^rND^1A01^nManoel C. A.^sRibeiro#^rND^1A02^nLeda Fátima^sJamal#^rND^1A03^nWi
lli^sMcFarland#^rND^1A04^nFrancisco Inácio^sBastos#^rND^1A01^nKarina Braga^sRibe
iro#^rND^1A01^nRita Barradas^sBarata#^rND^1A01^nJosé Cassio de^sMoraes#^rND^1A05
^nArthur L.^sReingold#Santa Casa de São Paulo^iA01^1Faculdade de Ciências Médica
s^cSão Paulo^pBrasil#Secretaria de Estado da Saúde de São Paulo^iA02^1Centro de 
Referência e Treinamento DST/AIDS^cSão Paulo^pBrasil#University of California^iA
03^cSan Francisco^pUSA#Fundação Oswaldo Cruz^iA04^1Instituto de Comunicação e In
formação Científica e Tecnológica em Saúde^cRio de Janeiro^pBrasil#University of
 California^iA05^1School of Public Health^cBerkeley^pUSA#^len^aThe objective of 
this study was to assess the profile of AIDS-related deaths in the post antiretr
oviral therapy (ART) scale up period in Brazil. A case-control study was conduct
ed including a nationally probabilistic sample of AIDS deaths and living control
s. Data were abstracted from medical records and nation-wide databases of AIDS c
ases, mortality, ART care, and laboratory testing. Interrupted (adjusted odds ra
tio - AOR 4.35, 95%CI: 3.15-6.00) or no use of ART (AOR 2.39, 95%CI: 1.57-3.65) 
was the strongest predictor of death, followed by late diagnosis (AOR 3.95, 95%C
I: 2.68-5.82). Criterion other than CD4 < 350 had a higher likelihood of death (
AOR 1.65, 95%CI: 1.14-2.40). Not receiving recommended vaccines (AOR, 1.76, 95%C
I: 1.21-2.56), presenting AIDS-related diseases (AOR 2.19, 95%CI: 1.22-3.93) and
 tuberculosis (AOR 1.50, 95%CI: 1.14-1.97) had higher odds of death. Being an in
jecting drug user (IDU) had a borderline association with higher odds of death, 
while homo/bisexual exposure showed a protective effect. Despite remarkable succ
esses, Brazilians continue to die of AIDS in the post-ART scale up period. Many 
factors contributing to continued mortality are preventable#^ddecs^i1#^tm^len^kH
IV infections^i1#^tm^len^kAnti-Retroviral Agents^i1#^tm^len^kMortality^i1#^tm^le
n^kHealth Services Accessibility^i1#^lpt^aAnalisou-se o perfil clínico e epidemi
ológico dos óbitos relacionados à AIDS no período posterior à implementação da t
erapia antirretroviral (TARV) no Brasil, em um estudo caso-controle, com amostra
 representativa de óbitos por AIDS e de pessoas vivendo com AIDS, utilizando dad
os secundários. Abandono (odds ratio ajustada - AOR = 4,35, IC95%: 3,15-6,00) ou
 não uso da TARV (AOR = 2,39, IC95%: 1,57-3,65) foi o mais forte preditor de mor
te, seguido de diagnóstico tardio (AOR = 3,95, IC95%: 2,68-5,82). Critério de de
finição de AIDS que não o "CD4 < 350" esteve associado a uma maior probabilidade
 de morte (AOR = 1,65, IC95%: 1,14-2,40). Pacientes que não receberam vacinas re
comendadas (AOR = 1,76, 95%CI: 1,21-2,56), apresentando doenças associadas à AID
S (AOR = 2,19, IC95%: 1,22-3,93) e com tuberculose (AOR = 1,50, IC95%: 1,14-1,97
), tiveram maior risco de morte. A categoria de exposição UDI apresentou maior c
hance de óbito. Apesar do sucesso com as introduções precoces da TARV, brasileir
os continuaram a morrer de AIDS no período posterior à implementação da terapia,
 e muitas das causas subjacentes a essa mortalidade são preveníveis.#^ddecs^i2#^
tm^lpt^kInfecções por HIV^i2#^tm^lpt^kAnti-Retrovirais^i2#^tm^lpt^kMortalidade^i
2#^tm^lpt^kAcesso aos Serviços de Saúde^i2#vancouv#18#20100205#05/Feb/2010#20100
602#02/Jun/2010#20100805#05/Aug/2010#11.htm##
04719000000000745000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083121000300087049000700090158000300097030001900100
03100030011913100020012206500090012401400130013303500100014601201940015601201690
03500100048005190100033005670100030006000100028006300100036006580100033006940100
03300727010003400760010003100794070007900825070011200904070005001016070012401066
07000700119008312060126008500100246608500270247608500350250308500220253808500420
25600831156026020850010037580850030037680850029037980850024038270850041038511170
00803892072000303900112000903903111001203912116000903924115001203933114000903945
113001203954002000703966#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#f#3#1#
article#1#oa#en#br1.1#1#4.0#TAB#11#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^f
s104^ls113#0102-311X#<b>The "AMA-Brazil" cooperative project</b>: <b>a nation-wi
de assessment of the clinical and epidemiological profile of AIDS-related deaths
 in Brazil in the antiretroviral treatment era</b>^len#<b>Projeto cooperativo AM
A-Brasil</b>: <b>um estudo nacional do perfil clinico e epidemiológico dos óbito
s relacionados à AIDS na era da terapia antirretroviral</b>^lpt#^rND^1A01^nMaria
 Amelia de Sousa Mascena^sVeras#^rND^1A01^nManoel C. A.^sRibeiro#^rND^1A02^nLeda
 Fátima^sJamal#^rND^1A03^nWilli^sMcFarland#^rND^1A04^nFrancisco Inácio^sBastos#^
rND^1A01^nKarina Braga^sRibeiro#^rND^1A01^nRita Barradas^sBarata#^rND^1A01^nJosé
 Cassio de^sMoraes#^rND^1A05^nArthur L.^sReingold#Santa Casa de São Paulo^iA01^1
Faculdade de Ciências Médicas^cSão Paulo^pBrasil#Secretaria de Estado da Saúde d
e São Paulo^iA02^1Centro de Referência e Treinamento DST/AIDS^cSão Paulo^pBrasil
#University of California^iA03^cSan Francisco^pUSA#Fundação Oswaldo Cruz^iA04^1I
nstituto de Comunicação e Informação Científica e Tecnológica em Saúde^cRio de J
aneiro^pBrasil#University of California^iA05^1School of Public Health^cBerkeley^
pUSA#^len^aThe objective of this study was to assess the profile of AIDS-related
 deaths in the post antiretroviral therapy (ART) scale up period in Brazil. A ca
se-control study was conducted including a nationally probabilistic sample of AI
DS deaths and living controls. Data were abstracted from medical records and nat
ion-wide databases of AIDS cases, mortality, ART care, and laboratory testing. I
nterrupted (adjusted odds ratio - AOR 4.35, 95%CI: 3.15-6.00) or no use of ART (
AOR 2.39, 95%CI: 1.57-3.65) was the strongest predictor of death, followed by la
te diagnosis (AOR 3.95, 95%CI: 2.68-5.82). Criterion other than CD4 &lt; 350 had
 a higher likelihood of death (AOR 1.65, 95%CI: 1.14-2.40). Not receiving recomm
ended vaccines (AOR, 1.76, 95%CI: 1.21-2.56), presenting AIDS-related diseases (
AOR 2.19, 95%CI: 1.22-3.93) and tuberculosis (AOR 1.50, 95%CI: 1.14-1.97) had hi
gher odds of death. Being an injecting drug user (IDU) had a borderline associat
ion with higher odds of death, while homo/bisexual exposure showed a protective 
effect. Despite remarkable successes, Brazilians continue to die of AIDS in the 
post-ART scale up period. Many factors contributing to continued mortality are p
reventable#^ddecs^i1#^tm^len^kHIV infections^i1#^tm^len^kAnti-Retroviral Agents^
i1#^tm^len^kMortality^i1#^tm^len^kHealth Services Accessibility^i1#^lpt^aAnaliso
u-se o perfil clínico e epidemiológico dos óbitos relacionados à AIDS no período
 posterior à implementação da terapia antirretroviral (TARV) no Brasil, em um es
tudo caso-controle, com amostra representativa de óbitos por AIDS e de pessoas v
ivendo com AIDS, utilizando dados secundários. Abandono (odds ratio ajustada - A
OR = 4,35, IC95%: 3,15-6,00) ou não uso da TARV (AOR = 2,39, IC95%: 1,57-3,65) f
oi o mais forte preditor de morte, seguido de diagnóstico tardio (AOR = 3,95, IC
95%: 2,68-5,82). Critério de definição de AIDS que não o "CD4 &lt; 350" esteve a
ssociado a uma maior probabilidade de morte (AOR = 1,65, IC95%: 1,14-2,40). Paci
entes que não receberam vacinas recomendadas (AOR = 1,76, 95%CI: 1,21-2,56), apr
esentando doenças associadas à AIDS (AOR = 2,19, IC95%: 1,22-3,93) e com tubercu
lose (AOR = 1,50, IC95%: 1,14-1,97), tiveram maior risco de morte. A categoria d
e exposição UDI apresentou maior chance de óbito. Apesar do sucesso com as intro
duções precoces da TARV, brasileiros continuaram a morrer de AIDS no período pos
terior à implementação da terapia, e muitas das causas subjacentes a essa mortal
idade são preveníveis.#^ddecs^i2#^tm^lpt^kInfecções por HIV^i2#^tm^lpt^kAnti-Ret
rovirais^i2#^tm^lpt^kMortalidade^i2#^tm^lpt^kAcesso aos Serviços de Saúde^i2#van
couv#18#20100205#05/Feb/2010#20100602#02/Jun/2010#20100805#05/Aug/2010#11.htm##
04925000000000769000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090121000300094049000700097158000300104
03000190010703100030012613100020012906500090013101400130014003500100015301201800
01630120155003430100048004980100032005460100030005780100028006080100036006360100
03300672010003300705010003400738010003000772070008100802070011400883070005200997
07001260104907000720117508312520124708500100249908500270250908500350253608500220
25710850042025930831216026350850010038510850030038610850029038910850024039200850
04103944117000803985072000303993112000903996111001204005116000904017115001204026
114000904038113001204047002000704059008008904066#v27s1#V:\SciELO\serial\csp\v27s
1\markup\11.htm#S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#tab#11#CSP330#nd#Cad.
 saúde pública#27#1#20110000#^fs104^ls113#0102-311X#The "AMA-Brazil" cooperative
 project: a nation-wide assessment of the clinical and epidemiological profile o
f AIDS-related deaths in Brazil in the antiretroviral treatment era^len#Projeto 
cooperativo AMA-Brasil: um estudo nacional do perfil clinico e epidemiológico do
s óbitos relacionados à AIDS na era da terapia antirretroviral^lpt#^rND^1A01^nMa
ria Amelia de Sousa Mascena^sVeras#^rND^1A01^nManoel C. A^sRibeiro#^rND^1A02^nLe
da Fátima^sJamal#^rND^1A03^nWilli^sMcFarland#^rND^1A04^nFrancisco Inácio^sBastos
#^rND^1A01^nKarina Braga^sRibeiro#^rND^1A01^nRita Barradas^sBarata#^rND^1A01^nJo
sé Cassio de^sMoraes#^rND^1A05^nArthur L^sReingold#^iA01^1Santa Casa de São Paul
o^2Faculdade de Ciências Médicas^cSão Paulo^pBrasil#^iA02^1Secretaria de Estado 
da Saúde de São Paulo^2Centro de Referência e Treinamento DST/AIDS^cSão Paulo^pB
rasil#^iA03^1University of California^cSan Francisco^pUSA#^iA04^1Fundação Oswald
o Cruz^2Instituto de Comunicação e Informação Científica e Tecnológica em Saúde^
cRio de Janeiro^pBrasil#^iA05^1University of California^2School of Public Health
^cBerkeley^pUSA#^len^aThe objective of this study was to assess the profile of A
IDS-related deaths in the post antiretroviral therapy (ART) scale up period in B
razil. A case-control study was conducted including a nationally probabilistic s
ample of AIDS deaths and living controls. Data were abstracted from medical reco
rds and nation-wide databases of AIDS cases, mortality, ART care, and laboratory
 testing. Interrupted (adjusted odds ratio - AOR 4.35, 95 percentCI: 3.15-6.00) 
or no use of ART (AOR 2.39, 95 percentCI: 1.57-3.65) was the strongest predictor
 of death, followed by late diagnosis (AOR 3.95, 95 percentCI: 2.68-5.82). Crite
rion other than CD4 < 350 had a higher likelihood of death (AOR 1.65, 95 percent
CI: 1.14-2.40). Not receiving recommended vaccines (AOR, 1.76, 95 percentCI: 1.2
1-2.56), presenting AIDS-related diseases (AOR 2.19, 95 percentCI: 1.22-3.93) an
d tuberculosis (AOR 1.50, 95 percentCI: 1.14-1.97) had higher odds of death. Bei
ng an injecting drug user (IDU) had a borderline association with higher odds of
 death, while homo/bisexual exposure showed a protective effect. Despite remarka
ble successes, Brazilians continue to die of AIDS in the post-ART scale up perio
d. Many factors contributing to continued mortality are preventable#^ddecs^i1#^t
m^len^kHIV infections^i1#^tm^len^kAnti-Retroviral Agents^i1#^tm^len^kMortality^i
1#^tm^len^kHealth Services Accessibility^i1#^lpt^aAnalisou-se o perfil clínico e
 epidemiológico dos óbitos relacionados à AIDS no período posterior à implementa
ção da terapia antirretroviral (TARV) no Brasil, em um estudo caso-controle, com
 amostra representativa de óbitos por AIDS e de pessoas vivendo com AIDS, utiliz
ando dados secundários. Abandono (odds ratio ajustada - AOR = 4,35, IC95 por cen
to: 3,15-6,00) ou não uso da TARV (AOR = 2,39, IC95 por cento: 1,57-3,65) foi o 
mais forte preditor de morte, seguido de diagnóstico tardio (AOR = 3,95, IC95 po
r cento: 2,68-5,82). Critério de definição de AIDS que não o "CD4 < 350" esteve 
associado a uma maior probabilidade de morte (AOR = 1,65, IC95 por cento: 1,14-2
,40). Pacientes que não receberam vacinas recomendadas (AOR = 1,76, 95 por cento
CI: 1,21-2,56), apresentando doenças associadas à AIDS (AOR = 2,19, IC95 por cen
to: 1,22-3,93) e com tuberculose (AOR = 1,50, IC95 por cento: 1,14-1,97), tivera
m maior risco de morte. A categoria de exposição UDI apresentou maior chance de 
óbito. Apesar do sucesso com as introduções precoces da TARV, brasileiros contin
uaram a morrer de AIDS no período posterior à implementação da terapia, e muitas
 das causas subjacentes a essa mortalidade são preveníveis.#^ddecs^i2#^tm^lpt^kI
nfecções por HIV^i2#^tm^lpt^kAnti-Retrovirais^i2#^tm^lpt^kMortalidade^i2#^tm^lpt
^kAcesso aos Serviços de Saúde^i2#vancouv#18#20100205#05/Feb/2010#20100602#02/Ju
n/2010#20100805#05/Aug/2010#11.htm#Internet^ihttp://www.scielo.br/scielo.php?scr
ipt=sci_arttext&pid=S0102-311X2011001300011##
00342000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012200067002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#5#1#article#121#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>ARTICLE    </b> ARTIGO</font
></p>     ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#6#2#article#121#<p>&nbsp;</p>     ^cY#11.htm
##
00513000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704029300067002000700360#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#7#3#article#121#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>The    "AMA-Brazil" coop
erative project: a nation-wide assessment of the clinical and    epidemiological
 profile of AIDS-related deaths in Brazil in the antiretroviral    treatment era
</b> </font></p>     ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#8#4#article#121#<p>&nbsp;</p>     ^cY#11.htm
##
00487000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704026700067002000700334#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#9#5#article#121#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Projeto cooperativo    AMA-Brasil: um estu
do nacional do perfil clinico e epidemiol&oacute;gico dos    &oacute;bitos relac
ionados &agrave; AIDS na era da terapia antirretroviral</b></font></p>     ^cY#1
1.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#10#6#article#121#<p>&nbsp;</p>     ^cY#11.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#11#7#article#121#<p>&nbsp;</p>     ^cY#11.ht
m##
00661000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704044000068002000700508#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#12#8#article#121#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><b>Maria Amelia    de Sousa Mascena Veras<su
p>I</sup>; Manoel C. A. Ribeiro<sup>I</sup>; Leda F&aacute;tima    Jamal<sup>II<
/sup>; Willi McFarland<sup>III</sup>; Francisco In&aacute;cio Bastos<sup>IV</sup
>;    Karina Braga Ribeiro<sup>I</sup>; Rita Barradas Barata<sup>I</sup>; Jos&ea
cute;    Cassio de Moraes<sup>I</sup>; Arthur L. Reingold<sup>V</sup></b></font>
</p>     ^cY#11.htm##
00412000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704019100068002000700259#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#13#9#article#121#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Faculdade    de Ci&ecirc;ncias M
&eacute;dicas da Santa Casa de S&atilde;o Paulo, S&atilde;o    Paulo, Brasil    
^cY#11.htm##
00386000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704016400069002000700233#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#14#10#article#121#<br>   <sup>II</sup>Centro
 de Refer&ecirc;ncia e Treinamento DST/AIDS, Secretaria de    Estado da Sa&uacut
e;de de S&atilde;o Paulo, S&atilde;o Paulo, Brasil    ^cY#11.htm##
00295000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007300069002000700142#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#15#11#article#121#<br>   <sup>III</sup>Unive
rsity of California, San Francisco, USA    ^cY#11.htm##
00437000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021500069002000700284#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#16#12#article#121#<br>   <sup>IV</sup>Instit
uto de Comunica&ccedil;&atilde;o e Informa&ccedil;&atilde;o    Cient&iacute;fica
 e Tecnol&oacute;gica em Sa&uacute;de, Funda&ccedil;&atilde;o    Oswaldo Cruz, R
io de Janeiro, Brasil    ^cY#11.htm##
00325000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010300069002000700172#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#17#13#article#121#<br>   <sup>V</sup>School 
of Public Health, University of California, Berkeley, USA</font></p>     ^cY#11.
htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#18#14#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#19#15#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#20#16#article#121#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#11.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#21#17#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#11.htm##
01549000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704132700069002000701396#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#22#18#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The objective of    this study was to asses
s the profile of AIDS-related deaths in the post antiretroviral    therapy (ART)
 scale up period in Brazil. A case-control study was conducted    including a na
tionally probabilistic sample of AIDS deaths and living controls.    Data were a
bstracted from medical records and nation-wide databases of AIDS    cases, morta
lity, ART care, and laboratory testing. Interrupted (adjusted odds    ratio - AO
R 4.35, 95%CI: 3.15-6.00) or no use of ART (AOR 2.39, 95%CI: 1.57-3.65)    was t
he strongest predictor of death, followed by late diagnosis (AOR 3.95,    95%CI:
 2.68-5.82). Criterion other than CD4 &lt; 350 had a higher likelihood    of dea
th (AOR 1.65, 95%CI: 1.14-2.40). Not receiving recommended vaccines (AOR,    1.7
6, 95%CI: 1.21-2.56), presenting AIDS-related diseases (AOR 2.19, 95%CI:    1.22
-3.93) and tuberculosis (AOR 1.50, 95%CI: 1.14-1.97) had higher odds of    death
. Being an injecting drug user (IDU) had a borderline association with    higher
 odds of death, while homo/bisexual exposure showed a protective effect.    Desp
ite remarkable successes, Brazilians continue to die of AIDS in the post-ART    
scale up period. Many factors contributing to continued mortality are preventabl
e</font></p>     ^cY#11.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704018800069002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#23#19#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">HIV infections;    Anti-Retroviral Agents; 
Mortality; Health Services Accessibility</font></p> <hr size="1" noshade>     ^c
Y#11.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#24#20#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#11.htm##
01712000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704149000069002000701559#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#25#21#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Analisou-se o perfil    cl&iacute;nico e ep
idemiol&oacute;gico dos &oacute;bitos relacionados &agrave;    AIDS no per&iacut
e;odo posterior &agrave; implementa&ccedil;&atilde;o da terapia    antirretrovir
al (TARV) no Brasil, em um estudo caso-controle, com amostra representativa    d
e &oacute;bitos por AIDS e de pessoas vivendo com AIDS, utilizando dados secund&
aacute;rios.    Abandono (odds ratio ajustada - AOR = 4,35, IC95%: 3,15-6,00) ou
 n&atilde;o    uso da TARV (AOR = 2,39, IC95%: 1,57-3,65) foi o mais forte predi
tor de morte,    seguido de diagn&oacute;stico tardio (AOR = 3,95, IC95%: 2,68-5
,82). Crit&eacute;rio    de defini&ccedil;&atilde;o de AIDS que n&atilde;o o "CD
4 &lt; 350" esteve associado    a uma maior probabilidade de morte (AOR = 1,65, 
IC95%: 1,14-2,40). Pacientes    que n&atilde;o receberam vacinas recomendadas (A
OR = 1,76, 95%CI: 1,21-2,56),    apresentando doen&ccedil;as associadas &agrave;
 AIDS (AOR = 2,19, IC95%: 1,22-3,93)    e com tuberculose (AOR = 1,50, IC95%: 1,
14-1,97), tiveram maior risco de morte.    A categoria de exposi&ccedil;&atilde;
o UDI apresentou maior chance de &oacute;bito.    Apesar do sucesso com as intro
du&ccedil;&otilde;es precoces da TARV, brasileiros    continuaram a morrer de AI
DS no per&iacute;odo posterior &agrave; implementa&ccedil;&atilde;o    da terapi
a, e muitas das causas subjacentes a essa mortalidade s&atilde;o preven&iacute;v
eis.</font></p>     ^cY#11.htm##
00436000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704021400069002000700283#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#26#22#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Infec&ccedil;&otilde;es    por HIV; Anti-Re
trovirais; Mortalidade; Acesso aos Servi&ccedil;os de Sa&uacute;de</font></p> <h
r size="1" noshade>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#27#23#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#28#24#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#29#25#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#11.h
tm##
01742000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704152000069002000701589#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#30#26#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Brazil's governmental    policy to provide 
free and universal access to antiretroviral therapy (ART)    to all its citizens
 in need was initially viewed with skepticism inside and    outside the country,
 with doubts raised as to whether such a lofty goal could    be achieved. Nevert
heless, Brazil passed <i>Federal Law nº. 9.313/96</i> <sup>1</sup>    in 1996 gu
aranteeing the right to receive ART within the Unified National Health    System
 (SUS) and launched an ambitious, nation-wide initiative to deliver ART    throu
gh a comprehensive network of accredited public health units. Concerns    that s
oon followed included the sustainability of the initiative given the high    cos
ts and complexity of the therapeutic regimens (now less complex with simplified 
   fixed-dose combinations) <sup>2</sup>; the necessity to procure, monitor, and
    dispense different drugs on a continuous basis over a large and heterogeneou
s    country; and the need to permanently monitor treatment, manage side effects
,    and optimize adherence. Available data to date document that ART adherence 
in    Brazil is comparable to the best standards in high-income countries <sup>3
</sup>    and that the survival of people living with AIDS increased dramaticall
y after    the introduction of ART <sup>4,5</sup>. Moreover, the much feared mas
sive emergence    and dissemination of HIV resistant to antiretroviral drugs has
 not materialized    <sup>6</sup>.</font></p>     ^cY#11.htm##
01312000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704109000069002000701159#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#31#27#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite these major    achievements, AIDS r
emains a major cause of mortality in Brazil. Trends in mortality    show an init
ial rapid reduction in AIDS-related deaths after 1996, slowing after    2000, an
d with disparities between the different regions of the country <sup>7</sup>.   
 AIDS mortality increased from the early 1980s through the mid-1990s, and starte
d    to decline before the wider availability of ART, initially among men but no
t    among women <sup>8</sup>. In 1996, the national AIDS mortality rate was 9.6
    per 100,000 inhabitants, declining to 7.6 in 1997. Mortality declined most m
arkedly    in the Southeast (the most industrialized and richest region and home
 to approximately    60% of reported AIDS cases), from 15.3 per 100,000 in 1996 
to 6.5 in 2007. In    contrast, in the North and Northeast regions (the least in
dustrialized and poorest)    mortality increased from 2.7 per 100,000 to 4.7 in 
the North and from 3.0 to    3.5 in the Northeast over the same period <sup>9</s
up>.</font></p>     ^cY#11.htm##
00856000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704063400069002000700703#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#32#28#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Recent studies    have shown substantial de
lays in receiving ART among persons eligible according    to Brazilian Ministry 
of Health guidelines <sup>10,11</sup>, compromising the    potential benefits of
 therapy to individuals and accentuating disparities within    society. Such del
ays appear to have a disproportionate impact on disenfranchised    populations, 
such as injecting drug users (IDU), jeopardizing the broad principles    of the 
program in terms of equity, comprehensiveness, and involvement of the    affecte
d populations <sup>12</sup>.</font></p>     ^cY#11.htm##
01549000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704132700069002000701396#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#33#29#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The clinical and    epidemiological charact
erization of "who", "why", and "how" people continue    to die of AIDS in the er
a of ART in the country with the earliest and most comprehensive    scale up is 
vital to maximizing the benefits of care and treatment programs    worldwide. Co
hort studies are considered the gold standard for assessing factors    leading t
o death; however, such studies are rare in low- and middle-income countries    d
ue to their high cost, complexity, and need for long-term follow-up. The latter 
   requirement is especially challenging given the long survival time with AIDS 
   in the ART era. Other epidemiological designs, particularly the case-control 
   study, may offer cheaper and simpler alternatives that can be carried out in 
   low-income contexts while improving generalizibility to municipalities, state
s,    or countries. The present study analyzes the clinical and epidemiological 
profile    of a probabilistic sample of AIDS deaths in Brazil compared to compar
able controls    during the post-ART scale up period, with the aims of assessing
 risk factors    for death, population level differences in mortality, and assoc
iations with    prevailing practices in different care facilities and localities
.</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#34#30#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#35#31#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methods</b></font></p>     ^cY#11.htm##
00342000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012000069002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#36#32#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Overall study    design</u></b></font
></p>     ^cY#11.htm##
00682000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046000069002000700529#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#37#33#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study had two    components, one descri
ptive of persons living and dying of AIDS, and a second    using a case-control 
design to characterize factors associated with death due    to AIDS in Brazil in
 2003. We selected the year 2003 as marking a point in time    when ART had achi
eved ample and consistent coverage in Brazil and in which mortality    data woul
d be complete.</font></p>     ^cY#11.htm##
00377000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015500069002000700224#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#38#34#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Study population,    sampling methods
, and sources of data</u></b></font></p>     ^cY#11.htm##
00840000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061800069002000700687#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#39#35#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Cases were persons    dying of AIDS obtaine
d from a probabilistic sample of all AIDS deaths reported    to the Mortality In
formation System (SIM) in 2003. Controls were selected from    a random sample o
f persons living with AIDS registered as cases in the National    AIDS Cases Dat
abase (SINAN-AIDS) in 2003 matched to the same municipalities    from which the 
cases were randomly selected. Potential controls were excluded    if the patient
 was found to have died during the period under analysis (i.e.,    up to Decembe
r 31, 2003).</font></p>     ^cY#11.htm##
00935000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704071300069002000700782#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#40#36#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Selection of subjects    and collection of 
data were based on a combination of medical record abstraction    and use of nat
ional level databases. In Brazil, AIDS cases are mandatorily reported    to SINA
N-AIDS using standard data collection forms with a minimum number of    required
 data elements <sup>13</sup>. Additional information was obtained from    other 
nationwide databases, including mortality (SIM), the database recording    ART i
nitiation and dispensing (SICLOM), and the National Laboratory Database    (SISC
EL) recording CD4+ cell counts and HIV viral loads performed for individual    p
atients by each laboratory.</font></p>     ^cY#11.htm##
01977000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704175500069002000701824#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#41#37#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A random, one-stage    cluster sampling str
ategy was used to produce a study population proportional    to the national AID
S mortality burden. Using SIM, a roster was created that    included all municip
alities where at least 30 AIDS deaths occurred in 2003,    stratified by Brazil'
s five macro-regions (South, Southeast, Central, North,    and Northeast). Using
 a start determined from a random numbers table, a 1 in    3 sampling fraction f
rom the roster of municipalities was chosen, creating a    random one-third samp
le of all eligible municipalities in Brazil. The final    sample included (munic
ipality followed by respective state) Porto Velho (Rond&ocirc;nia)    in the Nor
th; Jo&atilde;o Pessoa (Para&iacute;ba), Macei&oacute; (Alagoas),    Recife (Per
nambuco), and Salvador (Bahia) in the Northeast; Goi&acirc;nia (Goi&aacute;s)   
 in the Central; S&atilde;o Gon&ccedil;alo (Rio de Janeiro), Uberaba (Minas Gera
is),    Guarulhos, Santo Andr&eacute;, Jacare&iacute;, Barretos, Cruzeiro, Guaru
-j&aacute;,    Franca, Catanduva, Presidente Prudente, and Mar&iacute;lia (S&ati
lde;o Paulo)    in the Southeast; and S&atilde;o Jos&eacute;, Itaja&iacute; (San
ta Catarina),    Rio Grande, and S&atilde;o Leopoldo (Rio Grande do Sul) in the 
South. In each    of these randomly selected municipalities, data were collected
 on all persons    dying of AIDS and an equal number of persons with AIDS alive 
through 31 December,    2003 through a simple random sample. We increased the to
tal number of randomly    selected controls by 20% to account for some controls 
being discovered as deceased    before 31 December 2003 upon data collection and
 to account for missing data.</font></p>     ^cY#11.htm##
01278000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704105600069002000701125#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#42#38#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To ensure that    all persons dying of AIDS
 in the municipalities were included, the research    team further investigated 
deaths not initially registered as due to AIDS but    ascribed to unknown causes
, as well as all deaths due to diseases associated    with AIDS, and deaths amon
g people aged 20-49 years old using a list of ICD-10    (International Classific
ation of Diseases, 10<sup>th</sup> Review) codes for    diseases and conditions 
associated with AIDS. This list was originally produced    by the <i>Programa de
 Aprimoramento de Informa&ccedil;&atilde;o sobre Mortalidade</i>    - Pro-AIM, f
rom S&atilde;o Paulo City, which has been investigating deaths putatively    ass
ociated with AIDS since 1990 <sup>14</sup>. Also in the selected municipalities,
    original medical records were reviewed to confirm AIDS diagnoses and cause o
f    death in the suspected cases. When such a death was found to be associated 
with    AIDS, the person was included as a "case".</font></p>     ^cY#11.htm##
01842000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704162000069002000701689#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#43#39#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Data collection    procedures comprised bot
h the abstraction of information from medical records    and downloading from th
e above-mentioned databases. Data were transcribed into    a standardized case r
eport form devised for the study. The form included age,    sex, place of reside
nce, time elapsed since first HIV diagnosis, stage of the    disease at the time
 HIV infection was diagnosed, therapeutic regimens used up    to the last appoin
tment or death, disease stage at ART initiation, adherence    to ART as recorded
 in the medical record, prophylaxis for opportunistic infections,    vaccines ad
ministered to the patients since HIV diagnosis, and all co-infections    and/or 
opportunistic infections/diseases. Additional information included the    type o
f clinic where the cases and controls received follow-up care (e.g., public,    
private, affiliated with universities, etc.) and whether they were general insti
tutions    treating different medical conditions or HIV specialized services. Da
ta were    abstracted by trained health professionals with previous experience i
n surveillance    under the supervision of a senior researcher in each of the se
lected municipalities.    A supervisor was in charge of reviewing each case repo
rt form and double-checking    for missing and contradictory information. Case r
eport forms were reviewed a    second time by the investigators, with remaining 
inconsistencies and missing    information summarized and sent back to local sup
ervisors for reconciliation    or further abstraction.</font></p>     ^cY#11.htm
##
00342000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704012000069002000700189#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#44#40#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Statistical    analysis</u></b></font
></p>     ^cY#11.htm##
01286000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704106400069002000701133#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#45#41#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Data were analyzed    following standard me
thods for non-paired case-control studies. Variables were    first assessed for 
their association with case status (i.e. death) in a bivariate    analysis. A fi
nal multivariable model was selected using stepwise forward logistic    regressi
on, with candidate variables being those associated with death at the    level o
f p &lt; 0.05 in bivariate analyses. To account for the study design,    regions
 were defined as strata, municipalities were defined as clusters, and    estimat
es were weighted for the relative frequency of AIDS deaths reported for    each 
macro-region. The multivariable model was fitted using the Wald test, considerin
g    a statistical significance of 0.05 for retention in the final model. The fi
nal    model also took into consideration the plausibility of associations based
 on    previous studies carried out in Brazil and elsewhere. Analyses were carri
ed    out using SPSS version 17 (SPSS Inc., Chicago, USA).</font></p>     ^cY#11
.htm##
00341000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011900069002000700188#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#46#42#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b><u>Ethical considerations</u></b></font>
</p>     ^cY#11.htm##
00846000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704062400069002000700693#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#47#43#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The risks associated    with this study wer
e minimized due to the fact all information was abstracted    from existing seco
ndary sources. No individual patients or their families were    contacted by the
 study team and abstracted data had all identifying elements    removed. The stu
dy protocol was reviewed and approved by the institutional review    boards (IRB
s) of Santa Casa de S&atilde;o Paulo, the Centro de Refer&ecirc;ncia    e Treina
mento DST/AIDS in S&atilde;o Paulo, and several of the selected municipalities, 
   where required.</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#48#44#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#49#45#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#11.htm##
00801000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057900069002000700648#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#50#46#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">From the 64 Brazilian    municipalities wit
h 30 or more AIDS deaths registered in 2003, we randomly selected    22 municipa
lities stratified on macro-region of Brazil. Within this sample,    1,214 deaths
 were recorded; records could be found for 1,004 (97.2%). Of the    randomly sel
ected 1,439 controls, records were found for 1,115 (92.1%). With    statistical 
adjustment for clustering by location and the proportion of AIDS    burden, the 
sample is approximately representative of the nation.</font></p>     ^cY#11.htm#
#
00684000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046200069002000700531#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#51#47#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The largest portion    of the sample (43.5%
) were from the Southeast region, followed by the Northeast    (28%), the South 
(19.1%), Central (6.7%), and North (2.7%). Most patients (72.3%)    received fre
e care in public services, with the remainder using services at    private hospi
tals, university hospitals, or other organizations with varying    forms of paym
ent or benefits.</font></p>     ^cY#11.htm##
00552000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704033000069002000700399#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#52#48#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The majority of    patients were male and u
nder the age of 40. Nearly half (49.3%) had not completed    basic or elementary
 education. Characteristics of the study population are shown    in <a href="/im
g/revistas/csp/v27s1/11t01.jpg">Table 1</a>.</font></p>     ^cY#11.htm##
00550000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704032800069002000700397#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#53#49#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Cases significantly    differed from contro
ls in being more likely to be in the lowest education level    (odds ratio - OR 
= 1.74, 95% confidence interval - 95%CI:1.07-2.84), and less    likely to be in 
the homosexual transmission category (OR =</font></p>     ^cY#11.htm##
01394000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704117200069002000701241#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#54#50#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">0.65, 95%CI 0.50-0.84),    and to have been
 diagnosed according to criteria other than CD4 &lt; 350 (OR    = 2.97, 95%CI: 1
.96-4.51) (<a href="/img/revistas/csp/v27s1/11t02.jpg">Table    2</a>). The fact
or most strongly associated with death was never having received    ART (OR = 6.
8, 95%CI: 4.28-8.92); interrupted ART was also significantly associated    with 
death (OR = 3.58, 95%CI: 2.65-4.85). Other care related variables associated    
with death included not receiving prophylaxis for opportunistic infections (OR  
  = 1.4, 95%CI: 1.03-1.89) and not receiving vaccines recommended for HIV-positi
ve    patients (OR = 3.74, 95%CI: 2.74-5.10). Cases were also more likely to hav
e    any disease associated with AIDS (OR = 2.44, 95%CI: 1.34-4.45) and tubercul
osis    in particular (OR = 1.65, 95%CI: 1.27-2.13). Time since the first HIV-po
sitive    test result being less than one year (OR = 4.39, 95%CI: 3.25-5.93) and
 time    from AIDS diagnosis to death (OR = 5.84, 95%CI: 4.47-7.65) which are ma
rkers    of late diagnosis, were both found to be associated with increased mort
ality.</font></p>     ^cY#11.htm##
01223000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704100100069002000701070#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#55#51#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In the multivariate    analysis (<a href="#
t3">Table 3</a>), interrupted (adjusted odds ratio - AOR    = 4.35, 95%CI: 3.15-
6.00) or no use of ART (AOR = 2.39, 95%CI: 1.57-3.65) was    the strongest predi
ctor of death, followed by late diagnosis (i.e., less than    one year since dia
gnosis, AOR = 3.95, 95%CI: 2.68-5.82). Even after controlling    for time with A
IDS, persons diagnosed by a criterion other than CD4 &lt; 350    had a higher li
kelihood of death (AOR = 1.65, 95%CI: 1.14-2.40). Patients not    receiving reco
mmended vaccines (AOR = 1.76, 95%CI: 1.21-2.56), patients presenting    diseases
 associated with AIDS (AOR = 2.19, 95%CI: 1.22-3.93), and patients diagnosed    
with tuberculosis (AOR = 1.50, 95%CI: 1.14-1.97) had higher odds of death. Being
    in the IDU exposure category maintained a borderline association with higher
    odds of death, while homo/bisexual exposure showed a protective effect.</fon
t></p>     ^cY#11.htm##
00255000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704003300069002000700102#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#56#52#article#121#<p><a name="t3"></a></p>  
   ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#57#53#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00298000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704007600069002000700145#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#58#54#article#121#<p align="center"><img src
="/img/revistas/csp/v27s1/11t03.jpg"></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#59#55#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#60#56#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#11.htm
##
00711000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704048900069002000700558#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#61#57#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Brazil is widely    recognized for its lead
ership in guaranteeing free and ample access to ART for    all its citizens. The
 period of most rapid scale up in Brazil occurred from    1996 to 2003, whereas 
for much of the rest of the world the wide availability    of ART began after 20
03. The experiences of Brazil can serve as a sentinel of    what may happen in t
he post-ART scale up world internationally.</font></p>     ^cY#11.htm##
01318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704109600069002000701165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#62#58#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The first lesson    learned from our study 
is that vital statistics, surveillance data, and monitoring    and evaluation sy
stems continue to detect significant rates of AIDS-related    mortality. We foun
d that not receiving ART was an independent predictor of death    among AIDS pat
ients in Brazil. While not surprising in itself, this finding    serves as a poi
gnant reminder that there are remaining disparities in access    to, delivery, a
nd uptake of ART in the post scale-up period <sup>15</sup> and    that AIDS cont
inues to be a significant cause of death and suffering. In addition    to the he
terogeneity of services and their quality, stigma and discrimination    can also
 hamper the benefits of ART <sup>16</sup> as the groups with the lowest    uptak
e of ART are those who are most severely marginalized. Further efforts    are ne
eded to achieve maximal ART coverage at a level of high quality, especially    a
mong the stigmatized or hidden populations, who are often at highest risk of    
infection.</font></p>     ^cY#11.htm##
01466000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704124400069002000701313#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#63#59#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We also found that    late diagnosis was an
 independent predictor of mortality, as indicated by the    significant associat
ion of death with shorter intervals of time from diagnosis    when the criteria 
for AIDS diagnosis were conditions associated with more severe    immune-suppres
sion. This finding was independent of ART initiation, indicating    that the ful
l benefits of treatment are not realized when patients are not identified    ear
lier in the course of infection. The finding speaks to the need for enhanced    
campaigns to make Brazilians more aware of the risks of HIV infection, to seek  
  HIV testing and, when positive, to be brought into care earlier. The results  
  of our study reinforce the wider benefit of earlier initiation of ART. The lik
elihood    of survival was greater for persons whose eligibility criterion was C
D4 count    &lt; 350, compared to those whose criterion was CD4 &lt; 200 or havi
ng an opportunistic    infection, even after controlling for initiating ART. The
se findings, evident    in our data from 1996 to 2003, are in agreement with the
 most recent treatment    guidelines issued several years later <sup>17</sup>.</
font></p>     ^cY#11.htm##
01307000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704108500069002000701154#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#64#60#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We are encouraged    that our analysis conf
irms that earlier initiation of ART adopted by Brazil    leads to a significant 
lengthening of survival. Other findings point to the    possibility of further r
educing disparities in AIDS mortality. For example,    vaccination, prevention o
f tuberculosis, and prevention of other AIDS associated    illnesses can be addr
essed in routine, comprehensive treatment of HIV-infected    persons. The higher
 mortality among largely impoverished IDU points to potentially    preventable c
o-morbidities and causes of death in these populations. It is possible    that i
n the face of the impressive impact of ART, care providers may neglect    to inc
lude prophylaxes and vaccines in the routine care, in spite of existing    guide
lines and specialized services. As survival of AIDS patients lengthens,    their
 longer term health care needs, including dealing with ART side-effects,    non-
AIDS related treatment, and prevention will increasingly need to be considered.<
/font></p>     ^cY#11.htm##
01005000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704078300069002000700852#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#65#61#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We recognize limitations    in our study. P
rimarily, we were constrained to using data recorded in electronic    databases 
or retrievable from local medical records, with the quality and completeness    
of the data varying by location and type of services. It is therefore likely    
that other factors associated with mortality may have gone undetected in our    
study. Second, there may be under-reporting of AIDS-specific mortality, also    
varying by region. There may also be regional variations in causes of death    a
mong AIDS patients that were not detected due to small samples for some of    th
e regions. The retrospective nature of the design also limits the interpretation
    of causality.</font></p>     ^cY#11.htm##
01350000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704112800069002000701197#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#66#62#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Despite the limitations,    our approach il
lustrates the benefits of routinely examining data available    in Brazil on the
 national level, enhanced by data retrievable at the municipal    and facility l
evel. While cohort studies remain the gold standard for assessing    predictors 
of mortality, the long period of time entailed in assessing mortality    preclud
es the use of cohort studies in many areas. Our methods provide a basis    for a
ssessing the progress of the national response to the HIV epidemic using    a co
ncrete and verifiable endpoint (i.e. mortality). Ultimately, the aims of    exte
nding life and reducing disparities in mortality need to be assessed with    dea
th as the outcome. The experience of Brazil with ART scale up may differ    from
 the experience of other nations, regions, and locations <sup>17</sup>;    never
theless, our approach is one that could be widely adopted as an efficient,    lo
w cost method for assessing what has been achieved and what remains to be    don
e in the response to HIV around the world.</font></p>     ^cY#11.htm##
00725000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704050300069002000700572#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#67#63#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Brazil has made    significant strides in p
roviding universal ART access to people living with    HIV/AIDS since 1997. Data
 presented in this study highlight additional areas    where improvements can be
 made: HIV testing and counseling and treatment should    be a priority both to 
favor earlier entrance into treatment and to decrease    costs associated with t
he management of patients with advanced immunodeficiency.</font></p>     ^cY#11.
htm##
00417000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704019500069002000700264#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#68#64#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Case management    strategies should target
 IDU including interventions tailored to the special    needs of IDU.</font></p>
     ^cY#11.htm##
00512000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704029000069002000700359#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#69#65#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Key points highlighted    by this study inc
luded the need to implement vaccinations as stated by the national    and intern
ational guidelines and to offer comprehensive management of HIV and    tuberculo
sis.</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#70#66#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#71#67#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#11.h
tm##
01350000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704112800069002000701197#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#72#68#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">M. A. S. M. Veras    was responsible for th
e study conception and design, coordinating data collection,    analysis and int
erpretation, writing up the article and approving the final    version. M. C. A.
 Ribeiro participated in the design, data analysis, write-up    and approval of 
the final version. L. F. Jamal participated in the design, collection    and ana
lysis of data, write up and approval of the final version. W. McFarland    contr
ibuted towards the design, data analysis, write-up and approval of the    final 
version. F. I. Bastos participated in the data analysis, write-up and    approva
l of the final version. K. B. Ribeiro collaborated in the design, data    analys
is, write-up and approval of the final version. R. B. Barata contributed    towa
rds the design, analysis, write-up and approval of the final version. J.    C. M
oraes participated in the design, creation of the data base and approval    of t
he final version of the article. A. L. Reingold participated in the design,    w
rite-up and approval of the final version.</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#73#69#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00328000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010600069002000700175#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#74#70#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Acknowledgements</b></font></p>     ^cY#
11.htm##
02712000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704249000069002000702559#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#75#71#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">We acknowledge    C&eacute;lia Landman Szwa
rcwald, for the sampling design and the AMA Brazil    Study Group and the others
 members of the group: Mauro Niskier Sanchez; Santa    Catarina State: Ros&aacut
e;lie Kupka Knoll and Gorki Grinberg (Itaja&iacute;),    Fernanda Gonzaga de Pai
va and Dione Lucia P. Laurindo (S&atilde;o Jos&eacute;);    Alagoas State: Denis
e Le&atilde;o and Alessandra Pereira Viana (Macei&oacute;);    Rio de Janeiro St
ate: Rozidaili Santos Santana and Renata de Castro Guimar&atilde;es    (S&atilde
;o Gon&ccedil;alo); Minas Gerais State: C&iacute;ntia Miziara Treige    and Sara
 Borges Ferreira Gomes (Uberaba); Rio Grande do Sul State: Beatriz Castro    and
 Clarice Batista (Rio Grande e S&atilde;o Leopoldo); Bahia State: Joselina    So
eiro, Ana Rosa G. Menezes and Ines Dourado (Salvador); Pernambuco State: Ana    
Maria de Brito (Recife); Para&iacute;ba State: Julia Em&iacute;lia Vaz Sette    
C&acirc;mara, Mary Anne Videres de Albuquerque and Lucineide Alves Braga (Jo&ati
lde;o    Pessoa); Rond&ocirc;nia: Luciene Zanol and Marluce Socorro Castilho da 
Silva    (Porto Velho); S&atilde;o Paulo State: Rosangela de Jesus and S&iacute;
lvia    Helena Watanabe Garcia (Barretos); Marines Velasques Dias and Durval Boc
hi (Presidente    Prudente); Ana Chong and F&aacute;tima Cotrim (Santo Andr&eacu
te;); Aline Pelegrini    de Oliveira and Marisa de Carvalho Braga (Jacare&iacute
;); Maria do C&eacute;u    Lazaro Freitas and M&aacute;rcia Aparecida Souza Ara&
uacute;jo (Guaruj&aacute;);    Arlindo Barreto and Selma Boragina (Catanduva); A
ntonio Jorge Salom&atilde;o,    Fl&aacute;via Carina de Souza Le&atilde;o and Is
abel Cristina Bortoletto (Franca);    Regina C&eacute;lia Zappa and Selma del De
bbio Zaroni (Cruzeiro); Ermelinda    Antonia Tom&eacute; and Dalel Haddad (Guaru
lhos); Helo&iacute;sa Ferrari Lombardi    and Eliane Regina Catalano Monteiro (M
ar&iacute;lia); Goi&aacute;s State: Rejane    Alves Fraissat and Gilma Moreira d
e Souza (Goi&acirc;nia). Coordena&ccedil;&atilde;o    de Campo e Supervis&atilde
;o: Maria de F&aacute;tima Jorge, Rejane Alves Fraissat,    Cristiane Gon&ccedil
;alves da Silva, Marileide Janu&aacute;ria de Vasconcelos.    Alunos de inicia&c
cedil;&atilde;o cient&iacute;fica: Renata Soares da Costa    Assis, Mariane G. W
yatt, Ivan Cese Marchetti, Taiana Cunha Ribeiro, Mariana    Vendramini Castrigna
no de Oliveira, Vanessa Alice Machado Amorim</font></p>     ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#76#72#article#121#<p>&nbsp;</p>     ^cY#11.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#77#73#article#121#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#11.htm
##
00535000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704029900071002000700370#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#78#74#article#121#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Brasil. Lei    nº. 9.313, 
de 13 de novembro de 1996. Disp&otilde;e sobre a distribui&ccedil;&atilde;o    g
ratuita de medicamentos aos portadores de HIV e doentes de AIDS. Di&aacute;rio  
  Oficial da Uni&atilde;o 1996; 14 nov.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#79#75#article#121#</font></p>     ^cY#11.htm
##
00426000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704019000071002000700261#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#80#76#article#121#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Boyd MA. Improvements    i
n antiretroviral therapy outcomes over calendar time. Curr Opin HIV AIDS 2009;  
  4:194-9.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#81#77#article#121#</font></p>     ^cY#11.htm
##
00422000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704018600071002000700257#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#82#78#article#121#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Nemes MI, Carvalho    HB, 
Souza MF. Antiretroviral therapy adherence in Brazil. AIDS 2004; 18 Suppl    3:S
15-20.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#83#79#article#121#</font></p>     ^cY#11.htm
##
00469000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023300071002000700304#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#84#80#article#121#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Marins JR, Jamal    LF, Ch
en SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic improvement in    surviv
al of Brazilian AIDS patients. AIDS 2003; 17:1675-82.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#85#81#article#121#</font></p>     ^cY#11.htm
##
00543000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704030700071002000700378#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#86#82#article#121#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Guibu IA, Barros    MBA, C
ordeiro MRD, Tayra A, Alves MCGP, Pereira GFM. Estudo de sobrevida de    pacient
es de AIDS no Brasil, 1998 a 1999 - fase I - regi&otilde;es Sul e Sudeste.    Bo
letim Epidemiol&oacute;gico AIDST 2008; V:51-3.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#87#83#article#121#</font></p>     ^cY#11.htm
##
00704000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704046800071002000700539#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#88#84#article#121#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Baggaley RF,    Petersen M
L, Soares MA, Boily M-C, Bastos FI. Human Immunodeficiency Virus:    resistance 
to antiretroviral drugs in developing countries. In: Sosa AJ, Byarugaba    DK, A
m&aacute;bile-Cuevas CF, Hsueh P-R, Kariuki S, Okeke IN, editors. Antimicrobial 
   resistance in developing countries (Emerging infectious diseases of the 21st 
   century). New York: Springer; 2009. p. 75-94.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#89#85#article#121#</font></p>     ^cY#11.htm
##
00528000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704029200071002000700363#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#90#86#article#121#7#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">7. Hacker MA, Petersen    ML,
 Enriquez M, Bastos FI. Highly active antiretroviral therapy in Brazil: the    c
hallenge of universal access in a context of social inequality. Rev Panam Salud 
   P&uacute;blica 2004; 16:8-83.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#91#87#article#121#</font></p>     ^cY#11.htm
##
00491000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025500071002000700326#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#92#88#article#121#8#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">8. Lowndes CM,    Bastos FI, 
Giffin KM, Vaz dos Reis AC, d'Orsi E, Alary M. Differential trends    in mortali
ty from AIDS in men and women in Brazil (1984-1995). AIDS 2000; 14:1269-73.    ^
cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#93#89#article#121#</font></p>     ^cY#11.htm
##
00403000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704016700071002000700238#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#94#90#article#121#9#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">9. Minist&eacute;rio    da Sa
&uacute;de. Boletim Epidemiol&oacute;gico AIDST 2008; Ano V, nº. 1.    ^cY#11.ht
m##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#95#91#article#121#</font></p>     ^cY#11.htm
##
00714000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704047700072002000700549#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#96#92#article#121#10#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">10. Minist&eacute;rio    da 
Sa&uacute;de. UNGASS - resposta brasileira 2005-2007: relat&oacute;rio de    pro
gresso do pa&iacute;s. <a href="http://www.aids.gov.br/data/documents/stored" ta
rget="_blank">http://www.aids.gov.br/data/documents/storedDocuments/%7BB8EF5DAF-
23AE-4891-AD36-1903553A3174%7D/%7B99A24D99-A80D-4E04-B7C2-786F24B5B689%7D/ungas2
008%20portug06-final.pdf</a>    (accessed on 09/Sep/2009).    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#97#93#article#121#</font></p>     ^cY#11.htm
##
00501000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000300069704026400072002000700336#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#98#94#article#121#11#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">11. Souza Jr. PRB,    Szwarc
wald CL, Castilho EA. Atraso na introdu&ccedil;&atilde;o de terapia antiretrovir
al    em pacientes infectados pelo HIV no Brasil, 2003-2006. Clinics 2007; 62:57
9-84.    ^cY#11.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#99#95#article#121#</font></p>     ^cY#11.htm
##
00591000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704035300073002000700426#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#100#96#article#121#12#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">12. Malta M, Bastos    FI, 
Silva CM, Pereira GF, Lucena FF, Fonseca MG, et al. Differential survival    ben
efit of universal HAART access in Brazil: a nation-wide comparison of injecting 
   drug users versus men who have sex with men. J Acquir Immune Defic Syndr 2009
;    52:629-35.    ^cY#11.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#101#97#article#121#</font></p>     ^cY#11.ht
m##
00632000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000300070704039400073002000700467#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#102#98#article#121#13#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">13. Revis&atilde;o    da de
fini&ccedil;&atilde;o nacional de caso de AIDS em indiv&iacute;duos com    13 an
os de idade ou mais, para fins de vigil&acirc;ncia epidemiol&oacute;gica.    <a 
href="http://www.aids.gov.br/udtv/link203.htm" target="_blank">http://www.aids.g
ov.br/udtv/link203.htm</a>    (accessed on 15/Oct/2009).    ^cY#11.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#103#99#article#121#</font></p>     ^cY#11.ht
m##
00616000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037700074002000700451#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#104#100#article#121#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Veras MASM,    Drumond
 Jr. M, Lira MTA. A import&acirc;ncia da AIDS como causa de morte no    munic&ia
cute;pio de S&atilde;o Paulo. In: Secretaria Municipal da Sa&uacute;de,    organ
izador. Colet&acirc;neas de Textos do Pro-AIM. S&atilde;o Paulo: Secretaria    M
unicipal da Sa&uacute;de; 2003. p. 30-1.    ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#105#101#article#121#</font></p>     ^cY#11.h
tm##
00504000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026500074002000700339#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#106#102#article#121#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Nemes MI, Melchior    
R, Basso CR, Castanheira ER, Britto-Alves MT, Conway S. The variability and    p
redictors of quality of AIDS care services in Brazil. BMC Health Serv Res 2009; 
   9:51.    ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#107#103#article#121#</font></p>     ^cY#11.h
tm##
00550000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704031100074002000700385#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#108#104#article#121#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Oliveira IB.    Acesso
 universal? Obst&aacute;culos ao acesso, continuidade do uso e g&ecirc;nero    e
m um servi&ccedil;o especializado em HIV/AIDS em Salvador, Bahia, Brasil. Cad   
 Sa&uacute;de P&uacute;blica 2009; 25 Suppl 2:S259-68.    ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#109#105#article#121#</font></p>     ^cY#11.h
tm##
00496000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704025700074002000700331#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#110#106#article#121#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Consenso terap&ecirc;u
tico.    <a href="http://www.aids.gov.br/assistencia/conso2.htm" target="_blank"
>http://www.aids.gov.br/assistencia/conso2.htm</a>    (accessed on 16/Dec/2009).
    ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#111#107#article#121#</font></p>     ^cY#11.h
tm##
00511000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027200074002000700346#v27
s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#p#112#108#article#121#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Grinsztejn    B, Velos
o VG, Friedman RK, Moreira RI, Luz PM, Campos DP, et al. Early mortality    and 
cause of deaths in patients using HAART in Brazil and the United States.    AIDS
 2009; 23:2107.    ^cY#11.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#113#109#article#121#</font></p>     ^cY#11.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#114#110#article#121#<p>&nbsp;</p>     ^cY#11
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#115#111#article#121#<p>&nbsp;</p>     ^cY#11
.htm##
00410000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704018600071002000700257#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#116#112#article#121#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:    ^c
Y#11.htm##
00261000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003700071002000700108#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#117#113#article#121#<br>   </b> M. A. S. M. 
Veras    ^cY#11.htm##
00270000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004600071002000700117#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#118#114#article#121#<br>   Departamento de M
edicina Social    ^cY#11.htm##
00315000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009100071002000700162#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#119#115#article#121#<br>   Faculdade de Ci&e
circ;ncias M&eacute;dicas da Santa Casa de S&atilde;o Paulo    ^cY#11.htm##
00266000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004200071002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#120#116#article#121#<br>   Rua Dr. Cesario M
ota Jr. 61    ^cY#11.htm##
00277000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005300071002000700124#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#121#117#article#121#<br>   S&atilde;o Paulo,
 SP 01221-020, Brasil    ^cY#11.htm##
00315000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009100071002000700162#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#122#118#article#121#<br>   <a href="mailto:m
aria.veras@gmail.com">maria.veras@gmail.com</a></font></p>     ^cY#11.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#123#119#article#121#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 05/Feb/2010    ^cY#11.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#124#120#article#121#<br>   Final version res
ubmitted on 02/Jun/2010    ^cY#11.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\11.htm#S#p#125#121#article#121#<br>   Approved on 05/Au
g/2010</font></p>     ^cY#11.htm##
00510000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680110007000700120139000770300
02400216710000200240065000900242064001300251865000900264002000700273#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\11.htm#S#c#126#1#article#18#1#Brasil#Lei nº. 9.313,
 de 13 de novembro de 1996: Dispõe sobre a distribuição gratuita de medicamentos
 aos portadores de HIV e doentes de AIDS^lpt#Diário Oficial da União#2#19961114#
1996; 14 nov#20110000#11.htm##
00469000000000253000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100015000700120071000850300
01900156710000200175065000900177064000500186031000200191014000600193865000900199
002000700208#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#127#2#article#18
#2#^rND^sBoyd^nMA#Improvements in antiretroviral therapy outcomes over calendar 
time^len#Curr Opin HIV AIDS#2#20090000#2009#4#194-9#20110000#11.htm##
00534000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100019000860100
01600105012004700121030000500168065000900173064000500182031000300187032000400190
014000700194865000900201002000700210035001000217801000500227#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\11.htm#S#c#128#3#article#18#3#^rND^sNemes^nMI#^rND^sCarvalh
o^nHB#^rND^sSouza^nMF#Antiretroviral therapy adherence in Brazil^len#AIDS#200400
00#2004#18#^s3#S15-20#20110000#11.htm#0269-9370#AIDS##
00638000000000337000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870100
01500103010001700118010001600135010001800151810000600169012006400175030000500239
06500090024406400050025303100030025801400080026186500090026900200070027803500100
0285801000500295#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#129#4#articl
e#18#4#^rND^sMarins^nJR#^rND^sJamal^nLF#^rND^sChen^nSY#^rND^sBarros^nMB#^rND^sHu
des^nES#^rND^sBarbosa^nAA#et al#Dramatic improvement in survival of Brazilian AI
DS patients^len#AIDS#20030000#2003#17#1675-82#20110000#11.htm#0269-9370#AIDS##
00659000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100018000860100
02000104010001500124010001800139010001900157012010100176030002900277710000200306
065000900308064000500317031000200322014000500324865000900329002000700338#v27s1#V
:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#130#5#article#18#5#^rND^sGuibu^nIA#^
rND^sBarros^nMBA#^rND^sCordeiro^nMRD#^rND^sTayra^nA#^rND^sAlves^nMCGP#^rND^sPere
ira^nGFM#Estudo de sobrevida de pacientes de AIDS no Brasil, 1998 a 1999 - fase 
I - regiões Sul e Sudeste^lpt#Boletim Epidemiológico AIDST#2#20080000#2008#V#51-
3#20110000#11.htm##
00894000000000373000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100019000890100
01700108010001700125010001700142012009300159016001500252016002000267016002500287
01600170031201600170032901600160034601801040036206600090046606200090047506500090
0484064000500493014000600498865000900504002000700513#v27s1#V:\SciELO\serial\csp\
v27s1\markup\11.htm#S#c#131#6#article#18#6#^rND^sBaggaley^nRF#^rND^sPetersen^nML
#^rND^sSoares^nMA#^rND^sBoily^nM-C#^rND^sBastos^nFI#Human Immunodeficiency Virus
: resistance to antiretroviral drugs in developing countries^len#^rED^sSosa^nAJ#
^rED^sByarugaba^nDK#^rED^sAmábile-Cuevas^nCF#^rED^sHsueh^nP-R#^rED^sKariuki^nS#^
rED^sOkeke^nIN#Antimicrobial resistance in developing countries (Emerging infect
ious diseases of the 21st century)^len#New York#Springer#20090000#2009#75-94#201
10000#11.htm##
00615000000000289000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100019000870100
01800106010001700124012012000141030002400261710000200285065000900287064000500296
031000300301014000500304865000900309002000700318#v27s1#V:\SciELO\serial\csp\v27s
1\markup\11.htm#S#c#132#7#article#18#7#^rND^sHacker^nMA#^rND^sPetersen^nML#^rND^
sEnriquez^nM#^rND^sBastos^nFI#Highly active antiretroviral therapy in Brazil: th
e challenge of universal access in a context of social inequality^len#Rev Panam 
Salud Pública#2#20040000#2004#16#8-83#20110000#11.htm##
00649000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01700105010002300122010001600145010001500161012008600176030000500262065000900267
06400050027603100030028101400080028486500090029200200070030103500100030880100050
0318#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#133#8#article#18#8#^rND^
sLowndes^nCM#^rND^sBastos^nFI#^rND^sGiffin^nKM#^rND^sVaz dos Reis^nAC#^rND^sd'Or
si^nE#^rND^sAlary^nM#Differential trends in mortality from AIDS in men and women
 in Brazil (1984-1995)^len#AIDS#20000000#2000#14#1269-73#20110000#11.htm#0269-93
70#AIDS##
00383000000000229000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680110020000700300029000907100
00200119065000900121064000500130032000200135865000900137002000700146#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\11.htm#S#c#134#9#article#18#9#Ministério da Saúde#B
oletim Epidemiológico AIDST#2#20080000#2008#1#20110000#11.htm##
00593000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170020000720180075000920370
17100167110000900338109001200347865000900359002000700368#v27s1#V:\SciELO\serial\
csp\v27s1\markup\11.htm#S#c#135#10#article#18#10#Ministério da Saúde#UNGASS - re
sposta brasileira 2005-2007: relatório de progresso do país^lpt#http://www.aids.
gov.br/data/documents/storedDocuments/%7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D
/%7B99A24D99-A80D-4E04-B7C2-786F24B5B689%7D/ungas2008%20portug06-final.pdf#20090
909#09/Sep/2009#20110000#11.htm##
00594000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100021000930100
01900114012010500133030000800238065000900246064000500255031000300260014000700263
865000900270002000700279035001000286801000800296#v27s1#V:\SciELO\serial\csp\v27s
1\markup\11.htm#S#c#136#11#article#18#11#^rND^sSouza Jr.^nPRB#^rND^sSzwarcwald^n
CL#^rND^sCastilho^nEA#Atraso na introdução de terapia antiretroviral em paciente
s infectados pelo HIV no Brasil, 2003-2006^lpt#Clinics#20070000#2007#62#579-84#2
0110000#11.htm#1807-5932#Clinics##
00776000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100017000870100
01600104010001800120010001700138010001800155810000600173012015300179030002800332
06500090036006400050036903100030037401400070037786500090038400200070039303500100
0400801002800410#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#137#12#artic
le#18#12#^rND^sMalta^nM#^rND^sBastos^nFI#^rND^sSilva^nCM#^rND^sPereira^nGF#^rND^
sLucena^nFF#^rND^sFonseca^nMG#et al#Differential survival benefit of universal H
AART access in Brazil: a nation-wide comparison of injecting drug users versus m
en who have sex with men^len#J Acquir Immune Defic Syndr#20090000#2009#52#629-35
#20110000#11.htm#0894-9255#J Acquir Immune Defic Syndr##
00488000000000205000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690180133000720370040002051100
00900245109001200254865000900266002000700275#v27s1#V:\SciELO\serial\csp\v27s1\ma
rkup\11.htm#S#c#138#13#article#18#13#Revisão da definição nacional de caso de AI
DS em indivíduos com 13 anos de idade ou mais, para fins de vigilância epidemiol
ógica^lpt#http://www.aids.gov.br/udtv/link203.htm#20091015#15/Oct/2009#20110000#
11.htm##
00630000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100021000900100
01600111012007200127017003000199018003600229066001000265062003000275065000900305
064000500314014000500319865000900324002000700333#v27s1#V:\SciELO\serial\csp\v27s
1\markup\11.htm#S#c#139#14#article#18#14#^rND^sVeras^nMASM#^rND^sDrumond Jr.^nM#
^rND^sLira^nMTA#A importância da AIDS como causa de morte no município de São Pa
ulo^lpt#Secretaria Municipal da Saúde#Coletâneas de Textos do Pro-AIM^lpt#São Pa
ulo#Secretaria Municipal da Saúde#20030000#2003#30-1#20110000#11.htm##
00632000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100016000720100018000880100
01600106010002200122010002300144010001600167012007800183030002000261710000200281
065000900283064000500292031000200297014000300299865000900302002000700311#v27s1#V
:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#140#15#article#18#15#^rND^sNemes^nMI
#^rND^sMelchior^nR#^rND^sBasso^nCR#^rND^sCastanheira^nER#^rND^sBritto-Alves^nMT#
^rND^sConway^nS#The variability and predictors of quality of AIDS care services 
in Brazil^len#BMC Health Serv Res#2#20090000#2009#9#51#20110000#11.htm##
00563000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100019000720120141000910300
01800232710000200250065000900252064000500261031000300266032000400269014000800273
865000900281002000700290#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#141#
16#article#18#16#^rND^sOliveira^nIB#Acesso universal?: Obstáculos ao acesso, con
tinuidade do uso e gênero em um serviço especializado em HIV/AIDS em Salvador, B
ahia, Brasil^lpt#Cad Saúde Pública#2#20090000#2009#25#^s2#S259-68#20110000#11.ht
m##
00386000000000205000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690180025000720370046000971100
00900143109001200152865000900164002000700173#v27s1#V:\SciELO\serial\csp\v27s1\ma
rkup\11.htm#S#c#142#17#article#18#17#Consenso terapêutico^lpt#http://www.aids.go
v.br/assistencia/conso2.htm#20091216#16/Dec/2009#20110000#11.htm##
00675000000000337000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100017000920100
01900109010001800128010001400146010001700160810000600177012009600183030000500279
06500090028406400050029303100030029801400050030186500090030600200070031503500100
0322801000500332#v27s1#V:\SciELO\serial\csp\v27s1\markup\11.htm#S#c#143#18#artic
le#18#18#^rND^sGrinsztejn^nB#^rND^sVeloso^nVG#^rND^sFriedman^nRK#^rND^sMoreira^n
RI#^rND^sLuz^nPM#^rND^sCampos^nDP#et al#Early mortality and cause of deaths in p
atients using HAART in Brazil and the United States^len#AIDS#20090000#2009#23#21
07#20110000#11.htm#0269-9370#AIDS##
00262000000000169000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630910009000650920007000740020007000817030
00400088#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#o#1#1#article#1#201104
11#073721#12.htm#194##
03949000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400130013703500100015001201090
01600120106002690100032003750100044004070100039004510700073004900700087005630831
18200650085001001832085004701842085003101889085003101920085003001951083105901981
08500100304008500510305008500550310108500330315608500290318911700080321807200030
32261120009032291110012032381160009032501150012032591140009032711130012032800020
00703292#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#h#2#1#article#1#oa#en#
br1.1#1#4.0#GRA#TAB#12#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs114^ls128#0
102-311X#Evaluation of strategies by the Brazilian Ministry of Health to stimula
te the municipal response to AIDS^len#Avaliação de estratégias do Ministério da 
Saúde para incentivar a resposta municipal a AIDS no Brasil^lpt#^rND^1A01^nAlexa
ndre^sGrangeiro#^rND^1A02^nMaria Mercedes Loureiro^sEscuder#^rND^1A01^nEuclides 
Ayres de^sCastilho#Universidade de São Paulo^iA01^1Faculdade de Medicina^cSão Pa
ulo^pBrasil#Secretaria de Estado da Saúde de São Paulo^iA02^1Instituto de Saúde^
cSão Paulo^pBrasil#^len^aThe aim of this study was to evaluate strategies by the
 Brazilian Ministry of Health to expand the municipal response to AIDS. Cities "
included" and "not included" in Federal strategies for "municipalization" of the
 response were compared according to the response profile and trends in the epid
emic. Multinomial logistic regression was used, among other statistical procedur
es. Municipalities included from 1994 to 1998 showed higher chances of providing
 HIV diagnostic testing [OR = 15.0; 95%CI: 5.6-40.1], of having AIDS services [O
R = 18.4; 95%CI: 8.4-40.5], and reducing cases involving heterosexual [OR = 3.1;
 95%CI: 1.4-7.3], homosexual/bisexual [OR = 3.0; 95%CI: 1.4-6.2], and IDU transm
ission [OR = 6.6; 95%CI: 2.9-14.9] as compared to those "included in 2003" and "
not included". There were no associations between the included Municipalities, g
reater coverage in prevention, the reduction in cases due to vertical transmissi
on or blood transfusion, or mortality rates. Municipalities with a more structur
ed response were associated with better results. The findings suggest that the m
unicipalization policy contributed to improvement in the local response to AIDS.
#^ddecs^i1#^tm^len^kAcquired Immunodeficiency Syndrome^i1#^tm^len^kProgram Evalu
ation^i1#^tm^len^kDisease Prevention^i1#^tm^len^kDescentralization^i1#^lpt^aAval
iar as estratégias do Ministério da Saúde para ampliar a resposta municipal a AI
DS. Cidades "incluídas" e "não incluídas" nas estratégias federais de municipali
zação foram comparadas segundo perfil da resposta e da epidemia. Regressão logís
tica multinomial foi usada, entre outros procedimentos estatísticos. Municípios 
incluídos entre 1994/98 apresentaram maior chance de ofertar o diagnóstico do HI
V [OR = 15,0; IC95%: 5,6-40,1], possuir serviços de AIDS [OR = 18,4; IC95%: 8,4-
40,5] e reduzir casos por transmissão heterossexual [OR = 3,1; IC95%: 1,4-7,3], 
homo/bissexual [OR = 3,0; IC95%: 1,4-6,2] e uso de drogas injetáveis [OR = 6,6; 
IC95%: 2,9-14,9] do que os "incluídos em 2003" e os "não incluídos". Não houve a
ssociações entre municípios incluídos, a maior cobertura de prevenção e a reduçã
o de casos por transmissão vertical, transfusão de sangue e taxas de mortalidade
. Municípios com resposta mais estruturada associam-se a melhores resultados. Os
 achados sugerem que a política de municipalização contribuiu para aprimorar a r
esposta.#^ddecs^i2#^tm^lpt^kSíndrome de Imunodeficiência Adquirida^i2#^tm^lpt^kA
valiação de Programas e Projetos de Saúde^i2#^tm^lpt^kPrevenção de Doenças^i2#^t
m^lpt^kDescentralização^i2#vancouv#31#20091214#14/Dec/2009#20100406#06/Apr/2010#
20100419#19/Apr/2010#12.htm##
03963000000000649000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630710003000650400003000680010006000710420
00200077120000400079038000400083038000400087121000300091049000700094158000300101
03000190010403100030012313100020012606500090012801400130013703500100015001201160
01600120113002760100032003890100044004210100039004650700073005040700087005770831
18200664085001001846085004701856085003101903085003101934085003001965083105901995
08500100305408500510306408500550311508500330317008500290320311700080323207200030
32401120009032431110012032521160009032641150012032731140009032851130012032940020
00703306#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#f#3#1#article#1#oa#en#
br1.1#1#4.0#GRA#TAB#12#CSP330#nd#Cad. Saúde Pública#27#1#20110000#^fs114^ls128#0
102-311X#<b>Evaluation of strategies by the Brazilian Ministry of Health to stim
ulate the municipal response to AIDS</b>^len#<b>Avaliação de estratégias do Mini
stério da Saúde para incentivar a resposta municipal a AIDS no Brasil</b>^lpt#^r
ND^1A01^nAlexandre^sGrangeiro#^rND^1A02^nMaria Mercedes Loureiro^sEscuder#^rND^1
A01^nEuclides Ayres de^sCastilho#Universidade de São Paulo^iA01^1Faculdade de Me
dicina^cSão Paulo^pBrasil#Secretaria de Estado da Saúde de São Paulo^iA02^1Insti
tuto de Saúde^cSão Paulo^pBrasil#^len^aThe aim of this study was to evaluate str
ategies by the Brazilian Ministry of Health to expand the municipal response to 
AIDS. Cities "included" and "not included" in Federal strategies for "municipali
zation" of the response were compared according to the response profile and tren
ds in the epidemic. Multinomial logistic regression was used, among other statis
tical procedures. Municipalities included from 1994 to 1998 showed higher chance
s of providing HIV diagnostic testing [OR = 15.0; 95%CI: 5.6-40.1], of having AI
DS services [OR = 18.4; 95%CI: 8.4-40.5], and reducing cases involving heterosex
ual [OR = 3.1; 95%CI: 1.4-7.3], homosexual/bisexual [OR = 3.0; 95%CI: 1.4-6.2], 
and IDU transmission [OR = 6.6; 95%CI: 2.9-14.9] as compared to those "included 
in 2003" and "not included". There were no associations between the included Mun
icipalities, greater coverage in prevention, the reduction in cases due to verti
cal transmission or blood transfusion, or mortality rates. Municipalities with a
 more structured response were associated with better results. The findings sugg
est that the municipalization policy contributed to improvement in the local res
ponse to AIDS.#^ddecs^i1#^tm^len^kAcquired Immunodeficiency Syndrome^i1#^tm^len^
kProgram Evaluation^i1#^tm^len^kDisease Prevention^i1#^tm^len^kDescentralization
^i1#^lpt^aAvaliar as estratégias do Ministério da Saúde para ampliar a resposta 
municipal a AIDS. Cidades "incluídas" e "não incluídas" nas estratégias federais
 de municipalização foram comparadas segundo perfil da resposta e da epidemia. R
egressão logística multinomial foi usada, entre outros procedimentos estatístico
s. Municípios incluídos entre 1994/98 apresentaram maior chance de ofertar o dia
gnóstico do HIV [OR = 15,0; IC95%: 5,6-40,1], possuir serviços de AIDS [OR = 18,
4; IC95%: 8,4-40,5] e reduzir casos por transmissão heterossexual [OR = 3,1; IC9
5%: 1,4-7,3], homo/bissexual [OR = 3,0; IC95%: 1,4-6,2] e uso de drogas injetáve
is [OR = 6,6; IC95%: 2,9-14,9] do que os "incluídos em 2003" e os "não incluídos
". Não houve associações entre municípios incluídos, a maior cobertura de preven
ção e a redução de casos por transmissão vertical, transfusão de sangue e taxas 
de mortalidade. Municípios com resposta mais estruturada associam-se a melhores 
resultados. Os achados sugerem que a política de municipalização contribuiu para
 aprimorar a resposta.#^ddecs^i2#^tm^lpt^kSíndrome de Imunodeficiência Adquirida
^i2#^tm^lpt^kAvaliação de Programas e Projetos de Saúde^i2#^tm^lpt^kPrevenção de
 Doenças^i2#^tm^lpt^kDescentralização^i2#vancouv#31#20091214#14/Dec/2009#2010040
6#06/Apr/2010#20100419#19/Apr/2010#12.htm##
04153000000000673000450000400060000070200410000670500020004770600020004970000020
00517010002000537090008000557080002000630640007000650710003000720400003000750010
00600078042000200084120000400086038000400090038000400094121000300098049000700101
15800030010803000190011103100030013013100020013306500090013501400130014403500100
01570120109001670120106002760100032003820100044004140100039004580700075004970700
08900572083121700661085001001878085004701888085003101935085003101966085003001997
08311040202708500100313108500510314108500550319208500330324708500290328011700080
33090720003033171120009033201110012033291160009033411150012033501140009033621130
01203371002000703383008008903390#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#
S#l#4#1#article#1#^a2011#oa#en#br1.1#1#4.0#gra#tab#12#CSP330#nd#Cad. saúde públi
ca#27#1#20110000#^fs114^ls128#0102-311X#Evaluation of strategies by the Brazilia
n Ministry of Health to stimulate the municipal response to AIDS^len#Avaliação d
e estratégias do Ministério da Saúde para incentivar a resposta municipal a AIDS
 no Brasil^lpt#^rND^1A01^nAlexandre^sGrangeiro#^rND^1A02^nMaria Mercedes Loureir
o^sEscuder#^rND^1A01^nEuclides Ayres de^sCastilho#^iA01^1Universidade de São Pau
lo^2Faculdade de Medicina^cSão Paulo^pBrasil#^iA02^1Secretaria de Estado da Saúd
e de São Paulo^2Instituto de Saúde^cSão Paulo^pBrasil#^len^aThe aim of this stud
y was to evaluate strategies by the Brazilian Ministry of Health to expand the m
unicipal response to AIDS. Cities "included" and "not included" in Federal strat
egies for "municipalization" of the response were compared according to the resp
onse profile and trends in the epidemic. Multinomial logistic regression was use
d, among other statistical procedures. Municipalities included from 1994 to 1998
 showed higher chances of providing HIV diagnostic testing [OR = 15.0; 95 percen
tCI: 5.6-40.1], of having AIDS services [OR = 18.4; 95 percentCI: 8.4-40.5], and
 reducing cases involving heterosexual [OR = 3.1; 95 percentCI: 1.4-7.3], homose
xual/bisexual [OR = 3.0; 95 percentCI: 1.4-6.2], and IDU transmission [OR = 6.6;
 95 percentCI: 2.9-14.9] as compared to those "included in 2003" and "not includ
ed". There were no associations between the included Municipalities, greater cov
erage in prevention, the reduction in cases due to vertical transmission or bloo
d transfusion, or mortality rates. Municipalities with a more structured respons
e were associated with better results. The findings suggest that the municipaliz
ation policy contributed to improvement in the local response to AIDS.#^ddecs^i1
#^tm^len^kAcquired Immunodeficiency Syndrome^i1#^tm^len^kProgram Evaluation^i1#^
tm^len^kDisease Prevention^i1#^tm^len^kDescentralization^i1#^lpt^aAvaliar as est
ratégias do Ministério da Saúde para ampliar a resposta municipal a AIDS. Cidade
s "incluídas" e "não incluídas" nas estratégias federais de municipalização fora
m comparadas segundo perfil da resposta e da epidemia. Regressão logística multi
nomial foi usada, entre outros procedimentos estatísticos. Municípios incluídos 
entre 1994/98 apresentaram maior chance de ofertar o diagnóstico do HIV [OR = 15
,0; IC95 por cento: 5,6-40,1], possuir serviços de AIDS [OR = 18,4; IC95 por cen
to: 8,4-40,5] e reduzir casos por transmissão heterossexual [OR = 3,1; IC95 por 
cento: 1,4-7,3], homo/bissexual [OR = 3,0; IC95 por cento: 1,4-6,2] e uso de dro
gas injetáveis [OR = 6,6; IC95 por cento: 2,9-14,9] do que os "incluídos em 2003
" e os "não incluídos". Não houve associações entre municípios incluídos, a maio
r cobertura de prevenção e a redução de casos por transmissão vertical, transfus
ão de sangue e taxas de mortalidade. Municípios com resposta mais estruturada as
sociam-se a melhores resultados. Os achados sugerem que a política de municipali
zação contribuiu para aprimorar a resposta.#^ddecs^i2#^tm^lpt^kSíndrome de Imuno
deficiência Adquirida^i2#^tm^lpt^kAvaliação de Programas e Projetos de Saúde^i2#
^tm^lpt^kPrevenção de Doenças^i2#^tm^lpt^kDescentralização^i2#vancouv#31#2009121
4#14/Dec/2009#20100406#06/Apr/2010#20100419#19/Apr/2010#12.htm#Internet^ihttp://
www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-311X2011001300012##
00349000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704012900067002000700196#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#5#1#article#159#<p align="right"><font face=
"Verdana, Arial, Helvetica, sans-serif" size="2"><b>REVIEW    </b> REVIS&Atilde;
O</font></p>     ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#6#2#article#159#<p>&nbsp;</p>     ^cY#12.htm
##
00438000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704021800067002000700285#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#7#3#article#159#<p><a name="top"></a><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="4"><b>Evaluation    of strateg
ies by the Brazilian Ministry of Health to stimulate the municipal    response t
o AIDS</b></font></p>     ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704002200067002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#8#4#article#159#<p>&nbsp;</p>     ^cY#12.htm
##
00452000000000145000450000400060000070200410000670500020004770600020004970000020
0051701000200053709000800055708000400063704023200067002000700299#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#9#5#article#159#<p><font face="Verdana, Aria
l, Helvetica, sans-serif" size="3"><b>Avalia&ccedil;&atilde;o    de estrat&eacut
e;gias do Minist&eacute;rio da Sa&uacute;de para incentivar a    resposta munici
pal a AIDS no Brasil</b></font></p>     ^cY#12.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#10#6#article#159#<p>&nbsp;</p>     ^cY#12.ht
m##
00243000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704002200068002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#11#7#article#159#<p>&nbsp;</p>     ^cY#12.ht
m##
00432000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704021100068002000700279#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#12#8#article#159#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"> <b>Alexandre Grangeiro<sup>I</sup>;    Mari
a Mercedes Loureiro Escuder<sup>II</sup>; Euclides Ayres de Castilho<sup>I</sup>
</b></font></p>     ^cY#12.htm##
00388000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000200054709000800056708000400064704016700068002000700235#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#13#9#article#159#<p><font face="Verdana, Ari
al, Helvetica, sans-serif" size="2"><sup>I</sup>Faculdade    de Medicina, Univer
sidade de S&atilde;o Paulo, S&atilde;o Paulo, Brasil    ^cY#12.htm##
00374000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704015200069002000700221#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#14#10#article#159#<br>   <sup>II</sup>Instit
uto de Sa&uacute;de, Secretaria de Estado da Sa&uacute;de    de S&atilde;o Paulo
, S&atilde;o Paulo, Brasil</font></p>     ^cY#12.htm##
00339000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704011700069002000700186#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#15#11#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><a href="#back">Correspondence</a></font></
p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#16#12#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00266000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704004400069002000700113#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#17#13#article#159#<p>&nbsp;</p> <hr size="1"
 noshade>     ^cY#12.htm##
00320000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009800069002000700167#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#18#14#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>ABSTRACT</b></font></p>     ^cY#12.htm##
01568000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704134600069002000701415#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#19#15#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The aim of this    study was to evaluate st
rategies by the Brazilian Ministry of Health to expand    the municipal response
 to AIDS. Cities "included" and "not included" in Federal    strategies for "mun
icipalization" of the response were compared according to    the response profil
e and trends in the epidemic. Multinomial logistic regression    was used, among
 other statistical procedures. Municipalities included from 1994    to 1998 show
ed higher chances of providing HIV diagnostic testing &#91;OR =    15.0; 95%CI: 
5.6-40.1&#93;, of having AIDS services &#91;OR = 18.4; 95%CI: 8.4-40.5&#93;,    
and reducing cases involving heterosexual &#91;OR = 3.1; 95%CI: 1.4-7.3&#93;,   
 homosexual/bisexual &#91;OR = 3.0; 95%CI: 1.4-6.2&#93;, and IDU transmission   
 &#91;OR = 6.6; 95%CI: 2.9-14.9&#93; as compared to those "included in 2003"    
and "not included". There were no associations between the included Municipaliti
es,    greater coverage in prevention, the reduction in cases due to vertical tr
ansmission    or blood transfusion, or mortality rates. Municipalities with a mo
re structured    response were associated with better results. The findings sugg
est that the    municipalization policy contributed to improvement in the local 
response to    AIDS.</font></p>     ^cY#12.htm##
00423000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704020100069002000700270#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#20#16#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Acquired Immunodeficiency    Syndrome; Prog
ram Evaluation; Disease Prevention; Descentralization</font></p> <hr size="1" no
shade>     ^cY#12.htm##
00318000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009600069002000700165#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#21#17#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2"><b>RESUMO</b></font></p>     ^cY#12.htm##
01700000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704147800069002000701547#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#22#18#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Avaliar as estrat&eacute;gias    do Minist&
eacute;rio da Sa&uacute;de para ampliar a resposta municipal a AIDS.    Cidades 
"inclu&iacute;das" e "n&atilde;o inclu&iacute;das" nas estrat&eacute;gias    fed
erais de municipaliza&ccedil;&atilde;o foram comparadas segundo perfil da    res
posta e da epidemia. Regress&atilde;o log&iacute;stica multinomial foi usada,   
 entre outros procedimentos estat&iacute;sticos. Munic&iacute;pios inclu&iacute;
dos    entre 1994/98 apresentaram maior chance de ofertar o diagn&oacute;stico d
o HIV    &#91;OR = 15,0; IC95%: 5,6-40,1&#93;, possuir servi&ccedil;os de AIDS &
#91;OR    = 18,4; IC95%: 8,4-40,5&#93; e reduzir casos por transmiss&atilde;o he
terossexual    &#91;OR = 3,1; IC95%: 1,4-7,3&#93;, homo/bissexual &#91;OR = 3,0;
 IC95%: 1,4-6,2&#93;    e uso de drogas injet&aacute;veis &#91;OR = 6,6; IC95%: 
2,9-14,9&#93; do que    os "inclu&iacute;dos em 2003" e os "n&atilde;o inclu&iac
ute;dos". N&atilde;o    houve associa&ccedil;&otilde;es entre munic&iacute;pios 
inclu&iacute;dos, a    maior cobertura de preven&ccedil;&atilde;o e a redu&ccedi
l;&atilde;o de casos    por transmiss&atilde;o vertical, transfus&atilde;o de sa
ngue e taxas de mortalidade.    Munic&iacute;pios com resposta mais estruturada 
associam-se a melhores resultados.    Os achados sugerem que a pol&iacute;tica d
e municipaliza&ccedil;&atilde;o contribuiu    para aprimorar a resposta.</font><
/p>     ^cY#12.htm##
00524000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704030200069002000700371#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#23#19#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">S&iacute;ndrome    de Imunodefici&ecirc;nci
a Adquirida; Avalia&ccedil;&atilde;o de Programas e    Projetos de Sa&uacute;de;
 Preven&ccedil;&atilde;o de Doen&ccedil;as; Descentraliza&ccedil;&atilde;o</font
></p> <hr size="1" noshade>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#24#20#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#25#21#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#26#22#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Introduction</b></font></p>     ^cY#12.h
tm##
00694000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704047200069002000700541#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#27#23#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Brazil is known    for the results achieved
 in its response to the AIDS epidemic <sup>1,2,3</sup>,    as evidenced by the s
tabilization in the HIV infection rates and number of AIDS    cases <sup>4</sup>
, the increase in safe sex practices <sup>5,6</sup>, reduction    in situations 
involving prejudice <sup>7</sup>, and improvement in quality of    life for pers
ons with HIV <sup>8</sup>.</font></p>     ^cY#12.htm##
00691000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046900069002000700538#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#28#24#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Various factors    have been identified as 
responsible for achieving these results <sup>1,2,9</sup>,    including the early
 Brazilian response, beginning in the early 1980s with the    adoption of compre
hensive guidelines that included universality, comprehensive    care, defense of
 the rights of the most extensively affected groups, and participation    by bro
ad segments of society.</font></p>     ^cY#12.htm##
00758000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704053600069002000700605#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#29#25#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Another important    contribution came from
 the organizational structure of the Unified National    Health System (SUS) <su
p>1,2,9</sup>. Based on decentralization (including down    to the municipal lev
el), unified managerial control at each level in the system,    and social contr
ol, the structure enabled States and Municipalities to implement    policies for
 prevention and care of sexually transmitted infections (STI) and    AIDS <sup>4
,10</sup>.</font></p>     ^cY#12.htm##
01033000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081100069002000700880#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#30#26#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Policies implemented    at the local level 
largely reflected initiatives by the Ministry of Health,    that, since 1994, in
duced the strengthening of AIDS programs in areas where    the epidemic was expa
nding significantly. This article will refer to the Ministry    of Health's indu
ction of the local response as "strategies for municipalization    or expansion 
of the response to AIDS", a process that was implemented in two    phases. The f
irst, lasting from 1994 to 2002, was partially financed through    loan agreemen
ts with the World Bank <sup>11</sup>, subsidizing activities by    27 State Heal
th Departments and 151 priority Municipalities, which at the time    accounted f
or more than 70% of the AIDS cases in Brazil.</font></p>     ^cY#12.htm##
00944000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072200069002000700791#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#31#27#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The second phase,    launched in 2003, was 
charaterized by the institutionalization of financing    for AIDS-related activi
ties according to the rules of the SUS. To this end,    it was used as a referen
ce so-called "Incentive Policy", which allow the transfer    of additional Feder
al funds to the States and Municipalities. This transfer    is conditioned on th
e implementation of specific actions and compliance with    prerequisites, in th
e case of AIDS, for example, co-financing of activities    and annual submission
 of Action and Target Plans approved by the Health Councils    and Inter-Manager
ial Commissions <sup>12,13,14</sup>.</font></p>     ^cY#12.htm##
00973000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075100069002000700820#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#32#28#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Since the establishment    of the Incentive
 Policy for AIDS programs, various evaluations have been performed    <sup>12,13
,14</sup>, showing, among other results, an increase in the number    of Municip
alities included in the strategies for expansion of the response,    which were 
selected on the basis of recommendations by the Bipartite Inter-Managerial    Co
mmissions (consisting of State and Municipal Secretaries of Health) and epidemio
logical    relevance, defined by the number of AIDS cases, incidence rate, and p
opulation    and size. There was also an increase in funds transferred by the Mi
nistry of    Health and an improvement in the management process.</font></p>    
 ^cY#12.htm##
00952000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704073000069002000700799#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#33#29#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Due to the short    time transpired since i
mplementation, the evaluations have not allowed more    in-depth knowledge of th
e profile of activities and their relationship to the    epidemic. This motivate
d the Department of STD, AIDS, and Viral Hepatitis under    the Ministry of Heal
th (PNDST/AIDS) to request a new study. Some of the findings    are presented in
 this article and address two questions: "<i>What are the characteristics    of 
the response and of the Municipalities included in the Incentive Policy</i>?"   
 and "<i>What possible influence could this Policy have on trends in the epidemi
c    and AIDS-related mortality rates</i>?".</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#34#30#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00323000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010100069002000700170#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#35#31#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Methodology</b></font></p>     ^cY#12.ht
m##
00971000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704074900069002000700818#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#36#32#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A evaluation study    was conducted with Mu
nicipalities that had qualified for the Incentive Policy    as of December 30, 2
008. These Municipalities were characterized first according    to geopolitical 
and epidemiological indicators and health services supply. Next,    the profile 
of the programmatic response was analyzed within the context of    the Incentive
, in relation to scope, inclusion of population groups, sustainability,    and i
ntervention capacity. Finally, the Municipalities included in the Policy    were
 compared to others not included in order to observe differences in the    degre
e of implementation of the response and trends in the epidemic.</font></p>     ^
cY#12.htm##
01624000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704140200069002000701471#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#37#33#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Secondary data    were used in order to cha
racterize the Municipalities and analyze differences    between those included a
nd not included. Epidemiological, geopolitical, and    health structure indicato
rs were used, including procedures performed in the    SUS, with data obtained f
rom the System's Information Technology Department    (DATASUS. <a href="http://
w3.datasus.gov.br/datasus/datasus.php" target="_blank">http://w3.datasus.gov.br/
datasus/datasus.php</a>,    accessed on 14/Nov/2008). The Brazilian National STD
/AIDS Program provided the    data on AIDS diagnostic and treatment services, th
e clinical and immunological    situation of persons with HIV, and the supply of
 CD4+/CD8+ T-cell tests. The    Municipal Human Development Index (HDI-M) was ex
tracted from the website of    the United Nations Development Program (<a href="
http://www.pnud.org.br/atlas/" target="_blank">http://www.pnud.org.br/atlas/</a>
,    accessed on 18/Jul/2008). Analysis of the response profile induced in the c
ontext    of the Incentive Policy drew on information by the Action and Target P
lans <sup>15</sup>    submitted by the Municipalities in order to receive Federa
l funds in 2006. Fifty-four    new Municipalities were only included more recent
ly, in 2007 and 2008, and were    thus not included in the current analysis.</fo
nt></p>     ^cY#12.htm##
01188000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704096600069002000701035#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#38#34#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The indicators    used to characterize the 
Municipalities in the first phase of the evaluation    were: (a) geopolitical: g
eographic regions of the country; population estimate    for 2006; and HDI-M in 
2005; (b) epidemiological, considering the years 2002-2006:    absolute number o
f cases reported and categorized according to magnitude (50    or more cases; 20
-49; and 1-19); mean annual incidence rate per 100 thousand    inhabitants; exis
tence of reporting (yes/no) of cases in a given transmission    category; number
 of transmission categories with cases reported during the period;    and time s
ince onset of the epidemic, calculated from the year in which the    first case 
was reported in the Municipality; and (c) health structure in 2005:    per capit
a health expenditures; and primary healthcare procedures as a proportion    of t
otal procedures performed under the SUS.</font></p>     ^cY#12.htm##
01832000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704161000069002000701679#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#39#35#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For a profile analysis    of the Municipal 
AIDS programs' response, the Action and Target Plans were reviewed    systematic
ally and the relevant information was categorized dichotomously according    to 
a predefined script. Such information included: (a) the scope of the response:  
  measured by the existence (yes/no) of targets in the Action and Target Plan,  
  contemplating care for persons with HIV; reduction of vertical transmission   
 of HIV and syphilis; diagnosis of HIV infection; prevention in vulnerable popul
ations    and the general population; and/or diagnosis and treatment of STI; (b)
 populations    covered: having included targets in the area of care for persons
 with HIV, STI,    pregnant women, and HIV-exposed children, and in the area of 
prevention among    adult and young jail inmates, men who have sex with men, mal
e and female sex    workers, drug users, injecting drug users (IDU), transvestit
es and transgenders    and/or other vulnerable population groups like truck driv
ers and indigenous    peoples; (c) priority area for intervention: area (prevent
ion/care) that received    the most funds in the Action and Target Plan and have
 spent more resources for    the general population; (d) sustainability: having 
allocated resources from    the health departments in the areas of care and prev
ention; and (e) capacity    for intervention in the epidemic: having invested th
e largest proportion of    the resources in the supply of services to the popula
tion in the areas of prevention    and care.</font></p>     ^cY#12.htm##
01284000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704106200069002000701131#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#40#36#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This stage of the    study used cluster ana
lysis with the K-means technique. The criterion used to    select the model was 
the potential for interpreting the established groups,    which finally consiste
d of four clusters (response profiles). The clusters/profiles    were compared a
ccording to the Municipalities' demographic and epidemiological    indicators, b
y means of the chi-square statistic for categorical variables,    and when they 
were considered significant (p &lt; 0.05), standardized residuals    analysis (Z
res) was used <sup>16</sup>. This technique allowed analyzing differences    bet
ween the observed and expected values in contingency table cells, and for    thi
s study values greater than 1.96 were defined as concentration/excess of    Muni
cipalities, and values less than -1.96 were defined as absence/lack of Municipal
ities.    In the case of continuous variables, ANOVA was used, with Bonferroni i
nequality    to test multiple differences between means.</font></p>     ^cY#12.h
tm##
01195000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704097300069002000701042#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#41#37#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">For comparison    of the Municipalities inc
luded and not included in the Incentive, it was assumed    that the Municipaliti
es included in the strategies to expand the response to    HIV had greater capac
ity to intervene in and control the epidemic. It was further    assumed that the
 Municipalities with a greater supply of services for diagnosis,    prevention, 
and care and with a reduction in AIDS cases and mortality rates    had higher ch
ance of having been included longer in the municipalization strategies.    Meanw
hile, the more recently included Municipalities are only associated with    a gr
eater supply of services and decrease in mortality, and not with a reduction    
in cases, since there has not been sufficient time to observe such a trend.    T
he inverse situation is observed with the mortality rate, which should decrease 
   after an increase in the supply of services.</font></p>     ^cY#12.htm##
01052000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704083000069002000700899#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#42#38#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Thus, for the analysis,    the Municipaliti
es belonging to the Incentive Policy were subdivided according    to time since 
inclusion in the strategies to expand the response: (1) older    Municipalities,
 included from 1994 to 1998, and (2) more recent Municipalities,    included sin
ce 2003 with the establishment of the Incentive Policy. The group    of Municipa
lities not included in the Incentive was selected among Brazilian    cities with
 reported AIDS cases from 2002 to 2006, with the inclusion criterion    defined 
as having reported at least 20 cases spread over the course of at least    three
 years in the period analyzed. This criterion was used to allow comparison    be
tween the Municipalities with larger and more regular epidemics.</font></p>     
^cY#12.htm##
02483000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704226100069002000702330#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#43#39#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The indicators    used in the comparison, c
ategorized dichotomously (yes/no), were: (a) reduction    of the epidemic by tra
nsmission category, calculated as the difference in the    number of cases durin
g the periods 1997-2001 and 2002-2006, considering the    categories homosexuals
/bisexuals, heterosexuals, IDU, transfusion recipients    (of blood/blood produc
ts), and vertical or mother-to-child HIV transmission.    "Reduction" was define
d as those with a negative variation, and the others were    categorized as "not
 reduced", including Municipalities which, in a given transmission    category, 
did not show a variation in the number of cases or showed zero cases    during t
he periods analyzed; (b) reduction in the AIDS mortality rate, also    calculate
d as the difference between the mean rates in 1998-2002 and 2003-2007    and cat
egorized according to the same criteria used in case reduction; (c) having    pr
esented, from 2003 to 2006, a proportion of patients with late HIV diagnosis    
above the mean (62.5%) for Brazilian Municipalities, with "late" defined as    c
ases that began clinical follow-up with CD4+/CD8+ T-cell count less than 200/mm<
sup>3</sup>    or with AIDS-related symptoms/diseases, or were only diagnosed at
 death; (d)    having presented, from 2003 to 2006, a proportion of patients wit
h HIV diagnosis    at the time of death above the mean (33.3%) for Brazilian Mun
icipalities; (e)    having presented, in 2006, the mean number of CD4+/CD8+ T-ce
ll tests per patient    above the mean (1.69/patient) for Brazilian municipaliti
es; (f) existence of    AIDS outpatient clinics in the Municipality in 2007; (g)
 existence of Voluntary    Counseling and Testing Centers (VCT) in 2005, or an a
nnual supply of HIV tests    performed under the SUS higher than the mean (17.1 
per thousand inhabitants)    in the Brazilian municipalities from 2005 to 2007; 
(h) more than 75% of the    schools in the Municipality conducting prevention ac
tivities in 2005; and (i)    mean number of STI/AIDS consultations in primary ca
re per 100 thousand inhabitants    above the mean for Brazilian municipalities (
5.5 per 100 thousand inhabitants)    from 2003 to 2005.</font></p>     ^cY#12.ht
m##
00645000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042300069002000700492#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#44#40#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The statistical    procedure used for compa
rison of Municipalities was multinomial logistic regression    <sup>17</sup>, wi
th the model having included all the analytical variables,    which were elimina
ted successively, using as the criterion the descriptive significance    level (
p &gt; 0.10) and the least alteration in the odds ratios.</font></p>     ^cY#12.
htm##
01656000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704143400069002000701503#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#45#41#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">To minimize possible    confounding effects
, the analysis controlled for time since the beginning of    the epidemic, compl
exity of the health system (proportion of primary procedures),    and population
 size. In relation to the first variable, the idea was to control    the effects
 related to possible depletion of the number of cases due to time    since the e
pidemic began. In the second variable, the attempt was to keep the    preexistin
g health structures from influencing the analysis of services supply,    assumin
g a larger number of AIDS outpatient clinics in Municipalities with a    predomi
nance of high and medium-complexity procedures, while in those with a    greater
 preponderance of primary care there would be an expansion in diagnostic    and 
preventive activities. Controlling for population size aimed to minimize    the 
effects of different contexts on trends in the epidemic and services supply    a
nd also provides an indirect measure to adjust for the size of the epidemic,    
which tends to be larger in large cities. For evaluation of the mortality rates,
    hierarchical models were considered, conducted without and with the variable
s    "HIV infection diagnosis" and "AIDS outpatient clinics". The database manag
ement    and statistical analysis were done with SPSS version 16.0 for Windows (
SPSS    Inc., Chicago, USA).</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#46#42#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00319000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704009700069002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#47#43#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Results</b></font></p>     ^cY#12.htm##
01033000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704081100069002000700880#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#48#44#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study sample    consisted of 812 Munici
palities, of which 332 (40.8%) were not included and    480 (59.1%) were include
d in the Incentive Policy. Among the latter, 151 (18.6%    of the total sample) 
were included in the municipalization strategies from 1994    to 98 and 329 (40.
5% of the total sample) since 2003. As shown in <a href="/img/revistas/csp/v27s1
/12t01.jpg">Table    1</a>, the Municipalities that were included had older (20.
4 years) and more    complex epidemics, more cases (92.9% of the total studied),
 mean incidence of    24.5 per 100 thousand/inhabitants, and diversification of 
HIV transmission forms    (84.8% with the concurrent presence of heterosexual, h
omosexual/bisexual, and    IDU transmission).</font></p>     ^cY#12.htm##
00768000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054600069002000700615#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#49#45#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">These Municipalities    also had a HDI-M (0
.78) higher than the national mean and were concentrated    mainly in the Southe
ast region and in cities with more than 100 thousand inhabitants,    totaling 88
% of the study population and all the State capitals. The health    structure wa
s characterized by greater per capita expenditure (R$ 191.81/inhabitant)    and 
a slight predominance (51.4%) of primary care among the total procedures    perf
ormed under the SUS.</font></p>     ^cY#12.htm##
00947000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704072500069002000700794#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#50#46#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">These characteristics    were most prominen
t in Municipalities included from 1994 to 1998, which had    the most AIDS cases
, the highest mean incidence rate, and a health system that    mainly performed 
medium and high-complexity procedures. In comparison to these    Municipalities,
 the ones included in 2003 showed modest differences in the time    since the on
set of the epidemic (19.6 years) and geographic location. The most    striking d
ifferences were the lower proportion both of cities with large (&gt;    50) numb
ers of AIDS cases (66.6%) and cases in the IDU and vertical transmission    cate
gories (81.2% and 64.4%, respectively).</font></p>     ^cY#12.htm##
00766000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054400069002000700613#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#51#47#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">An analysis of    the programmatic response
 in the Municipalities included in the Incentive Policy    (<a href="/img/revist
as/csp/v27s1/12t02.jpg">Tables 2</a> and <a href="/img/revistas/csp/v27s1/12t03.
jpg">3</a>)    showed four profiles, characterized by different degrees in the s
cope of the    response, sustainability, capacity to intervene in the epidemic, 
and inclusion/exclusion    of priority population groups. These response profile
s were as follows:</font></p>     ^cY#12.htm##
01689000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704146700069002000701536#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#52#48#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">a) Profile 1, with    a comprehensive and s
ustainable response and greater capacity for intervention:    consisted of 91 Mu
nicipalities (21.3%); presented the best indicators for sustainability    (51.6%
) and investments in the supply of services and care for the population    (100%
); the group with the second best performance in reaching the set of minimum    
goals (82.4%), which included, concurrently, healthcare for persons with HIV,   
 HIV diagnosis, prevention of vertical HIV transmission, and prevention in the  
  overall population and specific groups. This was the group of Municipalities  
  with the best separate performance in diagnosis and treatment of STI (84.6%), 
   HIV diagnosis (100%), and prevention in specific population groups (96.7%).  
  These cities also showed the highest inclusion of drug users (61.5%) and jail 
   inmates (26.4%), the second highest inclusion of transvestites (17.6%), other
    vulnerable population groups (79.1%), and, concurrently, care for persons wi
th    HIV, STI carriers, pregnant women, and HIV-exposed children (50.5%). This 
group,    mainly cities with 200 thousand inhabitants or more (Zres: 4.38) and c
onsisting    of 12 State capitals (Zres: 3.19), included the largest population 
(average    of 518 thousand inhabitants) and the most AIDS cases, with 51.1% of 
the total    in the Municipalities included in the Incentive.</font></p>     ^cY
#12.htm##
01483000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704126100069002000701330#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#53#49#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">b) Profile 2, with    a comprehensive respo
nse and lower capacity for intervention: consisted of 60    Municipalities (14.1
%), the ones with the best performance in meeting (86.7%)    the set of minimum 
goals for the response to HIV, especially those related to    healthcare for per
sons with HIV (98.3%) and prevention of vertical transmission    (93.3%). They a
lso showed the widest diversity of population groups, including    the highest p
roportions of cities with activities related to sex workers (68.3%),    drug use
rs (46.7%), homosexuals (33.3%), and transvestites (18.3%). However,    none of 
the Municipalities in this group made investments focused on a greater    propor
tion of services supply in prevention and care. It was also the group    with th
e lowest percentage of cities with their own local resources allocated    in the
se areas. It had the third highest average population (189 thousand) and    the 
lowest proportion (9.6%) of AIDS cases in the cities included in the Incentive. 
   These Municipalities were concentrated in the North (Zres: 3.15) and South (Z
res:    2.73) of Brazil, especially in the States of Tocantins, Santa Catarina, 
and    Roraima.</font></p>     ^cY#12.htm##
01624000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704140200069002000701471#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#54#50#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">c) Profile 3, with    a limited response, e
xcluding priority population groups: consisting of the    largest number of Muni
cipalities, 147 (34.4%), this was the profile with the    lowest inclusion of sp
ecific population groups, given that none of these cities    conducted activitie
s for groups with the highest HIV prevalence rates, besides    having the least 
concurrent coverage (42.2%) in care for persons with HIV, STI    carriers, pregn
ant women, and HIV-exposed children. It also had the second lowest    coverage i
n the set of essential goals for the response (27.9%). A comparatively    small 
proportion conducted separate activities for HIV diagnosis (50.3%), prevention  
  of vertical transmission (81.6%), and diagnosis and treatment of STI (71.4%). 
   Sustainability (37.4%) and investments in actions to promote intervention (58
.5%)    showed medium indicators, comparable to those in Profile 1. This group h
ad the    lowest average population (155 thousand inhabitants) and especially in
cluded    cities with 20-49 thousand inhabitants (Zres: 3.54), concentrated in t
he Central    West (Zres: 3.22) and in the States of Mato Grosso, Minas Gerais, 
and Amazonas.    It had the lowest mean number of AIDS cases (183), accounting f
or 17.5% of the    epidemic in the Municipalities included in the Incentive.</fo
nt></p>     ^cY#12.htm##
01653000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704143100069002000701500#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#55#51#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">d) Profile 4, with    a limited response, m
ainly focusing on prevention: consisted of 129 Municipalities    (30.2%) with th
e lowest comprehensive response, no city that concurrently contemplated    the s
et of essential guidelines. It also had the lowest proportions of cities    that
 conducted separate activities involving care for persons with HIV (94.6%),    p
revention of vertical transmission of HIV and syphilis (79.1%), diagnosis and   
 treatment of STI (61.2%), and HIV diagnosis (2.3%). However, in relation to    
specific population groups, all of the Municipalities in this group included    
some social segment with higher prevalence rates, with the highest proportion   
 of cities working with homosexuals (34.1%) and sex workers (72.9%) and the seco
nd    highest working with drug users (47.3%) and jail inmates (23.3%). Only abo
ut    one-third (32.6%) of these Municipalities allocated their own local resour
ces    concurrently in the areas of prevention and care and conducted investment
s in    the supply of services and care for the population. These Municipalities
 had    the second largest mean number of AIDS cases (21.7% of the epidemic) and
 mean    population (198 thousand inhabitants) and included six State capitals a
nd a    major concentration of Municipalities in the States of Esp&iacute;rito S
anto    and Piau&iacute;.</font></p>     ^cY#12.htm##
00655000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704043300069002000700502#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#56#52#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The profiles analyzed    here showed simila
r characteristics (p &gt; 0.05) in relation to the proportion    of investments 
in prevention (mean: 32.8%) and for the general population (mean:    48%) and ta
rgeting of activities for persons with HIV (mean: 98.1%), STI carriers    (mean:
 93.2%), and pregnant women and HIV-exposed children (mean: 93.2%).</font></p>  
   ^cY#12.htm##
00616000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704039400069002000700463#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#57#53#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The Municipalities    with more comprehensi
ve responses included a higher proportion of cities incorporated    into the Inc
entive from 1994 to 1998 (the equivalent of 1.9 times more than    those include
d in 2003). The latter group represented 73.2% of the Municipalities    with mor
e limited response profiles.</font></p>     ^cY#12.htm##
01317000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704109500069002000701164#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#58#54#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Comparing Municipalities    that were inclu
ded to those not included (<a href="/img/revistas/csp/v27s1/12t04.jpg">Table    
4</a>), the chance were higher for Municipalities with a larger supply of HIV   
 diagnostic tests (OR = 15.0; 95%CI: 5.6-40.1) and AIDS outpatient services (OR 
   = 18.4; 95%CI: 8.4-40.5) to be included in the municipalization strategies fr
om    1994 to 1998. The same trend was true for Municipalities included in 2003,
 but    with lower odds: OR = 2.4 (95%CI: 1.6-3.8) and OR = 5.2 (95%CI: 3.2-8.4)
, respectively.    This characteristic becomes more evident to the extent that t
he Municipalities    included in the Incentive had nearly all of the Anonymous T
esting and Counseling    Centers (90.3%) and AIDS outpatient services (87.8%) an
d 81.6% of the cities    with HIV diagnostic services above the national average
, performing 2.1 times    more tests per 100 thousand inhabitants/year than the 
mean for the cities studied    (<a href="/img/revistas/csp/v27s1/12t01.jpg">Tabl
e 1</a>).</font></p>     ^cY#12.htm##
00869000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704064700069002000700716#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#59#55#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, the fact    that Municipalities in
cluded in the Incentive had a greater supply of AIDS services    did not mean hi
gher chance of performing timely diagnosis or making CD4+/CD8+    T-cell testing
 available at rates above the national average. Thus, the chance    of showing a
 reduction in the mortality rate were not associated with any of    the groups a
nalyzed, except when this trend was analyzed independently of the    presence of
 AIDS services. In this situation, the reduction in mortality was    associated 
with the Municipalities included in 2003.</font></p>     ^cY#12.htm##
00650000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704042800069002000700497#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#60#56#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">There was also    no association between wi
der coverage of preventive activities and inclusion    in the Incentive. The pro
portions were similar for cities included and not included    in the Incentive t
hat conducted preventive activities in more than 75% of the    schools and that 
conducted more STI/AIDS consultations in primary care clinics.</font></p>     ^c
Y#12.htm##
01197000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704097500069002000701044#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#61#57#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">On the other hand,    the downward trends i
n the number of cases among IDU (OR = 6.6; 95%CI: 2.9-14.9)    and due to sexual
 transmission, whether heterosexual (OR = 3.1; 95%CI: 1.4-7.3)    or homosexual/
bisexual (OR = 3.0; 95%CI: 1.4-6.2), were more closely associated    with the Mu
nicipalities included from 1994 to 1998. For the Municipalities included    in 2
003, the only related downward trend was in IDUs, but with lower odds (OR    = 2
.4; 95%CI: 1.5-3.7) (<a href="/img/revistas/csp/v27s1/12f01.jpg">Figure 1</a>). 
   The Municipalities with a reduction in cases due to blood transfusions and ve
rtical    transmission did not show an association with any of the groups analyz
ed, independently    of the year in which they were included. There were importa
nt proportions of    Municipalities with upward trends in cases due to vertical 
transmission (31.2%)    and transfusions (17.4%).</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#62#58#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#63#59#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Discussion</b></font></p>     ^cY#12.htm
##
01067000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704084500069002000700914#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#64#60#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The strategies    the municipalization cont
ributed to the induction of profiles in response to    the AIDS epidemic that we
re different in their scope, degrees of inclusion of    population groups, susta
inability, and capacity to intervene in the epidemic.    The most comprehensive 
profiles were associated with the Municipalities that    have been included long
er in the processes to expand the response, and they    in turn showed the best 
results in the supply of services and the reduction    of cases among heterosexu
als, homosexuals/bisexuals, and IDU. Meanwhile, the    municipalization strategi
es were not associated with wider coverage of preventive    activities or reduct
ion in mortality or AIDS cases due to vertical transmission    or transfusions.<
/font></p>     ^cY#12.htm##
01077000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704085500069002000700924#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#65#61#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">These findings    should be interpreted wit
h the study's limitations in mind. Due to the study    design and the specificit
ies of its object, it is not possible to establish    exclusive causal relations
 between the municipalization process, the greater    supply of services, and ch
anges in epidemiological trends. First, the development    of actions and the ep
idemic's behavior result from multiple factors and the    work of numerous gover
nment institutions and civil society organizations in    more than 25 years of r
esponse to AIDS <sup>1,2,9</sup>. Municipalization is    one of these factors, m
aking an important contribution to the expansion and    consolidation of the res
ponse by encouraging States and Municipalities to organize    and finance their 
programs.</font></p>     ^cY#12.htm##
00770000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704054800069002000700617#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#66#62#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Second, the analysis    of the effects of m
unicipalization on the epidemiological trends was based on    AIDS cases, while 
the long latency of HIV infection tends to make this measurement    imprecise. T
hus, at one extreme, one might suppose that the reduction in the    number of AI
DS cases observed since 1997 was entirely associated with the infections    that
 failed to occur prior to that year, rather than to the interventions promoted  
  by municipalization.</font></p>     ^cY#12.htm##
00954000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704073200069002000700801#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#67#63#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, the current    study's findings al
low us to point in a different direction, namely that there    is a clear hierar
chy in the chances of the municipalities show a downward trend    in cases, acco
rding to the time of inclusion in the mucipalization strategies.    Thus, Munici
palities that were not included showed upward trends and those included    from 
1994 to 1998 tended to be associated with a reduction in cases. This fact    all
ows us to suppose that if the reduction in cases began prior to the municipaliza
tion    strategies, it was expanded and intensified after this event, and its ef
fects    will be felt more strongly over time.</font></p>     ^cY#12.htm##
00998000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704077600069002000700845#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#68#64#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">This finding is    also reinforced by other
 aspects. The chance are significant that an important    share of the cases wer
e averted during the period analyzed. Various studies    indicate that the mean 
time between infection and development of AIDS varies    from 7 to 11 years, wit
h slightly more than half of the cases of HIV infection    presenting the diseas
e before this time <sup>18</sup>. Importantly, some of    these studies adopt a 
definition of AIDS (CD4+/CD8+ T-cell count &lt; 200cells/mm<sup>3</sup>)    with
 lower sensitivity than the Brazilian definition (CD4+/CD8+ T-cell count    &lt;
 350cells/mm<sup>3</sup>), thus leading to later identification of cases    <sup
>19</sup>.</font></p>     ^cY#12.htm##
00590000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704036800069002000700437#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#69#65#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Furthermore, none    of the Municipalities 
that showed a reduction in cases in heterosexuals had    displayed this trend be
fore 1998. Among those with a reduction in homosexuals,    this proportion was 1
6.5%, and more than one-third had been included in municipalization    since 199
4.</font></p>     ^cY#12.htm##
00670000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704044800069002000700517#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#70#66#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Finally, the analysis    was adjusted for f
actors that could intervene in the understanding of the association    between a
 downward trend in cases and municipalization, like the epidemic's    maturity, 
the response influenced by greater complexity in the health system,    and the e
xistence of different contexts of vulnerability due to the municipality's    siz
e.</font></p>     ^cY#12.htm##
01203000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704098100069002000701050#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#71#67#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">An important part    of the positive result
s in Brazil's AIDS policy may be related to the Municipalities    with more comp
rehensive response profiles, which include an important share    of the cities i
ncorporated into the municipalization strategies from 1994 to    1998 and the la
rgest proportion of AIDS cases that occurred during the period    analyzed. Thes
e profiles are close to those of successful experiences in various    parts of t
he world <sup>20</sup> and the guidelines for the Brazilian response    <sup>1,2
,9</sup>, while differing from the other Municipalities because they    present 
characteristics with a more balanced combination of scope, inclusion    of speci
fic population groups, sustainability, and greater capacity to intervene    in t
he epidemic, due to actions targeting the population with the highest prevalence
    and major investments in the provision of services.</font></p>     ^cY#12.ht
m##
01290000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704106800069002000701137#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#72#68#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The structuring    of the response to AIDS 
in Brazil may also help understand the lack of association    between municipali
zation and the reduction in cases due to vertical transmission    or transfusion
s. The reduction in these transmission categories was significant    throughout 
Brazil due to structural changes <sup>1,9</sup> that encompassed    Municipaliti
es both included and not included in municipalization. In the case    of transmi
ssion by blood and blood products, the implementation of the national    policy 
in the 1980s <sup>9,21</sup> banned commercialization of the blood, stimulated  
  the implementation of transfusion centers, and introduced mandatory serologica
l    screening of donations. As for vertical transmission, since 2000, mandatory
    diagnosis and treatment of HIV infection was incorporated nationwide into th
e    prenatal, childbirth, and postpartum services system, thus facilitating the
    decrease in mother-to-child transmission <sup>22,23</sup>.</font></p>     ^c
Y#12.htm##
01128000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704090600069002000700975#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#73#69#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Importantly, these    problems have still n
ot been overcome. The residual risk of transfusion-related    HIV infection rema
ins greater in Brazil than in high-income countries <sup>24</sup>,    due largel
y to persistent reliance on blood banks for HIV testing (blood banks    are the 
main source of HIV testing among Brazilian men) <sup>25</sup>. As for    vertica
l transmission, the Brazilian results are inferior to those of some other    mid
dle-income countries like Argentina, Botswana, and Thailand <sup>26</sup>.    Br
azil's coverage is estimated at around 40%, depending on the region of the    co
untry <sup>27,28</sup>, thus meaning a missed opportunity to avert cases (on    
the order of 56%) <sup>30</sup>. Greater prioritization of these issues by the  
  Incentive Policy is needed to help reverse this situation.</font></p>     ^cY#
12.htm##
00981000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075900069002000700828#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#74#70#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The study showed    strong capacity by muni
cipalization policies to induce the implementation of    services and to strengt
hen the local health system. However, this structure    was not associated with 
greater reduction of mortality rates. One hypothesis    is that the services in 
Municipalities included in the Incentive are acting    as references for treatme
nt of persons with HIV residing in Municipalities not    included, thereby contr
ibuting to the homogenization of the reduction in mortality    rates. The "regio
nalization" of care is characteristic of the Brazilian health    system in the t
reatment of more complex diseases, as discussed previously <sup>30</sup>.</font>
</p>     ^cY#12.htm##
00795000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704057300069002000700642#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#75#71#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">However, when the    analysis was adjusted 
for the existence of services, the Municipalities included    in 2003 showed hig
her chance of reducing mortality. This could reflect the incorporation    of new
 technologies in the initial phases of the Incentive, with a positive    impact 
on quality of care for persons with HIV. On this assumption, the impact    of th
e incorporation of new technologies on mortality probably occurred earlier    in
 the Municipalities included from 1994 to 1998.</font></p>     ^cY#12.htm##
00983000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704076100069002000700830#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#76#72#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A similar capacity    to induce the expansi
on of healthcare serves was not observed in the area of    prevention. This situ
ation was unexpected, given that the guidelines for the    Brazilian response an
d the Incentive Policy ascribe equal importance to prevention    and care. The l
ower degree of development of prevention activities has been    discussed previo
usly <sup>10</sup> and may relate partially to the characteristics    of the Bra
zilian health system, which shows incipient coverage in primary care    in large
 cities <sup>31</sup>, where the epidemic is concentrated, and the lower    prio
rity of health promotion activities as compared to individual patient care.</fon
t></p>     ^cY#12.htm##
00974000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704075200069002000700821#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#77#73#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In prevention,    the analysis of the respo
nse profile for Municipalities included under the Incentive    revealed the excl
usion of population groups with the highest HIV prevalence    (and this was true
, to varying degrees, in Municipalities with more limited    as well as more com
prehensive responses). This issue clearly revealed a mismatch    between the cha
racteristics of the response by the Municipalities, emphasizing    measures for 
the general population, and the epidemic's profile, heavily concentrated    in s
pecific groups like IDU and homosexuals/bisexuals, who show a significantly    h
igher risk of infection than the general population <sup>31</sup>.</font></p>   
  ^cY#12.htm##
00686000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704046400069002000700533#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#78#74#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">These population    groups have repeatedly 
been excluded from the response to the epidemic in various    contexts in Latin 
America, Asia, and Africa <sup>20</sup>, due to numerous situations    of prejud
ice that create barriers against access to health promotion activities    <sup>7
,20</sup>. Once these obstacles are overcome, the Brazilian results should    be
 more significant.</font></p>     ^cY#12.htm##
00834000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704061200069002000700681#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#79#75#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">Fifty-four Municipalities    were not inclu
ded in the analysis of the response profile, since they were incorporated    int
o the Incentive after 2006. These Municipalities typically had smaller epidemics
    and small to medium-sized populations, similar to the cities with more limit
ed    response profiles. One can assume that the inclusion of these Municipaliti
es    in the response profile model would not alter the findings, since no signi
ficant    changes occurred between 2007 and 2008 in the Incentive Policy's guide
lines.</font></p>     ^cY#12.htm##
00829000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704060700069002000700676#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#80#76#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">In short, this    study's findings showed t
hat induction of the response through the transfer    of Federal funds and the e
stablishment of technical guidelines strengthens decentralized    health structu
res, which to a greater or lesser degree foster more effective    control of the
 epidemic: more comprehensive responses are associated with the    best results.
 However, limitations to the response, especially in the area of    prevention, 
minimize the actions' impact and should be the object of further    intervention
.</font></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#81#77#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00324000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010200069002000700171#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#82#78#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Contributors</b></font></p>     ^cY#12.h
tm##
00505000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704028300069002000700352#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#83#79#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">A. Grangeiro and    M. M. L. Escuder partic
ipated in the original concept, data analysis, and writing    of the article. E.
 A. Castilho participated in the data analysis and writing    of the article.</f
ont></p>     ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#84#80#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00327000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010500069002000700174#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#85#81#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>Acknowledgments</b></font></p>     ^cY#1
2.htm##
00807000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704058500069002000700654#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#86#82#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="2">The authors wish    to thank the staff at t
he Planning Units of the National Department of STD,    AIDS, and Viral Hepatiti
s under the Brazilian Ministry of Health and the S&atilde;o    Paulo State AIDS 
Program, especially S&eacute;rgio D'Avila, Maria Alice Tironi,    Sandra Regina 
Miguel, Sara Sorrentino, and Vilma Cervantes, for their contributions    to the 
discussions on the Incentive Policy and for providing information and    data, a
s well as Paulo Roberto Teixeira for his critical analysis.</font></p>     ^cY#1
2.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002200069002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#87#83#article#159#<p>&nbsp;</p>     ^cY#12.h
tm##
00322000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704010000069002000700169#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#88#84#article#159#<p><font face="Verdana, Ar
ial, Helvetica, sans-serif" size="3"><b>References</b></font></p>     ^cY#12.htm
##
00561000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704032500071002000700396#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#89#85#article#159#1#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">1. Berkman A, Garcia    J, Mu
&ntilde;oz-Laboy M, Paiva V, Parker R. A critical analysis of the Brazilian    r
esponse to HIV/AIDS: lessons learned for controlling and mitigating the epidemic
    in developing countries. Am J Public Health 2005; 95:1162-72.    ^cY#12.htm#
#
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#90#86#article#159#</font></p>     ^cY#12.htm
##
00525000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704028900071002000700360#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#91#87#article#159#2#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">2. Grangeiro A,    Laurindo-S
ilva L, Teixeira PR. Resposta &agrave; AIDS no Brasil: contribui&ccedil;&otilde;
es    dos movimentos sociais e da reforma sanit&aacute;ria. Rev Panam Salud P&ua
cute;blica    2009; 26:87-94.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#92#88#article#159#</font></p>     ^cY#12.htm
##
00467000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704023100071002000700302#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#93#89#article#159#3#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">3. Teixeira PR,    Vit&oacute
;ria MA, Barcarolo J. Antiretroviral treatment in a resource-poor    setting: th
e Brazilian experience. AIDS 2004; 18 Suppl 3:S5-7.    ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#94#90#article#159#</font></p>     ^cY#12.htm
##
00494000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704025800071002000700329#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#95#91#article#159#4#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">4. Fonseca MGP,    Bastos FI.
 Twenty-five years of the AIDS epidemic in Brazil: principal epidemiological    
findings, 1980-2005. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S333-44.  
  ^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#96#92#article#159#</font></p>     ^cY#12.htm
##
00572000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704033600071002000700407#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#97#93#article#159#5#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">5. Berqu&oacute;    E, Barbos
a RM, Lima LP; Grupo de Estudos em Popula&ccedil;&atilde;o, Sexualidade    e AID
S. Uso do preservativo: tend&ecirc;ncias entre 1998 e 2005 na popula&ccedil;&ati
lde;o    brasileira. Rev Sa&uacute;de P&uacute;blica 2008; 42 Suppl 1:34-44.    
^cY#12.htm##
00242000000000145000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065704002000069002000700089#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#98#94#article#159#</font></p>     ^cY#12.htm
##
00646000000000157000450000400060000070200410000670500020004770600020004970000030
0051701000300054709000800057708000400065888000200069704041000071002000700481#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#99#95#article#159#6#<p><font fac
e="Verdana, Arial, Helvetica, sans-serif" size="2">6. Caiaffa WT,    Bastos FI, 
Freitas LL, Mingoti SA, Proietti FA, Carneiro-Proetti AB, et al.    The contribu
tion of two Brazilian multi-center studies to the assessment of    HIV and HCV i
nfection and prevention strategies among injecting drug users:    the AjUDE-Bras
il I and II Projects. Cad Sa&uacute;de P&uacute;blica 2006; 22:771-82.    ^cY#12
.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#100#96#article#159#</font></p>     ^cY#12.ht
m##
00547000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704031000072002000700382#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#101#97#article#159#7#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">7. Garcia S, Koyama    MAH; 
Grupo de Estudos em Popula&ccedil;&atilde;o, Sexualidade e AIDS. Estigma,    dis
crimina&ccedil;&atilde;o e HIV/AIDS no contexto brasileiro, 1998 e 2005.    Rev 
Sa&uacute;de P&uacute;blica 2008; 42 Suppl 1:72-83.    ^cY#12.htm##
00243000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066704002000070002000700090#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#102#98#article#159#</font></p>     ^cY#12.ht
m##
00570000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000300055709000800058708000400066888000200070704033300072002000700405#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#103#99#article#159#8#<p><font fa
ce="Verdana, Arial, Helvetica, sans-serif" size="2">8. Hacker MA, Kaida    A, Ho
gg RS, Bastos FI. The first ten years: achievements and challenges of the    Bra
zilian program of universal access to HIV/AIDS comprehensive management and    c
are, 1996 -2006. Cad Sa&uacute;de P&uacute;blica 2007; 23 Suppl 3:S345-59.    ^c
Y#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#104#100#article#159#</font></p>     ^cY#12.h
tm##
00581000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000200071704034300073002000700416#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#105#101#article#159#9#<p><font f
ace="Verdana, Arial, Helvetica, sans-serif" size="2">9. Teixeira PR.    Pol&iacu
te;ticas p&uacute;blicas em AIDS. In: Parker R, editor. Pol&iacute;ticas,    ins
titui&ccedil;&otilde;es e AIDS: enfrentando a epidemia no Brasil. Rio de    Jane
iro: Associa&ccedil;&atilde;o Brasileira Interdisciplinar de AIDS; 1997.    p. 4
3-68.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#106#102#article#159#</font></p>     ^cY#12.h
tm##
00525000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028600074002000700360#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#107#103#article#159#10#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">10. Paiva V, Pupo    LR, B
arboza R. O direito &agrave; preven&ccedil;&atilde;o e os desafios da redu&ccedi
l;&atilde;o    de vulnerabilidade ao HIV no Brasil. Rev Sa&uacute;de P&uacute;bl
ica 2006; 40    Suppl:109-19.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#108#104#article#159#</font></p>     ^cY#12.h
tm##
00607000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704036800074002000700442#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#109#105#article#159#11#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">11. World Bank.    Project
 performance assessment report: Brazil first and second AIDS and STD    control 
projects (Loan 3659-BR and 4392-BR). Operations Evaluation Department,    2004. 
<a href="http://www.worldbank.org/" target="_blank">http://www.worldbank.org/</a
>    (accessed on 15/Jul/2008).    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#110#106#article#159#</font></p>     ^cY#12.h
tm##
00679000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704044000074002000700514#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#111#107#article#159#12#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">12. Barboza R.    Gest&ati
lde;o do Programa Estadual DST/AIDS de S&atilde;o Paulo: uma an&aacute;lise    d
o processo de descentraliza&ccedil;&atilde;o das a&ccedil;&otilde;es no per&iacu
te;odo    de 1994 a 2003 &#91;Masters Thesis&#93;. S&atilde;o Paulo: Coordenador
ia de    Controle de Doen&ccedil;as, Secretaria de Estado da Sa&uacute;de de S&a
tilde;o    Paulo; 2006.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#112#108#article#159#</font></p>     ^cY#12.h
tm##
00544000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030500074002000700379#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#113#109#article#159#13#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">13. Pires DRF.    Alguns a
pontamentos sobre o processo de descentraliza&ccedil;&atilde;o do programa    de
 AIDS &#91;Masters Thesis&#93;. Rio de Janeiro: Instituto de Medicina Social,   
 Universidade do Estado do Rio de Janeiro; 2006.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#114#110#article#159#</font></p>     ^cY#12.h
tm##
00656000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704041700074002000700491#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#115#111#article#159#14#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">14. Taglieta MFB.    Avali
a&ccedil;&atilde;o da implanta&ccedil;&atilde;o do incentivo no &acirc;mbito    
do Programa Nacional de HIV/AIDS e outras DST em dois munic&iacute;pios do estad
o    de S&atilde;o Paulo &#91;Masters Thesis&#93;. Rio de Janeiro: Escola Nacion
al    de Sa&uacute;de P&uacute;blica, Funda&ccedil;&atilde;o Oswaldo Cruz; 2006.
    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#116#112#article#159#</font></p>     ^cY#12.h
tm##
00508000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704026900074002000700343#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#117#113#article#159#15#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">15. Minist&eacute;rio    d
a Sa&uacute;de. Programa Nacional de DST e Aids. <a href="http://www.pam.aids.go
v.br/pam/" target="_blank">http://www.pam.aids.gov.br/pam/</a>    (accessed on 1
7/Mar/2008).    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#118#114#article#159#</font></p>     ^cY#12.h
tm##
00517000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027800074002000700352#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#119#115#article#159#16#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">16. Pereira JCR.    An&aac
ute;lise de dados qualitativos: estrat&eacute;gias metodol&oacute;gicas    para 
as ci&ecirc;ncias da sa&uacute;de, humanas e sociais. 3<u>ª</u> Ed. S&atilde;o  
  Paulo: Edusp; 2001.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#120#116#article#159#</font></p>     ^cY#12.h
tm##
00437000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704019800074002000700272#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#121#117#article#159#17#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">17. Fox J. Applied    regr
ession analysis and generalized linear models. 2<sup>nd</sup> Ed. London:    Sag
e Publications; 2008.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#122#118#article#159#</font></p>     ^cY#12.h
tm##
00655000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704041600074002000700490#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#123#119#article#159#18#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">18. Time from HIV-1    ser
oconversion to AIDS and death before widespread use of highly-active antiretrovi
ral    therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubat
ion    and HIV Survival including the CASCADE EU Concerted Action. Concerted Act
ion    on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355:1131-37. 
   ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#124#120#article#159#</font></p>     ^cY#12.h
tm##
00518000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027900074002000700353#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#125#121#article#159#19#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">19. Campos DP,    Ribeiro 
SR, Grinsztejn B, Veloso VG, Valente JG, Bastos FI, et al. Survival    of AIDS p
atients using two case definitions, Rio de Janeiro, Brazil, 1986-2003.    AIDS 2
005; 19 Suppl 4:S22-6.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#126#122#article#159#</font></p>     ^cY#12.h
tm##
00460000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022100074002000700295#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#127#123#article#159#20#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">20. Piot P, Bartos    M, L
arson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action    
for HIV prevention. Lancet 2008; 372:845-59.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#128#124#article#159#</font></p>     ^cY#12.h
tm##
00444000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704020500074002000700279#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#129#125#article#159#21#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">21. Junqueira PC,    Rosem
blit J, Hamerschlak N. Hist&oacute;ria da hemoterapia no Brasil. Rev Bras    Hem
atol Hemoter 2005; 27:201-7.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#130#126#article#159#</font></p>     ^cY#12.h
tm##
00546000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704030700074002000700381#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#131#127#article#159#22#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">22. Serruya SJ,    Cecatti
 JG, Lago TG. O Programa de Humaniza&ccedil;&atilde;o do Pr&eacute;-natal    e N
ascimento do Minist&eacute;rio da Sa&uacute;de no Brasil: resultados iniciais.  
  Cad Sa&uacute;de P&uacute;blica 2004; 20:1281-9.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#132#128#article#159#</font></p>     ^cY#12.h
tm##
00619000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704038000074002000700454#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#133#129#article#159#23#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">23. Succi RCM;    Grupo de
 Estudos da Sociedade Brasileira de Pediatria para Avaliar a Transmiss&atilde;o 
   Materno-Infantil do HIV. Mother-to-child transmission of HIV in Brazil during
    the years 2000 and 2001: results of a multi-centric study. Cad Sa&uacute;de 
   P&uacute;blica 2007; 23 Suppl 3:S379-89.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#134#130#article#159#</font></p>     ^cY#12.h
tm##
00517000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027800074002000700352#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#135#131#article#159#24#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">24. Maresch C,    Schluter
 PJ, Wilson AD, Sleig A. Residual infectious disease risk in screened    blood t
ransfusion from a high-prevalence population: Santa Catarina, Brazil.    Transfu
sion 2008; 48:273-81.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#136#132#article#159#</font></p>     ^cY#12.h
tm##
00572000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704033300074002000700407#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#137#133#article#159#25#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">25. Fran&ccedil;a    Junio
r I, Calazans G, Zucchi EM; Grupo de Estudos em Popula&ccedil;&atilde;o,    Sexu
alidade e AIDS. Mudan&ccedil;as no &acirc;mbito da testagem anti-HIV no    Brasi
l entre 1998 e 2005. Rev Sa&uacute;de P&uacute;blica 2008; 42 Suppl 1:84-97.    
^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#138#134#article#159#</font></p>     ^cY#12.h
tm##
00462000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704022300074002000700297#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#139#135#article#159#26#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">26. United Nations    Join
t Programme on HIV/AIDS. Report on the global AIDS epidemic 2008. Geneva:    Uni
ted Nations Joint Programme on HIV/AIDS; 2008.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#140#136#article#159#</font></p>     ^cY#12.h
tm##
00568000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704032900074002000700403#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#141#137#article#159#27#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">27. Szwarcwald    CL, Barb
osa J&uacute;nior A, Souza J&uacute;nior PRB, Lemos KRV, Frias PG, Luhm    KR, e
t al. HIV testing during pregnancy: use of secondary data to estimate 2006    te
st coverage and prevalence in Brazil. Braz J Infect Dis 2008; 12:167-72.    ^cY#
12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#142#138#article#159#</font></p>     ^cY#12.h
tm##
00533000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704029400074002000700368#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#143#139#article#159#28#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">28. Veloso VG,    Portela 
MC, Vasconcellos MTL, Matzenbacher LA, Vasconcelos ALR, Grinsztejn B,    et al. 
HIV testing among pregnant women in Brazil: rates and predictors. Rev    Sa&uacu
te;de P&uacute;blica 2008; 42:859-67.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#144#140#article#159#</font></p>     ^cY#12.h
tm##
00511000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704027200074002000700346#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#145#141#article#159#29#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">29. Rodrigues CS,    Guima
r&atilde;es MDC, C&eacute;sar CC. Missed opportunities for congenital syphilis  
  and HIV perinatal transmission prevention. Rev Sa&uacute;de P&uacute;blica 200
8;    42:851-8.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#146#142#article#159#</font></p>     ^cY#12.h
tm##
00611000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704037200074002000700446#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#147#143#article#159#30#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">30. Reis CT, Czeresnia    
D, Barcellos C, Tassinari WS. A interioriza&ccedil;&atilde;o da epidemia de    H
IV/AIDS e o fluxo intermunicipal de interna&ccedil;&atilde;o hospitalar na    Zo
na da Mata, Minas Gerais, Brasil: uma an&aacute;lise espacial. Cad Sa&uacute;de 
   P&uacute;blica 2008; 24:1219-28.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#148#144#article#159#</font></p>     ^cY#12.h
tm##
00528000000000157000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067888000300071704028900074002000700363#v27
s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#p#149#145#article#159#31#<p><font 
face="Verdana, Arial, Helvetica, sans-serif" size="2">31. Barbosa J&uacute;nior 
   A, Szwarcwald CL, Pascon ARP, Souza Junior PB. Tend&ecirc;ncias da AIDS epide
mic    entre subgrupos sob maior risco no Brasil, 1980-2004. Cad Sa&uacute;de P&
uacute;blica    2009; 25:727-37.    ^cY#12.htm##
00244000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002000071002000700091#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#150#146#article#159#</font></p>     ^cY#12.h
tm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#151#147#article#159#<p>&nbsp;</p>     ^cY#12
.htm##
00246000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002200071002000700093#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#152#148#article#159#<p>&nbsp;</p>     ^cY#12
.htm##
00415000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704019100071002000700262#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#153#149#article#159#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2"><b><a name="back"></a><a href="#top"><img
 src="/img/revistas/csp/v27s1/seta.jpg" border="0"></a>    Correspondence:</b>  
   ^cY#12.htm##
00251000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704002700071002000700098#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#154#150#article#159#<br>   A. Grangeiro    ^
cY#12.htm##
00263000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003900071002000700110#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#155#151#article#159#<br>   Departamento de M
edicina    ^cY#12.htm##
00260000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003600071002000700107#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#156#152#article#159#<br>   Faculdade de Medi
cina    ^cY#12.htm##
00271000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704004700071002000700118#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#157#153#article#159#<br>   Universidade de S
&atilde;o Paulo    ^cY#12.htm##
00258000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704003400071002000700105#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#158#154#article#159#<br>   Rua Dr. Arnaldo 4
55    ^cY#12.htm##
00277000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005300071002000700124#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#159#155#article#159#<br>   S&atilde;o Paulo,
 SP 01246-903, Brasil    ^cY#12.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#160#156#article#159#<br>   <a href="mailto:a
le.grangeiro@gmail.com">ale.grangeiro@gmail.com</a></font></p>     ^cY#12.htm##
00319000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704009500071002000700166#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#161#157#article#159#<p><font face="Verdana, 
Arial, Helvetica, sans-serif" size="2">Submitted on 14/Dec/2009    ^cY#12.htm##
00279000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005500071002000700126#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#162#158#article#159#<br>   Final version res
ubmitted on 06/Apr/2010    ^cY#12.htm##
00274000000000145000450000400060000070200410000670500020004770600020004970000040
0051701000400055709000800059708000400067704005000071002000700121#v27s1#V:\SciELO
\serial\csp\v27s1\markup\12.htm#S#p#163#159#article#159#<br>   Approved on 19/Ap
r/2010</font></p>     ^cY#12.htm##
00705000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100016000870100
02100103010001500124010001600139012014700155030001900302065000900321064000500330
031000300335014000800338865000900346002000700355035001000362801001900372#v27s1#V
:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#164#1#article#31#1#^rND^sBerkman^nA#
^rND^sGarcia^nJ#^rND^sMuñoz-Laboy^nM#^rND^sPaiva^nV#^rND^sParker^nR#A critical a
nalysis of the Brazilian response to HIV/AIDS: lessons learned for controlling a
nd mitigating the epidemic in developing countries^len#Am J Public Health#200500
00#2005#95#1162-72#20110000#12.htm#0090-0036#Am J Public Health##
00566000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100024000890100
01900113012009100132030002400223710000200247065000900249064000500258031000300263
014000600266865000900272002000700281#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.
htm#S#c#165#2#article#31#2#^rND^sGrangeiro^nA#^rND^sLaurindo-Silva^nL#^rND^sTeix
eira^nPR#Resposta à AIDS no Brasil: contribuições dos movimentos sociais e da re
forma sanitária^lpt#Rev Panam Salud Pública#2#20090000#2009#26#87-94#20110000#12
.htm##
00572000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100018000890100
01900107012008200126030000500208065000900213064000500222031000300227032000400230
014000500234865000900239002000700248035001000255801000500265#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\12.htm#S#c#166#3#article#31#3#^rND^sTeixeira^nPR#^rND^sVitó
ria^nMA#^rND^sBarcarolo^nJ#Antiretroviral treatment in a resource-poor setting: 
the Brazilian experience^len#AIDS#20040000#2004#18#^s3#S5-7#20110000#12.htm#0269
-9370#AIDS##
00549000000000277000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700100017000890120
10000106030001800206710000200224065000900226064000500235031000300240032000400243
014000800247865000900255002000700264#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.
htm#S#c#167#4#article#31#4#^rND^sFonseca^nMGP#^rND^sBastos^nFI#Twenty-five years
 of the AIDS epidemic in Brazil: principal epidemiological findings, 1980-2005^l
en#Cad Saúde Pública#2#20070000#2007#23#^s3#S333-44#20110000#12.htm##
00630000000000313000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100018000860100
01500104011003000119010002600149012007800175030001800253710000200271065000900273
064000500282031000300287032000400290014000600294865000900300002000700309#v27s1#V
:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#168#5#article#31#5#^rND^sBerquó^nE#^
rND^sBarbosa^nRM#^rND^sLima^nLP#Grupo de Estudos em População#^rND^sSexualidade 
e^nAIDS#Uso do preservativo: tendências entre 1998 e 2005 na população brasileir
a^lpt#Rev Saúde Pública#2#20080000#2008#42#^s1#34-44#20110000#12.htm##
00770000000000325000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100018000700100017000880100
01800105010001800123010001900141010002700160810000600187012019100193030001800384
71000020040206500090040406400050041303100030041801400070042186500090042800200070
0437#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#169#6#article#31#6#^rND^
sCaiaffa^nWT#^rND^sBastos^nFI#^rND^sFreitas^nLL#^rND^sMingoti^nSA#^rND^sProietti
^nFA#^rND^sCarneiro-Proetti^nAB#et al#The contribution of two Brazilian multi-ce
nter studies to the assessment of HIV and HCV infection and prevention strategie
s among injecting drug users: the AjUDE-Brasil I and II Projects^len#Cad Saúde P
ública#2#20060000#2006#22#771-82#20110000#12.htm##
00599000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100016000700100018000860110
03000104010002600134012007400160030001800234710000200252065000900254064000500263
031000300268032000400271014000600275865000900281002000700290#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\12.htm#S#c#170#7#article#31#7#^rND^sGarcia^nS#^rND^sKoyama^
nMAH#Grupo de Estudos em População#^rND^sSexualidade e^nAIDS#Estigma, discrimina
ção e HIV/AIDS no contexto brasileiro, 1998 e 2005^lpt#Rev Saúde Pública#2#20080
000#2008#42#^s1#72-83#20110000#12.htm##
00657000000000301000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100017000700100015000870100
01500102010001700117012015600134030001800290710000200308065000900310064000500319
031000300324032000400327014000800331865000900339002000700348#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\12.htm#S#c#171#8#article#31#8#^rND^sHacker^nMA#^rND^sKaida^
nA#^rND^sHogg^nRS#^rND^sBastos^nFI#The first ten years: achievements and challen
ges of the Brazilian program of universal access to HIV/AIDS comprehensive manag
ement and care, 1996 -2006^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S345-59#
20110000#12.htm##
00569000000000265000450000400060000070200410000670500020004770600020004970000040
00517010002000557090008000577080003000651180002000680100019000700120031000890160
01600120018006900136066001500205062004700220065000900267064000500276014000600281
865000900287002000700296#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#172#
9#article#31#9#^rND^sTeixeira^nPR#Políticas públicas em AIDS^lpt#^rED^sParker^nR
#Políticas, instituições e AIDS: enfrentando a epidemia no Brasil^lpt#Rio de Jan
eiro#Associação Brasileira Interdisciplinar de AIDS#19970000#1997#43-68#20110000
#12.htm##
00550000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100015000870100
01700102012008700119030001800206710000200224065000900226064000500235031000900240
014000700249865000900256002000700265#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.
htm#S#c#173#10#article#31#10#^rND^sPaiva^nV#^rND^sPupo^nLR#^rND^sBarboza^nR#O di
reito à prevenção e os desafios da redução de vulnerabilidade ao HIV no Brasil^l
pt#Rev Saúde Pública#2#20060000#2006#40 Suppl#109-19#20110000#12.htm##
00560000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170011000720180158000830650
00900241064000500250037002600255110000900281109001200290865000900302002000700311
#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#174#11#article#31#11#World B
ank#Project performance assessment report: Brazil first and second AIDS and STD 
control projects (Loan 3659-BR and 4392-BR). Operations Evaluation Department^le
n#20040000#2004#http://www.worldbank.org/#20080715#15/Jul/2008#20110000#12.htm##
00594000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160017000720180135000890510
00700224046001000231050008100241045000900322044000500331865000900336002000700345
#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#175#12#article#31#12#^rND^sB
arboza^nR#Gestão do Programa Estadual DST/AIDS de São Paulo: uma análise do proc
esso de descentralização das ações no período de 1994 a 2003^lpt#Thesis#São Paul
o#Secretaria de Estado da Saúde de São Paulo^dCoordenadoria de Controle de Doenç
as#20060000#2006#20110000#12.htm##
00536000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160017000720180081000890510
00800170046001500178050007100193045000900264044000500273865000900278002000700287
#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#176#13#article#31#13#^rND^sP
ires^nDRF#Alguns apontamentos sobre o processo de descentralização do programa d
e AIDS^lpt#Masters#Rio de Janeiro#Universidade do Estado do Rio de Janeiro^dInst
ituto de Medicina Social#20060000#2006#20110000#12.htm##
00583000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160020000720180140000920510
00800232046001500240050005600255045000900311044000500320865000900325002000700334
#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#177#14#article#31#14#^rND^sT
aglieta^nMFB#Avaliação da implantação do incentivo no âmbito do Programa Naciona
l de HIV/AIDS e outras DST em dois municípios do estado de São Paulo^lpt#Masters
#Rio de Janeiro#Fundação Oswaldo Cruz^dEscola Nacional de Saúde Pública#20060000
#2006#20110000#12.htm##
00415000000000217000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690170020000720180036000920370
03200128110000900160109001200169865000900181002000700190#v27s1#V:\SciELO\serial\
csp\v27s1\markup\12.htm#S#c#178#15#article#31#15#Ministério da Saúde#Programa Na
cional de DST e Aids^lpt#http://www.pam.aids.gov.br/pam/#20080317#17/Mar/2008#20
110000#12.htm##
00488000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160019000720180106000910630
00300197066001000200062000600210065000900216064000500225865000900230002000700239
#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#179#16#article#31#16#^rND^sP
ereira^nJCR#Análise de dados qualitativos: estratégias metodológicas para as ciê
ncias da saúde, humanas e sociais^lpt#3ª#São Paulo#Edusp#20010000#2001#20110000#
12.htm##
00446000000000241000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160013000720180062000850630
00200147066000700149062001800156065000900174064000500183865000900188002000700197
#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#180#17#article#31#17#^rND^sF
ox^nJ#Applied regression analysis and generalized linear models^len#2#London#Sag
e Publications#20080000#2008#20110000#12.htm##
00699000000000253000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690120307000720300007003790650
00900386064000500395031000400400014000800404865000900412002000700421035001000428
801000700438#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#181#18#article#3
1#18#Time from HIV-1 seroconversion to AIDS and death before widespread use of h
ighly-active antiretroviral therapy: a collaborative re-analysis. Collaborative 
Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Act
ion. Concerted Action on SeroConversion to AIDS and Death in Europe^len#Lancet#2
0000000#2000#355#1131-37#20110000#12.htm#0099-5355#Lancet##
00690000000000349000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
02000107010001700127010001800144010001700162810000600179012009200185030000500277
06500090028206400050029103100030029603200040029901400060030386500090030900200070
0318035001000325801000500335#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#
182#19#article#31#19#^rND^sCampos^nDP#^rND^sRibeiro^nSR#^rND^sGrinsztejn^nB#^rND
^sVeloso^nVG#^rND^sValente^nJG#^rND^sBastos^nFI#et al#Survival of AIDS patients 
using two case definitions, Rio de Janeiro, Brazil, 1986-2003^len#AIDS#20050000#
2005#19#^s4#S22-6#20110000#12.htm#0269-9370#AIDS##
00600000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100014000720100016000860100
01600102010001600118010001400134012007300148030000700221065000900228064000500237
031000400242014000700246865000900253002000700262035001000269801000700279#v27s1#V
:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#183#20#article#31#20#^rND^sPiot^nP#^
rND^sBartos^nM#^rND^sLarson^nH#^rND^sZewdie^nD#^rND^sMane^nP#Coming to terms wit
h complexity: a call to action for HIV prevention^len#Lancet#20080000#2008#372#8
45-59#20110000#12.htm#0099-5355#Lancet##
00514000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100019000920100
02100111012003800132030002500170710000200195065000900197064000500206031000300211
014000600214865000900220002000700229#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.
htm#S#c#184#21#article#31#21#^rND^sJunqueira^nPC#^rND^sRosemblit^nJ#^rND^sHamers
chlak^nN#História da hemoterapia no Brasil^lpt#Rev Bras Hematol Hemoter#2#200500
00#2005#27#201-7#20110000#12.htm##
00571000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100018000720100018000900100
01500108012011000123030001800233710000200251065000900253064000500262031000300267
014000700270865000900277002000700286#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.
htm#S#c#185#22#article#31#22#^rND^sSerruya^nSJ#^rND^sCecatti^nJG#^rND^sLago^nTG#
O Programa de Humanização do Pré-natal e Nascimento do Ministério da Saúde no Br
asil: resultados iniciais^lpt#Cad Saúde Pública#2#20040000#2004#20#1281-9#201100
00#12.htm##
00641000000000265000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100123000720120115001950300
01800310710000200328065000900330064000500339031000300344032000400347014000800351
865000900359002000700368#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#186#
23#article#31#23#^rND^sSucci RCM; Grupo de Estudos da Sociedade Brasileira de Pe
diatria para Avaliar a Transmissão Materno-Infantil do^nHIV#Mother-to-child tran
smission of HIV in Brazil during the years 2000 and 2001: results of a multi-cen
tric study^len#Cad Saúde Pública#2#20070000#2007#23#^s3#S379-89#20110000#12.htm#
#
00641000000000301000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100019000890100
01700108010001500125012012500140030001200265065000900277064000500286031000300291
014000700294865000900301002000700310035001000317801001200327#v27s1#V:\SciELO\ser
ial\csp\v27s1\markup\12.htm#S#c#187#24#article#31#24#^rND^sMaresch^nC#^rND^sSchl
uter^nPJ#^rND^sWilson^nAD#^rND^sSleig^nA#Residual infectious disease risk in scr
eened blood transfusion from a high-prevalence population: Santa Catarina, Brazi
l^len#Transfusion#20080000#2008#48#273-81#20110000#12.htm#0041-1132#Transfusion#
#
00635000000000313000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100023000720100018000950100
01700113011003000130010002600160012007200186030001800258710000200276065000900278
064000500287031000300292032000400295014000600299865000900305002000700314#v27s1#V
:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#188#25#article#31#25#^rND^sFrança Ju
nior^nI#^rND^sCalazans^nG#^rND^sZucchi^nEM#Grupo de Estudos em População#^rND^sS
exualidade e^nAIDS#Mudanças no âmbito da testagem anti-HIV no Brasil entre 1998 
e 2005^lpt#Rev Saúde Pública#2#20080000#2008#42#^s1#84-97#20110000#12.htm##
00476000000000229000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690160050000720180044001220660
00700166062004300173065000900216064000500225865000900230002000700239#v27s1#V:\Sc
iELO\serial\csp\v27s1\markup\12.htm#S#c#189#26#article#31#26#^rND^sUnited Nation
s Joint Programme on^nHIV/AIDS#Report on the global AIDS epidemic 2008^len#Genev
a#United Nations Joint Programme on HIV/AIDS#20080000#2008#20110000#12.htm##
00693000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100021000720100024000930100
02400117010001700141010001600158010001500174810000600189012011200195030001800307
71000020032506500090032706400050033603100030034101400070034486500090035100200070
0360#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#190#27#article#31#27#^rN
D^sSzwarcwald^nCL#^rND^sBarbosa Júnior^nA#^rND^sSouza Júnior^nPRB#^rND^sLemos^nK
RV#^rND^sFrias^nPG#^rND^sLuhm^nKR#et al#HIV testing during pregnancy: use of sec
ondary data to estimate 2006 test coverage and prevalence in Brazil^len#Braz J I
nfect Dis#2#20080000#2008#12#167-72#20110000#12.htm##
00658000000000325000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100017000720100018000890100
02400107010002300131010002300154010002000177810000600197012006900203030001800272
71000020029006500090029206400050030103100030030601400070030986500090031600200070
0325#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.htm#S#c#191#28#article#31#28#^rN
D^sVeloso^nVG#^rND^sPortela^nMC#^rND^sVasconcellos^nMTL#^rND^sMatzenbacher^nLA#^
rND^sVasconcelos^nALR#^rND^sGrinsztejn^nB#et al#HIV testing among pregnant women
 in Brazil: rates and predictors^len#Rev Saúde Pública#2#20080000#2008#42#859-67
#20110000#12.htm##
00557000000000277000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100020000720100021000920100
01600113012009100129030001800220710000200238065000900240064000500249031000300254
014000600257865000900263002000700272#v27s1#V:\SciELO\serial\csp\v27s1\markup\12.
htm#S#c#192#29#article#31#29#^rND^sRodrigues^nCS#^rND^sGuimarães^nMDC#^rND^sCésa
r^nCC#Missed opportunities for congenital syphilis and HIV perinatal transmissio
n prevention^len#Rev Saúde Pública#2#20080000#2008#42#851-8#20110000#12.htm##
00651000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100015000720100019000870100
01900106010002000125012015500145030001800300710000200318065000900320064000500329
031000300334014000800337865000900345002000700354#v27s1#V:\SciELO\serial\csp\v27s
1\markup\12.htm#S#c#193#30#article#31#30#^rND^sReis^nCT#^rND^sCzeresnia^nD#^rND^
sBarcellos^nC#^rND^sTassinari^nWS#A interiorização da epidemia de HIV/AIDS e o f
luxo intermunicipal de internação hospitalar na Zona da Mata, Minas Gerais, Bras
il: uma análise espacial^lpt#Cad Saúde Pública#2#20080000#2008#24#1219-28#201100
00#12.htm##
00593000000000289000450000400060000070200410000670500020004770600020004970000040
00517010003000557090008000587080003000661180003000690100024000720100021000960100
01800117010002300135012008500158030001800243710000200261065000900263064000500272
031000300277014000700280865000900287002000700296#v27s1#V:\SciELO\serial\csp\v27s
1\markup\12.htm#S#c#194#31#article#31#31#^rND^sBarbosa Júnior^nA#^rND^sSzwarcwal
d^nCL#^rND^sPascon^nARP#^rND^sSouza Junior^nPB#Tendências da AIDS epidemic entre
 subgrupos sob maior risco no Brasil, 1980-2004^lpt#Cad Saúde Pública#2#20090000
#2009#25#727-37#20110000#12.htm##
